7352670
D009599_D006973 NONE Rebound <e2>hypertensive</e2> after <e1>sodium nitroprusside</e1> prevented by saralasin in rats .
D009599_D006973 NONE During the <e1>SNP</e1> infusion the control animals demonstrated a progressive <e2>increase in blood pressure</e2> to 61 torr , whereas the saralasin-treated animals showed no change .
D012504_D006973 NONE Rebound <e2>hypertensive</e2> after sodium nitroprusside prevented by <e1>saralasin</e1> in rats .
D012504_D006973 NONE During the SNP infusion the control animals demonstrated a progressive <e2>increase in blood pressure</e2> to 61 torr , whereas the <e1>saralasin-treated</e1> animals showed no change .
D000809_D007022 NONE The role of the renin -- <e1>angiotensin</e1> system in the maintenance of blood pressure during halothane anesthesia and sodium nitroprusside (SNP)-induced <e2>hypotension</e2> was evaluated .
D000809_D007022 NONE This demonstrates the participation of the renin -- <e1>angiotensin</e1> system in antagonizing the combined <e2>hypotensive</e2> effects of halothane and SNP .
D006221_D007022 CID The role of the renin -- angiotensin system in the maintenance of blood pressure during <e1>halothane</e1> anesthesia and sodium nitroprusside (SNP)-induced <e2>hypotension</e2> was evaluated .
D006221_D007022 CID This demonstrates the participation of the renin -- angiotensin system in antagonizing the combined <e2>hypotensive</e2> effects of <e1>halothane</e1> and SNP .
D009599_D007022 CID The role of the renin -- angiotensin system in the maintenance of blood pressure during halothane anesthesia and <e1>sodium nitroprusside</e1> (SNP)-induced <e2>hypotension</e2> was evaluated .
D009599_D007022 CID The role of the renin -- angiotensin system in the maintenance of blood pressure during halothane anesthesia and sodium nitroprusside <e1>(SNP)-induced</e1> <e2>hypotension</e2> was evaluated .
D009599_D007022 CID This demonstrates the participation of the renin -- angiotensin system in antagonizing the combined <e2>hypotensive</e2> effects of halothane and <e1>SNP</e1> .
15145918
D004967_D007022 NONE Differential modulation by <e1>estrogen</e1> of alpha2-adrenergic and I1-imidazoline receptor-mediated <e2>hypotension</e2> in female rats .
D004967_D007022 NONE We have recently shown that <e1>estrogen</e1> negatively modulates the <e2>hypotensive</e2> effect of clonidine ( mixed alpha2-/I1-receptor agonist ) in female rats and implicates the cardiovascular autonomic control in this interaction .
D004967_D007022 NONE These findings suggest that <e1>estrogen</e1> downregulates alpha2- but not I1-receptor-mediated <e2>hypotension</e2> and highlight a role for the cardiac autonomic control in alpha-methyldopa-estrogen interaction .
D004967_D007022 NONE These findings suggest that estrogen downregulates alpha2- but not I1-receptor-mediated <e2>hypotension</e2> and highlight a role for the cardiac autonomic control in <e1>alpha-methyldopa-estrogen</e1> interaction .
D048288_D007022 NONE Differential modulation by estrogen of alpha2-adrenergic and <e1>I1-imidazoline</e1> receptor-mediated <e2>hypotension</e2> in female rats .
D003000_D007022 NONE We have recently shown that estrogen negatively modulates the <e2>hypotensive</e2> effect of <e1>clonidine</e1> ( mixed alpha2-/I1-receptor agonist ) in female rats and implicates the cardiovascular autonomic control in this interaction .
C032302_D007022 CID In sham-operated rats , <e1>rilmenidine</e1> or alpha-methyldopa elicited similar <e2>hypotension</e2> that lasted at least 5 h and was associated with reductions in standard deviation of mean arterial pressure .
C032302_D007022 CID Ovx significantly enhanced the <e2>hypotensive</e2> response to alpha-methyldopa , in contrast to no effect on <e1>rilmenidine</e1> hypotension .
C032302_D007022 CID Ovx significantly enhanced the hypotensive response to alpha-methyldopa , in contrast to no effect on <e1>rilmenidine</e1> <e2>hypotension</e2> .
D008750_D007022 CID In sham-operated rats , rilmenidine or <e1>alpha-methyldopa</e1> elicited similar <e2>hypotension</e2> that lasted at least 5 h and was associated with reductions in standard deviation of mean arterial pressure .
D008750_D007022 CID Ovx significantly enhanced the <e2>hypotensive</e2> response to <e1>alpha-methyldopa</e1> , in contrast to no effect on rilmenidine hypotension .
D008750_D007022 CID Ovx significantly enhanced the hypotensive response to <e1>alpha-methyldopa</e1> , in contrast to no effect on rilmenidine <e2>hypotension</e2> .
D008750_D007022 CID The enhanced <e1>alpha-methyldopa</e1> <e2>hypotension</e2> in Ovx rats was paralleled with further reduction in SDRR and a reduced locomotor activity .
D008750_D007022 CID These findings suggest that estrogen downregulates alpha2- but not I1-receptor-mediated <e2>hypotension</e2> and highlight a role for the cardiac autonomic control in <e1>alpha-methyldopa-estrogen</e1> interaction .
D008750_D001523 NONE The enhanced <e1>alpha-methyldopa</e1> hypotension in Ovx rats was paralleled with further reduction in SDRR and <e2>a reduced locomotor activity</e2> .
11672959
D012460_D003872 CID A 34-year-old lady developed a constellation of <e2>dermatitis</e2> , fever , lymphadenopathy and hepatitis , beginning on the 17th day of a course of oral <e1>sulphasalazine</e1> for sero-negative rheumatoid arthritis .
D012460_D005334 CID A 34-year-old lady developed a constellation of dermatitis , <e2>fever</e2> , lymphadenopathy and hepatitis , beginning on the 17th day of a course of oral <e1>sulphasalazine</e1> for sero-negative rheumatoid arthritis .
D012460_D008206 CID A 34-year-old lady developed a constellation of dermatitis , fever , <e2>lymphadenopathy</e2> and hepatitis , beginning on the 17th day of a course of oral <e1>sulphasalazine</e1> for sero-negative rheumatoid arthritis .
D012460_D056486 CID A 34-year-old lady developed a constellation of dermatitis , fever , lymphadenopathy and <e2>hepatitis</e2> , beginning on the 17th day of a course of oral <e1>sulphasalazine</e1> for sero-negative rheumatoid arthritis .
D012460_D001172 NONE A 34-year-old lady developed a constellation of dermatitis , fever , lymphadenopathy and hepatitis , beginning on the 17th day of a course of oral <e1>sulphasalazine</e1> for sero-negative <e2>rheumatoid arthritis</e2> .
1664218
D000677_D002289 NONE Phase II study of the <e1>amsacrine</e1> analogue CI-921 ( NSC 343499 ) in <e2>non-small cell lung cancer</e2> .
C042315_D002289 NONE Phase II study of the amsacrine analogue <e1>CI-921</e1> ( NSC 343499 ) in <e2>non-small cell lung cancer</e2> .
C042315_D002289 NONE Phase II study of the amsacrine analogue CI-921 ( <e1>NSC 343499</e1> ) in <e2>non-small cell lung cancer</e2> .
6103707
D005445_D010146 CID There was <e2>pain</e2> on i.m. injection of <e1>flunitrazepam</e1> significantly more often than with isotonic saline .
16787750
D014635_D001927 CID <e1>Valproic acid</e1> induced <e2>encephalopathy--19</e2> new cases in Germany from 1994 to 2003 - -a side effect associated to VPA-therapy not only in young children .
D014635_D001927 CID Valproic acid induced <e2>encephalopathy--19</e2> new cases in Germany from 1994 to 2003 - -a side effect associated to <e1>VPA-therapy</e1> not only in young children .
D014635_D001927 CID Rare serious complications may occur in some patients , including haemorrhagic pancreatitis , bone marrow suppression , <e1>VPA-induced</e1> hepatotoxicity and VPA-induced <e2>encephalopathy</e2> .
D014635_D001927 CID Rare serious complications may occur in some patients , including haemorrhagic pancreatitis , bone marrow suppression , VPA-induced hepatotoxicity and <e1>VPA-induced</e1> <e2>encephalopathy</e2> .
D014635_D001927 CID The typical signs of <e1>VPA-induced</e1> <e2>encephalopathy</e2> are impaired consciousness , sometimes marked EEG background slowing , increased seizure frequency , with or without hyperammonemia .
D014635_D001927 CID There is still no proof of causative effect of <e1>VPA</e1> in patients with <e2>encephalopathy</e2> , but only of an association with an assumed causal relation .
D014635_D001927 CID We report 19 patients with <e1>VPA-associated</e1> <e2>encephalopathy</e2> in Germany from the years 1994 to 2003 , none of whom had been published previously .
D014635_D010195 CID Rare serious complications may occur in some patients , including haemorrhagic <e2>pancreatitis</e2> , bone marrow suppression , <e1>VPA-induced</e1> hepatotoxicity and VPA-induced encephalopathy .
D014635_D010195 CID Rare serious complications may occur in some patients , including haemorrhagic <e2>pancreatitis</e2> , bone marrow suppression , VPA-induced hepatotoxicity and <e1>VPA-induced</e1> encephalopathy .
D014635_D001855 CID Rare serious complications may occur in some patients , including haemorrhagic pancreatitis , <e2>bone marrow suppression</e2> , <e1>VPA-induced</e1> hepatotoxicity and VPA-induced encephalopathy .
D014635_D001855 CID Rare serious complications may occur in some patients , including haemorrhagic pancreatitis , <e2>bone marrow suppression</e2> , VPA-induced hepatotoxicity and <e1>VPA-induced</e1> encephalopathy .
D014635_D056486 CID Rare serious complications may occur in some patients , including haemorrhagic pancreatitis , bone marrow suppression , <e1>VPA-induced</e1> <e2>hepatotoxicity</e2> and VPA-induced encephalopathy .
D014635_D056486 CID Rare serious complications may occur in some patients , including haemorrhagic pancreatitis , bone marrow suppression , VPA-induced <e2>hepatotoxicity</e2> and <e1>VPA-induced</e1> encephalopathy .
D014635_D003244 CID The typical signs of <e1>VPA-induced</e1> encephalopathy are <e2>impaired consciousness</e2> , sometimes marked EEG background slowing , increased seizure frequency , with or without hyperammonemia .
D014635_D012640 NONE The typical signs of <e1>VPA-induced</e1> encephalopathy are impaired consciousness , sometimes marked EEG background slowing , increased <e2>seizure</e2> frequency , with or without hyperammonemia .
D014635_D022124 NONE The typical signs of <e1>VPA-induced</e1> encephalopathy are impaired consciousness , sometimes marked EEG background slowing , increased seizure frequency , with or without <e2>hyperammonemia</e2> .
9931093
D016559_D006973 CID Mechanisms of <e1>FK 506-induced</e1> <e2>hypertension</e2> in the rat .
D016559_D006973 CID The clinical utility of <e1>FK 506</e1> is complicated by substantial <e2>hypertension</e2> and nephrotoxicity .
D016559_D006973 CID To clarify the mechanisms of <e1>FK 506-induced</e1> <e2>hypertension</e2> , we studied the chronic effects of FK 506 on the synthesis of endothelin-1 ( ET-1 ) , the expression of mRNA of ET-1 and endothelin-converting enzyme-1 ( ECE-1 ) , the endothelial nitric oxide synthase ( eNOS ) activity , and the expression of mRNA of eNOS and C-type natriuretic peptide ( CNP ) in rat blood vessels .
D016559_D006973 CID To clarify the mechanisms of FK 506-induced <e2>hypertension</e2> , we studied the chronic effects of <e1>FK 506</e1> on the synthesis of endothelin-1 ( ET-1 ) , the expression of mRNA of ET-1 and endothelin-converting enzyme-1 ( ECE-1 ) , the endothelial nitric oxide synthase ( eNOS ) activity , and the expression of mRNA of eNOS and C-type natriuretic peptide ( CNP ) in rat blood vessels .
D016559_D006973 CID In addition , the effect of the specific endothelin type A receptor antagonist FR 139317 on <e1>FK 506-induced</e1> <e2>hypertension</e2> in rats was studied .
D016559_D006973 CID d-1 ) prevented <e1>FK 506-induced</e1> <e2>hypertension</e2> in rats .
D016559_D007674 NONE The clinical utility of <e1>FK 506</e1> is complicated by substantial hypertension and <e2>nephrotoxicity</e2> .
D009569_D006973 NONE To clarify the mechanisms of FK 506-induced <e2>hypertension</e2> , we studied the chronic effects of FK 506 on the synthesis of endothelin-1 ( ET-1 ) , the expression of mRNA of ET-1 and endothelin-converting enzyme-1 ( ECE-1 ) , the endothelial <e1>nitric oxide</e1> synthase ( eNOS ) activity , and the expression of mRNA of eNOS and C-type natriuretic peptide ( CNP ) in rat blood vessels .
C079574_D006973 NONE In addition , the effect of the specific endothelin type A receptor antagonist <e1>FR 139317</e1> on FK 506-induced <e2>hypertension</e2> in rats was studied .
230316
D006912_D020258 NONE <e2>Neurotoxicity</e2> of <e1>halogenated hydroxyquinolines</e1> : clinical analysis of cases reported outside Japan .
D006912_D020258 NONE An analysis is presented of 220 cases of possible <e2>neurotoxic</e2> reactions to <e1>halogenated hydroxyquinolines</e1> reported from outside Japan .
D007464_D009422 NONE In six of the probable cases the <e2>neurological disturbance</e2> consisted of an acute reversible encephalopathy usually related to the ingestion of a high dose of <e1>clioquinol</e1> over a short period .
D007464_D001927 CID In six of the probable cases the neurological disturbance consisted of an acute reversible <e2>encephalopathy</e2> usually related to the ingestion of a high dose of <e1>clioquinol</e1> over a short period .
D007464_C538178 NONE This was most frequently found in children , many of whom had received <e1>clioquinol</e1> as treatment for <e2>acrodermatitis enteropathica</e2> .
9727773
D001067_D006976 CID High incidence of <e2>primary pulmonary hypertension</e2> associated with <e1>appetite suppressants</e1> in Belgium .
D001067_D006976 CID <e2>Primary pulmonary hypertension</e2> is a rare , progressive and incurable disease , which has been associated with the intake of <e1>appetite suppressant</e1> drugs .
D001067_D006976 CID In 8 patients the diagnosis of <e2>primary pulmonary hypertension</e2> was uncertain , 5 of them had taken <e1>appetite suppressants</e1> .
D001067_D006976 CID A policy of unrestricted prescription of <e1>appetite suppressants</e1> may lead to a high incidence of associated <e2>primary pulmonary hypertension</e2> .
8302922
D000527_D007022 CID Epidural blood flow during <e1>prostaglandin E1</e1> or trimethaphan induced <e2>hypotension</e2> .
D000527_D007022 CID To evaluate the effect of <e1>prostaglandin E1</e1> ( PGE1 ) or trimethaphan ( TMP ) induced <e2>hypotension</e2> on epidural blood flow ( EBF ) during spinal surgery , EBF was measured using the heat clearance method in 30 patients who underwent postero-lateral interbody fusion under isoflurane anaesthesia .
D000527_D007022 CID To evaluate the effect of prostaglandin E1 ( <e1>PGE1</e1> ) or trimethaphan ( TMP ) induced <e2>hypotension</e2> on epidural blood flow ( EBF ) during spinal surgery , EBF was measured using the heat clearance method in 30 patients who underwent postero-lateral interbody fusion under isoflurane anaesthesia .
D000527_D007022 CID After starting <e1>PGE1</e1> or TMP , MAP and rate pressure product ( RPP ) decreased significantly compared with preinfusion values ( P < 0.01 ) , and the degree of <e2>hypotension</e2> due to PGE1 remained constant until 60 min after its discontinuation .
D000527_D007022 CID After starting PGE1 or TMP , MAP and rate pressure product ( RPP ) decreased significantly compared with preinfusion values ( P < 0.01 ) , and the degree of <e2>hypotension</e2> due to <e1>PGE1</e1> remained constant until 60 min after its discontinuation .
D000527_D007022 CID These results suggest that <e1>PGE1</e1> may be preferable to TMP for <e2>hypotensive</e2> anaesthesia in spinal surgery because TMP decreased EBF .
D014294_D007022 CID Epidural blood flow during prostaglandin E1 or <e1>trimethaphan</e1> induced <e2>hypotension</e2> .
D014294_D007022 CID To evaluate the effect of prostaglandin E1 ( PGE1 ) or <e1>trimethaphan</e1> ( TMP ) induced <e2>hypotension</e2> on epidural blood flow ( EBF ) during spinal surgery , EBF was measured using the heat clearance method in 30 patients who underwent postero-lateral interbody fusion under isoflurane anaesthesia .
D014294_D007022 CID To evaluate the effect of prostaglandin E1 ( PGE1 ) or trimethaphan ( <e1>TMP</e1> ) induced <e2>hypotension</e2> on epidural blood flow ( EBF ) during spinal surgery , EBF was measured using the heat clearance method in 30 patients who underwent postero-lateral interbody fusion under isoflurane anaesthesia .
D014294_D007022 CID After starting PGE1 or <e1>TMP</e1> , MAP and rate pressure product ( RPP ) decreased significantly compared with preinfusion values ( P < 0.01 ) , and the degree of <e2>hypotension</e2> due to PGE1 remained constant until 60 min after its discontinuation .
D014294_D007022 CID These results suggest that PGE1 may be preferable to <e1>TMP</e1> for <e2>hypotensive</e2> anaesthesia in spinal surgery because TMP decreased EBF .
D014294_D007022 CID These results suggest that PGE1 may be preferable to TMP for <e2>hypotensive</e2> anaesthesia in spinal surgery because <e1>TMP</e1> decreased EBF .
D007530_D007022 NONE To evaluate the effect of prostaglandin E1 ( PGE1 ) or trimethaphan ( TMP ) induced <e2>hypotension</e2> on epidural blood flow ( EBF ) during spinal surgery , EBF was measured using the heat clearance method in 30 patients who underwent postero-lateral interbody fusion under <e1>isoflurane</e1> anaesthesia .
3437726
D013034_D064420 NONE Therefore , patients belonging to the poor-metabolizer phenotype of <e1>sparteine/debrisoquine</e1> polymorphism in drug metabolism , which constitutes 6.4 % of the German population , may experience <e2>adverse drug reactions</e2> when treated with standard doses of one of these drugs alone .
D003647_D064420 NONE Therefore , patients belonging to the poor-metabolizer phenotype of <e1>sparteine/debrisoquine</e1> polymorphism in drug metabolism , which constitutes 6.4 % of the German population , may experience <e2>adverse drug reactions</e2> when treated with standard doses of one of these drugs alone .
12789195
D008914_D004194 NONE <e2>Pseudoacromegaly</e2> induced by the long-term use of <e1>minoxidil</e1> .
D008914_D004194 NONE We present a patient with <e2>pseudoacromegaly</e2> that resulted from the long-term use of <e1>minoxidil</e1> at an unusually high dose .
D008914_D004194 NONE This is the first case report of <e2>pseudoacromegaly</e2> as a side effect of <e1>minoxidil</e1> use .
12198388
D000109_D012640 NONE The relationship between hippocampal <e1>acetylcholine</e1> release and cholinergic convulsant sensitivity in withdrawal <e2>seizure-prone</e2> and withdrawal seizure-resistant selected mouse lines .
D000109_D012640 NONE The relationship between hippocampal <e1>acetylcholine</e1> release and cholinergic convulsant sensitivity in withdrawal seizure-prone and withdrawal <e2>seizure-resistant</e2> selected mouse lines .
D000109_D012640 NONE Hippocampal <e1>ACh</e1> also was measured during testing for handling-induced <e2>convulsions</e2> .
D000109_D012640 NONE When hippocampal <e1>ACh</e1> was measured during testing for handling-induced <e2>convulsions</e2> , extracellular ACh was significantly elevated ( 192 % ) in WSP mice , but was nonsignificantly elevated ( 59 % ) in WSR mice .
D000109_D012640 NONE When hippocampal ACh was measured during testing for handling-induced <e2>convulsions</e2> , extracellular <e1>ACh</e1> was significantly elevated ( 192 % ) in WSP mice , but was nonsignificantly elevated ( 59 % ) in WSR mice .
D000431_D012640 NONE METHODS : Cholinergic convulsant sensitivity was examined in <e1>alcohol-na</e1> ve Withdrawal <e2>Seizure-Prone</e2> ( WSP ) and-Resistant ( WSR ) mice .
D000431_D012640 NONE CONCLUSIONS : These results suggest that differences in cholinergic activity and postsynaptic sensitivity to cholinergic <e2>convulsants</e2> may be associated with <e1>ethanol</e1> withdrawal severity and implicate cholinergic mechanisms in alcohol withdrawal .
D000431_D012640 NONE CONCLUSIONS : These results suggest that differences in cholinergic activity and postsynaptic sensitivity to cholinergic <e2>convulsants</e2> may be associated with ethanol withdrawal severity and implicate cholinergic mechanisms in <e1>alcohol</e1> withdrawal .
D009538_D014202 NONE Animals were administered <e1>nicotine</e1> , carbachol , or neostigmine via timed tail vein infusion , and the latencies to onset of <e2>tremor</e2> and clonus were recorded and converted to threshold dose .
D002217_D014202 NONE Animals were administered nicotine , <e1>carbachol</e1> , or neostigmine via timed tail vein infusion , and the latencies to onset of <e2>tremor</e2> and clonus were recorded and converted to threshold dose .
D009388_D014202 NONE Animals were administered nicotine , carbachol , or <e1>neostigmine</e1> via timed tail vein infusion , and the latencies to onset of <e2>tremor</e2> and clonus were recorded and converted to threshold dose .
D009538_D012640 CID RESULTS : Sensitivity to several <e2>convulsion</e2> endpoints induced by <e1>nicotine</e1> , carbachol , and neostigmine were significantly greater in WSR versus WSP mice .
D002217_D012640 CID RESULTS : Sensitivity to several <e2>convulsion</e2> endpoints induced by nicotine , <e1>carbachol</e1> , and neostigmine were significantly greater in WSR versus WSP mice .
D009388_D012640 CID RESULTS : Sensitivity to several <e2>convulsion</e2> endpoints induced by nicotine , carbachol , and <e1>neostigmine</e1> were significantly greater in WSR versus WSP mice .
6518066
D008094_D004437 CID Maternal <e1>lithium</e1> and neonatal <e2>Ebstein 's anomaly</e2> : evaluation with cross-sectional echocardiography .
D008094_D006331 NONE Cross-sectional echocardiographic screening of newborns exposed to <e1>lithium</e1> during gestation can provide highly accurate , noninvasive assessment of the presence or absence of lithium-induced <e2>cardiac malformations</e2> .
D008094_D006331 NONE Cross-sectional echocardiographic screening of newborns exposed to lithium during gestation can provide highly accurate , noninvasive assessment of the presence or absence of <e1>lithium-induced</e1> <e2>cardiac malformations</e2> .
10520387
D004809_D007022 NONE We investigated the safety and efficacy of adding different doses of <e1>ephedrine</e1> to propofol in order to obtund the <e2>hypotensive</e2> response .
D004809_D007022 NONE The addition of <e1>ephedrine</e1> to propofol appears to be an effective method of obtunding the <e2>hypotensive</e2> response to propofol at all doses used in this study .
D015742_D007022 CID We investigated the safety and efficacy of adding different doses of ephedrine to <e1>propofol</e1> in order to obtund the <e2>hypotensive</e2> response .
D015742_D007022 CID The addition of ephedrine to <e1>propofol</e1> appears to be an effective method of obtunding the <e2>hypotensive</e2> response to propofol at all doses used in this study .
D015742_D007022 CID The addition of ephedrine to propofol appears to be an effective method of obtunding the <e2>hypotensive</e2> response to <e1>propofol</e1> at all doses used in this study .
D004809_D013610 CID However , marked <e2>tachycardia</e2> associated with the use of <e1>ephedrine</e1> in combination with propofol occurred in the majority of patients , occasionally reaching high levels in individual patients .
D004809_D013610 CID Due to the risk of this <e2>tachycardia</e2> inducing myocardial ischemia , we would not recommend the use in elderly patients of any of the <e1>ephedrine/propofol/mixtures</e1> studied .
D015742_D013610 CID However , marked <e2>tachycardia</e2> associated with the use of ephedrine in combination with <e1>propofol</e1> occurred in the majority of patients , occasionally reaching high levels in individual patients .
D015742_D013610 CID Due to the risk of this <e2>tachycardia</e2> inducing myocardial ischemia , we would not recommend the use in elderly patients of any of the <e1>ephedrine/propofol/mixtures</e1> studied .
D004809_D017202 NONE Due to the risk of this tachycardia inducing <e2>myocardial ischemia</e2> , we would not recommend the use in elderly patients of any of the <e1>ephedrine/propofol/mixtures</e1> studied .
D015742_D017202 NONE Due to the risk of this tachycardia inducing <e2>myocardial ischemia</e2> , we would not recommend the use in elderly patients of any of the <e1>ephedrine/propofol/mixtures</e1> studied .
6888657
D004967_D010911 NONE Characterization of <e1>estrogen-induced</e1> <e2>adenohypophyseal tumors</e2> in the Fischer 344 rat .
D004054_D010911 CID <e2>Pituitary tumors</e2> were induced in F344 female rats by chronic treatment with <e1>diethylstilbestrol</e1> ( DES , 8 - 10 mg ) implanted subcutaneously in silastic capsules .
D004054_D010911 CID <e2>Pituitary tumors</e2> were induced in F344 female rats by chronic treatment with diethylstilbestrol ( <e1>DES</e1> , 8 - 10 mg ) implanted subcutaneously in silastic capsules .
D004054_D009369 NONE The data extend the findings of other investigators , further establishing the <e1>DES-induced</e1> <e2>tumor</e2> as a model for study of PRL cellular control mechanisms .
15036754
D010755_D012640 NONE <e1>Organophosphate-induced</e1> <e2>convulsions</e2> and prevention of neuropathological damages .
D010755_D004194 NONE <e1>Organophosphate-induced</e1> convulsions and prevention of <e2>neuropathological damages</e2> .
D010755_D064420 NONE The acute <e2>toxicity</e2> of <e1>OPs</e1> is the result of their irreversible binding with AChEs in the central nervous system ( CNS ) , which elevates acetylcholine ( ACh ) levels .
D010755_D064420 NONE The rats treated with DFP-atropine showed severe typical <e1>OP-induced</e1> <e2>toxicity</e2> signs .
D000109_D064420 NONE The acute <e2>toxicity</e2> of OPs is the result of their irreversible binding with AChEs in the central nervous system ( CNS ) , which elevates <e1>acetylcholine</e1> ( ACh ) levels .
D000109_D064420 NONE The acute <e2>toxicity</e2> of OPs is the result of their irreversible binding with AChEs in the central nervous system ( CNS ) , which elevates acetylcholine ( <e1>ACh</e1> ) levels .
D007531_D064420 NONE The rats treated with <e1>DFP-atropine</e1> showed severe typical OP-induced <e2>toxicity</e2> signs .
D007531_D064420 NONE Atropine-MK801 did not offer any additional protection against <e1>DFP</e1> <e2>toxicity</e2> .
D007531_D064420 NONE In conclusion , CPA , diazepam and 2PAM in combination with atropine prevented the occurrence of serious signs of poisoning and thus reduced the <e2>toxicity</e2> of <e1>DFP</e1> in rat .
D001285_D064420 NONE The rats treated with <e1>DFP-atropine</e1> showed severe typical OP-induced <e2>toxicity</e2> signs .
D001285_D064420 NONE <e1>Atropine-MK801</e1> did not offer any additional protection against DFP <e2>toxicity</e2> .
D001285_D064420 NONE In conclusion , CPA , diazepam and 2PAM in combination with <e1>atropine</e1> prevented the occurrence of serious signs of poisoning and thus reduced the <e2>toxicity</e2> of DFP in rat .
C048599_D011041 NONE When <e1>CPA</e1> , diazepam or 2PAM was given immediately after DFP-atropine , these treatments prevented , delayed or shortened the occurrence of serious signs of <e2>poisoning</e2> .
C048599_D011041 NONE In conclusion , <e1>CPA</e1> , diazepam and 2PAM in combination with atropine prevented the occurrence of serious signs of <e2>poisoning</e2> and thus reduced the toxicity of DFP in rat .
D003975_D011041 NONE When CPA , <e1>diazepam</e1> or 2PAM was given immediately after DFP-atropine , these treatments prevented , delayed or shortened the occurrence of serious signs of <e2>poisoning</e2> .
D003975_D011041 NONE In conclusion , CPA , <e1>diazepam</e1> and 2PAM in combination with atropine prevented the occurrence of serious signs of <e2>poisoning</e2> and thus reduced the toxicity of DFP in rat .
D011220_D011041 NONE When CPA , diazepam or <e1>2PAM</e1> was given immediately after DFP-atropine , these treatments prevented , delayed or shortened the occurrence of serious signs of <e2>poisoning</e2> .
D011220_D011041 NONE In conclusion , CPA , diazepam and <e1>2PAM</e1> in combination with atropine prevented the occurrence of serious signs of <e2>poisoning</e2> and thus reduced the toxicity of DFP in rat .
D007531_D011041 NONE When CPA , diazepam or 2PAM was given immediately after <e1>DFP-atropine</e1> , these treatments prevented , delayed or shortened the occurrence of serious signs of <e2>poisoning</e2> .
D007531_D011041 NONE In conclusion , CPA , diazepam and 2PAM in combination with atropine prevented the occurrence of serious signs of <e2>poisoning</e2> and thus reduced the toxicity of <e1>DFP</e1> in rat .
D001285_D011041 NONE When CPA , diazepam or 2PAM was given immediately after <e1>DFP-atropine</e1> , these treatments prevented , delayed or shortened the occurrence of serious signs of <e2>poisoning</e2> .
D001285_D011041 NONE In conclusion , CPA , diazepam and 2PAM in combination with <e1>atropine</e1> prevented the occurrence of serious signs of <e2>poisoning</e2> and thus reduced the toxicity of DFP in rat .
D016291_D064420 NONE <e1>Atropine-MK801</e1> did not offer any additional protection against DFP <e2>toxicity</e2> .
C048599_D064420 NONE In conclusion , <e1>CPA</e1> , diazepam and 2PAM in combination with atropine prevented the occurrence of serious signs of poisoning and thus reduced the <e2>toxicity</e2> of DFP in rat .
D003975_D064420 NONE In conclusion , CPA , <e1>diazepam</e1> and 2PAM in combination with atropine prevented the occurrence of serious signs of poisoning and thus reduced the <e2>toxicity</e2> of DFP in rat .
D011220_D064420 NONE In conclusion , CPA , diazepam and <e1>2PAM</e1> in combination with atropine prevented the occurrence of serious signs of poisoning and thus reduced the <e2>toxicity</e2> of DFP in rat .
2887062
D004967_D015175 CID Immunohistochemical , electron microscopic and morphometric studies of <e1>estrogen-induced</e1> rat <e2>prolactinomas</e2> after bromocriptine treatment .
D004967_D015175 CID To clarify the effects of bromocriptine on <e2>prolactinoma</e2> cells in vivo , immunohistochemical , ultrastructural and morphometrical analyses were applied to <e1>estrogen-induced</e1> rat prolactinoma cells 1 h and 6 h after injection of bromocriptine ( 3 mg/kg of body weight ) .
D004967_D015175 CID To clarify the effects of bromocriptine on prolactinoma cells in vivo , immunohistochemical , ultrastructural and morphometrical analyses were applied to <e1>estrogen-induced</e1> rat <e2>prolactinoma</e2> cells 1 h and 6 h after injection of bromocriptine ( 3 mg/kg of body weight ) .
D001971_D015175 NONE Immunohistochemical , electron microscopic and morphometric studies of estrogen-induced rat <e2>prolactinomas</e2> after <e1>bromocriptine</e1> treatment .
D001971_D015175 NONE To clarify the effects of <e1>bromocriptine</e1> on <e2>prolactinoma</e2> cells in vivo , immunohistochemical , ultrastructural and morphometrical analyses were applied to estrogen-induced rat prolactinoma cells 1 h and 6 h after injection of bromocriptine ( 3 mg/kg of body weight ) .
D001971_D015175 NONE To clarify the effects of <e1>bromocriptine</e1> on prolactinoma cells in vivo , immunohistochemical , ultrastructural and morphometrical analyses were applied to estrogen-induced rat <e2>prolactinoma</e2> cells 1 h and 6 h after injection of bromocriptine ( 3 mg/kg of body weight ) .
D001971_D015175 NONE To clarify the effects of bromocriptine on <e2>prolactinoma</e2> cells in vivo , immunohistochemical , ultrastructural and morphometrical analyses were applied to estrogen-induced rat prolactinoma cells 1 h and 6 h after injection of <e1>bromocriptine</e1> ( 3 mg/kg of body weight ) .
D001971_D015175 NONE To clarify the effects of bromocriptine on prolactinoma cells in vivo , immunohistochemical , ultrastructural and morphometrical analyses were applied to estrogen-induced rat <e2>prolactinoma</e2> cells 1 h and 6 h after injection of <e1>bromocriptine</e1> ( 3 mg/kg of body weight ) .
D001971_D000236 NONE However , only secretory granules showed the positive reaction products for prolactin 6 h after <e1>bromocriptine</e1> treatment of the <e2>adenoma</e2> cells .
10669626
D014859_D061205 CID <e1>Warfarin-induced</e1> <e2>artery calcification</e2> is accelerated by growth and vitamin D.
D014859_D061205 CID The present studies demonstrate that growth and vitamin D treatment enhance the extent of <e2>artery calcification</e2> in rats given sufficient doses of <e1>Warfarin</e1> to inhibit gamma-carboxylation of matrix Gla protein , a calcification inhibitor known to be expressed by smooth muscle cells and macrophages in the artery wall .
D014859_D061205 CID The first series of experiments examined the influence of age and growth status on <e2>artery calcification</e2> in <e1>Warfarin-treated</e1> rats .
D014859_D061205 CID Treatment for 2 weeks with <e1>Warfarin</e1> caused massive focal <e2>calcification of the artery</e2> media in 20-day-old rats and less extensive focal calcification in 42-day-old rats .
D014859_D061205 CID In contrast , no <e2>artery calcification</e2> could be detected in 10-month-old adult rats even after 4 weeks of <e1>Warfarin</e1> treatment .
D014859_D061205 CID To directly examine the importance of growth to <e1>Warfarin-induced</e1> <e2>artery calcification</e2> in animals of the same age , 20-day-old rats were fed for 2 weeks either an ad libitum diet or a 6-g/d restricted diet that maintains weight but prevents growth .
D014859_D061205 CID Concurrent treatment of both dietary groups with <e1>Warfarin</e1> produced massive focal <e2>calcification of the artery</e2> media in the ad libitum-fed rats but no detectable artery calcification in the restricted-diet , growth-inhibited group .
D014859_D061205 CID Concurrent treatment of both dietary groups with <e1>Warfarin</e1> produced massive focal calcification of the artery media in the ad libitum-fed rats but no detectable <e2>artery calcification</e2> in the restricted-diet , growth-inhibited group .
D014859_D061205 CID Although the explanation for the association between <e2>artery calcification</e2> and growth status can not be determined from the present study , there was a relationship between higher serum phosphate and susceptibility to artery calcification , with 30 % higher levels of serum phosphate in young , ad libitum-fed rats compared with either of the groups that was resistant to <e1>Warfarin-induced</e1> artery calcification , ie , the 10-month-old rats and the restricted-diet , growth-inhibited young rats .
D014859_D061205 CID Although the explanation for the association between artery calcification and growth status can not be determined from the present study , there was a relationship between higher serum phosphate and susceptibility to <e2>artery calcification</e2> , with 30 % higher levels of serum phosphate in young , ad libitum-fed rats compared with either of the groups that was resistant to <e1>Warfarin-induced</e1> artery calcification , ie , the 10-month-old rats and the restricted-diet , growth-inhibited young rats .
D014859_D061205 CID Although the explanation for the association between artery calcification and growth status can not be determined from the present study , there was a relationship between higher serum phosphate and susceptibility to artery calcification , with 30 % higher levels of serum phosphate in young , ad libitum-fed rats compared with either of the groups that was resistant to <e1>Warfarin-induced</e1> <e2>artery calcification</e2> , ie , the 10-month-old rats and the restricted-diet , growth-inhibited young rats .
D014859_D061205 CID This observation suggests that increased susceptibility to <e1>Warfarin-induced</e1> <e2>artery calcification</e2> could be related to higher serum phosphate levels .
D014859_D061205 CID The second set of experiments examined the possible synergy between vitamin D and <e1>Warfarin</e1> in <e2>artery calcification</e2> .
D014859_D061205 CID High doses of the vitamin K antagonist <e1>Warfarin</e1> are also known to cause <e2>calcification of the artery</e2> media , but at treatment times of 2 weeks or longer yet not at 1 week .
D014859_D061205 CID High levels of matrix Gla protein are found at sites of <e2>artery calcification</e2> in rats treated with vitamin D plus <e1>Warfarin</e1> , and chemical analysis showed that the protein that accumulated was indeed not gamma-carboxylated .
D014807_D061205 NONE Warfarin-induced <e2>artery calcification</e2> is accelerated by growth and <e1>vitamin D.</e1>
D014807_D061205 NONE The present studies demonstrate that growth and <e1>vitamin D</e1> treatment enhance the extent of <e2>artery calcification</e2> in rats given sufficient doses of Warfarin to inhibit gamma-carboxylation of matrix Gla protein , a calcification inhibitor known to be expressed by smooth muscle cells and macrophages in the artery wall .
D014807_D061205 NONE The second set of experiments examined the possible synergy between <e1>vitamin D</e1> and Warfarin in <e2>artery calcification</e2> .
D014807_D061205 NONE High doses of <e1>vitamin D</e1> are known to cause <e2>calcification of the artery</e2> media in as little as 3 to 4 days .
D014807_D061205 NONE There was a close parallel between the effect of <e1>vitamin D</e1> dose on <e2>artery calcification</e2> and the effect of vitamin D dose on the elevation of serum calcium , which suggests that vitamin D may induce artery calcification through its effect on serum calcium .
D014807_D061205 NONE There was a close parallel between the effect of <e1>vitamin D</e1> dose on artery calcification and the effect of vitamin D dose on the elevation of serum calcium , which suggests that vitamin D may induce <e2>artery calcification</e2> through its effect on serum calcium .
D014807_D061205 NONE There was a close parallel between the effect of vitamin D dose on <e2>artery calcification</e2> and the effect of <e1>vitamin D</e1> dose on the elevation of serum calcium , which suggests that vitamin D may induce artery calcification through its effect on serum calcium .
D014807_D061205 NONE There was a close parallel between the effect of vitamin D dose on artery calcification and the effect of <e1>vitamin D</e1> dose on the elevation of serum calcium , which suggests that vitamin D may induce <e2>artery calcification</e2> through its effect on serum calcium .
D014807_D061205 NONE There was a close parallel between the effect of vitamin D dose on <e2>artery calcification</e2> and the effect of vitamin D dose on the elevation of serum calcium , which suggests that <e1>vitamin D</e1> may induce artery calcification through its effect on serum calcium .
D014807_D061205 NONE There was a close parallel between the effect of vitamin D dose on artery calcification and the effect of vitamin D dose on the elevation of serum calcium , which suggests that <e1>vitamin D</e1> may induce <e2>artery calcification</e2> through its effect on serum calcium .
D014807_D061205 NONE High levels of matrix Gla protein are found at sites of <e2>artery calcification</e2> in rats treated with <e1>vitamin D</e1> plus Warfarin , and chemical analysis showed that the protein that accumulated was indeed not gamma-carboxylated .
D014807_D002114 NONE The present studies demonstrate that growth and <e1>vitamin D</e1> treatment enhance the extent of artery calcification in rats given sufficient doses of Warfarin to inhibit gamma-carboxylation of matrix Gla protein , a <e2>calcification</e2> inhibitor known to be expressed by smooth muscle cells and macrophages in the artery wall .
D014807_D002114 NONE In the current study , we investigated the synergy between these 2 treatments and found that concurrent Warfarin administration dramatically increased the extent of <e2>calcification</e2> in the media of <e1>vitamin D-treated</e1> rats at 3 and 4 days .
D014807_D002114 NONE Because Warfarin treatment had no effect on the elevation in serum calcium produced by <e1>vitamin D</e1> , the synergy between Warfarin and vitamin D is probably best explained by the hypothesis that Warfarin inhibits the activity of matrix Gla protein as a <e2>calcification</e2> inhibitor .
D014807_D002114 NONE Because Warfarin treatment had no effect on the elevation in serum calcium produced by vitamin D , the synergy between Warfarin and <e1>vitamin D</e1> is probably best explained by the hypothesis that Warfarin inhibits the activity of matrix Gla protein as a <e2>calcification</e2> inhibitor .
D014859_D002114 NONE The present studies demonstrate that growth and vitamin D treatment enhance the extent of artery calcification in rats given sufficient doses of <e1>Warfarin</e1> to inhibit gamma-carboxylation of matrix Gla protein , a <e2>calcification</e2> inhibitor known to be expressed by smooth muscle cells and macrophages in the artery wall .
D014859_D002114 NONE Treatment for 2 weeks with <e1>Warfarin</e1> caused massive focal calcification of the artery media in 20-day-old rats and less extensive focal <e2>calcification</e2> in 42-day-old rats .
D014859_D002114 NONE In the current study , we investigated the synergy between these 2 treatments and found that concurrent <e1>Warfarin</e1> administration dramatically increased the extent of <e2>calcification</e2> in the media of vitamin D-treated rats at 3 and 4 days .
D014859_D002114 NONE Because <e1>Warfarin</e1> treatment had no effect on the elevation in serum calcium produced by vitamin D , the synergy between Warfarin and vitamin D is probably best explained by the hypothesis that Warfarin inhibits the activity of matrix Gla protein as a <e2>calcification</e2> inhibitor .
D014859_D002114 NONE Because Warfarin treatment had no effect on the elevation in serum calcium produced by vitamin D , the synergy between <e1>Warfarin</e1> and vitamin D is probably best explained by the hypothesis that Warfarin inhibits the activity of matrix Gla protein as a <e2>calcification</e2> inhibitor .
D014859_D002114 NONE Because Warfarin treatment had no effect on the elevation in serum calcium produced by vitamin D , the synergy between Warfarin and vitamin D is probably best explained by the hypothesis that <e1>Warfarin</e1> inhibits the activity of matrix Gla protein as a <e2>calcification</e2> inhibitor .
D010710_D061205 NONE Although the explanation for the association between <e2>artery calcification</e2> and growth status can not be determined from the present study , there was a relationship between higher serum <e1>phosphate</e1> and susceptibility to artery calcification , with 30 % higher levels of serum phosphate in young , ad libitum-fed rats compared with either of the groups that was resistant to Warfarin-induced artery calcification , ie , the 10-month-old rats and the restricted-diet , growth-inhibited young rats .
D010710_D061205 NONE Although the explanation for the association between artery calcification and growth status can not be determined from the present study , there was a relationship between higher serum <e1>phosphate</e1> and susceptibility to <e2>artery calcification</e2> , with 30 % higher levels of serum phosphate in young , ad libitum-fed rats compared with either of the groups that was resistant to Warfarin-induced artery calcification , ie , the 10-month-old rats and the restricted-diet , growth-inhibited young rats .
D010710_D061205 NONE Although the explanation for the association between artery calcification and growth status can not be determined from the present study , there was a relationship between higher serum <e1>phosphate</e1> and susceptibility to artery calcification , with 30 % higher levels of serum phosphate in young , ad libitum-fed rats compared with either of the groups that was resistant to Warfarin-induced <e2>artery calcification</e2> , ie , the 10-month-old rats and the restricted-diet , growth-inhibited young rats .
D010710_D061205 NONE Although the explanation for the association between <e2>artery calcification</e2> and growth status can not be determined from the present study , there was a relationship between higher serum phosphate and susceptibility to artery calcification , with 30 % higher levels of serum <e1>phosphate</e1> in young , ad libitum-fed rats compared with either of the groups that was resistant to Warfarin-induced artery calcification , ie , the 10-month-old rats and the restricted-diet , growth-inhibited young rats .
D010710_D061205 NONE Although the explanation for the association between artery calcification and growth status can not be determined from the present study , there was a relationship between higher serum phosphate and susceptibility to <e2>artery calcification</e2> , with 30 % higher levels of serum <e1>phosphate</e1> in young , ad libitum-fed rats compared with either of the groups that was resistant to Warfarin-induced artery calcification , ie , the 10-month-old rats and the restricted-diet , growth-inhibited young rats .
D010710_D061205 NONE Although the explanation for the association between artery calcification and growth status can not be determined from the present study , there was a relationship between higher serum phosphate and susceptibility to artery calcification , with 30 % higher levels of serum <e1>phosphate</e1> in young , ad libitum-fed rats compared with either of the groups that was resistant to Warfarin-induced <e2>artery calcification</e2> , ie , the 10-month-old rats and the restricted-diet , growth-inhibited young rats .
D010710_D061205 NONE This observation suggests that increased susceptibility to Warfarin-induced <e2>artery calcification</e2> could be related to higher serum <e1>phosphate</e1> levels .
D014812_D061205 NONE High doses of the <e1>vitamin K</e1> antagonist Warfarin are also known to cause <e2>calcification of the artery</e2> media , but at treatment times of 2 weeks or longer yet not at 1 week .
D002118_D061205 NONE There was a close parallel between the effect of vitamin D dose on <e2>artery calcification</e2> and the effect of vitamin D dose on the elevation of serum <e1>calcium</e1> , which suggests that vitamin D may induce artery calcification through its effect on serum calcium .
D002118_D061205 NONE There was a close parallel between the effect of vitamin D dose on artery calcification and the effect of vitamin D dose on the elevation of serum <e1>calcium</e1> , which suggests that vitamin D may induce <e2>artery calcification</e2> through its effect on serum calcium .
D002118_D061205 NONE There was a close parallel between the effect of vitamin D dose on <e2>artery calcification</e2> and the effect of vitamin D dose on the elevation of serum calcium , which suggests that vitamin D may induce artery calcification through its effect on serum <e1>calcium</e1> .
D002118_D061205 NONE There was a close parallel between the effect of vitamin D dose on artery calcification and the effect of vitamin D dose on the elevation of serum calcium , which suggests that vitamin D may induce <e2>artery calcification</e2> through its effect on serum <e1>calcium</e1> .
D002118_D002114 NONE Because Warfarin treatment had no effect on the elevation in serum <e1>calcium</e1> produced by vitamin D , the synergy between Warfarin and vitamin D is probably best explained by the hypothesis that Warfarin inhibits the activity of matrix Gla protein as a <e2>calcification</e2> inhibitor .
D015055_D061205 NONE High levels of matrix Gla protein are found at sites of <e2>artery calcification</e2> in rats treated with vitamin D plus Warfarin , and chemical analysis showed that the protein that accumulated was indeed not <e1>gamma-carboxylated</e1> .
D015055_D002114 NONE These observations indicate that although the <e1>gamma-carboxyglutamate</e1> residues of matrix Gla protein are apparently required for its function as a <e2>calcification</e2> inhibitor , they are not required for its accumulation at calcification sites .
D015055_D002114 NONE These observations indicate that although the <e1>gamma-carboxyglutamate</e1> residues of matrix Gla protein are apparently required for its function as a calcification inhibitor , they are not required for its accumulation at <e2>calcification</e2> sites .
18004067
D000431_D017114 NONE <e2>Acute liver failure</e2> in two patients with regular <e1>alcohol</e1> consumption ingesting paracetamol at therapeutic dosage .
D000082_D017114 NONE <e2>Acute liver failure</e2> in two patients with regular alcohol consumption ingesting <e1>paracetamol</e1> at therapeutic dosage .
D000431_D056486 NONE BACKGROUND : The possible role of <e1>alcohol</e1> in the development of <e2>hepatotoxicity</e2> associated with therapeutic doses of paracetamol ( acetaminophen ) is currently debated .
D000082_D056486 CID BACKGROUND : The possible role of alcohol in the development of <e2>hepatotoxicity</e2> associated with therapeutic doses of <e1>paracetamol</e1> ( acetaminophen ) is currently debated .
D000082_D056486 CID BACKGROUND : The possible role of alcohol in the development of <e2>hepatotoxicity</e2> associated with therapeutic doses of paracetamol ( <e1>acetaminophen</e1> ) is currently debated .
D000082_D056486 CID Possible risk factors for the development of <e2>hepatotoxicity</e2> in patients treated with therapeutic doses of <e1>paracetamol</e1> are discussed .
D000431_D017093 NONE CASE REPORT : We describe 2 patients who were regular consumers of <e1>alcohol</e1> and who developed <e2>liver failure</e2> within 3 - 5 days after hospitalization and stopping alcohol consumption while being treated with 4 g paracetamol/day .
D000431_D017093 NONE CASE REPORT : We describe 2 patients who were regular consumers of alcohol and who developed <e2>liver failure</e2> within 3 - 5 days after hospitalization and stopping <e1>alcohol</e1> consumption while being treated with 4 g paracetamol/day .
D000431_D017093 NONE CONCLUSION : In patients with risk factors , e.g. regular consumption of <e1>alcohol</e1> , <e2>liver failure</e2> is possible when therapeutic doses are ingested .
D000082_D017093 CID CASE REPORT : We describe 2 patients who were regular consumers of alcohol and who developed <e2>liver failure</e2> within 3 - 5 days after hospitalization and stopping alcohol consumption while being treated with 4 g <e1>paracetamol/day</e1> .
17439425
D019820_D006973 NONE Role of <e1>xanthine</e1> oxidase in dexamethasone-induced <e2>hypertension</e2> in rats .
D019820_D006973 NONE 2 . We studied the role of <e1>xanthine</e1> oxidase ( XO ) , which is implicated in the production of reactive oxygen species , in dexamethasone-induced <e2>hypertension</e2> ( dex-HT ) .
D019820_D006973 NONE 2 . We studied the role of <e1>xanthine</e1> oxidase ( XO ) , which is implicated in the production of reactive oxygen species , in dexamethasone-induced hypertension ( <e2>dex-HT</e2> ) .
D003907_D006973 CID Role of xanthine oxidase in <e1>dexamethasone-induced</e1> <e2>hypertension</e2> in rats .
D003907_D006973 CID 2 . We studied the role of xanthine oxidase ( XO ) , which is implicated in the production of reactive oxygen species , in <e1>dexamethasone-induced</e1> <e2>hypertension</e2> ( dex-HT ) .
D003907_D006973 CID 2 . We studied the role of xanthine oxidase ( XO ) , which is implicated in the production of reactive oxygen species , in <e1>dexamethasone-induced</e1> hypertension ( <e2>dex-HT</e2> ) .
D003907_D006973 CID 2 . We studied the role of xanthine oxidase ( XO ) , which is implicated in the production of reactive oxygen species , in dexamethasone-induced <e2>hypertension</e2> ( <e1>dex-HT</e1> ) .
D003907_D006973 CID 2 . We studied the role of xanthine oxidase ( XO ) , which is implicated in the production of reactive oxygen species , in dexamethasone-induced hypertension ( <e2><e1>dex-HT</e1></e2> ) .
D003907_D006973 CID <e1>Dex</e1> <e2>increased SBP</e2> ( 110 +/- 2 - 126 +/- 3 mmHg ; P < 0.001 ) and decreased thymus ( P < 0.001 ) and bodyweights ( P " < 0.01 ) .
D003907_D006973 CID 6 . Allopurinol did not prevent <e2><e1>dex-HT</e1></e2> .
D009569_D006973 NONE 1 . Glucocorticoid-induced <e2>hypertension</e2> ( GC-HT ) in the rat is associated with <e1>nitric oxide-redox</e1> imbalance .
D009569_D006973 NONE 1 . Glucocorticoid-induced hypertension ( <e2>GC-HT</e2> ) in the rat is associated with <e1>nitric oxide-redox</e1> imbalance .
D003907_D015431 CID <e1>Dex</e1> increased SBP ( 110 +/- 2 - 126 +/- 3 mmHg ; P < 0.001 ) and <e2>decreased thymus ( P < 0.001 ) and bodyweights</e2> ( P " < 0.01 ) .
D000493_D006973 NONE 6 . <e1>Allopurinol</e1> did not prevent <e2>dex-HT</e2> .
D000493_D006973 NONE This , together with our previous findings that <e1>allopurinol</e1> failed to prevent adrenocorticotrophic hormone induced <e2>hypertension</e2> , suggests that XO activity is not a major determinant of GC-HT in the rat .
D000493_D006973 NONE This , together with our previous findings that <e1>allopurinol</e1> failed to prevent adrenocorticotrophic hormone induced hypertension , suggests that XO activity is not a major determinant of <e2>GC-HT</e2> in the rat .
18996674
D004837_D011317 NONE Intracavernous <e1>epinephrine</e1> : a minimally invasive treatment for <e2>priapism</e2> in the emergency department .
D003042_D011317 CID A 45-year-old man , an admitted frequent <e1>cocaine</e1> user , presented to the Emergency Department ( ED ) on two separate occasions with a history of <e2>priapism</e2> after cocaine use .
D003042_D011317 CID A 45-year-old man , an admitted frequent cocaine user , presented to the Emergency Department ( ED ) on two separate occasions with a history of <e2>priapism</e2> after <e1>cocaine</e1> use .
9653867
D013974_D013971 CID <e1>Thyroxine</e1> abuse : an unusual case of <e2>thyrotoxicosis</e2> in pregnancy .
D013974_D013971 CID In particular it illustrates the derangements of thyroid function seen in pregnant women with eating disorders and reminds us that when a cause for <e2>thyrotoxicosis</e2> remains obscure , <e1>thyroxine</e1> abuse should be considered and explored .
D013974_D001068 NONE In particular it illustrates the derangements of thyroid function seen in pregnant women with <e2>eating disorders</e2> and reminds us that when a cause for thyrotoxicosis remains obscure , <e1>thyroxine</e1> abuse should be considered and explored .
2348231
D010431_D006940 NONE <e1>Pentoxifylline</e1> ( Trental ) does not inhibit dipyridamole-induced coronary <e2>hyperemia</e2> : implications for dipyridamole-thallium-201 myocardial imaging .
D010431_D006940 NONE Pentoxifylline ( <e1>Trental</e1> ) does not inhibit dipyridamole-induced coronary <e2>hyperemia</e2> : implications for dipyridamole-thallium-201 myocardial imaging .
D010431_D006940 NONE Whether <e1>pentoxifylline</e1> inhibits dipyridamole-induced coronary <e2>hyperemia</e2> like other methylxanthines such as theophylline and should be stopped prior to dipyridamole-thallium-201 imaging is unknown .
D010431_D006940 NONE Neither dose of <e1>pentoxifylline</e1> significantly decreased the dipyridamole-induced <e2>hyperemia</e2> , while peak coronary blood flow was significantly lower after theophylline ( p less than 0.01 ) .
D010431_D006940 NONE We conclude that <e1>pentoxyifylline</e1> does not inhibit dipyridamole-induced coronary <e2>hyperemia</e2> even at high doses .
D004176_D006940 CID Pentoxifylline ( Trental ) does not inhibit <e1>dipyridamole-induced</e1> coronary <e2>hyperemia</e2> : implications for dipyridamole-thallium-201 myocardial imaging .
D004176_D006940 CID Pentoxifylline ( Trental ) does not inhibit dipyridamole-induced coronary <e2>hyperemia</e2> : implications for <e1>dipyridamole-thallium-201</e1> myocardial imaging .
D004176_D006940 CID Whether pentoxifylline inhibits <e1>dipyridamole-induced</e1> coronary <e2>hyperemia</e2> like other methylxanthines such as theophylline and should be stopped prior to dipyridamole-thallium-201 imaging is unknown .
D004176_D006940 CID Whether pentoxifylline inhibits dipyridamole-induced coronary <e2>hyperemia</e2> like other methylxanthines such as theophylline and should be stopped prior to <e1>dipyridamole-thallium-201</e1> imaging is unknown .
D004176_D006940 CID Neither dose of pentoxifylline significantly decreased the <e1>dipyridamole-induced</e1> <e2>hyperemia</e2> , while peak coronary blood flow was significantly lower after theophylline ( p less than 0.01 ) .
D004176_D006940 CID We conclude that pentoxyifylline does not inhibit <e1>dipyridamole-induced</e1> coronary <e2>hyperemia</e2> even at high doses .
D013793_D006940 NONE Pentoxifylline ( Trental ) does not inhibit dipyridamole-induced coronary <e2>hyperemia</e2> : implications for <e1>dipyridamole-thallium-201</e1> myocardial imaging .
D013793_D006940 NONE Whether pentoxifylline inhibits dipyridamole-induced coronary <e2>hyperemia</e2> like other methylxanthines such as theophylline and should be stopped prior to <e1>dipyridamole-thallium-201</e1> imaging is unknown .
D004176_D016491 NONE <e1>Dipyridamole-thallium-201</e1> imaging is often performed in patients unable to exercise because of <e2>peripheral vascular disease</e2> .
D013793_D016491 NONE <e1>Dipyridamole-thallium-201</e1> imaging is often performed in patients unable to exercise because of <e2>peripheral vascular disease</e2> .
D010431_D007383 CID Many of these patients are taking <e1>pentoxifylline</e1> ( Trental ) , a methylxanthine derivative which may improve <e2>intermittent claudication</e2> .
D010431_D007383 CID Many of these patients are taking pentoxifylline ( <e1>Trental</e1> ) , a methylxanthine derivative which may improve <e2>intermittent claudication</e2> .
C008514_D007383 NONE Many of these patients are taking pentoxifylline ( Trental ) , a <e1>methylxanthine</e1> derivative which may improve <e2>intermittent claudication</e2> .
C008514_D006940 NONE Whether pentoxifylline inhibits dipyridamole-induced coronary <e2>hyperemia</e2> like other <e1>methylxanthines</e1> such as theophylline and should be stopped prior to dipyridamole-thallium-201 imaging is unknown .
D013806_D006940 NONE Whether pentoxifylline inhibits dipyridamole-induced coronary <e2>hyperemia</e2> like other methylxanthines such as <e1>theophylline</e1> and should be stopped prior to dipyridamole-thallium-201 imaging is unknown .
D013806_D006940 NONE Neither dose of pentoxifylline significantly decreased the dipyridamole-induced <e2>hyperemia</e2> , while peak coronary blood flow was significantly lower after <e1>theophylline</e1> ( p less than 0.01 ) .
10807237
D003042_D000783 NONE METHODS : A review of admissions during a 6-year period revealed 14 patients with <e1>cocaine-related</e1> <e2>aneurysms</e2> .
D003042_D000783 NONE Hunt and Hess grade ( P < 0.005 ) and age ( P < 0.007 ) were significant predictors of outcome for the patients with <e1>cocaine-related</e1> <e2>aneurysms</e2> .
D003042_D000783 NONE CONCLUSION : <e1>Cocaine</e1> use predisposed aneurysmal rupture at a significantly earlier age and in much smaller <e2>aneurysms</e2> .
D003042_D017542 CID CONCLUSION : <e1>Cocaine</e1> use predisposed <e2>aneurysmal rupture</e2> at a significantly earlier age and in much smaller aneurysms .
3865016
D005047_D054218 NONE A synergistic effect of <e1>etoposide</e1> and cyclosporin A was observed in a patient with <e2>acute T-lymphocytic leukemia</e2> in relapse .
D016572_D054218 NONE A synergistic effect of etoposide and <e1>cyclosporin A</e1> was observed in a patient with <e2>acute T-lymphocytic leukemia</e2> in relapse .
D005047_D017254 NONE The concomitant administration of <e1>etoposide</e1> and cyclosporin A resulted in eradication of hitherto refractory <e2>leukemic infiltration</e2> of bone marrow .
D016572_D017254 NONE The concomitant administration of etoposide and <e1>cyclosporin A</e1> resulted in eradication of hitherto refractory <e2>leukemic infiltration</e2> of bone marrow .
3192036
10791295
D001058_D010554 CID Development of <e1>apomorphine-induced</e1> <e2>aggressive behavior</e2> : comparison of adult male and female Wistar rats .
D001058_D010554 CID The development of <e1>apomorphine-induced</e1> ( 1.0 mg/kg s.c. once daily ) <e2>aggressive behavior</e2> of adult male and female Wistar rats obtained from the same breeder was studied in two consecutive sets .
D001058_D010554 CID In male animals , repeated <e1>apomorphine</e1> treatment induced a gradual development of <e2>aggressive behavior</e2> as evidenced by the increased intensity of aggressiveness and shortened latency before the first attack toward the opponent .
D001058_D010554 CID In male animals , repeated <e1>apomorphine</e1> treatment induced a gradual development of aggressive behavior as evidenced by the increased intensity of <e2>aggressiveness</e2> and shortened latency before the first attack toward the opponent .
D001058_D010554 CID In conclusion , the present study demonstrates gender differences in the development of the <e1>apomorphine-induced</e1> <e2>aggressive behavior</e2> and indicates that the female rats do not fill the validation criteria for use in this method .
1992636
D009853_D000743 CID <e2>Hemolytic anemia</e2> associated with the use of <e1>omeprazole</e1> .
D009853_D000743 CID We report the first case of a serious short-term adverse reaction with the use of <e1>omeprazole</e1> : <e2>hemolytic anemia</e2> .
D009853_D000743 CID The mechanism by which <e1>omeprazole</e1> caused the patient 's <e2>hemolytic anemia</e2> is uncertain , but physicians should be alerted to this possible adverse effect .
D009853_D053609 CID The patient developed weakness , <e2>lethargy</e2> , and shortness of breath 2 days after starting therapy with <e1>omeprazole</e1> .
D009853_D004417 CID The patient developed weakness , lethargy , and <e2>shortness of breath</e2> 2 days after starting therapy with <e1>omeprazole</e1> .
9660111
D014299_D007035 NONE In the acute experiment <e1>TRI</e1> ( given i.p. ) does not antagonize the reserpine <e2>hypothermia</e2> in mice and does not potentiate the 5-hydroxytryptophan head twitches in rats .
D012110_D007035 CID In the acute experiment TRI ( given i.p. ) does not antagonize the <e1>reserpine</e1> <e2>hypothermia</e2> in mice and does not potentiate the 5-hydroxytryptophan head twitches in rats .
D006916_D007035 NONE In the acute experiment TRI ( given i.p. ) does not antagonize the reserpine <e2>hypothermia</e2> in mice and does not potentiate the <e1>5-hydroxytryptophan</e1> head twitches in rats .
D014299_D006948 CID <e1>TRI</e1> given repeatedly to rats increases the locomotor <e2>hyperactivity</e2> induced by d-amphetamine , quinpirole and (+)-7-hydroxy-dipropyloaminotetralin ( dopamine D2 and D3 effects ) .
D003913_D006948 CID TRI given repeatedly to rats increases the locomotor <e2>hyperactivity</e2> induced by <e1>d-amphetamine</e1> , quinpirole and (+)-7-hydroxy-dipropyloaminotetralin ( dopamine D2 and D3 effects ) .
D019257_D006948 CID TRI given repeatedly to rats increases the locomotor <e2>hyperactivity</e2> induced by d-amphetamine , <e1>quinpirole</e1> and (+)-7-hydroxy-dipropyloaminotetralin ( dopamine D2 and D3 effects ) .
D004298_D006948 NONE TRI given repeatedly to rats increases the locomotor <e2>hyperactivity</e2> induced by d-amphetamine , quinpirole and (+)-7-hydroxy-dipropyloaminotetralin ( <e1>dopamine</e1> D2 and D3 effects ) .
D010656_D010554 NONE It increases the behaviour stimulation evoked by <e1>phenylephrine</e1> ( given intraventricularly ) in rats , evaluated in the open field test as well as the <e2>aggressiveness</e2> evoked by clonidine in mice , both these effects being mediated by an alpha1-adrenergic receptor .
D003000_D010554 NONE It increases the behaviour stimulation evoked by phenylephrine ( given intraventricularly ) in rats , evaluated in the open field test as well as the <e2>aggressiveness</e2> evoked by <e1>clonidine</e1> in mice , both these effects being mediated by an alpha1-adrenergic receptor .
19211690
D013739_D006973 NONE <e1>Testosterone-dependent</e1> <e2>hypertension</e2> and upregulation of intrarenal angiotensinogen in Dahl salt-sensitive rats .
D013739_D006973 NONE <e1>Testosterone</e1> contributes to the development of <e2>hypertension</e2> and renal injury in male DS rats on HS diet possibly through upregulation of the intrarenal renin-angiotensin system .
D017673_D006973 NONE Testosterone-dependent <e2>hypertension</e2> and upregulation of intrarenal angiotensinogen in Dahl <e1>salt-sensitive</e1> rats .
D013739_D007674 NONE In this study , the hypothesis was tested that there is a sexual dimorphism in HS-induced upregulation of intrarenal angiotensinogen mediated by <e1>testosterone</e1> that also causes increases in BP and <e2>renal injury</e2> .
D013739_D007674 NONE <e1>Testosterone</e1> replacement in castrated DS rats increased BP , <e2>renal injury</e2> , and upregulation of renal angiotensinogen associated with HS diet .
D013739_D007674 NONE <e1>Testosterone</e1> contributes to the development of hypertension and <e2>renal injury</e2> in male DS rats on HS diet possibly through upregulation of the intrarenal renin-angiotensin system .
D000809_D006973 NONE Testosterone contributes to the development of <e2>hypertension</e2> and renal injury in male DS rats on HS diet possibly through upregulation of the intrarenal <e1>renin-angiotensin</e1> system .
D000809_D007674 NONE Testosterone contributes to the development of hypertension and <e2>renal injury</e2> in male DS rats on HS diet possibly through upregulation of the intrarenal <e1>renin-angiotensin</e1> system .
18410508
D008694_D020258 NONE <e1>Methamphetamine-induced</e1> <e2>neurotoxicity</e2> and microglial activation are not mediated by fractalkine receptor signaling .
D008694_D020258 NONE Because the CNS damage caused by <e1>METH</e1> and MPTP is highly selective for the DA neuronal system in mouse models of <e2>neurotoxicity</e2> , we hypothesized that the CX3CR1 plays a role in METH-induced neurotoxicity and microglial activation .
D008694_D020258 NONE Because the CNS damage caused by <e1>METH</e1> and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity , we hypothesized that the CX3CR1 plays a role in METH-induced <e2>neurotoxicity</e2> and microglial activation .
D008694_D020258 NONE Because the CNS damage caused by METH and MPTP is highly selective for the DA neuronal system in mouse models of <e2>neurotoxicity</e2> , we hypothesized that the CX3CR1 plays a role in <e1>METH-induced</e1> neurotoxicity and microglial activation .
D008694_D020258 NONE Because the CNS damage caused by METH and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity , we hypothesized that the CX3CR1 plays a role in <e1>METH-induced</e1> <e2>neurotoxicity</e2> and microglial activation .
D008694_D020258 NONE Mice in which the CX3CR1 gene has been deleted and replaced with a cDNA encoding enhanced green fluorescent protein ( eGFP ) were treated with <e1>METH</e1> and examined for striatal <e2>neurotoxicity</e2> .
D008694_D020258 NONE We conclude from these studies that CX3CR1 signaling does not modulate <e1>METH</e1> <e2>neurotoxicity</e2> or microglial activation .
D015632_D009422 CID 9 ( 2006 ) , 917 ] recently identified the microglial-specific fractalkine receptor ( CX3CR1 ) as an important mediator of <e1>MPTP-induced</e1> <e2>neurodegeneration</e2> of DA neurons .
D015632_D009422 CID Because the <e2>CNS damage</e2> caused by METH and <e1>MPTP</e1> is highly selective for the DA neuronal system in mouse models of neurotoxicity , we hypothesized that the CX3CR1 plays a role in METH-induced neurotoxicity and microglial activation .
D004298_D009422 NONE 9 ( 2006 ) , 917 ] recently identified the microglial-specific fractalkine receptor ( CX3CR1 ) as an important mediator of MPTP-induced <e2>neurodegeneration</e2> of <e1>DA</e1> neurons .
D004298_D009422 NONE Because the <e2>CNS damage</e2> caused by METH and MPTP is highly selective for the <e1>DA</e1> neuronal system in mouse models of neurotoxicity , we hypothesized that the CX3CR1 plays a role in METH-induced neurotoxicity and microglial activation .
D008694_D009422 CID Because the <e2>CNS damage</e2> caused by <e1>METH</e1> and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity , we hypothesized that the CX3CR1 plays a role in METH-induced neurotoxicity and microglial activation .
D008694_D009422 CID Because the <e2>CNS damage</e2> caused by METH and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity , we hypothesized that the CX3CR1 plays a role in <e1>METH-induced</e1> neurotoxicity and microglial activation .
D015632_D020258 NONE Because the CNS damage caused by METH and <e1>MPTP</e1> is highly selective for the DA neuronal system in mouse models of <e2>neurotoxicity</e2> , we hypothesized that the CX3CR1 plays a role in METH-induced neurotoxicity and microglial activation .
D015632_D020258 NONE Because the CNS damage caused by METH and <e1>MPTP</e1> is highly selective for the DA neuronal system in mouse models of neurotoxicity , we hypothesized that the CX3CR1 plays a role in METH-induced <e2>neurotoxicity</e2> and microglial activation .
D004298_D020258 NONE Because the CNS damage caused by METH and MPTP is highly selective for the <e1>DA</e1> neuronal system in mouse models of <e2>neurotoxicity</e2> , we hypothesized that the CX3CR1 plays a role in METH-induced neurotoxicity and microglial activation .
D004298_D020258 NONE Because the CNS damage caused by METH and MPTP is highly selective for the <e1>DA</e1> neuronal system in mouse models of neurotoxicity , we hypothesized that the CX3CR1 plays a role in METH-induced <e2>neurotoxicity</e2> and microglial activation .
10743446
D007649_D006930 NONE Differential effects of systemically administered <e1>ketamine</e1> and lidocaine on dynamic and static <e2>hyperalgesia</e2> induced by intradermal capsaicin in humans .
D007649_D006930 NONE We have examined the effect of systemic administration of <e1>ketamine</e1> and lidocaine on brush-evoked ( dynamic ) pain and punctate-evoked ( static ) <e2>hyperalgesia</e2> induced by capsaicin .
D007649_D006930 NONE <e1>Ketamine</e1> reduced both the area of brush-evoked and punctate-evoked <e2>hyperalgesia</e2> significantly and it tended to reduce brush-evoked pain .
D007649_D006930 NONE The differential effects of <e1>ketamine</e1> and lidocaine on static and dynamic <e2>hyperalgesia</e2> suggest that the two types of hyperalgesia are mediated by separate mechanisms and have a distinct pharmacology .
D007649_D006930 NONE The differential effects of <e1>ketamine</e1> and lidocaine on static and dynamic hyperalgesia suggest that the two types of <e2>hyperalgesia</e2> are mediated by separate mechanisms and have a distinct pharmacology .
D008012_D006930 NONE Differential effects of systemically administered ketamine and <e1>lidocaine</e1> on dynamic and static <e2>hyperalgesia</e2> induced by intradermal capsaicin in humans .
D008012_D006930 NONE We have examined the effect of systemic administration of ketamine and <e1>lidocaine</e1> on brush-evoked ( dynamic ) pain and punctate-evoked ( static ) <e2>hyperalgesia</e2> induced by capsaicin .
D008012_D006930 NONE <e1>Lidocaine</e1> reduced the area of punctate-evoked <e2>hyperalgesia</e2> significantly .
D008012_D006930 NONE The differential effects of ketamine and <e1>lidocaine</e1> on static and dynamic <e2>hyperalgesia</e2> suggest that the two types of hyperalgesia are mediated by separate mechanisms and have a distinct pharmacology .
D008012_D006930 NONE The differential effects of ketamine and <e1>lidocaine</e1> on static and dynamic hyperalgesia suggest that the two types of <e2>hyperalgesia</e2> are mediated by separate mechanisms and have a distinct pharmacology .
D002211_D006930 CID Differential effects of systemically administered ketamine and lidocaine on dynamic and static <e2>hyperalgesia</e2> induced by intradermal <e1>capsaicin</e1> in humans .
D002211_D006930 CID We have examined the effect of systemic administration of ketamine and lidocaine on brush-evoked ( dynamic ) pain and punctate-evoked ( static ) <e2>hyperalgesia</e2> induced by <e1>capsaicin</e1> .
D007649_D010146 NONE We have examined the effect of systemic administration of <e1>ketamine</e1> and lidocaine on brush-evoked ( dynamic ) <e2>pain</e2> and punctate-evoked ( static ) hyperalgesia induced by capsaicin .
D007649_D010146 NONE <e1>Ketamine</e1> reduced both the area of brush-evoked and punctate-evoked hyperalgesia significantly and it tended to reduce brush-evoked <e2>pain</e2> .
D008012_D010146 NONE We have examined the effect of systemic administration of ketamine and <e1>lidocaine</e1> on brush-evoked ( dynamic ) <e2>pain</e2> and punctate-evoked ( static ) hyperalgesia induced by capsaicin .
D002211_D010146 CID We have examined the effect of systemic administration of ketamine and lidocaine on brush-evoked ( dynamic ) <e2>pain</e2> and punctate-evoked ( static ) hyperalgesia induced by <e1>capsaicin</e1> .
18442015
D014700_D006471 NONE Protective effect of <e1>verapamil</e1> on <e2>gastric hemorrhagic</e2> ulcers in severe atherosclerotic rats .
D014700_D006471 NONE This <e2>hemorrhagic</e2> ulcer and various ulcerogenic parameters were dose-dependently ameliorated by daily intragastric <e1>verapamil</e1> .
D014700_D006471 NONE Atherosclerosis could produce <e2>gastric hemorrhagic</e2> ulcer via aggravation of gastric acid back-diffusion , LPO generation , histamine release and microvascular permeability that could be ameliorated by <e1>verapamil</e1> in rats .
D014700_D014456 NONE Protective effect of <e1>verapamil</e1> on gastric hemorrhagic <e2>ulcers</e2> in severe atherosclerotic rats .
D014700_D014456 NONE Additionally , the protective effect of <e1>verapamil</e1> on this <e2>ulcer</e2> model was evaluated .
D014700_D014456 NONE This hemorrhagic <e2>ulcer</e2> and various ulcerogenic parameters were dose-dependently ameliorated by daily intragastric <e1>verapamil</e1> .
D014700_D014456 NONE Atherosclerosis could produce gastric hemorrhagic <e2>ulcer</e2> via aggravation of gastric acid back-diffusion , LPO generation , histamine release and microvascular permeability that could be ameliorated by <e1>verapamil</e1> in rats .
D014700_D050197 NONE Protective effect of <e1>verapamil</e1> on gastric hemorrhagic ulcers in severe <e2>atherosclerotic</e2> rats .
D014700_D050197 NONE <e2>Atherosclerosis</e2> could produce gastric hemorrhagic ulcer via aggravation of gastric acid back-diffusion , LPO generation , histamine release and microvascular permeability that could be ameliorated by <e1>verapamil</e1> in rats .
D006632_D006471 NONE The aim of this study is to examine the role of gastric acid back-diffusion , mast cell <e1>histamine</e1> release , lipid peroxide ( LPO ) generation and mucosal microvascular permeability in modulating <e2>gastric hemorrhage</e2> and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol .
D006632_D006471 NONE Moreover , a positive correlation of <e1>histamine</e1> to <e2>gastric hemorrhage</e2> and to ulcer was found in those atherosclerotic rats .
D006632_D006471 NONE Atherosclerosis could produce <e2>gastric hemorrhagic</e2> ulcer via aggravation of gastric acid back-diffusion , LPO generation , <e1>histamine</e1> release and microvascular permeability that could be ameliorated by verapamil in rats .
D006632_D014456 NONE The aim of this study is to examine the role of gastric acid back-diffusion , mast cell <e1>histamine</e1> release , lipid peroxide ( LPO ) generation and mucosal microvascular permeability in modulating gastric hemorrhage and <e2>ulcer</e2> in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol .
D006632_D014456 NONE Gastric acid back-diffusion , mucosal LPO generation , <e1>histamine</e1> concentration , microvascular permeability , luminal hemoglobin content and <e2>ulcer</e2> areas were determined .
D006632_D014456 NONE Severe gastric <e2>ulcers</e2> accompanied with increased ulcerogenic factors , including gastric acid back-diffusion , <e1>histamine</e1> release , LPO generation and luminal hemoglobin content were also observed in these rats .
D006632_D014456 NONE Moreover , a positive correlation of <e1>histamine</e1> to gastric hemorrhage and to <e2>ulcer</e2> was found in those atherosclerotic rats .
D006632_D014456 NONE Atherosclerosis could produce gastric hemorrhagic <e2>ulcer</e2> via aggravation of gastric acid back-diffusion , LPO generation , <e1>histamine</e1> release and microvascular permeability that could be ameliorated by verapamil in rats .
D006632_D050197 NONE The aim of this study is to examine the role of gastric acid back-diffusion , mast cell <e1>histamine</e1> release , lipid peroxide ( LPO ) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with <e2>atherosclerosis</e2> induced by coadministration of vitamin D2 and cholesterol .
D006632_D050197 NONE Moreover , a positive correlation of <e1>histamine</e1> to gastric hemorrhage and to ulcer was found in those <e2>atherosclerotic</e2> rats .
D006632_D050197 NONE <e2>Atherosclerosis</e2> could produce gastric hemorrhagic ulcer via aggravation of gastric acid back-diffusion , LPO generation , <e1>histamine</e1> release and microvascular permeability that could be ameliorated by verapamil in rats .
D004872_D006471 CID The aim of this study is to examine the role of gastric acid back-diffusion , mast cell histamine release , lipid peroxide ( LPO ) generation and mucosal microvascular permeability in modulating <e2>gastric hemorrhage</e2> and ulcer in rats with atherosclerosis induced by coadministration of <e1>vitamin D2</e1> and cholesterol .
D004872_D014456 CID The aim of this study is to examine the role of gastric acid back-diffusion , mast cell histamine release , lipid peroxide ( LPO ) generation and mucosal microvascular permeability in modulating gastric hemorrhage and <e2>ulcer</e2> in rats with atherosclerosis induced by coadministration of <e1>vitamin D2</e1> and cholesterol .
D004872_D050197 CID The aim of this study is to examine the role of gastric acid back-diffusion , mast cell histamine release , lipid peroxide ( LPO ) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with <e2>atherosclerosis</e2> induced by coadministration of <e1>vitamin D2</e1> and cholesterol .
D004872_D050197 CID Male Wistar rats were challenged intragastrically once daily for 9 days with 1.0 ml/kg of corn oil containing <e1>vitamin D2</e1> and cholesterol to induce <e2>atherosclerosis</e2> .
D002784_D006471 CID The aim of this study is to examine the role of gastric acid back-diffusion , mast cell histamine release , lipid peroxide ( LPO ) generation and mucosal microvascular permeability in modulating <e2>gastric hemorrhage</e2> and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and <e1>cholesterol</e1> .
D002784_D014456 CID The aim of this study is to examine the role of gastric acid back-diffusion , mast cell histamine release , lipid peroxide ( LPO ) generation and mucosal microvascular permeability in modulating gastric hemorrhage and <e2>ulcer</e2> in rats with atherosclerosis induced by coadministration of vitamin D2 and <e1>cholesterol</e1> .
D002784_D050197 CID The aim of this study is to examine the role of gastric acid back-diffusion , mast cell histamine release , lipid peroxide ( LPO ) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with <e2>atherosclerosis</e2> induced by coadministration of vitamin D2 and <e1>cholesterol</e1> .
D002784_D050197 CID Male Wistar rats were challenged intragastrically once daily for 9 days with 1.0 ml/kg of corn oil containing vitamin D2 and <e1>cholesterol</e1> to induce <e2>atherosclerosis</e2> .
D002784_D050197 CID Elevated <e2>atherosclerotic</e2> parameters , such as serum calcium , total <e1>cholesterol</e1> and low-density lipoprotein concentration were obtained in atherosclerotic rats .
D002784_D050197 CID Elevated atherosclerotic parameters , such as serum calcium , total <e1>cholesterol</e1> and low-density lipoprotein concentration were obtained in <e2>atherosclerotic</e2> rats .
D010634_D014456 NONE Gastric acid back-diffusion , mucosal LPO generation , histamine concentration , microvascular permeability , <e1>luminal</e1> hemoglobin content and <e2>ulcer</e2> areas were determined .
D010634_D014456 NONE Severe gastric <e2>ulcers</e2> accompanied with increased ulcerogenic factors , including gastric acid back-diffusion , histamine release , LPO generation and <e1>luminal</e1> hemoglobin content were also observed in these rats .
D002118_D050197 NONE Elevated <e2>atherosclerotic</e2> parameters , such as serum <e1>calcium</e1> , total cholesterol and low-density lipoprotein concentration were obtained in atherosclerotic rats .
D002118_D050197 NONE Elevated atherosclerotic parameters , such as serum <e1>calcium</e1> , total cholesterol and low-density lipoprotein concentration were obtained in <e2>atherosclerotic</e2> rats .
6286738
D002762_D064420 NONE <e1>Vitamin D3</e1> <e2>toxicity</e2> in dairy cows .
D002762_D064420 NONE Signs of <e1>vitamin D3</e1> <e2>toxicity</e2> were not observed in nonlactating nonpregnant cows ; however , pregnant cows commonly developed severe signs of vitamin D3 toxicity and 10 of 17 cows died .
D002762_D064420 NONE Signs of <e1>vitamin D3</e1> toxicity were not observed in nonlactating nonpregnant cows ; however , pregnant cows commonly developed severe signs of vitamin D3 <e2>toxicity</e2> and 10 of 17 cows died .
D002762_D064420 NONE Signs of vitamin D3 <e2>toxicity</e2> were not observed in nonlactating nonpregnant cows ; however , pregnant cows commonly developed severe signs of <e1>vitamin D3</e1> toxicity and 10 of 17 cows died .
D002762_D064420 NONE Signs of vitamin D3 toxicity were not observed in nonlactating nonpregnant cows ; however , pregnant cows commonly developed severe signs of <e1>vitamin D3</e1> <e2>toxicity</e2> and 10 of 17 cows died .
D002762_D064420 NONE Because of the extreme <e2>toxicity</e2> of <e1>vitamin D3</e1> in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever , we concluded that vitamin D3 can not be used practically to prevent milk fever when injected several weeks prepartum .
D002762_D064420 NONE Because of the extreme <e2>toxicity</e2> of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of <e1>vitamin D3</e1> that prevent milk fever and doses that induce milk fever , we concluded that vitamin D3 can not be used practically to prevent milk fever when injected several weeks prepartum .
D002762_D064420 NONE Because of the extreme <e2>toxicity</e2> of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever , we concluded that <e1>vitamin D3</e1> can not be used practically to prevent milk fever when injected several weeks prepartum .
D002762_D006934 CID Large parenteral doses of <e1>vitamin D3</e1> ( 15 to 17.5 x 10(6 ) IU vitamin D3 ) were associated with prolonged <e2>hypercalcemia</e2> , hyperphosphatemia , and large increases of vitamin D3 and its metabolites in the blood plasma of nonlactating nonpregnant and pregnant Jersey cows .
D002762_D006934 CID Large parenteral doses of vitamin D3 ( 15 to 17.5 x 10(6 ) IU <e1>vitamin D3</e1> ) were associated with prolonged <e2>hypercalcemia</e2> , hyperphosphatemia , and large increases of vitamin D3 and its metabolites in the blood plasma of nonlactating nonpregnant and pregnant Jersey cows .
D002762_D006934 CID Large parenteral doses of vitamin D3 ( 15 to 17.5 x 10(6 ) IU vitamin D3 ) were associated with prolonged <e2>hypercalcemia</e2> , hyperphosphatemia , and large increases of <e1>vitamin D3</e1> and its metabolites in the blood plasma of nonlactating nonpregnant and pregnant Jersey cows .
D002762_D054559 CID Large parenteral doses of <e1>vitamin D3</e1> ( 15 to 17.5 x 10(6 ) IU vitamin D3 ) were associated with prolonged hypercalcemia , <e2>hyperphosphatemia</e2> , and large increases of vitamin D3 and its metabolites in the blood plasma of nonlactating nonpregnant and pregnant Jersey cows .
D002762_D054559 CID Large parenteral doses of vitamin D3 ( 15 to 17.5 x 10(6 ) IU <e1>vitamin D3</e1> ) were associated with prolonged hypercalcemia , <e2>hyperphosphatemia</e2> , and large increases of vitamin D3 and its metabolites in the blood plasma of nonlactating nonpregnant and pregnant Jersey cows .
D002762_D054559 CID Large parenteral doses of vitamin D3 ( 15 to 17.5 x 10(6 ) IU vitamin D3 ) were associated with prolonged hypercalcemia , <e2>hyperphosphatemia</e2> , and large increases of <e1>vitamin D3</e1> and its metabolites in the blood plasma of nonlactating nonpregnant and pregnant Jersey cows .
D002762_D010319 NONE None of the cows treated with <e1>vitamin D3</e1> showed signs of <e2>milk fever</e2> during the peripartal period ; however , 22 % of the control cows developed clinical signs of milk fever during this period .
D002762_D010319 NONE None of the cows treated with <e1>vitamin D3</e1> showed signs of milk fever during the peripartal period ; however , 22 % of the control cows developed clinical signs of <e2>milk fever</e2> during this period .
D002762_D010319 NONE Because of the extreme toxicity of <e1>vitamin D3</e1> in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent <e2>milk fever</e2> and doses that induce milk fever , we concluded that vitamin D3 can not be used practically to prevent milk fever when injected several weeks prepartum .
D002762_D010319 NONE Because of the extreme toxicity of <e1>vitamin D3</e1> in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce <e2>milk fever</e2> , we concluded that vitamin D3 can not be used practically to prevent milk fever when injected several weeks prepartum .
D002762_D010319 NONE Because of the extreme toxicity of <e1>vitamin D3</e1> in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever , we concluded that vitamin D3 can not be used practically to prevent <e2>milk fever</e2> when injected several weeks prepartum .
D002762_D010319 NONE Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of <e1>vitamin D3</e1> that prevent <e2>milk fever</e2> and doses that induce milk fever , we concluded that vitamin D3 can not be used practically to prevent milk fever when injected several weeks prepartum .
D002762_D010319 NONE Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of <e1>vitamin D3</e1> that prevent milk fever and doses that induce <e2>milk fever</e2> , we concluded that vitamin D3 can not be used practically to prevent milk fever when injected several weeks prepartum .
D002762_D010319 NONE Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of <e1>vitamin D3</e1> that prevent milk fever and doses that induce milk fever , we concluded that vitamin D3 can not be used practically to prevent <e2>milk fever</e2> when injected several weeks prepartum .
D002762_D010319 NONE Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent <e2>milk fever</e2> and doses that induce milk fever , we concluded that <e1>vitamin D3</e1> can not be used practically to prevent milk fever when injected several weeks prepartum .
D002762_D010319 NONE Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce <e2>milk fever</e2> , we concluded that <e1>vitamin D3</e1> can not be used practically to prevent milk fever when injected several weeks prepartum .
D002762_D010319 NONE Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever , we concluded that <e1>vitamin D3</e1> can not be used practically to prevent <e2>milk fever</e2> when injected several weeks prepartum .
603022
D005702_D062787 NONE <e1>Galanthamine hydrobromide</e1> , an anticholinesterase drug capable of penetrating the blood-brain barrier , was used in a patient demonstrating central effects of scopolamine ( hyoscine ) <e2>overdosage</e2> .
D012601_D062787 CID Galanthamine hydrobromide , an anticholinesterase drug capable of penetrating the blood-brain barrier , was used in a patient demonstrating central effects of <e1>scopolamine</e1> ( hyoscine ) <e2>overdosage</e2> .
D012601_D062787 CID Galanthamine hydrobromide , an anticholinesterase drug capable of penetrating the blood-brain barrier , was used in a patient demonstrating central effects of scopolamine ( <e1>hyoscine</e1> ) <e2>overdosage</e2> .
1601297
D003042_D009202 NONE Electrocardiographic evidence of <e2>myocardial injury</e2> in psychiatrically hospitalized <e1>cocaine</e1> abusers .
D003042_D009202 NONE Eleven of the <e1>cocaine</e1> abusers and none of the controls had ECG evidence of significant <e2>myocardial injury</e2> defined as myocardial infarction , ischemia , and bundle branch block .
D003042_D012559 NONE The electrocardiograms ( ECG ) of 99 <e1>cocaine-abusing</e1> patients were compared with the ECGs of 50 <e2>schizophrenic</e2> controls .
D003042_D009203 CID Eleven of the <e1>cocaine</e1> abusers and none of the controls had ECG evidence of significant myocardial injury defined as <e2>myocardial infarction</e2> , ischemia , and bundle branch block .
D003042_D007511 NONE Eleven of the <e1>cocaine</e1> abusers and none of the controls had ECG evidence of significant myocardial injury defined as myocardial infarction , <e2>ischemia</e2> , and bundle branch block .
D003042_D002037 CID Eleven of the <e1>cocaine</e1> abusers and none of the controls had ECG evidence of significant myocardial injury defined as myocardial infarction , ischemia , and <e2>bundle branch block</e2> .
8643971
D017239_D006258 NONE A phase I/II study of <e1>paclitaxel</e1> plus cisplatin as first-line therapy for <e2>head and neck cancers</e2> : preliminary results .
D017239_D006258 NONE Preliminary results of an Eastern Cooperative Oncology Group study of single-agent <e1>paclitaxel</e1> ( Taxol ; Bristol-Myers Squibb Company , Princeton , NJ ) reported a 37 % response rate in patients with <e2>head and neck cancer</e2> , and the paclitaxel/cisplatin combination has been used successfully and has significantly improved median response duration in ovarian cancer patients .
D017239_D006258 NONE Preliminary results of an Eastern Cooperative Oncology Group study of single-agent paclitaxel ( <e1>Taxol</e1> ; Bristol-Myers Squibb Company , Princeton , NJ ) reported a 37 % response rate in patients with <e2>head and neck cancer</e2> , and the paclitaxel/cisplatin combination has been used successfully and has significantly improved median response duration in ovarian cancer patients .
D017239_D006258 NONE Preliminary results of an Eastern Cooperative Oncology Group study of single-agent paclitaxel ( Taxol ; Bristol-Myers Squibb Company , Princeton , NJ ) reported a 37 % response rate in patients with <e2>head and neck cancer</e2> , and the <e1>paclitaxel/cisplatin</e1> combination has been used successfully and has significantly improved median response duration in ovarian cancer patients .
D017239_D006258 NONE We initiated a phase I/II trial to determine the response and toxicity of escalating <e1>paclitaxel</e1> doses combined with fixed-dose cisplatin with granulocyte colony-stimulating factor support in patients with untreated locally advanced inoperable <e2>head and neck carcinoma</e2> .
D017239_D006258 NONE <e1>Paclitaxel/cisplatin</e1> is an effective first-line regimen for locoregionally advanced <e2>head and neck cancer</e2> and continued study is warranted .
D002945_D006258 NONE A phase I/II study of paclitaxel plus <e1>cisplatin</e1> as first-line therapy for <e2>head and neck cancers</e2> : preliminary results .
D002945_D006258 NONE Preliminary results of an Eastern Cooperative Oncology Group study of single-agent paclitaxel ( Taxol ; Bristol-Myers Squibb Company , Princeton , NJ ) reported a 37 % response rate in patients with <e2>head and neck cancer</e2> , and the <e1>paclitaxel/cisplatin</e1> combination has been used successfully and has significantly improved median response duration in ovarian cancer patients .
D002945_D006258 NONE We initiated a phase I/II trial to determine the response and toxicity of escalating paclitaxel doses combined with fixed-dose <e1>cisplatin</e1> with granulocyte colony-stimulating factor support in patients with untreated locally advanced inoperable <e2>head and neck carcinoma</e2> .
D002945_D006258 NONE <e1>Paclitaxel/cisplatin</e1> is an effective first-line regimen for locoregionally advanced <e2>head and neck cancer</e2> and continued study is warranted .
D017239_D010051 NONE Preliminary results of an Eastern Cooperative Oncology Group study of single-agent <e1>paclitaxel</e1> ( Taxol ; Bristol-Myers Squibb Company , Princeton , NJ ) reported a 37 % response rate in patients with head and neck cancer , and the paclitaxel/cisplatin combination has been used successfully and has significantly improved median response duration in <e2>ovarian cancer</e2> patients .
D017239_D010051 NONE Preliminary results of an Eastern Cooperative Oncology Group study of single-agent paclitaxel ( <e1>Taxol</e1> ; Bristol-Myers Squibb Company , Princeton , NJ ) reported a 37 % response rate in patients with head and neck cancer , and the paclitaxel/cisplatin combination has been used successfully and has significantly improved median response duration in <e2>ovarian cancer</e2> patients .
D017239_D010051 NONE Preliminary results of an Eastern Cooperative Oncology Group study of single-agent paclitaxel ( Taxol ; Bristol-Myers Squibb Company , Princeton , NJ ) reported a 37 % response rate in patients with head and neck cancer , and the <e1>paclitaxel/cisplatin</e1> combination has been used successfully and has significantly improved median response duration in <e2>ovarian cancer</e2> patients .
D002945_D010051 NONE Preliminary results of an Eastern Cooperative Oncology Group study of single-agent paclitaxel ( Taxol ; Bristol-Myers Squibb Company , Princeton , NJ ) reported a 37 % response rate in patients with head and neck cancer , and the <e1>paclitaxel/cisplatin</e1> combination has been used successfully and has significantly improved median response duration in <e2>ovarian cancer</e2> patients .
D017239_D064420 NONE We initiated a phase I/II trial to determine the response and <e2>toxicity</e2> of escalating <e1>paclitaxel</e1> doses combined with fixed-dose cisplatin with granulocyte colony-stimulating factor support in patients with untreated locally advanced inoperable head and neck carcinoma .
D017239_D064420 NONE The dose levels incorporate escalating <e1>paclitaxel</e1> doses , and intrapatient escalations within a given dose level are permitted if <e2>toxicity</e2> permits .
D002945_D064420 NONE We initiated a phase I/II trial to determine the response and <e2>toxicity</e2> of escalating paclitaxel doses combined with fixed-dose <e1>cisplatin</e1> with granulocyte colony-stimulating factor support in patients with untreated locally advanced inoperable head and neck carcinoma .
9523805
D011318_D009422 CID <e2>Transient neurologic symptoms</e2> after spinal anesthesia : a lower incidence with <e1>prilocaine</e1> and bupivacaine than with lidocaine .
D011318_D009422 CID Accordingly , the present , prospective double-blind study compares <e1>prilocaine</e1> with lidocaine and bupivacaine with respect to duration of action and relative risk of <e2>TNSs</e2> .
D011318_D009422 CID RESULTS : Nine of 30 patients receiving lidocaine experienced <e2>TNSs</e2> , 1 of 30 patients receiving <e1>prilocaine</e1> ( P = 0.03 ) had them , and none of 30 patients receiving bupivacaine had TNSs .
D011318_D009422 CID RESULTS : Nine of 30 patients receiving lidocaine experienced TNSs , 1 of 30 patients receiving <e1>prilocaine</e1> ( P = 0.03 ) had them , and none of 30 patients receiving bupivacaine had <e2>TNSs</e2> .
D011318_D009422 CID CONCLUSIONS : <e1>Prilocaine</e1> may be preferable to lidocaine for short surgical procedures because it has a similar duration of action but a lower incidence of <e2>TNSs</e2> .
D002045_D009422 NONE <e2>Transient neurologic symptoms</e2> after spinal anesthesia : a lower incidence with prilocaine and <e1>bupivacaine</e1> than with lidocaine .
D002045_D009422 NONE BACKGROUND : Recent evidence suggests that <e2>transient neurologic symptoms</e2> ( TNSs ) frequently follow lidocaine spinal anesthesia but are infrequent with <e1>bupivacaine</e1> .
D002045_D009422 NONE BACKGROUND : Recent evidence suggests that transient neurologic symptoms ( <e2>TNSs</e2> ) frequently follow lidocaine spinal anesthesia but are infrequent with <e1>bupivacaine</e1> .
D002045_D009422 NONE Accordingly , the present , prospective double-blind study compares prilocaine with lidocaine and <e1>bupivacaine</e1> with respect to duration of action and relative risk of <e2>TNSs</e2> .
D002045_D009422 NONE RESULTS : Nine of 30 patients receiving lidocaine experienced <e2>TNSs</e2> , 1 of 30 patients receiving prilocaine ( P = 0.03 ) had them , and none of 30 patients receiving <e1>bupivacaine</e1> had TNSs .
D002045_D009422 NONE RESULTS : Nine of 30 patients receiving lidocaine experienced TNSs , 1 of 30 patients receiving prilocaine ( P = 0.03 ) had them , and none of 30 patients receiving <e1>bupivacaine</e1> had <e2>TNSs</e2> .
D008012_D009422 CID <e2>Transient neurologic symptoms</e2> after spinal anesthesia : a lower incidence with prilocaine and bupivacaine than with <e1>lidocaine</e1> .
D008012_D009422 CID BACKGROUND : Recent evidence suggests that <e2>transient neurologic symptoms</e2> ( TNSs ) frequently follow <e1>lidocaine</e1> spinal anesthesia but are infrequent with bupivacaine .
D008012_D009422 CID BACKGROUND : Recent evidence suggests that transient neurologic symptoms ( <e2>TNSs</e2> ) frequently follow <e1>lidocaine</e1> spinal anesthesia but are infrequent with bupivacaine .
D008012_D009422 CID Accordingly , the present , prospective double-blind study compares prilocaine with <e1>lidocaine</e1> and bupivacaine with respect to duration of action and relative risk of <e2>TNSs</e2> .
D008012_D009422 CID RESULTS : Nine of 30 patients receiving <e1>lidocaine</e1> experienced <e2>TNSs</e2> , 1 of 30 patients receiving prilocaine ( P = 0.03 ) had them , and none of 30 patients receiving bupivacaine had TNSs .
D008012_D009422 CID RESULTS : Nine of 30 patients receiving <e1>lidocaine</e1> experienced TNSs , 1 of 30 patients receiving prilocaine ( P = 0.03 ) had them , and none of 30 patients receiving bupivacaine had <e2>TNSs</e2> .
D008012_D009422 CID CONCLUSIONS : Prilocaine may be preferable to <e1>lidocaine</e1> for short surgical procedures because it has a similar duration of action but a lower incidence of <e2>TNSs</e2> .
16167916
D020849_D054556 CID CONCLUSION : We suggest that the increased risk of <e2>venous thromboembolism</e2> due to <e1>raloxifene</e1> treatment may be related to increased tPA levels , but not TAFI levels .
8092427
D000658_D004342 CID Immediate <e2>allergic reactions</e2> to <e1>amoxicillin</e1> .
D000658_D004342 CID A detailed clinical history , together with skin tests , RAST ( radioallergosorbent test ) , and controlled challenge tests , was used to establish whether patients <e2>allergic</e2> to beta-lactam antibiotics had selective immediate allergic responses to <e1>amoxicillin</e1> ( AX ) or were cross-reacting with other penicillin derivatives .
D000658_D004342 CID A detailed clinical history , together with skin tests , RAST ( radioallergosorbent test ) , and controlled challenge tests , was used to establish whether patients allergic to beta-lactam antibiotics had selective immediate <e2>allergic</e2> responses to <e1>amoxicillin</e1> ( AX ) or were cross-reacting with other penicillin derivatives .
D000658_D004342 CID A detailed clinical history , together with skin tests , RAST ( radioallergosorbent test ) , and controlled challenge tests , was used to establish whether patients <e2>allergic</e2> to beta-lactam antibiotics had selective immediate allergic responses to amoxicillin ( <e1>AX</e1> ) or were cross-reacting with other penicillin derivatives .
D000658_D004342 CID A detailed clinical history , together with skin tests , RAST ( radioallergosorbent test ) , and controlled challenge tests , was used to establish whether patients allergic to beta-lactam antibiotics had selective immediate <e2>allergic</e2> responses to amoxicillin ( <e1>AX</e1> ) or were cross-reacting with other penicillin derivatives .
D000658_D004342 CID We selected the 54 ( 30.5 % ) cases of immediate <e1>AX</e1> <e2>allergy</e2> with good tolerance of PG .
D000658_D004342 CID Challenge tests with <e1>AX</e1> were performed in 23 subjects ( 43 % ) to establish the diagnosis of immediate <e2>allergic reaction</e2> to AX , and in 15 cases ( 28 % ) both skin test and RAST for AX were negative .
D000658_D004342 CID Challenge tests with AX were performed in 23 subjects ( 43 % ) to establish the diagnosis of immediate <e2>allergic reaction</e2> to <e1>AX</e1> , and in 15 cases ( 28 % ) both skin test and RAST for AX were negative .
D000658_D004342 CID Challenge tests with AX were performed in 23 subjects ( 43 % ) to establish the diagnosis of immediate <e2>allergic reaction</e2> to AX , and in 15 cases ( 28 % ) both skin test and RAST for <e1>AX</e1> were negative .
D000658_D004342 CID We describe the largest group of <e2><e1>AX-allergic</e1></e2> patients who have tolerated PG reported so far .
D047090_D004342 NONE A large group of patients with suspected <e2>allergic reactions</e2> to <e1>beta-lactam</e1> antibiotics was evaluated .
D047090_D004342 NONE A detailed clinical history , together with skin tests , RAST ( radioallergosorbent test ) , and controlled challenge tests , was used to establish whether patients <e2>allergic</e2> to <e1>beta-lactam</e1> antibiotics had selective immediate allergic responses to amoxicillin ( AX ) or were cross-reacting with other penicillin derivatives .
D047090_D004342 NONE A detailed clinical history , together with skin tests , RAST ( radioallergosorbent test ) , and controlled challenge tests , was used to establish whether patients allergic to <e1>beta-lactam</e1> antibiotics had selective immediate <e2>allergic</e2> responses to amoxicillin ( AX ) or were cross-reacting with other penicillin derivatives .
D047090_D004342 NONE A total of 177 patients were diagnosed as <e2>allergic</e2> to <e1>beta-lactam</e1> antibiotics .
D010406_D004342 NONE A detailed clinical history , together with skin tests , RAST ( radioallergosorbent test ) , and controlled challenge tests , was used to establish whether patients <e2>allergic</e2> to beta-lactam antibiotics had selective immediate allergic responses to amoxicillin ( AX ) or were cross-reacting with other <e1>penicillin</e1> derivatives .
D010406_D004342 NONE A detailed clinical history , together with skin tests , RAST ( radioallergosorbent test ) , and controlled challenge tests , was used to establish whether patients allergic to beta-lactam antibiotics had selective immediate <e2>allergic</e2> responses to amoxicillin ( AX ) or were cross-reacting with other <e1>penicillin</e1> derivatives .
D010400_D004342 NONE We selected the 54 ( 30.5 % ) cases of immediate AX <e2>allergy</e2> with good tolerance of <e1>PG</e1> .
D010400_D004342 NONE We describe the largest group of <e2>AX-allergic</e2> patients who have tolerated <e1>PG</e1> reported so far .
-1_D007645 NONE All the patients were skin test negative to <e1>BPO</e1> ; 49 of 51 ( 96 % ) were also negative to <e2>MDM</e2> , and 44 of 46 ( 96 % ) to PG .
D010400_D007645 NONE All the patients were skin test negative to BPO ; 49 of 51 ( 96 % ) were also negative to <e2>MDM</e2> , and 44 of 46 ( 96 % ) to <e1>PG</e1> .
11807648
D014148_D004827 NONE <e2>Epileptic seizures</e2> following cortical application of fibrin sealants containing <e1>tranexamic acid</e1> in rats .
D014148_D004827 NONE However , <e1>tAMCA</e1> has been shown to cause <e2>epileptic seizures</e2> .
D014148_D012640 CID We wanted to study whether <e1>tAMCA</e1> retains its <e2>convulsive</e2> action if incorporated into a FS .
D014148_D012640 CID FINDINGS : FS containing <e1>tAMCA</e1> caused paroxysmal brain activity which was associated with distinct <e2>convulsive</e2> behaviours .
D014148_D012640 CID The degree of these <e2>seizures</e2> increased with increasing concentration of <e1>tAMCA</e1> .
D014148_D012640 CID Thus , FS containing 47.5 mg/ml <e1>tAMCA</e1> evoked <e2>generalized seizures</e2> in all tested rats ( n=6 ) while the lowest concentration of tAMCA ( 0.5 mg/ml ) only evoked brief episodes of jerk-correlated convulsive potentials in 1 of 6 rats .
D014148_D012640 CID Thus , FS containing 47.5 mg/ml <e1>tAMCA</e1> evoked generalized seizures in all tested rats ( n=6 ) while the lowest concentration of tAMCA ( 0.5 mg/ml ) only evoked brief episodes of jerk-correlated <e2>convulsive</e2> potentials in 1 of 6 rats .
D014148_D012640 CID Thus , FS containing 47.5 mg/ml tAMCA evoked <e2>generalized seizures</e2> in all tested rats ( n=6 ) while the lowest concentration of <e1>tAMCA</e1> ( 0.5 mg/ml ) only evoked brief episodes of jerk-correlated convulsive potentials in 1 of 6 rats .
D014148_D012640 CID Thus , FS containing 47.5 mg/ml tAMCA evoked generalized seizures in all tested rats ( n=6 ) while the lowest concentration of <e1>tAMCA</e1> ( 0.5 mg/ml ) only evoked brief episodes of jerk-correlated <e2>convulsive</e2> potentials in 1 of 6 rats .
D014148_D012640 CID INTERPRETATION : <e1>Tranexamic acid</e1> retains its <e2>convulsive</e2> action within FS .
3101906
D007654_D003643 NONE In two of the three <e2>deaths</e2> probably associated with <e1>ketoconazole</e1> treatment the drug had been continued after the onset of jaundice and other symptoms of hepatitis .
D007654_D007565 CID In two of the three deaths probably associated with <e1>ketoconazole</e1> treatment the drug had been continued after the onset of <e2>jaundice</e2> and other symptoms of hepatitis .
D007654_D056486 CID In two of the three deaths probably associated with <e1>ketoconazole</e1> treatment the drug had been continued after the onset of jaundice and other symptoms of <e2>hepatitis</e2> .
D007654_D056486 CID Clinical and biochemical monitoring at regular intervals for evidence of <e2>hepatitis</e2> is advised during long term treatment with <e1>ketoconazole</e1> to prevent possible serious hepatic injury .
D007654_D056486 CID Clinical and biochemical monitoring at regular intervals for evidence of hepatitis is advised during long term treatment with <e1>ketoconazole</e1> to prevent possible serious <e2>hepatic injury</e2> .
17244258
D003520_D003556 CID In vitro characterization of parasympathetic and sympathetic responses in <e1>cyclophosphamide-induced</e1> <e2>cystitis</e2> in the rat .
D003520_D003556 CID In <e1>cyclophosphamide-induced</e1> <e2>cystitis</e2> in the rat , detrusor function is impaired and the expression and effects of muscarinic receptors altered .
26094
D008750_D003866 CID This was accounted for by a significant number of <e2>depressions</e2> occurring in <e1>methyl dopa</e1> treated patients with psychiatric histories .
D008750_D001523 NONE This was accounted for by a significant number of depressions occurring in <e1>methyl dopa</e1> treated patients with <e2>psychiatric</e2> histories .
1428568
D013999_D005901 NONE Eight <e2>glaucomatous</e2> patients chronically treated with <e1>timolol</e1> 0.5%/12h , suffering from depression diagnosed through DMS-III-R criteria , were included in the study .
D013999_D003866 CID Eight glaucomatous patients chronically treated with <e1>timolol</e1> 0.5%/12h , suffering from <e2>depression</e2> diagnosed through DMS-III-R criteria , were included in the study .
D013999_D003866 CID In a double blind cross-over study with control group , the patients under <e1>timolol</e1> treatment presented higher <e2>depression</e2> values measured through the Beck and the Zung-Conde scales ( p < 0.001 vs control ) .
D013999_D003866 CID These results suggest that betaxolol could be less of a <e2>depression-inducer</e2> than <e1>timolol</e1> in predisposed patients .
D015784_D003866 NONE These results suggest that <e1>betaxolol</e1> could be less of a <e2>depression-inducer</e2> than timolol in predisposed patients .
20722491
-1_D009369 NONE IMPORTANCE OF THE FIELD : <e1>Fluoropyrimidines</e1> , in particular 5-fluorouracil ( 5-FU ) , have been the mainstay of treatment for several solid <e2>tumors</e2> , including colorectal , breast and head and neck cancers , for > 40 years .
-1_D015179 NONE IMPORTANCE OF THE FIELD : <e1>Fluoropyrimidines</e1> , in particular 5-fluorouracil ( 5-FU ) , have been the mainstay of treatment for several solid tumors , including <e2>colorectal , breast and head and neck cancers</e2> , for > 40 years .
-1_D001943 NONE IMPORTANCE OF THE FIELD : <e1>Fluoropyrimidines</e1> , in particular 5-fluorouracil ( 5-FU ) , have been the mainstay of treatment for several solid tumors , including <e2>colorectal , breast and head and neck cancers</e2> , for > 40 years .
-1_D006258 NONE IMPORTANCE OF THE FIELD : <e1>Fluoropyrimidines</e1> , in particular 5-fluorouracil ( 5-FU ) , have been the mainstay of treatment for several solid tumors , including <e2>colorectal , breast and head and neck cancers</e2> , for > 40 years .
D005472_D009369 NONE IMPORTANCE OF THE FIELD : Fluoropyrimidines , in particular <e1>5-fluorouracil</e1> ( 5-FU ) , have been the mainstay of treatment for several solid <e2>tumors</e2> , including colorectal , breast and head and neck cancers , for > 40 years .
D005472_D009369 NONE IMPORTANCE OF THE FIELD : Fluoropyrimidines , in particular 5-fluorouracil ( <e1>5-FU</e1> ) , have been the mainstay of treatment for several solid <e2>tumors</e2> , including colorectal , breast and head and neck cancers , for > 40 years .
D005472_D015179 NONE IMPORTANCE OF THE FIELD : Fluoropyrimidines , in particular <e1>5-fluorouracil</e1> ( 5-FU ) , have been the mainstay of treatment for several solid tumors , including <e2>colorectal , breast and head and neck cancers</e2> , for > 40 years .
D005472_D015179 NONE IMPORTANCE OF THE FIELD : Fluoropyrimidines , in particular 5-fluorouracil ( <e1>5-FU</e1> ) , have been the mainstay of treatment for several solid tumors , including <e2>colorectal , breast and head and neck cancers</e2> , for > 40 years .
D005472_D001943 NONE IMPORTANCE OF THE FIELD : Fluoropyrimidines , in particular <e1>5-fluorouracil</e1> ( 5-FU ) , have been the mainstay of treatment for several solid tumors , including <e2>colorectal , breast and head and neck cancers</e2> , for > 40 years .
D005472_D001943 NONE IMPORTANCE OF THE FIELD : Fluoropyrimidines , in particular 5-fluorouracil ( <e1>5-FU</e1> ) , have been the mainstay of treatment for several solid tumors , including <e2>colorectal , breast and head and neck cancers</e2> , for > 40 years .
D005472_D006258 NONE IMPORTANCE OF THE FIELD : Fluoropyrimidines , in particular <e1>5-fluorouracil</e1> ( 5-FU ) , have been the mainstay of treatment for several solid tumors , including <e2>colorectal , breast and head and neck cancers</e2> , for > 40 years .
D005472_D006258 NONE IMPORTANCE OF THE FIELD : Fluoropyrimidines , in particular 5-fluorouracil ( <e1>5-FU</e1> ) , have been the mainstay of treatment for several solid tumors , including <e2>colorectal , breast and head and neck cancers</e2> , for > 40 years .
C110904_D007674 NONE WHAT THE READER WILL GAIN : The reader will gain better insight into the safety of <e1>capecitabine</e1> in special populations such as patients with advanced age , <e2>renal and kidney disease</e2> .
C110904_D007674 NONE <e1>Capecitabine</e1> has a well-established safety profile and can be given safely to patients with advanced age , <e2>hepatic and renal dysfunctions</e2> .
C110904_D003967 CID The most commonly reported toxic effects of <e1>capecitabine</e1> are <e2>diarrhea</e2> , nausea , vomiting , stomatitis and hand-foot syndrome .
C110904_D009325 CID The most commonly reported toxic effects of <e1>capecitabine</e1> are diarrhea , <e2>nausea</e2> , vomiting , stomatitis and hand-foot syndrome .
C110904_D014839 CID The most commonly reported toxic effects of <e1>capecitabine</e1> are diarrhea , nausea , <e2>vomiting</e2> , stomatitis and hand-foot syndrome .
C110904_D013280 CID The most commonly reported toxic effects of <e1>capecitabine</e1> are diarrhea , nausea , vomiting , <e2>stomatitis</e2> and hand-foot syndrome .
C110904_D060831 CID The most commonly reported toxic effects of <e1>capecitabine</e1> are diarrhea , nausea , vomiting , stomatitis and <e2>hand-foot syndrome</e2> .
C110904_D008107 NONE <e1>Capecitabine</e1> has a well-established safety profile and can be given safely to patients with advanced age , <e2>hepatic and renal dysfunctions</e2> .
9855119
D016559_D005922 NONE RESULTS : The main pathologic diagnoses ( some overlap ) were acute rejection ( AR ; n = 4 ) , chronic rejection ( CR ; n=5 ) , AR+CR ( n = 4 ) , recurrent <e2>IgA nephropathy</e2> ( n = 5 ) , normal findings ( n = 2 ) , minimal-type chronic <e1>FK506</e1> nephropathy ( n = 9 ) , and mild-type FK506 nephropathy ( n = 11 ) .
D016559_D005922 NONE RESULTS : The main pathologic diagnoses ( some overlap ) were acute rejection ( AR ; n = 4 ) , chronic rejection ( CR ; n=5 ) , AR+CR ( n = 4 ) , recurrent <e2>IgA nephropathy</e2> ( n = 5 ) , normal findings ( n = 2 ) , minimal-type chronic FK506 nephropathy ( n = 9 ) , and mild-type <e1>FK506</e1> nephropathy ( n = 11 ) .
D016559_D007674 NONE RESULTS : The main pathologic diagnoses ( some overlap ) were acute rejection ( AR ; n = 4 ) , chronic rejection ( CR ; n=5 ) , AR+CR ( n = 4 ) , recurrent IgA nephropathy ( n = 5 ) , normal findings ( n = 2 ) , minimal-type chronic <e1>FK506</e1> <e2>nephropathy</e2> ( n = 9 ) , and mild-type FK506 nephropathy ( n = 11 ) .
D016559_D007674 NONE RESULTS : The main pathologic diagnoses ( some overlap ) were acute rejection ( AR ; n = 4 ) , chronic rejection ( CR ; n=5 ) , AR+CR ( n = 4 ) , recurrent IgA nephropathy ( n = 5 ) , normal findings ( n = 2 ) , minimal-type chronic <e1>FK506</e1> nephropathy ( n = 9 ) , and mild-type FK506 <e2>nephropathy</e2> ( n = 11 ) .
D016559_D007674 NONE RESULTS : The main pathologic diagnoses ( some overlap ) were acute rejection ( AR ; n = 4 ) , chronic rejection ( CR ; n=5 ) , AR+CR ( n = 4 ) , recurrent IgA nephropathy ( n = 5 ) , normal findings ( n = 2 ) , minimal-type chronic FK506 <e2>nephropathy</e2> ( n = 9 ) , and mild-type <e1>FK506</e1> nephropathy ( n = 11 ) .
D016559_D007674 NONE RESULTS : The main pathologic diagnoses ( some overlap ) were acute rejection ( AR ; n = 4 ) , chronic rejection ( CR ; n=5 ) , AR+CR ( n = 4 ) , recurrent IgA nephropathy ( n = 5 ) , normal findings ( n = 2 ) , minimal-type chronic FK506 nephropathy ( n = 9 ) , and mild-type <e1>FK506</e1> <e2>nephropathy</e2> ( n = 11 ) .
D016559_D007674 NONE Of the nonepisode biopsies , 7 and 4 biopsies showed minimal-type and mild-type chronic <e1>FK506</e1> <e2>nephropathy</e2> , respectively .
D016559_D007674 NONE Chronic <e1>FK506</e1> <e2>nephropathy</e2> consisted of rough and foamy tubular vacuolization ( 5 biopsies ) , arteriolopathy ( angiodegeneration of the arteriolar wall ; 20 biopsies ) , focal segmental glomerulosclerosis ( 4 biopsies ) and the striped form of interstitial fibrosis ( 11 biopsies ) .
D016559_D007674 NONE The serum creatinine levels of patients in the mild-type chronic <e1>FK506</e1> <e2>nephropathy</e2> group , which included 7 episode biopsies , were statistically higher than those in the minimum-type chronic FK506-nephropathy group ( P < 0.001 ) .
D016559_D007674 NONE The serum creatinine levels of patients in the mild-type chronic <e1>FK506</e1> nephropathy group , which included 7 episode biopsies , were statistically higher than those in the minimum-type chronic <e2>FK506-nephropathy</e2> group ( P < 0.001 ) .
D016559_D007674 NONE The serum creatinine levels of patients in the mild-type chronic FK506 <e2>nephropathy</e2> group , which included 7 episode biopsies , were statistically higher than those in the minimum-type chronic <e1>FK506-nephropathy</e1> group ( P < 0.001 ) .
D016559_D007674 NONE The serum creatinine levels of patients in the mild-type chronic FK506 nephropathy group , which included 7 episode biopsies , were statistically higher than those in the minimum-type chronic <e2><e1>FK506-nephropathy</e1></e2> group ( P < 0.001 ) .
D016559_D007674 NONE CONCLUSIONS : This study demonstrates that chronic <e1>FK506</e1> <e2>nephropathy</e2> consists primarily of arteriolopathy manifesting as insudative hyalinosis of the arteriolar wall , and suggests that mild-type chronic FK506 nephropathy is a condition which may lead to deterioration of renal allograft function .
D016559_D007674 NONE CONCLUSIONS : This study demonstrates that chronic <e1>FK506</e1> nephropathy consists primarily of arteriolopathy manifesting as insudative hyalinosis of the arteriolar wall , and suggests that mild-type chronic FK506 <e2>nephropathy</e2> is a condition which may lead to deterioration of renal allograft function .
D016559_D007674 NONE CONCLUSIONS : This study demonstrates that chronic FK506 <e2>nephropathy</e2> consists primarily of arteriolopathy manifesting as insudative hyalinosis of the arteriolar wall , and suggests that mild-type chronic <e1>FK506</e1> nephropathy is a condition which may lead to deterioration of renal allograft function .
D016559_D007674 NONE CONCLUSIONS : This study demonstrates that chronic FK506 nephropathy consists primarily of arteriolopathy manifesting as insudative hyalinosis of the arteriolar wall , and suggests that mild-type chronic <e1>FK506</e1> <e2>nephropathy</e2> is a condition which may lead to deterioration of renal allograft function .
D016559_D005923 CID Chronic <e1>FK506</e1> nephropathy consisted of rough and foamy tubular vacuolization ( 5 biopsies ) , arteriolopathy ( angiodegeneration of the arteriolar wall ; 20 biopsies ) , <e2>focal segmental glomerulosclerosis</e2> ( 4 biopsies ) and the striped form of interstitial fibrosis ( 11 biopsies ) .
D016559_D005355 NONE Chronic <e1>FK506</e1> nephropathy consisted of rough and foamy tubular vacuolization ( 5 biopsies ) , arteriolopathy ( angiodegeneration of the arteriolar wall ; 20 biopsies ) , focal segmental glomerulosclerosis ( 4 biopsies ) and the striped form of <e2>interstitial fibrosis</e2> ( 11 biopsies ) .
D003404_D007674 NONE The serum <e1>creatinine</e1> levels of patients in the mild-type chronic FK506 <e2>nephropathy</e2> group , which included 7 episode biopsies , were statistically higher than those in the minimum-type chronic FK506-nephropathy group ( P < 0.001 ) .
D003404_D007674 NONE The serum <e1>creatinine</e1> levels of patients in the mild-type chronic FK506 nephropathy group , which included 7 episode biopsies , were statistically higher than those in the minimum-type chronic <e2>FK506-nephropathy</e2> group ( P < 0.001 ) .
16755009
D003975_D000647 CID <e1>Diazepam-</e1> , scopolamine- and ageing-induced <e2>amnesia</e2> served as the interoceptive behavioral models .
D003975_D000647 CID Furthermore , DCE reversed the <e2>amnesia</e2> induced by scopolamine ( 0.4 mg/kg , i.p. ) and <e1>diazepam</e1> ( 1 mg/kg , i.p. ) .
D012601_D000647 CID Diazepam- , <e1>scopolamine-</e1> and ageing-induced <e2>amnesia</e2> served as the interoceptive behavioral models .
D012601_D000647 CID Furthermore , DCE reversed the <e2>amnesia</e2> induced by <e1>scopolamine</e1> ( 0.4 mg/kg , i.p. ) and diazepam ( 1 mg/kg , i.p. ) .
D010936_D000647 NONE Furthermore , <e1>DCE</e1> reversed the <e2>amnesia</e2> induced by scopolamine ( 0.4 mg/kg , i.p. ) and diazepam ( 1 mg/kg , i.p. ) .
D010936_D003072 NONE Therefore , <e1>DCE</e1> may prove to be a useful remedy for the management of <e2>cognitive dysfunctions</e2> on account of its multifarious beneficial effects such as , memory improving property , cholesterol lowering property and anticholinesterase activity .
D002784_D003072 NONE Therefore , DCE may prove to be a useful remedy for the management of <e2>cognitive dysfunctions</e2> on account of its multifarious beneficial effects such as , memory improving property , <e1>cholesterol</e1> lowering property and anticholinesterase activity .
19843802
D004837_D006973 CID However , a bolus of <e1>epinephrine</e1> injected through an alternative catheter provoked a <e2>hypertensive</e2> crisis .
6534871
D007545_D009203 CID The effects of exercise on the severity of <e1>isoproterenol-induced</e1> <e2>myocardial infarction</e2> were studied in female albino rats of 20,40,60 and 80 weeks of age .
7449470
D004317_D066126 NONE Late , late <e1>doxorubicin</e1> <e2>cardiotoxicity</e2> .
D004317_D066126 NONE <e2>Cardiac toxicity</e2> is a major complication which limits the use of <e1>adriamycin</e1> as a chemotherapeutic agent .
11419773
D002110_D001145 NONE <e1>Caffeine-induced</e1> <e2>cardiac arrhythmia</e2> : an unrecognised danger of healthfood products .
D002110_D008945 NONE We describe a 25-year-old woman with pre-existing <e2>mitral valve prolapse</e2> who developed intractable ventricular fibrillation after consuming a " natural energy " guarana health drink containing a high concentration of <e1>caffeine</e1> .
D002110_D014693 CID We describe a 25-year-old woman with pre-existing mitral valve prolapse who developed intractable <e2>ventricular fibrillation</e2> after consuming a " natural energy " guarana health drink containing a high concentration of <e1>caffeine</e1> .
6287825
D013831_D010523 CID <e2>Peripheral neuropathy</e2> due to nutritional deficiency of <e1>thiamine</e1> and riboflavin was common ( 10.1 % ) and presented mainly as sensory and sensori-motor neuropathy .
D013831_D010523 CID Peripheral neuropathy due to nutritional deficiency of <e1>thiamine</e1> and riboflavin was common ( 10.1 % ) and presented mainly as sensory and <e2>sensori-motor neuropathy</e2> .
D013831_D044342 NONE Peripheral neuropathy due to <e2>nutritional deficiency</e2> of <e1>thiamine</e1> and riboflavin was common ( 10.1 % ) and presented mainly as sensory and sensori-motor neuropathy .
D012256_D010523 CID <e2>Peripheral neuropathy</e2> due to nutritional deficiency of thiamine and <e1>riboflavin</e1> was common ( 10.1 % ) and presented mainly as sensory and sensori-motor neuropathy .
D012256_D010523 CID Peripheral neuropathy due to nutritional deficiency of thiamine and <e1>riboflavin</e1> was common ( 10.1 % ) and presented mainly as sensory and <e2>sensori-motor neuropathy</e2> .
D012256_D044342 NONE Peripheral neuropathy due to <e2>nutritional deficiency</e2> of thiamine and <e1>riboflavin</e1> was common ( 10.1 % ) and presented mainly as sensory and sensori-motor neuropathy .
D007538_D009422 NONE <e1>Isoniazid</e1> was the most frequent agent in drug-induced <e2>neuropathy</e2> .
19820426
C558899_D066126 NONE Twin preterm neonates with <e2>cardiac toxicity</e2> related to <e1>lopinavir/ritonavir</e1> therapy .
C558899_D006327 CID One of the twins developed complete <e2>heart block</e2> and dilated cardiomyopathy related to <e1>lopinavir/ritonavir</e1> therapy , a boosted protease-inhibitor agent , while the other twin developed mild bradycardia .
C558899_D002311 CID One of the twins developed complete heart block and <e2>dilated cardiomyopathy</e2> related to <e1>lopinavir/ritonavir</e1> therapy , a boosted protease-inhibitor agent , while the other twin developed mild bradycardia .
C558899_D001919 CID One of the twins developed complete heart block and dilated cardiomyopathy related to <e1>lopinavir/ritonavir</e1> therapy , a boosted protease-inhibitor agent , while the other twin developed mild <e2>bradycardia</e2> .
9766615
D003024_D001480 NONE The newer atypical agents have a lower risk of <e2>EPS</e2> , but are associated in varying degrees with sedation , cardiovascular effects , anticholinergic effects , weight gain , sexual dysfunction , hepatic effects , lowered seizure threshold ( primarily <e1>clozapine</e1> ) , and agranulocytosis ( clozapine only ) .
D003024_D001480 NONE The newer atypical agents have a lower risk of <e2>EPS</e2> , but are associated in varying degrees with sedation , cardiovascular effects , anticholinergic effects , weight gain , sexual dysfunction , hepatic effects , lowered seizure threshold ( primarily clozapine ) , and agranulocytosis ( <e1>clozapine</e1> only ) .
D003024_D015430 NONE The newer atypical agents have a lower risk of EPS , but are associated in varying degrees with sedation , cardiovascular effects , anticholinergic effects , <e2>weight gain</e2> , sexual dysfunction , hepatic effects , lowered seizure threshold ( primarily <e1>clozapine</e1> ) , and agranulocytosis ( clozapine only ) .
D003024_D015430 NONE The newer atypical agents have a lower risk of EPS , but are associated in varying degrees with sedation , cardiovascular effects , anticholinergic effects , <e2>weight gain</e2> , sexual dysfunction , hepatic effects , lowered seizure threshold ( primarily clozapine ) , and agranulocytosis ( <e1>clozapine</e1> only ) .
D003024_D012735 NONE The newer atypical agents have a lower risk of EPS , but are associated in varying degrees with sedation , cardiovascular effects , anticholinergic effects , weight gain , <e2>sexual dysfunction</e2> , hepatic effects , lowered seizure threshold ( primarily <e1>clozapine</e1> ) , and agranulocytosis ( clozapine only ) .
D003024_D012735 NONE The newer atypical agents have a lower risk of EPS , but are associated in varying degrees with sedation , cardiovascular effects , anticholinergic effects , weight gain , <e2>sexual dysfunction</e2> , hepatic effects , lowered seizure threshold ( primarily clozapine ) , and agranulocytosis ( <e1>clozapine</e1> only ) .
D003024_D012640 NONE The newer atypical agents have a lower risk of EPS , but are associated in varying degrees with sedation , cardiovascular effects , anticholinergic effects , weight gain , sexual dysfunction , hepatic effects , lowered <e2>seizure</e2> threshold ( primarily <e1>clozapine</e1> ) , and agranulocytosis ( clozapine only ) .
D003024_D012640 NONE The newer atypical agents have a lower risk of EPS , but are associated in varying degrees with sedation , cardiovascular effects , anticholinergic effects , weight gain , sexual dysfunction , hepatic effects , lowered <e2>seizure</e2> threshold ( primarily clozapine ) , and agranulocytosis ( <e1>clozapine</e1> only ) .
D003024_D000380 CID The newer atypical agents have a lower risk of EPS , but are associated in varying degrees with sedation , cardiovascular effects , anticholinergic effects , weight gain , sexual dysfunction , hepatic effects , lowered seizure threshold ( primarily <e1>clozapine</e1> ) , and <e2>agranulocytosis</e2> ( clozapine only ) .
D003024_D000380 CID The newer atypical agents have a lower risk of EPS , but are associated in varying degrees with sedation , cardiovascular effects , anticholinergic effects , weight gain , sexual dysfunction , hepatic effects , lowered seizure threshold ( primarily clozapine ) , and <e2>agranulocytosis</e2> ( <e1>clozapine</e1> only ) .
16330766
C040029_D009437 NONE The aim of this study was to assess the effects of <e1>gabapentin</e1> , a drug effective in <e2>neuropathic pain</e2> patients , on brain processing of nociceptive information in normal and central sensitization states .
C040029_D006930 NONE Using functional magnetic resonance imaging ( fMRI ) in normal volunteers , we studied the <e1>gabapentin-induced</e1> modulation of brain activity in response to nociceptive mechanical stimulation of normal skin and capsaicin-induced <e2>secondary hyperalgesia</e2> .
D002211_D006930 CID Using functional magnetic resonance imaging ( fMRI ) in normal volunteers , we studied the gabapentin-induced modulation of brain activity in response to nociceptive mechanical stimulation of normal skin and <e1>capsaicin-induced</e1> <e2>secondary hyperalgesia</e2> .
6640832
D004317_D001749 NONE Early adjuvant <e1>adriamycin</e1> in superficial <e2>bladder carcinoma</e2> .
D004317_D001749 NONE <e1>Adriamycin</e1> ( 50 mg/50 ml ) was administered intravesically within 24 h after transurethral resection of TA-T1 ( O-A ) <e2>bladder tumors</e2> .
D004317_D002277 NONE Early adjuvant <e1>adriamycin</e1> in superficial <e2>bladder carcinoma</e2> .
8421099
D015282_D042882 CID Prospective study of the long-term effects of somatostatin analog ( <e1>octreotide</e1> ) on gallbladder function and <e2>gallstone</e2> formation in Chinese acromegalic patients .
D015282_D042882 CID After withdrawal of <e1>octreotide</e1> in 10 patients without <e2>gallstones</e2> , 8 patients assessed had return of normal gallbladder contractility within 1 month .
D015282_D042882 CID Our results suggest that the suppression of gallbladder contractility is the cause of the successive formation of bile sludge , <e2>gallstones</e2> , and cholecystitis during <e1>octreotide</e1> therapy in Chinese acromegalic patients .
D015282_D000172 NONE Prospective study of the long-term effects of somatostatin analog ( <e1>octreotide</e1> ) on gallbladder function and gallstone formation in Chinese <e2>acromegalic</e2> patients .
D015282_D000172 NONE This article reports the changes in gallbladder function examined by ultrasonography in 20 Chinese patients with active <e2>acromegaly</e2> treated with sc injection of the somatostatin analog <e1>octreotide</e1> in dosages of 300 - 1500 micrograms/day for a mean of 24.2 +/- 13.9 months .
D015282_D000172 NONE Our results suggest that the suppression of gallbladder contractility is the cause of the successive formation of bile sludge , gallstones , and cholecystitis during <e1>octreotide</e1> therapy in Chinese <e2>acromegalic</e2> patients .
D015282_D000172 NONE It is therefore very important to follow the changes of gallbladder function during long-term <e1>octreotide</e1> therapy of <e2>acromegalic</e2> patients .
D015282_D002764 NONE Our results suggest that the suppression of gallbladder contractility is the cause of the successive formation of bile sludge , gallstones , and <e2>cholecystitis</e2> during <e1>octreotide</e1> therapy in Chinese acromegalic patients .
7453952
D008094_D003919 CID Attenuation of the <e1>lithium-induced</e1> <e2>diabetes-insipidus-like syndrome</e2> by amiloride in rats .
D008094_D003919 CID In all the experiments , the attenuation of the <e1>lithium-induced</e1> <e2>diabetes-insipidus-like syndrome</e2> by amiloride was accompanied by a reduction of the ratio between the lithium concentration in the renal medulla and its levels in the blood and an elevation in the plasma potassium level .
D008094_D003919 CID In all the experiments , the attenuation of the lithium-induced <e2>diabetes-insipidus-like syndrome</e2> by amiloride was accompanied by a reduction of the ratio between the <e1>lithium</e1> concentration in the renal medulla and its levels in the blood and an elevation in the plasma potassium level .
D000584_D003919 NONE Attenuation of the lithium-induced <e2>diabetes-insipidus-like syndrome</e2> by <e1>amiloride</e1> in rats .
D000584_D003919 NONE In all the experiments , the attenuation of the lithium-induced <e2>diabetes-insipidus-like syndrome</e2> by <e1>amiloride</e1> was accompanied by a reduction of the ratio between the lithium concentration in the renal medulla and its levels in the blood and an elevation in the plasma potassium level .
D000584_D059606 NONE The effect of <e1>amiloride</e1> on lithium-induced <e2>polydipsia</e2> and polyuria and on the lithium concentration in the plasma , brain , kidney , thyroid and red blood cells was investigated in rats , chronically treated with LiCl .
D000584_D059606 NONE It is concluded that acute <e1>amiloride</e1> administration to lithium-treated patients suffering from <e2>polydipsia</e2> and polyuria might relieve these patients but prolonged amiloride supplementation would result in elevated lithium levels and might be hazardous .
D000584_D059606 NONE It is concluded that acute amiloride administration to lithium-treated patients suffering from <e2>polydipsia</e2> and polyuria might relieve these patients but prolonged <e1>amiloride</e1> supplementation would result in elevated lithium levels and might be hazardous .
D000584_D011141 NONE The effect of <e1>amiloride</e1> on lithium-induced polydipsia and <e2>polyuria</e2> and on the lithium concentration in the plasma , brain , kidney , thyroid and red blood cells was investigated in rats , chronically treated with LiCl .
D000584_D011141 NONE It is concluded that acute <e1>amiloride</e1> administration to lithium-treated patients suffering from polydipsia and <e2>polyuria</e2> might relieve these patients but prolonged amiloride supplementation would result in elevated lithium levels and might be hazardous .
D000584_D011141 NONE It is concluded that acute amiloride administration to lithium-treated patients suffering from polydipsia and <e2>polyuria</e2> might relieve these patients but prolonged <e1>amiloride</e1> supplementation would result in elevated lithium levels and might be hazardous .
D008094_D059606 NONE The effect of amiloride on <e1>lithium-induced</e1> <e2>polydipsia</e2> and polyuria and on the lithium concentration in the plasma , brain , kidney , thyroid and red blood cells was investigated in rats , chronically treated with LiCl .
D008094_D059606 NONE The effect of amiloride on lithium-induced <e2>polydipsia</e2> and polyuria and on the <e1>lithium</e1> concentration in the plasma , brain , kidney , thyroid and red blood cells was investigated in rats , chronically treated with LiCl .
D008094_D059606 NONE It is concluded that acute amiloride administration to <e1>lithium-treated</e1> patients suffering from <e2>polydipsia</e2> and polyuria might relieve these patients but prolonged amiloride supplementation would result in elevated lithium levels and might be hazardous .
D008094_D059606 NONE It is concluded that acute amiloride administration to lithium-treated patients suffering from <e2>polydipsia</e2> and polyuria might relieve these patients but prolonged amiloride supplementation would result in elevated <e1>lithium</e1> levels and might be hazardous .
D008094_D011141 NONE The effect of amiloride on <e1>lithium-induced</e1> polydipsia and <e2>polyuria</e2> and on the lithium concentration in the plasma , brain , kidney , thyroid and red blood cells was investigated in rats , chronically treated with LiCl .
D008094_D011141 NONE The effect of amiloride on lithium-induced polydipsia and <e2>polyuria</e2> and on the <e1>lithium</e1> concentration in the plasma , brain , kidney , thyroid and red blood cells was investigated in rats , chronically treated with LiCl .
D008094_D011141 NONE It is concluded that acute amiloride administration to <e1>lithium-treated</e1> patients suffering from polydipsia and <e2>polyuria</e2> might relieve these patients but prolonged amiloride supplementation would result in elevated lithium levels and might be hazardous .
D008094_D011141 NONE It is concluded that acute amiloride administration to lithium-treated patients suffering from polydipsia and <e2>polyuria</e2> might relieve these patients but prolonged amiloride supplementation would result in elevated <e1>lithium</e1> levels and might be hazardous .
D018021_D059606 NONE The effect of amiloride on lithium-induced <e2>polydipsia</e2> and polyuria and on the lithium concentration in the plasma , brain , kidney , thyroid and red blood cells was investigated in rats , chronically treated with <e1>LiCl</e1> .
D018021_D011141 NONE The effect of amiloride on lithium-induced polydipsia and <e2>polyuria</e2> and on the lithium concentration in the plasma , brain , kidney , thyroid and red blood cells was investigated in rats , chronically treated with <e1>LiCl</e1> .
D011188_D003919 NONE In all the experiments , the attenuation of the lithium-induced <e2>diabetes-insipidus-like syndrome</e2> by amiloride was accompanied by a reduction of the ratio between the lithium concentration in the renal medulla and its levels in the blood and an elevation in the plasma <e1>potassium</e1> level .
3564823
D008012_D013035 NONE Drug-induced arterial <e2>spasm</e2> relieved by <e1>lidocaine</e1> .
D013874_D002545 NONE Following major intracranial surgery in a 35-year-old man , <e1>sodium pentothal</e1> was intravenously infused to minimize <e2>cerebral ischaemia</e2> .
D008012_D020301 NONE Since the cranial condition precluded use of more usual methods , <e1>lidocaine</e1> was given intra-arterially , with careful cardiovascular monitoring , to counteract the <e2>vasospasm</e2> .
2304736
D011224_D014550 CID <e1>Prazosin-induced</e1> <e2>stress incontinence</e2> .
D011224_D014550 CID A case of genuine <e2>stress incontinence</e2> due to <e1>prazosin</e1> , a common antihypertensive drug , is presented .
D011224_D014550 CID Patients who present with <e2>stress incontinence</e2> while taking <e1>prazosin</e1> should change their antihypertensive medication before considering surgery , because their incontinence may resolve spontaneously with a change in drug therapy .
D011224_D014549 NONE Patients who present with stress incontinence while taking <e1>prazosin</e1> should change their antihypertensive medication before considering surgery , because their <e2>incontinence</e2> may resolve spontaneously with a change in drug therapy .
4071154
D007213_D051437 NONE <e1>Indomethacin-induced</e1> <e2>renal insufficiency</e2> : recurrence on rechallenge .
D007213_D051437 NONE We have reported a case of acute oliguric <e2>renal failure</e2> with hyperkalemia in a patient with cirrhosis , ascites , and cor pulmonale after <e1>indomethacin</e1> therapy .
D007213_D006947 CID We have reported a case of acute oliguric renal failure with <e2>hyperkalemia</e2> in a patient with cirrhosis , ascites , and cor pulmonale after <e1>indomethacin</e1> therapy .
D007213_D005355 CID We have reported a case of acute oliguric renal failure with hyperkalemia in a patient with <e2>cirrhosis</e2> , ascites , and cor pulmonale after <e1>indomethacin</e1> therapy .
D007213_D001201 CID We have reported a case of acute oliguric renal failure with hyperkalemia in a patient with cirrhosis , <e2>ascites</e2> , and cor pulmonale after <e1>indomethacin</e1> therapy .
D007213_D011660 CID We have reported a case of acute oliguric renal failure with hyperkalemia in a patient with cirrhosis , ascites , and <e2>cor pulmonale</e2> after <e1>indomethacin</e1> therapy .
D007213_D009846 CID Prompt restoration of renal function followed drug withdrawal , while re-exposure to a single dose of <e1>indomethacin</e1> caused recurrence of acute reversible <e2>oliguria</e2> .
3800626
D010423_D009408 CID <e2>Compression neuropathy of the radial nerve</e2> due to <e1>pentazocine-induced</e1> fibrous myopathy .
D010423_D009408 CID However , <e2>compression neuropathy</e2> due to fibrotic muscle affected by <e1>pentazocine-induced</e1> myopathy has not previously been reported .
D010423_D020425 CID <e2>Compression neuropathy of the radial nerve</e2> due to <e1>pentazocine-induced</e1> fibrous myopathy .
D010423_D005355 CID Compression neuropathy of the radial nerve due to <e1>pentazocine-induced</e1> <e2>fibrous myopathy</e2> .
D010423_D005355 CID <e2>Fibrous myopathy</e2> is a common , well-known side effect of repeated <e1>pentazocine</e1> injection .
D010423_D005355 CID In a 37-year-old woman with documented <e1>pentazocine-induced</e1> <e2>fibrous myopathy</e2> of triceps and deltoid muscles bilaterally and a three-week history of right wrist drop , electrodiagnostic examination showed a severe but partial lesion of the right radial nerve distal to the branches to the triceps , in addition to the fibrous myopathy .
D010423_D005355 CID In a 37-year-old woman with documented <e1>pentazocine-induced</e1> fibrous myopathy of triceps and deltoid muscles bilaterally and a three-week history of right wrist drop , electrodiagnostic examination showed a severe but partial lesion of the right radial nerve distal to the branches to the triceps , in addition to the <e2>fibrous myopathy</e2> .
D010423_D009135 CID Compression neuropathy of the radial nerve due to <e1>pentazocine-induced</e1> <e2>fibrous myopathy</e2> .
D010423_D009135 CID <e2>Fibrous myopathy</e2> is a common , well-known side effect of repeated <e1>pentazocine</e1> injection .
D010423_D009135 CID However , compression neuropathy due to fibrotic muscle affected by <e1>pentazocine-induced</e1> <e2>myopathy</e2> has not previously been reported .
D010423_D009135 CID In a 37-year-old woman with documented <e1>pentazocine-induced</e1> <e2>fibrous myopathy</e2> of triceps and deltoid muscles bilaterally and a three-week history of right wrist drop , electrodiagnostic examination showed a severe but partial lesion of the right radial nerve distal to the branches to the triceps , in addition to the fibrous myopathy .
D010423_D009135 CID In a 37-year-old woman with documented <e1>pentazocine-induced</e1> fibrous myopathy of triceps and deltoid muscles bilaterally and a three-week history of right wrist drop , electrodiagnostic examination showed a severe but partial lesion of the right radial nerve distal to the branches to the triceps , in addition to the <e2>fibrous myopathy</e2> .
15804801
D017239_D003323 CID <e2>Coronary aneurysm</e2> after implantation of a <e1>paclitaxel-eluting</e1> stent .
D017239_D003323 CID We present a 43-year-old man who developed a <e2>coronary aneurysm</e2> in the right coronary artery 6 months after receiving a <e1>paclitaxel-eluting</e1> stent .
11773892
D016572_D007674 CID BACKGROUND : The calcineurin inhibitors <e1>cyclosporine</e1> and tacrolimus are both known to be <e2>nephrotoxic</e2> .
D016559_D007674 CID BACKGROUND : The calcineurin inhibitors cyclosporine and <e1>tacrolimus</e1> are both known to be <e2>nephrotoxic</e2> .
D003404_D007676 NONE Patients were divided into three groups : Controls , no <e2>CRF</e2> or ESRD , n=748 ; CRF , sustained serum <e1>creatinine</e1> > 2.5 mg/dl , n=41 ; and ESRD , n=45 .
D003404_D007676 NONE Patients were divided into three groups : Controls , no CRF or <e2>ESRD</e2> , n=748 ; CRF , sustained serum <e1>creatinine</e1> > 2.5 mg/dl , n=41 ; and ESRD , n=45 .
D003404_D007676 NONE Patients were divided into three groups : Controls , no CRF or ESRD , n=748 ; <e2>CRF</e2> , sustained serum <e1>creatinine</e1> > 2.5 mg/dl , n=41 ; and ESRD , n=45 .
D003404_D007676 NONE Patients were divided into three groups : Controls , no CRF or ESRD , n=748 ; CRF , sustained serum <e1>creatinine</e1> > 2.5 mg/dl , n=41 ; and <e2>ESRD</e2> , n=45 .
D003404_D007676 NONE Compared with control patients , <e2>CRF</e2> and ESRD patients had higher preoperative serum <e1>creatinine</e1> levels , a greater percentage of patients with hepatorenal syndrome , higher percentage requirement for dialysis in the first 3 months postoperatively , and a higher 1-year serum creatinine .
D003404_D007676 NONE Compared with control patients , CRF and <e2>ESRD</e2> patients had higher preoperative serum <e1>creatinine</e1> levels , a greater percentage of patients with hepatorenal syndrome , higher percentage requirement for dialysis in the first 3 months postoperatively , and a higher 1-year serum creatinine .
D003404_D007676 NONE Compared with control patients , <e2>CRF</e2> and ESRD patients had higher preoperative serum creatinine levels , a greater percentage of patients with hepatorenal syndrome , higher percentage requirement for dialysis in the first 3 months postoperatively , and a higher 1-year serum <e1>creatinine</e1> .
D003404_D007676 NONE Compared with control patients , CRF and <e2>ESRD</e2> patients had higher preoperative serum creatinine levels , a greater percentage of patients with hepatorenal syndrome , higher percentage requirement for dialysis in the first 3 months postoperatively , and a higher 1-year serum <e1>creatinine</e1> .
D003404_D007676 NONE Multivariate stepwise logistic regression analysis using preoperative and postoperative variables identified that an increase of serum <e1>creatinine</e1> compared with average at 1 year , 3 months , and 4 weeks postoperatively were independent risk factors for the development of <e2>CRF</e2> or ESRD with odds ratios of 2.6 , 2.2 , and 1.6 , respectively .
D003404_D007676 NONE Multivariate stepwise logistic regression analysis using preoperative and postoperative variables identified that an increase of serum <e1>creatinine</e1> compared with average at 1 year , 3 months , and 4 weeks postoperatively were independent risk factors for the development of CRF or <e2>ESRD</e2> with odds ratios of 2.6 , 2.2 , and 1.6 , respectively .
D003404_D007676 NONE Patients who develop <e2>ESRD</e2> have a higher preoperative and 1-year serum <e1>creatinine</e1> and are more likely to have hepatorenal syndrome .
D003404_D007676 NONE However , an increase of serum <e1>creatinine</e1> at various times postoperatively is more predictive of the development of <e2>CRF</e2> or ESRD .
D003404_D007676 NONE However , an increase of serum <e1>creatinine</e1> at various times postoperatively is more predictive of the development of CRF or <e2>ESRD</e2> .
D003404_D006530 NONE Compared with control patients , CRF and ESRD patients had higher preoperative serum <e1>creatinine</e1> levels , a greater percentage of patients with <e2>hepatorenal syndrome</e2> , higher percentage requirement for dialysis in the first 3 months postoperatively , and a higher 1-year serum creatinine .
D003404_D006530 NONE Compared with control patients , CRF and ESRD patients had higher preoperative serum creatinine levels , a greater percentage of patients with <e2>hepatorenal syndrome</e2> , higher percentage requirement for dialysis in the first 3 months postoperatively , and a higher 1-year serum <e1>creatinine</e1> .
D003404_D006530 NONE Patients who develop ESRD have a higher preoperative and 1-year serum <e1>creatinine</e1> and are more likely to have <e2>hepatorenal syndrome</e2> .
17466854
D008775_D002386 NONE PURPOSE : To assess the incidence of postoperative emetic side effects after the administration of <e1>methylprednisolone</e1> and gentamicin into the posterior sub-Tenon 's space at the end of routine <e2>cataract</e2> surgery .
D005839_D002386 NONE PURPOSE : To assess the incidence of postoperative emetic side effects after the administration of methylprednisolone and <e1>gentamicin</e1> into the posterior sub-Tenon 's space at the end of routine <e2>cataract</e2> surgery .
D008775_D020250 CID CONCLUSIONS : The administration of <e1>methylprednisolone</e1> and gentamicin in the posterior sub-Tenon 's space was related to a high incidence of side effects including <e2>nausea , vomiting</e2> , and headache .
D008775_D006261 CID CONCLUSIONS : The administration of <e1>methylprednisolone</e1> and gentamicin in the posterior sub-Tenon 's space was related to a high incidence of side effects including nausea , vomiting , and <e2>headache</e2> .
D005839_D020250 CID CONCLUSIONS : The administration of methylprednisolone and <e1>gentamicin</e1> in the posterior sub-Tenon 's space was related to a high incidence of side effects including <e2>nausea , vomiting</e2> , and headache .
D005839_D006261 CID CONCLUSIONS : The administration of methylprednisolone and <e1>gentamicin</e1> in the posterior sub-Tenon 's space was related to a high incidence of side effects including nausea , vomiting , and <e2>headache</e2> .
8590259
C016986_D015814 CID The <e2>ocular hypotensive</e2> effects were statistically significant for <e1>apraclonidine-treated</e1> eyes throughout the study and also statistically significant for contralateral eyes from three hours after topical administration of 1 % apraclonidine .
C016986_D015814 CID The <e2>ocular hypotensive</e2> effects were statistically significant for apraclonidine-treated eyes throughout the study and also statistically significant for contralateral eyes from three hours after topical administration of 1 % <e1>apraclonidine</e1> .
14568327
D007980_D004409 CID Development of <e1>levodopa-induced</e1> <e2>dyskinesias</e2> in parkinsonian monkeys may depend upon rate of symptom onset and/or duration of symptoms .
D007980_D004409 CID <e1>Levodopa-induced</e1> <e2>dyskinesias</e2> ( LIDs ) present a major problem for the long-term management of Parkinson 's disease ( PD ) patients .
D007980_D004409 CID <e1>Levodopa-induced</e1> dyskinesias ( <e2>LIDs</e2> ) present a major problem for the long-term management of Parkinson 's disease ( PD ) patients .
D007980_D004409 CID Using macaque monkeys with different types of MPTP-induced parkinsonism , the current study evaluated the degree to which rate of symptom progression , symptom severity , and response to and duration of <e1>levodopa</e1> therapy may be involved in the development of <e2>LIDs</e2> .
D007980_D004409 CID Monkeys with acute ( short-term ) MPTP exposure , rapid symptom onset and short symptom duration prior to initiation of <e1>levodopa</e1> therapy developed <e2>dyskinesia</e2> between 11 and 24 days of daily levodopa administration .
D007980_D004409 CID Monkeys with acute ( short-term ) MPTP exposure , rapid symptom onset and short symptom duration prior to initiation of levodopa therapy developed <e2>dyskinesia</e2> between 11 and 24 days of daily <e1>levodopa</e1> administration .
D007980_D004409 CID In contrast , monkeys with long-term MPTP exposure , slow symptom progression and/or long symptom duration prior to initiation of <e1>levodopa</e1> therapy were more resistant to developing <e2>LIDs</e2> ( e.g. , dyskinesia developed no sooner than 146 days of chronic levodopa administration ) .
D007980_D004409 CID In contrast , monkeys with long-term MPTP exposure , slow symptom progression and/or long symptom duration prior to initiation of <e1>levodopa</e1> therapy were more resistant to developing LIDs ( e.g. , <e2>dyskinesia</e2> developed no sooner than 146 days of chronic levodopa administration ) .
D007980_D004409 CID In contrast , monkeys with long-term MPTP exposure , slow symptom progression and/or long symptom duration prior to initiation of levodopa therapy were more resistant to developing <e2>LIDs</e2> ( e.g. , dyskinesia developed no sooner than 146 days of chronic <e1>levodopa</e1> administration ) .
D007980_D004409 CID In contrast , monkeys with long-term MPTP exposure , slow symptom progression and/or long symptom duration prior to initiation of levodopa therapy were more resistant to developing LIDs ( e.g. , <e2>dyskinesia</e2> developed no sooner than 146 days of chronic <e1>levodopa</e1> administration ) .
D007980_D004409 CID These data suggest distinct differences in the propensity to develop <e2>LIDs</e2> in monkeys with different rates of symptom progression or symptom durations prior to <e1>levodopa</e1> and demonstrate the value of these models for further studying the pathophysiology of LIDs .
D007980_D004409 CID These data suggest distinct differences in the propensity to develop LIDs in monkeys with different rates of symptom progression or symptom durations prior to <e1>levodopa</e1> and demonstrate the value of these models for further studying the pathophysiology of <e2>LIDs</e2> .
D007980_D010300 NONE Development of <e1>levodopa-induced</e1> dyskinesias in <e2>parkinsonian</e2> monkeys may depend upon rate of symptom onset and/or duration of symptoms .
D007980_D010300 NONE <e1>Levodopa-induced</e1> dyskinesias ( LIDs ) present a major problem for the long-term management of <e2>Parkinson 's disease</e2> ( PD ) patients .
D007980_D010300 NONE <e1>Levodopa-induced</e1> dyskinesias ( LIDs ) present a major problem for the long-term management of Parkinson 's disease ( <e2>PD</e2> ) patients .
D015632_D010302 CID Using macaque monkeys with different types of <e1>MPTP-induced</e1> <e2>parkinsonism</e2> , the current study evaluated the degree to which rate of symptom progression , symptom severity , and response to and duration of levodopa therapy may be involved in the development of LIDs .
D015632_D004409 NONE Using macaque monkeys with different types of <e1>MPTP-induced</e1> parkinsonism , the current study evaluated the degree to which rate of symptom progression , symptom severity , and response to and duration of levodopa therapy may be involved in the development of <e2>LIDs</e2> .
D015632_D004409 NONE Monkeys with acute ( short-term ) <e1>MPTP</e1> exposure , rapid symptom onset and short symptom duration prior to initiation of levodopa therapy developed <e2>dyskinesia</e2> between 11 and 24 days of daily levodopa administration .
D015632_D004409 NONE In contrast , monkeys with long-term <e1>MPTP</e1> exposure , slow symptom progression and/or long symptom duration prior to initiation of levodopa therapy were more resistant to developing <e2>LIDs</e2> ( e.g. , dyskinesia developed no sooner than 146 days of chronic levodopa administration ) .
D015632_D004409 NONE In contrast , monkeys with long-term <e1>MPTP</e1> exposure , slow symptom progression and/or long symptom duration prior to initiation of levodopa therapy were more resistant to developing LIDs ( e.g. , <e2>dyskinesia</e2> developed no sooner than 146 days of chronic levodopa administration ) .
D007980_D010302 NONE Using macaque monkeys with different types of MPTP-induced <e2>parkinsonism</e2> , the current study evaluated the degree to which rate of symptom progression , symptom severity , and response to and duration of <e1>levodopa</e1> therapy may be involved in the development of LIDs .
9522143
D011318_D034381 CID Patients given <e1>prilocaine</e1> were more likely to develop <e2>hearing loss</e2> ( 10 out of 22 ) than those given bupivacaine ( 4 out of 22 ) ( P < 0.05 ) .
D011318_D034381 CID The average <e2>hearing loss</e2> for speech frequencies was about 10 dB after <e1>prilocaine</e1> and 15 dB after bupivacaine .
D002045_D034381 CID Patients given prilocaine were more likely to develop <e2>hearing loss</e2> ( 10 out of 22 ) than those given <e1>bupivacaine</e1> ( 4 out of 22 ) ( P < 0.05 ) .
D002045_D034381 CID The average <e2>hearing loss</e2> for speech frequencies was about 10 dB after prilocaine and 15 dB after <e1>bupivacaine</e1> .
15233872
C007145_D009203 NONE Cardioprotective effect of <e1>tincture of Crataegus</e1> on isoproterenol-induced <e2>myocardial infarction</e2> in rats .
C007145_D009203 NONE The present study was done to investigate the protective effect of <e1>TCR</e1> on experimentally induced <e2>myocardial infarction</e2> in rats .
D007545_D009203 CID Cardioprotective effect of tincture of Crataegus on <e1>isoproterenol-induced</e1> <e2>myocardial infarction</e2> in rats .
1378968
D008094_D007676 CID Effects of uninephrectomy and high protein feeding on <e1>lithium-induced</e1> <e2>chronic renal failure</e2> in rats .
D008094_D007674 NONE Rats with <e1>lithium-induced</e1> <e2>nephropathy</e2> were subjected to high protein ( HP ) feeding , uninephrectomy ( NX ) or a combination of these , in an attempt to induce glomerular hyperfiltration and further progression of renal failure .
D008094_D007674 NONE The results indicate that <e1>Li-induced</e1> <e2>nephropathy</e2> , even when the GFR is only modestly reduced , is associated with proteinuria and arterial systolic hypertension .
D008094_D051437 NONE Rats with <e1>lithium-induced</e1> nephropathy were subjected to high protein ( HP ) feeding , uninephrectomy ( NX ) or a combination of these , in an attempt to induce glomerular hyperfiltration and further progression of <e2>renal failure</e2> .
D008094_D051437 NONE HP failed to accentuante progression of <e2>renal failure</e2> and in fact tended to increase GFR and decrease plasma creatinine levels in <e1>lithium</e1> pretreated rats .
D008094_D011507 CID <e1>Lithium</e1> also caused <e2>proteinuria</e2> and systolic hypertension in absence of glomerulosclerosis .
D008094_D011507 CID The results indicate that <e1>Li-induced</e1> nephropathy , even when the GFR is only modestly reduced , is associated with <e2>proteinuria</e2> and arterial systolic hypertension .
D008094_D006973 CID <e1>Lithium</e1> also caused proteinuria and systolic <e2>hypertension</e2> in absence of glomerulosclerosis .
D008094_D006973 CID The results indicate that <e1>Li-induced</e1> nephropathy , even when the GFR is only modestly reduced , is associated with proteinuria and arterial systolic <e2>hypertension</e2> .
D008094_D005921 NONE <e1>Lithium</e1> also caused proteinuria and systolic hypertension in absence of <e2>glomerulosclerosis</e2> .
D003404_D051437 NONE HP failed to accentuante progression of <e2>renal failure</e2> and in fact tended to increase GFR and decrease plasma <e1>creatinine</e1> levels in lithium pretreated rats .
3503576
D003676_D006311 NONE Serial studies of <e2>auditory neurotoxicity</e2> in patients receiving <e1>deferoxamine</e1> therapy .
D003676_D006311 NONE <e2>Visual and auditory neurotoxicity</e2> was previously documented in 42 of 89 patients with transfusion-dependent anemia who were receiving iron chelation therapy with daily subcutaneous <e1>deferoxamine</e1> .
D003676_D006311 NONE Since 18 of the 22 patients were initially receiving <e1>deferoxamine</e1> doses in excess of the commonly recommended 50 mg/kg per dose , therapy was restarted with lower doses , usually 50 mg/kg per dose or less depending on the degree of <e2>auditory abnormality</e2> , and with the exception of two cases no further toxicity was demonstrated .
D003676_D006311 NONE Auditory deterioration and improvement , demonstrated serially in individual patients receiving and not receiving <e1>deferoxamine</e1> , respectively , provided convincing evidence for a cause-and-effect relation between deferoxamine administration and <e2>ototoxicity</e2> .
D003676_D006311 NONE Auditory deterioration and improvement , demonstrated serially in individual patients receiving and not receiving deferoxamine , respectively , provided convincing evidence for a cause-and-effect relation between <e1>deferoxamine</e1> administration and <e2>ototoxicity</e2> .
D007501_D014786 NONE <e2>Visual and auditory neurotoxicity</e2> was previously documented in 42 of 89 patients with transfusion-dependent anemia who were receiving <e1>iron</e1> chelation therapy with daily subcutaneous deferoxamine .
D007501_D006311 NONE <e2>Visual and auditory neurotoxicity</e2> was previously documented in 42 of 89 patients with transfusion-dependent anemia who were receiving <e1>iron</e1> chelation therapy with daily subcutaneous deferoxamine .
D007501_D000740 NONE Visual and auditory neurotoxicity was previously documented in 42 of 89 patients with transfusion-dependent <e2>anemia</e2> who were receiving <e1>iron</e1> chelation therapy with daily subcutaneous deferoxamine .
D003676_D014786 NONE <e2>Visual and auditory neurotoxicity</e2> was previously documented in 42 of 89 patients with transfusion-dependent anemia who were receiving iron chelation therapy with daily subcutaneous <e1>deferoxamine</e1> .
D003676_D000740 NONE Visual and auditory neurotoxicity was previously documented in 42 of 89 patients with transfusion-dependent <e2>anemia</e2> who were receiving iron chelation therapy with daily subcutaneous <e1>deferoxamine</e1> .
D003676_D064420 NONE Since 18 of the 22 patients were initially receiving <e1>deferoxamine</e1> doses in excess of the commonly recommended 50 mg/kg per dose , therapy was restarted with lower doses , usually 50 mg/kg per dose or less depending on the degree of auditory abnormality , and with the exception of two cases no further <e2>toxicity</e2> was demonstrated .
7628595
D014805_D064420 NONE Study of the role of <e1>vitamin B12</e1> and folinic acid supplementation in preventing hematologic <e2>toxicity</e2> of zidovudine .
D002955_D064420 NONE Study of the role of vitamin B12 and <e1>folinic acid</e1> supplementation in preventing hematologic <e2>toxicity</e2> of zidovudine .
D015215_D064420 NONE Study of the role of vitamin B12 and folinic acid supplementation in preventing hematologic <e2>toxicity</e2> of <e1>zidovudine</e1> .
D014805_D001855 NONE A prospective , randomized study was conducted to evaluate the role of <e1>vitamin B12</e1> and folinic acid supplementation in preventing zidovudine (ZDV)-induced <e2>bone marrow suppression</e2> .
D014805_D001855 NONE There was no correlation between <e1>vitamin B12</e1> or folate levels and development of <e2>myelosuppression</e2> .
D014805_D001855 NONE <e1>Vitamin B12</e1> and folinic acid supplementation of ZDV therapy does not seem useful in preventing or reducing ZDV-induced <e2>myelotoxicity</e2> in the overall treated population , although a beneficial effect in certain subgroups of patients can not be excluded .
D002955_D001855 NONE A prospective , randomized study was conducted to evaluate the role of vitamin B12 and <e1>folinic acid</e1> supplementation in preventing zidovudine (ZDV)-induced <e2>bone marrow suppression</e2> .
D002955_D001855 NONE Vitamin B12 and <e1>folinic acid</e1> supplementation of ZDV therapy does not seem useful in preventing or reducing ZDV-induced <e2>myelotoxicity</e2> in the overall treated population , although a beneficial effect in certain subgroups of patients can not be excluded .
D015215_D001855 CID A prospective , randomized study was conducted to evaluate the role of vitamin B12 and folinic acid supplementation in preventing <e1>zidovudine</e1> (ZDV)-induced <e2>bone marrow suppression</e2> .
D015215_D001855 CID A prospective , randomized study was conducted to evaluate the role of vitamin B12 and folinic acid supplementation in preventing zidovudine <e1>(ZDV)-induced</e1> <e2>bone marrow suppression</e2> .
D015215_D001855 CID Vitamin B12 and folinic acid supplementation of <e1>ZDV</e1> therapy does not seem useful in preventing or reducing ZDV-induced <e2>myelotoxicity</e2> in the overall treated population , although a beneficial effect in certain subgroups of patients can not be excluded .
D015215_D001855 CID Vitamin B12 and folinic acid supplementation of ZDV therapy does not seem useful in preventing or reducing <e1>ZDV-induced</e1> <e2>myelotoxicity</e2> in the overall treated population , although a beneficial effect in certain subgroups of patients can not be excluded .
D015215_D015658 NONE Seventy-five <e2>human immunodeficiency virus (HIV)-infected</e2> patients with CD4 + cell counts < 500/mm3 were randomized to receive either <e1>ZDV</e1> ( 500 mg daily ) alone ( group I , n = 38 ) or in combination with folinic acid ( 15 mg daily ) and intramascular vitamin B12 ( 1000 micrograms monthly ) ( group II , n = 37 ) .
D002955_D015658 NONE Seventy-five <e2>human immunodeficiency virus (HIV)-infected</e2> patients with CD4 + cell counts < 500/mm3 were randomized to receive either ZDV ( 500 mg daily ) alone ( group I , n = 38 ) or in combination with <e1>folinic acid</e1> ( 15 mg daily ) and intramascular vitamin B12 ( 1000 micrograms monthly ) ( group II , n = 37 ) .
D014805_D015658 NONE Seventy-five <e2>human immunodeficiency virus (HIV)-infected</e2> patients with CD4 + cell counts < 500/mm3 were randomized to receive either ZDV ( 500 mg daily ) alone ( group I , n = 38 ) or in combination with folinic acid ( 15 mg daily ) and intramascular <e1>vitamin B12</e1> ( 1000 micrograms monthly ) ( group II , n = 37 ) .
D005492_D001855 NONE There was no correlation between vitamin B12 or <e1>folate</e1> levels and development of <e2>myelosuppression</e2> .
16298782
D019331_D006311 NONE <e1>Nitro-L-arginine methyl ester</e1> : a potential protector against gentamicin <e2>ototoxicity</e2> .
D005839_D006311 NONE Nitro-L-arginine methyl ester : a potential protector against <e1>gentamicin</e1> <e2>ototoxicity</e2> .
D009569_D006316 NONE The <e1>nitric oxide</e1> ( NO ) inhibitor nitro-L-arginine methyl ester ( L-NAME ) may act as an otoprotectant against <e2>high-frequency hearing loss</e2> caused by gentamicin , but further studies are needed to confirm this .
D009569_D006316 NONE The nitric oxide ( <e1>NO</e1> ) inhibitor nitro-L-arginine methyl ester ( L-NAME ) may act as an otoprotectant against <e2>high-frequency hearing loss</e2> caused by gentamicin , but further studies are needed to confirm this .
D019331_D006316 NONE The nitric oxide ( NO ) inhibitor <e1>nitro-L-arginine methyl ester</e1> ( L-NAME ) may act as an otoprotectant against <e2>high-frequency hearing loss</e2> caused by gentamicin , but further studies are needed to confirm this .
D019331_D006316 NONE The nitric oxide ( NO ) inhibitor nitro-L-arginine methyl ester ( <e1>L-NAME</e1> ) may act as an otoprotectant against <e2>high-frequency hearing loss</e2> caused by gentamicin , but further studies are needed to confirm this .
D005839_D006316 NONE The nitric oxide ( NO ) inhibitor nitro-L-arginine methyl ester ( L-NAME ) may act as an otoprotectant against <e2>high-frequency hearing loss</e2> caused by <e1>gentamicin</e1> , but further studies are needed to confirm this .
D009569_D006311 NONE Their <e2>ototoxicity</e2> is a serious health problem and , as their ototoxic mechanism involves the production of <e1>NO</e1> , we need to assess the use of NO inhibitors for the prevention of aminoglycoside-induced sensorineural hearing loss .
D009569_D006311 NONE Their ototoxicity is a serious health problem and , as their <e2>ototoxic</e2> mechanism involves the production of <e1>NO</e1> , we need to assess the use of NO inhibitors for the prevention of aminoglycoside-induced sensorineural hearing loss .
D009569_D006311 NONE Their <e2>ototoxicity</e2> is a serious health problem and , as their ototoxic mechanism involves the production of NO , we need to assess the use of <e1>NO</e1> inhibitors for the prevention of aminoglycoside-induced sensorineural hearing loss .
D009569_D006311 NONE Their ototoxicity is a serious health problem and , as their <e2>ototoxic</e2> mechanism involves the production of NO , we need to assess the use of <e1>NO</e1> inhibitors for the prevention of aminoglycoside-induced sensorineural hearing loss .
D009569_D006319 NONE Their ototoxicity is a serious health problem and , as their ototoxic mechanism involves the production of <e1>NO</e1> , we need to assess the use of NO inhibitors for the prevention of aminoglycoside-induced <e2>sensorineural hearing loss</e2> .
D009569_D006319 NONE Their ototoxicity is a serious health problem and , as their ototoxic mechanism involves the production of NO , we need to assess the use of <e1>NO</e1> inhibitors for the prevention of aminoglycoside-induced <e2>sensorineural hearing loss</e2> .
D000617_D006311 NONE Their <e2>ototoxicity</e2> is a serious health problem and , as their ototoxic mechanism involves the production of NO , we need to assess the use of NO inhibitors for the prevention of <e1>aminoglycoside-induced</e1> sensorineural hearing loss .
D000617_D006311 NONE Their ototoxicity is a serious health problem and , as their <e2>ototoxic</e2> mechanism involves the production of NO , we need to assess the use of NO inhibitors for the prevention of <e1>aminoglycoside-induced</e1> sensorineural hearing loss .
D000617_D006319 NONE Their ototoxicity is a serious health problem and , as their ototoxic mechanism involves the production of NO , we need to assess the use of NO inhibitors for the prevention of <e1>aminoglycoside-induced</e1> <e2>sensorineural hearing loss</e2> .
D019331_D034381 NONE <e1>L-NAME</e1> reduced gentamicin-induced <e2>hearing loss</e2> in the high-frequency range , but gave no protection in the middle or low frequencies .
D005839_D034381 CID L-NAME reduced <e1>gentamicin-induced</e1> <e2>hearing loss</e2> in the high-frequency range , but gave no protection in the middle or low frequencies .
6538499
D011092_D064420 NONE Effect of <e1>polyethylene glycol 400</e1> on adriamycin <e2>toxicity</e2> in mice .
D004317_D064420 NONE Effect of polyethylene glycol 400 on <e1>adriamycin</e1> <e2>toxicity</e2> in mice .
D004317_D009202 CID Light microscopic analysis showed a significant protection against <e1>ADR-induced</e1> <e2>cardiac morphological alterations</e2> .
D004317_D007939 NONE Such treatment did not diminish the <e1>ADR</e1> antitumor activity in <e2>L1210 leukemia</e2> and in Ehrlich ascites tumor .
D004317_D002286 NONE Such treatment did not diminish the <e1>ADR</e1> antitumor activity in L1210 leukemia and in <e2>Ehrlich ascites tumor</e2> .
12653683
D012964_D009404 NONE Epithelial <e1>sodium</e1> channel ( ENaC ) subunit mRNA and protein expression in rats with puromycin aminonucleoside-induced <e2>nephrotic syndrome</e2> .
D012964_D009404 NONE In experimental <e2>nephrotic syndrome</e2> , urinary <e1>sodium</e1> excretion is decreased during the early phase of the disease .
D011692_D009404 CID Epithelial sodium channel ( ENaC ) subunit mRNA and protein expression in rats with <e1>puromycin aminonucleoside-induced</e1> <e2>nephrotic syndrome</e2> .
D011692_D009404 CID We examined the abundance of ENaC subunit mRNAs and proteins in <e1>puromycin aminonucleoside</e1> (PAN)-induced <e2>nephrotic syndrome</e2> .
D011692_D009404 CID We examined the abundance of ENaC subunit mRNAs and proteins in puromycin aminonucleoside <e1>(PAN)-induced</e1> <e2>nephrotic syndrome</e2> .
D011692_D009404 CID In conclusion , ENaC mRNA expression , especially alphaENaC , is increased in the very early phase of the experimental model of <e1>PAN-induced</e1> <e2>nephrotic syndrome</e2> in rats , but appears to escape from the regulation by aldosterone after day 3 .
D012964_D011507 NONE The time courses of urinary <e1>sodium</e1> excretion , plasma aldosterone concentration and <e2>proteinuria</e2> were studied in male Sprague-Dawley rats treated with a single dose of either PAN or vehicle .
D012964_D011507 NONE The kinetics of urinary <e1>sodium</e1> excretion and the appearance of <e2>proteinuria</e2> were comparable with those reported previously .
D000450_D011507 NONE The time courses of urinary sodium excretion , plasma <e1>aldosterone</e1> concentration and <e2>proteinuria</e2> were studied in male Sprague-Dawley rats treated with a single dose of either PAN or vehicle .
D011692_D011507 CID The time courses of urinary sodium excretion , plasma aldosterone concentration and <e2>proteinuria</e2> were studied in male Sprague-Dawley rats treated with a single dose of either <e1>PAN</e1> or vehicle .
D000450_D009404 NONE In conclusion , ENaC mRNA expression , especially alphaENaC , is increased in the very early phase of the experimental model of PAN-induced <e2>nephrotic syndrome</e2> in rats , but appears to escape from the regulation by <e1>aldosterone</e1> after day 3 .
3615541
D000661_D006948 CID Regional localization of the antagonism of <e1>amphetamine-induced</e1> <e2>hyperactivity</e2> by intracerebral calcitonin injections .
D002116_D006948 NONE Regional localization of the antagonism of amphetamine-induced <e2>hyperactivity</e2> by intracerebral <e1>calcitonin</e1> injections .
20084309
D008874_D020521 NONE Uni- and multivariate analyses were used to test the influence of the clinical variables : age , sex , <e2>stroke</e2> , myocardiopathy ( MP ) , duration of the test , mitral regurgitation ( MR ) and the <e1>MZ</e1> dose .
D008874_D009202 NONE Uni- and multivariate analyses were used to test the influence of the clinical variables : age , sex , stroke , <e2>myocardiopathy</e2> ( MP ) , duration of the test , mitral regurgitation ( MR ) and the <e1>MZ</e1> dose .
D008874_D009202 NONE Uni- and multivariate analyses were used to test the influence of the clinical variables : age , sex , stroke , myocardiopathy ( <e2>MP</e2> ) , duration of the test , mitral regurgitation ( MR ) and the <e1>MZ</e1> dose .
D008874_D009202 NONE The multivariate analysis showed that severe MR , <e2>MP</e2> ( EF<45 % ) and high doses of <e1>MZ</e1> ( > 5 mg ) were associated with events ( p<0.001 ) .
D008874_D008944 NONE Uni- and multivariate analyses were used to test the influence of the clinical variables : age , sex , stroke , myocardiopathy ( MP ) , duration of the test , <e2>mitral regurgitation</e2> ( MR ) and the <e1>MZ</e1> dose .
D008874_D008944 NONE Uni- and multivariate analyses were used to test the influence of the clinical variables : age , sex , stroke , myocardiopathy ( MP ) , duration of the test , mitral regurgitation ( <e2>MR</e2> ) and the <e1>MZ</e1> dose .
D008874_D008944 NONE The multivariate analysis showed that severe <e2>MR</e2> , MP ( EF<45 % ) and high doses of <e1>MZ</e1> ( > 5 mg ) were associated with events ( p<0.001 ) .
D008874_D000860 CID Mild <e2>hypoxia</e2> ( SO2<90 % ) was the most common event ( 11 patients ) ; 3 patients ( 2 % ) presented transient hypoxia due to upper airway obstruction by probe introduction and 8 ( 5.8 % ) due to hypoxia caused by <e1>MZ</e1> use .
D008874_D000860 CID Mild hypoxia ( SO2<90 % ) was the most common event ( 11 patients ) ; 3 patients ( 2 % ) presented transient <e2>hypoxia</e2> due to upper airway obstruction by probe introduction and 8 ( 5.8 % ) due to hypoxia caused by <e1>MZ</e1> use .
D008874_D000860 CID Mild hypoxia ( SO2<90 % ) was the most common event ( 11 patients ) ; 3 patients ( 2 % ) presented transient hypoxia due to upper airway obstruction by probe introduction and 8 ( 5.8 % ) due to <e2>hypoxia</e2> caused by <e1>MZ</e1> use .
D008874_D000402 NONE Mild hypoxia ( SO2<90 % ) was the most common event ( 11 patients ) ; 3 patients ( 2 % ) presented transient hypoxia due to upper <e2>airway obstruction</e2> by probe introduction and 8 ( 5.8 % ) due to hypoxia caused by <e1>MZ</e1> use .
1786266
D000928_D001480 NONE <e2>Rabbit syndrome</e2> , <e1>antidepressant</e1> use , and cerebral perfusion SPECT scan findings .
15325671
D003520_D066126 NONE <e2>Cardiac toxicity</e2> observed in association with high-dose <e1>cyclophosphamide-based</e1> chemotherapy for metastatic breast cancer .
D003520_D066126 NONE Incidence of transient <e1>cyclophosphamide-related</e1> <e2>cardiac toxicity</e2> ( 10 % ) is comparable to previous recorded literature .
D003520_D001943 NONE Cardiac toxicity observed in association with high-dose <e1>cyclophosphamide-based</e1> chemotherapy for metastatic <e2>breast cancer</e2> .
D003520_D001943 NONE STUDY DESIGN : We combined paclitaxel , melphalan and high-dose <e1>cyclophosphamide</e1> , thiotepa , and carboplatin in a triple sequential high-dose regimen for patients with metastatic <e2>breast cancer</e2> .
D003520_D001943 NONE Analysis was performed on 61 women with chemotherapy-responsive metastatic <e2>breast cancer</e2> receiving 96-h infusional <e1>cyclophosphamide</e1> as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure ( CHF ) and the following pretreatment characteristics : presence of electrocardiogram ( EKG ) abnormalities , age , hypertension , prior cardiac history , smoking , diabetes mellitus , prior use of anthracyclines , and left-sided chest irradiation .
D017239_D001943 NONE STUDY DESIGN : We combined <e1>paclitaxel</e1> , melphalan and high-dose cyclophosphamide , thiotepa , and carboplatin in a triple sequential high-dose regimen for patients with metastatic <e2>breast cancer</e2> .
D008558_D001943 NONE STUDY DESIGN : We combined paclitaxel , <e1>melphalan</e1> and high-dose cyclophosphamide , thiotepa , and carboplatin in a triple sequential high-dose regimen for patients with metastatic <e2>breast cancer</e2> .
D013852_D001943 NONE STUDY DESIGN : We combined paclitaxel , melphalan and high-dose cyclophosphamide , <e1>thiotepa</e1> , and carboplatin in a triple sequential high-dose regimen for patients with metastatic <e2>breast cancer</e2> .
D016190_D001943 NONE STUDY DESIGN : We combined paclitaxel , melphalan and high-dose cyclophosphamide , thiotepa , and <e1>carboplatin</e1> in a triple sequential high-dose regimen for patients with metastatic <e2>breast cancer</e2> .
D003520_D006333 CID Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional <e1>cyclophosphamide</e1> as part of a triple sequential high-dose regimen to assess association between presence of peritransplant <e2>congestive heart failure</e2> ( CHF ) and the following pretreatment characteristics : presence of electrocardiogram ( EKG ) abnormalities , age , hypertension , prior cardiac history , smoking , diabetes mellitus , prior use of anthracyclines , and left-sided chest irradiation .
D003520_D006333 CID Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional <e1>cyclophosphamide</e1> as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure ( <e2>CHF</e2> ) and the following pretreatment characteristics : presence of electrocardiogram ( EKG ) abnormalities , age , hypertension , prior cardiac history , smoking , diabetes mellitus , prior use of anthracyclines , and left-sided chest irradiation .
D003520_D006333 CID RESULTS : Six of 61 women ( 10 % ) developed clinically reversible grade 3 <e2>CHF</e2> following infusional <e1>cyclophosphamide</e1> with a median percent decline in ejection fraction of 31 % .
D003520_D006333 CID Routine EKG monitoring during infusional <e1>cyclophosphamide</e1> did not predict <e2>CHF</e2> development .
D003520_D006973 NONE Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional <e1>cyclophosphamide</e1> as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure ( CHF ) and the following pretreatment characteristics : presence of electrocardiogram ( EKG ) abnormalities , age , <e2>hypertension</e2> , prior cardiac history , smoking , diabetes mellitus , prior use of anthracyclines , and left-sided chest irradiation .
D003520_D003920 NONE Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional <e1>cyclophosphamide</e1> as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure ( CHF ) and the following pretreatment characteristics : presence of electrocardiogram ( EKG ) abnormalities , age , hypertension , prior cardiac history , smoking , <e2>diabetes mellitus</e2> , prior use of anthracyclines , and left-sided chest irradiation .
D018943_D001943 NONE Analysis was performed on 61 women with chemotherapy-responsive metastatic <e2>breast cancer</e2> receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure ( CHF ) and the following pretreatment characteristics : presence of electrocardiogram ( EKG ) abnormalities , age , hypertension , prior cardiac history , smoking , diabetes mellitus , prior use of <e1>anthracyclines</e1> , and left-sided chest irradiation .
D018943_D006333 NONE Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant <e2>congestive heart failure</e2> ( CHF ) and the following pretreatment characteristics : presence of electrocardiogram ( EKG ) abnormalities , age , hypertension , prior cardiac history , smoking , diabetes mellitus , prior use of <e1>anthracyclines</e1> , and left-sided chest irradiation .
D018943_D006333 NONE Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure ( <e2>CHF</e2> ) and the following pretreatment characteristics : presence of electrocardiogram ( EKG ) abnormalities , age , hypertension , prior cardiac history , smoking , diabetes mellitus , prior use of <e1>anthracyclines</e1> , and left-sided chest irradiation .
D018943_D006973 NONE Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure ( CHF ) and the following pretreatment characteristics : presence of electrocardiogram ( EKG ) abnormalities , age , <e2>hypertension</e2> , prior cardiac history , smoking , diabetes mellitus , prior use of <e1>anthracyclines</e1> , and left-sided chest irradiation .
D018943_D003920 NONE Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure ( CHF ) and the following pretreatment characteristics : presence of electrocardiogram ( EKG ) abnormalities , age , hypertension , prior cardiac history , smoking , <e2>diabetes mellitus</e2> , prior use of <e1>anthracyclines</e1> , and left-sided chest irradiation .
2802551
D012964_D007674 NONE <e1>Sodium</e1> status influences chronic amphotericin B <e2>nephrotoxicity</e2> in rats .
D000666_D007674 CID Sodium status influences chronic <e1>amphotericin B</e1> <e2>nephrotoxicity</e2> in rats .
D000666_D007674 CID The <e2>nephrotoxic</e2> potential of <e1>amphotericin B</e1> ( 5 mg/kg per day intraperitoneally for 3 weeks ) has been investigated in salt-depleted , normal-salt , and salt-loaded rats .
2505783
C004656_D006470 CID Based on clinical data , indicating that <e1>chloroacetaldehyde</e1> ( CAA ) is an important metabolite of oxazaphosphorine cytostatics , an experimental study was carried out in order to elucidate the role of CAA in the development of <e2>hemorrhagic cystitis</e2> .
C004656_D006470 CID Based on clinical data , indicating that chloroacetaldehyde ( <e1>CAA</e1> ) is an important metabolite of oxazaphosphorine cytostatics , an experimental study was carried out in order to elucidate the role of CAA in the development of <e2>hemorrhagic cystitis</e2> .
C004656_D006470 CID Based on clinical data , indicating that chloroacetaldehyde ( CAA ) is an important metabolite of oxazaphosphorine cytostatics , an experimental study was carried out in order to elucidate the role of <e1>CAA</e1> in the development of <e2>hemorrhagic cystitis</e2> .
C004656_D003556 CID Based on clinical data , indicating that <e1>chloroacetaldehyde</e1> ( CAA ) is an important metabolite of oxazaphosphorine cytostatics , an experimental study was carried out in order to elucidate the role of CAA in the development of <e2>hemorrhagic cystitis</e2> .
C004656_D003556 CID Based on clinical data , indicating that chloroacetaldehyde ( <e1>CAA</e1> ) is an important metabolite of oxazaphosphorine cytostatics , an experimental study was carried out in order to elucidate the role of CAA in the development of <e2>hemorrhagic cystitis</e2> .
C004656_D003556 CID Based on clinical data , indicating that chloroacetaldehyde ( CAA ) is an important metabolite of oxazaphosphorine cytostatics , an experimental study was carried out in order to elucidate the role of <e1>CAA</e1> in the development of <e2>hemorrhagic cystitis</e2> .
C004656_D001745 NONE The data demonstrate that <e1>CAA</e1> after i.v. administration does not contribute to <e2>bladder damage</e2> .
11532387
D018967_D013375 CID <e2>Withdrawal-emergent rabbit syndrome</e2> during dose reduction of <e1>risperidone</e1> .
D018967_D013375 CID The underlying mechanism of <e2>withdrawal-emergent RS</e2> in the present case may have been related to the pharmacological profile of <e1>risperidone</e1> , a serotonin-dopamine antagonist , suggesting the pathophysiologic influence of the serotonin system in the development of RS .
D018967_D001480 CID <e2>Withdrawal-emergent rabbit syndrome</e2> during dose reduction of <e1>risperidone</e1> .
D018967_D001480 CID The patient developed <e2>RS</e2> during dose reduction of <e1>risperidone</e1> .
D018967_D001480 CID The underlying mechanism of <e2>withdrawal-emergent RS</e2> in the present case may have been related to the pharmacological profile of <e1>risperidone</e1> , a serotonin-dopamine antagonist , suggesting the pathophysiologic influence of the serotonin system in the development of RS .
D018967_D001480 CID The underlying mechanism of withdrawal-emergent RS in the present case may have been related to the pharmacological profile of <e1>risperidone</e1> , a serotonin-dopamine antagonist , suggesting the pathophysiologic influence of the serotonin system in the development of <e2>RS</e2> .
D012701_D013375 NONE The underlying mechanism of <e2>withdrawal-emergent RS</e2> in the present case may have been related to the pharmacological profile of risperidone , a <e1>serotonin-dopamine</e1> antagonist , suggesting the pathophysiologic influence of the serotonin system in the development of RS .
D012701_D013375 NONE The underlying mechanism of <e2>withdrawal-emergent RS</e2> in the present case may have been related to the pharmacological profile of risperidone , a serotonin-dopamine antagonist , suggesting the pathophysiologic influence of the <e1>serotonin</e1> system in the development of RS .
D012701_D001480 NONE The underlying mechanism of <e2>withdrawal-emergent RS</e2> in the present case may have been related to the pharmacological profile of risperidone , a <e1>serotonin-dopamine</e1> antagonist , suggesting the pathophysiologic influence of the serotonin system in the development of RS .
D012701_D001480 NONE The underlying mechanism of withdrawal-emergent RS in the present case may have been related to the pharmacological profile of risperidone , a <e1>serotonin-dopamine</e1> antagonist , suggesting the pathophysiologic influence of the serotonin system in the development of <e2>RS</e2> .
D012701_D001480 NONE The underlying mechanism of <e2>withdrawal-emergent RS</e2> in the present case may have been related to the pharmacological profile of risperidone , a serotonin-dopamine antagonist , suggesting the pathophysiologic influence of the <e1>serotonin</e1> system in the development of RS .
D012701_D001480 NONE The underlying mechanism of withdrawal-emergent RS in the present case may have been related to the pharmacological profile of risperidone , a serotonin-dopamine antagonist , suggesting the pathophysiologic influence of the <e1>serotonin</e1> system in the development of <e2>RS</e2> .
D004298_D013375 NONE The underlying mechanism of <e2>withdrawal-emergent RS</e2> in the present case may have been related to the pharmacological profile of risperidone , a <e1>serotonin-dopamine</e1> antagonist , suggesting the pathophysiologic influence of the serotonin system in the development of RS .
D004298_D001480 NONE The underlying mechanism of <e2>withdrawal-emergent RS</e2> in the present case may have been related to the pharmacological profile of risperidone , a <e1>serotonin-dopamine</e1> antagonist , suggesting the pathophysiologic influence of the serotonin system in the development of RS .
D004298_D001480 NONE The underlying mechanism of withdrawal-emergent RS in the present case may have been related to the pharmacological profile of risperidone , a <e1>serotonin-dopamine</e1> antagonist , suggesting the pathophysiologic influence of the serotonin system in the development of <e2>RS</e2> .
7420681
D014031_D007674 NONE Clinical <e2>nephrotoxicity</e2> of <e1>tobramycin</e1> and gentamicin .
D014031_D007674 NONE Gentamicin sulfate and <e1>tobramycin sulfate</e1> continue to demonstrate ototoxicity and <e2>nephrotoxicity</e2> in both animal and clinical studies .
D005839_D007674 NONE Clinical <e2>nephrotoxicity</e2> of tobramycin and <e1>gentamicin</e1> .
D005839_D007674 NONE <e1>Gentamicin sulfate</e1> and tobramycin sulfate continue to demonstrate ototoxicity and <e2>nephrotoxicity</e2> in both animal and clinical studies .
D005839_D006311 NONE <e1>Gentamicin sulfate</e1> and tobramycin sulfate continue to demonstrate <e2>ototoxicity</e2> and nephrotoxicity in both animal and clinical studies .
D014031_D006311 NONE Gentamicin sulfate and <e1>tobramycin sulfate</e1> continue to demonstrate <e2>ototoxicity</e2> and nephrotoxicity in both animal and clinical studies .
D005839_D051437 CID In this study , 62 patients with confirmed initial normal renal function and treated with 2 to 5 mg/kg/day of <e1>gentamicin sulfate</e1> or tobramycin sulfate for a minimum of seven days were followed up prospectively for the development of aminoglycoside-related <e2>renal failure</e2> , defined as at least a one-third reduction in renal function .
D005839_D051437 CID Five of 33 ( 15 % ) of the tobramycin-treated patients and 16 of 29 ( 55.2 % ) of the <e1>gentamicin-treated</e1> patients had <e2>renal failure</e2> .
D005839_D051437 CID Thus , <e1>gentamicin</e1> was associated with <e2>renal failure</e2> more than three times as often as was tobramycin .
D014031_D051437 CID In this study , 62 patients with confirmed initial normal renal function and treated with 2 to 5 mg/kg/day of gentamicin sulfate or <e1>tobramycin sulfate</e1> for a minimum of seven days were followed up prospectively for the development of aminoglycoside-related <e2>renal failure</e2> , defined as at least a one-third reduction in renal function .
D014031_D051437 CID Five of 33 ( 15 % ) of the <e1>tobramycin-treated</e1> patients and 16 of 29 ( 55.2 % ) of the gentamicin-treated patients had <e2>renal failure</e2> .
D014031_D051437 CID Thus , gentamicin was associated with <e2>renal failure</e2> more than three times as often as was <e1>tobramycin</e1> .
D000617_D051437 NONE In this study , 62 patients with confirmed initial normal renal function and treated with 2 to 5 mg/kg/day of gentamicin sulfate or tobramycin sulfate for a minimum of seven days were followed up prospectively for the development of <e1>aminoglycoside-related</e1> <e2>renal failure</e2> , defined as at least a one-third reduction in renal function .
12905102
D003024_D003693 CID <e2>Delirium</e2> during <e1>clozapine</e1> treatment : incidence and associated risk factors .
D003024_D003693 CID BACKGROUND : Incidence and risk factors for <e2>delirium</e2> during <e1>clozapine</e1> treatment require further clarification .
D003024_D003693 CID METHODS : We used computerized pharmacy records to identify all adult psychiatric inpatients treated with <e1>clozapine</e1> ( 1995 - 96 ) , reviewed their medical records to score incidence and severity of <e2>delirium</e2> , and tested associations with potential risk factors .
D003024_D003693 CID CONCLUSIONS : <e2>Delirium</e2> was found in 10 % of <e1>clozapine-treated</e1> inpatients , particularly in older patients exposed to other central anticholinergics .
D003024_D001523 NONE METHODS : We used computerized pharmacy records to identify all adult <e2>psychiatric</e2> inpatients treated with <e1>clozapine</e1> ( 1995 - 96 ) , reviewed their medical records to score incidence and severity of delirium , and tested associations with potential risk factors .
8864707
D010672_D004827 NONE Magnetic resonance volumetry of the cerebellum in <e2>epileptic</e2> patients after <e1>phenytoin</e1> overdosages .
D010672_D062787 CID Magnetic resonance volumetry of the cerebellum in epileptic patients after <e1>phenytoin</e1> <e2>overdosages</e2> .
D010672_D062787 CID We conclude that <e1>phenytoin</e1> <e2>overdosage</e2> does not necessarily result in cerebellar atrophy and it is unlikely that phenytoin medication was the only cause of cerebellar atrophy in the remaining patients .
D010672_D062787 CID We conclude that phenytoin <e2>overdosage</e2> does not necessarily result in cerebellar atrophy and it is unlikely that <e1>phenytoin</e1> medication was the only cause of cerebellar atrophy in the remaining patients .
D010672_D002526 NONE The aim of this study was to evaluate the relationship between <e1>phenytoin</e1> medication and <e2>cerebellar atrophy</e2> in patients who had experienced clinical intoxication .
D010672_D002526 NONE We conclude that <e1>phenytoin</e1> overdosage does not necessarily result in <e2>cerebellar atrophy</e2> and it is unlikely that phenytoin medication was the only cause of cerebellar atrophy in the remaining patients .
D010672_D002526 NONE We conclude that <e1>phenytoin</e1> overdosage does not necessarily result in cerebellar atrophy and it is unlikely that phenytoin medication was the only cause of <e2>cerebellar atrophy</e2> in the remaining patients .
D010672_D002526 NONE We conclude that phenytoin overdosage does not necessarily result in <e2>cerebellar atrophy</e2> and it is unlikely that <e1>phenytoin</e1> medication was the only cause of cerebellar atrophy in the remaining patients .
D010672_D002526 NONE We conclude that phenytoin overdosage does not necessarily result in cerebellar atrophy and it is unlikely that <e1>phenytoin</e1> medication was the only cause of <e2>cerebellar atrophy</e2> in the remaining patients .
D010672_D012640 NONE Using linear regression we found that no correlation exists between <e2>seizure</e2> duration , elevation of <e1>phenytoin</e1> serum levels and cerebellar volume .
8372922
20003049
C031942_D013921 NONE Prolonged elevation of plasma <e1>argatroban</e1> in a cardiac transplant patient with a suspected history of heparin-induced <e2>thrombocytopenia</e2> with thrombosis .
C031942_D013921 NONE In the following report , a 65-year-old critically ill patient with a suspected history of <e2>HITT</e2> was administered <e1>argatroban</e1> for anticoagulation on bypass during heart transplantation .
C031942_D013927 NONE Prolonged elevation of plasma <e1>argatroban</e1> in a cardiac transplant patient with a suspected history of heparin-induced thrombocytopenia with <e2>thrombosis</e2> .
C031942_D013927 NONE In the following report , a 65-year-old critically ill patient with a suspected history of <e2>HITT</e2> was administered <e1>argatroban</e1> for anticoagulation on bypass during heart transplantation .
D006493_D013921 NONE Prolonged elevation of plasma argatroban in a cardiac transplant patient with a suspected history of <e1>heparin-induced</e1> <e2>thrombocytopenia</e2> with thrombosis .
D006493_D013921 NONE BACKGROUND : Direct thrombin inhibitors ( DTIs ) provide an alternative method of anticoagulation for patients with a history of <e1>heparin-induced</e1> <e2>thrombocytopenia</e2> ( HIT ) or HIT with thrombosis ( HITT ) undergoing cardiopulmonary bypass ( CPB ) .
D006493_D013921 NONE BACKGROUND : Direct thrombin inhibitors ( DTIs ) provide an alternative method of anticoagulation for patients with a history of <e1>heparin-induced</e1> thrombocytopenia ( <e2>HIT</e2> ) or HIT with thrombosis ( HITT ) undergoing cardiopulmonary bypass ( CPB ) .
D006493_D013921 NONE BACKGROUND : Direct thrombin inhibitors ( DTIs ) provide an alternative method of anticoagulation for patients with a history of <e1>heparin-induced</e1> thrombocytopenia ( HIT ) or <e2>HIT</e2> with thrombosis ( HITT ) undergoing cardiopulmonary bypass ( CPB ) .
D006493_D013921 NONE BACKGROUND : Direct thrombin inhibitors ( DTIs ) provide an alternative method of anticoagulation for patients with a history of <e1>heparin-induced</e1> thrombocytopenia ( HIT ) or HIT with thrombosis ( <e2>HITT</e2> ) undergoing cardiopulmonary bypass ( CPB ) .
D006493_D013927 NONE Prolonged elevation of plasma argatroban in a cardiac transplant patient with a suspected history of <e1>heparin-induced</e1> thrombocytopenia with <e2>thrombosis</e2> .
D006493_D013927 NONE BACKGROUND : Direct thrombin inhibitors ( DTIs ) provide an alternative method of anticoagulation for patients with a history of <e1>heparin-induced</e1> thrombocytopenia ( HIT ) or HIT with <e2>thrombosis</e2> ( HITT ) undergoing cardiopulmonary bypass ( CPB ) .
D006493_D013927 NONE BACKGROUND : Direct thrombin inhibitors ( DTIs ) provide an alternative method of anticoagulation for patients with a history of <e1>heparin-induced</e1> thrombocytopenia ( HIT ) or HIT with thrombosis ( <e2>HITT</e2> ) undergoing cardiopulmonary bypass ( CPB ) .
C031942_D016638 NONE In the following report , a 65-year-old <e2>critically ill</e2> patient with a suspected history of HITT was administered <e1>argatroban</e1> for anticoagulation on bypass during heart transplantation .
C031942_D008107 NONE RESULTS : Unexpectedly high concentrations of <e1>argatroban</e1> were measured in these samples ( range , 0 - 32 microg/mL ) , and a prolonged plasma argatroban half life ( t(1/2 ) ) of 514 minutes was observed ( published elimination t(1/2 ) is 39 - 51 minutes [ < or = 181 minutes with <e2>hepatic impairment</e2> ] ) .
C031942_D008107 NONE RESULTS : Unexpectedly high concentrations of argatroban were measured in these samples ( range , 0 - 32 microg/mL ) , and a prolonged plasma <e1>argatroban</e1> half life ( t(1/2 ) ) of 514 minutes was observed ( published elimination t(1/2 ) is 39 - 51 minutes [ < or = 181 minutes with <e2>hepatic impairment</e2> ] ) .
C031942_D001778 NONE CONCLUSIONS : Correlation of plasma <e1>argatroban</e1> concentration versus the patient 's coagulation variables and clinical course suggest that prolonged elevated levels of plasma argatroban may have contributed to the patient 's extended <e2>coagulopathy</e2> .
C031942_D001778 NONE CONCLUSIONS : Correlation of plasma argatroban concentration versus the patient 's coagulation variables and clinical course suggest that prolonged elevated levels of plasma <e1>argatroban</e1> may have contributed to the patient 's extended <e2>coagulopathy</e2> .
C031942_D001778 NONE This is the first report to measure plasma <e1>argatroban</e1> concentration in the context of CPB and extended <e2>coagulopathy</e2> .
17111419
C102006_D064420 NONE Severe <e1>citrate</e1> <e2>toxicity</e2> complicating volunteer apheresis platelet donation .
C102006_D064420 NONE We report a case of severe <e1>citrate</e1> <e2>toxicity</e2> during volunteer donor apheresis platelet collection .
C102006_D064420 NONE We conclude that careful screening for medications and underlying conditions predisposing to hypocalcemia is recommended to help prevent severe reactions due to <e1>citrate</e1> <e2>toxicity</e2> .
D002125_C536214 NONE Empirical treatment with intravenous <e1>calcium gluconate</e1> was initiated , and <e2>muscle contractions</e2> slowly subsided over approximately 10 to 15 minutes .
D002118_D006996 NONE The events are consistent with a severe reaction to <e1>calcium</e1> chelation by sodium citrate anticoagulant resulting in symptomatic systemic <e2>hypocalcemia</e2> .
C102006_D006996 CID The events are consistent with a severe reaction to calcium chelation by <e1>sodium citrate</e1> anticoagulant resulting in symptomatic systemic <e2>hypocalcemia</e2> .
C102006_D006996 CID We conclude that careful screening for medications and underlying conditions predisposing to <e2>hypocalcemia</e2> is recommended to help prevent severe reactions due to <e1>citrate</e1> toxicity .
D002034_D006996 NONE Upon additional retrospective analysis , it was noted that <e1>bumetanide</e1> is a loop diuretic that may cause significant <e2>hypocalcemia</e2> .
D049994_D006996 NONE Upon additional retrospective analysis , it was noted that bumetanide is a <e1>loop diuretic</e1> that may cause significant <e2>hypocalcemia</e2> .
2070391
D008012_D010146 CID Reduction in injection <e2>pain</e2> using buffered <e1>lidocaine</e1> as a local anesthetic before cardiac catheterization .
D008012_D010146 CID Previous reports have suggested that <e2>pain</e2> associated with the injection of <e1>lidocaine</e1> is related to the acidic pH of the solution .
D008012_D010146 CID To determine if the addition of a buffering solution to adjust the pH of <e1>lidocaine</e1> into the physiologic range would reduce <e2>pain</e2> during injection , we performed a blinded randomized study in patients undergoing cardiac catheterization .
D008012_D010146 CID Twenty patients were asked to quantify the severity of <e2>pain</e2> after receiving standard <e1>lidocaine</e1> in one femoral area and buffered lidocaine in the opposite femoral area .
D008012_D010146 CID Twenty patients were asked to quantify the severity of <e2>pain</e2> after receiving standard lidocaine in one femoral area and buffered <e1>lidocaine</e1> in the opposite femoral area .
D008012_D010146 CID The mean <e2>pain</e2> score for buffered <e1>lidocaine</e1> was significantly lower than the mean score for standard lidocaine ( 2.7 +/- 1.9 vs. 3.8 +/- 2.2 , P = 0.03 ) .
D008012_D010146 CID The mean <e2>pain</e2> score for buffered lidocaine was significantly lower than the mean score for standard <e1>lidocaine</e1> ( 2.7 +/- 1.9 vs. 3.8 +/- 2.2 , P = 0.03 ) .
D008012_D010146 CID The pH adjustment of standard <e1>lidocaine</e1> can be accomplished easily in the catheterization laboratory before injection and results in a reduction of the <e2>pain</e2> occurring during the infiltration of tissues .
2611118
D004008_D006521 NONE <e2>Chronic active hepatitis</e2> associated with <e1>diclofenac sodium</e1> therapy .
D004008_D006521 NONE The patient described developed <e2>chronic active hepatitis</e2> after six months therapy with <e1>diclofenac sodium</e1> which progressed despite the withdrawal of the drug , a finding not previously reported .
D004008_D056486 CID Although generally well-tolerated , asymptomatic <e2>abnormalities of liver function</e2> have been recorded and , less commonly , severe hepatitis induced by <e1>diclofenac</e1> .
D004008_D056486 CID Although generally well-tolerated , asymptomatic abnormalities of liver function have been recorded and , less commonly , severe <e2>hepatitis</e2> induced by <e1>diclofenac</e1> .
2484011
D000547_D003866 NONE The initial dose of <e1>amantadine</e1> <e2>depressed</e2> locomotor activity in all mouse strains studied with the BALB/C mice being the most sensitive .
D000547_D011596 CID Readministration of <e1>amantadine</e1> , after a drug-free overnight period , increased motility from respective saline control in all strains with exception of the BALB/C mice where <e2>suppression of motility</e2> occurred .
D000547_D011596 CID The biochemical results of brain biogenic amines of BALB/C mouse strain suggest a probable decrease of catecholamine turnover rate and/or metabolism by monoamine oxidase and a resulting increase in O-methylation of norepinephrine which may account for a <e2>behavioral depression</e2> caused by <e1>amantadine</e1> in the BALB/C mice .
D000588_D011596 NONE The biochemical results of brain biogenic <e1>amines</e1> of BALB/C mouse strain suggest a probable decrease of catecholamine turnover rate and/or metabolism by monoamine oxidase and a resulting increase in O-methylation of norepinephrine which may account for a <e2>behavioral depression</e2> caused by amantadine in the BALB/C mice .
D002395_D011596 NONE The biochemical results of brain biogenic amines of BALB/C mouse strain suggest a probable decrease of <e1>catecholamine</e1> turnover rate and/or metabolism by monoamine oxidase and a resulting increase in O-methylation of norepinephrine which may account for a <e2>behavioral depression</e2> caused by amantadine in the BALB/C mice .
D009638_D011596 NONE The biochemical results of brain biogenic amines of BALB/C mouse strain suggest a probable decrease of catecholamine turnover rate and/or metabolism by monoamine oxidase and a resulting increase in O-methylation of <e1>norepinephrine</e1> which may account for a <e2>behavioral depression</e2> caused by amantadine in the BALB/C mice .
9754849
D008691_D002819 CID <e2>Choreoathetoid movements</e2> associated with rapid adjustment to <e1>methadone</e1> .
D008691_D002819 CID This is a case report of euphoria and <e2>choreoathetoid movements</e2> both transiently induced by rapid adjustment to the selective mu-opioid receptor agonist <e1>methadone</e1> in an inpatient previously abusing heroine and cocaine .
D003042_D002819 CID <e2>Choreatiform hyperkinesias</e2> are known to be occasional movement abnormalities during intoxications with <e1>cocaine</e1> but not opiates .
D003042_D002819 CID This is a case report of euphoria and <e2>choreoathetoid movements</e2> both transiently induced by rapid adjustment to the selective mu-opioid receptor agonist methadone in an inpatient previously abusing heroine and <e1>cocaine</e1> .
D003042_D006948 CID <e2>Choreatiform hyperkinesias</e2> are known to be occasional movement abnormalities during intoxications with <e1>cocaine</e1> but not opiates .
D003042_D020820 NONE Choreatiform hyperkinesias are known to be occasional <e2>movement abnormalities</e2> during intoxications with <e1>cocaine</e1> but not opiates .
D003932_D002819 NONE This is a case report of euphoria and <e2>choreoathetoid movements</e2> both transiently induced by rapid adjustment to the selective mu-opioid receptor agonist methadone in an inpatient previously abusing <e1>heroine</e1> and cocaine .
354896
D008012_D006323 CID <e1>Lidocaine-induced</e1> <e2>cardiac asystole</e2> .
D008012_D003866 NONE Intravenous administration of a single 50-mg bolus of <e1>lidocaine</e1> in a 67-year-old man resulted in profound <e2>depression</e2> of the activity of the sinoatrial and atrioventricular nodal pacemakers .
D008012_D001919 NONE The patient had no apparent associated conditions which might have predisposed him to the development of <e2>bradyarrhythmias</e2> ; and , thus , this probably represented a true idiosyncrasy to <e1>lidocaine</e1> .
20619828
D002997_D001008 CID RESULTS : <e1>Clomipramine</e1> exposure in immature rats produced significant behavioral and biochemical changes that include enhanced <e2>anxiety</e2> ( elevated plus maze and marble burying ) , behavioral inflexibility ( perseveration in the spontaneous alternation task and impaired reversal learning ) , working memory impairment ( e.g. , win-shift paradigm ) , hoarding , and corticostriatal dysfunction .
D002997_-1 NONE RESULTS : <e1>Clomipramine</e1> exposure in immature rats produced significant behavioral and biochemical changes that include enhanced anxiety ( elevated plus maze and marble burying ) , <e2>behavioral inflexibility</e2> ( perseveration in the spontaneous alternation task and impaired reversal learning ) , working memory impairment ( e.g. , win-shift paradigm ) , hoarding , and corticostriatal dysfunction .
D002997_-1 NONE RESULTS : <e1>Clomipramine</e1> exposure in immature rats produced significant behavioral and biochemical changes that include enhanced anxiety ( elevated plus maze and marble burying ) , behavioral inflexibility ( perseveration in the spontaneous alternation task and impaired reversal learning ) , working memory impairment ( e.g. , win-shift paradigm ) , hoarding , and <e2>corticostriatal dysfunction</e2> .
D002997_D008569 CID RESULTS : <e1>Clomipramine</e1> exposure in immature rats produced significant behavioral and biochemical changes that include enhanced anxiety ( elevated plus maze and marble burying ) , behavioral inflexibility ( perseveration in the spontaneous alternation task and impaired reversal learning ) , working <e2>memory impairment</e2> ( e.g. , win-shift paradigm ) , hoarding , and corticostriatal dysfunction .
D002997_D060845 CID RESULTS : <e1>Clomipramine</e1> exposure in immature rats produced significant behavioral and biochemical changes that include enhanced anxiety ( elevated plus maze and marble burying ) , behavioral inflexibility ( perseveration in the spontaneous alternation task and impaired reversal learning ) , working memory impairment ( e.g. , win-shift paradigm ) , <e2>hoarding</e2> , and corticostriatal dysfunction .
18329269
D006220_D002375 CID SAR studies led to compound 14 with excellent potency ( K(i ) = 0.4 nM ) , selectivity ( A(1)/A(2A ) > 100 ) , and efficacy ( MED 10 mg/kg p.o. ) in the rat <e1>haloperidol-induced</e1> <e2>catalepsy</e2> model for Parkinson 's disease .
D006220_D010300 NONE SAR studies led to compound 14 with excellent potency ( K(i ) = 0.4 nM ) , selectivity ( A(1)/A(2A ) > 100 ) , and efficacy ( MED 10 mg/kg p.o. ) in the rat <e1>haloperidol-induced</e1> catalepsy model for <e2>Parkinson 's disease</e2> .
18752389
C492458_D017093 NONE <e1>Simvastatin-ezetimibe-induced</e1> <e2>hepatic failure</e2> necessitating liver transplantation .
C492458_D017093 NONE To our knowledge , this is the first case report of <e1>simvastatin-ezetimibe-induced</e1> <e2>liver failure</e2> that resulted in liver transplantation .
C108606_D056486 NONE However , <e2>hepatotoxic</e2> events have not been widely published with <e1>ezetimibe</e1> or the combination agent simvastatin-ezetimibe .
C108606_D056486 NONE <e1>Ezetimibe</e1> undergoes extensive glucuronidation by uridine diphosphate glucoronosyltransferases ( UGT ) in the intestine and liver and may have inhibited the glucuronidation of simvastatin hydroxy acid , resulting in increased simvastatin exposure and subsequent <e2>hepatotoxicity</e2> .
C108606_D056486 NONE We postulate that the mechanism of the simvastatinezetimibe-induced <e2>hepatotoxicity</e2> is the increased simvastatin exposure by <e1>ezetimibe</e1> inhibition of UGT enzymes .
C492458_D056486 CID However , <e2>hepatotoxic</e2> events have not been widely published with ezetimibe or the combination agent <e1>simvastatin-ezetimibe</e1> .
C492458_D056486 CID <e1>Simvastatinezetimibe</e1> and escitalopram ( which she was taking for depression ) were discontinued , and other potential causes of <e2>hepatotoxicity</e2> were excluded .
C492458_D056486 CID We postulate that the mechanism of the <e1>simvastatinezetimibe-induced</e1> <e2>hepatotoxicity</e2> is the increased simvastatin exposure by ezetimibe inhibition of UGT enzymes .
C492458_D056486 CID Clinicians should be aware of potential <e2>hepatotoxicity</e2> with <e1>simvastatin-ezetimibe</e1> especially in elderly patients and should carefully monitor serum aminotransferase levels when starting therapy and titrating the dosage .
D019821_D017114 NONE We describe a 70-year-old Hispanic woman who developed <e2>fulminant hepatic failure</e2> necessitating liver transplantation 10 weeks after conversion from <e1>simvastatin</e1> 40 mg/day to simvastatin 10 mg-ezetimibe 40 mg/day .
C492458_D017114 CID We describe a 70-year-old Hispanic woman who developed <e2>fulminant hepatic failure</e2> necessitating liver transplantation 10 weeks after conversion from simvastatin 40 mg/day to <e1>simvastatin 10 mg-ezetimibe 40 mg/day</e1> .
D019821_D056486 NONE The patient 's lipid panel had been maintained with <e1>simvastatin</e1> for 18 months before the conversion without evidence of <e2>hepatotoxicity</e2> .
D019821_D056486 NONE Ezetimibe undergoes extensive glucuronidation by uridine diphosphate glucoronosyltransferases ( UGT ) in the intestine and liver and may have inhibited the glucuronidation of simvastatin hydroxy acid , resulting in increased <e1>simvastatin</e1> exposure and subsequent <e2>hepatotoxicity</e2> .
D019821_D056486 NONE We postulate that the mechanism of the simvastatinezetimibe-induced <e2>hepatotoxicity</e2> is the increased <e1>simvastatin</e1> exposure by ezetimibe inhibition of UGT enzymes .
C492458_D003866 NONE <e1>Simvastatinezetimibe</e1> and escitalopram ( which she was taking for <e2>depression</e2> ) were discontinued , and other potential causes of hepatotoxicity were excluded .
D015283_D003866 NONE Simvastatinezetimibe and <e1>escitalopram</e1> ( which she was taking for <e2>depression</e2> ) were discontinued , and other potential causes of hepatotoxicity were excluded .
D015283_D056486 NONE Simvastatinezetimibe and <e1>escitalopram</e1> ( which she was taking for depression ) were discontinued , and other potential causes of <e2>hepatotoxicity</e2> were excluded .
D014530_D056486 NONE Ezetimibe undergoes extensive glucuronidation by <e1>uridine diphosphate</e1> glucoronosyltransferases ( UGT ) in the intestine and liver and may have inhibited the glucuronidation of simvastatin hydroxy acid , resulting in increased simvastatin exposure and subsequent <e2>hepatotoxicity</e2> .
C532833_D056486 NONE Ezetimibe undergoes extensive glucuronidation by uridine diphosphate glucoronosyltransferases ( UGT ) in the intestine and liver and may have inhibited the glucuronidation of <e1>simvastatin hydroxy acid</e1> , resulting in increased simvastatin exposure and subsequent <e2>hepatotoxicity</e2> .
8996652
D000617_D006311 NONE <e2>Ototoxicity</e2> appeared closely related to a prolonged administration and higher total dose of ototoxic drugs , particularly <e1>aminoglycosides</e1> and furosemide .
D000617_D006311 NONE Ototoxicity appeared closely related to a prolonged administration and higher total dose of <e2>ototoxic</e2> drugs , particularly <e1>aminoglycosides</e1> and furosemide .
D005665_D006311 NONE <e2>Ototoxicity</e2> appeared closely related to a prolonged administration and higher total dose of ototoxic drugs , particularly aminoglycosides and <e1>furosemide</e1> .
D005665_D006311 NONE Ototoxicity appeared closely related to a prolonged administration and higher total dose of <e2>ototoxic</e2> drugs , particularly aminoglycosides and <e1>furosemide</e1> .
19759529
D004298_D012559 NONE <e2>Schizophrenia</e2> has been initially associated with dysfunction in <e1>dopamine</e1> neurotransmission .
D018698_D012559 NONE However , the observation that antagonists of the <e1>glutamate</e1> N-methyl-D-aspartate ( NMDA ) receptor produce <e2>schizophrenic-like</e2> symptoms in humans has led to the idea of a dysfunctioning of the glutamatergic system via its NMDA receptor .
D016202_D012559 NONE However , the observation that antagonists of the glutamate <e1>N-methyl-D-aspartate</e1> ( NMDA ) receptor produce <e2>schizophrenic-like</e2> symptoms in humans has led to the idea of a dysfunctioning of the glutamatergic system via its NMDA receptor .
D016202_D012559 NONE However , the observation that antagonists of the glutamate N-methyl-D-aspartate ( <e1>NMDA</e1> ) receptor produce <e2>schizophrenic-like</e2> symptoms in humans has led to the idea of a dysfunctioning of the glutamatergic system via its NMDA receptor .
D016202_D012559 NONE However , the observation that antagonists of the glutamate N-methyl-D-aspartate ( NMDA ) receptor produce <e2>schizophrenic-like</e2> symptoms in humans has led to the idea of a dysfunctioning of the glutamatergic system via its <e1>NMDA</e1> receptor .
-1_D006948 NONE This study aimed at investigating the potential antipsychotic-like properties of <e1>SSR103800</e1> , with a particular focus on models of <e2>hyperactivity</e2> , involving either drug challenge ( ie , amphetamine and MK-801 ) or transgenic mice ( ie , NMDA Nr1(neo-/- ) and DAT(-/- ) ) .
-1_D006948 NONE Results showed that <e1>SSR103800</e1> ( 10 - 30 mg/kg p.o. ) blocked <e2>hyperactivity</e2> induced by the non-competitive NMDA receptor antagonist , MK-801 and partially reversed spontaneous hyperactivity of NMDA Nr1(neo-/- ) mice .
-1_D006948 NONE Results showed that <e1>SSR103800</e1> ( 10 - 30 mg/kg p.o. ) blocked hyperactivity induced by the non-competitive NMDA receptor antagonist , MK-801 and partially reversed spontaneous <e2>hyperactivity</e2> of NMDA Nr1(neo-/- ) mice .
-1_D006948 NONE In contrast , <e1>SSR103800</e1> failed to affect <e2>hyperactivity</e2> induced by amphetamine or naturally observed in dopamine transporter ( DAT(-/- ) ) knockout mice ( 10 - 30 mg/kg p.o. ) .
D000661_D006948 CID This study aimed at investigating the potential antipsychotic-like properties of SSR103800 , with a particular focus on models of <e2>hyperactivity</e2> , involving either drug challenge ( ie , <e1>amphetamine</e1> and MK-801 ) or transgenic mice ( ie , NMDA Nr1(neo-/- ) and DAT(-/- ) ) .
D000661_D006948 CID In contrast , SSR103800 failed to affect <e2>hyperactivity</e2> induced by <e1>amphetamine</e1> or naturally observed in dopamine transporter ( DAT(-/- ) ) knockout mice ( 10 - 30 mg/kg p.o. ) .
D016291_D006948 CID This study aimed at investigating the potential antipsychotic-like properties of SSR103800 , with a particular focus on models of <e2>hyperactivity</e2> , involving either drug challenge ( ie , amphetamine and <e1>MK-801</e1> ) or transgenic mice ( ie , NMDA Nr1(neo-/- ) and DAT(-/- ) ) .
D016291_D006948 CID Results showed that SSR103800 ( 10 - 30 mg/kg p.o. ) blocked <e2>hyperactivity</e2> induced by the non-competitive NMDA receptor antagonist , <e1>MK-801</e1> and partially reversed spontaneous hyperactivity of NMDA Nr1(neo-/- ) mice .
D016291_D006948 CID Results showed that SSR103800 ( 10 - 30 mg/kg p.o. ) blocked hyperactivity induced by the non-competitive NMDA receptor antagonist , <e1>MK-801</e1> and partially reversed spontaneous <e2>hyperactivity</e2> of NMDA Nr1(neo-/- ) mice .
D016202_D006948 NONE This study aimed at investigating the potential antipsychotic-like properties of SSR103800 , with a particular focus on models of <e2>hyperactivity</e2> , involving either drug challenge ( ie , amphetamine and MK-801 ) or transgenic mice ( ie , <e1>NMDA</e1> Nr1(neo-/- ) and DAT(-/- ) ) .
D016202_D006948 NONE Results showed that SSR103800 ( 10 - 30 mg/kg p.o. ) blocked <e2>hyperactivity</e2> induced by the non-competitive <e1>NMDA</e1> receptor antagonist , MK-801 and partially reversed spontaneous hyperactivity of NMDA Nr1(neo-/- ) mice .
D016202_D006948 NONE Results showed that SSR103800 ( 10 - 30 mg/kg p.o. ) blocked hyperactivity induced by the non-competitive <e1>NMDA</e1> receptor antagonist , MK-801 and partially reversed spontaneous <e2>hyperactivity</e2> of NMDA Nr1(neo-/- ) mice .
D016202_D006948 NONE Results showed that SSR103800 ( 10 - 30 mg/kg p.o. ) blocked <e2>hyperactivity</e2> induced by the non-competitive NMDA receptor antagonist , MK-801 and partially reversed spontaneous hyperactivity of <e1>NMDA</e1> Nr1(neo-/- ) mice .
D016202_D006948 NONE Results showed that SSR103800 ( 10 - 30 mg/kg p.o. ) blocked hyperactivity induced by the non-competitive NMDA receptor antagonist , MK-801 and partially reversed spontaneous <e2>hyperactivity</e2> of <e1>NMDA</e1> Nr1(neo-/- ) mice .
D004298_D006948 NONE In contrast , SSR103800 failed to affect <e2>hyperactivity</e2> induced by amphetamine or naturally observed in <e1>dopamine</e1> transporter ( DAT(-/- ) ) knockout mice ( 10 - 30 mg/kg p.o. ) .
D006220_D006948 NONE Importantly , both classical ( <e1>haloperidol</e1> ) and atypical ( olanzapine , clozapine and aripiprazole ) antipsychotics were effective in all these models of <e2>hyperactivity</e2> .
C076029_D006948 NONE Importantly , both classical ( haloperidol ) and atypical ( <e1>olanzapine</e1> , clozapine and aripiprazole ) antipsychotics were effective in all these models of <e2>hyperactivity</e2> .
D003024_D006948 NONE Importantly , both classical ( haloperidol ) and atypical ( olanzapine , <e1>clozapine</e1> and aripiprazole ) antipsychotics were effective in all these models of <e2>hyperactivity</e2> .
C094645_D006948 NONE Importantly , both classical ( haloperidol ) and atypical ( olanzapine , clozapine and <e1>aripiprazole</e1> ) antipsychotics were effective in all these models of <e2>hyperactivity</e2> .
-1_D002375 NONE However , unlike these latter , <e1>SSR103800</e1> did not produce <e2>catalepsy</e2> ( retention on the bar test ) up to 30 mg/kg p.o. Together these findings show that the GlyT1 inhibitor , SSR103800 , produces antipsychotic-like effects , which differ from those observed with compounds primarily targeting the dopaminergic system , and has a reduced side-effect potential as compared with these latter drugs .
-1_D002375 NONE However , unlike these latter , SSR103800 did not produce <e2>catalepsy</e2> ( retention on the bar test ) up to 30 mg/kg p.o. Together these findings show that the GlyT1 inhibitor , <e1>SSR103800</e1> , produces antipsychotic-like effects , which differ from those observed with compounds primarily targeting the dopaminergic system , and has a reduced side-effect potential as compared with these latter drugs .
8170551
D000086_D053040 NONE <e1>Acetazolamide-induced</e1> <e2>nephrolithiasis</e2> : implications for treatment of neuromuscular disorders .
D000086_D053040 NONE <e2>Nephrolithiasis</e2> is a complication of <e1>acetazolamide</e1> but does not preclude its use .
D000086_D009468 NONE <e1>Acetazolamide-induced</e1> nephrolithiasis : implications for treatment of <e2>neuromuscular disorders</e2> .
D000086_D007669 CID Three patients on <e1>acetazolamide</e1> ( 15 % ) developed <e2>renal calculi</e2> .
10342929
D000806_D000799 CID <e2>Angioedema</e2> due to <e1>ACE inhibitors</e1> : common and inadequately diagnosed .
D000806_D000799 CID The estimated incidence of <e2>angioedema</e2> during <e1>angiotensin-converting enzyme ( ACE ) inhibitor</e1> treatment is between 1 and 7 per thousand patients .
15275829
D000109_D012640 NONE The alpha3 and beta4 nicotinic <e1>acetylcholine</e1> receptor subunits are necessary for nicotine-induced <e2>seizures</e2> and hypolocomotion in mice .
D000109_D012640 NONE Binding of nicotine to nicotinic <e1>acetylcholine</e1> receptors ( nAChRs ) elicits a series of dose-dependent behaviors that go from altered exploration , sedation , and tremors , to <e2>seizures</e2> and death .
D000109_D006948 NONE The alpha3 and beta4 nicotinic <e1>acetylcholine</e1> receptor subunits are necessary for nicotine-induced seizures and <e2>hypolocomotion</e2> in mice .
D009538_D012640 CID The alpha3 and beta4 nicotinic acetylcholine receptor subunits are necessary for <e1>nicotine-induced</e1> <e2>seizures</e2> and hypolocomotion in mice .
D009538_D012640 CID Binding of <e1>nicotine</e1> to nicotinic acetylcholine receptors ( nAChRs ) elicits a series of dose-dependent behaviors that go from altered exploration , sedation , and tremors , to <e2>seizures</e2> and death .
D009538_D012640 CID We examined the role of the beta4 subunits in <e1>nicotine-induced</e1> <e2>seizures</e2> and hypolocomotion in beta4 homozygous null ( beta4 -/- ) and alpha3 heterozygous ( +/- ) mice .
D009538_D012640 CID beta4 -/- mice were less sensitive to the effects of <e1>nicotine</e1> both at low doses , measured as decreased exploration in an open field , and at high doses , measured as sensitivity to nicotine-induced <e2>seizures</e2> .
D009538_D012640 CID beta4 -/- mice were less sensitive to the effects of nicotine both at low doses , measured as decreased exploration in an open field , and at high doses , measured as sensitivity to <e1>nicotine-induced</e1> <e2>seizures</e2> .
D009538_D012640 CID alpha3 +/- mice were partially resistant to <e1>nicotine-induced</e1> <e2>seizures</e2> when compared to wild-type littermates .
D009538_D012640 CID Together , these results suggest that the beta4 and the alpha3 subunits are mediators of <e1>nicotine-induced</e1> <e2>seizures</e2> and hypolocomotion .
D009538_D006948 NONE The alpha3 and beta4 nicotinic acetylcholine receptor subunits are necessary for <e1>nicotine-induced</e1> seizures and <e2>hypolocomotion</e2> in mice .
D009538_D006948 NONE We examined the role of the beta4 subunits in <e1>nicotine-induced</e1> seizures and <e2>hypolocomotion</e2> in beta4 homozygous null ( beta4 -/- ) and alpha3 heterozygous ( +/- ) mice .
D009538_D006948 NONE Together , these results suggest that the beta4 and the alpha3 subunits are mediators of <e1>nicotine-induced</e1> seizures and <e2>hypolocomotion</e2> .
D009538_D014202 NONE Binding of <e1>nicotine</e1> to nicotinic acetylcholine receptors ( nAChRs ) elicits a series of dose-dependent behaviors that go from altered exploration , sedation , and <e2>tremors</e2> , to seizures and death .
D009538_D003643 NONE Binding of <e1>nicotine</e1> to nicotinic acetylcholine receptors ( nAChRs ) elicits a series of dose-dependent behaviors that go from altered exploration , sedation , and tremors , to seizures and <e2>death</e2> .
D000109_D014202 NONE Binding of nicotine to nicotinic <e1>acetylcholine</e1> receptors ( nAChRs ) elicits a series of dose-dependent behaviors that go from altered exploration , sedation , and <e2>tremors</e2> , to seizures and death .
D000109_D003643 NONE Binding of nicotine to nicotinic <e1>acetylcholine</e1> receptors ( nAChRs ) elicits a series of dose-dependent behaviors that go from altered exploration , sedation , and tremors , to seizures and <e2>death</e2> .
9812111
D006220_D011618 NONE A randomized , placebo-controlled dose-comparison trial of <e1>haloperidol</e1> for <e2>psychosis</e2> and disruptive behaviors in Alzheimer 's disease .
D006220_D011618 NONE OBJECTIVE : The goal of this study was to compare the efficacy and side effects of two doses of <e1>haloperidol</e1> and placebo in the treatment of <e2>psychosis</e2> and disruptive behaviors in patients with Alzheimer 's disease .
D006220_D011618 NONE RESULTS : For the 60 patients who completed phase A , standard-dose <e1>haloperidol</e1> was efficacious and superior to both low-dose haloperidol and placebo for scores on the Brief Psychiatric Rating Scale <e2>psychosis</e2> factor and on psychomotor agitation .
D006220_D011618 NONE RESULTS : For the 60 patients who completed phase A , standard-dose haloperidol was efficacious and superior to both low-dose <e1>haloperidol</e1> and placebo for scores on the Brief Psychiatric Rating Scale <e2>psychosis</e2> factor and on psychomotor agitation .
D006220_D011618 NONE The narrow therapeutic window observed with <e1>haloperidol</e1> may also apply to other neuroleptics used in Alzheimer 's disease patients with <e2>psychosis</e2> and disruptive behaviors .
D006220_D019958 NONE A randomized , placebo-controlled dose-comparison trial of <e1>haloperidol</e1> for psychosis and <e2>disruptive behaviors</e2> in Alzheimer 's disease .
D006220_D019958 NONE OBJECTIVE : The goal of this study was to compare the efficacy and side effects of two doses of <e1>haloperidol</e1> and placebo in the treatment of psychosis and <e2>disruptive behaviors</e2> in patients with Alzheimer 's disease .
D006220_D019958 NONE The narrow therapeutic window observed with <e1>haloperidol</e1> may also apply to other neuroleptics used in Alzheimer 's disease patients with psychosis and <e2>disruptive behaviors</e2> .
D006220_D000544 NONE A randomized , placebo-controlled dose-comparison trial of <e1>haloperidol</e1> for psychosis and disruptive behaviors in <e2>Alzheimer 's disease</e2> .
D006220_D000544 NONE OBJECTIVE : The goal of this study was to compare the efficacy and side effects of two doses of <e1>haloperidol</e1> and placebo in the treatment of psychosis and disruptive behaviors in patients with <e2>Alzheimer 's disease</e2> .
D006220_D000544 NONE METHOD : In a 6-week random-assignment , double-blind , placebo-controlled trial ( phase A ) , <e1>haloperidol</e1> , 2 - 3 mg/day ( standard dose ) , and haloperidol , 0.50 - 0.75 mg/day ( low dose ) , were compared in 71 outpatients with <e2>Alzheimer 's disease</e2> .
D006220_D000544 NONE METHOD : In a 6-week random-assignment , double-blind , placebo-controlled trial ( phase A ) , haloperidol , 2 - 3 mg/day ( standard dose ) , and <e1>haloperidol</e1> , 0.50 - 0.75 mg/day ( low dose ) , were compared in 71 outpatients with <e2>Alzheimer 's disease</e2> .
D006220_D000544 NONE The narrow therapeutic window observed with <e1>haloperidol</e1> may also apply to other neuroleptics used in <e2>Alzheimer 's disease</e2> patients with psychosis and disruptive behaviors .
D006220_D011595 NONE RESULTS : For the 60 patients who completed phase A , standard-dose <e1>haloperidol</e1> was efficacious and superior to both low-dose haloperidol and placebo for scores on the Brief Psychiatric Rating Scale psychosis factor and on <e2>psychomotor agitation</e2> .
D006220_D011595 NONE RESULTS : For the 60 patients who completed phase A , standard-dose haloperidol was efficacious and superior to both low-dose <e1>haloperidol</e1> and placebo for scores on the Brief Psychiatric Rating Scale psychosis factor and on <e2>psychomotor agitation</e2> .
D006220_D001480 CID CONCLUSIONS : The results indicated a favorable therapeutic profile for <e1>haloperidol</e1> in doses of 2 - 3 mg/day , although a subgroup developed moderate to severe <e2>extrapyramidal signs</e2> .
9351491
D018967_D011618 NONE Previous clinical studies have proposed that <e1>risperidone</e1> 's pharmacologic profile may produce improved efficacy for negative <e2>psychotic symptoms</e2> and decreased propensity for extrapyramidal side effects ; features shared by so-called ' atypical ' neuroleptics .
D018967_D010302 CID <e2>Drug-induced parkinsonism</e2> was observed in subjects treated with <e1>risperidone</e1> ( 42 % ) and haloperidol ( 29 % ) and was observed at occupancy levels above 60 % .
D006220_D010302 CID <e2>Drug-induced parkinsonism</e2> was observed in subjects treated with risperidone ( 42 % ) and <e1>haloperidol</e1> ( 29 % ) and was observed at occupancy levels above 60 % .
8829025
D016559_D006973 CID Two groups of patients receiving <e1>tacrolimus</e1> were compared over a period of 1 year , one group comprising <e2>hypertensive</e2> patients who were receiving nifedipine , and the other comprising nonhypertensive patients not receiving nifedipine .
D016559_D006973 CID The observed positive impact of nifedipine on reducing the nephrotoxicity associated with <e1>tacrolimus</e1> in liver transplant recipients should be an important factor in selecting an agent to treat <e2>hypertension</e2> in this population .
D009543_D006973 NONE Two groups of patients receiving tacrolimus were compared over a period of 1 year , one group comprising <e2>hypertensive</e2> patients who were receiving <e1>nifedipine</e1> , and the other comprising nonhypertensive patients not receiving nifedipine .
D009543_D006973 NONE Two groups of patients receiving tacrolimus were compared over a period of 1 year , one group comprising <e2>hypertensive</e2> patients who were receiving nifedipine , and the other comprising nonhypertensive patients not receiving <e1>nifedipine</e1> .
D009543_D006973 NONE The observed positive impact of <e1>nifedipine</e1> on reducing the nephrotoxicity associated with tacrolimus in liver transplant recipients should be an important factor in selecting an agent to treat <e2>hypertension</e2> in this population .
D009543_D007674 NONE The observed positive impact of <e1>nifedipine</e1> on reducing the <e2>nephrotoxicity</e2> associated with tacrolimus in liver transplant recipients should be an important factor in selecting an agent to treat hypertension in this population .
D016559_D007674 NONE The observed positive impact of nifedipine on reducing the <e2>nephrotoxicity</e2> associated with <e1>tacrolimus</e1> in liver transplant recipients should be an important factor in selecting an agent to treat hypertension in this population .
2670794
D000809_D011665 NONE Effects of an inhibitor of <e1>angiotensin</e1> converting enzyme ( Captopril ) on <e2>pulmonary and renal insufficiency</e2> due to intravascular coagulation in the rat .
D000809_D011665 NONE Injection of Captopril ( 1 mg/kg ) , an inhibitor of <e1>angiotensin</e1> converting enzyme ( ACE ) , reduced both <e2>pulmonary and renal insufficiency</e2> in this rat model .
D000809_D051437 NONE Effects of an inhibitor of <e1>angiotensin</e1> converting enzyme ( Captopril ) on <e2>pulmonary and renal insufficiency</e2> due to intravascular coagulation in the rat .
D000809_D051437 NONE Injection of Captopril ( 1 mg/kg ) , an inhibitor of <e1>angiotensin</e1> converting enzyme ( ACE ) , reduced both <e2>pulmonary and renal insufficiency</e2> in this rat model .
D000809_D004211 NONE Effects of an inhibitor of <e1>angiotensin</e1> converting enzyme ( Captopril ) on pulmonary and renal insufficiency due to <e2>intravascular coagulation</e2> in the rat .
D002216_D011665 NONE Effects of an inhibitor of angiotensin converting enzyme ( <e1>Captopril</e1> ) on <e2>pulmonary and renal insufficiency</e2> due to intravascular coagulation in the rat .
D002216_D011665 NONE Injection of <e1>Captopril</e1> ( 1 mg/kg ) , an inhibitor of angiotensin converting enzyme ( ACE ) , reduced both <e2>pulmonary and renal insufficiency</e2> in this rat model .
D002216_D051437 NONE Effects of an inhibitor of angiotensin converting enzyme ( <e1>Captopril</e1> ) on <e2>pulmonary and renal insufficiency</e2> due to intravascular coagulation in the rat .
D002216_D051437 NONE Injection of <e1>Captopril</e1> ( 1 mg/kg ) , an inhibitor of angiotensin converting enzyme ( ACE ) , reduced both <e2>pulmonary and renal insufficiency</e2> in this rat model .
D002216_D004211 NONE Effects of an inhibitor of angiotensin converting enzyme ( <e1>Captopril</e1> ) on pulmonary and renal insufficiency due to <e2>intravascular coagulation</e2> in the rat .
D014148_D004211 CID Induction of <e2>intravascular coagulation</e2> and inhibition of fibrinolysis by injection of thrombin and <e1>tranexamic acid</e1> ( AMCA ) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after trauma or sepsis in man .
D014148_D004211 CID Induction of <e2>intravascular coagulation</e2> and inhibition of fibrinolysis by injection of thrombin and tranexamic acid ( <e1>AMCA</e1> ) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after trauma or sepsis in man .
D014148_D011665 NONE Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and <e1>tranexamic acid</e1> ( AMCA ) in the rat gives rise to <e2>pulmonary and renal insufficiency</e2> resembling that occurring after trauma or sepsis in man .
D014148_D011665 NONE Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and tranexamic acid ( <e1>AMCA</e1> ) in the rat gives rise to <e2>pulmonary and renal insufficiency</e2> resembling that occurring after trauma or sepsis in man .
D014148_D051437 NONE Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and <e1>tranexamic acid</e1> ( AMCA ) in the rat gives rise to <e2>pulmonary and renal insufficiency</e2> resembling that occurring after trauma or sepsis in man .
D014148_D051437 NONE Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and tranexamic acid ( <e1>AMCA</e1> ) in the rat gives rise to <e2>pulmonary and renal insufficiency</e2> resembling that occurring after trauma or sepsis in man .
D014148_D014947 NONE Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and <e1>tranexamic acid</e1> ( AMCA ) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after <e2>trauma</e2> or sepsis in man .
D014148_D014947 NONE Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and tranexamic acid ( <e1>AMCA</e1> ) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after <e2>trauma</e2> or sepsis in man .
D014148_D018805 NONE Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and <e1>tranexamic acid</e1> ( AMCA ) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after trauma or <e2>sepsis</e2> in man .
D014148_D018805 NONE Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and tranexamic acid ( <e1>AMCA</e1> ) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after trauma or <e2>sepsis</e2> in man .
D014508_D007674 NONE <e2>Renal damage</e2> as reflected by an increase in serum <e1>urea</e1> and in kidney weight was prevented by Captopril .
D002216_D007674 NONE <e2>Renal damage</e2> as reflected by an increase in serum urea and in kidney weight was prevented by <e1>Captopril</e1> .
D002216_D007674 NONE <e1>Captopril</e1> may , by the same mechanism , reduce the increase in glomerular filtration that is known to occur after an injection of thrombin , thereby diminishing the aggregation of fibrin monomers in the glomeruli , with the result that less fibrin will be deposited and thus less <e2>kidney damage</e2> will be produced .
1728522
D019980_D006099 CID <e2>Granulomatous hepatitis</e2> due to <e1>combination of amoxicillin and clavulanic acid</e1> .
D019980_D006099 CID We report the case of a patient with <e1>amoxicillin-clavulanic acid-induced</e1> hepatitis with histologic multiple <e2>granulomas</e2> .
D019980_D056486 CID <e2>Granulomatous hepatitis</e2> due to <e1>combination of amoxicillin and clavulanic acid</e1> .
D019980_D056486 CID We report the case of a patient with <e1>amoxicillin-clavulanic acid-induced</e1> <e2>hepatitis</e2> with histologic multiple granulomas .
7890216
D015282_D042882 CID Composition of <e2>gall bladder stones</e2> associated with <e1>octreotide</e1> : response to oral ursodeoxycholic acid .
D015282_D042882 CID <e1>Octreotide</e1> , an effective treatment for acromegaly , induces <e2>gall bladder stones</e2> in 13 - 60 % of patients .
D015282_D042882 CID Because knowledge of stone composition is essential for studies of their pathogenesis , treatment , and prevention , this was investigated by direct and indirect methods in 14 <e1>octreotide</e1> treated acromegalic patients with <e2>gall stones</e2> .
D015282_D042882 CID In conclusion , <e1>octreotide</e1> induced <e2>gall stones</e2> are generally small , multiple , and cholesterol rich although , in common with spontaneous gall stone disease , at presentation some patients will have a blocked cystic duct and some gall stones containing calcium .
D015282_D042882 CID In conclusion , <e1>octreotide</e1> induced gall stones are generally small , multiple , and cholesterol rich although , in common with spontaneous <e2>gall stone disease</e2> , at presentation some patients will have a blocked cystic duct and some gall stones containing calcium .
D015282_D042882 CID In conclusion , <e1>octreotide</e1> induced gall stones are generally small , multiple , and cholesterol rich although , in common with spontaneous gall stone disease , at presentation some patients will have a blocked cystic duct and some <e2>gall stones</e2> containing calcium .
D014580_D042882 NONE Composition of <e2>gall bladder stones</e2> associated with octreotide : response to oral <e1>ursodeoxycholic acid</e1> .
D015282_D000172 NONE <e1>Octreotide</e1> , an effective treatment for <e2>acromegaly</e2> , induces gall bladder stones in 13 - 60 % of patients .
D015282_D000172 NONE Because knowledge of stone composition is essential for studies of their pathogenesis , treatment , and prevention , this was investigated by direct and indirect methods in 14 <e1>octreotide</e1> treated <e2>acromegalic</e2> patients with gall stones .
D002784_D042882 NONE Chemical analysis of <e2>gall stones</e2> retrieved at cholecystectomy from two patients , showed that they contained 71 % and 87 % <e1>cholesterol</e1> by weight .
D002784_D042882 NONE After one year of treatment , five of the remaining nine patients showed either partial ( n = 3 ) or complete ( n = 2 ) <e2>gall stone</e2> dissolution , suggesting that their stones were <e1>cholesterol</e1> rich .
D002784_D042882 NONE In conclusion , octreotide induced <e2>gall stones</e2> are generally small , multiple , and <e1>cholesterol</e1> rich although , in common with spontaneous gall stone disease , at presentation some patients will have a blocked cystic duct and some gall stones containing calcium .
D002784_D042882 NONE In conclusion , octreotide induced gall stones are generally small , multiple , and <e1>cholesterol</e1> rich although , in common with spontaneous <e2>gall stone disease</e2> , at presentation some patients will have a blocked cystic duct and some gall stones containing calcium .
D002784_D042882 NONE In conclusion , octreotide induced gall stones are generally small , multiple , and <e1>cholesterol</e1> rich although , in common with spontaneous gall stone disease , at presentation some patients will have a blocked cystic duct and some <e2>gall stones</e2> containing calcium .
D002118_D042882 NONE In conclusion , octreotide induced <e2>gall stones</e2> are generally small , multiple , and cholesterol rich although , in common with spontaneous gall stone disease , at presentation some patients will have a blocked cystic duct and some gall stones containing <e1>calcium</e1> .
D002118_D042882 NONE In conclusion , octreotide induced gall stones are generally small , multiple , and cholesterol rich although , in common with spontaneous <e2>gall stone disease</e2> , at presentation some patients will have a blocked cystic duct and some gall stones containing <e1>calcium</e1> .
D002118_D042882 NONE In conclusion , octreotide induced gall stones are generally small , multiple , and cholesterol rich although , in common with spontaneous gall stone disease , at presentation some patients will have a blocked cystic duct and some <e2>gall stones</e2> containing <e1>calcium</e1> .
9390208
D008942_D001943 NONE Treatment of previously treated metastatic <e2>breast cancer</e2> by <e1>mitoxantrone</e1> and 48-hour continuous infusion of high-dose 5-FU and leucovorin ( MFL ): low palliative benefit and high treatment-related toxicity .
D008942_D001943 NONE From October 1993 to November 1995 , we treated 13 patients with previously chemotherapy-treated metastatic <e2>breast cancer</e2> by <e1>mitoxantrone</e1> , 12 mg/m2 , on day 1 and continuous infusion of 5-FU , 3000 mg/m2 , together with leucovorin , 300 mg/m2 , for 48 h from day 1 to 2 .
D008942_D064420 NONE Treatment of previously treated metastatic breast cancer by <e1>mitoxantrone</e1> and 48-hour continuous infusion of high-dose 5-FU and leucovorin ( MFL ): low palliative benefit and high treatment-related <e2>toxicity</e2> .
D005472_D001943 NONE Treatment of previously treated metastatic <e2>breast cancer</e2> by mitoxantrone and 48-hour continuous infusion of high-dose <e1>5-FU</e1> and leucovorin ( MFL ): low palliative benefit and high treatment-related toxicity .
D005472_D001943 NONE From October 1993 to November 1995 , we treated 13 patients with previously chemotherapy-treated metastatic <e2>breast cancer</e2> by mitoxantrone , 12 mg/m2 , on day 1 and continuous infusion of <e1>5-FU</e1> , 3000 mg/m2 , together with leucovorin , 300 mg/m2 , for 48 h from day 1 to 2 .
D005472_D064420 NONE Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose <e1>5-FU</e1> and leucovorin ( MFL ): low palliative benefit and high treatment-related <e2>toxicity</e2> .
D002955_D001943 NONE Treatment of previously treated metastatic <e2>breast cancer</e2> by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and <e1>leucovorin</e1> ( MFL ): low palliative benefit and high treatment-related toxicity .
D002955_D001943 NONE From October 1993 to November 1995 , we treated 13 patients with previously chemotherapy-treated metastatic <e2>breast cancer</e2> by mitoxantrone , 12 mg/m2 , on day 1 and continuous infusion of 5-FU , 3000 mg/m2 , together with <e1>leucovorin</e1> , 300 mg/m2 , for 48 h from day 1 to 2 .
D002955_D064420 NONE Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and <e1>leucovorin</e1> ( MFL ): low palliative benefit and high treatment-related <e2>toxicity</e2> .
C085788_D001943 NONE Treatment of previously treated metastatic <e2>breast cancer</e2> by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin ( <e1>MFL</e1> ): low palliative benefit and high treatment-related toxicity .
C085788_D064420 NONE Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin ( <e1>MFL</e1> ): low palliative benefit and high treatment-related <e2>toxicity</e2> .
C085788_D064420 NONE The <e1>MFL regimen</e1> achieves little palliative benefit and induces severe <e2>toxicity</e2> at a fairly high rate .
7088431
D004054_D018262 CID Development of <e2>clear cell adenocarcinoma</e2> in <e1>DES-exposed</e1> offspring under observation .
D004054_D018262 CID Two cases of <e2>clear cell adenocarcinoma of the vagina</e2> detected at follow-up in young women exposed in utero to <e1>diethylstilbestrol</e1> are reported .
D004054_D014625 CID Two cases of <e2>clear cell adenocarcinoma of the vagina</e2> detected at follow-up in young women exposed in utero to <e1>diethylstilbestrol</e1> are reported .
18417364
D009538_D009759 CID <e1>Nicotine-induced</e1> <e2>nystagmus</e2> correlates with midpontine activation .
D009538_D009759 CID The pathomechanism of <e1>nicotine-induced</e1> <e2>nystagmus</e2> ( NIN ) is unknown .
D009538_D009759 CID The pathomechanism of <e1>nicotine-induced</e1> nystagmus ( <e2>NIN</e2> ) is unknown .
D010100_D009759 NONE <e2>NIN</e2> correlated with blood <e1>oxygen</e1> level-dependent ( BOLD ) activity levels in a midpontine site in the posterior basis pontis .
9869257
C087567_D000647 NONE In the mouse passive-avoidance test , <e1>PG-9</e1> ( 10 - 30 mg/kg , i.p. ) , administered 20 min before the training session , prevented <e2>amnesia</e2> induced by both the non selective antimuscarinic drug scopolamine and the M1-selective antagonist S-(-)-ET-126 .
C087567_D000647 NONE In the same experimental conditions , <e1>PG-9</e1> ( 5 - 20 microg per mouse , i.c.v. ) was also able to prevent antimuscarine-induced <e2>amnesia</e2> , demonstrating a central localization of the activity .
D012601_D000647 CID In the mouse passive-avoidance test , PG-9 ( 10 - 30 mg/kg , i.p. ) , administered 20 min before the training session , prevented <e2>amnesia</e2> induced by both the non selective antimuscarinic drug <e1>scopolamine</e1> and the M1-selective antagonist S-(-)-ET-126 .
C098725_D000647 CID In the mouse passive-avoidance test , PG-9 ( 10 - 30 mg/kg , i.p. ) , administered 20 min before the training session , prevented <e2>amnesia</e2> induced by both the non selective antimuscarinic drug scopolamine and the M1-selective antagonist <e1>S-(-)-ET-126</e1> .
3015567
D009599_D007022 CID <e1>Nitroprusside-induced</e1> <e2>hypotension</e2> evokes ACTH secretion which is primarily mediated by enhanced secretion of immunoreactive corticotropin-releasing factor ( irCRF ) into the hypophysial-portal circulation .
D009599_D007022 CID Suppression of irCRF secretion in response to <e1>nitroprusside-induced</e1> <e2>hypotension</e2> is observed and occurs at a plasma corticosterone level between 8 - 12 micrograms/dl .
D003345_D007022 NONE Suppression of irCRF secretion in response to nitroprusside-induced <e2>hypotension</e2> is observed and occurs at a plasma <e1>corticosterone</e1> level between 8 - 12 micrograms/dl .
8739323
D008466_D007674 NONE The <e2>nephrotoxic</e2> action of anticancer drugs such as <e1>nitrogranulogen</e1> ( NG ) , methotrexate ( MTX ) , 5-fluorouracil ( 5-FU ) and cyclophosphamide ( CY ) administered alone or in combination [ MTX + 5-FU + CY ( CMF ) ] was evaluated in experiments on Wistar rats .
D008466_D007674 NONE The <e2>nephrotoxic</e2> action of anticancer drugs such as nitrogranulogen ( <e1>NG</e1> ) , methotrexate ( MTX ) , 5-fluorouracil ( 5-FU ) and cyclophosphamide ( CY ) administered alone or in combination [ MTX + 5-FU + CY ( CMF ) ] was evaluated in experiments on Wistar rats .
D008727_D007674 NONE The <e2>nephrotoxic</e2> action of anticancer drugs such as nitrogranulogen ( NG ) , <e1>methotrexate</e1> ( MTX ) , 5-fluorouracil ( 5-FU ) and cyclophosphamide ( CY ) administered alone or in combination [ MTX + 5-FU + CY ( CMF ) ] was evaluated in experiments on Wistar rats .
D008727_D007674 NONE The <e2>nephrotoxic</e2> action of anticancer drugs such as nitrogranulogen ( NG ) , methotrexate ( <e1>MTX</e1> ) , 5-fluorouracil ( 5-FU ) and cyclophosphamide ( CY ) administered alone or in combination [ MTX + 5-FU + CY ( CMF ) ] was evaluated in experiments on Wistar rats .
D008727_D007674 NONE The <e2>nephrotoxic</e2> action of anticancer drugs such as nitrogranulogen ( NG ) , methotrexate ( MTX ) , 5-fluorouracil ( 5-FU ) and cyclophosphamide ( CY ) administered alone or in combination [ <e1>MTX</e1> + 5-FU + CY ( CMF ) ] was evaluated in experiments on Wistar rats .
D008727_D007674 NONE Our studies indicate that <e2>nephrotoxicity</e2> of <e1>MTX</e1> + 5-FU + CY administered jointly is lower than in monotherapy .
D005472_D007674 NONE The <e2>nephrotoxic</e2> action of anticancer drugs such as nitrogranulogen ( NG ) , methotrexate ( MTX ) , <e1>5-fluorouracil</e1> ( 5-FU ) and cyclophosphamide ( CY ) administered alone or in combination [ MTX + 5-FU + CY ( CMF ) ] was evaluated in experiments on Wistar rats .
D005472_D007674 NONE The <e2>nephrotoxic</e2> action of anticancer drugs such as nitrogranulogen ( NG ) , methotrexate ( MTX ) , 5-fluorouracil ( <e1>5-FU</e1> ) and cyclophosphamide ( CY ) administered alone or in combination [ MTX + 5-FU + CY ( CMF ) ] was evaluated in experiments on Wistar rats .
D005472_D007674 NONE The <e2>nephrotoxic</e2> action of anticancer drugs such as nitrogranulogen ( NG ) , methotrexate ( MTX ) , 5-fluorouracil ( 5-FU ) and cyclophosphamide ( CY ) administered alone or in combination [ MTX + <e1>5-FU</e1> + CY ( CMF ) ] was evaluated in experiments on Wistar rats .
D005472_D007674 NONE Our studies indicate that <e2>nephrotoxicity</e2> of MTX + <e1>5-FU</e1> + CY administered jointly is lower than in monotherapy .
D003520_D007674 NONE The <e2>nephrotoxic</e2> action of anticancer drugs such as nitrogranulogen ( NG ) , methotrexate ( MTX ) , 5-fluorouracil ( 5-FU ) and <e1>cyclophosphamide</e1> ( CY ) administered alone or in combination [ MTX + 5-FU + CY ( CMF ) ] was evaluated in experiments on Wistar rats .
D003520_D007674 NONE The <e2>nephrotoxic</e2> action of anticancer drugs such as nitrogranulogen ( NG ) , methotrexate ( MTX ) , 5-fluorouracil ( 5-FU ) and cyclophosphamide ( <e1>CY</e1> ) administered alone or in combination [ MTX + 5-FU + CY ( CMF ) ] was evaluated in experiments on Wistar rats .
D003520_D007674 NONE The <e2>nephrotoxic</e2> action of anticancer drugs such as nitrogranulogen ( NG ) , methotrexate ( MTX ) , 5-fluorouracil ( 5-FU ) and cyclophosphamide ( CY ) administered alone or in combination [ MTX + 5-FU + <e1>CY</e1> ( CMF ) ] was evaluated in experiments on Wistar rats .
D003520_D007674 NONE Our studies indicate that <e2>nephrotoxicity</e2> of MTX + 5-FU + <e1>CY</e1> administered jointly is lower than in monotherapy .
D003520_D006470 CID <e1>CY</e1> caused <e2>hemorrhagic cystitis</e2> in 40 % of rats , but it did not cause this complication when combined with 5-FU and MTX .
D003520_D003556 CID <e1>CY</e1> caused <e2>hemorrhagic cystitis</e2> in 40 % of rats , but it did not cause this complication when combined with 5-FU and MTX .
D005472_D006470 NONE CY caused <e2>hemorrhagic cystitis</e2> in 40 % of rats , but it did not cause this complication when combined with <e1>5-FU</e1> and MTX .
D005472_D003556 NONE CY caused <e2>hemorrhagic cystitis</e2> in 40 % of rats , but it did not cause this complication when combined with <e1>5-FU</e1> and MTX .
D008727_D006470 NONE CY caused <e2>hemorrhagic cystitis</e2> in 40 % of rats , but it did not cause this complication when combined with 5-FU and <e1>MTX</e1> .
D008727_D003556 NONE CY caused <e2>hemorrhagic cystitis</e2> in 40 % of rats , but it did not cause this complication when combined with 5-FU and <e1>MTX</e1> .
20880751
D007980_D004409 CID <e1>Levodopa-induced</e1> <e2>dyskinesias</e2> in patients with Parkinson 's disease : filling the bench-to-bedside gap .
D007980_D004409 CID Although preclinical and clinical findings suggest pulsatile stimulation of striatal postsynaptic receptors as a key mechanism underlying <e1>levodopa-induced</e1> <e2>dyskinesias</e2> , their pathogenesis is still unclear .
D007980_D004409 CID Recent preclinical and clinical data from promising lines of research focus on the differential role of presynaptic versus postsynaptic mechanisms , dopamine receptor subtypes , ionotropic and metabotropic glutamate receptors , and non-dopaminergic neurotransmitter systems in the pathophysiology of <e1>levodopa-induced</e1> <e2>dyskinesias</e2> .
D007980_D010300 NONE <e1>Levodopa-induced</e1> dyskinesias in patients with <e2>Parkinson 's disease</e2> : filling the bench-to-bedside gap .
D007980_D010300 NONE <e1>Levodopa</e1> is the most effective drug for the treatment of <e2>Parkinson 's disease</e2> .
D004298_D004409 NONE However , the long-term use of this <e1>dopamine</e1> precursor is complicated by highly disabling fluctuations and <e2>dyskinesias</e2> .
D004298_D004409 NONE Recent preclinical and clinical data from promising lines of research focus on the differential role of presynaptic versus postsynaptic mechanisms , <e1>dopamine</e1> receptor subtypes , ionotropic and metabotropic glutamate receptors , and non-dopaminergic neurotransmitter systems in the pathophysiology of levodopa-induced <e2>dyskinesias</e2> .
D018698_D004409 NONE Recent preclinical and clinical data from promising lines of research focus on the differential role of presynaptic versus postsynaptic mechanisms , dopamine receptor subtypes , ionotropic and metabotropic <e1>glutamate</e1> receptors , and non-dopaminergic neurotransmitter systems in the pathophysiology of levodopa-induced <e2>dyskinesias</e2> .
20098969
D008694_D001145 NONE BACKGROUND : <e1>Methamphetamine</e1> is a very addictive , powerful stimulant that increases wakefulness and physical activity and can produce other effects such as <e2>cardiac dysrhythmias</e2> , hypertension , hallucinations , and violent behavior .
D008694_D006973 NONE BACKGROUND : <e1>Methamphetamine</e1> is a very addictive , powerful stimulant that increases wakefulness and physical activity and can produce other effects such as cardiac dysrhythmias , <e2>hypertension</e2> , hallucinations , and violent behavior .
D008694_D006212 NONE BACKGROUND : <e1>Methamphetamine</e1> is a very addictive , powerful stimulant that increases wakefulness and physical activity and can produce other effects such as cardiac dysrhythmias , hypertension , <e2>hallucinations</e2> , and violent behavior .
D008694_D001523 NONE BACKGROUND : <e1>Methamphetamine</e1> is a very addictive , powerful stimulant that increases wakefulness and physical activity and can produce other effects such as cardiac dysrhythmias , hypertension , hallucinations , and <e2>violent behavior</e2> .
D008694_D014987 NONE Dental patients abusing <e1>methamphetamine</e1> can present with poor oral hygiene , <e2>xerostomia</e2> , rampant caries ( " meth mouth " ) , and excessive tooth wear .
D008694_D003731 CID Dental patients abusing <e1>methamphetamine</e1> can present with poor oral hygiene , xerostomia , rampant <e2>caries</e2> ( " meth mouth " ) , and excessive tooth wear .
D008694_D003731 CID She reported her use of <e1>methamphetamine</e1> for five years and had not experienced any major <e2>carious episodes</e2> before she started using the drug .
D008694_-1 NONE Dental patients abusing <e1>methamphetamine</e1> can present with poor oral hygiene , xerostomia , rampant caries ( " <e2>meth mouth</e2> " ) , and excessive tooth wear .
D008694_-1 NONE CLINICAL SIGNIFICANCE : This clinical case showing oral manifestations of <e2>meth mouth</e2> was presented to help dental practitioners recognize and manage patients who may be abusing <e1>methamphetamines</e1> .
D008694_D057085 NONE Dental patients abusing <e1>methamphetamine</e1> can present with poor oral hygiene , xerostomia , rampant caries ( " meth mouth " ) , and excessive <e2>tooth wear</e2> .
16428221
D008774_D020293 CID <e2>Cerebral vasculitis</e2> following oral <e1>methylphenidate</e1> intake in an adult : a case report .
D008774_D020293 CID <e2>Cerebral vasculitis</e2> associated with amphetamine abuse is well documented , and in rare cases ischaemic stroke has been reported after <e1>methylphenidate</e1> intake in children .
D008774_D019969 NONE Cerebral vasculitis associated with <e2>amphetamine abuse</e2> is well documented , and in rare cases ischaemic stroke has been reported after <e1>methylphenidate</e1> intake in children .
D008774_D002544 NONE Cerebral vasculitis associated with amphetamine abuse is well documented , and in rare cases <e2>ischaemic stroke</e2> has been reported after <e1>methylphenidate</e1> intake in children .
D008774_D002544 NONE We report the case of a 63-year-old female who was treated with <e1>methylphenidate</e1> due to hyperactivity and suffered from multiple <e2>ischaemic strokes</e2> .
D008774_D006948 NONE We report the case of a 63-year-old female who was treated with <e1>methylphenidate</e1> due to <e2>hyperactivity</e2> and suffered from multiple ischaemic strokes .
D008774_D014657 NONE We conclude that <e1>methylphenidate</e1> mediated <e2>vasculitis</e2> should be considered in patients with neurological symptoms and a history of methylphenidate therapy .
D008774_D014657 NONE We conclude that methylphenidate mediated <e2>vasculitis</e2> should be considered in patients with neurological symptoms and a history of <e1>methylphenidate</e1> therapy .
220563
C023470_D010523 CID <e1>Perhexiline maleate</e1> and <e2>peripheral neuropathy</e2> .
C023470_D010523 CID <e2>Peripheral neuropathy</e2> has been noted as a complication of therapy with <e1>perhexiline maleate</e1> , a drug widely used in France ( and in clinical trials in the United States ) for the prophylactic treatment of angina pectoris .
C023470_D000787 NONE Peripheral neuropathy has been noted as a complication of therapy with <e1>perhexiline maleate</e1> , a drug widely used in France ( and in clinical trials in the United States ) for the prophylactic treatment of <e2>angina pectoris</e2> .
9721172
D007052_D001649 NONE A previously healthy child who developed acute , severe , rapidly progressive <e2>vanishing bile duct syndrome</e2> shortly after Stevens-Johnson syndrome is described ; this was temporally associated with <e1>ibuprofen</e1> use .
D007052_D013262 CID A previously healthy child who developed acute , severe , rapidly progressive vanishing bile duct syndrome shortly after <e2>Stevens-Johnson syndrome</e2> is described ; this was temporally associated with <e1>ibuprofen</e1> use .
D014580_D002779 NONE Despite therapy with <e1>ursodeoxycholic acid</e1> , prednisone , and then tacrolimus , her <e2>cholestatic disease</e2> was unrelenting , with cirrhosis shown by biopsy 6 months after presentation .
D014580_D005355 NONE Despite therapy with <e1>ursodeoxycholic acid</e1> , prednisone , and then tacrolimus , her cholestatic disease was unrelenting , with <e2>cirrhosis</e2> shown by biopsy 6 months after presentation .
D011241_D002779 NONE Despite therapy with ursodeoxycholic acid , <e1>prednisone</e1> , and then tacrolimus , her <e2>cholestatic disease</e2> was unrelenting , with cirrhosis shown by biopsy 6 months after presentation .
D011241_D005355 NONE Despite therapy with ursodeoxycholic acid , <e1>prednisone</e1> , and then tacrolimus , her cholestatic disease was unrelenting , with <e2>cirrhosis</e2> shown by biopsy 6 months after presentation .
D016559_D002779 NONE Despite therapy with ursodeoxycholic acid , prednisone , and then <e1>tacrolimus</e1> , her <e2>cholestatic disease</e2> was unrelenting , with cirrhosis shown by biopsy 6 months after presentation .
D016559_D005355 NONE Despite therapy with ursodeoxycholic acid , prednisone , and then <e1>tacrolimus</e1> , her cholestatic disease was unrelenting , with <e2>cirrhosis</e2> shown by biopsy 6 months after presentation .
7919560
D000667_D004892 CID <e2>Erythema multiforme</e2> and hypersensitivity myocarditis caused by <e1>ampicillin</e1> .
D000667_D004892 CID OBJECTIVE : To report a case of <e2>erythema multiforme</e2> and hypersensitivity myocarditis caused by <e1>ampicillin</e1> .
D000667_D009205 CID Erythema multiforme and <e2>hypersensitivity myocarditis</e2> caused by <e1>ampicillin</e1> .
D000667_D009205 CID OBJECTIVE : To report a case of erythema multiforme and <e2>hypersensitivity myocarditis</e2> caused by <e1>ampicillin</e1> .
D000667_D018805 NONE CASE SUMMARY : A 13-year-old boy was treated with <e1>ampicillin</e1> and gentamicin because of suspected <e2>septicemia</e2> .
D005839_D018805 NONE CASE SUMMARY : A 13-year-old boy was treated with ampicillin and <e1>gentamicin</e1> because of suspected <e2>septicemia</e2> .
D010406_D009205 NONE CONCLUSIONS : <e2>Hypersensitivity myocarditis</e2> is a rare and dangerous manifestation of allergy to <e1>penicillins</e1> .
D010406_D004342 NONE CONCLUSIONS : Hypersensitivity myocarditis is a rare and dangerous manifestation of <e2>allergy</e2> to <e1>penicillins</e1> .
2425813
D011239_D006529 CID <e2>Liver enlargement</e2> and muscle wastage occurred in Wistar rats following the subcutaneous administration of <e1>prednisolone</e1> .
D011239_D009133 CID Liver enlargement and <e2>muscle wastage</e2> occurred in Wistar rats following the subcutaneous administration of <e1>prednisolone</e1> .
12695819
D016559_D020258 NONE MR imaging with quantitative diffusion mapping of <e1>tacrolimus-induced</e1> <e2>neurotoxicity</e2> in organ transplant patients .
D016559_D020258 NONE Diffusion-weighted imaging may be useful in predicting the outcomes of the lesions of <e1>tacrolimus-induced</e1> <e2>neurotoxicity</e2> .
D016559_D009422 NONE Brain MR studies , including DW imaging , were prospectively performed in 14 organ transplant patients receiving <e1>tacrolimus</e1> who developed <e2>neurologic complications</e2> .
6133211
D012460_D015212 NONE Three infants , born of two mothers with <e2>inflammatory bowel disease</e2> who received treatment with <e1>sulphasalazine</e1> throughout pregnancy , were found to have major congenital anomalies .
D012460_D000013 NONE Three infants , born of two mothers with inflammatory bowel disease who received treatment with <e1>sulphasalazine</e1> throughout pregnancy , were found to have major <e2>congenital anomalies</e2> .
2355241
D007980_D002543 NONE The low incidence of <e2>cerebral haemorrhage</e2> as a cause of death in patients with Parkinson 's disease may reflect the hypotensive effect of <e1>levodopa</e1> and a hypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain .
D007980_D003643 NONE The low incidence of cerebral haemorrhage as a cause of <e2>death</e2> in patients with Parkinson 's disease may reflect the hypotensive effect of <e1>levodopa</e1> and a hypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain .
D007980_D010300 NONE The low incidence of cerebral haemorrhage as a cause of death in patients with <e2>Parkinson 's disease</e2> may reflect the hypotensive effect of <e1>levodopa</e1> and a hypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain .
D007980_D010300 NONE The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson 's disease may reflect the hypotensive effect of <e1>levodopa</e1> and a hypotensive mechanism due to reduced noradrenaline levels in the <e2>parkinsonian</e2> brain .
D007980_D007022 CID The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson 's disease may reflect the <e2>hypotensive</e2> effect of <e1>levodopa</e1> and a hypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain .
D007980_D007022 CID The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson 's disease may reflect the hypotensive effect of <e1>levodopa</e1> and a <e2>hypotensive</e2> mechanism due to reduced noradrenaline levels in the parkinsonian brain .
D009638_D002543 NONE The low incidence of <e2>cerebral haemorrhage</e2> as a cause of death in patients with Parkinson 's disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced <e1>noradrenaline</e1> levels in the parkinsonian brain .
D009638_D003643 NONE The low incidence of cerebral haemorrhage as a cause of <e2>death</e2> in patients with Parkinson 's disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced <e1>noradrenaline</e1> levels in the parkinsonian brain .
D009638_D010300 NONE The low incidence of cerebral haemorrhage as a cause of death in patients with <e2>Parkinson 's disease</e2> may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced <e1>noradrenaline</e1> levels in the parkinsonian brain .
D009638_D010300 NONE The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson 's disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced <e1>noradrenaline</e1> levels in the <e2>parkinsonian</e2> brain .
D009638_D007022 NONE The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson 's disease may reflect the <e2>hypotensive</e2> effect of levodopa and a hypotensive mechanism due to reduced <e1>noradrenaline</e1> levels in the parkinsonian brain .
D009638_D007022 NONE The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson 's disease may reflect the hypotensive effect of levodopa and a <e2>hypotensive</e2> mechanism due to reduced <e1>noradrenaline</e1> levels in the parkinsonian brain .
17608141
D008694_D020258 NONE Attenuation of <e1>methamphetamine-induced</e1> nigrostriatal dopaminergic <e2>neurotoxicity</e2> in mice by lipopolysaccharide pretreatment .
D008694_D020258 NONE In this study , we examined the roles of lipopolysaccharide , a pro-inflammatory and inflammatory factor , treatment in modulating the <e1>methamphetamine-induced</e1> nigrostriatal dopamine <e2>neurotoxicity</e2> .
D008694_D020258 NONE We concluded a critical time window for systemic lipopolysaccharide pretreatment in exerting effective protection against <e1>methamphetamine-induced</e1> nigrostriatal dopamine <e2>neurotoxicity</e2> .
D008070_D020258 NONE Attenuation of methamphetamine-induced nigrostriatal dopaminergic <e2>neurotoxicity</e2> in mice by <e1>lipopolysaccharide</e1> pretreatment .
D008070_D020258 NONE In this study , we examined the roles of <e1>lipopolysaccharide</e1> , a pro-inflammatory and inflammatory factor , treatment in modulating the methamphetamine-induced nigrostriatal dopamine <e2>neurotoxicity</e2> .
D008070_D020258 NONE We concluded a critical time window for systemic <e1>lipopolysaccharide</e1> pretreatment in exerting effective protection against methamphetamine-induced nigrostriatal dopamine <e2>neurotoxicity</e2> .
D008694_D009422 NONE Immunological activation has been proposed to play a role in <e1>methamphetamine-induced</e1> <e2>dopaminergic terminal damage</e2> .
D004298_D020258 NONE In this study , we examined the roles of lipopolysaccharide , a pro-inflammatory and inflammatory factor , treatment in modulating the methamphetamine-induced nigrostriatal <e1>dopamine</e1> <e2>neurotoxicity</e2> .
D004298_D020258 NONE We concluded a critical time window for systemic lipopolysaccharide pretreatment in exerting effective protection against methamphetamine-induced nigrostriatal <e1>dopamine</e1> <e2>neurotoxicity</e2> .
D008070_D005334 NONE <e1>Lipopolysaccharide</e1> pretreatment did not affect the basal body temperature or methamphetamine-elicited <e2>hyperthermia</e2> three days later .
D008694_D005334 CID Lipopolysaccharide pretreatment did not affect the basal body temperature or <e1>methamphetamine-elicited</e1> <e2>hyperthermia</e2> three days later .
1130930
D002512_D007674 NONE <e2>Nephrotoxicity</e2> of combined <e1>cephalothin-gentamicin</e1> regimen .
D005839_D007674 NONE <e2>Nephrotoxicity</e2> of combined <e1>cephalothin-gentamicin</e1> regimen .
D002512_D007683 CID Two patients developed <e2>acute tubular necrosis</e2> , characterized clinically by acute oliguric renal failure , while they were receiving a combination of <e1>cephalothin sodium</e1> and gentamicin sulfate therapy .
D002512_D009846 NONE Two patients developed acute tubular necrosis , characterized clinically by acute <e2>oliguric renal failure</e2> , while they were receiving a combination of <e1>cephalothin sodium</e1> and gentamicin sulfate therapy .
D002512_D051437 NONE Two patients developed acute tubular necrosis , characterized clinically by acute <e2>oliguric renal failure</e2> , while they were receiving a combination of <e1>cephalothin sodium</e1> and gentamicin sulfate therapy .
D005839_D007683 CID Two patients developed <e2>acute tubular necrosis</e2> , characterized clinically by acute oliguric renal failure , while they were receiving a combination of cephalothin sodium and <e1>gentamicin sulfate</e1> therapy .
D005839_D009846 NONE Two patients developed acute tubular necrosis , characterized clinically by acute <e2>oliguric renal failure</e2> , while they were receiving a combination of cephalothin sodium and <e1>gentamicin sulfate</e1> therapy .
D005839_D051437 NONE Two patients developed acute tubular necrosis , characterized clinically by acute <e2>oliguric renal failure</e2> , while they were receiving a combination of cephalothin sodium and <e1>gentamicin sulfate</e1> therapy .
8649546
D007980_D004409 CID Improvement of <e1>levodopa-induced</e1> <e2>dyskinesia</e2> by propranolol in Parkinson 's disease .
D007980_D004409 CID This study suggests that administration of low doses of beta-blockers may improve <e1>levodopa-induced</e1> ballistic and choreic <e2>dyskinesia</e2> in PD .
D007980_D010300 NONE Improvement of <e1>levodopa-induced</e1> dyskinesia by propranolol in <e2>Parkinson 's disease</e2> .
D007980_D010300 NONE This study suggests that administration of low doses of beta-blockers may improve <e1>levodopa-induced</e1> ballistic and choreic dyskinesia in <e2>PD</e2> .
D011433_D004409 NONE Improvement of levodopa-induced <e2>dyskinesia</e2> by <e1>propranolol</e1> in Parkinson 's disease .
D011433_D004409 NONE Seven patients suffering from Parkinson 's disease ( PD ) with severely disabling <e2>dyskinesia</e2> received low-dose <e1>propranolol</e1> as an adjunct to the currently used medical treatment .
D011433_D010300 NONE Improvement of levodopa-induced dyskinesia by <e1>propranolol</e1> in <e2>Parkinson 's disease</e2> .
D011433_D010300 NONE Seven patients suffering from <e2>Parkinson 's disease</e2> ( PD ) with severely disabling dyskinesia received low-dose <e1>propranolol</e1> as an adjunct to the currently used medical treatment .
D011433_D010300 NONE Seven patients suffering from Parkinson 's disease ( <e2>PD</e2> ) with severely disabling dyskinesia received low-dose <e1>propranolol</e1> as an adjunct to the currently used medical treatment .
9406968
D014667_D003919 NONE Upregulation of the expression of <e1>vasopressin</e1> gene in the paraventricular and supraoptic nuclei of the lithium-induced <e2>diabetes insipidus</e2> rat .
D008094_D003919 NONE Upregulation of the expression of vasopressin gene in the paraventricular and supraoptic nuclei of the <e1>lithium-induced</e1> <e2>diabetes insipidus</e2> rat .
D008094_D003919 NONE These results suggest that dehydration and/or the activation of visceral afferent inputs may contribute to the elevation of plasma AVP and the upregulation of AVP gene expression in the PVN and the SON of the <e1>Li-induced</e1> <e2>diabetes insipidus</e2> rat .
D001127_D011141 NONE The expression of <e1>arginine vasopressin</e1> ( AVP ) gene in the paraventricular ( PVN ) and supraoptic nuclei ( SON ) was investigated in rats with lithium (Li)-induced <e2>polyuria</e2> , using in situ hybridization histochemistry and radioimmunoassay .
D001127_D011141 NONE The expression of arginine vasopressin ( <e1>AVP</e1> ) gene in the paraventricular ( PVN ) and supraoptic nuclei ( SON ) was investigated in rats with lithium (Li)-induced <e2>polyuria</e2> , using in situ hybridization histochemistry and radioimmunoassay .
D008094_D011141 NONE The expression of arginine vasopressin ( AVP ) gene in the paraventricular ( PVN ) and supraoptic nuclei ( SON ) was investigated in rats with <e1>lithium</e1> (Li)-induced <e2>polyuria</e2> , using in situ hybridization histochemistry and radioimmunoassay .
D008094_D011141 NONE The expression of arginine vasopressin ( AVP ) gene in the paraventricular ( PVN ) and supraoptic nuclei ( SON ) was investigated in rats with lithium <e1>(Li)-induced</e1> <e2>polyuria</e2> , using in situ hybridization histochemistry and radioimmunoassay .
D018021_D011141 CID The male Wistar rats consuming a diet that contained <e1>LiCl</e1> ( 60 mmol/kg ) for 4 weeks developed marked <e2>polyuria</e2> .
D001127_D003681 NONE These results suggest that <e2>dehydration</e2> and/or the activation of visceral afferent inputs may contribute to the elevation of plasma <e1>AVP</e1> and the upregulation of AVP gene expression in the PVN and the SON of the Li-induced diabetes insipidus rat .
D001127_D003681 NONE These results suggest that <e2>dehydration</e2> and/or the activation of visceral afferent inputs may contribute to the elevation of plasma AVP and the upregulation of <e1>AVP</e1> gene expression in the PVN and the SON of the Li-induced diabetes insipidus rat .
D001127_D003919 NONE These results suggest that dehydration and/or the activation of visceral afferent inputs may contribute to the elevation of plasma <e1>AVP</e1> and the upregulation of AVP gene expression in the PVN and the SON of the Li-induced <e2>diabetes insipidus</e2> rat .
D001127_D003919 NONE These results suggest that dehydration and/or the activation of visceral afferent inputs may contribute to the elevation of plasma AVP and the upregulation of <e1>AVP</e1> gene expression in the PVN and the SON of the Li-induced <e2>diabetes insipidus</e2> rat .
D008094_D003681 NONE These results suggest that <e2>dehydration</e2> and/or the activation of visceral afferent inputs may contribute to the elevation of plasma AVP and the upregulation of AVP gene expression in the PVN and the SON of the <e1>Li-induced</e1> diabetes insipidus rat .
3187073
D005472_D002637 CID It is concluded that patients on <e1>5-FU</e1> treatment should be under close supervision and that the treatment should be discontinued if <e2>chest pain</e2> or tachyarrhythmia is observed .
D005472_D013610 NONE It is concluded that patients on <e1>5-FU</e1> treatment should be under close supervision and that the treatment should be discontinued if chest pain or <e2>tachyarrhythmia</e2> is observed .
17400887
D013726_D020078 NONE <e2>Neuroinflammation</e2> and behavioral abnormalities after neonatal <e1>terbutaline</e1> treatment in rats : implications for autism .
D013726_D001523 NONE Neuroinflammation and <e2>behavioral abnormalities</e2> after neonatal <e1>terbutaline</e1> treatment in rats : implications for autism .
D013726_D001321 CID Neuroinflammation and behavioral abnormalities after neonatal <e1>terbutaline</e1> treatment in rats : implications for <e2>autism</e2> .
D013726_D001321 CID <e1>Terbutaline</e1> , a beta2-adrenoceptor agonist used to arrest preterm labor , has been associated with increased concordance for <e2>autism</e2> in dizygotic twins .
D013726_D007752 NONE <e1>Terbutaline</e1> , a beta2-adrenoceptor agonist used to arrest <e2>preterm labor</e2> , has been associated with increased concordance for autism in dizygotic twins .
9522152
D002045_D009461 NONE A transient <e2>neurological deficit</e2> following intrathecal injection of 1 % hyperbaric <e1>bupivacaine</e1> for unilateral spinal anaesthesia .
D002045_D009461 NONE We describe a case of transient <e2>neurological deficit</e2> that occurred after unilateral spinal anaesthesia with 8 mg of 1 % hyperbaric <e1>bupivacaine</e1> slowly injected through a 25-gauge pencil-point spinal needle .
17562951
D007479_D051436 NONE METHODS AND RESULTS : The present study is a multicenter , randomized , double-blind comparison of <e1>iopamidol</e1> and iodixanol in patients with <e2>chronic kidney disease</e2> ( estimated glomerular filtration rate , 20 to 59 mL/min ) who underwent cardiac angiography or percutaneous coronary interventions .
C044834_D051436 NONE METHODS AND RESULTS : The present study is a multicenter , randomized , double-blind comparison of iopamidol and <e1>iodixanol</e1> in patients with <e2>chronic kidney disease</e2> ( estimated glomerular filtration rate , 20 to 59 mL/min ) who underwent cardiac angiography or percutaneous coronary interventions .
D000111_D003920 NONE In 414 patients , contrast volume , presence of <e2>diabetes mellitus</e2> , use of <e1>N-acetylcysteine</e1> , mean baseline SCr , and estimated glomerular filtration rate were comparable in the 2 groups .
D007479_D003920 NONE In patients with <e2>diabetes</e2> , SCr increases > or = 0.5 mg/dL were 5.1 % ( 4 of 78 patients ) with <e1>iopamidol</e1> and 13.0 % ( 12 of 92 patients ) with iodixanol ( P=0.11 ) , whereas SCr increases > or = 25 % were 10.3 % and 15.2 % , respectively ( P=0.37 ) .
D007479_D003920 NONE Mean post-SCr increases were significantly less with <e1>iopamidol</e1> ( all patients : 0.07 versus 0.12 mg/dL , 6.2 versus 10.6 micromol/L , P=0.03 ; patients with <e2>diabetes</e2> : 0.07 versus 0.16 mg/dL , 6.2 versus 14.1 micromol/L , P=0.01 ) .
D007479_D003920 NONE CONCLUSIONS : The rate of contrast-induced nephropathy , defined by multiple end points , is not statistically different after the intraarterial administration of <e1>iopamidol</e1> or iodixanol to high-risk patients , with or without <e2>diabetes mellitus</e2> .
C044834_D003920 NONE In patients with <e2>diabetes</e2> , SCr increases > or = 0.5 mg/dL were 5.1 % ( 4 of 78 patients ) with iopamidol and 13.0 % ( 12 of 92 patients ) with <e1>iodixanol</e1> ( P=0.11 ) , whereas SCr increases > or = 25 % were 10.3 % and 15.2 % , respectively ( P=0.37 ) .
C044834_D003920 NONE CONCLUSIONS : The rate of contrast-induced nephropathy , defined by multiple end points , is not statistically different after the intraarterial administration of iopamidol or <e1>iodixanol</e1> to high-risk patients , with or without <e2>diabetes mellitus</e2> .
D007479_D007674 CID CONCLUSIONS : The rate of contrast-induced <e2>nephropathy</e2> , defined by multiple end points , is not statistically different after the intraarterial administration of <e1>iopamidol</e1> or iodixanol to high-risk patients , with or without diabetes mellitus .
C044834_D007674 CID CONCLUSIONS : The rate of contrast-induced <e2>nephropathy</e2> , defined by multiple end points , is not statistically different after the intraarterial administration of iopamidol or <e1>iodixanol</e1> to high-risk patients , with or without diabetes mellitus .
12574103
D003907_D006973 CID Prenatal <e1>dexamethasone</e1> programs <e2>hypertension</e2> and renal injury in the rat .
D003907_D006973 CID The purpose of the present study was to determine if prenatal <e1>dexamethasone</e1> programmed a progressive <e2>increase in blood pressure</e2> and renal injury in rats .
D003907_D006973 CID Male rats that received prenatal <e1>dexamethasone</e1> on days 15 and 16 , 17 and 18 , and 13 and 14 of gestation had <e2>elevated blood pressures</e2> at 6 months of age ; the latter group did not have a reduction in glomerular number .
D003907_D006973 CID This study shows that prenatal <e1>dexamethasone</e1> in rats results in a reduction in glomerular number , glomerulosclerosis , and <e2>hypertension</e2> when administered at specific points during gestation .
D003907_D007674 CID Prenatal <e1>dexamethasone</e1> programs hypertension and <e2>renal injury</e2> in the rat .
D003907_D007674 CID The purpose of the present study was to determine if prenatal <e1>dexamethasone</e1> programmed a progressive increase in blood pressure and <e2>renal injury</e2> in rats .
D003907_D007674 CID Offspring of rats administered <e1>dexamethasone</e1> on days 15 and 16 gestation had a 20 % <e2>reduction in glomerular number</e2> compared with control at 6 to 9 months of age ( 22 527+/-509 versus 28 050+/-561 , P<0.05 ) , which was comparable to the percent reduction in glomeruli measured at 3 weeks of age .
D003907_D007674 CID Male rats that received prenatal <e1>dexamethasone</e1> on days 15 and 16 , 17 and 18 , and 13 and 14 of gestation had elevated blood pressures at 6 months of age ; the latter group did not have a <e2>reduction in glomerular number</e2> .
D003907_D007674 CID This study shows that prenatal <e1>dexamethasone</e1> in rats results in a <e2>reduction in glomerular number</e2> , glomerulosclerosis , and hypertension when administered at specific points during gestation .
D003907_D005921 NONE Adult rats given <e1>dexamethasone</e1> on days 15 and 16 of gestation had more glomeruli with <e2>glomerulosclerosis</e2> than control rats .
D003907_D005921 NONE This study shows that prenatal <e1>dexamethasone</e1> in rats results in a reduction in glomerular number , <e2>glomerulosclerosis</e2> , and hypertension when administered at specific points during gestation .
18023325
D004221_D014826 CID Acute <e2>vocal fold palsy</e2> after acute <e1>disulfiram</e1> intoxication .
D004221_D014826 CID Acute peripheral neuropathy caused by a <e1>disulfiram</e1> overdose is very rare and there is no report of it leading to <e2>vocal fold palsy</e2> .
D004221_D010523 CID Acute <e2>peripheral neuropathy</e2> caused by a <e1>disulfiram</e1> overdose is very rare and there is no report of it leading to vocal fold palsy .
D004221_D062787 NONE Acute peripheral neuropathy caused by a <e1>disulfiram</e1> <e2>overdose</e2> is very rare and there is no report of it leading to vocal fold palsy .
D004221_D010243 NONE This was a case of acute <e2>palsy</e2> of the recurrent laryngeal nerve and superimposed severe acute sensorimotor axonal polyneuropathy caused by high-dose <e1>disulfiram</e1> intoxication .
D004221_D011115 NONE This was a case of acute palsy of the recurrent laryngeal nerve and superimposed severe acute sensorimotor axonal <e2>polyneuropathy</e2> caused by high-dose <e1>disulfiram</e1> intoxication .
12369736
D003042_D009069 CID Effects of 5-HT1B receptor ligands microinjected into the accumbal shell or core on the <e1>cocaine-induced</e1> <e2>locomotor hyperactivity</e2> in rats .
D003042_D009069 CID The present study was designed to examine the effect of 5-HT1B receptor ligands microinjected into the subregions of the nucleus accumbens ( the shell and the core ) on the <e2>locomotor hyperactivity</e2> induced by <e1>cocaine</e1> in rats .
D003042_D009069 CID GR 55562 ( 0.1 - 10 microg/side ) , administered intra-accumbens shell prior to <e1>cocaine</e1> , dose-dependently attenuated the psychostimulant-induced <e2>locomotor hyperactivity</e2> .
D003042_D009069 CID Our findings indicate that <e1>cocaine</e1> induced <e2>hyperlocomotion</e2> is modified by 5-HT1B receptor ligands microinjected into the accumbens shell , but not core , this modification consisting in inhibitory and facilitatory effects of the 5-HT1B receptor antagonist ( GR 55562 ) and agonist ( CP 93129 ) , respectively .
C103477_D009069 NONE <e1>GR 55562</e1> ( 0.1 - 10 microg/side ) , administered intra-accumbens shell prior to cocaine , dose-dependently attenuated the psychostimulant-induced <e2>locomotor hyperactivity</e2> .
C103477_D009069 NONE Our findings indicate that cocaine induced <e2>hyperlocomotion</e2> is modified by 5-HT1B receptor ligands microinjected into the accumbens shell , but not core , this modification consisting in inhibitory and facilitatory effects of the 5-HT1B receptor antagonist ( <e1>GR 55562</e1> ) and agonist ( CP 93129 ) , respectively .
C065046_D009069 CID Our findings indicate that cocaine induced <e2>hyperlocomotion</e2> is modified by 5-HT1B receptor ligands microinjected into the accumbens shell , but not core , this modification consisting in inhibitory and facilitatory effects of the 5-HT1B receptor antagonist ( GR 55562 ) and agonist ( <e1>CP 93129</e1> ) , respectively .
8953972
D004837_D013345 CID Fatal <e2>intracranial bleeding</e2> associated with prehospital use of <e1>epinephrine</e1> .
D004837_D012128 NONE The sudden onset of <e2>respiratory distress</e2> , rash , and a history of a new medicine led the two paramedics on the scene to administer subcutaneous <e1>epinephrine</e1> .
D004837_D005076 NONE The sudden onset of respiratory distress , <e2>rash</e2> , and a history of a new medicine led the two paramedics on the scene to administer subcutaneous <e1>epinephrine</e1> .
D004837_D006323 CID <e1>Epinephrine</e1> has a proven role in <e2>cardiac arrest</e2> in prehospital care ; however , use by paramedics in patients with suspected allergic reaction and severe hypertension should be viewed with caution .
D004837_D004342 NONE <e1>Epinephrine</e1> has a proven role in cardiac arrest in prehospital care ; however , use by paramedics in patients with suspected <e2>allergic reaction</e2> and severe hypertension should be viewed with caution .
D004837_D006973 NONE <e1>Epinephrine</e1> has a proven role in cardiac arrest in prehospital care ; however , use by paramedics in patients with suspected allergic reaction and severe <e2>hypertension</e2> should be viewed with caution .
20588063
D011692_D009401 CID Permeability , ultrastructural changes , and distribution of novel proteins in the glomerular barrier in early <e1>puromycin aminonucleoside</e1> <e2>nephrosis</e2> .
D011692_D009401 CID Using <e1>puromycin aminonucleoside</e1> <e2>nephrosis</e2> ( PAN ) rats , we studied early ultrastructural and permeability changes in relation to the expression of the podocyte-associated molecules nephrin , a-actinin , dendrin , and plekhh2 , the last two of which were only recently discovered in podocytes .
9293063
D003613_D001650 CID <e2>Bile duct hamartoma</e2> occurring in association with long-term treatment with <e1>danazol</e1> .
D003613_D001650 CID We report a case of <e2>bile duct hamartoma</e2> which developed in a patient who had been on long-term <e1>danazol</e1> treatment .
D003613_D006222 CID <e2>Bile duct hamartoma</e2> occurring in association with long-term treatment with <e1>danazol</e1> .
D003613_D006222 CID We report a case of <e2>bile duct hamartoma</e2> which developed in a patient who had been on long-term <e1>danazol</e1> treatment .
6634932
C002616_D017180 NONE <e1>UM-272</e1> ( N , N-dimethylpropranolol ) , a quaternary antiarrhythmic agent , was administered sublingually to dogs with ouabain-induced <e2>ventricular tachycardias</e2> .
C002616_D017180 NONE UM-272 ( <e1>N , N-dimethylpropranolol</e1> ) , a quaternary antiarrhythmic agent , was administered sublingually to dogs with ouabain-induced <e2>ventricular tachycardias</e2> .
C002616_D017180 NONE Sublingual <e1>UM-272</e1> converted <e2>ventricular tachycardia</e2> to sinus rhythm in all 5 dogs .
D010042_D017180 CID UM-272 ( N , N-dimethylpropranolol ) , a quaternary antiarrhythmic agent , was administered sublingually to dogs with <e1>ouabain-induced</e1> <e2>ventricular tachycardias</e2> .
15602202
D017963_D009395 CID Recurrent acute <e2>interstitial nephritis</e2> induced by <e1>azithromycin</e1> .
D017963_D009395 CID A 14-year-old girl is reported with recurrent , <e1>azithromycin-induced</e1> , acute <e2>interstitial nephritis</e2> .
8638206
D001279_D010243 CID Persistent <e2>paralysis</e2> after prolonged use of <e1>atracurium</e1> in the absence of corticosteroids .
D001279_D010243 CID <e1>Atracurium besylate</e1> , a short-acting benzylisoquinolinium NMBA that is eliminated independently of renal or hepatic function , has also been associated with persistent <e2>paralysis</e2> , but only when used with corticosteroids .
D001279_D010243 CID We report a case of <e1>atracurium-related</e1> <e2>paralysis</e2> persisting for approximately 50 hours in a patient who was not treated with corticosteroids .
D014673_D010243 CID Reports of persistent <e2>paralysis</e2> after the discontinuance of these drugs have most often involved aminosteroid-based NMBAs such as <e1>vecuronium bromide</e1> , especially when used in conjunction with corticosteroids .
-1_D010243 NONE Atracurium besylate , a short-acting <e1>benzylisoquinolinium</e1> NMBA that is eliminated independently of renal or hepatic function , has also been associated with persistent <e2>paralysis</e2> , but only when used with corticosteroids .
15632880
D013148_D051437 CID <e1>Spironolactone-induced</e1> <e2>renal insufficiency</e2> and hyperkalemia in patients with heart failure .
D013148_D051437 CID BACKGROUND : A previous randomized controlled trial evaluating the use of <e1>spironolactone</e1> in heart failure patients reported a low risk of hyperkalemia ( 2 % ) and <e2>renal insufficiency</e2> ( 0 % ) .
D013148_D051437 CID We therefore sought to determine the prevalence and clinical associations of hyperkalemia and <e2>renal insufficiency</e2> in heart failure patients treated with <e1>spironolactone</e1> .
D013148_D051437 CID RESULTS : Sixty-seven of 926 patients ( 7.2 % ) required discontinuation of <e1>spironolactone</e1> due to hyperkalemia ( n = 33 ) or <e2>renal failure</e2> ( n = 34 ) .
D013148_D051437 CID CONCLUSIONS : <e1>Spironolactone-induced</e1> hyperkalemia and <e2>renal insufficiency</e2> are more common in our clinical experience than reported previously .
D013148_D006947 CID <e1>Spironolactone-induced</e1> renal insufficiency and <e2>hyperkalemia</e2> in patients with heart failure .
D013148_D006947 CID BACKGROUND : A previous randomized controlled trial evaluating the use of <e1>spironolactone</e1> in heart failure patients reported a low risk of <e2>hyperkalemia</e2> ( 2 % ) and renal insufficiency ( 0 % ) .
D013148_D006947 CID We therefore sought to determine the prevalence and clinical associations of <e2>hyperkalemia</e2> and renal insufficiency in heart failure patients treated with <e1>spironolactone</e1> .
D013148_D006947 CID RESULTS : Sixty-seven of 926 patients ( 7.2 % ) required discontinuation of <e1>spironolactone</e1> due to <e2>hyperkalemia</e2> ( n = 33 ) or renal failure ( n = 34 ) .
D013148_D006947 CID CONCLUSIONS : <e1>Spironolactone-induced</e1> <e2>hyperkalemia</e2> and renal insufficiency are more common in our clinical experience than reported previously .
D013148_D006333 NONE <e1>Spironolactone-induced</e1> renal insufficiency and hyperkalemia in patients with <e2>heart failure</e2> .
D013148_D006333 NONE BACKGROUND : A previous randomized controlled trial evaluating the use of <e1>spironolactone</e1> in <e2>heart failure</e2> patients reported a low risk of hyperkalemia ( 2 % ) and renal insufficiency ( 0 % ) .
D013148_D006333 NONE Because treatments for <e2>heart failure</e2> have changed since the benefits of <e1>spironolactone</e1> were reported , the prevalence of these complications may differ in current clinical practice .
D013148_D006333 NONE We therefore sought to determine the prevalence and clinical associations of hyperkalemia and renal insufficiency in <e2>heart failure</e2> patients treated with <e1>spironolactone</e1> .
D013148_D006333 NONE METHODS : We performed a case control study of <e2>heart failure</e2> patients treated with <e1>spironolactone</e1> in our clinical practice .
D011188_D006947 NONE Cases were patients who developed <e2>hyperkalemia</e2> ( <e1>K(+</e1> ) > 5.0 mEq/L ) or renal insufficiency ( Cr > or=2.5 mg/dL ) , and they were compared to 2 randomly selected controls per case .
D011188_D006947 NONE Patients who developed <e2>hyperkalemia</e2> were older and more likely to have diabetes , had higher baseline serum <e1>potassium</e1> levels and lower baseline potassium supplement doses , and were more likely to be treated with beta-blockers than controls ( n = 134 ) .
D011188_D006947 NONE Patients who developed <e2>hyperkalemia</e2> were older and more likely to have diabetes , had higher baseline serum potassium levels and lower baseline <e1>potassium</e1> supplement doses , and were more likely to be treated with beta-blockers than controls ( n = 134 ) .
D011188_D051437 NONE Cases were patients who developed hyperkalemia ( <e1>K(+</e1> ) > 5.0 mEq/L ) or <e2>renal insufficiency</e2> ( Cr > or=2.5 mg/dL ) , and they were compared to 2 randomly selected controls per case .
D002857_D006947 NONE Cases were patients who developed <e2>hyperkalemia</e2> ( K(+ ) > 5.0 mEq/L ) or renal insufficiency ( <e1>Cr</e1> > or=2.5 mg/dL ) , and they were compared to 2 randomly selected controls per case .
D002857_D051437 NONE Cases were patients who developed hyperkalemia ( K(+ ) > 5.0 mEq/L ) or <e2>renal insufficiency</e2> ( <e1>Cr</e1> > or=2.5 mg/dL ) , and they were compared to 2 randomly selected controls per case .
D011188_D003920 NONE Patients who developed hyperkalemia were older and more likely to have <e2>diabetes</e2> , had higher baseline serum <e1>potassium</e1> levels and lower baseline potassium supplement doses , and were more likely to be treated with beta-blockers than controls ( n = 134 ) .
D011188_D003920 NONE Patients who developed hyperkalemia were older and more likely to have <e2>diabetes</e2> , had higher baseline serum potassium levels and lower baseline <e1>potassium</e1> supplement doses , and were more likely to be treated with beta-blockers than controls ( n = 134 ) .
D003404_D051437 NONE Patients who developed <e2>renal insufficiency</e2> had lower baseline body weight and higher baseline serum <e1>creatinine</e1> , required higher doses of loop diuretics , and were more likely to be treated with thiazide diuretics than controls .
D049971_D051437 NONE Patients who developed <e2>renal insufficiency</e2> had lower baseline body weight and higher baseline serum creatinine , required higher doses of loop diuretics , and were more likely to be treated with <e1>thiazide</e1> diuretics than controls .
6386793
D004308_D003866 NONE A double-blind study of the efficacy and safety of <e1>dothiepin hydrochloride</e1> in the treatment of major <e2>depressive disorder</e2> .
D004308_D003866 NONE In a 6-week double-blind parallel treatment study , <e1>dothiepin</e1> and amitriptyline were compared to placebo in the treatment of 33 <e2>depressed</e2> outpatients .
D004308_D003866 NONE <e1>Dothiepin</e1> and amitriptyline were equally effective in alleviating the symptoms of <e2>depressive illness</e2> , and both were significantly superior to placebo .
D004308_D003866 NONE <e1>Dothiepin</e1> thus was found to be an effective antidepressant drug associated with fewer side effects than amitriptyline in the treatment of <e2>depressed</e2> outpatients .
D000639_D003866 NONE In a 6-week double-blind parallel treatment study , dothiepin and <e1>amitriptyline</e1> were compared to placebo in the treatment of 33 <e2>depressed</e2> outpatients .
D000639_D003866 NONE Dothiepin and <e1>amitriptyline</e1> were equally effective in alleviating the symptoms of <e2>depressive illness</e2> , and both were significantly superior to placebo .
D000639_D003866 NONE Dothiepin thus was found to be an effective antidepressant drug associated with fewer side effects than <e1>amitriptyline</e1> in the treatment of <e2>depressed</e2> outpatients .
D004308_D014786 NONE The overall incidence of side effects and the frequency and severity of <e2>blurred vision</e2> , dry mouth , and drowsiness were significantly less with <e1>dothiepin</e1> than with amitriptyline .
D004308_D014987 NONE The overall incidence of side effects and the frequency and severity of blurred vision , <e2>dry mouth</e2> , and drowsiness were significantly less with <e1>dothiepin</e1> than with amitriptyline .
D000639_D014786 CID The overall incidence of side effects and the frequency and severity of <e2>blurred vision</e2> , dry mouth , and drowsiness were significantly less with dothiepin than with <e1>amitriptyline</e1> .
D000639_D014987 CID The overall incidence of side effects and the frequency and severity of blurred vision , <e2>dry mouth</e2> , and drowsiness were significantly less with dothiepin than with <e1>amitriptyline</e1> .
D000928_D003866 NONE Dothiepin thus was found to be an effective <e1>antidepressant</e1> drug associated with fewer side effects than amitriptyline in the treatment of <e2>depressed</e2> outpatients .
2673163
D003042_D020521 NONE <e2>Stroke</e2> associated with <e1>cocaine</e1> use .
D003042_D020521 NONE We describe eight patients in whom <e1>cocaine</e1> use was related to <e2>stroke</e2> and review 39 cases from the literature .
D003042_D020521 NONE <e2>Stroke</e2> followed <e1>cocaine</e1> use by inhalation , intranasal , intravenous , and intramuscular routes .
D003042_D020521 NONE These data indicate that ( 1 ) the apparent incidence of <e2>stroke</e2> related to <e1>cocaine</e1> use is increasing ; ( 2 ) cocaine-associated stroke occurs primarily in young adults ; ( 3 ) stroke may follow any route of cocaine administration ; ( 4 ) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations ; and ( 5 ) in cocaine-associated stroke , the frequency of intracranial hemorrhage exceeds that of cerebral infarction .
D003042_D020521 NONE These data indicate that ( 1 ) the apparent incidence of stroke related to <e1>cocaine</e1> use is increasing ; ( 2 ) cocaine-associated <e2>stroke</e2> occurs primarily in young adults ; ( 3 ) stroke may follow any route of cocaine administration ; ( 4 ) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations ; and ( 5 ) in cocaine-associated stroke , the frequency of intracranial hemorrhage exceeds that of cerebral infarction .
D003042_D020521 NONE These data indicate that ( 1 ) the apparent incidence of stroke related to <e1>cocaine</e1> use is increasing ; ( 2 ) cocaine-associated stroke occurs primarily in young adults ; ( 3 ) <e2>stroke</e2> may follow any route of cocaine administration ; ( 4 ) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations ; and ( 5 ) in cocaine-associated stroke , the frequency of intracranial hemorrhage exceeds that of cerebral infarction .
D003042_D020521 NONE These data indicate that ( 1 ) the apparent incidence of stroke related to <e1>cocaine</e1> use is increasing ; ( 2 ) cocaine-associated stroke occurs primarily in young adults ; ( 3 ) stroke may follow any route of cocaine administration ; ( 4 ) <e2>stroke</e2> after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations ; and ( 5 ) in cocaine-associated stroke , the frequency of intracranial hemorrhage exceeds that of cerebral infarction .
D003042_D020521 NONE These data indicate that ( 1 ) the apparent incidence of stroke related to <e1>cocaine</e1> use is increasing ; ( 2 ) cocaine-associated stroke occurs primarily in young adults ; ( 3 ) stroke may follow any route of cocaine administration ; ( 4 ) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations ; and ( 5 ) in cocaine-associated <e2>stroke</e2> , the frequency of intracranial hemorrhage exceeds that of cerebral infarction .
D003042_D020521 NONE These data indicate that ( 1 ) the apparent incidence of <e2>stroke</e2> related to cocaine use is increasing ; ( 2 ) <e1>cocaine-associated</e1> stroke occurs primarily in young adults ; ( 3 ) stroke may follow any route of cocaine administration ; ( 4 ) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations ; and ( 5 ) in cocaine-associated stroke , the frequency of intracranial hemorrhage exceeds that of cerebral infarction .
D003042_D020521 NONE These data indicate that ( 1 ) the apparent incidence of stroke related to cocaine use is increasing ; ( 2 ) <e1>cocaine-associated</e1> <e2>stroke</e2> occurs primarily in young adults ; ( 3 ) stroke may follow any route of cocaine administration ; ( 4 ) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations ; and ( 5 ) in cocaine-associated stroke , the frequency of intracranial hemorrhage exceeds that of cerebral infarction .
D003042_D020521 NONE These data indicate that ( 1 ) the apparent incidence of stroke related to cocaine use is increasing ; ( 2 ) <e1>cocaine-associated</e1> stroke occurs primarily in young adults ; ( 3 ) <e2>stroke</e2> may follow any route of cocaine administration ; ( 4 ) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations ; and ( 5 ) in cocaine-associated stroke , the frequency of intracranial hemorrhage exceeds that of cerebral infarction .
D003042_D020521 NONE These data indicate that ( 1 ) the apparent incidence of stroke related to cocaine use is increasing ; ( 2 ) <e1>cocaine-associated</e1> stroke occurs primarily in young adults ; ( 3 ) stroke may follow any route of cocaine administration ; ( 4 ) <e2>stroke</e2> after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations ; and ( 5 ) in cocaine-associated stroke , the frequency of intracranial hemorrhage exceeds that of cerebral infarction .
D003042_D020521 NONE These data indicate that ( 1 ) the apparent incidence of stroke related to cocaine use is increasing ; ( 2 ) <e1>cocaine-associated</e1> stroke occurs primarily in young adults ; ( 3 ) stroke may follow any route of cocaine administration ; ( 4 ) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations ; and ( 5 ) in cocaine-associated <e2>stroke</e2> , the frequency of intracranial hemorrhage exceeds that of cerebral infarction .
D003042_D020521 NONE These data indicate that ( 1 ) the apparent incidence of <e2>stroke</e2> related to cocaine use is increasing ; ( 2 ) cocaine-associated stroke occurs primarily in young adults ; ( 3 ) stroke may follow any route of <e1>cocaine</e1> administration ; ( 4 ) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations ; and ( 5 ) in cocaine-associated stroke , the frequency of intracranial hemorrhage exceeds that of cerebral infarction .
D003042_D020521 NONE These data indicate that ( 1 ) the apparent incidence of stroke related to cocaine use is increasing ; ( 2 ) cocaine-associated <e2>stroke</e2> occurs primarily in young adults ; ( 3 ) stroke may follow any route of <e1>cocaine</e1> administration ; ( 4 ) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations ; and ( 5 ) in cocaine-associated stroke , the frequency of intracranial hemorrhage exceeds that of cerebral infarction .
D003042_D020521 NONE These data indicate that ( 1 ) the apparent incidence of stroke related to cocaine use is increasing ; ( 2 ) cocaine-associated stroke occurs primarily in young adults ; ( 3 ) <e2>stroke</e2> may follow any route of <e1>cocaine</e1> administration ; ( 4 ) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations ; and ( 5 ) in cocaine-associated stroke , the frequency of intracranial hemorrhage exceeds that of cerebral infarction .
D003042_D020521 NONE These data indicate that ( 1 ) the apparent incidence of stroke related to cocaine use is increasing ; ( 2 ) cocaine-associated stroke occurs primarily in young adults ; ( 3 ) stroke may follow any route of <e1>cocaine</e1> administration ; ( 4 ) <e2>stroke</e2> after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations ; and ( 5 ) in cocaine-associated stroke , the frequency of intracranial hemorrhage exceeds that of cerebral infarction .
D003042_D020521 NONE These data indicate that ( 1 ) the apparent incidence of stroke related to cocaine use is increasing ; ( 2 ) cocaine-associated stroke occurs primarily in young adults ; ( 3 ) stroke may follow any route of <e1>cocaine</e1> administration ; ( 4 ) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations ; and ( 5 ) in cocaine-associated <e2>stroke</e2> , the frequency of intracranial hemorrhage exceeds that of cerebral infarction .
D003042_D020521 NONE These data indicate that ( 1 ) the apparent incidence of <e2>stroke</e2> related to cocaine use is increasing ; ( 2 ) cocaine-associated stroke occurs primarily in young adults ; ( 3 ) stroke may follow any route of cocaine administration ; ( 4 ) stroke after <e1>cocaine</e1> use is frequently associated with intracranial aneurysms and arteriovenous malformations ; and ( 5 ) in cocaine-associated stroke , the frequency of intracranial hemorrhage exceeds that of cerebral infarction .
D003042_D020521 NONE These data indicate that ( 1 ) the apparent incidence of stroke related to cocaine use is increasing ; ( 2 ) cocaine-associated <e2>stroke</e2> occurs primarily in young adults ; ( 3 ) stroke may follow any route of cocaine administration ; ( 4 ) stroke after <e1>cocaine</e1> use is frequently associated with intracranial aneurysms and arteriovenous malformations ; and ( 5 ) in cocaine-associated stroke , the frequency of intracranial hemorrhage exceeds that of cerebral infarction .
D003042_D020521 NONE These data indicate that ( 1 ) the apparent incidence of stroke related to cocaine use is increasing ; ( 2 ) cocaine-associated stroke occurs primarily in young adults ; ( 3 ) <e2>stroke</e2> may follow any route of cocaine administration ; ( 4 ) stroke after <e1>cocaine</e1> use is frequently associated with intracranial aneurysms and arteriovenous malformations ; and ( 5 ) in cocaine-associated stroke , the frequency of intracranial hemorrhage exceeds that of cerebral infarction .
D003042_D020521 NONE These data indicate that ( 1 ) the apparent incidence of stroke related to cocaine use is increasing ; ( 2 ) cocaine-associated stroke occurs primarily in young adults ; ( 3 ) stroke may follow any route of cocaine administration ; ( 4 ) <e2>stroke</e2> after <e1>cocaine</e1> use is frequently associated with intracranial aneurysms and arteriovenous malformations ; and ( 5 ) in cocaine-associated stroke , the frequency of intracranial hemorrhage exceeds that of cerebral infarction .
D003042_D020521 NONE These data indicate that ( 1 ) the apparent incidence of stroke related to cocaine use is increasing ; ( 2 ) cocaine-associated stroke occurs primarily in young adults ; ( 3 ) stroke may follow any route of cocaine administration ; ( 4 ) stroke after <e1>cocaine</e1> use is frequently associated with intracranial aneurysms and arteriovenous malformations ; and ( 5 ) in cocaine-associated <e2>stroke</e2> , the frequency of intracranial hemorrhage exceeds that of cerebral infarction .
D003042_D020521 NONE These data indicate that ( 1 ) the apparent incidence of <e2>stroke</e2> related to cocaine use is increasing ; ( 2 ) cocaine-associated stroke occurs primarily in young adults ; ( 3 ) stroke may follow any route of cocaine administration ; ( 4 ) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations ; and ( 5 ) in <e1>cocaine-associated</e1> stroke , the frequency of intracranial hemorrhage exceeds that of cerebral infarction .
D003042_D020521 NONE These data indicate that ( 1 ) the apparent incidence of stroke related to cocaine use is increasing ; ( 2 ) cocaine-associated <e2>stroke</e2> occurs primarily in young adults ; ( 3 ) stroke may follow any route of cocaine administration ; ( 4 ) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations ; and ( 5 ) in <e1>cocaine-associated</e1> stroke , the frequency of intracranial hemorrhage exceeds that of cerebral infarction .
D003042_D020521 NONE These data indicate that ( 1 ) the apparent incidence of stroke related to cocaine use is increasing ; ( 2 ) cocaine-associated stroke occurs primarily in young adults ; ( 3 ) <e2>stroke</e2> may follow any route of cocaine administration ; ( 4 ) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations ; and ( 5 ) in <e1>cocaine-associated</e1> stroke , the frequency of intracranial hemorrhage exceeds that of cerebral infarction .
D003042_D020521 NONE These data indicate that ( 1 ) the apparent incidence of stroke related to cocaine use is increasing ; ( 2 ) cocaine-associated stroke occurs primarily in young adults ; ( 3 ) stroke may follow any route of cocaine administration ; ( 4 ) <e2>stroke</e2> after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations ; and ( 5 ) in <e1>cocaine-associated</e1> stroke , the frequency of intracranial hemorrhage exceeds that of cerebral infarction .
D003042_D020521 NONE These data indicate that ( 1 ) the apparent incidence of stroke related to cocaine use is increasing ; ( 2 ) cocaine-associated stroke occurs primarily in young adults ; ( 3 ) stroke may follow any route of cocaine administration ; ( 4 ) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations ; and ( 5 ) in <e1>cocaine-associated</e1> <e2>stroke</e2> , the frequency of intracranial hemorrhage exceeds that of cerebral infarction .
D003042_D002532 NONE These data indicate that ( 1 ) the apparent incidence of stroke related to <e1>cocaine</e1> use is increasing ; ( 2 ) cocaine-associated stroke occurs primarily in young adults ; ( 3 ) stroke may follow any route of cocaine administration ; ( 4 ) stroke after cocaine use is frequently associated with <e2>intracranial aneurysms</e2> and arteriovenous malformations ; and ( 5 ) in cocaine-associated stroke , the frequency of intracranial hemorrhage exceeds that of cerebral infarction .
D003042_D002532 NONE These data indicate that ( 1 ) the apparent incidence of stroke related to cocaine use is increasing ; ( 2 ) <e1>cocaine-associated</e1> stroke occurs primarily in young adults ; ( 3 ) stroke may follow any route of cocaine administration ; ( 4 ) stroke after cocaine use is frequently associated with <e2>intracranial aneurysms</e2> and arteriovenous malformations ; and ( 5 ) in cocaine-associated stroke , the frequency of intracranial hemorrhage exceeds that of cerebral infarction .
D003042_D002532 NONE These data indicate that ( 1 ) the apparent incidence of stroke related to cocaine use is increasing ; ( 2 ) cocaine-associated stroke occurs primarily in young adults ; ( 3 ) stroke may follow any route of <e1>cocaine</e1> administration ; ( 4 ) stroke after cocaine use is frequently associated with <e2>intracranial aneurysms</e2> and arteriovenous malformations ; and ( 5 ) in cocaine-associated stroke , the frequency of intracranial hemorrhage exceeds that of cerebral infarction .
D003042_D002532 NONE These data indicate that ( 1 ) the apparent incidence of stroke related to cocaine use is increasing ; ( 2 ) cocaine-associated stroke occurs primarily in young adults ; ( 3 ) stroke may follow any route of cocaine administration ; ( 4 ) stroke after <e1>cocaine</e1> use is frequently associated with <e2>intracranial aneurysms</e2> and arteriovenous malformations ; and ( 5 ) in cocaine-associated stroke , the frequency of intracranial hemorrhage exceeds that of cerebral infarction .
D003042_D002532 NONE These data indicate that ( 1 ) the apparent incidence of stroke related to cocaine use is increasing ; ( 2 ) cocaine-associated stroke occurs primarily in young adults ; ( 3 ) stroke may follow any route of cocaine administration ; ( 4 ) stroke after cocaine use is frequently associated with <e2>intracranial aneurysms</e2> and arteriovenous malformations ; and ( 5 ) in <e1>cocaine-associated</e1> stroke , the frequency of intracranial hemorrhage exceeds that of cerebral infarction .
D003042_D001165 NONE These data indicate that ( 1 ) the apparent incidence of stroke related to <e1>cocaine</e1> use is increasing ; ( 2 ) cocaine-associated stroke occurs primarily in young adults ; ( 3 ) stroke may follow any route of cocaine administration ; ( 4 ) stroke after cocaine use is frequently associated with intracranial aneurysms and <e2>arteriovenous malformations</e2> ; and ( 5 ) in cocaine-associated stroke , the frequency of intracranial hemorrhage exceeds that of cerebral infarction .
D003042_D001165 NONE These data indicate that ( 1 ) the apparent incidence of stroke related to cocaine use is increasing ; ( 2 ) <e1>cocaine-associated</e1> stroke occurs primarily in young adults ; ( 3 ) stroke may follow any route of cocaine administration ; ( 4 ) stroke after cocaine use is frequently associated with intracranial aneurysms and <e2>arteriovenous malformations</e2> ; and ( 5 ) in cocaine-associated stroke , the frequency of intracranial hemorrhage exceeds that of cerebral infarction .
D003042_D001165 NONE These data indicate that ( 1 ) the apparent incidence of stroke related to cocaine use is increasing ; ( 2 ) cocaine-associated stroke occurs primarily in young adults ; ( 3 ) stroke may follow any route of <e1>cocaine</e1> administration ; ( 4 ) stroke after cocaine use is frequently associated with intracranial aneurysms and <e2>arteriovenous malformations</e2> ; and ( 5 ) in cocaine-associated stroke , the frequency of intracranial hemorrhage exceeds that of cerebral infarction .
D003042_D001165 NONE These data indicate that ( 1 ) the apparent incidence of stroke related to cocaine use is increasing ; ( 2 ) cocaine-associated stroke occurs primarily in young adults ; ( 3 ) stroke may follow any route of cocaine administration ; ( 4 ) stroke after <e1>cocaine</e1> use is frequently associated with intracranial aneurysms and <e2>arteriovenous malformations</e2> ; and ( 5 ) in cocaine-associated stroke , the frequency of intracranial hemorrhage exceeds that of cerebral infarction .
D003042_D001165 NONE These data indicate that ( 1 ) the apparent incidence of stroke related to cocaine use is increasing ; ( 2 ) cocaine-associated stroke occurs primarily in young adults ; ( 3 ) stroke may follow any route of cocaine administration ; ( 4 ) stroke after cocaine use is frequently associated with intracranial aneurysms and <e2>arteriovenous malformations</e2> ; and ( 5 ) in <e1>cocaine-associated</e1> stroke , the frequency of intracranial hemorrhage exceeds that of cerebral infarction .
D003042_D020300 NONE These data indicate that ( 1 ) the apparent incidence of stroke related to <e1>cocaine</e1> use is increasing ; ( 2 ) cocaine-associated stroke occurs primarily in young adults ; ( 3 ) stroke may follow any route of cocaine administration ; ( 4 ) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations ; and ( 5 ) in cocaine-associated stroke , the frequency of <e2>intracranial hemorrhage</e2> exceeds that of cerebral infarction .
D003042_D020300 NONE These data indicate that ( 1 ) the apparent incidence of stroke related to cocaine use is increasing ; ( 2 ) <e1>cocaine-associated</e1> stroke occurs primarily in young adults ; ( 3 ) stroke may follow any route of cocaine administration ; ( 4 ) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations ; and ( 5 ) in cocaine-associated stroke , the frequency of <e2>intracranial hemorrhage</e2> exceeds that of cerebral infarction .
D003042_D020300 NONE These data indicate that ( 1 ) the apparent incidence of stroke related to cocaine use is increasing ; ( 2 ) cocaine-associated stroke occurs primarily in young adults ; ( 3 ) stroke may follow any route of <e1>cocaine</e1> administration ; ( 4 ) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations ; and ( 5 ) in cocaine-associated stroke , the frequency of <e2>intracranial hemorrhage</e2> exceeds that of cerebral infarction .
D003042_D020300 NONE These data indicate that ( 1 ) the apparent incidence of stroke related to cocaine use is increasing ; ( 2 ) cocaine-associated stroke occurs primarily in young adults ; ( 3 ) stroke may follow any route of cocaine administration ; ( 4 ) stroke after <e1>cocaine</e1> use is frequently associated with intracranial aneurysms and arteriovenous malformations ; and ( 5 ) in cocaine-associated stroke , the frequency of <e2>intracranial hemorrhage</e2> exceeds that of cerebral infarction .
D003042_D020300 NONE These data indicate that ( 1 ) the apparent incidence of stroke related to cocaine use is increasing ; ( 2 ) cocaine-associated stroke occurs primarily in young adults ; ( 3 ) stroke may follow any route of cocaine administration ; ( 4 ) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations ; and ( 5 ) in <e1>cocaine-associated</e1> stroke , the frequency of <e2>intracranial hemorrhage</e2> exceeds that of cerebral infarction .
D003042_D002544 CID These data indicate that ( 1 ) the apparent incidence of stroke related to <e1>cocaine</e1> use is increasing ; ( 2 ) cocaine-associated stroke occurs primarily in young adults ; ( 3 ) stroke may follow any route of cocaine administration ; ( 4 ) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations ; and ( 5 ) in cocaine-associated stroke , the frequency of intracranial hemorrhage exceeds that of <e2>cerebral infarction</e2> .
D003042_D002544 CID These data indicate that ( 1 ) the apparent incidence of stroke related to cocaine use is increasing ; ( 2 ) <e1>cocaine-associated</e1> stroke occurs primarily in young adults ; ( 3 ) stroke may follow any route of cocaine administration ; ( 4 ) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations ; and ( 5 ) in cocaine-associated stroke , the frequency of intracranial hemorrhage exceeds that of <e2>cerebral infarction</e2> .
D003042_D002544 CID These data indicate that ( 1 ) the apparent incidence of stroke related to cocaine use is increasing ; ( 2 ) cocaine-associated stroke occurs primarily in young adults ; ( 3 ) stroke may follow any route of <e1>cocaine</e1> administration ; ( 4 ) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations ; and ( 5 ) in cocaine-associated stroke , the frequency of intracranial hemorrhage exceeds that of <e2>cerebral infarction</e2> .
D003042_D002544 CID These data indicate that ( 1 ) the apparent incidence of stroke related to cocaine use is increasing ; ( 2 ) cocaine-associated stroke occurs primarily in young adults ; ( 3 ) stroke may follow any route of cocaine administration ; ( 4 ) stroke after <e1>cocaine</e1> use is frequently associated with intracranial aneurysms and arteriovenous malformations ; and ( 5 ) in cocaine-associated stroke , the frequency of intracranial hemorrhage exceeds that of <e2>cerebral infarction</e2> .
D003042_D002544 CID These data indicate that ( 1 ) the apparent incidence of stroke related to cocaine use is increasing ; ( 2 ) cocaine-associated stroke occurs primarily in young adults ; ( 3 ) stroke may follow any route of cocaine administration ; ( 4 ) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations ; and ( 5 ) in <e1>cocaine-associated</e1> stroke , the frequency of intracranial hemorrhage exceeds that of <e2>cerebral infarction</e2> .
19803309
D013390_D009224 NONE We report an undiagnosed case of <e2>myotonia congenita</e2> in a 24-year-old previously healthy primigravida , who developed life threatening masseter spasm following a standard dose of intravenous <e1>suxamethonium</e1> for induction of anaesthesia .
D013390_D014313 CID We report an undiagnosed case of myotonia congenita in a 24-year-old previously healthy primigravida , who developed life threatening <e2>masseter spasm</e2> following a standard dose of intravenous <e1>suxamethonium</e1> for induction of anaesthesia .
234669
D000628_D014693 CID Effects of <e1>aminophylline</e1> on the threshold for initiating <e2>ventricular fibrillation</e2> during respiratory failure .
D000628_D014693 CID The effects of <e1>aminophylline</e1> on the <e2>ventricular fibrillation</e2> threshold during normal acid-base conditions and during respiratory failure were studied in anesthetized open chest dogs .
D000628_D014693 CID During the infusion of <e1>aminophylline</e1> , the <e2>ventricular fibrillation</e2> threshold was reduced by 30 to 40 percent of the control when pH and partial pressures of oxygen ( PO2 ) and carbon dioxide ( CO2 ) were kept within normal limits .
D000628_D014693 CID When respiratory failure was produced by hypoventilation ( pH 7.05 to 7.25 ; PC02 70 to 100 mm Hg : P02 20 to 40 mm Hg ) , infusion of <e1>aminophylline</e1> resulted in an even greater decrease in <e2>ventricular fibrillation</e2> threshold to 60 percent of the control level .
D000628_D012131 NONE Effects of <e1>aminophylline</e1> on the threshold for initiating ventricular fibrillation during <e2>respiratory failure</e2> .
D000628_D012131 NONE The effects of <e1>aminophylline</e1> on the ventricular fibrillation threshold during normal acid-base conditions and during <e2>respiratory failure</e2> were studied in anesthetized open chest dogs .
D000628_D012131 NONE When <e2>respiratory failure</e2> was produced by hypoventilation ( pH 7.05 to 7.25 ; PC02 70 to 100 mm Hg : P02 20 to 40 mm Hg ) , infusion of <e1>aminophylline</e1> resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level .
D000628_D012131 NONE These experiments suggest that although many factors may contribute to the increased incidence of ventricular arrhythmias in <e2>respiratory failure</e2> , pharmacologic agents , particularly <e1>aminophylline</e1> , may play a significant role .
D010100_D014693 NONE During the infusion of aminophylline , the <e2>ventricular fibrillation</e2> threshold was reduced by 30 to 40 percent of the control when pH and partial pressures of <e1>oxygen</e1> ( PO2 ) and carbon dioxide ( CO2 ) were kept within normal limits .
C093415_D014693 NONE During the infusion of aminophylline , the <e2>ventricular fibrillation</e2> threshold was reduced by 30 to 40 percent of the control when pH and partial pressures of oxygen ( <e1>PO2</e1> ) and carbon dioxide ( CO2 ) were kept within normal limits .
D002245_D014693 NONE During the infusion of aminophylline , the <e2>ventricular fibrillation</e2> threshold was reduced by 30 to 40 percent of the control when pH and partial pressures of oxygen ( PO2 ) and <e1>carbon dioxide</e1> ( CO2 ) were kept within normal limits .
D002245_D014693 NONE During the infusion of aminophylline , the <e2>ventricular fibrillation</e2> threshold was reduced by 30 to 40 percent of the control when pH and partial pressures of oxygen ( PO2 ) and carbon dioxide ( <e1>CO2</e1> ) were kept within normal limits .
D000628_D007040 NONE When respiratory failure was produced by <e2>hypoventilation</e2> ( pH 7.05 to 7.25 ; PC02 70 to 100 mm Hg : P02 20 to 40 mm Hg ) , infusion of <e1>aminophylline</e1> resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level .
D000628_D001145 NONE These experiments suggest that although many factors may contribute to the increased incidence of <e2>ventricular arrhythmias</e2> in respiratory failure , pharmacologic agents , particularly <e1>aminophylline</e1> , may play a significant role .
3985451
D014859_D006470 NONE <e1>Warfarin-induced</e1> iliopsoas <e2>hemorrhage</e2> with subsequent femoral nerve palsy .
D014859_D020428 CID <e1>Warfarin-induced</e1> iliopsoas hemorrhage with subsequent <e2>femoral nerve palsy</e2> .
D014859_D020428 CID Anticoagulant-induced <e2>femoral nerve palsy</e2> represents the most common form of <e1>warfarin-induced</e1> peripheral neuropathy ; it is characterized by severe pain in the inguinal region , varying degrees of motor and sensory impairment , and flexure contracture of the involved extremity .
D014859_D009135 CID We present the case of a 28-year-old man on chronic <e1>warfarin</e1> therapy who sustained a minor <e2>muscle tear</e2> and developed increasing pain and a flexure contracture of the right hip .
D014859_D010146 NONE We present the case of a 28-year-old man on chronic <e1>warfarin</e1> therapy who sustained a minor muscle tear and developed increasing <e2>pain</e2> and a flexure contracture of the right hip .
D014859_D010146 NONE Anticoagulant-induced femoral nerve palsy represents the most common form of <e1>warfarin-induced</e1> peripheral neuropathy ; it is characterized by severe <e2>pain</e2> in the inguinal region , varying degrees of motor and sensory impairment , and flexure contracture of the involved extremity .
D014859_D003286 NONE We present the case of a 28-year-old man on chronic <e1>warfarin</e1> therapy who sustained a minor muscle tear and developed increasing pain and a flexure <e2>contracture</e2> of the right hip .
D014859_D003286 NONE Anticoagulant-induced femoral nerve palsy represents the most common form of <e1>warfarin-induced</e1> peripheral neuropathy ; it is characterized by severe pain in the inguinal region , varying degrees of motor and sensory impairment , and flexure <e2>contracture</e2> of the involved extremity .
D014859_D010523 NONE Anticoagulant-induced femoral nerve palsy represents the most common form of <e1>warfarin-induced</e1> <e2>peripheral neuropathy</e2> ; it is characterized by severe pain in the inguinal region , varying degrees of motor and sensory impairment , and flexure contracture of the involved extremity .
D014859_D015417 NONE Anticoagulant-induced femoral nerve palsy represents the most common form of <e1>warfarin-induced</e1> peripheral neuropathy ; it is characterized by severe pain in the inguinal region , varying degrees of <e2>motor and sensory impairment</e2> , and flexure contracture of the involved extremity .
19356053
D020123_D011507 CID Clinically significant <e2>proteinuria</e2> following the administration of <e1>sirolimus</e1> to renal transplant recipients .
D020123_D011507 CID To date there has been little documentation of clinically significant <e2>proteinuria</e2> linked with the use of <e1>sirolimus</e1> .
D020123_D011507 CID We have encountered several patients who developed substantial <e2>proteinuria</e2> associated with <e1>sirolimus</e1> use .
D020123_D011507 CID In each patient , the close temporal association between the commencement of <e1>sirolimus</e1> therapy and <e2>proteinuria</e2> implicated sirolimus as the most likely etiology of the proteinuria .
D020123_D011507 CID In each patient , the close temporal association between the commencement of <e1>sirolimus</e1> therapy and proteinuria implicated sirolimus as the most likely etiology of the <e2>proteinuria</e2> .
D020123_D011507 CID In each patient , the close temporal association between the commencement of sirolimus therapy and <e2>proteinuria</e2> implicated <e1>sirolimus</e1> as the most likely etiology of the proteinuria .
D020123_D011507 CID In each patient , the close temporal association between the commencement of sirolimus therapy and proteinuria implicated <e1>sirolimus</e1> as the most likely etiology of the <e2>proteinuria</e2> .
D020123_D011507 CID In 7 of the 28 patients there was a striking temporal association between the initiation of <e1>sirolimus</e1> and the development of nephrotic-range <e2>proteinuria</e2> .
D020123_D011507 CID <e2>Proteinuria</e2> correlated most strongly with <e1>sirolimus</e1> therapy when compared to other demographic and clinical variables .
D020123_D011507 CID In most patients , discontinuation of <e1>sirolimus</e1> resulted in a decrease , but not resolution , of <e2>proteinuria</e2> .
D020123_D011507 CID CONCLUSIONS : <e1>Sirolimus</e1> induces or aggravates pre-existing <e2>proteinuria</e2> in an unpredictable subset of renal allograft recipients .
D020123_D011507 CID <e2>Proteinuria</e2> may improve , but does not resolve , when <e1>sirolimus</e1> is withdrawn .
D020123_D007674 NONE BACKGROUND : <e1>Sirolimus</e1> is the latest immunosuppressive agent used to prevent rejection , and may have less <e2>nephrotoxicity</e2> than calcineurin inhibitor (CNI)-based regimens .
D003404_D011507 NONE In these patients , the magnitude of <e2>proteinuria</e2> was assessed on morning urine samples by turbidometric measurement or random urine protein : <e1>creatinine</e1> ratios , an estimate of grams of proteinuria/day .
D003404_D011507 NONE In these patients , the magnitude of proteinuria was assessed on morning urine samples by turbidometric measurement or random urine protein : <e1>creatinine</e1> ratios , an estimate of grams of <e2>proteinuria/day</e2> .
D020123_D009404 NONE In 7 of the 28 patients there was a striking temporal association between the initiation of <e1>sirolimus</e1> and the development of <e2>nephrotic-range</e2> proteinuria .
7802851
D000525_D016584 NONE The efficacy of <e1>alprazolam</e1> and placebo in <e2>panic disorder</e2> with agoraphobia , and the side-effect and adverse effect profiles of both drug groups were measured .
D000525_D016584 NONE METHOD : In London and Toronto 154 patients who met DSM-III criteria for <e2>panic disorder</e2> with agoraphobia were randomised to <e1>alprazolam</e1> or placebo .
D000525_D000379 NONE The efficacy of <e1>alprazolam</e1> and placebo in panic disorder with <e2>agoraphobia</e2> , and the side-effect and adverse effect profiles of both drug groups were measured .
D000525_D000379 NONE METHOD : In London and Toronto 154 patients who met DSM-III criteria for panic disorder with <e2>agoraphobia</e2> were randomised to <e1>alprazolam</e1> or placebo .
D000525_D003866 CID Compared with placebo subjects , <e1>alprazolam</e1> patients developed more adverse reactions ( 21 % v. 0 % ) of <e2>depression</e2> , enuresis , disinhibition and aggression ; and more side-effects , particularly sedation , irritability , impaired memory , weight loss and ataxia .
D000525_D004775 CID Compared with placebo subjects , <e1>alprazolam</e1> patients developed more adverse reactions ( 21 % v. 0 % ) of depression , <e2>enuresis</e2> , disinhibition and aggression ; and more side-effects , particularly sedation , irritability , impaired memory , weight loss and ataxia .
D000525_D001523 NONE Compared with placebo subjects , <e1>alprazolam</e1> patients developed more adverse reactions ( 21 % v. 0 % ) of depression , enuresis , disinhibition and <e2>aggression</e2> ; and more side-effects , particularly sedation , irritability , impaired memory , weight loss and ataxia .
D000525_D001523 NONE Compared with placebo subjects , <e1>alprazolam</e1> patients developed more adverse reactions ( 21 % v. 0 % ) of depression , enuresis , disinhibition and aggression ; and more side-effects , particularly sedation , <e2>irritability</e2> , impaired memory , weight loss and ataxia .
D000525_D008569 CID Compared with placebo subjects , <e1>alprazolam</e1> patients developed more adverse reactions ( 21 % v. 0 % ) of depression , enuresis , disinhibition and aggression ; and more side-effects , particularly sedation , irritability , <e2>impaired memory</e2> , weight loss and ataxia .
D000525_D015431 CID Compared with placebo subjects , <e1>alprazolam</e1> patients developed more adverse reactions ( 21 % v. 0 % ) of depression , enuresis , disinhibition and aggression ; and more side-effects , particularly sedation , irritability , impaired memory , <e2>weight loss</e2> and ataxia .
D000525_D001259 CID Compared with placebo subjects , <e1>alprazolam</e1> patients developed more adverse reactions ( 21 % v. 0 % ) of depression , enuresis , disinhibition and aggression ; and more side-effects , particularly sedation , irritability , impaired memory , weight loss and <e2>ataxia</e2> .
6503301
D003606_D006504 CID <e2>Veno-occlusive liver disease</e2> after <e1>dacarbazine</e1> therapy ( DTIC ) for melanoma .
D003606_D006504 CID <e2>Veno-occlusive liver disease</e2> after dacarbazine therapy ( <e1>DTIC</e1> ) for melanoma .
D003606_D006504 CID A case of <e2>veno-occlusive disease of the liver</e2> with fatal outcome after <e1>dacarbazine</e1> ( DTIC ) therapy for melanoma is reported .
D003606_D006504 CID A case of <e2>veno-occlusive disease of the liver</e2> with fatal outcome after dacarbazine ( <e1>DTIC</e1> ) therapy for melanoma is reported .
D003606_D008545 NONE Veno-occlusive liver disease after <e1>dacarbazine</e1> therapy ( DTIC ) for <e2>melanoma</e2> .
D003606_D008545 NONE Veno-occlusive liver disease after dacarbazine therapy ( <e1>DTIC</e1> ) for <e2>melanoma</e2> .
D003606_D008545 NONE A case of veno-occlusive disease of the liver with fatal outcome after <e1>dacarbazine</e1> ( DTIC ) therapy for <e2>melanoma</e2> is reported .
D003606_D008545 NONE A case of veno-occlusive disease of the liver with fatal outcome after dacarbazine ( <e1>DTIC</e1> ) therapy for <e2>melanoma</e2> is reported .
3714122
C005238_D020258 NONE The correlation between <e2>neurotoxic</e2> esterase inhibition and <e1>mipafox-induced</e1> neuropathic damage in rats .
C005238_D020258 NONE The correlation between neuropathic damage and inhibition of <e2>neurotoxic</e2> esterase or neuropathy target enzyme ( NTE ) was examined in rats acutely exposed to <e1>Mipafox</e1> ( N , N'-diisopropylphosphorodiamidofluoridate ) , a neurotoxic organophosphate .
C005238_D020258 NONE The correlation between neuropathic damage and inhibition of neurotoxic esterase or neuropathy target enzyme ( NTE ) was examined in rats acutely exposed to <e1>Mipafox</e1> ( N , N'-diisopropylphosphorodiamidofluoridate ) , a <e2>neurotoxic</e2> organophosphate .
C005238_D020258 NONE The correlation between neuropathic damage and inhibition of <e2>neurotoxic</e2> esterase or neuropathy target enzyme ( NTE ) was examined in rats acutely exposed to Mipafox ( <e1>N , N'-diisopropylphosphorodiamidofluoridate</e1> ) , a neurotoxic organophosphate .
C005238_D020258 NONE The correlation between neuropathic damage and inhibition of neurotoxic esterase or neuropathy target enzyme ( NTE ) was examined in rats acutely exposed to Mipafox ( <e1>N , N'-diisopropylphosphorodiamidofluoridate</e1> ) , a <e2>neurotoxic</e2> organophosphate .
C005238_D009422 NONE The correlation between neurotoxic esterase inhibition and <e1>mipafox-induced</e1> <e2>neuropathic damage</e2> in rats .
C005238_D009422 NONE The correlation between <e2>neuropathic damage</e2> and inhibition of neurotoxic esterase or neuropathy target enzyme ( NTE ) was examined in rats acutely exposed to <e1>Mipafox</e1> ( N , N'-diisopropylphosphorodiamidofluoridate ) , a neurotoxic organophosphate .
C005238_D009422 NONE The correlation between neuropathic damage and inhibition of neurotoxic esterase or <e2>neuropathy</e2> target enzyme ( NTE ) was examined in rats acutely exposed to <e1>Mipafox</e1> ( N , N'-diisopropylphosphorodiamidofluoridate ) , a neurotoxic organophosphate .
C005238_D009422 NONE The correlation between <e2>neuropathic damage</e2> and inhibition of neurotoxic esterase or neuropathy target enzyme ( NTE ) was examined in rats acutely exposed to Mipafox ( <e1>N , N'-diisopropylphosphorodiamidofluoridate</e1> ) , a neurotoxic organophosphate .
C005238_D009422 NONE The correlation between neuropathic damage and inhibition of neurotoxic esterase or <e2>neuropathy</e2> target enzyme ( NTE ) was examined in rats acutely exposed to Mipafox ( <e1>N , N'-diisopropylphosphorodiamidofluoridate</e1> ) , a neurotoxic organophosphate .
C005238_D009422 NONE These data indicate that a critical percentage of NTE inhibition in brain and spinal cord sampled shortly after <e1>Mipafox</e1> exposure can predict <e2>neuropathic damage</e2> in rats several weeks later .
D010755_D009422 NONE The correlation between <e2>neuropathic damage</e2> and inhibition of neurotoxic esterase or neuropathy target enzyme ( NTE ) was examined in rats acutely exposed to Mipafox ( N , N'-diisopropylphosphorodiamidofluoridate ) , a neurotoxic <e1>organophosphate</e1> .
D010755_D009422 NONE The correlation between neuropathic damage and inhibition of neurotoxic esterase or <e2>neuropathy</e2> target enzyme ( NTE ) was examined in rats acutely exposed to Mipafox ( N , N'-diisopropylphosphorodiamidofluoridate ) , a neurotoxic <e1>organophosphate</e1> .
D010755_D020258 NONE The correlation between neuropathic damage and inhibition of <e2>neurotoxic</e2> esterase or neuropathy target enzyme ( NTE ) was examined in rats acutely exposed to Mipafox ( N , N'-diisopropylphosphorodiamidofluoridate ) , a neurotoxic <e1>organophosphate</e1> .
D010755_D020258 NONE The correlation between neuropathic damage and inhibition of neurotoxic esterase or neuropathy target enzyme ( NTE ) was examined in rats acutely exposed to Mipafox ( N , N'-diisopropylphosphorodiamidofluoridate ) , a <e2>neurotoxic</e2> <e1>organophosphate</e1> .
C005238_D013118 CID In contrast , dosages of <e1>Mipafox</e1> ( less than or equal to 5 mg/kg ) which inhibited mean NTE activity in spinal cord less than or equal to 61 % and brain less than or equal to 60 % produced this degree of <e2>cord damage</e2> in only 9 % of the animals .
2559236
D004317_D007674 NONE Effect of converting enzyme inhibition on the course of <e1>adriamycin-induced</e1> <e2>nephropathy</e2> .
D004317_D007674 NONE Groups 3 and 4 were studied at four and at six months to assess the effect of enalapril on progression of <e2>renal injury</e2> in <e1>adriamycin</e1> nephrosis .
D004656_D009401 NONE The effect of the converting enzyme inhibitor ( CEI ) <e1>enalapril</e1> was assessed in Munich-Wistar rats with established adriamycin <e2>nephrosis</e2> .
D004656_D009401 NONE Groups 3 and 4 were studied at four and at six months to assess the effect of <e1>enalapril</e1> on progression of renal injury in adriamycin <e2>nephrosis</e2> .
D004317_D009401 CID The effect of the converting enzyme inhibitor ( CEI ) enalapril was assessed in Munich-Wistar rats with established <e1>adriamycin</e1> <e2>nephrosis</e2> .
D004317_D009401 CID Groups 3 and 4 were studied at four and at six months to assess the effect of enalapril on progression of renal injury in <e1>adriamycin</e1> <e2>nephrosis</e2> .
D004317_D000419 CID Rats were given a single dose of <e1>adriamycin</e1> and one month later divided into four groups matched for <e2>albuminuria</e2> , blood pressure , and plasma albumin concentration .
D004656_D000419 NONE These short-term studies showed that <e1>enalapril</e1> reduced arterial blood pressure ( 101 +/- 2 vs. 124 +/- 3 mm Hg , group 2 vs. 1 , P less than 0.05 ) and glomerular capillary pressure ( 54 +/- 1 vs. 61 +/- 2 mm Hg , P less than 0.05 ) without reducing <e2>albuminuria</e2> ( 617 +/- 50 vs. 570 +/- 47 mg/day ) or GFR ( 1.03 +/- 0.04 vs. 1.04 +/- 0.11 ml/min ) .
D004656_D000419 NONE Chronic <e1>enalapril</e1> treatment reduced blood pressure without reducing <e2>albuminuria</e2> in group 4 .
D004656_D007674 NONE Groups 3 and 4 were studied at four and at six months to assess the effect of <e1>enalapril</e1> on progression of <e2>renal injury</e2> in adriamycin nephrosis .
10739826
D003276_D054556 CID Recurrent use of newer <e1>oral contraceptives</e1> and the risk of <e2>venous thromboembolism</e2> .
D003276_D054556 CID The epidemiological studies that assessed the risk of <e2>venous thromboembolism</e2> ( VTE ) associated with newer <e1>oral contraceptives</e1> ( OC ) did not distinguish between patterns of OC use , namely first-time users , repeaters and switchers .
D003276_D054556 CID The epidemiological studies that assessed the risk of venous thromboembolism ( <e2>VTE</e2> ) associated with newer <e1>oral contraceptives</e1> ( OC ) did not distinguish between patterns of OC use , namely first-time users , repeaters and switchers .
D003276_D054556 CID The epidemiological studies that assessed the risk of <e2>venous thromboembolism</e2> ( VTE ) associated with newer oral contraceptives ( <e1>OC</e1> ) did not distinguish between patterns of OC use , namely first-time users , repeaters and switchers .
D003276_D054556 CID The epidemiological studies that assessed the risk of venous thromboembolism ( <e2>VTE</e2> ) associated with newer oral contraceptives ( <e1>OC</e1> ) did not distinguish between patterns of OC use , namely first-time users , repeaters and switchers .
D003276_D054556 CID The epidemiological studies that assessed the risk of <e2>venous thromboembolism</e2> ( VTE ) associated with newer oral contraceptives ( OC ) did not distinguish between patterns of <e1>OC</e1> use , namely first-time users , repeaters and switchers .
D003276_D054556 CID The epidemiological studies that assessed the risk of venous thromboembolism ( <e2>VTE</e2> ) associated with newer oral contraceptives ( OC ) did not distinguish between patterns of <e1>OC</e1> use , namely first-time users , repeaters and switchers .
D003276_D054556 CID The adjusted rate ratio of <e2>VTE</e2> for repeat users of third generation <e1>OC</e1> was 0.6 ( 95 % CI:0.3 - 1.2 ) relative to repeat users of second generation pills , whereas it was 1.3 ( 95 % CI:0.7 - 2.4 ) for switchers from second to third generation pills relative to switchers from third to second generation pills .
12627929
C067311_D054556 CID Increased frequency of <e2>venous thromboembolism</e2> with the combination of <e1>docetaxel</e1> and thalidomide in patients with metastatic androgen-independent prostate cancer .
C067311_D054556 CID STUDY OBJECTIVE : To evaluate the frequency of <e2>venous thromboembolism</e2> ( VTE ) in patients with advanced androgen-independent prostate cancer who were treated with <e1>docetaxel</e1> alone or in combination with thalidomide .
C067311_D054556 CID STUDY OBJECTIVE : To evaluate the frequency of venous thromboembolism ( <e2>VTE</e2> ) in patients with advanced androgen-independent prostate cancer who were treated with <e1>docetaxel</e1> alone or in combination with thalidomide .
C067311_D054556 CID MEASUREMENTS AND MAIN RESULTS : None of 23 patients who received <e1>docetaxel</e1> alone developed <e2>VTE</e2> , whereas 9 of 47 patients ( 19 % ) who received docetaxel plus thalidomide developed VTE ( p=0.025 ) .
C067311_D054556 CID MEASUREMENTS AND MAIN RESULTS : None of 23 patients who received <e1>docetaxel</e1> alone developed VTE , whereas 9 of 47 patients ( 19 % ) who received docetaxel plus thalidomide developed <e2>VTE</e2> ( p=0.025 ) .
C067311_D054556 CID MEASUREMENTS AND MAIN RESULTS : None of 23 patients who received docetaxel alone developed <e2>VTE</e2> , whereas 9 of 47 patients ( 19 % ) who received <e1>docetaxel</e1> plus thalidomide developed VTE ( p=0.025 ) .
C067311_D054556 CID MEASUREMENTS AND MAIN RESULTS : None of 23 patients who received docetaxel alone developed VTE , whereas 9 of 47 patients ( 19 % ) who received <e1>docetaxel</e1> plus thalidomide developed <e2>VTE</e2> ( p=0.025 ) .
C067311_D054556 CID CONCLUSION : The addition of thalidomide to <e1>docetaxel</e1> in the treatment of prostate cancer significantly increases the frequency of <e2>VTE</e2> .
C067311_D011471 NONE Increased frequency of venous thromboembolism with the combination of <e1>docetaxel</e1> and thalidomide in patients with metastatic androgen-independent <e2>prostate cancer</e2> .
C067311_D011471 NONE STUDY OBJECTIVE : To evaluate the frequency of venous thromboembolism ( VTE ) in patients with advanced androgen-independent <e2>prostate cancer</e2> who were treated with <e1>docetaxel</e1> alone or in combination with thalidomide .
C067311_D011471 NONE CONCLUSION : The addition of thalidomide to <e1>docetaxel</e1> in the treatment of <e2>prostate cancer</e2> significantly increases the frequency of VTE .
D013792_D054556 CID Increased frequency of <e2>venous thromboembolism</e2> with the combination of docetaxel and <e1>thalidomide</e1> in patients with metastatic androgen-independent prostate cancer .
D013792_D054556 CID STUDY OBJECTIVE : To evaluate the frequency of <e2>venous thromboembolism</e2> ( VTE ) in patients with advanced androgen-independent prostate cancer who were treated with docetaxel alone or in combination with <e1>thalidomide</e1> .
D013792_D054556 CID STUDY OBJECTIVE : To evaluate the frequency of venous thromboembolism ( <e2>VTE</e2> ) in patients with advanced androgen-independent prostate cancer who were treated with docetaxel alone or in combination with <e1>thalidomide</e1> .
D013792_D054556 CID MEASUREMENTS AND MAIN RESULTS : None of 23 patients who received docetaxel alone developed <e2>VTE</e2> , whereas 9 of 47 patients ( 19 % ) who received docetaxel plus <e1>thalidomide</e1> developed VTE ( p=0.025 ) .
D013792_D054556 CID MEASUREMENTS AND MAIN RESULTS : None of 23 patients who received docetaxel alone developed VTE , whereas 9 of 47 patients ( 19 % ) who received docetaxel plus <e1>thalidomide</e1> developed <e2>VTE</e2> ( p=0.025 ) .
D013792_D054556 CID CONCLUSION : The addition of <e1>thalidomide</e1> to docetaxel in the treatment of prostate cancer significantly increases the frequency of <e2>VTE</e2> .
D013792_D011471 NONE Increased frequency of venous thromboembolism with the combination of docetaxel and <e1>thalidomide</e1> in patients with metastatic androgen-independent <e2>prostate cancer</e2> .
D013792_D011471 NONE STUDY OBJECTIVE : To evaluate the frequency of venous thromboembolism ( VTE ) in patients with advanced androgen-independent <e2>prostate cancer</e2> who were treated with docetaxel alone or in combination with <e1>thalidomide</e1> .
D013792_D011471 NONE CONCLUSION : The addition of <e1>thalidomide</e1> to docetaxel in the treatment of <e2>prostate cancer</e2> significantly increases the frequency of VTE .
8919272
D014635_D001927 CID Morphological features of <e2>encephalopathy</e2> after chronic administration of the antiepileptic drug <e1>valproate</e1> to rats .
D014635_D001927 CID Long-term intragastric application of the antiepileptic drug <e1>sodium valproate</e1> ( Vupral " Polfa " ) at the effective dose of 200 mg/kg b. w. once daily to rats for 1 , 3 , 6 , 9 and 12 months revealed neurological disorders indicating cerebellum damage ( " valproate <e2>encephalopathy</e2> " ) .
D014635_D001927 CID Long-term intragastric application of the antiepileptic drug sodium valproate ( Vupral " Polfa " ) at the effective dose of 200 mg/kg b. w. once daily to rats for 1 , 3 , 6 , 9 and 12 months revealed neurological disorders indicating cerebellum damage ( " <e1>valproate</e1> <e2>encephalopathy</e2> " ) .
D014635_D001927 CID The possible influence of the hepatic damage , mainly hyperammonemia , upon the development of <e1>valproate</e1> <e2>encephalopathy</e2> is discussed .
D014635_D009422 NONE Long-term intragastric application of the antiepileptic drug <e1>sodium valproate</e1> ( Vupral " Polfa " ) at the effective dose of 200 mg/kg b. w. once daily to rats for 1 , 3 , 6 , 9 and 12 months revealed <e2>neurological disorders</e2> indicating cerebellum damage ( " valproate encephalopathy " ) .
D014635_D009422 NONE Long-term intragastric application of the antiepileptic drug sodium valproate ( Vupral " Polfa " ) at the effective dose of 200 mg/kg b. w. once daily to rats for 1 , 3 , 6 , 9 and 12 months revealed <e2>neurological disorders</e2> indicating cerebellum damage ( " <e1>valproate</e1> encephalopathy " ) .
D014635_D002526 NONE Long-term intragastric application of the antiepileptic drug <e1>sodium valproate</e1> ( Vupral " Polfa " ) at the effective dose of 200 mg/kg b. w. once daily to rats for 1 , 3 , 6 , 9 and 12 months revealed neurological disorders indicating <e2>cerebellum damage</e2> ( " valproate encephalopathy " ) .
D014635_D002526 NONE Long-term intragastric application of the antiepileptic drug sodium valproate ( Vupral " Polfa " ) at the effective dose of 200 mg/kg b. w. once daily to rats for 1 , 3 , 6 , 9 and 12 months revealed neurological disorders indicating <e2>cerebellum damage</e2> ( " <e1>valproate</e1> encephalopathy " ) .
D014635_D056486 NONE The possible influence of the <e2>hepatic damage</e2> , mainly hyperammonemia , upon the development of <e1>valproate</e1> encephalopathy is discussed .
D014635_D022124 NONE The possible influence of the hepatic damage , mainly <e2>hyperammonemia</e2> , upon the development of <e1>valproate</e1> encephalopathy is discussed .
18439803
C108761_D012640 NONE Acute effects of <e1>N-(2-propylpentanoyl)urea</e1> on hippocampal amino acid neurotransmitters in pilocarpine-induced <e2>seizure</e2> in rats .
C108761_D012640 NONE <e1>VPU</e1> was more potent than VPA , exhibiting the median effective dose ( ED(50 ) ) of 49 mg/kg in protecting rats against pilocarpine-induced <e2>seizure</e2> whereas the corresponding value for VPA was 322 mg/kg .
C108761_D012640 NONE Based on the finding that <e1>VPU</e1> and VPA could protect the animals against pilocarpine-induced <e2>seizure</e2> it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of glutamate and aspartate .
C108761_D012640 NONE Therefore , like VPA , the finding that <e1>VPU</e1> could drastically reduce pilocarpine-induced increases in glutamate and aspartate should account , at least partly , for its anticonvulsant activity observed in pilocarpine-induced <e2>seizure</e2> in experimental animals .
D000596_D012640 NONE Acute effects of N-(2-propylpentanoyl)urea on hippocampal <e1>amino acid</e1> neurotransmitters in pilocarpine-induced <e2>seizure</e2> in rats .
D000596_D012640 NONE Based on the finding that VPU and VPA could protect the animals against pilocarpine-induced <e2>seizure</e2> it is suggested that the reduction of inhibitory <e1>amino acid</e1> neurotransmitters was comparatively minor and offset by a pronounced reduction of glutamate and aspartate .
D010862_D012640 CID Acute effects of N-(2-propylpentanoyl)urea on hippocampal amino acid neurotransmitters in <e1>pilocarpine-induced</e1> <e2>seizure</e2> in rats .
D010862_D012640 CID VPU was more potent than VPA , exhibiting the median effective dose ( ED(50 ) ) of 49 mg/kg in protecting rats against <e1>pilocarpine-induced</e1> <e2>seizure</e2> whereas the corresponding value for VPA was 322 mg/kg .
D010862_D012640 CID Based on the finding that VPU and VPA could protect the animals against <e1>pilocarpine-induced</e1> <e2>seizure</e2> it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of glutamate and aspartate .
D010862_D012640 CID Therefore , like VPA , the finding that VPU could drastically reduce <e1>pilocarpine-induced</e1> increases in glutamate and aspartate should account , at least partly , for its anticonvulsant activity observed in pilocarpine-induced <e2>seizure</e2> in experimental animals .
D010862_D012640 CID Therefore , like VPA , the finding that VPU could drastically reduce pilocarpine-induced increases in glutamate and aspartate should account , at least partly , for its anticonvulsant activity observed in <e1>pilocarpine-induced</e1> <e2>seizure</e2> in experimental animals .
D014635_D012640 NONE VPU was more potent than <e1>VPA</e1> , exhibiting the median effective dose ( ED(50 ) ) of 49 mg/kg in protecting rats against pilocarpine-induced <e2>seizure</e2> whereas the corresponding value for VPA was 322 mg/kg .
D014635_D012640 NONE VPU was more potent than VPA , exhibiting the median effective dose ( ED(50 ) ) of 49 mg/kg in protecting rats against pilocarpine-induced <e2>seizure</e2> whereas the corresponding value for <e1>VPA</e1> was 322 mg/kg .
D014635_D012640 NONE Based on the finding that VPU and <e1>VPA</e1> could protect the animals against pilocarpine-induced <e2>seizure</e2> it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of glutamate and aspartate .
D014635_D012640 NONE Therefore , like <e1>VPA</e1> , the finding that VPU could drastically reduce pilocarpine-induced increases in glutamate and aspartate should account , at least partly , for its anticonvulsant activity observed in pilocarpine-induced <e2>seizure</e2> in experimental animals .
D018698_D012640 NONE Based on the finding that VPU and VPA could protect the animals against pilocarpine-induced <e2>seizure</e2> it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of <e1>glutamate</e1> and aspartate .
D018698_D012640 NONE Therefore , like VPA , the finding that VPU could drastically reduce pilocarpine-induced increases in <e1>glutamate</e1> and aspartate should account , at least partly , for its anticonvulsant activity observed in pilocarpine-induced <e2>seizure</e2> in experimental animals .
D001224_D012640 NONE Based on the finding that VPU and VPA could protect the animals against pilocarpine-induced <e2>seizure</e2> it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of glutamate and <e1>aspartate</e1> .
D001224_D012640 NONE Therefore , like VPA , the finding that VPU could drastically reduce pilocarpine-induced increases in glutamate and <e1>aspartate</e1> should account , at least partly , for its anticonvulsant activity observed in pilocarpine-induced <e2>seizure</e2> in experimental animals .
1720453
D007069_D007674 CID Long-term follow-up of <e1>ifosfamide</e1> <e2>renal toxicity</e2> in children treated for malignant mesenchymal tumors : an International Society of Pediatric Oncology report .
D007069_C535700 NONE Long-term follow-up of <e1>ifosfamide</e1> renal toxicity in children treated for <e2>malignant mesenchymal tumors</e2> : an International Society of Pediatric Oncology report .
D007069_C535700 NONE The renal function of 74 children with <e2>malignant mesenchymal tumors</e2> in complete remission and who have received the same <e1>ifosfamide</e1> chemotherapy protocol ( International Society of Pediatric Oncology Malignant Mesenchymal Tumor Study 84 [ SIOP MMT 84 ] ) were studied 1 year after the completion of treatment .
D007069_C535700 NONE The renal function of 74 children with malignant mesenchymal tumors in complete remission and who have received the same <e1>ifosfamide</e1> chemotherapy protocol ( International Society of Pediatric Oncology <e2>Malignant Mesenchymal Tumor</e2> Study 84 [ SIOP MMT 84 ] ) were studied 1 year after the completion of treatment .
D007069_C535700 NONE This low percentage ( 5 % ) of TDFS must be evaluated with respect to the efficacy of <e1>ifosfamide</e1> in the treatment of <e2>mesenchymal tumors</e2> in children .
D003404_D006030 NONE Renal function was investigated by measuring plasma and urinary electrolytes , <e2>glucosuria</e2> , proteinuria , aminoaciduria , urinary pH , osmolarity , <e1>creatinine</e1> clearance , phosphate tubular reabsorption , beta 2 microglobulinuria , and lysozymuria .
D003404_D011507 NONE Renal function was investigated by measuring plasma and urinary electrolytes , glucosuria , <e2>proteinuria</e2> , aminoaciduria , urinary pH , osmolarity , <e1>creatinine</e1> clearance , phosphate tubular reabsorption , beta 2 microglobulinuria , and lysozymuria .
D003404_D000608 NONE Renal function was investigated by measuring plasma and urinary electrolytes , glucosuria , proteinuria , <e2>aminoaciduria</e2> , urinary pH , osmolarity , <e1>creatinine</e1> clearance , phosphate tubular reabsorption , beta 2 microglobulinuria , and lysozymuria .
D010710_D006030 NONE Renal function was investigated by measuring plasma and urinary electrolytes , <e2>glucosuria</e2> , proteinuria , aminoaciduria , urinary pH , osmolarity , creatinine clearance , <e1>phosphate</e1> tubular reabsorption , beta 2 microglobulinuria , and lysozymuria .
D010710_D011507 NONE Renal function was investigated by measuring plasma and urinary electrolytes , glucosuria , <e2>proteinuria</e2> , aminoaciduria , urinary pH , osmolarity , creatinine clearance , <e1>phosphate</e1> tubular reabsorption , beta 2 microglobulinuria , and lysozymuria .
D010710_D000608 NONE Renal function was investigated by measuring plasma and urinary electrolytes , glucosuria , proteinuria , <e2>aminoaciduria</e2> , urinary pH , osmolarity , creatinine clearance , <e1>phosphate</e1> tubular reabsorption , beta 2 microglobulinuria , and lysozymuria .
D010710_D064420 NONE Two subsets of patients were identified from this latter group : the first included four patients ( 5 % of the total population ) who developed major <e2>toxicity</e2> resulting in Fanconi 's syndrome ( TDFS ) ; and the second group included five patients with elevated beta 2 microglobulinuria and low <e1>phosphate</e1> reabsorption .
D010710_D005198 NONE Two subsets of patients were identified from this latter group : the first included four patients ( 5 % of the total population ) who developed major toxicity resulting in <e2>Fanconi 's syndrome</e2> ( TDFS ) ; and the second group included five patients with elevated beta 2 microglobulinuria and low <e1>phosphate</e1> reabsorption .
D010710_D005198 NONE Two subsets of patients were identified from this latter group : the first included four patients ( 5 % of the total population ) who developed major toxicity resulting in Fanconi 's syndrome ( <e2>TDFS</e2> ) ; and the second group included five patients with elevated beta 2 microglobulinuria and low <e1>phosphate</e1> reabsorption .
D007069_D064420 NONE Severe <e2>toxicity</e2> was correlated with the higher cumulative dose of 60 g/m2 of <e1>ifosfamide</e1> , a younger age ( less than 2 1/2 years old ) , and a predominance of vesicoprostatic tumor involvement .
D007069_D009369 NONE Severe toxicity was correlated with the higher cumulative dose of 60 g/m2 of <e1>ifosfamide</e1> , a younger age ( less than 2 1/2 years old ) , and a predominance of vesicoprostatic <e2>tumor</e2> involvement .
9245658
D009538_D002318 CID The role of <e1>nicotine</e1> in smoking-related <e2>cardiovascular disease</e2> .
D009538_D002318 CID <e1>Nicotine</e1> activates the sympathetic nervous system and in this way could contribute to <e2>cardiovascular disease</e2> .
D009538_D050197 CID Animal studies and mechanistic studies indicate that <e1>nicotine</e1> could play a role in accelerating <e2>atherosclerosis</e2> , but evidence among humans is too inadequate to be definitive about such an effect .
D009538_D013927 NONE <e1>Nicotine</e1> does not appear to enhance <e2>thrombosis</e2> among humans .
9746003
D002220_D004832 CID Inappropriate use of <e1>carbamazepine</e1> and vigabatrin in typical <e2>absence seizures</e2> .
D002220_D004832 CID <e1>Carbamazepine</e1> and vigabatrin are contraindicated in typical <e2>absence seizures</e2> .
D020888_D004832 CID Inappropriate use of carbamazepine and <e1>vigabatrin</e1> in typical <e2>absence seizures</e2> .
D020888_D004832 CID Carbamazepine and <e1>vigabatrin</e1> are contraindicated in typical <e2>absence seizures</e2> .
D002220_D009207 CID Frequency of absences increased in four children treated with <e1>carbamazepine</e1> and two of these developed <e2>myoclonic jerks</e2> , which resolved on withdrawal of carbamazepine .
D002220_D009207 CID Frequency of absences increased in four children treated with carbamazepine and two of these developed <e2>myoclonic jerks</e2> , which resolved on withdrawal of <e1>carbamazepine</e1> .
18081909
C026098_D001927 CID <e2>Encephalopathy</e2> induced by <e1>levetiracetam</e1> added to valproate .
C026098_D001927 CID BACKGROUND : We report on the manifestation of a <e1>levetiracetam</e1> (LEV)-induced <e2>encephalopathy</e2> .
C026098_D001927 CID BACKGROUND : We report on the manifestation of a levetiracetam <e1>(LEV)-induced</e1> <e2>encephalopathy</e2> .
D014635_D001927 CID <e2>Encephalopathy</e2> induced by levetiracetam added to <e1>valproate</e1> .
C026098_C562694 NONE FINDINGS : A 28-year-old man suffering from <e2>idiopathic epilepsy</e2> with generalized seizures was treated with <e1>LEV</e1> ( 3000 mg ) added to valproate ( VPA ) ( 2000 mg ) .
C026098_D012640 NONE FINDINGS : A 28-year-old man suffering from idiopathic epilepsy with generalized <e2>seizures</e2> was treated with <e1>LEV</e1> ( 3000 mg ) added to valproate ( VPA ) ( 2000 mg ) .
C026098_D012640 NONE OUTCOME : Following discontinuation of <e1>LEV</e1> , EEG and neuropsychological findings improved and <e2>seizure</e2> frequency decreased .
D014635_C562694 NONE FINDINGS : A 28-year-old man suffering from <e2>idiopathic epilepsy</e2> with generalized seizures was treated with LEV ( 3000 mg ) added to <e1>valproate</e1> ( VPA ) ( 2000 mg ) .
D014635_C562694 NONE FINDINGS : A 28-year-old man suffering from <e2>idiopathic epilepsy</e2> with generalized seizures was treated with LEV ( 3000 mg ) added to valproate ( <e1>VPA</e1> ) ( 2000 mg ) .
D014635_D012640 NONE FINDINGS : A 28-year-old man suffering from idiopathic epilepsy with generalized <e2>seizures</e2> was treated with LEV ( 3000 mg ) added to <e1>valproate</e1> ( VPA ) ( 2000 mg ) .
D014635_D012640 NONE FINDINGS : A 28-year-old man suffering from idiopathic epilepsy with generalized <e2>seizures</e2> was treated with LEV ( 3000 mg ) added to valproate ( <e1>VPA</e1> ) ( 2000 mg ) .
20520283
C522667_D012559 NONE Efficacy and safety of <e1>asenapine</e1> in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of <e2>schizophrenia</e2> .
C522667_D012559 NONE <e1>Asenapine</e1> is approved by the Food and Drugs Administration in adults for acute treatment of <e2>schizophrenia</e2> or of manic or mixed episodes associated with bipolar I disorder with or without psychotic features .
C522667_D012559 NONE In a double-blind 6-week trial , 458 patients with acute <e2>schizophrenia</e2> were randomly assigned to fixed-dose treatment with <e1>asenapine</e1> at 5 mg twice daily ( BID ) , asenapine at 10 mg BID , placebo , or haloperidol at 4 mg BID ( to verify assay sensitivity ) .
C522667_D012559 NONE In a double-blind 6-week trial , 458 patients with acute <e2>schizophrenia</e2> were randomly assigned to fixed-dose treatment with asenapine at 5 mg twice daily ( BID ) , <e1>asenapine</e1> at 10 mg BID , placebo , or haloperidol at 4 mg BID ( to verify assay sensitivity ) .
D006220_D012559 NONE Efficacy and safety of asenapine in a placebo- and <e1>haloperidol-controlled</e1> trial in patients with acute exacerbation of <e2>schizophrenia</e2> .
D006220_D012559 NONE In a double-blind 6-week trial , 458 patients with acute <e2>schizophrenia</e2> were randomly assigned to fixed-dose treatment with asenapine at 5 mg twice daily ( BID ) , asenapine at 10 mg BID , placebo , or <e1>haloperidol</e1> at 4 mg BID ( to verify assay sensitivity ) .
C522667_D001714 NONE <e1>Asenapine</e1> is approved by the Food and Drugs Administration in adults for acute treatment of schizophrenia or of <e2>manic</e2> or mixed episodes associated with bipolar I disorder with or without psychotic features .
C522667_D001714 NONE <e1>Asenapine</e1> is approved by the Food and Drugs Administration in adults for acute treatment of schizophrenia or of manic or mixed episodes associated with <e2>bipolar I disorder</e2> with or without psychotic features .
C522667_D011618 NONE <e1>Asenapine</e1> is approved by the Food and Drugs Administration in adults for acute treatment of schizophrenia or of manic or mixed episodes associated with bipolar I disorder with or without <e2>psychotic</e2> features .
C522667_D001480 CID <e2>Extrapyramidal symptoms</e2> reported as AEs occurred in 15 % and 18 % , 34 % , and 10 % of the <e1>asenapine</e1> at 5 and 10 mg BID , haloperidol , and placebo groups , respectively .
C522667_D001480 CID Post hoc analyses indicated that efficacy was similar with <e1>asenapine</e1> and haloperidol ; greater contrasts were seen in AEs , especially <e2>extrapyramidal symptoms</e2> .
D006220_D001480 CID <e2>Extrapyramidal symptoms</e2> reported as AEs occurred in 15 % and 18 % , 34 % , and 10 % of the asenapine at 5 and 10 mg BID , <e1>haloperidol</e1> , and placebo groups , respectively .
D006220_D001480 CID Post hoc analyses indicated that efficacy was similar with asenapine and <e1>haloperidol</e1> ; greater contrasts were seen in AEs , especially <e2>extrapyramidal symptoms</e2> .
7504976
D002231_D056486 CID <e2>Toxic hepatitis</e2> induced by antithyroid drugs : four cases including one with cross-reactivity between <e1>carbimazole</e1> and benzylthiouracil .
D002231_D056486 CID Two patients had a <e2>cholestatic hepatitis</e2> induced by <e1>carbimazole</e1> ( N omercazole ) .
D002231_D056486 CID Two patients had a <e2>cholestatic hepatitis</e2> induced by carbimazole ( <e1>N omercazole</e1> ) .
D002231_D056486 CID Two others had a mixed ( cholestatic and cytolytic ) <e2>hepatitis</e2> following <e1>carbimazole</e1> .
D002231_D056486 CID One of the latter two patients further experienced a cytolytic <e2>hepatitis</e2> which appeared after Benzylthiouracil ( Basd ne ) had replaced <e1>carbimazole</e1> .
C019269_D056486 NONE <e2>Toxic hepatitis</e2> induced by antithyroid drugs : four cases including one with cross-reactivity between carbimazole and <e1>benzylthiouracil</e1> .
C019269_D056486 NONE One of the latter two patients further experienced a cytolytic <e2>hepatitis</e2> which appeared after <e1>Benzylthiouracil</e1> ( Basd ne ) had replaced carbimazole .
C019269_D056486 NONE One of the latter two patients further experienced a cytolytic <e2>hepatitis</e2> which appeared after Benzylthiouracil ( <e1>Basd ne</e1> ) had replaced carbimazole .
D002231_D002779 CID Two patients had a <e2>cholestatic hepatitis</e2> induced by <e1>carbimazole</e1> ( N omercazole ) .
D002231_D002779 CID Two patients had a <e2>cholestatic hepatitis</e2> induced by carbimazole ( <e1>N omercazole</e1> ) .
D002231_D002779 CID Two others had a mixed ( <e2>cholestatic</e2> and cytolytic ) hepatitis following <e1>carbimazole</e1> .
11007689
D016572_D057049 CID <e1>Cyclosporine</e1> and tacrolimus-associated <e2>thrombotic microangiopathy</e2> .
D016572_D057049 CID The development of <e2>thrombotic microangiopathy</e2> ( TMA ) associated with the use of <e1>cyclosporine</e1> has been well documented .
D016572_D057049 CID The development of thrombotic microangiopathy ( <e2>TMA</e2> ) associated with the use of <e1>cyclosporine</e1> has been well documented .
D016572_D057049 CID As a result , switching to tacrolimus has been reported to be a viable therapeutic option in the setting of <e1>cyclosporine-induced</e1> <e2>TMA</e2> .
D016572_D057049 CID However , literature regarding the incidence of the recurrence of <e2>TMA</e2> in patients exposed sequentially to <e1>cyclosporine</e1> and tacrolimus is limited .
D016572_D057049 CID We report a case of a living donor renal transplant recipient who developed <e1>cyclosporine-induced</e1> <e2>TMA</e2> that responded to the withdrawal of cyclosporine in conjunction with plasmapheresis and fresh frozen plasma replacement therapy .
D016572_D057049 CID We report a case of a living donor renal transplant recipient who developed cyclosporine-induced <e2>TMA</e2> that responded to the withdrawal of <e1>cyclosporine</e1> in conjunction with plasmapheresis and fresh frozen plasma replacement therapy .
D016572_D057049 CID Patients who are switched from <e1>cyclosporine</e1> to tacrolimus or vice versa should be closely monitored for the signs and symptoms of recurrent <e2>TMA</e2> .
D016559_D057049 CID Cyclosporine and <e1>tacrolimus-associated</e1> <e2>thrombotic microangiopathy</e2> .
D016559_D057049 CID As a result , switching to <e1>tacrolimus</e1> has been reported to be a viable therapeutic option in the setting of cyclosporine-induced <e2>TMA</e2> .
D016559_D057049 CID With the more widespread application of <e1>tacrolimus</e1> in organ transplantation , tacrolimus-associated <e2>TMA</e2> has also been recognized .
D016559_D057049 CID With the more widespread application of tacrolimus in organ transplantation , <e1>tacrolimus-associated</e1> <e2>TMA</e2> has also been recognized .
D016559_D057049 CID However , literature regarding the incidence of the recurrence of <e2>TMA</e2> in patients exposed sequentially to cyclosporine and <e1>tacrolimus</e1> is limited .
D016559_D057049 CID Introduction of <e1>tacrolimus</e1> as an alternative immunosuppressive agent resulted in the recurrence of <e2>TMA</e2> and the subsequent loss of the renal allograft .
D016559_D057049 CID Patients who are switched from cyclosporine to <e1>tacrolimus</e1> or vice versa should be closely monitored for the signs and symptoms of recurrent <e2>TMA</e2> .
8682684
D000082_D007022 CID <e1>Acetaminophen-induced</e1> <e2>hypotension</e2> .
D000082_D007022 CID However , <e1>acetaminophen</e1> has been demonstrated to produce symptoms of anaphylaxis , including <e2>hypotension</e2> , in sensitive individuals .
D000082_D007022 CID This article describes two critically ill patients in whom transient episodes of <e2>hypotension</e2> reproducibly developed after administration of <e1>acetaminophen</e1> .
D000082_D007022 CID The reports illustrate the need for clinicians to consider <e1>acetaminophen</e1> in patients with <e2>hypotension</e2> of unknown origin .
D000082_D002318 NONE The potential for <e1>acetaminophen</e1> to produce <e2>cardiovascular toxicities</e2> is very low .
D000082_D000707 NONE However , <e1>acetaminophen</e1> has been demonstrated to produce symptoms of <e2>anaphylaxis</e2> , including hypotension , in sensitive individuals .
D000082_D016638 NONE This article describes two <e2>critically ill</e2> patients in whom transient episodes of hypotension reproducibly developed after administration of <e1>acetaminophen</e1> .
15737522
D002443_D001660 CID <e1>Ceftriaxone-associated</e1> <e2>biliary pseudolithiasis</e2> in paediatric surgical patients .
D002443_D001660 CID It is well known that <e1>ceftriaxone</e1> leads to <e2>pseudolithiasis</e2> in some patients .
D002443_D001660 CID In this study , we prospectively evaluated the incidence and clinical importance of <e2>pseudolithiasis</e2> in paediatric surgical patients receiving <e1>ceftriaxone</e1> treatment , who often had to fast in the post-operative period .
19767176
C020972_D013226 NONE <e1>Pyrrolidine dithiocarbamate</e1> protects the piriform cortex in the pilocarpine <e2>status epilepticus</e2> model .
C020972_D013226 NONE The effect of <e1>PDTC</e1> on <e2>status epilepticus-associated</e2> cell loss in the hippocampus and piriform cortex was evaluated in the rat fractionated pilocarpine model .
C020972_D013226 NONE Treatment with 150 mg/kg <e1>PDTC</e1> before and following <e2>status epilepticus</e2> significantly increased the mortality rate to 100 % .
C020972_D013226 NONE Administration of 50 mg/kg <e1>PDTC</e1> ( low-dose ) did not exert major effects on the development of a <e2>status epilepticus</e2> or the mortality rate .
C020972_D013226 NONE A significant decrease in neuronal density of the hippocampal hilar formation was identified in vehicle- and <e1>PDTC-treated</e1> rats following <e2>status epilepticus</e2> .
D010862_D013226 CID Pyrrolidine dithiocarbamate protects the piriform cortex in the <e1>pilocarpine</e1> <e2>status epilepticus</e2> model .
D010862_D013226 CID The effect of PDTC on <e2>status epilepticus-associated</e2> cell loss in the hippocampus and piriform cortex was evaluated in the rat fractionated <e1>pilocarpine</e1> model .
D010100_D009410 NONE Both , production of reactive <e1>oxygen</e1> species as well as activation of NF-kappaB have been implicated in severe <e2>neuronal damage</e2> in different sub-regions of the hippocampus as well as in the surrounding cortices .
D010100_D009410 NONE These data might indicate that the generation of reactive <e1>oxygen</e1> species and activation of NF-kappaB plays a more central role in seizure-associated <e2>neuronal damage</e2> in the temporal cortex as compared to the hippocampal hilus .
C020972_D009410 NONE In conclusion , the NF-kappaB inhibitor and antioxidant <e1>PDTC</e1> protected the piriform cortex , whereas it did not affect hilar <e2>neuronal loss</e2> .
D010100_D012640 NONE These data might indicate that the generation of reactive <e1>oxygen</e1> species and activation of NF-kappaB plays a more central role in <e2>seizure-associated</e2> neuronal damage in the temporal cortex as compared to the hippocampal hilus .
10193204
C009438_D013927 NONE Effects of <e1>tetrandrine</e1> and fangchinoline on experimental <e2>thrombosis</e2> in mice and human platelet aggregation .
C009438_D013927 NONE The present study was undertaken to investigate the effects of <e1>TET</e1> and FAN on the experimental <e2>thrombosis</e2> induced by collagen plus epinephrine ( EP ) in mice , and platelet aggregation and blood coagulation in vitro .
C009438_D013927 NONE In the in vivo study , the administration ( 50 mg/kg , i.p. ) of <e1>TET</e1> and FAN in mice showed the inhibition of <e2>thrombosis</e2> by 55 % and 35 % , respectively , while acetylsalicylic acid ( ASA , 50 mg/kg , i.p. ) , a positive control , showed only 30 % inhibition .
C009438_D001791 NONE Effects of <e1>tetrandrine</e1> and fangchinoline on experimental thrombosis in mice and human <e2>platelet aggregation</e2> .
C009438_D001791 NONE The present study was undertaken to investigate the effects of <e1>TET</e1> and FAN on the experimental thrombosis induced by collagen plus epinephrine ( EP ) in mice , and <e2>platelet aggregation</e2> and blood coagulation in vitro .
C009438_D001791 NONE In the vitro human <e2>platelet aggregations</e2> induced by the agonists used in tests , <e1>TET</e1> and FAN showed the inhibitions dose dependently .
C060802_D013927 NONE Effects of tetrandrine and <e1>fangchinoline</e1> on experimental <e2>thrombosis</e2> in mice and human platelet aggregation .
C060802_D013927 NONE The present study was undertaken to investigate the effects of TET and <e1>FAN</e1> on the experimental <e2>thrombosis</e2> induced by collagen plus epinephrine ( EP ) in mice , and platelet aggregation and blood coagulation in vitro .
C060802_D013927 NONE In the in vivo study , the administration ( 50 mg/kg , i.p. ) of TET and <e1>FAN</e1> in mice showed the inhibition of <e2>thrombosis</e2> by 55 % and 35 % , respectively , while acetylsalicylic acid ( ASA , 50 mg/kg , i.p. ) , a positive control , showed only 30 % inhibition .
C060802_D001791 NONE Effects of tetrandrine and <e1>fangchinoline</e1> on experimental thrombosis in mice and human <e2>platelet aggregation</e2> .
C060802_D001791 NONE The present study was undertaken to investigate the effects of TET and <e1>FAN</e1> on the experimental thrombosis induced by collagen plus epinephrine ( EP ) in mice , and <e2>platelet aggregation</e2> and blood coagulation in vitro .
C060802_D001791 NONE In the vitro human <e2>platelet aggregations</e2> induced by the agonists used in tests , TET and <e1>FAN</e1> showed the inhibitions dose dependently .
C009438_D001778 NONE The present study was undertaken to investigate the effects of <e1>TET</e1> and FAN on the experimental thrombosis induced by collagen plus epinephrine ( EP ) in mice , and platelet aggregation and <e2>blood coagulation</e2> in vitro .
C060802_D001778 NONE The present study was undertaken to investigate the effects of TET and <e1>FAN</e1> on the experimental thrombosis induced by collagen plus epinephrine ( EP ) in mice , and platelet aggregation and <e2>blood coagulation</e2> in vitro .
D004837_D013927 CID The present study was undertaken to investigate the effects of TET and FAN on the experimental <e2>thrombosis</e2> induced by collagen plus <e1>epinephrine</e1> ( EP ) in mice , and platelet aggregation and blood coagulation in vitro .
D004837_D013927 CID The present study was undertaken to investigate the effects of TET and FAN on the experimental <e2>thrombosis</e2> induced by collagen plus epinephrine ( <e1>EP</e1> ) in mice , and platelet aggregation and blood coagulation in vitro .
D004837_D001791 NONE The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus <e1>epinephrine</e1> ( EP ) in mice , and <e2>platelet aggregation</e2> and blood coagulation in vitro .
D004837_D001791 NONE The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus epinephrine ( <e1>EP</e1> ) in mice , and <e2>platelet aggregation</e2> and blood coagulation in vitro .
D004837_D001778 NONE The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus <e1>epinephrine</e1> ( EP ) in mice , and platelet aggregation and <e2>blood coagulation</e2> in vitro .
D004837_D001778 NONE The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus epinephrine ( <e1>EP</e1> ) in mice , and platelet aggregation and <e2>blood coagulation</e2> in vitro .
D001241_D013927 NONE In the in vivo study , the administration ( 50 mg/kg , i.p. ) of TET and FAN in mice showed the inhibition of <e2>thrombosis</e2> by 55 % and 35 % , respectively , while <e1>acetylsalicylic acid</e1> ( ASA , 50 mg/kg , i.p. ) , a positive control , showed only 30 % inhibition .
D001241_D013927 NONE In the in vivo study , the administration ( 50 mg/kg , i.p. ) of TET and FAN in mice showed the inhibition of <e2>thrombosis</e2> by 55 % and 35 % , respectively , while acetylsalicylic acid ( <e1>ASA</e1> , 50 mg/kg , i.p. ) , a positive control , showed only 30 % inhibition .
7083920
D000638_D006327 CID A case is presented of a reversible <e2>intra-Hisian block</e2> occurring under <e1>amiodarone</e1> treatment for atrial tachycardia in a patient without clear intraventricular conduction abnormalities .
D000638_D013617 NONE A case is presented of a reversible intra-Hisian block occurring under <e1>amiodarone</e1> treatment for <e2>atrial tachycardia</e2> in a patient without clear intraventricular conduction abnormalities .
D000638_D006345 NONE A case is presented of a reversible intra-Hisian block occurring under <e1>amiodarone</e1> treatment for atrial tachycardia in a patient without clear <e2>intraventricular conduction abnormalities</e2> .
D000638_D001282 NONE Thirty days after <e1>amiodarone</e1> discontinuation , His bundle electrograms showed <e2>atrial flutter</e2> without intra-Hisian or infra-Hisian delay .
8558192
C030852_C562729 NONE Phase II trial of <e1>vinorelbine</e1> in metastatic <e2>squamous cell esophageal carcinoma</e2> .
C030852_C562729 NONE PURPOSE : To evaluate the response rate and toxic effects of <e1>vinorelbine</e1> ( VNB ) administered as a single agent in metastatic <e2>squamous cell esophageal carcinoma</e2> .
C030852_C562729 NONE PURPOSE : To evaluate the response rate and toxic effects of vinorelbine ( <e1>VNB</e1> ) administered as a single agent in metastatic <e2>squamous cell esophageal carcinoma</e2> .
C030852_C562729 NONE CONCLUSION : These data indicate that <e1>VNB</e1> is an active agent in metastatic <e2>esophageal squamous cell carcinoma</e2> .
D002945_D064420 NONE Thirty patients without prior chemotherapy and 16 pretreated with <e1>cisplatin-based</e1> chemotherapy were assessable for <e2>toxicity</e2> and response .
C030852_D064420 NONE <e1>VNB</e1> was well tolerated and zero instances of WHO grade 4 nonhematologic <e2>toxicity</e2> occurred .
C030852_D064420 NONE Given its excellent tolerance profile and low <e2>toxicity</e2> , further evaluation of <e1>VNB</e1> in combination therapy is warranted .
19299179
D015662_D002779 NONE Severe and long lasting <e2>cholestasis</e2> after high-dose <e1>co-trimoxazole</e1> treatment for Pneumocystis pneumonia in HIV-infected patients -- a report of two cases .
D015662_D011020 NONE Severe and long lasting cholestasis after high-dose <e1>co-trimoxazole</e1> treatment for <e2>Pneumocystis pneumonia</e2> in HIV-infected patients -- a report of two cases .
D015662_D011020 NONE <e2>Pneumocystis pneumonia</e2> ( PCP ) , a common opportunistic infection in HIV-infected individuals , is generally treated with high doses of <e1>co-trimoxazole</e1> .
D015662_D011020 NONE Pneumocystis pneumonia ( <e2>PCP</e2> ) , a common opportunistic infection in HIV-infected individuals , is generally treated with high doses of <e1>co-trimoxazole</e1> .
D015662_D011020 NONE Here , we report two cases of severely immunocompromised HIV-infected patients who developed severe intrahepatic cholestasis , and in one patient lesions mimicking liver abscess formation on radiologic exams , during <e1>co-trimoxazole</e1> treatment for <e2>PCP</e2> .
D015662_D015658 NONE Severe and long lasting cholestasis after high-dose <e1>co-trimoxazole</e1> treatment for Pneumocystis pneumonia in <e2>HIV-infected</e2> patients -- a report of two cases .
D015662_D015658 NONE Pneumocystis pneumonia ( PCP ) , a common opportunistic infection in <e2>HIV-infected</e2> individuals , is generally treated with high doses of <e1>co-trimoxazole</e1> .
D015662_D015658 NONE Here , we report two cases of severely immunocompromised <e2>HIV-infected</e2> patients who developed severe intrahepatic cholestasis , and in one patient lesions mimicking liver abscess formation on radiologic exams , during <e1>co-trimoxazole</e1> treatment for PCP .
D015662_D009894 NONE Pneumocystis pneumonia ( PCP ) , a common <e2>opportunistic infection</e2> in HIV-infected individuals , is generally treated with high doses of <e1>co-trimoxazole</e1> .
D015662_D002780 CID Here , we report two cases of severely immunocompromised HIV-infected patients who developed severe <e2>intrahepatic cholestasis</e2> , and in one patient lesions mimicking liver abscess formation on radiologic exams , during <e1>co-trimoxazole</e1> treatment for PCP .
D015662_D008100 NONE Here , we report two cases of severely immunocompromised HIV-infected patients who developed severe intrahepatic cholestasis , and in one patient lesions mimicking <e2>liver abscess</e2> formation on radiologic exams , during <e1>co-trimoxazole</e1> treatment for PCP .
19889778
12639165
D013988_D002779 CID <e1>Ticlopidine-induced</e1> <e2>cholestatic hepatitis</e2> .
D013988_D002779 CID OBJECTIVE : To report 2 cases of <e1>ticlopidine-induced</e1> <e2>cholestatic hepatitis</e2> , investigate its mechanism , and compare the observed main characteristics with those of the published cases .
D013988_D002779 CID CASE SUMMARIES : Two patients developed prolonged <e2>cholestatic hepatitis</e2> after receiving <e1>ticlopidine</e1> following percutaneous coronary angioplasty , with complete remission during the follow-up period .
D013988_D002779 CID DISCUSSION : <e2>Cholestatic hepatitis</e2> is a rare complication of the antiplatelet agent <e1>ticlopidine</e1> ; several cases have been reported but few in the English literature .
D013988_D002779 CID Our patients developed jaundice following treatment with <e1>ticlopidine</e1> and showed the clinical and laboratory characteristics of <e2>cholestatic hepatitis</e2> , which resolved after discontinuation of the drug .
D013988_D002779 CID The mechanisms of this <e1>ticlopidine-induced</e1> <e2>cholestasis</e2> are unclear .
D013988_D002779 CID CONCLUSIONS : <e2>Cholestatic hepatitis</e2> is a rare adverse effect of <e1>ticlopidine</e1> that may be immune mediated .
D013988_D056486 CID <e1>Ticlopidine-induced</e1> <e2>cholestatic hepatitis</e2> .
D013988_D056486 CID OBJECTIVE : To report 2 cases of <e1>ticlopidine-induced</e1> <e2>cholestatic hepatitis</e2> , investigate its mechanism , and compare the observed main characteristics with those of the published cases .
D013988_D056486 CID CASE SUMMARIES : Two patients developed prolonged <e2>cholestatic hepatitis</e2> after receiving <e1>ticlopidine</e1> following percutaneous coronary angioplasty , with complete remission during the follow-up period .
D013988_D056486 CID DISCUSSION : <e2>Cholestatic hepatitis</e2> is a rare complication of the antiplatelet agent <e1>ticlopidine</e1> ; several cases have been reported but few in the English literature .
D013988_D056486 CID Our patients developed jaundice following treatment with <e1>ticlopidine</e1> and showed the clinical and laboratory characteristics of <e2>cholestatic hepatitis</e2> , which resolved after discontinuation of the drug .
D013988_D056486 CID CONCLUSIONS : <e2>Cholestatic hepatitis</e2> is a rare adverse effect of <e1>ticlopidine</e1> that may be immune mediated .
D013988_D007565 CID Our patients developed <e2>jaundice</e2> following treatment with <e1>ticlopidine</e1> and showed the clinical and laboratory characteristics of cholestatic hepatitis , which resolved after discontinuation of the drug .
12063090
D004177_D003248 NONE <e1>Metamizol</e1> potentiates morphine antinociception but not <e2>constipation</e2> after chronic treatment .
D004177_D003248 NONE This work evaluates the antinociceptive and <e2>constipating</e2> effects of the combination of 3.2 mg/kg s.c. morphine with 177.8 mg/kg s.c. <e1>metamizol</e1> in acutely and chronically treated ( once a day for 12 days ) rats .
D004177_D003248 NONE The combination inhibited intestinal transit similar to that produced by morphine regardless of the time of treatment , suggesting that <e1>metamizol</e1> did not potentiate morphine-induced <e2>constipation</e2> .
D009020_D003248 CID Metamizol potentiates <e1>morphine</e1> antinociception but not <e2>constipation</e2> after chronic treatment .
D009020_D003248 CID This work evaluates the antinociceptive and <e2>constipating</e2> effects of the combination of 3.2 mg/kg s.c. <e1>morphine</e1> with 177.8 mg/kg s.c. metamizol in acutely and chronically treated ( once a day for 12 days ) rats .
D009020_D003248 CID In independent groups , <e1>morphine</e1> inhibited the intestinal transit in 48+/-4 % and 38+/-4 % after acute and chronic treatment , respectively , suggesting that tolerance did not develop to the <e2>constipating</e2> effects .
D009020_D003248 CID The combination inhibited intestinal transit similar to that produced by <e1>morphine</e1> regardless of the time of treatment , suggesting that metamizol did not potentiate morphine-induced <e2>constipation</e2> .
D009020_D003248 CID The combination inhibited intestinal transit similar to that produced by morphine regardless of the time of treatment , suggesting that metamizol did not potentiate <e1>morphine-induced</e1> <e2>constipation</e2> .
D002606_D010146 NONE On the 13th day , antinociceptive effects were assessed using a model of inflammatory nociception , <e2>pain-induced</e2> functional impairment model , and the <e1>charcoal</e1> meal test was used to evaluate the intestinal transit .
D009020_D059350 NONE These findings show a significant interaction between <e1>morphine</e1> and metamizol in chronically treated rats , suggesting that this combination could be useful for the treatment of <e2>chronic pain</e2> .
D004177_D059350 NONE These findings show a significant interaction between morphine and <e1>metamizol</e1> in chronically treated rats , suggesting that this combination could be useful for the treatment of <e2>chronic pain</e2> .
9672936
D008614_D012640 CID <e1>Pethidine-associated</e1> <e2>seizure</e2> in a healthy adolescent receiving pethidine for postoperative pain control .
D008614_D012640 CID Pethidine-associated <e2>seizure</e2> in a healthy adolescent receiving <e1>pethidine</e1> for postoperative pain control .
D008614_D010149 NONE <e1>Pethidine-associated</e1> seizure in a healthy adolescent receiving pethidine for <e2>postoperative pain</e2> control .
D008614_D010149 NONE Pethidine-associated seizure in a healthy adolescent receiving <e1>pethidine</e1> for <e2>postoperative pain</e2> control .
D008614_D010149 NONE A healthy 17-year-old male received standard intermittent doses of <e1>pethidine</e1> via a patient-controlled analgesia ( PCA ) pump for management of <e2>postoperative pain</e2> control .
1749407
D003042_D009203 CID <e1>Cocaine-induced</e1> <e2>myocardial infarction</e2> : clinical observations and pathogenetic considerations .
D003042_D009203 CID Clinical and experimental data published to date suggest several possible mechanisms by which <e1>cocaine</e1> may result in <e2>acute myocardial infarction</e2> .
D003042_D009203 CID In individuals with preexisting , high-grade coronary arterial narrowing , <e2>acute myocardial infarction</e2> may result from an increase in myocardial oxygen demand associated with <e1>cocaine-induced</e1> increase in rate-pressure product .
D010100_D009203 NONE In individuals with preexisting , high-grade coronary arterial narrowing , <e2>acute myocardial infarction</e2> may result from an increase in myocardial <e1>oxygen</e1> demand associated with cocaine-induced increase in rate-pressure product .
D003042_D013035 NONE With regard to <e2>spasm</e2> , the clinical findings are largely circumstantial , and the locus of <e1>cocaine-induced</e1> vasoconstriction remains speculative .
D003042_D013927 NONE Finally , the contribution of a primary , <e2>thrombotic</e2> effect of <e1>cocaine</e1> has not been excluded .
4812392
D001379_D011565 NONE Treatment of <e2>psoriasis</e2> with <e1>azathioprine</e1> .
D001379_D011565 NONE <e1>Azathioprine</e1> treatment benefited 19 ( 66 % ) out of 29 patients suffering from severe <e2>psoriasis</e2> .
D001379_D056486 NONE Liver biopsies should be undertaken at regular intervals if <e1>azathioprine</e1> therapy is continued so that structural <e2>liver damage</e2> may be detected at an early and reversible stage .
18343374
D002996_D012170 CID Central <e2>retinal vein occlusion</e2> associated with <e1>clomiphene-induced</e1> ovulation .
D002996_D012170 CID OBJECTIVE : To report a case of central <e2>retinal vein occlusion</e2> associated with <e1>clomiphene citrate</e1> ( CC ) .
D002996_D012170 CID OBJECTIVE : To report a case of central <e2>retinal vein occlusion</e2> associated with clomiphene citrate ( <e1>CC</e1> ) .
D002996_D012170 CID MAIN OUTCOME MEASURE(S ): Central <e2>retinal vein occlusion</e2> after ovulation induction with <e1>CC</e1> .
D002996_D012170 CID RESULT(S ): A 36-year-old Chinese woman developed central <e2>retinal vein occlusion</e2> after eight courses of <e1>CC</e1> .
D002996_D012170 CID CONCLUSION(S ): This is the first reported case of central <e2>retinal vein occlusion</e2> after treatment with <e1>CC</e1> .
D002996_D013923 NONE A search of the literature on the <e2>thromboembolic</e2> complications of <e1>CC</e1> does not include this severe ophthalmic complication , although mild visual disturbance after CC intake is not uncommon .
D002996_D013923 NONE A search of the literature on the <e2>thromboembolic</e2> complications of CC does not include this severe ophthalmic complication , although mild visual disturbance after <e1>CC</e1> intake is not uncommon .
D002996_D014786 CID A search of the literature on the thromboembolic complications of <e1>CC</e1> does not include this severe ophthalmic complication , although mild <e2>visual disturbance</e2> after CC intake is not uncommon .
D002996_D014786 CID A search of the literature on the thromboembolic complications of CC does not include this severe ophthalmic complication , although mild <e2>visual disturbance</e2> after <e1>CC</e1> intake is not uncommon .
D002996_D007247 NONE Extra caution is warranted in treating <e2>infertility</e2> patients with <e1>CC</e1> , and patients should be well informed of this side effect before commencement of therapy .
6203452
D002945_D002277 NONE Five patients with <e2>carcinoma</e2> developed thrombotic microangiopathy ( characterized by renal insufficiency , microangiopathic hemolytic anemia , and usually thrombocytopenia ) after treatment with <e1>cisplatin</e1> , bleomycin , and a vinca alkaloid .
D002945_D057049 NONE Five patients with carcinoma developed <e2>thrombotic microangiopathy</e2> ( characterized by renal insufficiency , microangiopathic hemolytic anemia , and usually thrombocytopenia ) after treatment with <e1>cisplatin</e1> , bleomycin , and a vinca alkaloid .
D002945_D051437 NONE Five patients with carcinoma developed thrombotic microangiopathy ( characterized by <e2>renal insufficiency</e2> , microangiopathic hemolytic anemia , and usually thrombocytopenia ) after treatment with <e1>cisplatin</e1> , bleomycin , and a vinca alkaloid .
D002945_D051437 NONE Diagnosis of this potentially fatal complication may be delayed or missed if renal tissue or the peripheral blood smear is not examined , because <e2>renal failure</e2> may be ascribed to <e1>cisplatin</e1> nephrotoxicity and the anemia and thrombocytopenia to drug-induced bone marrow suppression .
D002945_D000743 NONE Five patients with carcinoma developed thrombotic microangiopathy ( characterized by renal insufficiency , <e2>microangiopathic hemolytic anemia</e2> , and usually thrombocytopenia ) after treatment with <e1>cisplatin</e1> , bleomycin , and a vinca alkaloid .
D002945_D013921 NONE Five patients with carcinoma developed thrombotic microangiopathy ( characterized by renal insufficiency , microangiopathic hemolytic anemia , and usually <e2>thrombocytopenia</e2> ) after treatment with <e1>cisplatin</e1> , bleomycin , and a vinca alkaloid .
D002945_D013921 NONE Diagnosis of this potentially fatal complication may be delayed or missed if renal tissue or the peripheral blood smear is not examined , because renal failure may be ascribed to <e1>cisplatin</e1> nephrotoxicity and the anemia and <e2>thrombocytopenia</e2> to drug-induced bone marrow suppression .
D001761_D002277 NONE Five patients with <e2>carcinoma</e2> developed thrombotic microangiopathy ( characterized by renal insufficiency , microangiopathic hemolytic anemia , and usually thrombocytopenia ) after treatment with cisplatin , <e1>bleomycin</e1> , and a vinca alkaloid .
D001761_D057049 NONE Five patients with carcinoma developed <e2>thrombotic microangiopathy</e2> ( characterized by renal insufficiency , microangiopathic hemolytic anemia , and usually thrombocytopenia ) after treatment with cisplatin , <e1>bleomycin</e1> , and a vinca alkaloid .
D001761_D051437 NONE Five patients with carcinoma developed thrombotic microangiopathy ( characterized by <e2>renal insufficiency</e2> , microangiopathic hemolytic anemia , and usually thrombocytopenia ) after treatment with cisplatin , <e1>bleomycin</e1> , and a vinca alkaloid .
D001761_D000743 NONE Five patients with carcinoma developed thrombotic microangiopathy ( characterized by renal insufficiency , <e2>microangiopathic hemolytic anemia</e2> , and usually thrombocytopenia ) after treatment with cisplatin , <e1>bleomycin</e1> , and a vinca alkaloid .
D001761_D013921 NONE Five patients with carcinoma developed thrombotic microangiopathy ( characterized by renal insufficiency , microangiopathic hemolytic anemia , and usually <e2>thrombocytopenia</e2> ) after treatment with cisplatin , <e1>bleomycin</e1> , and a vinca alkaloid .
D014748_D002277 NONE Five patients with <e2>carcinoma</e2> developed thrombotic microangiopathy ( characterized by renal insufficiency , microangiopathic hemolytic anemia , and usually thrombocytopenia ) after treatment with cisplatin , bleomycin , and a <e1>vinca alkaloid</e1> .
D014748_D057049 NONE Five patients with carcinoma developed <e2>thrombotic microangiopathy</e2> ( characterized by renal insufficiency , microangiopathic hemolytic anemia , and usually thrombocytopenia ) after treatment with cisplatin , bleomycin , and a <e1>vinca alkaloid</e1> .
D014748_D051437 NONE Five patients with carcinoma developed thrombotic microangiopathy ( characterized by <e2>renal insufficiency</e2> , microangiopathic hemolytic anemia , and usually thrombocytopenia ) after treatment with cisplatin , bleomycin , and a <e1>vinca alkaloid</e1> .
D014748_D000743 NONE Five patients with carcinoma developed thrombotic microangiopathy ( characterized by renal insufficiency , <e2>microangiopathic hemolytic anemia</e2> , and usually thrombocytopenia ) after treatment with cisplatin , bleomycin , and a <e1>vinca alkaloid</e1> .
D014748_D013921 NONE Five patients with carcinoma developed thrombotic microangiopathy ( characterized by renal insufficiency , microangiopathic hemolytic anemia , and usually <e2>thrombocytopenia</e2> ) after treatment with cisplatin , bleomycin , and a <e1>vinca alkaloid</e1> .
D002945_D007674 CID Diagnosis of this potentially fatal complication may be delayed or missed if renal tissue or the peripheral blood smear is not examined , because renal failure may be ascribed to <e1>cisplatin</e1> <e2>nephrotoxicity</e2> and the anemia and thrombocytopenia to drug-induced bone marrow suppression .
D002945_D000740 NONE Diagnosis of this potentially fatal complication may be delayed or missed if renal tissue or the peripheral blood smear is not examined , because renal failure may be ascribed to <e1>cisplatin</e1> nephrotoxicity and the <e2>anemia</e2> and thrombocytopenia to drug-induced bone marrow suppression .
D002945_D001855 NONE Diagnosis of this potentially fatal complication may be delayed or missed if renal tissue or the peripheral blood smear is not examined , because renal failure may be ascribed to <e1>cisplatin</e1> nephrotoxicity and the anemia and thrombocytopenia to drug-induced <e2>bone marrow suppression</e2> .
11279304
D018943_D066126 NONE Brain natriuretic peptide is a predictor of <e1>anthracycline-induced</e1> <e2>cardiotoxicity</e2> .
D018943_D066126 NONE <e1>Anthracyclines</e1> are effective antineoplastic drugs , but they frequently cause dose-related <e2>cardiotoxicity</e2> .
D018943_D066126 NONE The <e2>cardiotoxicity</e2> of conventional <e1>anthracycline</e1> therapy highlights a need to search for methods that are highly sensitive and capable of predicting cardiac dysfunction .
D018943_D066126 NONE We measured the plasma level of brain natriuretic peptide ( BNP ) to determine whether BNP might serve as a simple diagnostic indicator of <e1>anthracycline-induced</e1> <e2>cardiotoxicity</e2> in patients with acute leukemia treated with a daunorubicin (DNR)-containing regimen .
D018943_D066126 NONE These preliminary results suggest that BNP may be useful as an early and sensitive indicator of <e1>anthracycline-induced</e1> <e2>cardiotoxicity</e2> .
D018943_D006331 NONE The cardiotoxicity of conventional <e1>anthracycline</e1> therapy highlights a need to search for methods that are highly sensitive and capable of predicting <e2>cardiac dysfunction</e2> .
D018943_D015470 NONE We measured the plasma level of brain natriuretic peptide ( BNP ) to determine whether BNP might serve as a simple diagnostic indicator of <e1>anthracycline-induced</e1> cardiotoxicity in patients with <e2>acute leukemia</e2> treated with a daunorubicin (DNR)-containing regimen .
D003630_D066126 NONE We measured the plasma level of brain natriuretic peptide ( BNP ) to determine whether BNP might serve as a simple diagnostic indicator of anthracycline-induced <e2>cardiotoxicity</e2> in patients with acute leukemia treated with a <e1>daunorubicin</e1> (DNR)-containing regimen .
D003630_D066126 NONE We measured the plasma level of brain natriuretic peptide ( BNP ) to determine whether BNP might serve as a simple diagnostic indicator of anthracycline-induced <e2>cardiotoxicity</e2> in patients with acute leukemia treated with a daunorubicin <e1>(DNR)-containing</e1> regimen .
D003630_D015470 NONE We measured the plasma level of brain natriuretic peptide ( BNP ) to determine whether BNP might serve as a simple diagnostic indicator of anthracycline-induced cardiotoxicity in patients with <e2>acute leukemia</e2> treated with a <e1>daunorubicin</e1> (DNR)-containing regimen .
D003630_D015470 NONE We measured the plasma level of brain natriuretic peptide ( BNP ) to determine whether BNP might serve as a simple diagnostic indicator of anthracycline-induced cardiotoxicity in patients with <e2>acute leukemia</e2> treated with a daunorubicin <e1>(DNR)-containing</e1> regimen .
D003630_D015470 NONE Thirteen patients with <e2>acute leukemia</e2> were treated with a <e1>DNR-containing</e1> regimen .
D003630_D006333 CID On the other hand , BNP did not increase in the patients without <e2>heart failure</e2> given <e1>DNR</e1> , even at more than 700 mg/m(2 ) .
20067456
D016642_D012735 NONE The effects of the adjunctive <e1>bupropion</e1> on male <e2>sexual dysfunction</e2> induced by a selective serotonin reuptake inhibitor : a double-blind placebo-controlled and randomized study .
D016642_D012735 NONE OBJECTIVE : To determine the safety and efficacy of adjunctive <e1>bupropion</e1> sustained-release ( SR ) on male <e2>sexual dysfunction</e2> ( SD ) induced by a selective serotonin reuptake inhibitor ( SSRI ) , as SD is a common side-effect of SSRIs and the most effective treatments have yet to be determined .
D016642_D012735 NONE OBJECTIVE : To determine the safety and efficacy of adjunctive <e1>bupropion</e1> sustained-release ( SR ) on male sexual dysfunction ( <e2>SD</e2> ) induced by a selective serotonin reuptake inhibitor ( SSRI ) , as SD is a common side-effect of SSRIs and the most effective treatments have yet to be determined .
D016642_D012735 NONE OBJECTIVE : To determine the safety and efficacy of adjunctive <e1>bupropion</e1> sustained-release ( SR ) on male sexual dysfunction ( SD ) induced by a selective serotonin reuptake inhibitor ( SSRI ) , as <e2>SD</e2> is a common side-effect of SSRIs and the most effective treatments have yet to be determined .
D016642_D012735 NONE CONCLUSIONS : <e1>Bupropion</e1> is an effective treatment for male <e2>SD</e2> induced by SSRIs .
D017367_D012735 NONE The effects of the adjunctive bupropion on male <e2>sexual dysfunction</e2> induced by a <e1>selective serotonin reuptake inhibitor</e1> : a double-blind placebo-controlled and randomized study .
D017367_D012735 NONE OBJECTIVE : To determine the safety and efficacy of adjunctive bupropion sustained-release ( SR ) on male <e2>sexual dysfunction</e2> ( SD ) induced by a <e1>selective serotonin reuptake inhibitor</e1> ( SSRI ) , as SD is a common side-effect of SSRIs and the most effective treatments have yet to be determined .
D017367_D012735 NONE OBJECTIVE : To determine the safety and efficacy of adjunctive bupropion sustained-release ( SR ) on male sexual dysfunction ( <e2>SD</e2> ) induced by a <e1>selective serotonin reuptake inhibitor</e1> ( SSRI ) , as SD is a common side-effect of SSRIs and the most effective treatments have yet to be determined .
D017367_D012735 NONE OBJECTIVE : To determine the safety and efficacy of adjunctive bupropion sustained-release ( SR ) on male sexual dysfunction ( SD ) induced by a <e1>selective serotonin reuptake inhibitor</e1> ( SSRI ) , as <e2>SD</e2> is a common side-effect of SSRIs and the most effective treatments have yet to be determined .
D017367_D012735 NONE OBJECTIVE : To determine the safety and efficacy of adjunctive bupropion sustained-release ( SR ) on male <e2>sexual dysfunction</e2> ( SD ) induced by a selective serotonin reuptake inhibitor ( <e1>SSRI</e1> ) , as SD is a common side-effect of SSRIs and the most effective treatments have yet to be determined .
D017367_D012735 NONE OBJECTIVE : To determine the safety and efficacy of adjunctive bupropion sustained-release ( SR ) on male sexual dysfunction ( <e2>SD</e2> ) induced by a selective serotonin reuptake inhibitor ( <e1>SSRI</e1> ) , as SD is a common side-effect of SSRIs and the most effective treatments have yet to be determined .
D017367_D012735 NONE OBJECTIVE : To determine the safety and efficacy of adjunctive bupropion sustained-release ( SR ) on male sexual dysfunction ( SD ) induced by a selective serotonin reuptake inhibitor ( <e1>SSRI</e1> ) , as <e2>SD</e2> is a common side-effect of SSRIs and the most effective treatments have yet to be determined .
D017367_D012735 NONE OBJECTIVE : To determine the safety and efficacy of adjunctive bupropion sustained-release ( SR ) on male <e2>sexual dysfunction</e2> ( SD ) induced by a selective serotonin reuptake inhibitor ( SSRI ) , as SD is a common side-effect of <e1>SSRIs</e1> and the most effective treatments have yet to be determined .
D017367_D012735 NONE OBJECTIVE : To determine the safety and efficacy of adjunctive bupropion sustained-release ( SR ) on male sexual dysfunction ( <e2>SD</e2> ) induced by a selective serotonin reuptake inhibitor ( SSRI ) , as SD is a common side-effect of <e1>SSRIs</e1> and the most effective treatments have yet to be determined .
D017367_D012735 NONE OBJECTIVE : To determine the safety and efficacy of adjunctive bupropion sustained-release ( SR ) on male sexual dysfunction ( SD ) induced by a selective serotonin reuptake inhibitor ( SSRI ) , as <e2>SD</e2> is a common side-effect of <e1>SSRIs</e1> and the most effective treatments have yet to be determined .
D017367_D012735 NONE In linear regression analyses the CGI-SF score was not affected significantly by the duration of <e2>SD</e2> , type of <e1>SSRI</e1> used and age .
D017367_D012735 NONE CONCLUSIONS : Bupropion is an effective treatment for male <e2>SD</e2> induced by <e1>SSRIs</e1> .
8231633
D002118_D064420 NONE Effects of <e1>calcium</e1> channel blockers on bupivacaine-induced <e2>toxicity</e2> .
D002118_D064420 NONE The purpose of this study was to investigate the influence of <e1>calcium</e1> channel blockers on bupivacaine-induced acute <e2>toxicity</e2> .
D002045_D064420 NONE Effects of calcium channel blockers on <e1>bupivacaine-induced</e1> <e2>toxicity</e2> .
D002045_D064420 NONE The purpose of this study was to investigate the influence of calcium channel blockers on <e1>bupivacaine-induced</e1> acute <e2>toxicity</e2> .
D002045_D012640 CID The convulsant activity of <e1>bupivacaine</e1> was not significantly modified but calcium channel blockers decreased the time of latency to obtain bupivacaine-induced <e2>convulsions</e2> ; this effect was less pronounced with bepridil .
D002045_D012640 CID The convulsant activity of bupivacaine was not significantly modified but calcium channel blockers decreased the time of latency to obtain <e1>bupivacaine-induced</e1> <e2>convulsions</e2> ; this effect was less pronounced with bepridil .
D002118_D012640 NONE The convulsant activity of bupivacaine was not significantly modified but <e1>calcium</e1> channel blockers decreased the time of latency to obtain bupivacaine-induced <e2>convulsions</e2> ; this effect was less pronounced with bepridil .
D015764_D012640 NONE The convulsant activity of bupivacaine was not significantly modified but calcium channel blockers decreased the time of latency to obtain bupivacaine-induced <e2>convulsions</e2> ; this effect was less pronounced with <e1>bepridil</e1> .
2549018
D005473_D017109 CID <e1>Fluoxetine-induced</e1> <e2>akathisia</e2> : clinical and theoretical implications .
D005473_D017109 CID Five patients receiving <e1>fluoxetine</e1> for the treatment of obsessive compulsive disorder or major depression developed <e2>akathisia</e2> .
D005473_D017109 CID The typical <e1>fluoxetine-induced</e1> symptoms of restlessness , constant pacing , purposeless movements of the feet and legs , and marked anxiety were indistinguishable from those of neuroleptic-induced <e2>akathisia</e2> .
D005473_D017109 CID Three patients who had experienced neuroleptic-induced <e2>akathisia</e2> in the past reported that the symptoms of <e1>fluoxetine-induced</e1> akathisia were identical , although somewhat milder .
D005473_D017109 CID Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of <e1>fluoxetine-induced</e1> <e2>akathisia</e2> were identical , although somewhat milder .
D005473_D017109 CID <e2>Akathisia</e2> appeared to be a common side effect of <e1>fluoxetine</e1> and generally responded well to treatment with the beta-adrenergic antagonist propranolol , dose reduction , or both .
D005473_D017109 CID The authors suggest that <e1>fluoxetine-induced</e1> <e2>akathisia</e2> may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine-induced akathisia and tricyclic antidepressant-induced " jitteriness " may be identical .
D005473_D017109 CID The authors suggest that <e1>fluoxetine-induced</e1> akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine-induced <e2>akathisia</e2> and tricyclic antidepressant-induced " jitteriness " may be identical .
D005473_D017109 CID The authors suggest that fluoxetine-induced <e2>akathisia</e2> may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of <e1>fluoxetine-induced</e1> akathisia and tricyclic antidepressant-induced " jitteriness " may be identical .
D005473_D017109 CID The authors suggest that fluoxetine-induced akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of <e1>fluoxetine-induced</e1> <e2>akathisia</e2> and tricyclic antidepressant-induced " jitteriness " may be identical .
D005473_D009771 NONE Five patients receiving <e1>fluoxetine</e1> for the treatment of <e2>obsessive compulsive disorder</e2> or major depression developed akathisia .
D005473_D003865 NONE Five patients receiving <e1>fluoxetine</e1> for the treatment of obsessive compulsive disorder or <e2>major depression</e2> developed akathisia .
D005473_D001008 NONE The typical <e1>fluoxetine-induced</e1> symptoms of restlessness , constant pacing , purposeless movements of the feet and legs , and marked <e2>anxiety</e2> were indistinguishable from those of neuroleptic-induced akathisia .
D011433_D017109 NONE <e2>Akathisia</e2> appeared to be a common side effect of fluoxetine and generally responded well to treatment with the beta-adrenergic antagonist <e1>propranolol</e1> , dose reduction , or both .
D000928_D017109 NONE The authors suggest that fluoxetine-induced <e2>akathisia</e2> may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine-induced akathisia and tricyclic <e1>antidepressant-induced</e1> " jitteriness " may be identical .
D000928_D017109 NONE The authors suggest that fluoxetine-induced akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine-induced <e2>akathisia</e2> and tricyclic <e1>antidepressant-induced</e1> " jitteriness " may be identical .
3997294
D000638_D010996 CID Pneumonitis with <e2>pleural and pericardial effusion</e2> and neuropathy during <e1>amiodarone</e1> therapy .
D000638_D010490 CID Pneumonitis with <e2>pleural and pericardial effusion</e2> and neuropathy during <e1>amiodarone</e1> therapy .
D000638_D009422 NONE Pneumonitis with pleural and pericardial effusion and <e2>neuropathy</e2> during <e1>amiodarone</e1> therapy .
D000638_D002318 NONE A patient with <e2>sinuatrial disease</e2> and implanted pacemaker was treated with <e1>amiodarone</e1> ( maximum dose 1000 mg , maintenance dose 800 mg daily ) for 10 months , for control of supraventricular tachyarrhythmias .
D000638_D013617 NONE A patient with sinuatrial disease and implanted pacemaker was treated with <e1>amiodarone</e1> ( maximum dose 1000 mg , maintenance dose 800 mg daily ) for 10 months , for control of <e2>supraventricular tachyarrhythmias</e2> .
D000638_D011014 CID Review of this and previously reported cases indicates the need for early diagnosis of <e1>amiodarone</e1> <e2>pneumonitis</e2> , immediate withdrawal of amiodarone , and prompt but continued steroid therapy to ensure full recovery .
D000638_D011014 CID Review of this and previously reported cases indicates the need for early diagnosis of amiodarone <e2>pneumonitis</e2> , immediate withdrawal of <e1>amiodarone</e1> , and prompt but continued steroid therapy to ensure full recovery .
D013256_D011014 NONE Review of this and previously reported cases indicates the need for early diagnosis of amiodarone <e2>pneumonitis</e2> , immediate withdrawal of amiodarone , and prompt but continued <e1>steroid</e1> therapy to ensure full recovery .
2265898
C009265_D004827 CID Serial <e2>epilepsy</e2> caused by <e1>levodopa/carbidopa</e1> administration in two patients on hemodialysis .
C009265_D007676 NONE Two patients with similar clinical features are presented : both patients had <e2>chronic renal failure</e2> , on hemodialysis for many years but recently begun on a high-flux dialyzer ; both had been receiving a <e1>carbidopa/levodopa</e1> preparation ; and both had the onset of hallucinosis and recurrent seizures , which were refractory to anticonvulsants .
C009265_D001523 NONE Two patients with similar clinical features are presented : both patients had chronic renal failure , on hemodialysis for many years but recently begun on a high-flux dialyzer ; both had been receiving a <e1>carbidopa/levodopa</e1> preparation ; and both had the onset of <e2>hallucinosis</e2> and recurrent seizures , which were refractory to anticonvulsants .
C009265_D012640 NONE Two patients with similar clinical features are presented : both patients had chronic renal failure , on hemodialysis for many years but recently begun on a high-flux dialyzer ; both had been receiving a <e1>carbidopa/levodopa</e1> preparation ; and both had the onset of hallucinosis and recurrent <e2>seizures</e2> , which were refractory to anticonvulsants .
1147734
D011441_D008107 NONE <e2>Liver disease</e2> caused by <e1>propylthiouracil</e1> .
D011441_D006521 CID This report presents the clinical , laboratory , and light and electron microscopic observations on a patient with <e2>chronic active ( aggressive ) hepatitis</e2> caused by the administration of <e1>propylthiouracil</e1> .
14659530
D009569_D008881 NONE <e1>NO-induced</e1> <e2>migraine</e2> attack : strong increase in plasma calcitonin gene-related peptide ( CGRP ) concentration and negative correlation with platelet serotonin release .
D015740_D008881 NONE NO-induced <e2>migraine</e2> attack : strong increase in plasma <e1>calcitonin gene-related peptide</e1> ( CGRP ) concentration and negative correlation with platelet serotonin release .
D015740_D008881 NONE NO-induced <e2>migraine</e2> attack : strong increase in plasma calcitonin gene-related peptide ( <e1>CGRP</e1> ) concentration and negative correlation with platelet serotonin release .
D015740_D008881 NONE The aim of the present study was to investigate changes in the plasma <e1>calcitonin gene-related peptide</e1> ( CGRP ) concentration and platelet serotonin ( 5-hydroxytriptamine , 5-HT ) content during the immediate headache and the delayed genuine <e2>migraine</e2> attack provoked by nitroglycerin .
D015740_D008881 NONE The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide ( <e1>CGRP</e1> ) concentration and platelet serotonin ( 5-hydroxytriptamine , 5-HT ) content during the immediate headache and the delayed genuine <e2>migraine</e2> attack provoked by nitroglycerin .
D015740_D008881 NONE Plasma <e1>CGRP</e1> concentration increased significantly ( P<0.01 ) during the <e2>migraine</e2> attack and returned to baseline after the cessation of the migraine .
D015740_D008881 NONE Plasma <e1>CGRP</e1> concentration increased significantly ( P<0.01 ) during the migraine attack and returned to baseline after the cessation of the <e2>migraine</e2> .
D015740_D008881 NONE However , plasma <e1>CGRP</e1> concentrations failed to change during immediate headache and in the subjects with no <e2>migraine</e2> attack .
D015740_D008881 NONE Basal <e1>CGRP</e1> concentration was significantly higher and platelet 5-HT content tended to be lower in subjects who experienced a <e2>migraine</e2> attack .
D015740_D008881 NONE In conclusion , the fact that plasma <e1>CGRP</e1> concentration correlates with the timing and severity of a <e2>migraine</e2> headache suggests a direct relationship between CGRP and migraine .
D015740_D008881 NONE In conclusion , the fact that plasma <e1>CGRP</e1> concentration correlates with the timing and severity of a migraine headache suggests a direct relationship between CGRP and <e2>migraine</e2> .
D015740_D008881 NONE In conclusion , the fact that plasma CGRP concentration correlates with the timing and severity of a <e2>migraine</e2> headache suggests a direct relationship between <e1>CGRP</e1> and migraine .
D015740_D008881 NONE In conclusion , the fact that plasma CGRP concentration correlates with the timing and severity of a migraine headache suggests a direct relationship between <e1>CGRP</e1> and <e2>migraine</e2> .
D015740_D008881 NONE In contrast , serotonin release from platelets does not provoke <e2>migraine</e2> , it may even counteract the headache and the concomitant <e1>CGRP</e1> release in this model .
D012701_D008881 NONE NO-induced <e2>migraine</e2> attack : strong increase in plasma calcitonin gene-related peptide ( CGRP ) concentration and negative correlation with platelet <e1>serotonin</e1> release .
D012701_D008881 NONE The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide ( CGRP ) concentration and platelet <e1>serotonin</e1> ( 5-hydroxytriptamine , 5-HT ) content during the immediate headache and the delayed genuine <e2>migraine</e2> attack provoked by nitroglycerin .
D012701_D008881 NONE The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide ( CGRP ) concentration and platelet serotonin ( <e1>5-hydroxytriptamine</e1> , 5-HT ) content during the immediate headache and the delayed genuine <e2>migraine</e2> attack provoked by nitroglycerin .
D012701_D008881 NONE The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide ( CGRP ) concentration and platelet serotonin ( 5-hydroxytriptamine , <e1>5-HT</e1> ) content during the immediate headache and the delayed genuine <e2>migraine</e2> attack provoked by nitroglycerin .
D012701_D008881 NONE Basal CGRP concentration was significantly higher and platelet <e1>5-HT</e1> content tended to be lower in subjects who experienced a <e2>migraine</e2> attack .
D012701_D008881 NONE Platelet <e1>serotonin</e1> content decreased significantly ( P<0.01 ) after nitroglycerin in subjects with no <e2>migraine</e2> attack but no consistent change was observed in patients with migraine attack .
D012701_D008881 NONE Platelet <e1>serotonin</e1> content decreased significantly ( P<0.01 ) after nitroglycerin in subjects with no migraine attack but no consistent change was observed in patients with <e2>migraine</e2> attack .
D012701_D008881 NONE In contrast , <e1>serotonin</e1> release from platelets does not provoke <e2>migraine</e2> , it may even counteract the headache and the concomitant CGRP release in this model .
D015740_D006261 NONE The aim of the present study was to investigate changes in the plasma <e1>calcitonin gene-related peptide</e1> ( CGRP ) concentration and platelet serotonin ( 5-hydroxytriptamine , 5-HT ) content during the immediate <e2>headache</e2> and the delayed genuine migraine attack provoked by nitroglycerin .
D015740_D006261 NONE The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide ( <e1>CGRP</e1> ) concentration and platelet serotonin ( 5-hydroxytriptamine , 5-HT ) content during the immediate <e2>headache</e2> and the delayed genuine migraine attack provoked by nitroglycerin .
D015740_D006261 NONE However , plasma <e1>CGRP</e1> concentrations failed to change during immediate <e2>headache</e2> and in the subjects with no migraine attack .
D015740_D006261 NONE In conclusion , the fact that plasma <e1>CGRP</e1> concentration correlates with the timing and severity of a migraine <e2>headache</e2> suggests a direct relationship between CGRP and migraine .
D015740_D006261 NONE In conclusion , the fact that plasma CGRP concentration correlates with the timing and severity of a migraine <e2>headache</e2> suggests a direct relationship between <e1>CGRP</e1> and migraine .
D015740_D006261 NONE In contrast , serotonin release from platelets does not provoke migraine , it may even counteract the <e2>headache</e2> and the concomitant <e1>CGRP</e1> release in this model .
D012701_D006261 NONE The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide ( CGRP ) concentration and platelet <e1>serotonin</e1> ( 5-hydroxytriptamine , 5-HT ) content during the immediate <e2>headache</e2> and the delayed genuine migraine attack provoked by nitroglycerin .
D012701_D006261 NONE The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide ( CGRP ) concentration and platelet serotonin ( <e1>5-hydroxytriptamine</e1> , 5-HT ) content during the immediate <e2>headache</e2> and the delayed genuine migraine attack provoked by nitroglycerin .
D012701_D006261 NONE The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide ( CGRP ) concentration and platelet serotonin ( 5-hydroxytriptamine , <e1>5-HT</e1> ) content during the immediate <e2>headache</e2> and the delayed genuine migraine attack provoked by nitroglycerin .
D012701_D006261 NONE In contrast , <e1>serotonin</e1> release from platelets does not provoke migraine , it may even counteract the <e2>headache</e2> and the concomitant CGRP release in this model .
D005996_D006261 NONE The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide ( CGRP ) concentration and platelet serotonin ( 5-hydroxytriptamine , 5-HT ) content during the immediate <e2>headache</e2> and the delayed genuine migraine attack provoked by <e1>nitroglycerin</e1> .
D005996_D008881 NONE The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide ( CGRP ) concentration and platelet serotonin ( 5-hydroxytriptamine , 5-HT ) content during the immediate headache and the delayed genuine <e2>migraine</e2> attack provoked by <e1>nitroglycerin</e1> .
D005996_D008881 NONE Blood was collected from the antecubital vein four times : 60 min before and after the <e1>nitroglycerin</e1> application , and 60 and 120 min after the beginning of the <e2>migraine</e2> attack ( mean 344 and 404 min ; 12 subjects ) .
D005996_D008881 NONE Platelet serotonin content decreased significantly ( P<0.01 ) after <e1>nitroglycerin</e1> in subjects with no <e2>migraine</e2> attack but no consistent change was observed in patients with migraine attack .
D005996_D008881 NONE Platelet serotonin content decreased significantly ( P<0.01 ) after <e1>nitroglycerin</e1> in subjects with no migraine attack but no consistent change was observed in patients with <e2>migraine</e2> attack .
9034419
C047426_D012640 CID <e2>Seizure</e2> resulting from a <e1>venlafaxine</e1> overdose .
C047426_D012640 CID After the ingestion of 26 <e1>venlafaxine</e1> 50-mg tablets , the patient experienced a witnessed generalized <e2>seizure</e2> .
C047426_D012640 CID DISCUSSION : To our knowledge , this is the first reported case of <e1>venlafaxine</e1> overdose that resulted in a generalized <e2>seizure</e2> .
C047426_D012640 CID CONCLUSIONS : The <e1>venlafaxine</e1> overdose in our patient resulted in a single episode of generalized <e2>seizure</e2> but elicited no further sequelae .
C047426_D062787 CID Seizure resulting from a <e1>venlafaxine</e1> <e2>overdose</e2> .
C047426_D062787 CID OBJECTIVE : To report a case of <e1>venlafaxine</e1> <e2>overdose</e2> .
C047426_D062787 CID CASE SUMMARY : A 40-year-old woman with major depression took an <e2>overdose</e2> of <e1>venlafaxine</e1> in an apparent suicide attempt .
C047426_D062787 CID DISCUSSION : To our knowledge , this is the first reported case of <e1>venlafaxine</e1> <e2>overdose</e2> that resulted in a generalized seizure .
C047426_D062787 CID CONCLUSIONS : The <e1>venlafaxine</e1> <e2>overdose</e2> in our patient resulted in a single episode of generalized seizure but elicited no further sequelae .
C047426_D003865 NONE CASE SUMMARY : A 40-year-old woman with <e2>major depression</e2> took an overdose of <e1>venlafaxine</e1> in an apparent suicide attempt .
18560792
D010479_D006349 NONE <e2>Valvular heart disease</e2> in patients with Parkinson 's disease treated with <e1>pergolide</e1> .
D010479_D006349 NONE <e2>Valvular heart abnormalities</e2> have been reported in patients with Parkinson 's disease ( PD ) treated with <e1>pergolide</e1> .
D010479_D006349 NONE A restrictive pattern of <e2>valvular regurgitation</e2> , suggestive of the role of <e1>pergolide</e1> , was observed in 12/30 ( 40 % ) patients including two with heart failure .
D010479_D006349 NONE <e1>Pergolide</e1> was discontinued in 10 patients with <e2>valvular heart disease</e2> , resulting in a lower regurgitation grade ( p=0.01 ) at the second transthoracic echocardiography and the two patients with heart failure returned to nearly normal clinical examination .
D010479_D006349 NONE This study supports the high frequency of restrictive <e2>valve regurgitation</e2> in PD patients treated with <e1>pergolide</e1> and reveals that a significant improvement is usual when the treatment is converted to non-ergot dopamine agonists .
D010479_D010300 NONE Valvular heart disease in patients with <e2>Parkinson 's disease</e2> treated with <e1>pergolide</e1> .
D010479_D010300 NONE Valvular heart abnormalities have been reported in patients with <e2>Parkinson 's disease</e2> ( PD ) treated with <e1>pergolide</e1> .
D010479_D010300 NONE Valvular heart abnormalities have been reported in patients with Parkinson 's disease ( <e2>PD</e2> ) treated with <e1>pergolide</e1> .
D010479_D010300 NONE METHODS : All <e2>PD</e2> patients in the Amiens area treated with <e1>pergolide</e1> were invited to attend a cardiologic assessment including transthoracic echocardiography .
D010479_D010300 NONE This study supports the high frequency of restrictive valve regurgitation in <e2>PD</e2> patients treated with <e1>pergolide</e1> and reveals that a significant improvement is usual when the treatment is converted to non-ergot dopamine agonists .
D010479_D006333 NONE A restrictive pattern of valvular regurgitation , suggestive of the role of <e1>pergolide</e1> , was observed in 12/30 ( 40 % ) patients including two with <e2>heart failure</e2> .
D010479_D006333 NONE <e1>Pergolide</e1> was discontinued in 10 patients with valvular heart disease , resulting in a lower regurgitation grade ( p=0.01 ) at the second transthoracic echocardiography and the two patients with <e2>heart failure</e2> returned to nearly normal clinical examination .
D004298_D006349 NONE This study supports the high frequency of restrictive <e2>valve regurgitation</e2> in PD patients treated with pergolide and reveals that a significant improvement is usual when the treatment is converted to non-ergot <e1>dopamine</e1> agonists .
D004298_D010300 NONE This study supports the high frequency of restrictive valve regurgitation in <e2>PD</e2> patients treated with pergolide and reveals that a significant improvement is usual when the treatment is converted to non-ergot <e1>dopamine</e1> agonists .
16181582
D014635_D001927 CID <e1>Valproate-induced</e1> <e2>encephalopathy</e2> .
D014635_D001927 CID <e1>Valproate-induced</e1> <e2>encephalopathy</e2> is a rare syndrome that may manifest in otherwise normal epileptic individuals .
D014635_D001927 CID A case of <e1>valproate-induced</e1> <e2>encephalopathy</e2> is presented .
D014635_D004827 NONE <e1>Valproate-induced</e1> encephalopathy is a rare syndrome that may manifest in otherwise normal <e2>epileptic</e2> individuals .
869641
D007980_D001919 NONE Mediation of enhanced reflex vagal <e2>bradycardia</e2> by <e1>L-dopa</e1> via central dopamine formation in dogs .
D007980_D001919 NONE In addition , reflex <e2>bradycardia</e2> caused by injected norepinephrine was significantly enhanced by <e1>L-dopa</e1> , DL-Threo-dihydroxyphenylserine had no effect on blood pressure , heart rate or reflex responses to norepinephrine .
D007980_D001919 NONE FLA-63 , a dopamine-beta-oxidase inhibitor , did not have any effect on the hypotension , <e2>bradycardia</e2> or reflex-enhancing effect of <e1>L-dopa</e1> .
D007980_D001919 NONE However , <e1>L-dopa</e1> restored the <e2>bradycardia</e2> caused by norepinephrine in addition to decreasing blood pressure and heart rate .
D007980_D001919 NONE It is concluded that <e1>L-dopa</e1> enhances reflex <e2>bradycardia</e2> through central alpha-receptor stimulation .
D004298_D001919 NONE Mediation of enhanced reflex vagal <e2>bradycardia</e2> by L-dopa via central <e1>dopamine</e1> formation in dogs .
D004298_D001919 NONE FLA-63 , a <e1>dopamine-beta-oxidase</e1> inhibitor , did not have any effect on the hypotension , <e2>bradycardia</e2> or reflex-enhancing effect of L-dopa .
D009638_D001919 CID In addition , reflex <e2>bradycardia</e2> caused by injected <e1>norepinephrine</e1> was significantly enhanced by L-dopa , DL-Threo-dihydroxyphenylserine had no effect on blood pressure , heart rate or reflex responses to norepinephrine .
D009638_D001919 CID In addition , reflex <e2>bradycardia</e2> caused by injected norepinephrine was significantly enhanced by L-dopa , DL-Threo-dihydroxyphenylserine had no effect on blood pressure , heart rate or reflex responses to <e1>norepinephrine</e1> .
D009638_D001919 CID However , L-dopa restored the <e2>bradycardia</e2> caused by <e1>norepinephrine</e1> in addition to decreasing blood pressure and heart rate .
D009638_D001919 CID 5-HTP ( 5 mg/kg i.v. ) decreased blood pressure and heart rate and decreased the reflex <e2>bradycardia</e2> to <e1>norepinephrine</e1> .
D015103_D001919 NONE In addition , reflex <e2>bradycardia</e2> caused by injected norepinephrine was significantly enhanced by L-dopa , <e1>DL-Threo-dihydroxyphenylserine</e1> had no effect on blood pressure , heart rate or reflex responses to norepinephrine .
D005406_D007022 NONE <e1>FLA-63</e1> , a dopamine-beta-oxidase inhibitor , did not have any effect on the <e2>hypotension</e2> , bradycardia or reflex-enhancing effect of L-dopa .
D005406_D001919 NONE <e1>FLA-63</e1> , a dopamine-beta-oxidase inhibitor , did not have any effect on the hypotension , <e2>bradycardia</e2> or reflex-enhancing effect of L-dopa .
D004298_D007022 NONE FLA-63 , a <e1>dopamine-beta-oxidase</e1> inhibitor , did not have any effect on the <e2>hypotension</e2> , bradycardia or reflex-enhancing effect of L-dopa .
D007980_D007022 NONE FLA-63 , a dopamine-beta-oxidase inhibitor , did not have any effect on the <e2>hypotension</e2> , bradycardia or reflex-enhancing effect of <e1>L-dopa</e1> .
D006916_D001919 NONE <e1>5-HTP</e1> ( 5 mg/kg i.v. ) decreased blood pressure and heart rate and decreased the reflex <e2>bradycardia</e2> to norepinephrine .
7423039
D004317_D066126 CID Metabolic involvement in <e1>adriamycin</e1> <e2>cardiotoxicity</e2> .
D004317_D066126 CID The <e2>cardiotoxic</e2> effects of <e1>adriamycin</e1> were studied in mammalian myocardial cells in culture as a model system .
8386779
D017693_D004414 NONE <e1>Sodium bicarbonate</e1> alleviates <e2>penile pain</e2> induced by intracavernous injections for erectile dysfunction .
D017693_D004414 NONE In an attempt to determine whether <e2>penile pain</e2> associated with intracorporeal injections could be due to the acidity of the medication , we performed a randomized study comparing the incidence of penile pain following intracorporeal injections with or without the addition of <e1>sodium bicarbonate</e1> to the intracorporeal medications. A total of 38 consecutive patients who presented to our clinic with impotence received 0.2 ml. of a combination of 3 drugs : 6 mg. papaverine , 100 micrograms .
D017693_D004414 NONE In an attempt to determine whether penile pain associated with intracorporeal injections could be due to the acidity of the medication , we performed a randomized study comparing the incidence of <e2>penile pain</e2> following intracorporeal injections with or without the addition of <e1>sodium bicarbonate</e1> to the intracorporeal medications. A total of 38 consecutive patients who presented to our clinic with impotence received 0.2 ml. of a combination of 3 drugs : 6 mg. papaverine , 100 micrograms .
D017693_D004414 NONE Of the 19 patients without <e1>sodium bicarbonate</e1> added to the medication 11 ( 58 % ) complained of <e2>penile pain</e2> due to the medication , while only 1 of the 19 men ( 5 % ) who received sodium bicarbonate complained of penile pain .
D017693_D004414 NONE Of the 19 patients without <e1>sodium bicarbonate</e1> added to the medication 11 ( 58 % ) complained of penile pain due to the medication , while only 1 of the 19 men ( 5 % ) who received sodium bicarbonate complained of <e2>penile pain</e2> .
D017693_D004414 NONE Of the 19 patients without sodium bicarbonate added to the medication 11 ( 58 % ) complained of <e2>penile pain</e2> due to the medication , while only 1 of the 19 men ( 5 % ) who received <e1>sodium bicarbonate</e1> complained of penile pain .
D017693_D004414 NONE Of the 19 patients without sodium bicarbonate added to the medication 11 ( 58 % ) complained of penile pain due to the medication , while only 1 of the 19 men ( 5 % ) who received <e1>sodium bicarbonate</e1> complained of <e2>penile pain</e2> .
D017693_D007172 NONE <e1>Sodium bicarbonate</e1> alleviates penile pain induced by intracavernous injections for <e2>erectile dysfunction</e2> .
D017693_D007172 NONE In an attempt to determine whether penile pain associated with intracorporeal injections could be due to the acidity of the medication , we performed a randomized study comparing the incidence of penile pain following intracorporeal injections with or without the addition of <e1>sodium bicarbonate</e1> to the intracorporeal medications. A total of 38 consecutive patients who presented to our clinic with <e2>impotence</e2> received 0.2 ml. of a combination of 3 drugs : 6 mg. papaverine , 100 micrograms .
D010208_D004414 NONE In an attempt to determine whether <e2>penile pain</e2> associated with intracorporeal injections could be due to the acidity of the medication , we performed a randomized study comparing the incidence of penile pain following intracorporeal injections with or without the addition of sodium bicarbonate to the intracorporeal medications. A total of 38 consecutive patients who presented to our clinic with impotence received 0.2 ml. of a combination of 3 drugs : 6 mg. <e1>papaverine</e1> , 100 micrograms .
D010208_D004414 NONE In an attempt to determine whether penile pain associated with intracorporeal injections could be due to the acidity of the medication , we performed a randomized study comparing the incidence of <e2>penile pain</e2> following intracorporeal injections with or without the addition of sodium bicarbonate to the intracorporeal medications. A total of 38 consecutive patients who presented to our clinic with impotence received 0.2 ml. of a combination of 3 drugs : 6 mg. <e1>papaverine</e1> , 100 micrograms .
D010208_D007172 NONE In an attempt to determine whether penile pain associated with intracorporeal injections could be due to the acidity of the medication , we performed a randomized study comparing the incidence of penile pain following intracorporeal injections with or without the addition of sodium bicarbonate to the intracorporeal medications. A total of 38 consecutive patients who presented to our clinic with <e2>impotence</e2> received 0.2 ml. of a combination of 3 drugs : 6 mg. <e1>papaverine</e1> , 100 micrograms .
11569530
D016593_D016171 CID <e2>TDP</e2> is a side-effect that has led to withdrawal of several drugs from the market ( e.g. <e1>terfenadine</e1> and terodiline ) .
D016593_D016171 CID Four compounds known to increase QT interval and cause <e2>TDP</e2> were investigated : <e1>terfenadine</e1> , terodiline , cisapride and E4031 .
D016593_D016171 CID For compounds that have shown <e2>TDP</e2> in the clinic ( <e1>terfenadine</e1> , terodiline , cisapride ) there is little differentiation between the dog ED50 and the efficacious free plasma concentrations in man ( < 10-fold ) reflecting their limited safety margins .
C010637_D016171 CID <e2>TDP</e2> is a side-effect that has led to withdrawal of several drugs from the market ( e.g. terfenadine and <e1>terodiline</e1> ) .
C010637_D016171 CID Four compounds known to increase QT interval and cause <e2>TDP</e2> were investigated : terfenadine , <e1>terodiline</e1> , cisapride and E4031 .
C010637_D016171 CID For compounds that have shown <e2>TDP</e2> in the clinic ( terfenadine , <e1>terodiline</e1> , cisapride ) there is little differentiation between the dog ED50 and the efficacious free plasma concentrations in man ( < 10-fold ) reflecting their limited safety margins .
D020117_D016171 CID Four compounds known to increase QT interval and cause <e2>TDP</e2> were investigated : terfenadine , terodiline , <e1>cisapride</e1> and E4031 .
D020117_D016171 CID For compounds that have shown <e2>TDP</e2> in the clinic ( terfenadine , terodiline , <e1>cisapride</e1> ) there is little differentiation between the dog ED50 and the efficacious free plasma concentrations in man ( < 10-fold ) reflecting their limited safety margins .
C063968_D016171 NONE Four compounds known to increase QT interval and cause <e2>TDP</e2> were investigated : terfenadine , terodiline , cisapride and <e1>E4031</e1> .
6308277
D002110_D064420 NONE Reduction in <e1>caffeine</e1> <e2>toxicity</e2> by acetaminophen .
D002110_D064420 NONE Because salicylates have been reported to augment the stimulatory effects of <e1>caffeine</e1> on the CNS , attention was focused on the possibility that the presence of acetaminophen ( 52 micrograms/mL ) reduced the CNS <e2>toxicity</e2> of caffeine .
D002110_D064420 NONE Because salicylates have been reported to augment the stimulatory effects of caffeine on the CNS , attention was focused on the possibility that the presence of acetaminophen ( 52 micrograms/mL ) reduced the CNS <e2>toxicity</e2> of <e1>caffeine</e1> .
D000082_D064420 NONE Reduction in caffeine <e2>toxicity</e2> by <e1>acetaminophen</e1> .
D000082_D064420 NONE Because salicylates have been reported to augment the stimulatory effects of caffeine on the CNS , attention was focused on the possibility that the presence of <e1>acetaminophen</e1> ( 52 micrograms/mL ) reduced the CNS <e2>toxicity</e2> of caffeine .
D000082_D012640 NONE Studies in DBA/2J mice showed that : 1 ) pretreatment with <e1>acetaminophen</e1> ( 100 mg/kg ) increased the interval between the administration of caffeine ( 300 to 450 mg/kg IP ) and the onset of fatal <e2>convulsions</e2> by a factor of about two ; and 2 ) pretreatment with acetaminophen ( 75 mg/kg ) reduced the incidence of audiogenic seizures produced in the presence of caffeine ( 12.5 to 75 mg/kg IP ) .
D000082_D012640 NONE Studies in DBA/2J mice showed that : 1 ) pretreatment with <e1>acetaminophen</e1> ( 100 mg/kg ) increased the interval between the administration of caffeine ( 300 to 450 mg/kg IP ) and the onset of fatal convulsions by a factor of about two ; and 2 ) pretreatment with acetaminophen ( 75 mg/kg ) reduced the incidence of audiogenic <e2>seizures</e2> produced in the presence of caffeine ( 12.5 to 75 mg/kg IP ) .
D000082_D012640 NONE Studies in DBA/2J mice showed that : 1 ) pretreatment with acetaminophen ( 100 mg/kg ) increased the interval between the administration of caffeine ( 300 to 450 mg/kg IP ) and the onset of fatal <e2>convulsions</e2> by a factor of about two ; and 2 ) pretreatment with <e1>acetaminophen</e1> ( 75 mg/kg ) reduced the incidence of audiogenic seizures produced in the presence of caffeine ( 12.5 to 75 mg/kg IP ) .
D000082_D012640 NONE Studies in DBA/2J mice showed that : 1 ) pretreatment with acetaminophen ( 100 mg/kg ) increased the interval between the administration of caffeine ( 300 to 450 mg/kg IP ) and the onset of fatal convulsions by a factor of about two ; and 2 ) pretreatment with <e1>acetaminophen</e1> ( 75 mg/kg ) reduced the incidence of audiogenic <e2>seizures</e2> produced in the presence of caffeine ( 12.5 to 75 mg/kg IP ) .
D000082_D012640 NONE The frequency of sound-induced <e2>seizures</e2> after 12.5 or 25 mg/kg caffeine was reduced from 50 to 5 % by <e1>acetaminophen</e1> .
D000082_D012640 NONE In the absence of caffeine , <e1>acetaminophen</e1> ( up to 300 mg/kg ) did not modify the <e2>seizures</e2> induced by maximal electroshock and did not alter the convulsant dose of pentylenetetrezol in mice ( tests performed by the Anticonvulsant Screening Project of NINCDS ) .
D002110_D012640 CID Studies in DBA/2J mice showed that : 1 ) pretreatment with acetaminophen ( 100 mg/kg ) increased the interval between the administration of <e1>caffeine</e1> ( 300 to 450 mg/kg IP ) and the onset of fatal <e2>convulsions</e2> by a factor of about two ; and 2 ) pretreatment with acetaminophen ( 75 mg/kg ) reduced the incidence of audiogenic seizures produced in the presence of caffeine ( 12.5 to 75 mg/kg IP ) .
D002110_D012640 CID Studies in DBA/2J mice showed that : 1 ) pretreatment with acetaminophen ( 100 mg/kg ) increased the interval between the administration of <e1>caffeine</e1> ( 300 to 450 mg/kg IP ) and the onset of fatal convulsions by a factor of about two ; and 2 ) pretreatment with acetaminophen ( 75 mg/kg ) reduced the incidence of audiogenic <e2>seizures</e2> produced in the presence of caffeine ( 12.5 to 75 mg/kg IP ) .
D002110_D012640 CID Studies in DBA/2J mice showed that : 1 ) pretreatment with acetaminophen ( 100 mg/kg ) increased the interval between the administration of caffeine ( 300 to 450 mg/kg IP ) and the onset of fatal <e2>convulsions</e2> by a factor of about two ; and 2 ) pretreatment with acetaminophen ( 75 mg/kg ) reduced the incidence of audiogenic seizures produced in the presence of <e1>caffeine</e1> ( 12.5 to 75 mg/kg IP ) .
D002110_D012640 CID Studies in DBA/2J mice showed that : 1 ) pretreatment with acetaminophen ( 100 mg/kg ) increased the interval between the administration of caffeine ( 300 to 450 mg/kg IP ) and the onset of fatal convulsions by a factor of about two ; and 2 ) pretreatment with acetaminophen ( 75 mg/kg ) reduced the incidence of audiogenic <e2>seizures</e2> produced in the presence of <e1>caffeine</e1> ( 12.5 to 75 mg/kg IP ) .
D002110_D012640 CID The frequency of sound-induced <e2>seizures</e2> after 12.5 or 25 mg/kg <e1>caffeine</e1> was reduced from 50 to 5 % by acetaminophen .
D002110_D012640 CID In the absence of <e1>caffeine</e1> , acetaminophen ( up to 300 mg/kg ) did not modify the <e2>seizures</e2> induced by maximal electroshock and did not alter the convulsant dose of pentylenetetrezol in mice ( tests performed by the Anticonvulsant Screening Project of NINCDS ) .
D010433_D012640 CID In the absence of caffeine , acetaminophen ( up to 300 mg/kg ) did not modify the <e2>seizures</e2> induced by maximal electroshock and did not alter the convulsant dose of <e1>pentylenetetrezol</e1> in mice ( tests performed by the Anticonvulsant Screening Project of NINCDS ) .
16574712
D018817_D003072 CID <e1>MDMA</e1> polydrug users show process-specific central executive impairments coupled with <e2>impaired social and emotional judgement processes</e2> .
D018817_D008569 NONE In recent years working <e2>memory deficits</e2> have been reported in users of <e1>MDMA</e1> ( 3,4-methylenedioxymethamphetamine , ecstasy ) .
D018817_D008569 NONE In recent years working <e2>memory deficits</e2> have been reported in users of MDMA ( <e1>3,4-methylenedioxymethamphetamine</e1> , ecstasy ) .
D018817_D008569 NONE In recent years working <e2>memory deficits</e2> have been reported in users of MDMA ( 3,4-methylenedioxymethamphetamine , <e1>ecstasy</e1> ) .
6773726
D005996_D007022 CID Provocation of postural <e2>hypotension</e2> by <e1>nitroglycerin</e1> in diabetic autonomic neuropathy ?
D005996_D003929 NONE Provocation of postural hypotension by <e1>nitroglycerin</e1> in <e2>diabetic autonomic neuropathy</e2> ?
D005996_D003920 NONE The effect of <e1>nitroglycerin</e1> on heart rate and systolic blood pressure was compared in 5 normal subjects , 12 <e2>diabetic</e2> subjects without autonomic neuropathy , and 5 diabetic subjects with autonomic neuropathy .
D005996_D003920 NONE The effect of <e1>nitroglycerin</e1> on heart rate and systolic blood pressure was compared in 5 normal subjects , 12 diabetic subjects without autonomic neuropathy , and 5 <e2>diabetic</e2> subjects with autonomic neuropathy .
D005996_D003920 NONE The magnitude and time course of the increase in heart rate and the decrease in systolic blood pressure after <e1>nitroglycerin</e1> were similar in the normal and <e2>diabetic</e2> subjects without autonomic neuropathy , whereas a lesser increase in heart rate and a greater decrease in systolic blood pressure occurred in the diabetic subjects with autonomic neuropathy .
D005996_D003920 NONE The magnitude and time course of the increase in heart rate and the decrease in systolic blood pressure after <e1>nitroglycerin</e1> were similar in the normal and diabetic subjects without autonomic neuropathy , whereas a lesser increase in heart rate and a greater decrease in systolic blood pressure occurred in the <e2>diabetic</e2> subjects with autonomic neuropathy .
D005996_D009422 NONE The effect of <e1>nitroglycerin</e1> on heart rate and systolic blood pressure was compared in 5 normal subjects , 12 diabetic subjects without <e2>autonomic neuropathy</e2> , and 5 diabetic subjects with autonomic neuropathy .
D005996_D009422 NONE The effect of <e1>nitroglycerin</e1> on heart rate and systolic blood pressure was compared in 5 normal subjects , 12 diabetic subjects without autonomic neuropathy , and 5 diabetic subjects with <e2>autonomic neuropathy</e2> .
D005996_D009422 NONE The magnitude and time course of the increase in heart rate and the decrease in systolic blood pressure after <e1>nitroglycerin</e1> were similar in the normal and diabetic subjects without <e2>autonomic neuropathy</e2> , whereas a lesser increase in heart rate and a greater decrease in systolic blood pressure occurred in the diabetic subjects with autonomic neuropathy .
D005996_D009422 NONE The magnitude and time course of the increase in heart rate and the decrease in systolic blood pressure after <e1>nitroglycerin</e1> were similar in the normal and diabetic subjects without autonomic neuropathy , whereas a lesser increase in heart rate and a greater decrease in systolic blood pressure occurred in the diabetic subjects with <e2>autonomic neuropathy</e2> .
15130900
D003520_D001749 CID <e2>Urinary bladder cancer</e2> in Wegener 's granulomatosis : risks and relation to <e1>cyclophosphamide</e1> .
D003520_D001749 CID OBJECTIVE : To assess and characterise the risk of <e2>bladder cancer</e2> , and its relation to <e1>cyclophosphamide</e1> , in patients with Wegener 's granulomatosis .
D003520_D001749 CID Nested within the cohort , a matched case-control study was performed to estimate the association between <e1>cyclophosphamide</e1> and <e2>bladder cancer</e2> using odds ratios ( ORs ) as relative risk .
D003520_D001749 CID The risk of <e2>bladder cancer</e2> doubled for every 10 g increment in <e1>cyclophosphamide</e1> ( OR = 2.0 , 95 % confidence interval ( CI ) 0.8 to 4.9 ) .
D003520_D001749 CID CONCLUSION : The results indicate a dose-response relationship between <e1>cyclophosphamide</e1> and the risk of <e2>bladder cancer</e2> , high cumulative risks in the entire cohort , and also the possibility of risk factors operating even before Wegener 's granulomatosis .
D003520_D014890 NONE Urinary bladder cancer in <e2>Wegener 's granulomatosis</e2> : risks and relation to <e1>cyclophosphamide</e1> .
D003520_D014890 NONE OBJECTIVE : To assess and characterise the risk of bladder cancer , and its relation to <e1>cyclophosphamide</e1> , in patients with <e2>Wegener 's granulomatosis</e2> .
D003520_D014890 NONE CONCLUSION : The results indicate a dose-response relationship between <e1>cyclophosphamide</e1> and the risk of bladder cancer , high cumulative risks in the entire cohort , and also the possibility of risk factors operating even before <e2>Wegener 's granulomatosis</e2> .
150790
D011736_D002653 NONE A <e1>pyridoxine-dependent</e1> <e2>behavioral disorder</e2> unmasked by isoniazid .
D007538_D002653 CID A pyridoxine-dependent <e2>behavioral disorder</e2> unmasked by <e1>isoniazid</e1> .
D007538_D002653 CID A 3-year-old girl had <e2>behavioral deterioration</e2> , with hyperkinesis , irritability , and sleeping difficulties after the therapeutic administration of <e1>isoniazid</e1> .
D007538_D006948 CID A 3-year-old girl had behavioral deterioration , with <e2>hyperkinesis</e2> , irritability , and sleeping difficulties after the therapeutic administration of <e1>isoniazid</e1> .
D007538_D001523 NONE A 3-year-old girl had behavioral deterioration , with hyperkinesis , <e2>irritability</e2> , and sleeping difficulties after the therapeutic administration of <e1>isoniazid</e1> .
D007538_D012893 NONE A 3-year-old girl had behavioral deterioration , with hyperkinesis , irritability , and <e2>sleeping difficulties</e2> after the therapeutic administration of <e1>isoniazid</e1> .
D011736_D006948 NONE Periodic withdrawal of <e1>pyridoxine</e1> was associated with return of the <e2>hyperkinesis</e2> .
3719553
D005472_D004342 NONE <e2>Allergic reaction</e2> to <e1>5-fluorouracil</e1> infusion .
D005472_D004342 NONE An <e2>allergic reaction</e2> consisting of angioneurotic edema secondary to continuous infusion <e1>5-fluorouracil</e1> occurred in a patient with recurrent carcinoma of the oral cavity , cirrhosis , and cisplatin-induced impaired renal function .
D005472_D000799 CID An allergic reaction consisting of <e2>angioneurotic edema</e2> secondary to continuous infusion <e1>5-fluorouracil</e1> occurred in a patient with recurrent carcinoma of the oral cavity , cirrhosis , and cisplatin-induced impaired renal function .
D005472_D009062 NONE An allergic reaction consisting of angioneurotic edema secondary to continuous infusion <e1>5-fluorouracil</e1> occurred in a patient with recurrent <e2>carcinoma of the oral cavity</e2> , cirrhosis , and cisplatin-induced impaired renal function .
D005472_D005355 NONE An allergic reaction consisting of angioneurotic edema secondary to continuous infusion <e1>5-fluorouracil</e1> occurred in a patient with recurrent carcinoma of the oral cavity , <e2>cirrhosis</e2> , and cisplatin-induced impaired renal function .
D005472_D007674 NONE An allergic reaction consisting of angioneurotic edema secondary to continuous infusion <e1>5-fluorouracil</e1> occurred in a patient with recurrent carcinoma of the oral cavity , cirrhosis , and cisplatin-induced <e2>impaired renal function</e2> .
D002945_D004342 NONE An <e2>allergic reaction</e2> consisting of angioneurotic edema secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity , cirrhosis , and <e1>cisplatin-induced</e1> impaired renal function .
D002945_D000799 NONE An allergic reaction consisting of <e2>angioneurotic edema</e2> secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity , cirrhosis , and <e1>cisplatin-induced</e1> impaired renal function .
D002945_D009062 NONE An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent <e2>carcinoma of the oral cavity</e2> , cirrhosis , and <e1>cisplatin-induced</e1> impaired renal function .
D002945_D005355 NONE An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity , <e2>cirrhosis</e2> , and <e1>cisplatin-induced</e1> impaired renal function .
D002945_D007674 NONE An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity , cirrhosis , and <e1>cisplatin-induced</e1> <e2>impaired renal function</e2> .
D004155_D004342 NONE Oral <e1>diphenhydramine</e1> and prednisone were ineffective in preventing the recurrence of the <e2>allergic reaction</e2> .
D011241_D004342 NONE Oral diphenhydramine and <e1>prednisone</e1> were ineffective in preventing the recurrence of the <e2>allergic reaction</e2> .
12090760
D015215_D000740 CID Antagonism between interleukin 3 and erythropoietin in mice with <e1>azidothymidine-induced</e1> <e2>anemia</e2> and in bone marrow endothelial cells .
D015215_D000740 CID <e1>Azidothymidine</e1> (AZT)-induced <e2>anemia</e2> in mice can be reversed by the administration of IGF-IL-3 ( fusion protein of insulin-like growth factor II ( IGF II ) and interleukin 3 ) .
D015215_D000740 CID Azidothymidine <e1>(AZT)-induced</e1> <e2>anemia</e2> in mice can be reversed by the administration of IGF-IL-3 ( fusion protein of insulin-like growth factor II ( IGF II ) and interleukin 3 ) .
15120741
D010862_D013226 CID Similar to rats , systemic <e1>pilocarpine</e1> injection causes <e2>status epilepticus</e2> ( SE ) and the eventual development of spontaneous seizures and mossy fiber sprouting in C57BL/6 and CD1 mice , but the physiological correlates of these events have not been identified in mice .
D010862_D013226 CID Similar to rats , systemic <e1>pilocarpine</e1> injection causes status epilepticus ( <e2>SE</e2> ) and the eventual development of spontaneous seizures and mossy fiber sprouting in C57BL/6 and CD1 mice , but the physiological correlates of these events have not been identified in mice .
D010862_D013226 CID In Mg(2+)-free bathing medium containing bicuculline , conditions designed to increase excitability in the slices , electrical stimulation of the hilus resulted in a single population spike in granule cells from control mice and <e1>pilocarpine-treated</e1> mice that did not experience <e2>SE</e2> .
D010862_D012640 CID Similar to rats , systemic <e1>pilocarpine</e1> injection causes status epilepticus ( SE ) and the eventual development of spontaneous <e2>seizures</e2> and mossy fiber sprouting in C57BL/6 and CD1 mice , but the physiological correlates of these events have not been identified in mice .
D008274_D013226 NONE In <e1>Mg(2+)-free</e1> bathing medium containing bicuculline , conditions designed to increase excitability in the slices , electrical stimulation of the hilus resulted in a single population spike in granule cells from control mice and pilocarpine-treated mice that did not experience <e2>SE</e2> .
D001640_D013226 NONE In Mg(2+)-free bathing medium containing <e1>bicuculline</e1> , conditions designed to increase excitability in the slices , electrical stimulation of the hilus resulted in a single population spike in granule cells from control mice and pilocarpine-treated mice that did not experience <e2>SE</e2> .
D018698_D013226 NONE In <e2>SE</e2> survivors , similar stimulation resulted in a population spike followed , at a variable latency , by negative DC shifts and repetitive afterdischarges of 3 - 60 s duration , which were blocked by ionotropic <e1>glutamate</e1> receptor antagonists .
D018698_D013226 NONE Focal <e1>glutamate</e1> photostimulation of the granule cell layer at sites distant from the recording pipette resulted in population responses of 1 - 30 s duration in slices from <e2>SE</e2> survivors but not other groups .
14765563
D011803_D020922 NONE Although the United States Food and Drug Administration banned its use for <e2>nocturnal leg cramps</e2> due to lack of safety and efficacy , <e1>quinine</e1> is widely available in beverages including tonic water and bitter lemon .
D011803_D002493 NONE Numerous anecdotal reports suggest that products containing <e1>quinine</e1> may produce <e2>neurological complications</e2> , including confusion , altered mental status , seizures , and coma , particularly in older women .
D011803_D003221 CID Numerous anecdotal reports suggest that products containing <e1>quinine</e1> may produce neurological complications , including <e2>confusion</e2> , altered mental status , seizures , and coma , particularly in older women .
D011803_D012640 CID Numerous anecdotal reports suggest that products containing <e1>quinine</e1> may produce neurological complications , including confusion , altered mental status , <e2>seizures</e2> , and coma , particularly in older women .
D011803_D003128 CID Numerous anecdotal reports suggest that products containing <e1>quinine</e1> may produce neurological complications , including confusion , altered mental status , seizures , and <e2>coma</e2> , particularly in older women .
10835440
D009553_D020521 NONE Effect of intravenous <e1>nimodipine</e1> on blood pressure and outcome after <e2>acute stroke</e2> .
D009553_D020521 NONE BACKGROUND AND PURPOSE : The Intravenous <e1>Nimodipine</e1> West European <e2>Stroke</e2> Trial ( INWEST ) found a correlation between nimodipine-induced reduction in blood pressure ( BP ) and an unfavorable outcome in acute stroke .
D009553_D020521 NONE BACKGROUND AND PURPOSE : The Intravenous <e1>Nimodipine</e1> West European Stroke Trial ( INWEST ) found a correlation between nimodipine-induced reduction in blood pressure ( BP ) and an unfavorable outcome in <e2>acute stroke</e2> .
D009553_D020521 NONE BACKGROUND AND PURPOSE : The Intravenous Nimodipine West European <e2>Stroke</e2> Trial ( INWEST ) found a correlation between <e1>nimodipine-induced</e1> reduction in blood pressure ( BP ) and an unfavorable outcome in acute stroke .
D009553_D020521 NONE BACKGROUND AND PURPOSE : The Intravenous Nimodipine West European Stroke Trial ( INWEST ) found a correlation between <e1>nimodipine-induced</e1> reduction in blood pressure ( BP ) and an unfavorable outcome in <e2>acute stroke</e2> .
D009553_D020521 NONE CONCLUSIONS : DBP , but not SBP , reduction was associated with neurological worsening after the intravenous administration of high-dose <e1>nimodipine</e1> after <e2>acute stroke</e2> .
D009553_D007022 CID BACKGROUND AND PURPOSE : The Intravenous <e1>Nimodipine</e1> West European Stroke Trial ( INWEST ) found a correlation between nimodipine-induced <e2>reduction in blood pressure</e2> ( BP ) and an unfavorable outcome in acute stroke .
D009553_D007022 CID BACKGROUND AND PURPOSE : The Intravenous Nimodipine West European Stroke Trial ( INWEST ) found a correlation between <e1>nimodipine-induced</e1> <e2>reduction in blood pressure</e2> ( BP ) and an unfavorable outcome in acute stroke .
D009553_D007022 CID <e1>Nimodipine</e1> treatment resulted in a statistically significant <e2>reduction in systolic BP</e2> ( SBP ) and diastolic BP ( DBP ) from baseline compared with placebo during the first few days .
D009553_D002544 NONE METHODS : Patients with a clinical diagnosis of <e2>ischemic stroke</e2> ( within 24 hours ) were consecutively allocated to receive placebo ( n=100 ) , 1 mg/h ( low-dose ) <e1>nimodipine</e1> ( n=101 ) , or 2 mg/h ( high-dose ) nimodipine ( n=94 ) .
D009553_D002544 NONE METHODS : Patients with a clinical diagnosis of <e2>ischemic stroke</e2> ( within 24 hours ) were consecutively allocated to receive placebo ( n=100 ) , 1 mg/h ( low-dose ) nimodipine ( n=101 ) , or 2 mg/h ( high-dose ) <e1>nimodipine</e1> ( n=94 ) .
18464113
D019259_D006509 NONE <e1>Lamivudine</e1> for the prevention of <e2>hepatitis B</e2> virus reactivation in hepatitis-B surface antigen ( HBSAG ) seropositive cancer patients undergoing cytotoxic chemotherapy .
D019259_D006509 NONE In this study , cancer patients who have solid and hematological malignancies with chronic <e2>HBV infection</e2> received the antiviral agent <e1>lamivudine</e1> prior and during CT compared with historical control group who did not receive lamivudine .
D019259_D006509 NONE In this study , cancer patients who have solid and hematological malignancies with chronic <e2>HBV infection</e2> received the antiviral agent lamivudine prior and during CT compared with historical control group who did not receive <e1>lamivudine</e1> .
D019259_D009369 NONE <e1>Lamivudine</e1> for the prevention of hepatitis B virus reactivation in hepatitis-B surface antigen ( HBSAG ) seropositive <e2>cancer</e2> patients undergoing cytotoxic chemotherapy .
D019259_D009369 NONE In this study , <e2>cancer</e2> patients who have solid and hematological malignancies with chronic HBV infection received the antiviral agent <e1>lamivudine</e1> prior and during CT compared with historical control group who did not receive lamivudine .
D019259_D009369 NONE In this study , <e2>cancer</e2> patients who have solid and hematological malignancies with chronic HBV infection received the antiviral agent lamivudine prior and during CT compared with historical control group who did not receive <e1>lamivudine</e1> .
D019259_D009369 NONE Our study suggests that prophylactic <e1>lamivudine</e1> significantly decreases the incidence of HBV reactivation and overall morbidity in <e2>cancer</e2> patients during and after immunosuppressive therapy .
D006514_D006509 CID Lamivudine for the prevention of <e2>hepatitis B</e2> virus reactivation in <e1>hepatitis-B surface antigen</e1> ( HBSAG ) seropositive cancer patients undergoing cytotoxic chemotherapy .
D006514_D006509 CID Lamivudine for the prevention of <e2>hepatitis B</e2> virus reactivation in hepatitis-B surface antigen ( <e1>HBSAG</e1> ) seropositive cancer patients undergoing cytotoxic chemotherapy .
D006514_D009369 NONE Lamivudine for the prevention of hepatitis B virus reactivation in <e1>hepatitis-B surface antigen</e1> ( HBSAG ) seropositive <e2>cancer</e2> patients undergoing cytotoxic chemotherapy .
D006514_D009369 NONE Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis-B surface antigen ( <e1>HBSAG</e1> ) seropositive <e2>cancer</e2> patients undergoing cytotoxic chemotherapy .
D019259_D019337 NONE In this study , cancer patients who have solid and <e2>hematological malignancies</e2> with chronic HBV infection received the antiviral agent <e1>lamivudine</e1> prior and during CT compared with historical control group who did not receive lamivudine .
D019259_D019337 NONE In this study , cancer patients who have solid and <e2>hematological malignancies</e2> with chronic HBV infection received the antiviral agent lamivudine prior and during CT compared with historical control group who did not receive <e1>lamivudine</e1> .
D019259_D056486 NONE In the prophylactic <e1>lamivudine</e1> group severe <e2>hepatitis</e2> were observed only in 1 patient ( 2.7 % ) of 37 patients ( p < 0.006 ) .
2924746
D002220_D064420 NONE Chronic <e1>carbamazepine</e1> treatment in the rat : efficacy , <e2>toxicity</e2> , and effect on plasma and tissue folate concentrations .
D005492_D064420 NONE Chronic carbamazepine treatment in the rat : efficacy , <e2>toxicity</e2> , and effect on plasma and tissue <e1>folate</e1> concentrations .
D019946_D012640 NONE In the course of developing this model , a common vehicle , <e1>propylene glycol</e1> , by itself in high doses , was found to exhibit protective properties against induced <e2>seizures</e2> and inhibited weight gain .
D019946_D015430 NONE In the course of developing this model , a common vehicle , <e1>propylene glycol</e1> , by itself in high doses , was found to exhibit protective properties against induced seizures and inhibited <e2>weight gain</e2> .
D005481_D012640 CID <e2>Seizures</e2> induced by <e1>hexafluorodiethyl ether</e1> ( HFDE ) were also found to be a more sensitive measure of protection by CBZ than seizures induced by maximal electroshock ( MES ) .
D005481_D012640 CID Seizures induced by <e1>hexafluorodiethyl ether</e1> ( HFDE ) were also found to be a more sensitive measure of protection by CBZ than <e2>seizures</e2> induced by maximal electroshock ( MES ) .
D005481_D012640 CID <e2>Seizures</e2> induced by hexafluorodiethyl ether ( <e1>HFDE</e1> ) were also found to be a more sensitive measure of protection by CBZ than seizures induced by maximal electroshock ( MES ) .
D005481_D012640 CID Seizures induced by hexafluorodiethyl ether ( <e1>HFDE</e1> ) were also found to be a more sensitive measure of protection by CBZ than <e2>seizures</e2> induced by maximal electroshock ( MES ) .
D005481_D012640 CID Oral administration of CBZ as an aqueous suspension every 8 h at a dose of 250 mg/kg was continuously protective against <e1>HFDE-induced</e1> <e2>seizures</e2> and was minimally toxic as measured by weight gain over 8 weeks of treatment .
D002220_D012640 NONE <e2>Seizures</e2> induced by hexafluorodiethyl ether ( HFDE ) were also found to be a more sensitive measure of protection by <e1>CBZ</e1> than seizures induced by maximal electroshock ( MES ) .
D002220_D012640 NONE Seizures induced by hexafluorodiethyl ether ( HFDE ) were also found to be a more sensitive measure of protection by <e1>CBZ</e1> than <e2>seizures</e2> induced by maximal electroshock ( MES ) .
D002220_D012640 NONE Oral administration of <e1>CBZ</e1> as an aqueous suspension every 8 h at a dose of 250 mg/kg was continuously protective against HFDE-induced <e2>seizures</e2> and was minimally toxic as measured by weight gain over 8 weeks of treatment .
D002220_D015430 NONE Oral administration of <e1>CBZ</e1> as an aqueous suspension every 8 h at a dose of 250 mg/kg was continuously protective against HFDE-induced seizures and was minimally toxic as measured by <e2>weight gain</e2> over 8 weeks of treatment .
D005481_D015430 NONE Oral administration of CBZ as an aqueous suspension every 8 h at a dose of 250 mg/kg was continuously protective against <e1>HFDE-induced</e1> seizures and was minimally toxic as measured by <e2>weight gain</e2> over 8 weeks of treatment .
2224762
C027260_D009369 NONE A Phase I study of intravenous ( IV ) bolus <e1>4'-0-tetrahydropyranyladriamycin</e1> ( Pirarubicin ) was done in 55 patients in good performance status with refractory <e2>tumors</e2> .
C027260_D009369 NONE A Phase I study of intravenous ( IV ) bolus 4'-0-tetrahydropyranyladriamycin ( <e1>Pirarubicin</e1> ) was done in 55 patients in good performance status with refractory <e2>tumors</e2> .
10721819
D007545_D013610 NONE Effects of long-term pretreatment with <e1>isoproterenol</e1> on bromocriptine-induced <e2>tachycardia</e2> in conscious rats .
D007545_D013610 NONE It has been shown that bromocriptine-induced <e2>tachycardia</e2> , which persisted after adrenalectomy , is ( i ) mediated by central dopamine D2 receptor activation and ( ii ) reduced by 5-day <e1>isoproterenol</e1> pretreatment , supporting therefore the hypothesis that this effect is dependent on sympathetic outflow to the heart .
D007545_D013610 NONE This study was conducted to examine whether prolonged pretreatment with <e1>isoproterenol</e1> could abolish bromocriptine-induced <e2>tachycardia</e2> in conscious rats .
D007545_D013610 NONE Bromocriptine-induced hypotension was unaffected by <e1>isoproterenol</e1> pretreatment , while <e2>tachycardia</e2> was reversed to significant bradycardia , an effect that was partly reduced by i.v. domperidone ( 0.5 mg/kg ) .
D007545_D013610 NONE These results show that 15-day <e1>isoproterenol</e1> pretreatment not only abolished but reversed bromocriptine-induced <e2>tachycardia</e2> to bradycardia , an effect that is mainly related to further cardiac beta-adrenoceptor desensitization rather than to impairment of autonomic regulation of the heart .
D001971_D013610 CID Effects of long-term pretreatment with isoproterenol on <e1>bromocriptine-induced</e1> <e2>tachycardia</e2> in conscious rats .
D001971_D013610 CID It has been shown that <e1>bromocriptine-induced</e1> <e2>tachycardia</e2> , which persisted after adrenalectomy , is ( i ) mediated by central dopamine D2 receptor activation and ( ii ) reduced by 5-day isoproterenol pretreatment , supporting therefore the hypothesis that this effect is dependent on sympathetic outflow to the heart .
D001971_D013610 CID This study was conducted to examine whether prolonged pretreatment with isoproterenol could abolish <e1>bromocriptine-induced</e1> <e2>tachycardia</e2> in conscious rats .
D001971_D013610 CID In control rats , intravenous <e1>bromocriptine</e1> ( 150 microg/kg ) induced significant hypotension and <e2>tachycardia</e2> .
D001971_D013610 CID <e1>Bromocriptine-induced</e1> hypotension was unaffected by isoproterenol pretreatment , while <e2>tachycardia</e2> was reversed to significant bradycardia , an effect that was partly reduced by i.v. domperidone ( 0.5 mg/kg ) .
D001971_D013610 CID These results show that 15-day isoproterenol pretreatment not only abolished but reversed <e1>bromocriptine-induced</e1> <e2>tachycardia</e2> to bradycardia , an effect that is mainly related to further cardiac beta-adrenoceptor desensitization rather than to impairment of autonomic regulation of the heart .
D001971_D013610 CID They suggest that , in normal conscious rats , the central <e2>tachycardia</e2> of <e1>bromocriptine</e1> appears to predominate and to mask the bradycardia of this agonist at peripheral dopamine D2 receptors .
D004298_D013610 NONE It has been shown that bromocriptine-induced <e2>tachycardia</e2> , which persisted after adrenalectomy , is ( i ) mediated by central <e1>dopamine</e1> D2 receptor activation and ( ii ) reduced by 5-day isoproterenol pretreatment , supporting therefore the hypothesis that this effect is dependent on sympathetic outflow to the heart .
D004298_D013610 NONE They suggest that , in normal conscious rats , the central <e2>tachycardia</e2> of bromocriptine appears to predominate and to mask the bradycardia of this agonist at peripheral <e1>dopamine</e1> D2 receptors .
D007545_D006332 CID <e1>Isoproterenol</e1> pretreatment for 15 days caused <e2>cardiac hypertrophy</e2> without affecting baseline blood pressure and heart rate .
D001971_D007022 CID In control rats , intravenous <e1>bromocriptine</e1> ( 150 microg/kg ) induced significant <e2>hypotension</e2> and tachycardia .
D001971_D007022 CID <e1>Bromocriptine-induced</e1> <e2>hypotension</e2> was unaffected by isoproterenol pretreatment , while tachycardia was reversed to significant bradycardia , an effect that was partly reduced by i.v. domperidone ( 0.5 mg/kg ) .
D001971_D001919 NONE <e1>Bromocriptine-induced</e1> hypotension was unaffected by isoproterenol pretreatment , while tachycardia was reversed to significant <e2>bradycardia</e2> , an effect that was partly reduced by i.v. domperidone ( 0.5 mg/kg ) .
D001971_D001919 NONE These results show that 15-day isoproterenol pretreatment not only abolished but reversed <e1>bromocriptine-induced</e1> tachycardia to <e2>bradycardia</e2> , an effect that is mainly related to further cardiac beta-adrenoceptor desensitization rather than to impairment of autonomic regulation of the heart .
D001971_D001919 NONE They suggest that , in normal conscious rats , the central tachycardia of <e1>bromocriptine</e1> appears to predominate and to mask the <e2>bradycardia</e2> of this agonist at peripheral dopamine D2 receptors .
D007545_D007022 NONE Bromocriptine-induced <e2>hypotension</e2> was unaffected by <e1>isoproterenol</e1> pretreatment , while tachycardia was reversed to significant bradycardia , an effect that was partly reduced by i.v. domperidone ( 0.5 mg/kg ) .
D007545_D001919 CID Bromocriptine-induced hypotension was unaffected by <e1>isoproterenol</e1> pretreatment , while tachycardia was reversed to significant <e2>bradycardia</e2> , an effect that was partly reduced by i.v. domperidone ( 0.5 mg/kg ) .
D007545_D001919 CID These results show that 15-day <e1>isoproterenol</e1> pretreatment not only abolished but reversed bromocriptine-induced tachycardia to <e2>bradycardia</e2> , an effect that is mainly related to further cardiac beta-adrenoceptor desensitization rather than to impairment of autonomic regulation of the heart .
D004294_D007022 NONE Bromocriptine-induced <e2>hypotension</e2> was unaffected by isoproterenol pretreatment , while tachycardia was reversed to significant bradycardia , an effect that was partly reduced by i.v. <e1>domperidone</e1> ( 0.5 mg/kg ) .
D004294_D013610 NONE Bromocriptine-induced hypotension was unaffected by isoproterenol pretreatment , while <e2>tachycardia</e2> was reversed to significant bradycardia , an effect that was partly reduced by i.v. <e1>domperidone</e1> ( 0.5 mg/kg ) .
D004294_D001919 CID Bromocriptine-induced hypotension was unaffected by isoproterenol pretreatment , while tachycardia was reversed to significant <e2>bradycardia</e2> , an effect that was partly reduced by i.v. <e1>domperidone</e1> ( 0.5 mg/kg ) .
D004298_D001919 NONE They suggest that , in normal conscious rats , the central tachycardia of bromocriptine appears to predominate and to mask the <e2>bradycardia</e2> of this agonist at peripheral <e1>dopamine</e1> D2 receptors .
18754075
D004164_D011507 NONE Massive <e2>proteinuria</e2> and acute renal failure after oral <e1>bisphosphonate</e1> ( alendronate ) administration in a patient with focal segmental glomerulosclerosis .
D004164_D011507 NONE This report demonstrates that not only intravenous , but also oral <e1>bisphosphonates</e1> can aggravate <e2>proteinuria</e2> and acute renal failure .
D004164_D058186 NONE Massive proteinuria and <e2>acute renal failure</e2> after oral <e1>bisphosphonate</e1> ( alendronate ) administration in a patient with focal segmental glomerulosclerosis .
D004164_D058186 NONE The amount of daily urinary protein decreased from 15.6 to 2.8 g. Within 14 days of the oral <e1>bisphosphonate</e1> ( alendronate sodium ) administration , the amount of daily urinary protein increased rapidly up to 12.8 g with <e2>acute renal failure</e2> .
D004164_D058186 NONE This report demonstrates that not only intravenous , but also oral <e1>bisphosphonates</e1> can aggravate proteinuria and <e2>acute renal failure</e2> .
D004164_D005923 NONE Massive proteinuria and acute renal failure after oral <e1>bisphosphonate</e1> ( alendronate ) administration in a patient with <e2>focal segmental glomerulosclerosis</e2> .
D019386_D011507 CID Massive <e2>proteinuria</e2> and acute renal failure after oral bisphosphonate ( <e1>alendronate</e1> ) administration in a patient with focal segmental glomerulosclerosis .
D019386_D058186 CID Massive proteinuria and <e2>acute renal failure</e2> after oral bisphosphonate ( <e1>alendronate</e1> ) administration in a patient with focal segmental glomerulosclerosis .
D019386_D058186 CID The amount of daily urinary protein decreased from 15.6 to 2.8 g. Within 14 days of the oral bisphosphonate ( <e1>alendronate sodium</e1> ) administration , the amount of daily urinary protein increased rapidly up to 12.8 g with <e2>acute renal failure</e2> .
D019386_D005923 NONE Massive proteinuria and acute renal failure after oral bisphosphonate ( <e1>alendronate</e1> ) administration in a patient with <e2>focal segmental glomerulosclerosis</e2> .
D013256_D009404 NONE A 61-year-old Japanese man with <e2>nephrotic syndrome</e2> due to focal segmental glomerulosclerosis was initially responding well to <e1>steroid</e1> therapy .
D013256_D005923 NONE A 61-year-old Japanese man with nephrotic syndrome due to <e2>focal segmental glomerulosclerosis</e2> was initially responding well to <e1>steroid</e1> therapy .
6747681
D002330_D005910 NONE Intra-arterial <e1>BCNU</e1> chemotherapy for treatment of <e2>malignant gliomas</e2> of the central nervous system .
D002330_D005910 NONE Because of the rapid systemic clearance of <e1>BCNU</e1> ( 1,3-bis-(2-chloroethyl)-1-nitrosourea ) , intra-arterial administration should provide a substantial advantage over intravenous administration for the treatment of <e2>malignant gliomas</e2> .
D002330_D005910 NONE Because of the rapid systemic clearance of BCNU ( <e1>1,3-bis-(2-chloroethyl)-1-nitrosourea</e1> ) , intra-arterial administration should provide a substantial advantage over intravenous administration for the treatment of <e2>malignant gliomas</e2> .
D002330_D001254 NONE Twenty-four patients with recurrent Grade I to IV <e2>astrocytomas</e2> , whose resection and irradiation therapy had failed , received two to eight courses of intra-arterial <e1>BCNU</e1> therapy .
D000431_D014786 NONE The frequency of <e2>visual loss</e2> decreased after the concentration of the <e1>ethanol</e1> diluent was lowered .
2522601
D002220_D004342 CID <e2>Hypersensitivity</e2> to <e1>carbamazepine</e1> presenting with a leukemoid reaction , eosinophilia , erythroderma , and renal failure .
D002220_D004342 CID We report a patient in whom <e2>hypersensitivity</e2> to <e1>carbamazepine</e1> presented with generalized erythroderma , a severe leukemoid reaction , eosinophilia , hyponatremia , and renal failure .
D002220_D007955 CID Hypersensitivity to <e1>carbamazepine</e1> presenting with a <e2>leukemoid reaction</e2> , eosinophilia , erythroderma , and renal failure .
D002220_D007955 CID We report a patient in whom hypersensitivity to <e1>carbamazepine</e1> presented with generalized erythroderma , a severe <e2>leukemoid reaction</e2> , eosinophilia , hyponatremia , and renal failure .
D002220_D004802 NONE Hypersensitivity to <e1>carbamazepine</e1> presenting with a leukemoid reaction , <e2>eosinophilia</e2> , erythroderma , and renal failure .
D002220_D004802 NONE We report a patient in whom hypersensitivity to <e1>carbamazepine</e1> presented with generalized erythroderma , a severe leukemoid reaction , <e2>eosinophilia</e2> , hyponatremia , and renal failure .
D002220_D003873 CID Hypersensitivity to <e1>carbamazepine</e1> presenting with a leukemoid reaction , eosinophilia , <e2>erythroderma</e2> , and renal failure .
D002220_D003873 CID We report a patient in whom hypersensitivity to <e1>carbamazepine</e1> presented with generalized <e2>erythroderma</e2> , a severe leukemoid reaction , eosinophilia , hyponatremia , and renal failure .
D002220_D051437 CID Hypersensitivity to <e1>carbamazepine</e1> presenting with a leukemoid reaction , eosinophilia , erythroderma , and <e2>renal failure</e2> .
D002220_D051437 CID We report a patient in whom hypersensitivity to <e1>carbamazepine</e1> presented with generalized erythroderma , a severe leukemoid reaction , eosinophilia , hyponatremia , and <e2>renal failure</e2> .
D002220_D007010 CID We report a patient in whom hypersensitivity to <e1>carbamazepine</e1> presented with generalized erythroderma , a severe leukemoid reaction , eosinophilia , <e2>hyponatremia</e2> , and renal failure .
11426838
-1_D012640 NONE In behavioral studies , pre-treatment of mice with <e1>BD1018</e1> , BD1063 , or LR132 significantly attenuated cocaine-induced <e2>convulsions</e2> and lethality .
-1_D012640 NONE In behavioral studies , pre-treatment of mice with BD1018 , BD1063 , or <e1>LR132</e1> significantly attenuated cocaine-induced <e2>convulsions</e2> and lethality .
C093337_D012640 NONE In behavioral studies , pre-treatment of mice with BD1018 , <e1>BD1063</e1> , or LR132 significantly attenuated cocaine-induced <e2>convulsions</e2> and lethality .
D003042_D012640 CID In behavioral studies , pre-treatment of mice with BD1018 , BD1063 , or LR132 significantly attenuated <e1>cocaine-induced</e1> <e2>convulsions</e2> and lethality .
D003042_D012640 CID To further validate the hypothesis that the <e1>anti-cocaine</e1> effects of the novel ligands involved antagonism of sigma receptors , an antisense oligodeoxynucleotide against sigma1 receptors was also shown to significantly attenuate the <e2>convulsive</e2> and locomotor stimulatory effects of cocaine .
D003042_D012640 CID To further validate the hypothesis that the anti-cocaine effects of the novel ligands involved antagonism of sigma receptors , an antisense oligodeoxynucleotide against sigma1 receptors was also shown to significantly attenuate the <e2>convulsive</e2> and locomotor stimulatory effects of <e1>cocaine</e1> .
C050232_D064420 NONE In contrast to the protection provided by the putative antagonists , the well-characterized sigma receptor agonist <e1>di-o-tolylguanidine</e1> ( DTG ) and the novel sigma receptor agonist BD1031 ( 3R-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane ) each worsened the behavioral <e2>toxicity</e2> of cocaine .
C050232_D064420 NONE In contrast to the protection provided by the putative antagonists , the well-characterized sigma receptor agonist di-o-tolylguanidine ( <e1>DTG</e1> ) and the novel sigma receptor agonist BD1031 ( 3R-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane ) each worsened the behavioral <e2>toxicity</e2> of cocaine .
-1_D064420 NONE In contrast to the protection provided by the putative antagonists , the well-characterized sigma receptor agonist di-o-tolylguanidine ( DTG ) and the novel sigma receptor agonist <e1>BD1031</e1> ( 3R-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane ) each worsened the behavioral <e2>toxicity</e2> of cocaine .
-1_D064420 NONE In contrast to the protection provided by the putative antagonists , the well-characterized sigma receptor agonist di-o-tolylguanidine ( DTG ) and the novel sigma receptor agonist BD1031 ( <e1>3R-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane</e1> ) each worsened the behavioral <e2>toxicity</e2> of cocaine .
D003042_D064420 NONE In contrast to the protection provided by the putative antagonists , the well-characterized sigma receptor agonist di-o-tolylguanidine ( DTG ) and the novel sigma receptor agonist BD1031 ( 3R-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane ) each worsened the behavioral <e2>toxicity</e2> of <e1>cocaine</e1> .
D009838_D012640 NONE To further validate the hypothesis that the anti-cocaine effects of the novel ligands involved antagonism of sigma receptors , an antisense <e1>oligodeoxynucleotide</e1> against sigma1 receptors was also shown to significantly attenuate the <e2>convulsive</e2> and locomotor stimulatory effects of cocaine .
19957053
D010656_D002534 CID <e1>Phenylephrine</e1> but not ephedrine <e2>reduces frontal lobe oxygenation</e2> following anesthesia-induced hypotension .
D010656_D007022 NONE <e1>Phenylephrine</e1> but not ephedrine reduces frontal lobe oxygenation following anesthesia-induced <e2>hypotension</e2> .
D010656_D007022 NONE We describe the effect of <e1>phenylephrine</e1> and ephedrine on frontal lobe oxygenation ( S(c)O(2 ) ) following anesthesia-induced <e2>hypotension</e2> .
D010656_D007022 NONE CONCLUSIONS : The utilization of <e1>phenylephrine</e1> to correct <e2>hypotension</e2> induced by anesthesia has a negative impact on S(c)O(2 ) while ephedrine maintains frontal lobe oxygenation potentially related to an increase in CO .
D004809_D002534 NONE Phenylephrine but not <e1>ephedrine</e1> <e2>reduces frontal lobe oxygenation</e2> following anesthesia-induced hypotension .
D004809_D007022 NONE Phenylephrine but not <e1>ephedrine</e1> reduces frontal lobe oxygenation following anesthesia-induced <e2>hypotension</e2> .
D004809_D007022 NONE We describe the effect of phenylephrine and <e1>ephedrine</e1> on frontal lobe oxygenation ( S(c)O(2 ) ) following anesthesia-induced <e2>hypotension</e2> .
D004809_D007022 NONE CONCLUSIONS : The utilization of phenylephrine to correct <e2>hypotension</e2> induced by anesthesia has a negative impact on S(c)O(2 ) while <e1>ephedrine</e1> maintains frontal lobe oxygenation potentially related to an increase in CO .
12684739
D020888_D019966 NONE OBJECTIVES : Given its preclinical success for treating <e2>substance abuse</e2> and the increased risk of visual field defects ( VFD ) associated with cumulative lifetime exposure , we explored the effects of sub-chronic low dose <e1>GVG</e1> on cocaine-induced increases in nucleus accumbens ( NAcc ) dopamine ( DA ) .
D020888_D005128 CID OBJECTIVES : Given its preclinical success for treating substance abuse and the increased risk of <e2>visual field defects</e2> ( VFD ) associated with cumulative lifetime exposure , we explored the effects of sub-chronic low dose <e1>GVG</e1> on cocaine-induced increases in nucleus accumbens ( NAcc ) dopamine ( DA ) .
D020888_D005128 CID OBJECTIVES : Given its preclinical success for treating substance abuse and the increased risk of visual field defects ( <e2>VFD</e2> ) associated with cumulative lifetime exposure , we explored the effects of sub-chronic low dose <e1>GVG</e1> on cocaine-induced increases in nucleus accumbens ( NAcc ) dopamine ( DA ) .
D003042_D019966 NONE OBJECTIVES : Given its preclinical success for treating <e2>substance abuse</e2> and the increased risk of visual field defects ( VFD ) associated with cumulative lifetime exposure , we explored the effects of sub-chronic low dose GVG on <e1>cocaine-induced</e1> increases in nucleus accumbens ( NAcc ) dopamine ( DA ) .
D003042_D005128 NONE OBJECTIVES : Given its preclinical success for treating substance abuse and the increased risk of <e2>visual field defects</e2> ( VFD ) associated with cumulative lifetime exposure , we explored the effects of sub-chronic low dose GVG on <e1>cocaine-induced</e1> increases in nucleus accumbens ( NAcc ) dopamine ( DA ) .
D003042_D005128 NONE OBJECTIVES : Given its preclinical success for treating substance abuse and the increased risk of visual field defects ( <e2>VFD</e2> ) associated with cumulative lifetime exposure , we explored the effects of sub-chronic low dose GVG on <e1>cocaine-induced</e1> increases in nucleus accumbens ( NAcc ) dopamine ( DA ) .
D004298_D019966 NONE OBJECTIVES : Given its preclinical success for treating <e2>substance abuse</e2> and the increased risk of visual field defects ( VFD ) associated with cumulative lifetime exposure , we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens ( NAcc ) <e1>dopamine</e1> ( DA ) .
D004298_D019966 NONE OBJECTIVES : Given its preclinical success for treating <e2>substance abuse</e2> and the increased risk of visual field defects ( VFD ) associated with cumulative lifetime exposure , we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens ( NAcc ) dopamine ( <e1>DA</e1> ) .
D004298_D005128 NONE OBJECTIVES : Given its preclinical success for treating substance abuse and the increased risk of <e2>visual field defects</e2> ( VFD ) associated with cumulative lifetime exposure , we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens ( NAcc ) <e1>dopamine</e1> ( DA ) .
D004298_D005128 NONE OBJECTIVES : Given its preclinical success for treating substance abuse and the increased risk of visual field defects ( <e2>VFD</e2> ) associated with cumulative lifetime exposure , we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens ( NAcc ) <e1>dopamine</e1> ( DA ) .
D004298_D005128 NONE OBJECTIVES : Given its preclinical success for treating substance abuse and the increased risk of <e2>visual field defects</e2> ( VFD ) associated with cumulative lifetime exposure , we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens ( NAcc ) dopamine ( <e1>DA</e1> ) .
D004298_D005128 NONE OBJECTIVES : Given its preclinical success for treating substance abuse and the increased risk of visual field defects ( <e2>VFD</e2> ) associated with cumulative lifetime exposure , we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens ( NAcc ) dopamine ( <e1>DA</e1> ) .
17919553
C106791_D056486 CID Acute <e2>hepatitis</e2> attack after exposure to <e1>telithromycin</e1> .
C106791_D056486 CID The patient had suffered a previous episode of " acute <e2>hepatitis</e2> of unknown origin , " that occurred after <e1>telithromycin</e1> usage .
C106791_D056486 CID Based on a score of 8 on the Naranjo adverse drug reaction probability scale , <e1>telithromycin</e1> was the probable cause of acute <e2>hepatitis</e2> in this patient , and pathological findings suggested drug-induced toxic hepatitis .
C106791_D056486 CID Based on a score of 8 on the Naranjo adverse drug reaction probability scale , <e1>telithromycin</e1> was the probable cause of acute hepatitis in this patient , and pathological findings suggested drug-induced <e2>toxic hepatitis</e2> .
C106791_D056486 CID Recurrence of <e2>hepatitis</e2> attack might have been avoided if the initial incident had been communicated to the attending physician who prescribed <e1>telithromycin</e1> the second time .
C106791_D056486 CID CONCLUSION : Here we report a case of acute <e2>hepatitis</e2> probably associated with the administration of <e1>telithromycin</e1> .
C106791_D012141 NONE He had been prescribed <e1>telithromycin</e1> 400 mg/d PO to treat an <e2>upper respiratory tract infection</e2> 7 days prior .
C106791_D064420 NONE Based on a score of 8 on the Naranjo <e2>adverse drug reaction</e2> probability scale , <e1>telithromycin</e1> was the probable cause of acute hepatitis in this patient , and pathological findings suggested drug-induced toxic hepatitis .
7248170
D010634_D006529 CID <e1>Phenobarbitone-induced</e1> <e2>enlargement of the liver</e2> in the rat : its relationship to carbon tetrachloride-induced cirrhosis .
D010634_D006529 CID The yield of severe cirrhosis of the liver ( defined as a shrunken finely nodular liver with micronodular histology , ascites greater than 30 ml , plasma albumin less than 2.2 g/dl , splenomegaly 2 - 3 times normal , and testicular atrophy approximately half normal weight ) after 12 doses of carbon tetrachloride given intragastrically in the <e1>phenobarbitone-primed</e1> rat was increased from 25 % to 56 % by giving the initial " calibrating " dose of carbon tetrachloride at the peak of the phenobarbitone-induced <e2>enlargement of the liver</e2> .
D010634_D006529 CID The yield of severe cirrhosis of the liver ( defined as a shrunken finely nodular liver with micronodular histology , ascites greater than 30 ml , plasma albumin less than 2.2 g/dl , splenomegaly 2 - 3 times normal , and testicular atrophy approximately half normal weight ) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25 % to 56 % by giving the initial " calibrating " dose of carbon tetrachloride at the peak of the <e1>phenobarbitone-induced</e1> <e2>enlargement of the liver</e2> .
D010634_D005355 NONE <e1>Phenobarbitone-induced</e1> enlargement of the liver in the rat : its relationship to carbon tetrachloride-induced <e2>cirrhosis</e2> .
D002251_D006529 NONE Phenobarbitone-induced <e2>enlargement of the liver</e2> in the rat : its relationship to <e1>carbon tetrachloride-induced</e1> cirrhosis .
D002251_D006529 NONE The yield of severe cirrhosis of the liver ( defined as a shrunken finely nodular liver with micronodular histology , ascites greater than 30 ml , plasma albumin less than 2.2 g/dl , splenomegaly 2 - 3 times normal , and testicular atrophy approximately half normal weight ) after 12 doses of <e1>carbon tetrachloride</e1> given intragastrically in the phenobarbitone-primed rat was increased from 25 % to 56 % by giving the initial " calibrating " dose of carbon tetrachloride at the peak of the phenobarbitone-induced <e2>enlargement of the liver</e2> .
D002251_D006529 NONE The yield of severe cirrhosis of the liver ( defined as a shrunken finely nodular liver with micronodular histology , ascites greater than 30 ml , plasma albumin less than 2.2 g/dl , splenomegaly 2 - 3 times normal , and testicular atrophy approximately half normal weight ) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25 % to 56 % by giving the initial " calibrating " dose of <e1>carbon tetrachloride</e1> at the peak of the phenobarbitone-induced <e2>enlargement of the liver</e2> .
D002251_D005355 NONE Phenobarbitone-induced enlargement of the liver in the rat : its relationship to <e1>carbon tetrachloride-induced</e1> <e2>cirrhosis</e2> .
D002251_D008103 CID The yield of severe <e2>cirrhosis of the liver</e2> ( defined as a shrunken finely nodular liver with micronodular histology , ascites greater than 30 ml , plasma albumin less than 2.2 g/dl , splenomegaly 2 - 3 times normal , and testicular atrophy approximately half normal weight ) after 12 doses of <e1>carbon tetrachloride</e1> given intragastrically in the phenobarbitone-primed rat was increased from 25 % to 56 % by giving the initial " calibrating " dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver .
D002251_D008103 CID The yield of severe <e2>cirrhosis of the liver</e2> ( defined as a shrunken finely nodular liver with micronodular histology , ascites greater than 30 ml , plasma albumin less than 2.2 g/dl , splenomegaly 2 - 3 times normal , and testicular atrophy approximately half normal weight ) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25 % to 56 % by giving the initial " calibrating " dose of <e1>carbon tetrachloride</e1> at the peak of the phenobarbitone-induced enlargement of the liver .
D002251_D001201 NONE The yield of severe cirrhosis of the liver ( defined as a shrunken finely nodular liver with micronodular histology , <e2>ascites</e2> greater than 30 ml , plasma albumin less than 2.2 g/dl , splenomegaly 2 - 3 times normal , and testicular atrophy approximately half normal weight ) after 12 doses of <e1>carbon tetrachloride</e1> given intragastrically in the phenobarbitone-primed rat was increased from 25 % to 56 % by giving the initial " calibrating " dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver .
D002251_D001201 NONE The yield of severe cirrhosis of the liver ( defined as a shrunken finely nodular liver with micronodular histology , <e2>ascites</e2> greater than 30 ml , plasma albumin less than 2.2 g/dl , splenomegaly 2 - 3 times normal , and testicular atrophy approximately half normal weight ) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25 % to 56 % by giving the initial " calibrating " dose of <e1>carbon tetrachloride</e1> at the peak of the phenobarbitone-induced enlargement of the liver .
D002251_D013163 NONE The yield of severe cirrhosis of the liver ( defined as a shrunken finely nodular liver with micronodular histology , ascites greater than 30 ml , plasma albumin less than 2.2 g/dl , <e2>splenomegaly</e2> 2 - 3 times normal , and testicular atrophy approximately half normal weight ) after 12 doses of <e1>carbon tetrachloride</e1> given intragastrically in the phenobarbitone-primed rat was increased from 25 % to 56 % by giving the initial " calibrating " dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver .
D002251_D013163 NONE The yield of severe cirrhosis of the liver ( defined as a shrunken finely nodular liver with micronodular histology , ascites greater than 30 ml , plasma albumin less than 2.2 g/dl , <e2>splenomegaly</e2> 2 - 3 times normal , and testicular atrophy approximately half normal weight ) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25 % to 56 % by giving the initial " calibrating " dose of <e1>carbon tetrachloride</e1> at the peak of the phenobarbitone-induced enlargement of the liver .
D002251_D001284 NONE The yield of severe cirrhosis of the liver ( defined as a shrunken finely nodular liver with micronodular histology , ascites greater than 30 ml , plasma albumin less than 2.2 g/dl , splenomegaly 2 - 3 times normal , and testicular <e2>atrophy</e2> approximately half normal weight ) after 12 doses of <e1>carbon tetrachloride</e1> given intragastrically in the phenobarbitone-primed rat was increased from 25 % to 56 % by giving the initial " calibrating " dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver .
D002251_D001284 NONE The yield of severe cirrhosis of the liver ( defined as a shrunken finely nodular liver with micronodular histology , ascites greater than 30 ml , plasma albumin less than 2.2 g/dl , splenomegaly 2 - 3 times normal , and testicular <e2>atrophy</e2> approximately half normal weight ) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25 % to 56 % by giving the initial " calibrating " dose of <e1>carbon tetrachloride</e1> at the peak of the phenobarbitone-induced enlargement of the liver .
D010634_D008103 CID The yield of severe <e2>cirrhosis of the liver</e2> ( defined as a shrunken finely nodular liver with micronodular histology , ascites greater than 30 ml , plasma albumin less than 2.2 g/dl , splenomegaly 2 - 3 times normal , and testicular atrophy approximately half normal weight ) after 12 doses of carbon tetrachloride given intragastrically in the <e1>phenobarbitone-primed</e1> rat was increased from 25 % to 56 % by giving the initial " calibrating " dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver .
D010634_D008103 CID The yield of severe <e2>cirrhosis of the liver</e2> ( defined as a shrunken finely nodular liver with micronodular histology , ascites greater than 30 ml , plasma albumin less than 2.2 g/dl , splenomegaly 2 - 3 times normal , and testicular atrophy approximately half normal weight ) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25 % to 56 % by giving the initial " calibrating " dose of carbon tetrachloride at the peak of the <e1>phenobarbitone-induced</e1> enlargement of the liver .
D010634_D001201 NONE The yield of severe cirrhosis of the liver ( defined as a shrunken finely nodular liver with micronodular histology , <e2>ascites</e2> greater than 30 ml , plasma albumin less than 2.2 g/dl , splenomegaly 2 - 3 times normal , and testicular atrophy approximately half normal weight ) after 12 doses of carbon tetrachloride given intragastrically in the <e1>phenobarbitone-primed</e1> rat was increased from 25 % to 56 % by giving the initial " calibrating " dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver .
D010634_D001201 NONE The yield of severe cirrhosis of the liver ( defined as a shrunken finely nodular liver with micronodular histology , <e2>ascites</e2> greater than 30 ml , plasma albumin less than 2.2 g/dl , splenomegaly 2 - 3 times normal , and testicular atrophy approximately half normal weight ) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25 % to 56 % by giving the initial " calibrating " dose of carbon tetrachloride at the peak of the <e1>phenobarbitone-induced</e1> enlargement of the liver .
D010634_D013163 NONE The yield of severe cirrhosis of the liver ( defined as a shrunken finely nodular liver with micronodular histology , ascites greater than 30 ml , plasma albumin less than 2.2 g/dl , <e2>splenomegaly</e2> 2 - 3 times normal , and testicular atrophy approximately half normal weight ) after 12 doses of carbon tetrachloride given intragastrically in the <e1>phenobarbitone-primed</e1> rat was increased from 25 % to 56 % by giving the initial " calibrating " dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver .
D010634_D013163 NONE The yield of severe cirrhosis of the liver ( defined as a shrunken finely nodular liver with micronodular histology , ascites greater than 30 ml , plasma albumin less than 2.2 g/dl , <e2>splenomegaly</e2> 2 - 3 times normal , and testicular atrophy approximately half normal weight ) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25 % to 56 % by giving the initial " calibrating " dose of carbon tetrachloride at the peak of the <e1>phenobarbitone-induced</e1> enlargement of the liver .
D010634_D001284 NONE The yield of severe cirrhosis of the liver ( defined as a shrunken finely nodular liver with micronodular histology , ascites greater than 30 ml , plasma albumin less than 2.2 g/dl , splenomegaly 2 - 3 times normal , and testicular <e2>atrophy</e2> approximately half normal weight ) after 12 doses of carbon tetrachloride given intragastrically in the <e1>phenobarbitone-primed</e1> rat was increased from 25 % to 56 % by giving the initial " calibrating " dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver .
D010634_D001284 NONE The yield of severe cirrhosis of the liver ( defined as a shrunken finely nodular liver with micronodular histology , ascites greater than 30 ml , plasma albumin less than 2.2 g/dl , splenomegaly 2 - 3 times normal , and testicular <e2>atrophy</e2> approximately half normal weight ) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25 % to 56 % by giving the initial " calibrating " dose of carbon tetrachloride at the peak of the <e1>phenobarbitone-induced</e1> enlargement of the liver .
17242861
D010862_D012640 NONE QTLs for susceptibility to <e1>pilocarpine-induced</e1> <e2>seizures</e2> , a model of temporal lobe epilepsy , have not been reported , and CSS have not previously been used to localize seizure susceptibility genes .
D010862_D012640 NONE QTLs for susceptibility to <e1>pilocarpine-induced</e1> seizures , a model of temporal lobe epilepsy , have not been reported , and CSS have not previously been used to localize <e2>seizure</e2> susceptibility genes .
D010862_D012640 NONE We report QTLs identified using a B6 ( host ) x A/J ( donor ) CSS panel to localize genes involved in susceptibility to <e1>pilocarpine-induced</e1> <e2>seizures</e2> .
D010862_D012640 NONE Three hundred fifty-five adult male CSS mice , 58 B6 , and 39 A/J were tested for susceptibility to <e1>pilocarpine-induced</e1> <e2>seizures</e2> .
D010862_D004833 CID QTLs for susceptibility to <e1>pilocarpine-induced</e1> seizures , a model of <e2>temporal lobe epilepsy</e2> , have not been reported , and CSS have not previously been used to localize seizure susceptibility genes .
15278670
C009250_D012640 NONE The effects of <e1>sevoflurane</e1> on lidocaine-induced <e2>convulsions</e2> .
C009250_D012640 NONE The influence of <e1>sevoflurane</e1> on lidocaine-induced <e2>convulsions</e2> was studied in cats .
C009250_D012640 NONE The <e2>convulsive</e2> threshold ( mean +/- SD ) was 41.4 +/- 6.5 mg. l(-1 ) with lidocaine infusion ( 6 mg.kg(-1).min(-1 ) ) , increasing significantly to 66.6 +/- 10.9 mg. l(-1 ) when the end-tidal concentration of <e1>sevoflurane</e1> was 0.8 % .
C009250_D012640 NONE There was no significant difference in the <e2>convulsive</e2> threshold between <e1>sevoflurane</e1> and enflurane .
C009250_D012640 NONE The rise in blood pressure became less marked when higher concentrations of <e1>sevoflurane</e1> or enflurane were administered and the blood pressure at <e2>convulsions</e2> decreased significantly in 1.6 % sevoflurane , and in 0.8 % and 1.6 % enflurane .
C009250_D012640 NONE The rise in blood pressure became less marked when higher concentrations of sevoflurane or enflurane were administered and the blood pressure at <e2>convulsions</e2> decreased significantly in 1.6 % <e1>sevoflurane</e1> , and in 0.8 % and 1.6 % enflurane .
C009250_D012640 NONE It is suggested that <e1>sevoflurane</e1> reduces the <e2>convulsive</e2> effect of lidocaine toxicity but carries some risk due to circulatory depression .
D008012_D012640 CID The effects of sevoflurane on <e1>lidocaine-induced</e1> <e2>convulsions</e2> .
D008012_D012640 CID The influence of sevoflurane on <e1>lidocaine-induced</e1> <e2>convulsions</e2> was studied in cats .
D008012_D012640 CID The <e2>convulsive</e2> threshold ( mean +/- SD ) was 41.4 +/- 6.5 mg. l(-1 ) with <e1>lidocaine</e1> infusion ( 6 mg.kg(-1).min(-1 ) ) , increasing significantly to 66.6 +/- 10.9 mg. l(-1 ) when the end-tidal concentration of sevoflurane was 0.8 % .
D008012_D012640 CID It is suggested that sevoflurane reduces the <e2>convulsive</e2> effect of <e1>lidocaine</e1> toxicity but carries some risk due to circulatory depression .
D004737_D012640 NONE There was no significant difference in the <e2>convulsive</e2> threshold between sevoflurane and <e1>enflurane</e1> .
D004737_D012640 NONE The rise in blood pressure became less marked when higher concentrations of sevoflurane or <e1>enflurane</e1> were administered and the blood pressure at <e2>convulsions</e2> decreased significantly in 1.6 % sevoflurane , and in 0.8 % and 1.6 % enflurane .
D004737_D012640 NONE The rise in blood pressure became less marked when higher concentrations of sevoflurane or enflurane were administered and the blood pressure at <e2>convulsions</e2> decreased significantly in 1.6 % sevoflurane , and in 0.8 % and 1.6 % <e1>enflurane</e1> .
D001030_D012640 NONE <e1>Apamin</e1> ( 10 ng ) had a tendency to decrease the <e2>convulsive</e2> threshold ( 21.6 +/- 2.2 to 19.9 +/- 2.5 mg. l(-1 ) ) but this was not statistically significant .
C009250_D064420 NONE It is suggested that <e1>sevoflurane</e1> reduces the convulsive effect of lidocaine <e2>toxicity</e2> but carries some risk due to circulatory depression .
C009250_D003866 NONE It is suggested that <e1>sevoflurane</e1> reduces the convulsive effect of lidocaine toxicity but carries some risk due to circulatory <e2>depression</e2> .
D008012_D064420 NONE It is suggested that sevoflurane reduces the convulsive effect of <e1>lidocaine</e1> <e2>toxicity</e2> but carries some risk due to circulatory depression .
D008012_D003866 NONE It is suggested that sevoflurane reduces the convulsive effect of <e1>lidocaine</e1> toxicity but carries some risk due to circulatory <e2>depression</e2> .
3856631
D008727_D008577 NONE Remission induction of <e2>meningeal leukemia</e2> with high-dose intravenous <e1>methotrexate</e1> .
D008727_D054198 NONE Twenty children with <e2>acute lymphoblastic leukemia</e2> who developed meningeal disease were treated with a high-dose intravenous <e1>methotrexate</e1> regimen that was designed to achieve and maintain CSF methotrexate concentrations of 10(-5 ) mol/L without the need for concomitant intrathecal dosing .
D008727_D054198 NONE Twenty children with <e2>acute lymphoblastic leukemia</e2> who developed meningeal disease were treated with a high-dose intravenous methotrexate regimen that was designed to achieve and maintain CSF <e1>methotrexate</e1> concentrations of 10(-5 ) mol/L without the need for concomitant intrathecal dosing .
D008727_D054198 NONE High-dose intravenous <e1>methotrexate</e1> is an effective treatment for the induction of remission after meningeal relapse in <e2>acute lymphoblastic leukemia</e2> .
D008727_D002493 NONE Twenty children with acute lymphoblastic leukemia who developed <e2>meningeal disease</e2> were treated with a high-dose intravenous <e1>methotrexate</e1> regimen that was designed to achieve and maintain CSF methotrexate concentrations of 10(-5 ) mol/L without the need for concomitant intrathecal dosing .
D008727_D002493 NONE Twenty children with acute lymphoblastic leukemia who developed <e2>meningeal disease</e2> were treated with a high-dose intravenous methotrexate regimen that was designed to achieve and maintain CSF <e1>methotrexate</e1> concentrations of 10(-5 ) mol/L without the need for concomitant intrathecal dosing .
D001663_D064420 NONE The most common <e2>toxicities</e2> encountered were transient serum transaminase and <e1>bilirubin</e1> elevations , neutropenia , and mucositis .
D001663_D009503 NONE The most common toxicities encountered were transient serum transaminase and <e1>bilirubin</e1> elevations , <e2>neutropenia</e2> , and mucositis .
D001663_D052016 NONE The most common toxicities encountered were transient serum transaminase and <e1>bilirubin</e1> elevations , neutropenia , and <e2>mucositis</e2> .
15957009
C507242_D008569 NONE The selective 5-HT6 receptor antagonist <e1>Ro4368554</e1> restores memory performance in cholinergic and serotonergic models of <e2>memory deficiency</e2> in the rat .
C507242_D008569 NONE Both , <e1>Ro4368554</e1> ( 3 and 10 mg/kg , intraperitoneally ( i.p. ) ) and metrifonate ( 10 mg/kg , p.o. , respectively ) reversed <e2>memory deficits</e2> induced by scopolamine and TRP depletion ( 10 mg/kg , i.p. , and 3 mg/kg , p.o. , respectively ) .
C507242_D008569 NONE In conclusion , although <e1>Ro4368554</e1> did not improve a time-related retention deficit , it reversed a cholinergic and a serotonergic <e2>memory deficit</e2> , suggesting that both mechanisms may be involved in the facilitation of object memory by Ro4368554 and , possibly , other 5-HT(6 ) receptor antagonists .
C507242_D008569 NONE In conclusion , although Ro4368554 did not improve a time-related retention deficit , it reversed a cholinergic and a serotonergic <e2>memory deficit</e2> , suggesting that both mechanisms may be involved in the facilitation of object memory by <e1>Ro4368554</e1> and , possibly , other 5-HT(6 ) receptor antagonists .
D014236_D008569 NONE Both , Ro4368554 ( 3 and 10 mg/kg , intraperitoneally ( i.p. ) ) and <e1>metrifonate</e1> ( 10 mg/kg , p.o. , respectively ) reversed <e2>memory deficits</e2> induced by scopolamine and TRP depletion ( 10 mg/kg , i.p. , and 3 mg/kg , p.o. , respectively ) .
D012601_D008569 CID Both , Ro4368554 ( 3 and 10 mg/kg , intraperitoneally ( i.p. ) ) and metrifonate ( 10 mg/kg , p.o. , respectively ) reversed <e2>memory deficits</e2> induced by <e1>scopolamine</e1> and TRP depletion ( 10 mg/kg , i.p. , and 3 mg/kg , p.o. , respectively ) .
D014364_D008569 NONE Both , Ro4368554 ( 3 and 10 mg/kg , intraperitoneally ( i.p. ) ) and metrifonate ( 10 mg/kg , p.o. , respectively ) reversed <e2>memory deficits</e2> induced by scopolamine and <e1>TRP</e1> depletion ( 10 mg/kg , i.p. , and 3 mg/kg , p.o. , respectively ) .
D012701_D008569 NONE In conclusion , although Ro4368554 did not improve a time-related retention deficit , it reversed a cholinergic and a serotonergic <e2>memory deficit</e2> , suggesting that both mechanisms may be involved in the facilitation of object memory by Ro4368554 and , possibly , other <e1>5-HT(6</e1> ) receptor antagonists .
15188772
D004837_D018487 NONE Severe reversible <e2>left ventricular systolic and diastolic dysfunction</e2> due to accidental iatrogenic <e1>epinephrine</e1> overdose .
D004837_D018487 NONE A 35-year-old woman whose cervix uteri was inadvertently injected with 8 mg of <e1>epinephrine</e1> developed myocardial stunning that was characterized by severe hemodynamic compromise , profound , albeit transient , <e2>left ventricular systolic and diastolic dysfunction</e2> , and only modestly elevated biochemical markers of myocardial necrosis .
D004837_D062787 NONE Severe reversible left ventricular systolic and diastolic dysfunction due to accidental iatrogenic <e1>epinephrine</e1> <e2>overdose</e2> .
D002395_D009202 NONE <e1>Catecholamine-induced</e1> <e2>cardiomyopathy</e2> due to chronic excess of endogenous catecholamines has been recognized for decades as a clinical phenomenon .
D002395_D009202 NONE Catecholamine-induced <e2>cardiomyopathy</e2> due to chronic excess of endogenous <e1>catecholamines</e1> has been recognized for decades as a clinical phenomenon .
D004837_D017682 CID A 35-year-old woman whose cervix uteri was inadvertently injected with 8 mg of <e1>epinephrine</e1> developed <e2>myocardial stunning</e2> that was characterized by severe hemodynamic compromise , profound , albeit transient , left ventricular systolic and diastolic dysfunction , and only modestly elevated biochemical markers of myocardial necrosis .
D004837_D009202 NONE A 35-year-old woman whose cervix uteri was inadvertently injected with 8 mg of <e1>epinephrine</e1> developed myocardial stunning that was characterized by severe hemodynamic compromise , profound , albeit transient , left ventricular systolic and diastolic dysfunction , and only modestly elevated biochemical markers of <e2>myocardial necrosis</e2> .
17615423
D019821_D012206 CID Severe <e2>rhabdomyolysis</e2> and acute renal failure secondary to concomitant use of <e1>simvastatin</e1> , amiodarone , and atazanavir .
D019821_D012206 CID OBJECTIVE : To report a case of a severe interaction between <e1>simvastatin</e1> , amiodarone , and atazanavir resulting in <e2>rhabdomyolysis</e2> and acute renal failure .
D019821_D012206 CID DISCUSSION : The risk of <e2>rhabdomyolysis</e2> is increased in the presence of concomitant drugs that inhibit <e1>simvastatin</e1> metabolism .
D019821_D058186 CID Severe rhabdomyolysis and <e2>acute renal failure</e2> secondary to concomitant use of <e1>simvastatin</e1> , amiodarone , and atazanavir .
D019821_D058186 CID OBJECTIVE : To report a case of a severe interaction between <e1>simvastatin</e1> , amiodarone , and atazanavir resulting in rhabdomyolysis and <e2>acute renal failure</e2> .
D000638_D012206 CID Severe <e2>rhabdomyolysis</e2> and acute renal failure secondary to concomitant use of simvastatin , <e1>amiodarone</e1> , and atazanavir .
D000638_D012206 CID OBJECTIVE : To report a case of a severe interaction between simvastatin , <e1>amiodarone</e1> , and atazanavir resulting in <e2>rhabdomyolysis</e2> and acute renal failure .
D000638_D058186 CID Severe rhabdomyolysis and <e2>acute renal failure</e2> secondary to concomitant use of simvastatin , <e1>amiodarone</e1> , and atazanavir .
D000638_D058186 CID OBJECTIVE : To report a case of a severe interaction between simvastatin , <e1>amiodarone</e1> , and atazanavir resulting in rhabdomyolysis and <e2>acute renal failure</e2> .
C413408_D012206 CID Severe <e2>rhabdomyolysis</e2> and acute renal failure secondary to concomitant use of simvastatin , amiodarone , and <e1>atazanavir</e1> .
C413408_D012206 CID OBJECTIVE : To report a case of a severe interaction between simvastatin , amiodarone , and <e1>atazanavir</e1> resulting in <e2>rhabdomyolysis</e2> and acute renal failure .
C413408_D058186 CID Severe rhabdomyolysis and <e2>acute renal failure</e2> secondary to concomitant use of simvastatin , amiodarone , and <e1>atazanavir</e1> .
C413408_D058186 CID OBJECTIVE : To report a case of a severe interaction between simvastatin , amiodarone , and <e1>atazanavir</e1> resulting in rhabdomyolysis and <e2>acute renal failure</e2> .
D019821_D015658 NONE <e1>Simvastatin</e1> , amiodarone , and the patient 's <e2>human immunodeficiency virus</e2> medications were all temporarily discontinued and the patient was given forced alkaline diuresis and started on dialysis .
D000638_D015658 NONE Simvastatin , <e1>amiodarone</e1> , and the patient 's <e2>human immunodeficiency virus</e2> medications were all temporarily discontinued and the patient was given forced alkaline diuresis and started on dialysis .
12584269
D020123_D007674 CID These are <e2>nephrotoxic</e2> , but <e1>SRL</e1> seems to act differently displaying only minor nephrotoxic effects , although this question is still open .
D020123_D007674 CID These are nephrotoxic , but <e1>SRL</e1> seems to act differently displaying only minor <e2>nephrotoxic</e2> effects , although this question is still open .
D020123_D007674 CID In a number of treatment protocols where <e1>SRL</e1> was combined with a calcineurin inhibitor indications of a synergistic <e2>nephrotoxic</e2> effect were described .
D020123_D007674 CID CONCLUSION : This rat study demonstrated a synergistic <e2>nephrotoxic</e2> effect of CsA plus <e1>SRL</e1> , whereas FK506 plus SRL was better tolerated .
D020123_D007674 CID CONCLUSION : This rat study demonstrated a synergistic <e2>nephrotoxic</e2> effect of CsA plus SRL , whereas FK506 plus <e1>SRL</e1> was better tolerated .
D016572_D005355 NONE The semi-quantitative scoring was significantly worst in the group treated with <e1>CsA</e1> plus SRL ( P<0.001 compared with controls ) and the analysis of the total grade of <e2>fibrosis</e2> also showed the highest proportion in the same group and was significantly different from controls ( P<0.02 ) .
D020123_D005355 NONE The semi-quantitative scoring was significantly worst in the group treated with CsA plus <e1>SRL</e1> ( P<0.001 compared with controls ) and the analysis of the total grade of <e2>fibrosis</e2> also showed the highest proportion in the same group and was significantly different from controls ( P<0.02 ) .
D020123_D005355 NONE The FK506 plus <e1>SRL</e1> combination showed only a marginally higher degree of <e2>fibrosis</e2> as compared with controls ( P=0.05 ) .
D016559_D005355 NONE The <e1>FK506</e1> plus SRL combination showed only a marginally higher degree of <e2>fibrosis</e2> as compared with controls ( P=0.05 ) .
D016572_D007674 CID CONCLUSION : This rat study demonstrated a synergistic <e2>nephrotoxic</e2> effect of <e1>CsA</e1> plus SRL , whereas FK506 plus SRL was better tolerated .
D016559_D007674 CID CONCLUSION : This rat study demonstrated a synergistic <e2>nephrotoxic</e2> effect of CsA plus SRL , whereas <e1>FK506</e1> plus SRL was better tolerated .
14976857
D011405_-1 NONE Transient <e2>platypnea-orthodeoxia-like syndrome</e2> induced by <e1>propafenone</e1> overdose in a young woman with Ebstein 's anomaly .
D011405_D062787 NONE Transient platypnea-orthodeoxia-like syndrome induced by <e1>propafenone</e1> <e2>overdose</e2> in a young woman with Ebstein 's anomaly .
D011405_D062787 NONE This shunt of blood via a patent foramen ovale occurred in the presence of a normal pulmonary artery pressure , and was probably precipitated by a <e1>propafenone</e1> <e2>overdose</e2> .
D011405_D004437 NONE Transient platypnea-orthodeoxia-like syndrome induced by <e1>propafenone</e1> overdose in a young woman with <e2>Ebstein 's anomaly</e2> .
D011405_D054092 NONE This shunt of blood via a <e2>patent foramen ovale</e2> occurred in the presence of a normal pulmonary artery pressure , and was probably precipitated by a <e1>propafenone</e1> overdose .
11166519
D003042_D012640 CID Acute <e1>cocaine-induced</e1> <e2>seizures</e2> : differential sensitivity of six inbred mouse strains .
D003042_D012640 CID Mature male and female mice from six inbred stains were tested for susceptibility to behavioral <e2>seizures</e2> induced by a single injection of <e1>cocaine</e1> .
D003042_D012640 CID Additional studies of these murine strains may be useful for investigating genetic influences on <e1>cocaine-induced</e1> <e2>seizures</e2> .
6209318
D008801_D001145 NONE International <e1>mexiletine</e1> and placebo antiarrhythmic coronary trial : I. Report on <e2>arrhythmia</e2> and other findings .
D008801_D009203 NONE The antiarrhythmic effects of the sustained release form of <e1>mexiletine</e1> ( Mexitil-Perlongets ) were evaluated in a double-blind placebo trial in 630 patients with recent documented <e2>myocardial infarction</e2> .
D008801_D009203 NONE The antiarrhythmic effects of the sustained release form of mexiletine ( <e1>Mexitil-Perlongets</e1> ) were evaluated in a double-blind placebo trial in 630 patients with recent documented <e2>myocardial infarction</e2> .
D008801_D003643 NONE There were more <e2>deaths</e2> in the <e1>mexiletine</e1> group ( 7.6 % ) than in the placebo group ( 4.8 % ) ; the difference was not statistically significant .
D008801_D014202 CID Previously recognized side effects , particularly <e2>tremor</e2> and gastrointestinal problems , were more frequent in the <e1>mexiletine</e1> group than in the placebo group .
D008801_D012817 CID Previously recognized side effects , particularly tremor and <e2>gastrointestinal problems</e2> , were more frequent in the <e1>mexiletine</e1> group than in the placebo group .
20196116
D000995_D017114 CID <e1>Antituberculosis</e1> therapy-induced <e2>acute liver failure</e2> : magnitude , profile , prognosis , and predictors of outcome .
D000995_D017114 CID <e1>Antituberculosis</e1> therapy (ATT)-associated <e2>acute liver failure</e2> ( ATT-ALF ) is the commonest drug-induced ALF in South Asia .
D000995_D017114 CID <e1>Antituberculosis</e1> therapy (ATT)-associated acute liver failure ( <e2>ATT-ALF</e2> ) is the commonest drug-induced ALF in South Asia .
D000995_D017114 CID <e1>Antituberculosis</e1> therapy (ATT)-associated acute liver failure ( ATT-ALF ) is the commonest drug-induced <e2>ALF</e2> in South Asia .
D001663_D001927 NONE In multivariate analysis , three factors independently predicted mortality : serum <e1>bilirubin</e1> ( > or=10.8 mg/dL ) , prothrombin time ( PT ) prolongation ( > or=26 seconds ) , and grade III/IV <e2>encephalopathy</e2> at presentation .
20477932
D003042_D008569 CID <e1>Cocaine</e1> causes <e2>memory and learning impairments</e2> in rats : involvement of nuclear factor kappa B and oxidative stress , and prevention by topiramate .
D003042_D007859 CID <e1>Cocaine</e1> causes <e2>memory and learning impairments</e2> in rats : involvement of nuclear factor kappa B and oxidative stress , and prevention by topiramate .
C052342_D008569 NONE Cocaine causes <e2>memory and learning impairments</e2> in rats : involvement of nuclear factor kappa B and oxidative stress , and prevention by <e1>topiramate</e1> .
C052342_D007859 NONE Cocaine causes <e2>memory and learning impairments</e2> in rats : involvement of nuclear factor kappa B and oxidative stress , and prevention by <e1>topiramate</e1> .
D003042_D064420 NONE Different mechanisms have been suggested for <e1>cocaine</e1> <e2>toxicity</e2> including an increase in oxidative stress but the association between oxidative status in the brain and cocaine induced-behaviour is poorly understood .
D003042_D064420 NONE Different mechanisms have been suggested for cocaine <e2>toxicity</e2> including an increase in oxidative stress but the association between oxidative status in the brain and <e1>cocaine</e1> induced-behaviour is poorly understood .
D009569_D019970 NONE Therefore NFkappaB activity , oxidative stress , neuronal <e1>nitric oxide</e1> synthase ( nNOS ) activity , spatial learning and memory as well as the effect of topiramate , a previously proposed therapy for <e2>cocaine addiction</e2> , were evaluated in an experimental model of cocaine administration in rats .
C052342_D019970 NONE Therefore NFkappaB activity , oxidative stress , neuronal nitric oxide synthase ( nNOS ) activity , spatial learning and memory as well as the effect of <e1>topiramate</e1> , a previously proposed therapy for <e2>cocaine addiction</e2> , were evaluated in an experimental model of cocaine administration in rats .
D003042_D019970 NONE Therefore NFkappaB activity , oxidative stress , neuronal nitric oxide synthase ( nNOS ) activity , spatial learning and memory as well as the effect of topiramate , a previously proposed therapy for <e2>cocaine addiction</e2> , were evaluated in an experimental model of <e1>cocaine</e1> administration in rats .
7265370
D014223_D053040 CID <e1>Triamterene</e1> <e2>nephrolithiasis</e2> complicating dyazide therapy .
D014223_D053040 CID A case of <e1>triamterene</e1> <e2>nephrolithiasis</e2> is reported in a man after 4 years of hydrochlorothiazide-triamterene therapy for hypertension .
D014223_D053040 CID Factors affecting <e1>triamterene</e1> <e2>nephrolithiasis</e2> are discussed and 2 previously reported cases are reviewed .
C020743_D053040 NONE Triamterene <e2>nephrolithiasis</e2> complicating <e1>dyazide</e1> therapy .
C020743_D053040 NONE A case of triamterene <e2>nephrolithiasis</e2> is reported in a man after 4 years of <e1>hydrochlorothiazide-triamterene</e1> therapy for hypertension .
D014223_D006973 NONE A case of <e1>triamterene</e1> nephrolithiasis is reported in a man after 4 years of hydrochlorothiazide-triamterene therapy for <e2>hypertension</e2> .
C020743_D006973 NONE A case of triamterene nephrolithiasis is reported in a man after 4 years of <e1>hydrochlorothiazide-triamterene</e1> therapy for <e2>hypertension</e2> .
424937
D008750_D056486 CID Patterns of <e2>hepatic injury</e2> induced by <e1>methyldopa</e1> .
D008750_D056486 CID The remaining patient in the series developed fulminant hepatitis when the drug was accidentally recommenced 1 year after a prior episode of <e1>methyldopa-induced</e1> <e2>hepatitis</e2> .
D008750_D056486 CID In this latter patient , and in 2 others , the causal relationship between <e1>methyldopa</e1> and hepatic dysfunction was proved with the recurrence of <e2>hepatitis</e2> within 2 weeks of re-exposure to the drug .
D008750_D008107 NONE Twelve patients with <e2>liver disease</e2> related to <e1>methyldopa</e1> were seen between 1967 and 1977 .
D008750_D008107 NONE In this latter patient , and in 2 others , the causal relationship between <e1>methyldopa</e1> and <e2>hepatic dysfunction</e2> was proved with the recurrence of hepatitis within 2 weeks of re-exposure to the drug .
D008750_D017093 NONE One patient died , having presented in <e2>hepatic failure</e2> , and another , who had been taking <e1>methyldopa</e1> for 7 years , showed slower clinical and biochemical resolution over a period of several months .
D008750_D017114 NONE The remaining patient in the series developed <e2>fulminant hepatitis</e2> when the drug was accidentally recommenced 1 year after a prior episode of <e1>methyldopa-induced</e1> hepatitis .
20470218
D008727_D056784 NONE CNS complications included posterior reversible <e2>leukoencephalopathy</e2> syndrome ( n = 10 ) , stroke ( n = 5 ) , temporal lobe epilepsy ( n = 2 ) , high-dose <e1>methotrexate</e1> toxicity ( n = 2 ) , syndrome of inappropriate antidiuretic hormone secretion ( n = 1 ) , and other unclassified events ( n = 7 ) .
D008727_D020521 NONE CNS complications included posterior reversible leukoencephalopathy syndrome ( n = 10 ) , <e2>stroke</e2> ( n = 5 ) , temporal lobe epilepsy ( n = 2 ) , high-dose <e1>methotrexate</e1> toxicity ( n = 2 ) , syndrome of inappropriate antidiuretic hormone secretion ( n = 1 ) , and other unclassified events ( n = 7 ) .
D008727_D004833 NONE CNS complications included posterior reversible leukoencephalopathy syndrome ( n = 10 ) , stroke ( n = 5 ) , <e2>temporal lobe epilepsy</e2> ( n = 2 ) , high-dose <e1>methotrexate</e1> toxicity ( n = 2 ) , syndrome of inappropriate antidiuretic hormone secretion ( n = 1 ) , and other unclassified events ( n = 7 ) .
D008727_D064420 NONE CNS complications included posterior reversible leukoencephalopathy syndrome ( n = 10 ) , stroke ( n = 5 ) , temporal lobe epilepsy ( n = 2 ) , high-dose <e1>methotrexate</e1> <e2>toxicity</e2> ( n = 2 ) , syndrome of inappropriate antidiuretic hormone secretion ( n = 1 ) , and other unclassified events ( n = 7 ) .
D008727_D007177 NONE CNS complications included posterior reversible leukoencephalopathy syndrome ( n = 10 ) , stroke ( n = 5 ) , temporal lobe epilepsy ( n = 2 ) , high-dose <e1>methotrexate</e1> toxicity ( n = 2 ) , syndrome of <e2>inappropriate antidiuretic hormone secretion</e2> ( n = 1 ) , and other unclassified events ( n = 7 ) .
15572383
D004317_D007674 NONE Individual differences in renal ACE activity in healthy rats predict susceptibility to <e1>adriamycin-induced</e1> <e2>renal damage</e2> .
D004317_D007674 NONE Therefore , we studied the predictive effect of renal ACE activity for the severity of <e2>renal damage</e2> induced by a single injection of <e1>adriamycin</e1> in rats .
D004317_D007674 NONE RESULTS : As anticipated , <e1>adriamycin</e1> elicited nephrotic range proteinuria , <e2>renal interstitial damage</e2> and mild focal glomerulosclerosis .
D004317_D007674 NONE CONCLUSION : Individual differences in renal ACE activity predict the severity of <e1>adriamycin-induced</e1> <e2>renal damage</e2> in this outbred rat strain .
D004317_D011507 CID After 1 week of recovery , <e2>proteinuria</e2> was induced by <e1>adriamycin</e1> [ 1.5 mg/kg intravenously ( i.v. ) n = 18 ; controls , saline i.v. n = 9 ] .
D004317_D011507 CID RESULTS : As anticipated , <e1>adriamycin</e1> elicited nephrotic range <e2>proteinuria</e2> , renal interstitial damage and mild focal glomerulosclerosis .
D004317_D011507 CID Baseline renal ACE positively correlated with the relative rise in <e2>proteinuria</e2> after <e1>adriamycin</e1> ( r = 0.62 , P<0.01 ) , renal interstitial alpha-smooth muscle actin ( r = 0.49 , P<0.05 ) , interstitial macrophage influx ( r = 0.56 , P<0.05 ) , interstitial collagen III ( r = 0.53 , P<0.05 ) , glomerular alpha-smooth muscle actin ( r = 0.74 , P<0.01 ) and glomerular desmin ( r = 0.48 , P<0.05 ) .
D004317_D009404 NONE RESULTS : As anticipated , <e1>adriamycin</e1> elicited <e2>nephrotic</e2> range proteinuria , renal interstitial damage and mild focal glomerulosclerosis .
D004317_D005923 NONE RESULTS : As anticipated , <e1>adriamycin</e1> elicited nephrotic range proteinuria , renal interstitial damage and mild <e2>focal glomerulosclerosis</e2> .
7582165
D000305_D004342 NONE <e2>Pseudo-allergic reactions</e2> to <e1>corticosteroids</e1> : diagnosis and alternatives .
D010248_D004342 NONE Corticosteroids different from <e1>paramethasone</e1> also produced <e2>hypersensitivity</e2> reactions in these patients ; however , a few of them were tolerated .
D010248_D004342 NONE To our knowledge , this is the first report of a <e2>pseudo-allergy</e2> caused by <e1>paramethasone</e1> .
18208574
D006493_D013927 CID Higher optical density of an antigen assay predicts <e2>thrombosis</e2> in patients with <e1>heparin-induced</e1> thrombocytopenia .
D006493_D013927 CID OBJECTIVES : To correlate optical density and percent inhibition of a two-step <e1>heparin-induced</e1> thrombocytopenia ( HIT ) antigen assay with <e2>thrombosis</e2> ; the assay utilizes reaction inhibition characteristics of a high heparin concentration .
D006493_D013927 CID OBJECTIVES : To correlate optical density and percent inhibition of a two-step heparin-induced thrombocytopenia ( HIT ) antigen assay with <e2>thrombosis</e2> ; the assay utilizes reaction inhibition characteristics of a high <e1>heparin</e1> concentration .
D006493_D013921 CID Higher optical density of an antigen assay predicts thrombosis in patients with <e1>heparin-induced</e1> <e2>thrombocytopenia</e2> .
D006493_D013921 CID OBJECTIVES : To correlate optical density and percent inhibition of a two-step <e1>heparin-induced</e1> <e2>thrombocytopenia</e2> ( HIT ) antigen assay with thrombosis ; the assay utilizes reaction inhibition characteristics of a high heparin concentration .
D006493_D013921 CID OBJECTIVES : To correlate optical density and percent inhibition of a two-step <e1>heparin-induced</e1> thrombocytopenia ( <e2>HIT</e2> ) antigen assay with thrombosis ; the assay utilizes reaction inhibition characteristics of a high heparin concentration .
D006493_D013921 CID OBJECTIVES : To correlate optical density and percent inhibition of a two-step heparin-induced <e2>thrombocytopenia</e2> ( HIT ) antigen assay with thrombosis ; the assay utilizes reaction inhibition characteristics of a high <e1>heparin</e1> concentration .
D006493_D013921 CID OBJECTIVES : To correlate optical density and percent inhibition of a two-step heparin-induced thrombocytopenia ( <e2>HIT</e2> ) antigen assay with thrombosis ; the assay utilizes reaction inhibition characteristics of a high <e1>heparin</e1> concentration .
D006493_D013921 CID PATIENTS AND METHODS : Patients with more than 50 % decrease in platelet count or <e2>thrombocytopenia</e2> ( < 150 x 10(9)/L ) after exposure to <e1>heparin</e1> , who had a positive two-step antigen assay [ optical density ( OD ) > 0.4 and > 50 inhibition with high concentration of heparin ] were included in the study .
D006493_D013921 CID PATIENTS AND METHODS : Patients with more than 50 % decrease in platelet count or <e2>thrombocytopenia</e2> ( < 150 x 10(9)/L ) after exposure to heparin , who had a positive two-step antigen assay [ optical density ( OD ) > 0.4 and > 50 inhibition with high concentration of <e1>heparin</e1> ] were included in the study .
19884587
D013449_D000757 CID <e1>Sulfonamides</e1> were associated with <e2>anencephaly</e2> ( adjusted OR [ AOR ] = 3.4 ; 95 % confidence interval [ CI ] , 1.3 - 8.8 ) , hypoplastic left heart syndrome ( AOR = 3.2 ; 95 % CI , 1.3 - 7.6 ) , coarctation of the aorta ( AOR = 2.7 ; 95 % CI , 1.3 - 5.6 ) , choanal atresia ( AOR = 8.0 ; 95 % CI , 2.7 - 23.5 ) , transverse limb deficiency ( AOR = 2.5 ; 95 % CI , 1.0 - 5.9 ) , and diaphragmatic hernia ( AOR = 2.4 ; 95 % CI , 1.1 - 5.4 ) .
D013449_D018636 CID <e1>Sulfonamides</e1> were associated with anencephaly ( adjusted OR [ AOR ] = 3.4 ; 95 % confidence interval [ CI ] , 1.3 - 8.8 ) , <e2>hypoplastic left heart syndrome</e2> ( AOR = 3.2 ; 95 % CI , 1.3 - 7.6 ) , coarctation of the aorta ( AOR = 2.7 ; 95 % CI , 1.3 - 5.6 ) , choanal atresia ( AOR = 8.0 ; 95 % CI , 2.7 - 23.5 ) , transverse limb deficiency ( AOR = 2.5 ; 95 % CI , 1.0 - 5.9 ) , and diaphragmatic hernia ( AOR = 2.4 ; 95 % CI , 1.1 - 5.4 ) .
D013449_D001017 CID <e1>Sulfonamides</e1> were associated with anencephaly ( adjusted OR [ AOR ] = 3.4 ; 95 % confidence interval [ CI ] , 1.3 - 8.8 ) , hypoplastic left heart syndrome ( AOR = 3.2 ; 95 % CI , 1.3 - 7.6 ) , <e2>coarctation of the aorta</e2> ( AOR = 2.7 ; 95 % CI , 1.3 - 5.6 ) , choanal atresia ( AOR = 8.0 ; 95 % CI , 2.7 - 23.5 ) , transverse limb deficiency ( AOR = 2.5 ; 95 % CI , 1.0 - 5.9 ) , and diaphragmatic hernia ( AOR = 2.4 ; 95 % CI , 1.1 - 5.4 ) .
D013449_D002754 CID <e1>Sulfonamides</e1> were associated with anencephaly ( adjusted OR [ AOR ] = 3.4 ; 95 % confidence interval [ CI ] , 1.3 - 8.8 ) , hypoplastic left heart syndrome ( AOR = 3.2 ; 95 % CI , 1.3 - 7.6 ) , coarctation of the aorta ( AOR = 2.7 ; 95 % CI , 1.3 - 5.6 ) , <e2>choanal atresia</e2> ( AOR = 8.0 ; 95 % CI , 2.7 - 23.5 ) , transverse limb deficiency ( AOR = 2.5 ; 95 % CI , 1.0 - 5.9 ) , and diaphragmatic hernia ( AOR = 2.4 ; 95 % CI , 1.1 - 5.4 ) .
D013449_D017880 CID <e1>Sulfonamides</e1> were associated with anencephaly ( adjusted OR [ AOR ] = 3.4 ; 95 % confidence interval [ CI ] , 1.3 - 8.8 ) , hypoplastic left heart syndrome ( AOR = 3.2 ; 95 % CI , 1.3 - 7.6 ) , coarctation of the aorta ( AOR = 2.7 ; 95 % CI , 1.3 - 5.6 ) , choanal atresia ( AOR = 8.0 ; 95 % CI , 2.7 - 23.5 ) , <e2>transverse limb deficiency</e2> ( AOR = 2.5 ; 95 % CI , 1.0 - 5.9 ) , and diaphragmatic hernia ( AOR = 2.4 ; 95 % CI , 1.1 - 5.4 ) .
D013449_D006548 CID <e1>Sulfonamides</e1> were associated with anencephaly ( adjusted OR [ AOR ] = 3.4 ; 95 % confidence interval [ CI ] , 1.3 - 8.8 ) , hypoplastic left heart syndrome ( AOR = 3.2 ; 95 % CI , 1.3 - 7.6 ) , coarctation of the aorta ( AOR = 2.7 ; 95 % CI , 1.3 - 5.6 ) , choanal atresia ( AOR = 8.0 ; 95 % CI , 2.7 - 23.5 ) , transverse limb deficiency ( AOR = 2.5 ; 95 % CI , 1.0 - 5.9 ) , and <e2>diaphragmatic hernia</e2> ( AOR = 2.4 ; 95 % CI , 1.1 - 5.4 ) .
D009582_D000853 CID <e1>Nitrofurantoins</e1> were associated with <e2>anophthalmia</e2> or microphthalmos ( AOR = 3.7 ; 95 % CI , 1.1 - 12.2 ) , hypoplastic left heart syndrome ( AOR = 4.2 ; 95 % CI , 1.9 - 9.1 ) , atrial septal defects ( AOR = 1.9 ; 95 % CI , 1.1 - 3.4 ) , and cleft lip with cleft palate ( AOR = 2.1 ; 95 % CI , 1.2 - 3.9 ) .
D009582_D008850 CID <e1>Nitrofurantoins</e1> were associated with anophthalmia or <e2>microphthalmos</e2> ( AOR = 3.7 ; 95 % CI , 1.1 - 12.2 ) , hypoplastic left heart syndrome ( AOR = 4.2 ; 95 % CI , 1.9 - 9.1 ) , atrial septal defects ( AOR = 1.9 ; 95 % CI , 1.1 - 3.4 ) , and cleft lip with cleft palate ( AOR = 2.1 ; 95 % CI , 1.2 - 3.9 ) .
D009582_D018636 CID <e1>Nitrofurantoins</e1> were associated with anophthalmia or microphthalmos ( AOR = 3.7 ; 95 % CI , 1.1 - 12.2 ) , <e2>hypoplastic left heart syndrome</e2> ( AOR = 4.2 ; 95 % CI , 1.9 - 9.1 ) , atrial septal defects ( AOR = 1.9 ; 95 % CI , 1.1 - 3.4 ) , and cleft lip with cleft palate ( AOR = 2.1 ; 95 % CI , 1.2 - 3.9 ) .
D009582_D006344 CID <e1>Nitrofurantoins</e1> were associated with anophthalmia or microphthalmos ( AOR = 3.7 ; 95 % CI , 1.1 - 12.2 ) , hypoplastic left heart syndrome ( AOR = 4.2 ; 95 % CI , 1.9 - 9.1 ) , <e2>atrial septal defects</e2> ( AOR = 1.9 ; 95 % CI , 1.1 - 3.4 ) , and cleft lip with cleft palate ( AOR = 2.1 ; 95 % CI , 1.2 - 3.9 ) .
D009582_D002971 CID <e1>Nitrofurantoins</e1> were associated with anophthalmia or microphthalmos ( AOR = 3.7 ; 95 % CI , 1.1 - 12.2 ) , hypoplastic left heart syndrome ( AOR = 4.2 ; 95 % CI , 1.9 - 9.1 ) , atrial septal defects ( AOR = 1.9 ; 95 % CI , 1.1 - 3.4 ) , and <e2>cleft lip</e2> with cleft palate ( AOR = 2.1 ; 95 % CI , 1.2 - 3.9 ) .
D009582_D002972 CID <e1>Nitrofurantoins</e1> were associated with anophthalmia or microphthalmos ( AOR = 3.7 ; 95 % CI , 1.1 - 12.2 ) , hypoplastic left heart syndrome ( AOR = 4.2 ; 95 % CI , 1.9 - 9.1 ) , atrial septal defects ( AOR = 1.9 ; 95 % CI , 1.1 - 3.4 ) , and cleft lip with <e2>cleft palate</e2> ( AOR = 2.1 ; 95 % CI , 1.2 - 3.9 ) .
D010406_D000014 NONE CONCLUSIONS : Reassuringly , <e1>penicillins</e1> , erythromycins , and cephalosporins , although used commonly by pregnant women , were not associated with many <e2>birth defects</e2> .
D004917_D000014 NONE CONCLUSIONS : Reassuringly , penicillins , <e1>erythromycins</e1> , and cephalosporins , although used commonly by pregnant women , were not associated with many <e2>birth defects</e2> .
D002511_D000014 NONE CONCLUSIONS : Reassuringly , penicillins , erythromycins , and <e1>cephalosporins</e1> , although used commonly by pregnant women , were not associated with many <e2>birth defects</e2> .
D013449_D000014 CID <e1>Sulfonamides</e1> and nitrofurantoins were associated with several <e2>birth defects</e2> , indicating a need for additional scrutiny .
D009582_D000014 CID Sulfonamides and <e1>nitrofurantoins</e1> were associated with several <e2>birth defects</e2> , indicating a need for additional scrutiny .
17343925
D012906_D034381 CID The influence of <e1>smoking</e1> during pregnancy on the developing cochlea has not been estimated , although smoking has been positively associated with <e2>hearing loss</e2> in adults .
D012906_D034381 CID The influence of smoking during pregnancy on the developing cochlea has not been estimated , although <e1>smoking</e1> has been positively associated with <e2>hearing loss</e2> in adults .
8387218
D016049_D064420 NONE The use and <e2>toxicity</e2> of <e1>didanosine</e1> ( ddI ) in HIV antibody-positive individuals intolerant to zidovudine ( AZT )
D016049_D064420 NONE The use and <e2>toxicity</e2> of didanosine ( <e1>ddI</e1> ) in HIV antibody-positive individuals intolerant to zidovudine ( AZT )
D016049_D015658 NONE The use and toxicity of <e1>didanosine</e1> ( ddI ) in <e2>HIV antibody-positive</e2> individuals intolerant to zidovudine ( AZT )
D016049_D015658 NONE The use and toxicity of didanosine ( <e1>ddI</e1> ) in <e2>HIV antibody-positive</e2> individuals intolerant to zidovudine ( AZT )
D015215_D064420 NONE The use and <e2>toxicity</e2> of didanosine ( ddI ) in HIV antibody-positive individuals intolerant to <e1>zidovudine</e1> ( AZT )
D015215_D064420 NONE The use and <e2>toxicity</e2> of didanosine ( ddI ) in HIV antibody-positive individuals intolerant to zidovudine ( <e1>AZT</e1> )
D015215_D015658 NONE The use and toxicity of didanosine ( ddI ) in <e2>HIV antibody-positive</e2> individuals intolerant to <e1>zidovudine</e1> ( AZT )
D015215_D015658 NONE The use and toxicity of didanosine ( ddI ) in <e2>HIV antibody-positive</e2> individuals intolerant to zidovudine ( <e1>AZT</e1> )
D016049_D018149 CID Seven patients developed <e2>glucose tolerance curves</e2> characteristic of diabetes but these were mild , did not require treatment and returned to normal on ceasing <e1>didanosine</e1> .
D016049_D003920 NONE Seven patients developed glucose tolerance curves characteristic of <e2>diabetes</e2> but these were mild , did not require treatment and returned to normal on ceasing <e1>didanosine</e1> .
1639466
D002118_D009400 NONE Adverse effect of the <e1>calcium</e1> channel blocker nitrendipine on <e2>nephrosclerosis</e2> in rats with renovascular hypertension .
D002118_D006978 NONE Adverse effect of the <e1>calcium</e1> channel blocker nitrendipine on nephrosclerosis in rats with <e2>renovascular hypertension</e2> .
D002118_D006978 NONE The effect of a 6-week treatment with the <e1>calcium</e1> channel blocker nitrendipine or the angiotensin converting enzyme inhibitor enalapril on blood pressure , albuminuria , renal hemodynamics , and morphology of the nonclipped kidney was studied in rats with two-kidney , one clip <e2>renovascular hypertension</e2> .
D009568_D009400 CID Adverse effect of the calcium channel blocker <e1>nitrendipine</e1> on <e2>nephrosclerosis</e2> in rats with renovascular hypertension .
D009568_D006978 NONE Adverse effect of the calcium channel blocker <e1>nitrendipine</e1> on nephrosclerosis in rats with <e2>renovascular hypertension</e2> .
D009568_D006978 NONE The effect of a 6-week treatment with the calcium channel blocker <e1>nitrendipine</e1> or the angiotensin converting enzyme inhibitor enalapril on blood pressure , albuminuria , renal hemodynamics , and morphology of the nonclipped kidney was studied in rats with two-kidney , one clip <e2>renovascular hypertension</e2> .
D002118_D000419 NONE The effect of a 6-week treatment with the <e1>calcium</e1> channel blocker nitrendipine or the angiotensin converting enzyme inhibitor enalapril on blood pressure , <e2>albuminuria</e2> , renal hemodynamics , and morphology of the nonclipped kidney was studied in rats with two-kidney , one clip renovascular hypertension .
D009568_D000419 CID The effect of a 6-week treatment with the calcium channel blocker <e1>nitrendipine</e1> or the angiotensin converting enzyme inhibitor enalapril on blood pressure , <e2>albuminuria</e2> , renal hemodynamics , and morphology of the nonclipped kidney was studied in rats with two-kidney , one clip renovascular hypertension .
D009568_D000419 CID In contrast , in the <e1>nitrendipine-treated</e1> group <e2>albuminuria</e2> increased from 12.8 +/- 2 progressively to 163 +/- 55 compared with 19.2 +/- 9 mg/24 hr in the hypertensive controls .
D000809_D000419 NONE The effect of a 6-week treatment with the calcium channel blocker nitrendipine or the <e1>angiotensin</e1> converting enzyme inhibitor enalapril on blood pressure , <e2>albuminuria</e2> , renal hemodynamics , and morphology of the nonclipped kidney was studied in rats with two-kidney , one clip renovascular hypertension .
D000809_D006978 NONE The effect of a 6-week treatment with the calcium channel blocker nitrendipine or the <e1>angiotensin</e1> converting enzyme inhibitor enalapril on blood pressure , albuminuria , renal hemodynamics , and morphology of the nonclipped kidney was studied in rats with two-kidney , one clip <e2>renovascular hypertension</e2> .
D004656_D000419 NONE The effect of a 6-week treatment with the calcium channel blocker nitrendipine or the angiotensin converting enzyme inhibitor <e1>enalapril</e1> on blood pressure , <e2>albuminuria</e2> , renal hemodynamics , and morphology of the nonclipped kidney was studied in rats with two-kidney , one clip renovascular hypertension .
D004656_D006978 NONE The effect of a 6-week treatment with the calcium channel blocker nitrendipine or the angiotensin converting enzyme inhibitor <e1>enalapril</e1> on blood pressure , albuminuria , renal hemodynamics , and morphology of the nonclipped kidney was studied in rats with two-kidney , one clip <e2>renovascular hypertension</e2> .
D004656_D006973 NONE Six weeks after clipping of one renal artery , <e2>hypertensive</e2> rats ( 178 +/- 4 mm Hg ) were randomly assigned to three groups : untreated hypertensive controls ( n = 8) , <e1>enalapril-treated</e1> ( n = 8) , or nitrendipine-treated ( n = 10 ) .
D004656_D006973 NONE Six weeks after clipping of one renal artery , hypertensive rats ( 178 +/- 4 mm Hg ) were randomly assigned to three groups : untreated <e2>hypertensive</e2> controls ( n = 8) , <e1>enalapril-treated</e1> ( n = 8) , or nitrendipine-treated ( n = 10 ) .
D004656_D006973 NONE In addition , glomerular size was higher in the nitrendipine-treated group ( 14.9 +/- 0.17 10(-3 ) mm2 ) but lower in the <e1>enalapril-treated</e1> group ( 11.5 +/- 0.15 10(-3 ) mm2 ) compared with the <e2>hypertensive</e2> controls ( 12.1 +/- 0.17 10(-3 ) mm2 ) .
D009568_D006973 NONE Six weeks after clipping of one renal artery , <e2>hypertensive</e2> rats ( 178 +/- 4 mm Hg ) were randomly assigned to three groups : untreated hypertensive controls ( n = 8) , enalapril-treated ( n = 8) , or <e1>nitrendipine-treated</e1> ( n = 10 ) .
D009568_D006973 NONE Six weeks after clipping of one renal artery , hypertensive rats ( 178 +/- 4 mm Hg ) were randomly assigned to three groups : untreated <e2>hypertensive</e2> controls ( n = 8) , enalapril-treated ( n = 8) , or <e1>nitrendipine-treated</e1> ( n = 10 ) .
D009568_D006973 NONE In contrast , in the <e1>nitrendipine-treated</e1> group albuminuria increased from 12.8 +/- 2 progressively to 163 +/- 55 compared with 19.2 +/- 9 mg/24 hr in the <e2>hypertensive</e2> controls .
D009568_D006973 NONE Furthermore , glomerulosclerosis index was significantly increased in the <e1>nitrendipine-treated</e1> group compared with the <e2>hypertensive</e2> controls ( 0.38 +/- 0.1 versus 0.13 +/- 0.04 ) .
D009568_D006973 NONE In addition , glomerular size was higher in the <e1>nitrendipine-treated</e1> group ( 14.9 +/- 0.17 10(-3 ) mm2 ) but lower in the enalapril-treated group ( 11.5 +/- 0.15 10(-3 ) mm2 ) compared with the <e2>hypertensive</e2> controls ( 12.1 +/- 0.17 10(-3 ) mm2 ) .
D004656_D005921 NONE Renal plasma flow increased , but albumin excretion and <e2>glomerulosclerosis</e2> did not change after <e1>enalapril</e1> treatment .
D009568_D005921 NONE Furthermore , <e2>glomerulosclerosis</e2> index was significantly increased in the <e1>nitrendipine-treated</e1> group compared with the hypertensive controls ( 0.38 +/- 0.1 versus 0.13 +/- 0.04 ) .
16858720
D014859_D002543 CID <e2>Cerebral haemorrhage</e2> induced by <e1>warfarin</e1> - the influence of drug-drug interactions .
D014859_D002543 CID PURPOSE : To evaluate the frequency , severity and preventability of <e1>warfarin-induced</e1> <e2>cerebral haemorrhages</e2> due to warfarin and warfarin-drug interactions in patients living in the county of Osterg tland , Sweden .
D014859_D002543 CID PURPOSE : To evaluate the frequency , severity and preventability of warfarin-induced <e2>cerebral haemorrhages</e2> due to <e1>warfarin</e1> and warfarin-drug interactions in patients living in the county of Osterg tland , Sweden .
D014859_D002543 CID PURPOSE : To evaluate the frequency , severity and preventability of warfarin-induced <e2>cerebral haemorrhages</e2> due to warfarin and <e1>warfarin-drug</e1> interactions in patients living in the county of Osterg tland , Sweden .
D014859_D002543 CID Medical records were studied retrospectively to evaluate whether <e1>warfarin</e1> and warfarin-drug interactions could have caused the <e2>cerebral haemorrhage</e2> .
D014859_D002543 CID Medical records were studied retrospectively to evaluate whether warfarin and <e1>warfarin-drug</e1> interactions could have caused the <e2>cerebral haemorrhage</e2> .
D014859_D002543 CID RESULTS : Among 593 patients with <e2>cerebral haemorrhage</e2> , 59 ( 10 % ) were assessed as related to <e1>warfarin</e1> treatment .
D014859_D002543 CID CONCLUSIONS : <e1>Warfarin-induced</e1> <e2>cerebral haemorrhages</e2> are a major clinical problem with a high fatality rate .
D014859_D002543 CID A significant proportion of <e1>warfarin-related</e1> <e2>cerebral haemorrhages</e2> might have been prevented if greater caution had been taken when prescribing drugs known to interact with warfarin .
D014859_D002543 CID A significant proportion of warfarin-related <e2>cerebral haemorrhages</e2> might have been prevented if greater caution had been taken when prescribing drugs known to interact with <e1>warfarin</e1> .
D014859_D006470 NONE A <e1>warfarin-drug</e1> interaction could have contributed to the <e2>haemorrhage</e2> in 24 ( 41 % ) of the warfarin patients and in 7 of these ( 12 % ) the bleeding complication was considered being possible to avoid .
D014859_D006470 NONE A <e1>warfarin-drug</e1> interaction could have contributed to the haemorrhage in 24 ( 41 % ) of the warfarin patients and in 7 of these ( 12 % ) the <e2>bleeding</e2> complication was considered being possible to avoid .
D014859_D006470 NONE A warfarin-drug interaction could have contributed to the <e2>haemorrhage</e2> in 24 ( 41 % ) of the <e1>warfarin</e1> patients and in 7 of these ( 12 % ) the bleeding complication was considered being possible to avoid .
D014859_D006470 NONE A warfarin-drug interaction could have contributed to the haemorrhage in 24 ( 41 % ) of the <e1>warfarin</e1> patients and in 7 of these ( 12 % ) the <e2>bleeding</e2> complication was considered being possible to avoid .
3173179
D014700_D009203 CID <e1>Verapamil</e1> withdrawal as a possible cause of <e2>myocardial infarction</e2> in a hypertensive woman with a normal coronary angiogram .
D014700_D009203 CID We report a case in which <e2>myocardial infarction</e2> coincided with the introduction of captopril and the withdrawal of <e1>verapamil</e1> in a previously asymptomatic woman with severe hypertension .
D014700_D006973 NONE <e1>Verapamil</e1> withdrawal as a possible cause of myocardial infarction in a <e2>hypertensive</e2> woman with a normal coronary angiogram .
D014700_D006973 NONE We report a case in which myocardial infarction coincided with the introduction of captopril and the withdrawal of <e1>verapamil</e1> in a previously asymptomatic woman with severe <e2>hypertension</e2> .
D002216_D009203 NONE We report a case in which <e2>myocardial infarction</e2> coincided with the introduction of <e1>captopril</e1> and the withdrawal of verapamil in a previously asymptomatic woman with severe hypertension .
D002216_D006973 NONE We report a case in which myocardial infarction coincided with the introduction of <e1>captopril</e1> and the withdrawal of verapamil in a previously asymptomatic woman with severe <e2>hypertension</e2> .
12202650
D002211_D063806 NONE <e1>Capsaicin-induced</e1> <e2>muscle pain</e2> alters the excitability of the human jaw-stretch reflex .
D002211_D010146 CID <e1>Capsaicin</e1> ( 10 micro g ) was injected into the masseter muscle to induce <e2>pain</e2> in 11 healthy volunteers .
1833784
D004298_D006948 NONE Evidence for an involvement of D1 and D2 <e1>dopamine</e1> receptors in mediating nicotine-induced <e2>hyperactivity</e2> in rats .
D009538_D006948 CID Evidence for an involvement of D1 and D2 dopamine receptors in mediating <e1>nicotine-induced</e1> <e2>hyperactivity</e2> in rats .
D009538_D006948 CID <e1>Nicotine</e1> ( 1.0 mg/kg ) caused a significant <e2>increase in locomotor activity</e2> in rats that were habituated to the test environment , but had only a weak and delayed stimulant action in rats that were unfamiliar with the test environment .
D009538_D006948 CID <e1>Nicotine-induced</e1> <e2>hyperactivity</e2> was blocked by the selective D1 antagonist SCH 23390 , the selective D2 antagonist raclopride and the D1/D2 antagonist fluphenazine .
D009538_D006948 CID Pretreatment with the D2 agonist PHNO enhanced <e1>nicotine-induced</e1> <e2>hyperactivity</e2> , whereas the D1 agonist SKF 38393 had no effect .
D009538_D006948 CID The results indicate that acute <e1>nicotine</e1> injection induces a pronounced <e2>hyperactivity</e2> in rats habituated to the test environment .
C534628_D006948 NONE Nicotine-induced <e2>hyperactivity</e2> was blocked by the selective D1 antagonist <e1>SCH 23390</e1> , the selective D2 antagonist raclopride and the D1/D2 antagonist fluphenazine .
D020891_D006948 NONE Nicotine-induced <e2>hyperactivity</e2> was blocked by the selective D1 antagonist SCH 23390 , the selective D2 antagonist <e1>raclopride</e1> and the D1/D2 antagonist fluphenazine .
D005476_D006948 NONE Nicotine-induced <e2>hyperactivity</e2> was blocked by the selective D1 antagonist SCH 23390 , the selective D2 antagonist raclopride and the D1/D2 antagonist <e1>fluphenazine</e1> .
-1_D006948 NONE Pretreatment with the D2 agonist <e1>PHNO</e1> enhanced nicotine-induced <e2>hyperactivity</e2> , whereas the D1 agonist SKF 38393 had no effect .
D015647_D006948 NONE Pretreatment with the D2 agonist PHNO enhanced nicotine-induced <e2>hyperactivity</e2> , whereas the D1 agonist <e1>SKF 38393</e1> had no effect .
3371379
D014700_D020258 CID <e1>Verapamil-induced</e1> carbamazepine <e2>neurotoxicity</e2> .
D014700_D020258 CID Two patients with signs of carbamazepine <e2>neurotoxicity</e2> after combined treatment with <e1>verapamil</e1> showed complete recovery after discontinuation of the calcium entry blocker .
D002220_D020258 CID Verapamil-induced <e1>carbamazepine</e1> <e2>neurotoxicity</e2> .
D002220_D020258 CID Two patients with signs of <e1>carbamazepine</e1> <e2>neurotoxicity</e2> after combined treatment with verapamil showed complete recovery after discontinuation of the calcium entry blocker .
D002118_D020258 NONE Two patients with signs of carbamazepine <e2>neurotoxicity</e2> after combined treatment with verapamil showed complete recovery after discontinuation of the <e1>calcium</e1> entry blocker .
20080419
D010862_D004827 CID In this study , we investigated the therapeutic potential of bone marrow mononuclear cells ( BMCs ) in a model of <e2>epilepsy</e2> induced by <e1>pilocarpine</e1> in rats .
10457883
16938416
D013739_D050197 CID High-dose <e1>testosterone</e1> is associated with <e2>atherosclerosis</e2> in postmenopausal women .
D013739_D050197 CID METHODS : In a population-based study in 513 naturally postmenopausal women aged 54 - 67 years , we studied the association between self-reported intramuscularly administered high-dose <e1>estrogen-testosterone</e1> therapy ( estradiol- and testosterone esters ) and aortic <e2>atherosclerosis</e2> .
D013739_D050197 CID CONCLUSION : Our results suggest that high-dose <e1>testosterone</e1> therapy may adversely affect <e2>atherosclerosis</e2> in postmenopausal women and indicate that androgen replacement in these women may not be harmless .
D004967_D050197 NONE METHODS : In a population-based study in 513 naturally postmenopausal women aged 54 - 67 years , we studied the association between self-reported intramuscularly administered high-dose <e1>estrogen-testosterone</e1> therapy ( estradiol- and testosterone esters ) and aortic <e2>atherosclerosis</e2> .
C032109_D050197 NONE METHODS : In a population-based study in 513 naturally postmenopausal women aged 54 - 67 years , we studied the association between self-reported intramuscularly administered high-dose estrogen-testosterone therapy ( <e1>estradiol- and testosterone esters</e1> ) and aortic <e2>atherosclerosis</e2> .
D002784_D003920 NONE The association remained after additional adjustment for <e2>diabetes</e2> , <e1>cholesterol</e1> level , systolic blood pressure , or alcohol use .
D000431_D003920 NONE The association remained after additional adjustment for <e2>diabetes</e2> , cholesterol level , systolic blood pressure , or <e1>alcohol</e1> use .
17612891
D003024_D009205 CID Acute <e2>myocarditis</e2> associated with <e1>clozapine</e1> .
D003024_D009205 CID OBJECTIVE : A case of acute <e2>myocarditis</e2> associated with the commencement of <e1>clozapine</e1> is described , highlighting the onset , course and possible contributing factors .
D003024_D009205 CID RESULTS : A 20-year-old male with schizophrenia developed a sudden onset of <e2>myocarditis</e2> after commencement of <e1>clozapine</e1> .
D003024_D009205 CID CONCLUSIONS : <e2>Myocarditis</e2> is an increasingly recognized complication associated with the use of <e1>clozapine</e1> .
D003024_D012559 NONE RESULTS : A 20-year-old male with <e2>schizophrenia</e2> developed a sudden onset of myocarditis after commencement of <e1>clozapine</e1> .
D003024_D011618 NONE Considering that <e1>clozapine</e1> remains the gold standard in treatment of resistant <e2>psychosis</e2> , there is an urgent need to raise awareness among medical and paramedical staff involved in the care of these patients .
12716030
D006493_D002543 NONE In <e2>ICH</e2> induction using 0.014-unit collagenase , <e1>heparin</e1> enhanced the hematoma volume 3.4-fold over that seen in control ICH animals and the bleeding 7.6-fold .
D006493_D002543 NONE In ICH induction using 0.014-unit collagenase , <e1>heparin</e1> enhanced the hematoma volume 3.4-fold over that seen in control <e2>ICH</e2> animals and the bleeding 7.6-fold .
D006493_D006406 CID In ICH induction using 0.014-unit collagenase , <e1>heparin</e1> enhanced the <e2>hematoma</e2> volume 3.4-fold over that seen in control ICH animals and the bleeding 7.6-fold .
D006493_D006470 NONE In ICH induction using 0.014-unit collagenase , <e1>heparin</e1> enhanced the hematoma volume 3.4-fold over that seen in control ICH animals and the <e2>bleeding</e2> 7.6-fold .
16274958
D017255_D055154 CID Recurrent <e2>dysphonia</e2> and <e1>acitretin</e1> .
D017255_D055154 CID We report the case of a woman complaining of <e2>dysphonia</e2> while she was treated by <e1>acitretin</e1> .
D017255_D055154 CID To our knowledge , this is the first case of <e1>acitretin-induced</e1> <e2>dysphonia</e2> .
19631624
D018817_D007859 CID <e2>Learning and memory deficits</e2> in <e1>ecstasy</e1> users and their neural correlates during a face-learning task .
D018817_D007859 CID It has been consistently shown that <e1>ecstasy</e1> users display <e2>impairments in learning and memory</e2> performance .
D018817_D008569 CID <e2>Learning and memory deficits</e2> in <e1>ecstasy</e1> users and their neural correlates during a face-learning task .
D018817_D008569 CID It has been consistently shown that <e1>ecstasy</e1> users display <e2>impairments in learning and memory</e2> performance .
D002188_D007859 NONE <e2>Deficits in learning and memory</e2> : parahippocampal hyperactivity and frontocortical hypoactivity in <e1>cannabis</e1> users .
D002188_D008569 NONE <e2>Deficits in learning and memory</e2> : parahippocampal hyperactivity and frontocortical hypoactivity in <e1>cannabis</e1> users .
D002188_D006948 NONE Deficits in learning and memory : parahippocampal <e2>hyperactivity</e2> and frontocortical hypoactivity in <e1>cannabis</e1> users .
D018817_D006948 NONE A conjunction analysis of the encode and recall phases of the task revealed <e1>ecstasy-specific</e1> <e2>hyperactivity</e2> in bilateral frontal regions , left temporal , right parietal , bilateral temporal , and bilateral occipital brain regions .
D018817_D020258 NONE These <e1>ecstasy-specific</e1> effects may be related to the vulnerability of isocortical and allocortical regions to the <e2>neurotoxic</e2> effects of ecstasy .
D018817_D020258 NONE These ecstasy-specific effects may be related to the vulnerability of isocortical and allocortical regions to the <e2>neurotoxic</e2> effects of <e1>ecstasy</e1> .
1732369
D004280_D009369 NONE <e1>Dobutamine</e1> stress echocardiography : a sensitive indicator of diminished myocardial function in asymptomatic doxorubicin-treated long-term survivors of childhood <e2>cancer</e2> .
D004280_D009369 NONE To develop a more sensitive echocardiographic screening test for cardiac damage due to doxorubicin , a cohort study was performed using <e1>dobutamine</e1> infusion to differentiate asymptomatic long-term survivors of childhood <e2>cancer</e2> treated with doxorubicin from healthy control subjects .
D004317_D009369 NONE Dobutamine stress echocardiography : a sensitive indicator of diminished myocardial function in asymptomatic <e1>doxorubicin-treated</e1> long-term survivors of childhood <e2>cancer</e2> .
D004317_D009369 NONE To develop a more sensitive echocardiographic screening test for cardiac damage due to <e1>doxorubicin</e1> , a cohort study was performed using dobutamine infusion to differentiate asymptomatic long-term survivors of childhood <e2>cancer</e2> treated with doxorubicin from healthy control subjects .
D004317_D009369 NONE To develop a more sensitive echocardiographic screening test for cardiac damage due to doxorubicin , a cohort study was performed using dobutamine infusion to differentiate asymptomatic long-term survivors of childhood <e2>cancer</e2> treated with <e1>doxorubicin</e1> from healthy control subjects .
D004317_D009202 CID <e1>Doxorubicin</e1> is an effective anticancer chemotherapeutic agent known to cause acute and chronic <e2>cardiomyopathy</e2> .
D004317_D006331 NONE To develop a more sensitive echocardiographic screening test for <e2>cardiac damage</e2> due to <e1>doxorubicin</e1> , a cohort study was performed using dobutamine infusion to differentiate asymptomatic long-term survivors of childhood cancer treated with doxorubicin from healthy control subjects .
D004317_D006331 NONE To develop a more sensitive echocardiographic screening test for <e2>cardiac damage</e2> due to doxorubicin , a cohort study was performed using dobutamine infusion to differentiate asymptomatic long-term survivors of childhood cancer treated with <e1>doxorubicin</e1> from healthy control subjects .
D004280_D006331 NONE To develop a more sensitive echocardiographic screening test for <e2>cardiac damage</e2> due to doxorubicin , a cohort study was performed using <e1>dobutamine</e1> infusion to differentiate asymptomatic long-term survivors of childhood cancer treated with doxorubicin from healthy control subjects .
3629586
D015790_D006402 NONE The hematologic effects of <e1>cefonicid</e1> and cefazedone in the dog : a potential model of cephalosporin <e2>hematotoxicity</e2> in man .
D015790_D006402 NONE A nonregenerative anemia was the most compromising of the <e2>cytopenias</e2> and occurred in approximately 50 % of dogs receiving 400 - 500 mg/kg <e1>cefonicid</e1> or 540 - 840 mg/kg cefazedone .
D015790_D006402 NONE Upon rechallenge with either cephalosporin , the <e2>hematologic syndrome</e2> was reproduced in most dogs tested ; <e1>cefonicid</e1> ( but not cefazedone)-treated dogs showed a substantially reduced induction period ( 15 +/- 5 days ) compared to that of the first exposure to the drug ( 61 +/- 24 days ) .
D015790_D006402 NONE We conclude that the administration of high doses of <e1>cefonicid</e1> or cefazedone to dogs can induce <e2>hematotoxicity</e2> similar to the cephalosporin-induced blood dyscrasias described in man and thus provides a useful model for studying the mechanisms of these disorders .
D015790_D006402 NONE We conclude that the administration of high doses of <e1>cefonicid</e1> or cefazedone to dogs can induce hematotoxicity similar to the cephalosporin-induced <e2>blood dyscrasias</e2> described in man and thus provides a useful model for studying the mechanisms of these disorders .
C021341_D006402 NONE The hematologic effects of cefonicid and <e1>cefazedone</e1> in the dog : a potential model of cephalosporin <e2>hematotoxicity</e2> in man .
C021341_D006402 NONE A nonregenerative anemia was the most compromising of the <e2>cytopenias</e2> and occurred in approximately 50 % of dogs receiving 400 - 500 mg/kg cefonicid or 540 - 840 mg/kg <e1>cefazedone</e1> .
C021341_D006402 NONE Upon rechallenge with either cephalosporin , the <e2>hematologic syndrome</e2> was reproduced in most dogs tested ; cefonicid ( but not <e1>cefazedone)-treated</e1> dogs showed a substantially reduced induction period ( 15 +/- 5 days ) compared to that of the first exposure to the drug ( 61 +/- 24 days ) .
C021341_D006402 NONE We conclude that the administration of high doses of cefonicid or <e1>cefazedone</e1> to dogs can induce <e2>hematotoxicity</e2> similar to the cephalosporin-induced blood dyscrasias described in man and thus provides a useful model for studying the mechanisms of these disorders .
C021341_D006402 NONE We conclude that the administration of high doses of cefonicid or <e1>cefazedone</e1> to dogs can induce hematotoxicity similar to the cephalosporin-induced <e2>blood dyscrasias</e2> described in man and thus provides a useful model for studying the mechanisms of these disorders .
D002511_D006402 NONE The hematologic effects of cefonicid and cefazedone in the dog : a potential model of <e1>cephalosporin</e1> <e2>hematotoxicity</e2> in man .
D002511_D006402 NONE <e1>Cephalosporin</e1> antibiotics cause a variety of <e2>hematologic disturbances</e2> in man , the pathogeneses and hematopathology of which remain poorly characterized .
D002511_D006402 NONE Upon rechallenge with either <e1>cephalosporin</e1> , the <e2>hematologic syndrome</e2> was reproduced in most dogs tested ; cefonicid ( but not cefazedone)-treated dogs showed a substantially reduced induction period ( 15 +/- 5 days ) compared to that of the first exposure to the drug ( 61 +/- 24 days ) .
D002511_D006402 NONE We conclude that the administration of high doses of cefonicid or cefazedone to dogs can induce <e2>hematotoxicity</e2> similar to the <e1>cephalosporin-induced</e1> blood dyscrasias described in man and thus provides a useful model for studying the mechanisms of these disorders .
D002511_D006402 NONE We conclude that the administration of high doses of cefonicid or cefazedone to dogs can induce hematotoxicity similar to the <e1>cephalosporin-induced</e1> <e2>blood dyscrasias</e2> described in man and thus provides a useful model for studying the mechanisms of these disorders .
D015790_D064420 NONE In four subacute <e2>toxicity</e2> studies , the intravenous administration of <e1>cefonicid</e1> or cefazedone to beagle dogs caused a dose-dependent incidence of anemia , neutropenia , and thrombocytopenia after 1 - 3 months of treatment .
D015790_D000740 CID In four subacute toxicity studies , the intravenous administration of <e1>cefonicid</e1> or cefazedone to beagle dogs caused a dose-dependent incidence of <e2>anemia</e2> , neutropenia , and thrombocytopenia after 1 - 3 months of treatment .
D015790_D000740 CID A nonregenerative <e2>anemia</e2> was the most compromising of the cytopenias and occurred in approximately 50 % of dogs receiving 400 - 500 mg/kg <e1>cefonicid</e1> or 540 - 840 mg/kg cefazedone .
D015790_D009503 CID In four subacute toxicity studies , the intravenous administration of <e1>cefonicid</e1> or cefazedone to beagle dogs caused a dose-dependent incidence of anemia , <e2>neutropenia</e2> , and thrombocytopenia after 1 - 3 months of treatment .
D015790_D013921 CID In four subacute toxicity studies , the intravenous administration of <e1>cefonicid</e1> or cefazedone to beagle dogs caused a dose-dependent incidence of anemia , neutropenia , and <e2>thrombocytopenia</e2> after 1 - 3 months of treatment .
C021341_D064420 NONE In four subacute <e2>toxicity</e2> studies , the intravenous administration of cefonicid or <e1>cefazedone</e1> to beagle dogs caused a dose-dependent incidence of anemia , neutropenia , and thrombocytopenia after 1 - 3 months of treatment .
C021341_D000740 CID In four subacute toxicity studies , the intravenous administration of cefonicid or <e1>cefazedone</e1> to beagle dogs caused a dose-dependent incidence of <e2>anemia</e2> , neutropenia , and thrombocytopenia after 1 - 3 months of treatment .
C021341_D000740 CID A nonregenerative <e2>anemia</e2> was the most compromising of the cytopenias and occurred in approximately 50 % of dogs receiving 400 - 500 mg/kg cefonicid or 540 - 840 mg/kg <e1>cefazedone</e1> .
C021341_D009503 CID In four subacute toxicity studies , the intravenous administration of cefonicid or <e1>cefazedone</e1> to beagle dogs caused a dose-dependent incidence of anemia , <e2>neutropenia</e2> , and thrombocytopenia after 1 - 3 months of treatment .
C021341_D013921 CID In four subacute toxicity studies , the intravenous administration of cefonicid or <e1>cefazedone</e1> to beagle dogs caused a dose-dependent incidence of anemia , neutropenia , and <e2>thrombocytopenia</e2> after 1 - 3 months of treatment .
14698717
D010672_D011605 NONE <e2>Acute psychosis</e2> due to treatment with <e1>phenytoin</e1> in a nonepileptic patient .
D010672_D011605 NONE The case of a nonepileptic patient who developed <e2>psychosis</e2> following <e1>phenytoin</e1> treatment for trigeminal neuralgia is described .
D010672_D011605 NONE This case suggests that the <e2>psychotic symptoms</e2> that occur following <e1>phenytoin</e1> treatment in some epileptic patients may be the direct result of medication , unrelated to seizures .
D010672_D014277 NONE The case of a nonepileptic patient who developed psychosis following <e1>phenytoin</e1> treatment for <e2>trigeminal neuralgia</e2> is described .
D010672_D004827 NONE This case suggests that the psychotic symptoms that occur following <e1>phenytoin</e1> treatment in some <e2>epileptic</e2> patients may be the direct result of medication , unrelated to seizures .
D010672_D012640 NONE This case suggests that the psychotic symptoms that occur following <e1>phenytoin</e1> treatment in some epileptic patients may be the direct result of medication , unrelated to <e2>seizures</e2> .
17931375
D006493_D003288 CID A study on the effect of the duration of subcutaneous <e1>heparin</e1> injection on <e2>bruising</e2> and pain .
D006493_D003288 CID AIM : This study was carried out to determine the effect of injection duration on <e2>bruising</e2> and pain following the administration of the subcutaneous injection of <e1>heparin</e1> .
D006493_D003288 CID BACKGROUND : Although different methods to prevent <e2>bruising</e2> and pain following the subcutaneous injection of <e1>heparin</e1> have been widely studied and described , the effect of injection duration on the occurrence of bruising and pain is little documented .
D006493_D003288 CID BACKGROUND : Although different methods to prevent bruising and pain following the subcutaneous injection of <e1>heparin</e1> have been widely studied and described , the effect of injection duration on the occurrence of <e2>bruising</e2> and pain is little documented .
D006493_D003288 CID Dimensions of the <e2>bruising</e2> on the <e1>heparin</e1> applied areas were measured using transparent millimetric measuring paper .
D006493_D003288 CID CONCLUSIONS : It was determined that injection duration had an effect on <e2>bruising</e2> and pain following the subcutaneous administration of <e1>heparin</e1> .
D006493_D010146 CID A study on the effect of the duration of subcutaneous <e1>heparin</e1> injection on bruising and <e2>pain</e2> .
D006493_D010146 CID AIM : This study was carried out to determine the effect of injection duration on bruising and <e2>pain</e2> following the administration of the subcutaneous injection of <e1>heparin</e1> .
D006493_D010146 CID BACKGROUND : Although different methods to prevent bruising and <e2>pain</e2> following the subcutaneous injection of <e1>heparin</e1> have been widely studied and described , the effect of injection duration on the occurrence of bruising and pain is little documented .
D006493_D010146 CID BACKGROUND : Although different methods to prevent bruising and pain following the subcutaneous injection of <e1>heparin</e1> have been widely studied and described , the effect of injection duration on the occurrence of bruising and <e2>pain</e2> is little documented .
D006493_D010146 CID CONCLUSIONS : It was determined that injection duration had an effect on bruising and <e2>pain</e2> following the subcutaneous administration of <e1>heparin</e1> .
2696505
D007741_D007022 CID A randomized comparison of <e1>labetalol</e1> and nitroprusside for induced <e2>hypotension</e2> .
D007741_D007022 CID In a randomized study , <e1>labetalol-induced</e1> <e2>hypotension</e2> and nitroprusside-induced hypotension were compared in 20 patients ( 10 in each group ) scheduled for major orthopedic procedures .
D007741_D007022 CID In a randomized study , <e1>labetalol-induced</e1> hypotension and nitroprusside-induced <e2>hypotension</e2> were compared in 20 patients ( 10 in each group ) scheduled for major orthopedic procedures .
D009599_D007022 CID A randomized comparison of labetalol and <e1>nitroprusside</e1> for induced <e2>hypotension</e2> .
D009599_D007022 CID In a randomized study , labetalol-induced <e2>hypotension</e2> and <e1>nitroprusside-induced</e1> hypotension were compared in 20 patients ( 10 in each group ) scheduled for major orthopedic procedures .
D009599_D007022 CID In a randomized study , labetalol-induced hypotension and <e1>nitroprusside-induced</e1> <e2>hypotension</e2> were compared in 20 patients ( 10 in each group ) scheduled for major orthopedic procedures .
D009599_D016534 CID Nitroprusside infusion was associated with a significant ( p less than 0.05 ) <e2>increase in heart rate and cardiac output</e2> ; rebound hypertension was observed in three patients after discontinuation of <e1>nitroprusside</e1> .
D009599_D006973 NONE Nitroprusside infusion was associated with a significant ( p less than 0.05 ) increase in heart rate and cardiac output ; rebound <e2>hypertension</e2> was observed in three patients after discontinuation of <e1>nitroprusside</e1> .
10579464
C121249_D006948 NONE <e1>NRA0160</e1> and clozapine antagonized locomotor <e2>hyperactivity</e2> induced by methamphetamine ( MAP ) in mice .
D003024_D006948 NONE NRA0160 and <e1>clozapine</e1> antagonized locomotor <e2>hyperactivity</e2> induced by methamphetamine ( MAP ) in mice .
D008694_D006948 CID NRA0160 and clozapine antagonized locomotor <e2>hyperactivity</e2> induced by <e1>methamphetamine</e1> ( MAP ) in mice .
D008694_D006948 CID NRA0160 and clozapine antagonized locomotor <e2>hyperactivity</e2> induced by methamphetamine ( <e1>MAP</e1> ) in mice .
C121249_D002375 CID <e1>NRA0160</e1> and clozapine significantly induced <e2>catalepsy</e2> in rats , although their effects did not exceed 50 % induction even at the highest dose given .
D003024_D002375 CID NRA0160 and <e1>clozapine</e1> significantly induced <e2>catalepsy</e2> in rats , although their effects did not exceed 50 % induction even at the highest dose given .
19356307
D012601_D003704 NONE Components of lemon essential oil attenuate <e2>dementia</e2> induced by <e1>scopolamine</e1> .
C008281_D003704 NONE The <e2>anti-dementia</e2> effects of <e1>s-limonene</e1> and s-perillyl alcohol were observed using the passive avoidance test ( PA ) and the open field habituation test ( OFH ) .
C032208_D003704 NONE The <e2>anti-dementia</e2> effects of s-limonene and <e1>s-perillyl alcohol</e1> were observed using the passive avoidance test ( PA ) and the open field habituation test ( OFH ) .
D012601_D008569 CID These lemon essential oils showed strong ability to improve <e2>memory impaired</e2> by <e1>scopolamine</e1> ; however , s-perillyl alcohol relieved the deficit of associative memory in PA only , and did not improve non-associative memory significantly in OFH .
D012601_D008569 CID These lemon essential oils showed strong ability to improve memory impaired by <e1>scopolamine</e1> ; however , s-perillyl alcohol relieved the <e2>deficit of associative memory</e2> in PA only , and did not improve non-associative memory significantly in OFH .
C032208_D008569 NONE These lemon essential oils showed strong ability to improve <e2>memory impaired</e2> by scopolamine ; however , <e1>s-perillyl alcohol</e1> relieved the deficit of associative memory in PA only , and did not improve non-associative memory significantly in OFH .
C032208_D008569 NONE These lemon essential oils showed strong ability to improve memory impaired by scopolamine ; however , <e1>s-perillyl alcohol</e1> relieved the <e2>deficit of associative memory</e2> in PA only , and did not improve non-associative memory significantly in OFH .
2273650
D012601_D000647 CID <e2>Amnesia</e2> produced by <e1>scopolamine</e1> and cycloheximide were reversed by morphine given 30 min before the test trial ( pre-test ) , and pre-test morphine also facilitated the memory retrieval in the animals administered naloxone during the training trial .
D012601_D000647 CID Similarly , pre-test <e1>scopolamine</e1> partially reversed the scopolamine-induced <e2>amnesia</e2> , but not significantly ; and pre-test cycloheximide failed to reverse the cycloheximide-induced amnesia .
D012601_D000647 CID Similarly , pre-test <e1>scopolamine</e1> partially reversed the scopolamine-induced amnesia , but not significantly ; and pre-test cycloheximide failed to reverse the cycloheximide-induced <e2>amnesia</e2> .
D012601_D000647 CID Similarly , pre-test scopolamine partially reversed the <e1>scopolamine-induced</e1> <e2>amnesia</e2> , but not significantly ; and pre-test cycloheximide failed to reverse the cycloheximide-induced amnesia .
D012601_D000647 CID Similarly , pre-test scopolamine partially reversed the <e1>scopolamine-induced</e1> amnesia , but not significantly ; and pre-test cycloheximide failed to reverse the cycloheximide-induced <e2>amnesia</e2> .
D003513_D000647 CID <e2>Amnesia</e2> produced by scopolamine and <e1>cycloheximide</e1> were reversed by morphine given 30 min before the test trial ( pre-test ) , and pre-test morphine also facilitated the memory retrieval in the animals administered naloxone during the training trial .
D003513_D000647 CID Similarly , pre-test scopolamine partially reversed the scopolamine-induced <e2>amnesia</e2> , but not significantly ; and pre-test <e1>cycloheximide</e1> failed to reverse the cycloheximide-induced amnesia .
D003513_D000647 CID Similarly , pre-test scopolamine partially reversed the scopolamine-induced amnesia , but not significantly ; and pre-test <e1>cycloheximide</e1> failed to reverse the cycloheximide-induced <e2>amnesia</e2> .
D003513_D000647 CID Similarly , pre-test scopolamine partially reversed the scopolamine-induced <e2>amnesia</e2> , but not significantly ; and pre-test cycloheximide failed to reverse the <e1>cycloheximide-induced</e1> amnesia .
D003513_D000647 CID Similarly , pre-test scopolamine partially reversed the scopolamine-induced amnesia , but not significantly ; and pre-test cycloheximide failed to reverse the <e1>cycloheximide-induced</e1> <e2>amnesia</e2> .
D009020_D000647 NONE <e2>Amnesia</e2> produced by scopolamine and cycloheximide were reversed by <e1>morphine</e1> given 30 min before the test trial ( pre-test ) , and pre-test morphine also facilitated the memory retrieval in the animals administered naloxone during the training trial .
D009020_D000647 NONE <e2>Amnesia</e2> produced by scopolamine and cycloheximide were reversed by morphine given 30 min before the test trial ( pre-test ) , and pre-test <e1>morphine</e1> also facilitated the memory retrieval in the animals administered naloxone during the training trial .
D009270_D000647 NONE <e2>Amnesia</e2> produced by scopolamine and cycloheximide were reversed by morphine given 30 min before the test trial ( pre-test ) , and pre-test morphine also facilitated the memory retrieval in the animals administered <e1>naloxone</e1> during the training trial .
18217897
D013792_D008228 NONE <e1>Thalidomide</e1> has limited single-agent activity in relapsed or refractory indolent <e2>non-Hodgkin lymphomas</e2> : a phase II trial of the Cancer and Leukemia Group B.
D013792_D009369 NONE <e1>Thalidomide</e1> has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas : a phase II trial of the <e2>Cancer</e2> and Leukemia Group B.
D013792_D007938 NONE <e1>Thalidomide</e1> has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas : a phase II trial of the Cancer and <e2>Leukemia</e2> Group B.
D013792_D009101 NONE <e1>Thalidomide</e1> is an immunomodulatory agent with demonstrated activity in <e2>multiple myeloma</e2> , mantle cell lymphoma and lymphoplasmacytic lymphoma .
D013792_D020522 NONE <e1>Thalidomide</e1> is an immunomodulatory agent with demonstrated activity in multiple myeloma , <e2>mantle cell lymphoma</e2> and lymphoplasmacytic lymphoma .
D013792_D008223 NONE <e1>Thalidomide</e1> is an immunomodulatory agent with demonstrated activity in multiple myeloma , mantle cell lymphoma and <e2>lymphoplasmacytic lymphoma</e2> .
D013792_D008223 NONE Between July 2001 and April 2004 , 24 patients with relapsed/refractory indolent <e2>lymphomas</e2> received <e1>thalidomide</e1> 200 mg daily with escalation by 100 mg daily every 1 - 2 weeks as tolerated , up to a maximum of 800 mg daily .
D013792_D008223 NONE Our results failed to demonstrate an important response rate to single agent <e1>thalidomide</e1> in indolent <e2>lymphomas</e2> and contrast with the higher activity level reported with the second generation immunomodulatory agent , lenalidomide .
C467567_D008223 NONE Our results failed to demonstrate an important response rate to single agent thalidomide in indolent <e2>lymphomas</e2> and contrast with the higher activity level reported with the second generation immunomodulatory agent , <e1>lenalidomide</e1> .
3070035
D002216_D051437 NONE Reversibility of <e1>captopril-induced</e1> <e2>renal insufficiency</e2> after prolonged use in an unusual case of renovascular hypertension .
D002216_D051437 NONE This indicates reversibility in <e1>captopril-induced</e1> <e2>renal failure</e2> even after its prolonged use and suggests that no organic damage occurs to glomerular arterioles following chronic ACE inhibition .
D002216_D006978 NONE Reversibility of <e1>captopril-induced</e1> renal insufficiency after prolonged use in an unusual case of <e2>renovascular hypertension</e2> .
D002216_D006973 NONE We report a case of severe <e2>hypertension</e2> with an occluded renal artery to a solitary kidney , who developed sudden deterioration of renal function following treatment with <e1>captopril</e1> .
D002216_D058186 CID We report a case of severe hypertension with an occluded renal artery to a solitary kidney , who developed <e2>sudden deterioration of renal function</e2> following treatment with <e1>captopril</e1> .
1987816
D008094_D011141 CID <e1>Lithium-induced</e1> <e2>polyuria</e2> seems to be related to extrarenal as well as to renal effects .
4008111
D000638_D012848 CID <e1>Amiodarone-induced</e1> <e2>sinoatrial block</e2> .
D000638_D012848 CID We observed <e2>sinoatrial block</e2> due to chronic <e1>amiodarone</e1> administration in a 5-year-old boy with primary cardiomyopathy , Wolff-Parkinson-White syndrome and supraventricular tachycardia .
D000638_D012848 CID Reduction in the dosage of <e1>amiodarone</e1> resulted in the disappearance of the <e2>sinoatrial block</e2> and the persistence of asymptomatic sinus bradycardia .
D000638_D009202 NONE We observed sinoatrial block due to chronic <e1>amiodarone</e1> administration in a 5-year-old boy with <e2>primary cardiomyopathy</e2> , Wolff-Parkinson-White syndrome and supraventricular tachycardia .
D000638_D014927 NONE We observed sinoatrial block due to chronic <e1>amiodarone</e1> administration in a 5-year-old boy with primary cardiomyopathy , <e2>Wolff-Parkinson-White syndrome</e2> and supraventricular tachycardia .
D000638_D013617 NONE We observed sinoatrial block due to chronic <e1>amiodarone</e1> administration in a 5-year-old boy with primary cardiomyopathy , Wolff-Parkinson-White syndrome and <e2>supraventricular tachycardia</e2> .
D000638_D012804 NONE Reduction in the dosage of <e1>amiodarone</e1> resulted in the disappearance of the sinoatrial block and the persistence of asymptomatic <e2>sinus bradycardia</e2> .
3425586
D003622_D000743 CID <e1>Dapsone-associated</e1> Heinz body <e2>hemolytic anemia</e2> in a Cambodian woman with hemoglobin E trait .
D003622_D000743 CID A Cambodian woman with hemoglobin E trait ( AE ) and leprosy developed a Heinz body <e2>hemolytic anemia</e2> while taking a dose of <e1>dapsone</e1> ( 50 mg/day ) not usually associated with clinical hemolysis .
D003622_D000743 CID Thus , AE RBCs appear to have an increased sensitivity to oxidant stress both in vitro and in vivo , since <e1>dapsone</e1> does not cause <e2>hemolytic anemia</e2> at this dose in hematologically normal individuals .
D003622_D007918 NONE A Cambodian woman with hemoglobin E trait ( AE ) and <e2>leprosy</e2> developed a Heinz body hemolytic anemia while taking a dose of <e1>dapsone</e1> ( 50 mg/day ) not usually associated with clinical hemolysis .
D003622_D006461 NONE A Cambodian woman with hemoglobin E trait ( AE ) and leprosy developed a Heinz body hemolytic anemia while taking a dose of <e1>dapsone</e1> ( 50 mg/day ) not usually associated with clinical <e2>hemolysis</e2> .
15338796
D000420_D014202 CID <e2>Tremor</e2> side effects of <e1>salbutamol</e1> , quantified by a laser pointer technique .
D000420_D014202 CID OBJECTIVE : To study <e2>tremor</e2> side effects of <e1>salbutamol</e1> an easily applicable , quick and low-priced method is needed .
D000420_D014202 CID To determine sensitivity we assessed <e2>tremor</e2> in 44 patients with obstructive lung disease after administration of cumulative doses of <e1>salbutamol</e1> .
D000420_D014202 CID RESULTS : <e1>Salbutamol</e1> significantly increased <e2>tremor</e2> severity in patients in a dose-dependent way .
D000420_D008173 NONE To determine sensitivity we assessed tremor in 44 patients with <e2>obstructive lung disease</e2> after administration of cumulative doses of <e1>salbutamol</e1> .
3358181
D012312_D014693 CID <e2>Ventricular tachyarrhythmias</e2> during cesarean section after <e1>ritodrine</e1> therapy : interaction with anesthetics .
D012312_D007752 NONE This case illustrates that patients receiving <e1>ritodrine</e1> for <e2>preterm labor</e2> may risk interactions between the residual betamimetic effects of ritodrine and the effects of anesthetics during cesarean section .
D012312_D007752 NONE This case illustrates that patients receiving ritodrine for <e2>preterm labor</e2> may risk interactions between the residual betamimetic effects of <e1>ritodrine</e1> and the effects of anesthetics during cesarean section .
D012312_D002318 NONE Such interactions may result in serious <e2>cardiovascular complications</e2> even after cessation of an infusion of <e1>ritodrine</e1> .
D010656_D007022 NONE After delivery of the infant , there should be no contraindication to the use of an alpha-adrenergic vasopressor such as <e1>phenylephrine</e1> to treat <e2>hypotensive</e2> patients with tachycardia .
D010656_D013610 NONE After delivery of the infant , there should be no contraindication to the use of an alpha-adrenergic vasopressor such as <e1>phenylephrine</e1> to treat hypotensive patients with <e2>tachycardia</e2> .
19581773
C417083_D009157 CID Development of <e2>ocular myasthenia</e2> during <e1>pegylated interferon</e1> and ribavirin treatment for chronic hepatitis C.
C417083_D009157 CID The <e2>ocular myasthenia</e2> associated with combination therapy of <e1>pegylated IFN alpha-2b</e1> and ribavirin for CHC is very rarely reported ; therefore , we present this case with a review of the various eye complications of IFN therapy .
C417083_D009157 CID The <e2>ocular myasthenia</e2> associated with combination therapy of pegylated IFN alpha-2b and ribavirin for CHC is very rarely reported ; therefore , we present this case with a review of the various eye complications of <e1>IFN</e1> therapy .
C417083_D019698 NONE Development of ocular myasthenia during <e1>pegylated interferon</e1> and ribavirin treatment for <e2>chronic hepatitis C.</e2>
C417083_D019698 NONE A 63-year-old male experienced sudden diplopia after 9 weeks of administration of <e1>pegylated interferon ( IFN ) alpha-2b</e1> and ribavirin for <e2>chronic hepatitis C</e2> ( CHC ) .
C417083_D019698 NONE A 63-year-old male experienced sudden diplopia after 9 weeks of administration of <e1>pegylated interferon ( IFN ) alpha-2b</e1> and ribavirin for chronic hepatitis C ( <e2>CHC</e2> ) .
C417083_D019698 NONE The ocular myasthenia associated with combination therapy of <e1>pegylated IFN alpha-2b</e1> and ribavirin for <e2>CHC</e2> is very rarely reported ; therefore , we present this case with a review of the various eye complications of IFN therapy .
C417083_D019698 NONE The ocular myasthenia associated with combination therapy of pegylated IFN alpha-2b and ribavirin for <e2>CHC</e2> is very rarely reported ; therefore , we present this case with a review of the various eye complications of <e1>IFN</e1> therapy .
D012254_D009157 CID Development of <e2>ocular myasthenia</e2> during pegylated interferon and <e1>ribavirin</e1> treatment for chronic hepatitis C.
D012254_D009157 CID The <e2>ocular myasthenia</e2> associated with combination therapy of pegylated IFN alpha-2b and <e1>ribavirin</e1> for CHC is very rarely reported ; therefore , we present this case with a review of the various eye complications of IFN therapy .
D012254_D019698 NONE Development of ocular myasthenia during pegylated interferon and <e1>ribavirin</e1> treatment for <e2>chronic hepatitis C.</e2>
D012254_D019698 NONE A 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon ( IFN ) alpha-2b and <e1>ribavirin</e1> for <e2>chronic hepatitis C</e2> ( CHC ) .
D012254_D019698 NONE A 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon ( IFN ) alpha-2b and <e1>ribavirin</e1> for chronic hepatitis C ( <e2>CHC</e2> ) .
D012254_D019698 NONE The ocular myasthenia associated with combination therapy of pegylated IFN alpha-2b and <e1>ribavirin</e1> for <e2>CHC</e2> is very rarely reported ; therefore , we present this case with a review of the various eye complications of IFN therapy .
C417083_D004172 NONE A 63-year-old male experienced sudden <e2>diplopia</e2> after 9 weeks of administration of <e1>pegylated interferon ( IFN ) alpha-2b</e1> and ribavirin for chronic hepatitis C ( CHC ) .
D012254_D004172 NONE A 63-year-old male experienced sudden <e2>diplopia</e2> after 9 weeks of administration of pegylated interferon ( IFN ) alpha-2b and <e1>ribavirin</e1> for chronic hepatitis C ( CHC ) .
9088814
D000527_D007022 CID Combined effects of prolonged <e1>prostaglandin E1-induced</e1> <e2>hypotension</e2> and haemodilution on human hepatic function .
D000527_D007022 CID Combined effects of prolonged <e1>prostaglandin E1</e1> (PGE1)-induced <e2>hypotension</e2> and haemodilution on hepatic function were studied in 30 patients undergoing hip surgery .
D000527_D007022 CID Combined effects of prolonged prostaglandin E1 <e1>(PGE1)-induced</e1> <e2>hypotension</e2> and haemodilution on hepatic function were studied in 30 patients undergoing hip surgery .
D000527_D007022 CID Controlled <e2>hypotension</e2> in groups A and C was induced with <e1>PGE1</e1> to maintain mean arterial blood pressure at 55 mmHg for 180 min .
D000527_D007022 CID The results suggest that a prolonged combination of more than 120 min of <e1>PGE1-induced</e1> <e2>hypotension</e2> and moderate haemodilution would cause impairment of hepatic function .
D000527_D020141 NONE Combined effects of prolonged <e1>prostaglandin E1-induced</e1> hypotension and <e2>haemodilution</e2> on human hepatic function .
D000527_D020141 NONE Combined effects of prolonged <e1>prostaglandin E1</e1> (PGE1)-induced hypotension and <e2>haemodilution</e2> on hepatic function were studied in 30 patients undergoing hip surgery .
D000527_D020141 NONE Combined effects of prolonged prostaglandin E1 <e1>(PGE1)-induced</e1> hypotension and <e2>haemodilution</e2> on hepatic function were studied in 30 patients undergoing hip surgery .
D000527_D020141 NONE The results suggest that a prolonged combination of more than 120 min of <e1>PGE1-induced</e1> hypotension and moderate <e2>haemodilution</e2> would cause impairment of hepatic function .
D003911_D020141 NONE <e2>Haemodilution</e2> in groups B and C was produced by withdrawing approximately 1000 mL of blood and replacing it with the same amount of <e1>dextran</e1> solution , and final haematocrit values were 21 or 22 % .
D001663_D007022 NONE AKBR and biological hepatic function tests showed no change throughout the time course in groups A and B. In group C , AKBR showed a significant decrease at 120 min ( -40 % ) and at 180 min ( -49 % ) after the start of <e2>hypotension</e2> and at 60 min ( -32 % ) after recovery of normotension , and SGOT , SGPT , LDH and total <e1>bilirubin</e1> showed significant increases after operation .
D000527_D008107 CID The results suggest that a prolonged combination of more than 120 min of <e1>PGE1-induced</e1> hypotension and moderate haemodilution would cause <e2>impairment of hepatic function</e2> .
18726058
D010208_D020301 NONE BACKGROUND : <e1>Papaverine hydrochloride</e1> is a direct-acting vasodilator used to manage <e2>vasospasm</e2> during various neurosurgical operations .
D010208_D020301 NONE METHODS : We conducted a retrospective review of 70 consecutive microvascular decompression operations and studied those patients who received topical <e1>papaverine</e1> for <e2>vasospasm</e2> .
D010208_D020301 NONE Topical <e1>papaverine</e1> was used as a direct therapeutic action to manage <e2>vasospasm</e2> in a total of 11 patients .
D010208_D020301 NONE CONCLUSIONS : Topical <e1>papaverine</e1> for the treatment of <e2>vasospasm</e2> was associated with the onset of a transient disturbance in neurophysiological function of the ascending auditory brainstem pathway .
D010208_D003389 NONE Transient <e2>cranial nerve dysfunction</e2> has been described in a few cases with topical <e1>papaverine</e1> .
D010208_D003389 NONE Recommendations to avoid potential <e2>cranial nerve deficits</e2> from <e1>papaverine</e1> are provided .
17639754
D014859_D006470 CID We report 3 cases of serious <e2>bleeding</e2> complications that appear to be the result of the interaction between <e1>warfarin</e1> and levofloxacin .
D064704_D006470 CID We report 3 cases of serious <e2>bleeding</e2> complications that appear to be the result of the interaction between warfarin and <e1>levofloxacin</e1> .
19473225
D018698_D010523 NONE Long-term <e1>glutamate</e1> supplementation failed to protect against <e2>peripheral neurotoxicity</e2> of paclitaxel .
D018698_D010523 NONE Toxic <e2>peripheral neuropathy</e2> is still a significant limiting factor for chemotherapy with paclitaxel ( PAC ) , although <e1>glutamate</e1> and its closely related amino acid glutamine were claimed to ameliorate PAC neurotoxicity .
D018698_D010523 NONE Toxic <e2>peripheral neuropathy</e2> is still a significant limiting factor for chemotherapy with paclitaxel ( PAC ) , although glutamate and its closely related amino acid <e1>glutamine</e1> were claimed to ameliorate PAC neurotoxicity .
D018698_D010523 NONE This pilot trial aimed to evaluate the role of <e1>glutamate</e1> supplementation for preventing PAC-induced <e2>peripheral neuropathy</e2> in a randomized , placebo-controlled , double-blinded clinical and electro-diagnostic study .
D018698_D010523 NONE This pilot study leads to the conclusion that <e1>glutamate</e1> supplementation at the chosen regimen fails to protect against <e2>peripheral neurotoxicity</e2> of PAC .
D017239_D010523 CID Long-term glutamate supplementation failed to protect against <e2>peripheral neurotoxicity</e2> of <e1>paclitaxel</e1> .
D017239_D010523 CID Toxic <e2>peripheral neuropathy</e2> is still a significant limiting factor for chemotherapy with <e1>paclitaxel</e1> ( PAC ) , although glutamate and its closely related amino acid glutamine were claimed to ameliorate PAC neurotoxicity .
D017239_D010523 CID Toxic <e2>peripheral neuropathy</e2> is still a significant limiting factor for chemotherapy with paclitaxel ( <e1>PAC</e1> ) , although glutamate and its closely related amino acid glutamine were claimed to ameliorate PAC neurotoxicity .
D017239_D010523 CID Toxic <e2>peripheral neuropathy</e2> is still a significant limiting factor for chemotherapy with paclitaxel ( PAC ) , although glutamate and its closely related amino acid glutamine were claimed to ameliorate <e1>PAC</e1> neurotoxicity .
D017239_D010523 CID This pilot trial aimed to evaluate the role of glutamate supplementation for preventing <e1>PAC-induced</e1> <e2>peripheral neuropathy</e2> in a randomized , placebo-controlled , double-blinded clinical and electro-diagnostic study .
D017239_D010523 CID This pilot study leads to the conclusion that glutamate supplementation at the chosen regimen fails to protect against <e2>peripheral neurotoxicity</e2> of <e1>PAC</e1> .
D017239_D020258 NONE Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with <e1>paclitaxel</e1> ( PAC ) , although glutamate and its closely related amino acid glutamine were claimed to ameliorate PAC <e2>neurotoxicity</e2> .
D017239_D020258 NONE Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with paclitaxel ( <e1>PAC</e1> ) , although glutamate and its closely related amino acid glutamine were claimed to ameliorate PAC <e2>neurotoxicity</e2> .
D017239_D020258 NONE Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with paclitaxel ( PAC ) , although glutamate and its closely related amino acid glutamine were claimed to ameliorate <e1>PAC</e1> <e2>neurotoxicity</e2> .
D018698_D020258 NONE Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with paclitaxel ( PAC ) , although <e1>glutamate</e1> and its closely related amino acid glutamine were claimed to ameliorate PAC <e2>neurotoxicity</e2> .
D018698_D020258 NONE Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with paclitaxel ( PAC ) , although glutamate and its closely related amino acid <e1>glutamine</e1> were claimed to ameliorate PAC <e2>neurotoxicity</e2> .
D000596_D010523 NONE Toxic <e2>peripheral neuropathy</e2> is still a significant limiting factor for chemotherapy with paclitaxel ( PAC ) , although glutamate and its closely related <e1>amino acid</e1> glutamine were claimed to ameliorate PAC neurotoxicity .
D000596_D020258 NONE Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with paclitaxel ( PAC ) , although glutamate and its closely related <e1>amino acid</e1> glutamine were claimed to ameliorate PAC <e2>neurotoxicity</e2> .
D017239_D010051 NONE Forty-three <e2>ovarian cancer</e2> patients were available for analysis following six cycles of the same <e1>PAC-containing</e1> regimen : 23 had been supplemented by glutamate all along the treatment period , at a daily dose of three times 500 mg ( group G ) , and 20 had received a placebo ( group P ) .
D018698_D010051 NONE Forty-three <e2>ovarian cancer</e2> patients were available for analysis following six cycles of the same PAC-containing regimen : 23 had been supplemented by <e1>glutamate</e1> all along the treatment period , at a daily dose of three times 500 mg ( group G ) , and 20 had received a placebo ( group P ) .
435349
D013390_D005207 CID <e1>Suxamethonium</e1> infusion rate and observed <e2>fasciculations</e2> .
D013390_D013746 NONE The infusion was discontinued either when there was no muscular response to <e2>tetanic</e2> stimulation of the ulnar nerve or when <e1>Sch</e1> 120 mg was exceeded .
3827439
D000666_D058186 CID Recurrent reversible <e2>acute renal failure</e2> from <e1>amphotericin</e1> .
D000666_D058186 CID A patient with cryptogenic cirrhosis and disseminated sporotrichosis developed <e2>acute renal failure</e2> immediately following the administration of <e1>amphotericin B</e1> on four separate occasions .
D000666_D058186 CID We propose that <e1>amphotericin</e1> , in the setting of reduced effective arterial volume , may activate tubuloglomerular feedback , thereby contributing to <e2>acute renal failure</e2> .
D000666_D005355 NONE A patient with cryptogenic <e2>cirrhosis</e2> and disseminated sporotrichosis developed acute renal failure immediately following the administration of <e1>amphotericin B</e1> on four separate occasions .
D000666_D013174 NONE A patient with cryptogenic cirrhosis and disseminated <e2>sporotrichosis</e2> developed acute renal failure immediately following the administration of <e1>amphotericin B</e1> on four separate occasions .
20667451
D003474_D003072 NONE <e1>Curcumin</e1> ameliorates <e2>cognitive dysfunction</e2> and oxidative damage in phenobarbitone and carbamazepine administered rats .
D003474_D003072 NONE Therefore , the present study was carried out to investigate the effect of chronic <e1>curcumin</e1> administration on phenobarbitone- and carbamazepine-induced <e2>cognitive impairment</e2> and oxidative stress in rats .
D003474_D003072 NONE Concomitant <e1>curcumin</e1> administration prevented the <e2>cognitive impairment</e2> and decreased the increased oxidative stress induced by these antiepileptic drugs .
D003474_D003072 NONE These results show that <e1>curcumin</e1> has beneficial effect in mitigating the <e2>deterioration of cognitive functions</e2> and oxidative damage in rats treated with phenobarbitone and carbamazepine without significantly altering their serum concentrations .
D003474_D003072 NONE The findings suggest that <e1>curcumin</e1> can be considered as a potential safe and effective adjuvant to phenobarbitone and carbamazepine therapy in preventing <e2>cognitive impairment</e2> associated with these drugs .
D010634_D003072 CID Curcumin ameliorates <e2>cognitive dysfunction</e2> and oxidative damage in <e1>phenobarbitone</e1> and carbamazepine administered rats .
D010634_D003072 CID The antiepileptic drugs , <e1>phenobarbitone</e1> and carbamazepine are well known to cause <e2>cognitive impairment</e2> on chronic use .
D010634_D003072 CID Therefore , the present study was carried out to investigate the effect of chronic curcumin administration on <e1>phenobarbitone-</e1> and carbamazepine-induced <e2>cognitive impairment</e2> and oxidative stress in rats .
D010634_D003072 CID The administration of <e1>phenobarbitone</e1> and carbamazepine for 21days caused a significant <e2>impairment of learning and memory</e2> as well as an increased oxidative stress .
D010634_D003072 CID These results show that curcumin has beneficial effect in mitigating the <e2>deterioration of cognitive functions</e2> and oxidative damage in rats treated with <e1>phenobarbitone</e1> and carbamazepine without significantly altering their serum concentrations .
D010634_D003072 CID The findings suggest that curcumin can be considered as a potential safe and effective adjuvant to <e1>phenobarbitone</e1> and carbamazepine therapy in preventing <e2>cognitive impairment</e2> associated with these drugs .
D002220_D003072 CID Curcumin ameliorates <e2>cognitive dysfunction</e2> and oxidative damage in phenobarbitone and <e1>carbamazepine</e1> administered rats .
D002220_D003072 CID The antiepileptic drugs , phenobarbitone and <e1>carbamazepine</e1> are well known to cause <e2>cognitive impairment</e2> on chronic use .
D002220_D003072 CID Therefore , the present study was carried out to investigate the effect of chronic curcumin administration on phenobarbitone- and <e1>carbamazepine-induced</e1> <e2>cognitive impairment</e2> and oxidative stress in rats .
D002220_D003072 CID The administration of phenobarbitone and <e1>carbamazepine</e1> for 21days caused a significant <e2>impairment of learning and memory</e2> as well as an increased oxidative stress .
D002220_D003072 CID These results show that curcumin has beneficial effect in mitigating the <e2>deterioration of cognitive functions</e2> and oxidative damage in rats treated with phenobarbitone and <e1>carbamazepine</e1> without significantly altering their serum concentrations .
D002220_D003072 CID The findings suggest that curcumin can be considered as a potential safe and effective adjuvant to phenobarbitone and <e1>carbamazepine</e1> therapy in preventing <e2>cognitive impairment</e2> associated with these drugs .
12907309
C121465_D020258 NONE Neuroprotective action of <e1>MPEP</e1> , a selective mGluR5 antagonist , in methamphetamine-induced dopaminergic <e2>neurotoxicity</e2> is associated with a decrease in dopamine outflow and inhibition of hyperthermia in rats .
C121465_D005334 NONE Neuroprotective action of <e1>MPEP</e1> , a selective mGluR5 antagonist , in methamphetamine-induced dopaminergic neurotoxicity is associated with a decrease in dopamine outflow and inhibition of <e2>hyperthermia</e2> in rats .
C121465_D005334 NONE Neuroprotection rendered by <e1>MPEP</e1> may be associated with the reduction of the methamphetamine-induced dopamine efflux in the striatum due to the blockade of extrastriatal mGluR5 , and with a decrease in <e2>hyperthermia</e2> .
D008694_D020258 NONE Neuroprotective action of MPEP , a selective mGluR5 antagonist , in <e1>methamphetamine-induced</e1> dopaminergic <e2>neurotoxicity</e2> is associated with a decrease in dopamine outflow and inhibition of hyperthermia in rats .
D008694_D005334 CID Neuroprotective action of MPEP , a selective mGluR5 antagonist , in <e1>methamphetamine-induced</e1> dopaminergic neurotoxicity is associated with a decrease in dopamine outflow and inhibition of <e2>hyperthermia</e2> in rats .
D008694_D005334 CID Moreover , it transiently diminished the <e1>methamphetamine</e1> ( 10 mg/kg sc)-induced <e2>hyperthermia</e2> and reduced basal body temperature .
D008694_D005334 CID Neuroprotection rendered by MPEP may be associated with the reduction of the <e1>methamphetamine-induced</e1> dopamine efflux in the striatum due to the blockade of extrastriatal mGluR5 , and with a decrease in <e2>hyperthermia</e2> .
D004298_D020258 NONE Neuroprotective action of MPEP , a selective mGluR5 antagonist , in methamphetamine-induced dopaminergic <e2>neurotoxicity</e2> is associated with a decrease in <e1>dopamine</e1> outflow and inhibition of hyperthermia in rats .
D004298_D005334 NONE Neuroprotective action of MPEP , a selective mGluR5 antagonist , in methamphetamine-induced dopaminergic neurotoxicity is associated with a decrease in <e1>dopamine</e1> outflow and inhibition of <e2>hyperthermia</e2> in rats .
D004298_D005334 NONE Neuroprotection rendered by MPEP may be associated with the reduction of the methamphetamine-induced <e1>dopamine</e1> efflux in the striatum due to the blockade of extrastriatal mGluR5 , and with a decrease in <e2>hyperthermia</e2> .
C121465_D064420 NONE The results of this study suggest that the blockade of mGluR5 by <e1>MPEP</e1> may protect dopaminergic neurones against methamphetamine-induced <e2>toxicity</e2> .
D008694_D064420 NONE The results of this study suggest that the blockade of mGluR5 by MPEP may protect dopaminergic neurones against <e1>methamphetamine-induced</e1> <e2>toxicity</e2> .
11391224
D003042_D006974 NONE These 13 included cases of <e2>malignant hypertension</e2> , thrombotic microangiopathy , lupus nephritis , Henoch-Schonlein nephritis , crescentic glomerulonephritis , and <e1>cocaine-related</e1> acute renal failure .
D003042_D057049 NONE These 13 included cases of malignant hypertension , <e2>thrombotic microangiopathy</e2> , lupus nephritis , Henoch-Schonlein nephritis , crescentic glomerulonephritis , and <e1>cocaine-related</e1> acute renal failure .
D003042_D008181 NONE These 13 included cases of malignant hypertension , thrombotic microangiopathy , <e2>lupus nephritis</e2> , Henoch-Schonlein nephritis , crescentic glomerulonephritis , and <e1>cocaine-related</e1> acute renal failure .
D003042_D011695 NONE These 13 included cases of malignant hypertension , thrombotic microangiopathy , lupus nephritis , <e2>Henoch-Schonlein nephritis</e2> , crescentic glomerulonephritis , and <e1>cocaine-related</e1> acute renal failure .
D003042_D005921 NONE These 13 included cases of malignant hypertension , thrombotic microangiopathy , lupus nephritis , Henoch-Schonlein nephritis , crescentic <e2>glomerulonephritis</e2> , and <e1>cocaine-related</e1> acute renal failure .
D003042_D058186 CID These 13 included cases of malignant hypertension , thrombotic microangiopathy , lupus nephritis , Henoch-Schonlein nephritis , crescentic glomerulonephritis , and <e1>cocaine-related</e1> <e2>acute renal failure</e2> .
14596845
D000661_D019966 NONE A diet promoting <e2>sugar dependency</e2> causes behavioral cross-sensitization to a low dose of <e1>amphetamine</e1> .
D000661_D006948 CID A diet promoting sugar dependency causes <e2>behavioral cross-sensitization</e2> to a low dose of <e1>amphetamine</e1> .
D000661_D006948 CID The present study examined whether female rats on various regimens of sugar access would show <e2>behavioral cross-sensitization</e2> to a low dose of <e1>amphetamine</e1> .
D000661_D006948 CID The animals that had experienced cyclic sucrose and chow were <e2>hyperactive</e2> in response to <e1>amphetamine</e1> compared with four control groups ( ad libitum 10 % sucrose and chow followed by amphetamine injection , cyclic chow followed by amphetamine injection , ad libitum chow with amphetamine , or cyclic 10 % sucrose and chow with a saline injection ) .
D000661_D006948 CID The animals that had experienced cyclic sucrose and chow were <e2>hyperactive</e2> in response to amphetamine compared with four control groups ( ad libitum 10 % sucrose and chow followed by <e1>amphetamine</e1> injection , cyclic chow followed by amphetamine injection , ad libitum chow with amphetamine , or cyclic 10 % sucrose and chow with a saline injection ) .
D000661_D006948 CID The animals that had experienced cyclic sucrose and chow were <e2>hyperactive</e2> in response to amphetamine compared with four control groups ( ad libitum 10 % sucrose and chow followed by amphetamine injection , cyclic chow followed by <e1>amphetamine</e1> injection , ad libitum chow with amphetamine , or cyclic 10 % sucrose and chow with a saline injection ) .
D000661_D006948 CID The animals that had experienced cyclic sucrose and chow were <e2>hyperactive</e2> in response to amphetamine compared with four control groups ( ad libitum 10 % sucrose and chow followed by amphetamine injection , cyclic chow followed by amphetamine injection , ad libitum chow with <e1>amphetamine</e1> , or cyclic 10 % sucrose and chow with a saline injection ) .
D013395_D006948 CID The animals that had experienced cyclic <e1>sucrose</e1> and chow were <e2>hyperactive</e2> in response to amphetamine compared with four control groups ( ad libitum 10 % sucrose and chow followed by amphetamine injection , cyclic chow followed by amphetamine injection , ad libitum chow with amphetamine , or cyclic 10 % sucrose and chow with a saline injection ) .
D013395_D006948 CID The animals that had experienced cyclic sucrose and chow were <e2>hyperactive</e2> in response to amphetamine compared with four control groups ( ad libitum 10 % <e1>sucrose</e1> and chow followed by amphetamine injection , cyclic chow followed by amphetamine injection , ad libitum chow with amphetamine , or cyclic 10 % sucrose and chow with a saline injection ) .
D013395_D006948 CID The animals that had experienced cyclic sucrose and chow were <e2>hyperactive</e2> in response to amphetamine compared with four control groups ( ad libitum 10 % sucrose and chow followed by amphetamine injection , cyclic chow followed by amphetamine injection , ad libitum chow with amphetamine , or cyclic 10 % <e1>sucrose</e1> and chow with a saline injection ) .
19445921
C066201_D009203 NONE Cardioprotective effect of <e1>salvianolic acid A</e1> on isoproterenol-induced <e2>myocardial infarction</e2> in rats .
C066201_D009203 NONE The present study was designed to evaluate the cardioprotective potential of <e1>salvianolic acid A</e1> on isoproterenol-induced <e2>myocardial infarction</e2> in rats .
C066201_D009203 NONE The results of our study suggest that <e1>salvianolic acid A</e1> possessing antioxidant activity has a significant protective effect against isoproterenol-induced <e2>myocardial infarction</e2> .
D007545_D009203 CID Cardioprotective effect of salvianolic acid A on <e1>isoproterenol-induced</e1> <e2>myocardial infarction</e2> in rats .
D007545_D009203 CID The present study was designed to evaluate the cardioprotective potential of salvianolic acid A on <e1>isoproterenol-induced</e1> <e2>myocardial infarction</e2> in rats .
D007545_D009203 CID The results of our study suggest that salvianolic acid A possessing antioxidant activity has a significant protective effect against <e1>isoproterenol-induced</e1> <e2>myocardial infarction</e2> .
D000244_D012131 NONE In addition , mitochondrial <e2>respiratory dysfunction</e2> characterized by decreased respiratory control ratio and <e1>ADP/O</e1> was observed in isoproterenol-treated rats .
D007545_D012131 NONE In addition , mitochondrial <e2>respiratory dysfunction</e2> characterized by decreased respiratory control ratio and ADP/O was observed in <e1>isoproterenol-treated</e1> rats .
C066201_D006331 NONE Administration of <e1>salvianolic acid A</e1> for a period of 8 days significantly attenuated isoproterenol-induced <e2>cardiac dysfunction</e2> and myocardial injury and improved mitochondrial respiratory function .
C066201_D009202 NONE Administration of <e1>salvianolic acid A</e1> for a period of 8 days significantly attenuated isoproterenol-induced cardiac dysfunction and <e2>myocardial injury</e2> and improved mitochondrial respiratory function .
C066201_D009202 NONE The protective role of <e1>salvianolic acid A</e1> against isoproterenol-induced <e2>myocardial damage</e2> was further confirmed by histopathological examination .
D007545_D006331 NONE Administration of salvianolic acid A for a period of 8 days significantly attenuated <e1>isoproterenol-induced</e1> <e2>cardiac dysfunction</e2> and myocardial injury and improved mitochondrial respiratory function .
D007545_D009202 NONE Administration of salvianolic acid A for a period of 8 days significantly attenuated <e1>isoproterenol-induced</e1> cardiac dysfunction and <e2>myocardial injury</e2> and improved mitochondrial respiratory function .
D007545_D009202 NONE The protective role of salvianolic acid A against <e1>isoproterenol-induced</e1> <e2>myocardial damage</e2> was further confirmed by histopathological examination .
7930386
D002997_D012893 CID <e1>Clomipramine-induced</e1> <e2>sleep disturbance</e2> does not impair its prolactin-releasing action .
D002997_D012893 CID The present study was undertaken to examine the role of <e2>sleep disturbance</e2> , induced by <e1>clomipramine</e1> administration , on the secretory rate of prolactin ( PRL ) in addition to the direct drug effect .
9587734
D013390_D006323 CID <e1>Suxamethonium-induced</e1> <e2>cardiac arrest</e2> and death following 5 days of immobilization .
D013390_D006323 CID The present report describes a case of <e2>cardiac arrest</e2> and subsequent death as a result of hyperkalaemia following the use of <e1>suxamethonium</e1> in a 23-year-old Malawian woman .
D013390_D006323 CID Forty seconds after injection of <e1>suxamethonium</e1> , bradycardia and <e2>cardiac arrest</e2> occurred .
D013390_D003643 NONE <e1>Suxamethonium-induced</e1> cardiac arrest and <e2>death</e2> following 5 days of immobilization .
D013390_D003643 NONE The present report describes a case of cardiac arrest and subsequent <e2>death</e2> as a result of hyperkalaemia following the use of <e1>suxamethonium</e1> in a 23-year-old Malawian woman .
D013390_D003643 NONE It is postulated that her <e2>death</e2> was caused by hypersensitivity to <e1>suxamethonium</e1> , associated with her 5-day immobilization .
D013390_D006947 CID The present report describes a case of cardiac arrest and subsequent death as a result of <e2>hyperkalaemia</e2> following the use of <e1>suxamethonium</e1> in a 23-year-old Malawian woman .
D013390_D006947 CID Apart from the reduction in the patient 's level of consciousness , there were no signs of motor neurone damage or of any of the other known predisposing conditions for <e2>hyperkalaemia</e2> following the administration of <e1>suxamethonium</e1> .
D013390_D001919 CID Forty seconds after injection of <e1>suxamethonium</e1> , <e2>bradycardia</e2> and cardiac arrest occurred .
D013390_D004342 CID It is postulated that her death was caused by <e2>hypersensitivity</e2> to <e1>suxamethonium</e1> , associated with her 5-day immobilization .
11752354
D003276_D009203 CID <e1>Oral contraceptives</e1> and the risk of <e2>myocardial infarction</e2> .
D003276_D009203 CID BACKGROUND : An association between the use of <e1>oral contraceptives</e1> and the risk of <e2>myocardial infarction</e2> has been found in some , but not all , studies .
D003276_D009203 CID We investigated this association , according to the type of progestagen included in third-generation ( i.e. , desogestrel or gestodene ) and second-generation ( i.e. , levonorgestrel ) <e1>oral contraceptives</e1> , the dose of estrogen , and the presence or absence of prothrombotic mutations METHODS : In a nationwide , population-based , case-control study , we identified and enrolled 248 women 18 through 49 years of age who had had a first <e2>myocardial infarction</e2> between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age , calendar year of the index event , and area of residence .
D003276_D009203 CID We investigated this association , according to the type of progestagen included in third-generation ( i.e. , desogestrel or gestodene ) and second-generation ( i.e. , levonorgestrel ) <e1>oral contraceptives</e1> , the dose of estrogen , and the presence or absence of prothrombotic mutations METHODS : In a nationwide , population-based , case-control study , we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a <e2>myocardial infarction</e2> and who were matched for age , calendar year of the index event , and area of residence .
D003276_D009203 CID An analysis for factor V Leiden and the G20210A mutation in the prothrombin gene was conducted in 217 patients and 763 controls RESULTS : The odds ratio for <e2>myocardial infarction</e2> among women who used any type of combined <e1>oral contraceptive</e1> , as compared with nonusers , was 2.0 ( 95 percent confidence interval , 1.5 to 2.8 ) .
D003276_D009203 CID Among women who used <e1>oral contraceptives</e1> , the odds ratio was 2.1 ( 95 percent confidence interval , 1.5 to 3.0 ) for those without a prothrombotic mutation and 1.9 ( 95 percent confidence interval , 0.6 to 5.5 ) for those with a mutation CONCLUSIONS : The risk of <e2>myocardial infarction</e2> was increased among women who used second-generation oral contraceptives .
D003276_D009203 CID Among women who used oral contraceptives , the odds ratio was 2.1 ( 95 percent confidence interval , 1.5 to 3.0 ) for those without a prothrombotic mutation and 1.9 ( 95 percent confidence interval , 0.6 to 5.5 ) for those with a mutation CONCLUSIONS : The risk of <e2>myocardial infarction</e2> was increased among women who used second-generation <e1>oral contraceptives</e1> .
D003276_D009203 CID The risk of <e2>myocardial infarction</e2> was similar among women who used <e1>oral contraceptives</e1> whether or not they had a prothrombotic mutation .
D011372_D009203 NONE We investigated this association , according to the type of <e1>progestagen</e1> included in third-generation ( i.e. , desogestrel or gestodene ) and second-generation ( i.e. , levonorgestrel ) oral contraceptives , the dose of estrogen , and the presence or absence of prothrombotic mutations METHODS : In a nationwide , population-based , case-control study , we identified and enrolled 248 women 18 through 49 years of age who had had a first <e2>myocardial infarction</e2> between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age , calendar year of the index event , and area of residence .
D011372_D009203 NONE We investigated this association , according to the type of <e1>progestagen</e1> included in third-generation ( i.e. , desogestrel or gestodene ) and second-generation ( i.e. , levonorgestrel ) oral contraceptives , the dose of estrogen , and the presence or absence of prothrombotic mutations METHODS : In a nationwide , population-based , case-control study , we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a <e2>myocardial infarction</e2> and who were matched for age , calendar year of the index event , and area of residence .
D017135_D009203 NONE We investigated this association , according to the type of progestagen included in third-generation ( i.e. , <e1>desogestrel</e1> or gestodene ) and second-generation ( i.e. , levonorgestrel ) oral contraceptives , the dose of estrogen , and the presence or absence of prothrombotic mutations METHODS : In a nationwide , population-based , case-control study , we identified and enrolled 248 women 18 through 49 years of age who had had a first <e2>myocardial infarction</e2> between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age , calendar year of the index event , and area of residence .
D017135_D009203 NONE We investigated this association , according to the type of progestagen included in third-generation ( i.e. , <e1>desogestrel</e1> or gestodene ) and second-generation ( i.e. , levonorgestrel ) oral contraceptives , the dose of estrogen , and the presence or absence of prothrombotic mutations METHODS : In a nationwide , population-based , case-control study , we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a <e2>myocardial infarction</e2> and who were matched for age , calendar year of the index event , and area of residence .
C033273_D009203 NONE We investigated this association , according to the type of progestagen included in third-generation ( i.e. , desogestrel or <e1>gestodene</e1> ) and second-generation ( i.e. , levonorgestrel ) oral contraceptives , the dose of estrogen , and the presence or absence of prothrombotic mutations METHODS : In a nationwide , population-based , case-control study , we identified and enrolled 248 women 18 through 49 years of age who had had a first <e2>myocardial infarction</e2> between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age , calendar year of the index event , and area of residence .
C033273_D009203 NONE We investigated this association , according to the type of progestagen included in third-generation ( i.e. , desogestrel or <e1>gestodene</e1> ) and second-generation ( i.e. , levonorgestrel ) oral contraceptives , the dose of estrogen , and the presence or absence of prothrombotic mutations METHODS : In a nationwide , population-based , case-control study , we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a <e2>myocardial infarction</e2> and who were matched for age , calendar year of the index event , and area of residence .
D016912_D009203 NONE We investigated this association , according to the type of progestagen included in third-generation ( i.e. , desogestrel or gestodene ) and second-generation ( i.e. , <e1>levonorgestrel</e1> ) oral contraceptives , the dose of estrogen , and the presence or absence of prothrombotic mutations METHODS : In a nationwide , population-based , case-control study , we identified and enrolled 248 women 18 through 49 years of age who had had a first <e2>myocardial infarction</e2> between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age , calendar year of the index event , and area of residence .
D016912_D009203 NONE We investigated this association , according to the type of progestagen included in third-generation ( i.e. , desogestrel or gestodene ) and second-generation ( i.e. , <e1>levonorgestrel</e1> ) oral contraceptives , the dose of estrogen , and the presence or absence of prothrombotic mutations METHODS : In a nationwide , population-based , case-control study , we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a <e2>myocardial infarction</e2> and who were matched for age , calendar year of the index event , and area of residence .
D004967_D009203 NONE We investigated this association , according to the type of progestagen included in third-generation ( i.e. , desogestrel or gestodene ) and second-generation ( i.e. , levonorgestrel ) oral contraceptives , the dose of <e1>estrogen</e1> , and the presence or absence of prothrombotic mutations METHODS : In a nationwide , population-based , case-control study , we identified and enrolled 248 women 18 through 49 years of age who had had a first <e2>myocardial infarction</e2> between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age , calendar year of the index event , and area of residence .
D004967_D009203 NONE We investigated this association , according to the type of progestagen included in third-generation ( i.e. , desogestrel or gestodene ) and second-generation ( i.e. , levonorgestrel ) oral contraceptives , the dose of <e1>estrogen</e1> , and the presence or absence of prothrombotic mutations METHODS : In a nationwide , population-based , case-control study , we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a <e2>myocardial infarction</e2> and who were matched for age , calendar year of the index event , and area of residence .
7444978
D013307_D020258 NONE Age-dependent sensitivity of the rat to <e2>neurotoxic</e2> effects of <e1>streptomycin</e1> .
D013307_D004409 CID <e2>Abnormal movements</e2> and deafness occurred only in rats treated during the preweaning period ; within this period the greatest sensitivities for these abnormalities occurred from 2 to 11 - 17 and 5 to 11 days of age , respectively , indicating that the cochlea is more sensitive to <e1>streptomycin</e1> than the site ( vestibular or central ) responsible for the dyskinesias .
D013307_D004409 CID Abnormal movements and deafness occurred only in rats treated during the preweaning period ; within this period the greatest sensitivities for these abnormalities occurred from 2 to 11 - 17 and 5 to 11 days of age , respectively , indicating that the cochlea is more sensitive to <e1>streptomycin</e1> than the site ( vestibular or central ) responsible for the <e2>dyskinesias</e2> .
D013307_D003638 CID Abnormal movements and <e2>deafness</e2> occurred only in rats treated during the preweaning period ; within this period the greatest sensitivities for these abnormalities occurred from 2 to 11 - 17 and 5 to 11 days of age , respectively , indicating that the cochlea is more sensitive to <e1>streptomycin</e1> than the site ( vestibular or central ) responsible for the dyskinesias .
18544179
D005283_D009325 NONE Omitting <e1>fentanyl</e1> reduces <e2>nausea</e2> and vomiting , without increasing pain , after sevoflurane for day surgery .
D005283_D009325 NONE RESULTS : Omission of <e1>fentanyl</e1> did not reduce the overall incidence of postoperative nausea and vomiting , but did reduce the incidence of vomiting and/or moderate to severe <e2>nausea</e2> prior to discharge from 20 % and 17 % with fentanyl and fentanyl-dexamethasone , respectively , to 5 % ( P = 0.013 ) .
D005283_D009325 NONE RESULTS : Omission of fentanyl did not reduce the overall incidence of postoperative nausea and vomiting , but did reduce the incidence of vomiting and/or moderate to severe <e2>nausea</e2> prior to discharge from 20 % and 17 % with <e1>fentanyl</e1> and fentanyl-dexamethasone , respectively , to 5 % ( P = 0.013 ) .
D005283_D009325 NONE RESULTS : Omission of fentanyl did not reduce the overall incidence of postoperative nausea and vomiting , but did reduce the incidence of vomiting and/or moderate to severe <e2>nausea</e2> prior to discharge from 20 % and 17 % with fentanyl and <e1>fentanyl-dexamethasone</e1> , respectively , to 5 % ( P = 0.013 ) .
D005283_D009325 NONE Combining the two <e1>fentanyl</e1> groups revealed further significant benefits from the avoidance of opioids , reducing postoperative nausea and vomiting and <e2>nausea</e2> prior to discharge from 35 % and 33 % to 22 % and 19 % ( P = 0.049 and P = 0.035 ) , respectively , while nausea in the first 24 h was decreased from 42 % to 27 % ( P = 0.034 ) .
D005283_D009325 NONE Combining the two <e1>fentanyl</e1> groups revealed further significant benefits from the avoidance of opioids , reducing postoperative nausea and vomiting and nausea prior to discharge from 35 % and 33 % to 22 % and 19 % ( P = 0.049 and P = 0.035 ) , respectively , while <e2>nausea</e2> in the first 24 h was decreased from 42 % to 27 % ( P = 0.034 ) .
D005283_D014839 NONE Omitting <e1>fentanyl</e1> reduces nausea and <e2>vomiting</e2> , without increasing pain , after sevoflurane for day surgery .
D005283_D014839 NONE RESULTS : Omission of <e1>fentanyl</e1> did not reduce the overall incidence of postoperative nausea and vomiting , but did reduce the incidence of <e2>vomiting</e2> and/or moderate to severe nausea prior to discharge from 20 % and 17 % with fentanyl and fentanyl-dexamethasone , respectively , to 5 % ( P = 0.013 ) .
D005283_D014839 NONE RESULTS : Omission of fentanyl did not reduce the overall incidence of postoperative nausea and vomiting , but did reduce the incidence of <e2>vomiting</e2> and/or moderate to severe nausea prior to discharge from 20 % and 17 % with <e1>fentanyl</e1> and fentanyl-dexamethasone , respectively , to 5 % ( P = 0.013 ) .
D005283_D014839 NONE RESULTS : Omission of fentanyl did not reduce the overall incidence of postoperative nausea and vomiting , but did reduce the incidence of <e2>vomiting</e2> and/or moderate to severe nausea prior to discharge from 20 % and 17 % with fentanyl and <e1>fentanyl-dexamethasone</e1> , respectively , to 5 % ( P = 0.013 ) .
D005283_D010146 NONE Omitting <e1>fentanyl</e1> reduces nausea and vomiting , without increasing <e2>pain</e2> , after sevoflurane for day surgery .
D005283_D010146 NONE <e2>Pain</e2> severity and analgesic requirements were unaffected by the omission of <e1>fentanyl</e1> .
C009250_D009325 NONE Omitting fentanyl reduces <e2>nausea</e2> and vomiting , without increasing pain , after <e1>sevoflurane</e1> for day surgery .
C009250_D014839 NONE Omitting fentanyl reduces nausea and <e2>vomiting</e2> , without increasing pain , after <e1>sevoflurane</e1> for day surgery .
C009250_D010146 NONE Omitting fentanyl reduces nausea and vomiting , without increasing <e2>pain</e2> , after <e1>sevoflurane</e1> for day surgery .
C009250_D010146 NONE METHODS : This double-blind study examined the incidence and severity of postoperative nausea and vomiting and <e2>pain</e2> in the first 24 h after <e1>sevoflurane</e1> anaesthesia in 216 adult day surgery patients .
C009250_D020250 NONE BACKGROUND AND OBJECTIVE : Despite advantages of induction and maintenance of anaesthesia with <e1>sevoflurane</e1> , <e2>postoperative nausea and vomiting</e2> occurs frequently .
C009250_D020250 NONE METHODS : This double-blind study examined the incidence and severity of <e2>postoperative nausea and vomiting</e2> and pain in the first 24 h after <e1>sevoflurane</e1> anaesthesia in 216 adult day surgery patients .
C009250_D020250 NONE CONCLUSION : As fentanyl exacerbated <e2>postoperative nausea and vomiting</e2> without an improvement in postoperative pain and also had adverse cardiorespiratory effects , it appears to be an unnecessary and possibly detrimental supplement to <e1>sevoflurane</e1> in day surgery .
D005283_D020250 CID RESULTS : Omission of <e1>fentanyl</e1> did not reduce the overall incidence of <e2>postoperative nausea and vomiting</e2> , but did reduce the incidence of vomiting and/or moderate to severe nausea prior to discharge from 20 % and 17 % with fentanyl and fentanyl-dexamethasone , respectively , to 5 % ( P = 0.013 ) .
D005283_D020250 CID RESULTS : Omission of fentanyl did not reduce the overall incidence of <e2>postoperative nausea and vomiting</e2> , but did reduce the incidence of vomiting and/or moderate to severe nausea prior to discharge from 20 % and 17 % with <e1>fentanyl</e1> and fentanyl-dexamethasone , respectively , to 5 % ( P = 0.013 ) .
D005283_D020250 CID RESULTS : Omission of fentanyl did not reduce the overall incidence of <e2>postoperative nausea and vomiting</e2> , but did reduce the incidence of vomiting and/or moderate to severe nausea prior to discharge from 20 % and 17 % with fentanyl and <e1>fentanyl-dexamethasone</e1> , respectively , to 5 % ( P = 0.013 ) .
D005283_D020250 CID Combining the two <e1>fentanyl</e1> groups revealed further significant benefits from the avoidance of opioids , reducing <e2>postoperative nausea and vomiting</e2> and nausea prior to discharge from 35 % and 33 % to 22 % and 19 % ( P = 0.049 and P = 0.035 ) , respectively , while nausea in the first 24 h was decreased from 42 % to 27 % ( P = 0.034 ) .
D005283_D020250 CID CONCLUSION : As <e1>fentanyl</e1> exacerbated <e2>postoperative nausea and vomiting</e2> without an improvement in postoperative pain and also had adverse cardiorespiratory effects , it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery .
D003907_D020250 NONE RESULTS : Omission of fentanyl did not reduce the overall incidence of <e2>postoperative nausea and vomiting</e2> , but did reduce the incidence of vomiting and/or moderate to severe nausea prior to discharge from 20 % and 17 % with fentanyl and <e1>fentanyl-dexamethasone</e1> , respectively , to 5 % ( P = 0.013 ) .
D003907_D020250 NONE <e1>Dexamethasone</e1> had no significant effect on the incidence or severity of <e2>postoperative nausea and vomiting</e2> .
D003907_D014839 NONE RESULTS : Omission of fentanyl did not reduce the overall incidence of postoperative nausea and vomiting , but did reduce the incidence of <e2>vomiting</e2> and/or moderate to severe nausea prior to discharge from 20 % and 17 % with fentanyl and <e1>fentanyl-dexamethasone</e1> , respectively , to 5 % ( P = 0.013 ) .
D003907_D009325 NONE RESULTS : Omission of fentanyl did not reduce the overall incidence of postoperative nausea and vomiting , but did reduce the incidence of vomiting and/or moderate to severe <e2>nausea</e2> prior to discharge from 20 % and 17 % with fentanyl and <e1>fentanyl-dexamethasone</e1> , respectively , to 5 % ( P = 0.013 ) .
D005283_D012131 CID <e1>Fentanyl</e1> did reduce minor intraoperative movement but had no sevoflurane-sparing effect and increased <e2>respiratory depression</e2> , hypotension and bradycardia .
D005283_D007022 CID <e1>Fentanyl</e1> did reduce minor intraoperative movement but had no sevoflurane-sparing effect and increased respiratory depression , <e2>hypotension</e2> and bradycardia .
D005283_D001919 CID <e1>Fentanyl</e1> did reduce minor intraoperative movement but had no sevoflurane-sparing effect and increased respiratory depression , hypotension and <e2>bradycardia</e2> .
C009250_D012131 NONE Fentanyl did reduce minor intraoperative movement but had no <e1>sevoflurane-sparing</e1> effect and increased <e2>respiratory depression</e2> , hypotension and bradycardia .
C009250_D007022 NONE Fentanyl did reduce minor intraoperative movement but had no <e1>sevoflurane-sparing</e1> effect and increased respiratory depression , <e2>hypotension</e2> and bradycardia .
C009250_D001919 NONE Fentanyl did reduce minor intraoperative movement but had no <e1>sevoflurane-sparing</e1> effect and increased respiratory depression , hypotension and <e2>bradycardia</e2> .
D005283_D010149 NONE CONCLUSION : As <e1>fentanyl</e1> exacerbated postoperative nausea and vomiting without an improvement in <e2>postoperative pain</e2> and also had adverse cardiorespiratory effects , it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery .
C009250_D010149 NONE CONCLUSION : As fentanyl exacerbated postoperative nausea and vomiting without an improvement in <e2>postoperative pain</e2> and also had adverse cardiorespiratory effects , it appears to be an unnecessary and possibly detrimental supplement to <e1>sevoflurane</e1> in day surgery .
17241784
D019821_D009135 CID Progressive <e2>myopathy</e2> with up-regulation of MHC-I associated with <e1>statin</e1> therapy .
D019821_D009135 CID <e1>Statins</e1> can cause a necrotizing <e2>myopathy</e2> and hyperCKaemia which is reversible on cessation of the drug .
D019821_D009135 CID What is less well known is a phenomenon whereby <e1>statins</e1> may induce a <e2>myopathy</e2> , which persists or may progress after stopping the drug .
D019821_D009135 CID These observations suggest that <e1>statins</e1> may initiate an immune-mediated <e2>myopathy</e2> that persists after withdrawal of the drug and responds to immunosuppressive therapy .
D019821_D009135 CID The mechanism of this <e2>myopathy</e2> is uncertain but may involve the induction by <e1>statins</e1> of an endoplasmic reticulum stress response with associated up-regulation of MHC-I expression and antigen presentation by muscle fibres .
D019821_-1 NONE <e1>Statins</e1> can cause a necrotizing myopathy and <e2>hyperCKaemia</e2> which is reversible on cessation of the drug .
19308880
D014635_D003221 CID <e2>Confusion</e2> , a rather serious adverse drug reaction with <e1>valproic acid</e1> : a review of the French Pharmacovigilance database .
D014635_D003221 CID INTRODUCTION : <e2>Confusion</e2> is an adverse drug reaction frequently observed with <e1>valproic acid</e1> .
D014635_D003221 CID METHODS : Using the French Pharmacovigilance database , we selected the cases of <e2>confusion</e2> reported since 1985 with <e1>valproic acid</e1> .
D014635_D003221 CID RESULTS : 272 cases of <e2>confusion</e2> were reported with <e1>valproic acid</e1> : 153 women and 119 men .
D014635_D003221 CID <e2>Confusion</e2> mostly occurred during the two first weeks following <e1>valproic acid</e1> exposure ( 39.7 % ) .
D014635_D003221 CID CONCLUSION : This work shows that <e2>confusion</e2> with <e1>valproic acid</e1> is a serious , rather frequent but reversible adverse drug reaction .
18182964
D003000_D001289 NONE <e1>Clonidine</e1> for <e2>attention-deficit/hyperactivity disorder</e2> : II .
D003000_D001289 NONE OBJECTIVE : To examine the safety and tolerability of <e1>clonidine</e1> used alone or with methylphenidate in children with <e2>attention-deficit/hyperactivity disorder</e2> ( ADHD ) .
D003000_D001289 NONE OBJECTIVE : To examine the safety and tolerability of <e1>clonidine</e1> used alone or with methylphenidate in children with attention-deficit/hyperactivity disorder ( <e2>ADHD</e2> ) .
D003000_D001289 NONE METHOD : In a 16-week multicenter , double-blind trial , 122 children with <e2>ADHD</e2> were randomly assigned to <e1>clonidine</e1> ( n = 31 ) , methylphenidate ( n = 29 ) , clonidine and methylphenidate ( n = 32 ) , or placebo ( n = 30 ) .
D003000_D001289 NONE METHOD : In a 16-week multicenter , double-blind trial , 122 children with <e2>ADHD</e2> were randomly assigned to clonidine ( n = 31 ) , methylphenidate ( n = 29 ) , <e1>clonidine</e1> and methylphenidate ( n = 32 ) , or placebo ( n = 30 ) .
D003000_D001289 NONE CONCLUSIONS : <e1>Clonidine</e1> , used alone or with methylphenidate , appears safe and well tolerated in childhood <e2>ADHD</e2> .
D008774_D001289 NONE OBJECTIVE : To examine the safety and tolerability of clonidine used alone or with <e1>methylphenidate</e1> in children with <e2>attention-deficit/hyperactivity disorder</e2> ( ADHD ) .
D008774_D001289 NONE OBJECTIVE : To examine the safety and tolerability of clonidine used alone or with <e1>methylphenidate</e1> in children with attention-deficit/hyperactivity disorder ( <e2>ADHD</e2> ) .
D008774_D001289 NONE METHOD : In a 16-week multicenter , double-blind trial , 122 children with <e2>ADHD</e2> were randomly assigned to clonidine ( n = 31 ) , <e1>methylphenidate</e1> ( n = 29 ) , clonidine and methylphenidate ( n = 32 ) , or placebo ( n = 30 ) .
D008774_D001289 NONE METHOD : In a 16-week multicenter , double-blind trial , 122 children with <e2>ADHD</e2> were randomly assigned to clonidine ( n = 31 ) , methylphenidate ( n = 29 ) , clonidine and <e1>methylphenidate</e1> ( n = 32 ) , or placebo ( n = 30 ) .
D008774_D001289 NONE CONCLUSIONS : Clonidine , used alone or with <e1>methylphenidate</e1> , appears safe and well tolerated in childhood <e2>ADHD</e2> .
D003000_D001919 CID RESULTS : There were more incidents of <e2>bradycardia</e2> in subjects treated with <e1>clonidine</e1> compared with those not treated with clonidine ( 17.5 % versus 3.4 % ; p = .02 ) , but no other significant group differences regarding electrocardiogram and other cardiovascular outcomes .
D003000_D001919 CID RESULTS : There were more incidents of <e2>bradycardia</e2> in subjects treated with clonidine compared with those not treated with <e1>clonidine</e1> ( 17.5 % versus 3.4 % ; p = .02 ) , but no other significant group differences regarding electrocardiogram and other cardiovascular outcomes .
D003000_D001919 CID Physicians prescribing <e1>clonidine</e1> should monitor for <e2>bradycardia</e2> and advise patients about the high likelihood of initial drowsiness .
D003000_D006970 NONE <e2>Drowsiness</e2> was common on <e1>clonidine</e1> , but generally resolved by 6 to 8 weeks .
D003000_D006970 NONE Physicians prescribing <e1>clonidine</e1> should monitor for bradycardia and advise patients about the high likelihood of initial <e2>drowsiness</e2> .
20528871
C104457_D015458 NONE Salvage therapy with <e1>nelarabine</e1> , etoposide , and cyclophosphamide in relapsed/refractory paediatric <e2>T-cell lymphoblastic leukaemia and lymphoma</e2> .
C104457_D015458 NONE A combination of 5 d of <e1>nelarabine</e1> ( AraG ) with 5 d of etoposide ( VP ) and cyclophosphamide ( CPM ) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed <e2>T-cell leukaemia or lymphoma</e2> .
C104457_D015458 NONE A combination of 5 d of nelarabine ( <e1>AraG</e1> ) with 5 d of etoposide ( VP ) and cyclophosphamide ( CPM ) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed <e2>T-cell leukaemia or lymphoma</e2> .
C104457_D016399 NONE Salvage therapy with <e1>nelarabine</e1> , etoposide , and cyclophosphamide in relapsed/refractory paediatric <e2>T-cell lymphoblastic leukaemia and lymphoma</e2> .
C104457_D016399 NONE A combination of 5 d of <e1>nelarabine</e1> ( AraG ) with 5 d of etoposide ( VP ) and cyclophosphamide ( CPM ) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed <e2>T-cell leukaemia or lymphoma</e2> .
C104457_D016399 NONE A combination of 5 d of nelarabine ( <e1>AraG</e1> ) with 5 d of etoposide ( VP ) and cyclophosphamide ( CPM ) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed <e2>T-cell leukaemia or lymphoma</e2> .
D005047_D015458 NONE Salvage therapy with nelarabine , <e1>etoposide</e1> , and cyclophosphamide in relapsed/refractory paediatric <e2>T-cell lymphoblastic leukaemia and lymphoma</e2> .
D005047_D015458 NONE A combination of 5 d of nelarabine ( AraG ) with 5 d of <e1>etoposide</e1> ( VP ) and cyclophosphamide ( CPM ) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed <e2>T-cell leukaemia or lymphoma</e2> .
D005047_D015458 NONE A combination of 5 d of nelarabine ( AraG ) with 5 d of etoposide ( <e1>VP</e1> ) and cyclophosphamide ( CPM ) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed <e2>T-cell leukaemia or lymphoma</e2> .
D005047_D016399 NONE Salvage therapy with nelarabine , <e1>etoposide</e1> , and cyclophosphamide in relapsed/refractory paediatric <e2>T-cell lymphoblastic leukaemia and lymphoma</e2> .
D005047_D016399 NONE A combination of 5 d of nelarabine ( AraG ) with 5 d of <e1>etoposide</e1> ( VP ) and cyclophosphamide ( CPM ) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed <e2>T-cell leukaemia or lymphoma</e2> .
D005047_D016399 NONE A combination of 5 d of nelarabine ( AraG ) with 5 d of etoposide ( <e1>VP</e1> ) and cyclophosphamide ( CPM ) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed <e2>T-cell leukaemia or lymphoma</e2> .
D003520_D015458 NONE Salvage therapy with nelarabine , etoposide , and <e1>cyclophosphamide</e1> in relapsed/refractory paediatric <e2>T-cell lymphoblastic leukaemia and lymphoma</e2> .
D003520_D015458 NONE A combination of 5 d of nelarabine ( AraG ) with 5 d of etoposide ( VP ) and <e1>cyclophosphamide</e1> ( CPM ) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed <e2>T-cell leukaemia or lymphoma</e2> .
D003520_D015458 NONE A combination of 5 d of nelarabine ( AraG ) with 5 d of etoposide ( VP ) and cyclophosphamide ( <e1>CPM</e1> ) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed <e2>T-cell leukaemia or lymphoma</e2> .
D003520_D016399 NONE Salvage therapy with nelarabine , etoposide , and <e1>cyclophosphamide</e1> in relapsed/refractory paediatric <e2>T-cell lymphoblastic leukaemia and lymphoma</e2> .
D003520_D016399 NONE A combination of 5 d of nelarabine ( AraG ) with 5 d of etoposide ( VP ) and <e1>cyclophosphamide</e1> ( CPM ) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed <e2>T-cell leukaemia or lymphoma</e2> .
D003520_D016399 NONE A combination of 5 d of nelarabine ( AraG ) with 5 d of etoposide ( VP ) and cyclophosphamide ( <e1>CPM</e1> ) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed <e2>T-cell leukaemia or lymphoma</e2> .
C104457_D009422 CID The most common side effects attributable to the <e1>AraG</e1> included Grade 2 and 3 sensory and motor <e2>neuropathy</e2> and musculoskeletal pain .
C104457_D009422 CID Our experience supports the safety of giving <e1>AraG</e1> as salvage therapy in synchrony with etoposide and cyclophosphamide , although <e2>neurological toxicity</e2> must be closely monitored .
C104457_D059352 CID The most common side effects attributable to the <e1>AraG</e1> included Grade 2 and 3 sensory and motor neuropathy and <e2>musculoskeletal pain</e2> .
C104457_D006402 CID <e2>Haematological toxicity</e2> was greater for the combination than <e1>AraG</e1> alone , although median time to neutrophil and platelet recovery was consistent with other salvage therapies .
D005047_D009422 NONE Our experience supports the safety of giving AraG as salvage therapy in synchrony with <e1>etoposide</e1> and cyclophosphamide , although <e2>neurological toxicity</e2> must be closely monitored .
D003520_D009422 NONE Our experience supports the safety of giving AraG as salvage therapy in synchrony with etoposide and <e1>cyclophosphamide</e1> , although <e2>neurological toxicity</e2> must be closely monitored .
10704919
D013629_D006461 CID <e2>Hemolysis</e2> of human erythrocytes induced by <e1>tamoxifen</e1> is related to disruption of membrane structure .
D013629_D006461 CID <e1>TAM</e1> induces <e2>hemolysis</e2> of erythrocytes as a function of concentration .
D013629_D006461 CID The extension of <e2>hemolysis</e2> is variable with erythrocyte samples , but 12.5 microM <e1>TAM</e1> induces total hemolysis of all tested suspensions .
D013629_D006461 CID The extension of hemolysis is variable with erythrocyte samples , but 12.5 microM <e1>TAM</e1> induces total <e2>hemolysis</e2> of all tested suspensions .
D013629_D006461 CID The <e2>hemolytic</e2> effect of <e1>TAM</e1> is prevented by low concentrations of alpha-tocopherol ( alpha-T ) and alpha-tocopherol acetate ( alpha-TAc ) ( inactivated functional hydroxyl ) indicating that TAM-induced hemolysis is not related to oxidative membrane damage .
D013629_D006461 CID The hemolytic effect of <e1>TAM</e1> is prevented by low concentrations of alpha-tocopherol ( alpha-T ) and alpha-tocopherol acetate ( alpha-TAc ) ( inactivated functional hydroxyl ) indicating that TAM-induced <e2>hemolysis</e2> is not related to oxidative membrane damage .
D013629_D006461 CID The <e2>hemolytic</e2> effect of TAM is prevented by low concentrations of alpha-tocopherol ( alpha-T ) and alpha-tocopherol acetate ( alpha-TAc ) ( inactivated functional hydroxyl ) indicating that <e1>TAM-induced</e1> hemolysis is not related to oxidative membrane damage .
D013629_D006461 CID The hemolytic effect of TAM is prevented by low concentrations of alpha-tocopherol ( alpha-T ) and alpha-tocopherol acetate ( alpha-TAc ) ( inactivated functional hydroxyl ) indicating that <e1>TAM-induced</e1> <e2>hemolysis</e2> is not related to oxidative membrane damage .
D013629_D006461 CID This was further evidenced by absence of oxygen consumption and hemoglobin oxidation both determined in parallel with <e1>TAM-induced</e1> <e2>hemolysis</e2> .
D013629_D006461 CID <e2>Hemolysis</e2> caused by <e1>TAM</e1> was not preceded by the leakage of K(+ ) from the cells , also excluding a colloid-osmotic type mechanism of hemolysis , according to the effects on osmotic fragility curves .
D013629_D006461 CID Hemolysis caused by <e1>TAM</e1> was not preceded by the leakage of K(+ ) from the cells , also excluding a colloid-osmotic type mechanism of <e2>hemolysis</e2> , according to the effects on osmotic fragility curves .
D013629_D006461 CID These effects suggest that the protection from <e2>hemolysis</e2> by tocopherols is related to a decreased <e1>TAM</e1> incorporation in condensed membranes and the structural damage of the erythrocyte membrane is consequently avoided .
D013629_D006461 CID Therefore , <e1>TAM-induced</e1> <e2>hemolysis</e2> results from a structural perturbation of red cell membrane , leading to changes in the framework of the erythrocyte membrane and its cytoskeleton caused by its high partition in the membrane .
D013629_D001943 NONE <e1>Tamoxifen</e1> ( TAM ) , the antiestrogenic drug most widely prescribed in the chemotherapy of <e2>breast cancer</e2> , induces changes in normal discoid shape of erythrocytes and hemolytic anemia .
D013629_D001943 NONE Tamoxifen ( <e1>TAM</e1> ) , the antiestrogenic drug most widely prescribed in the chemotherapy of <e2>breast cancer</e2> , induces changes in normal discoid shape of erythrocytes and hemolytic anemia .
D013629_D000743 CID <e1>Tamoxifen</e1> ( TAM ) , the antiestrogenic drug most widely prescribed in the chemotherapy of breast cancer , induces changes in normal discoid shape of erythrocytes and <e2>hemolytic anemia</e2> .
D013629_D000743 CID Tamoxifen ( <e1>TAM</e1> ) , the antiestrogenic drug most widely prescribed in the chemotherapy of breast cancer , induces changes in normal discoid shape of erythrocytes and <e2>hemolytic anemia</e2> .
D013629_D000743 CID This work evaluates the effects of <e1>TAM</e1> on isolated human erythrocytes , attempting to identify the underlying mechanisms on TAM-induced <e2>hemolytic anemia</e2> and the involvement of biomembranes in its cytostatic action mechanisms .
D013629_D000743 CID This work evaluates the effects of TAM on isolated human erythrocytes , attempting to identify the underlying mechanisms on <e1>TAM-induced</e1> <e2>hemolytic anemia</e2> and the involvement of biomembranes in its cytostatic action mechanisms .
D013629_D000743 CID These defects explain the abnormal erythrocyte shape and decreased mechanical stability promoted by <e1>TAM</e1> , resulting in <e2>hemolytic anemia</e2> .
D024502_D006461 NONE The <e2>hemolytic</e2> effect of TAM is prevented by low concentrations of <e1>alpha-tocopherol</e1> ( alpha-T ) and alpha-tocopherol acetate ( alpha-TAc ) ( inactivated functional hydroxyl ) indicating that TAM-induced hemolysis is not related to oxidative membrane damage .
D024502_D006461 NONE The hemolytic effect of TAM is prevented by low concentrations of <e1>alpha-tocopherol</e1> ( alpha-T ) and alpha-tocopherol acetate ( alpha-TAc ) ( inactivated functional hydroxyl ) indicating that TAM-induced <e2>hemolysis</e2> is not related to oxidative membrane damage .
D024502_D006461 NONE The <e2>hemolytic</e2> effect of TAM is prevented by low concentrations of alpha-tocopherol ( <e1>alpha-T</e1> ) and alpha-tocopherol acetate ( alpha-TAc ) ( inactivated functional hydroxyl ) indicating that TAM-induced hemolysis is not related to oxidative membrane damage .
D024502_D006461 NONE The hemolytic effect of TAM is prevented by low concentrations of alpha-tocopherol ( <e1>alpha-T</e1> ) and alpha-tocopherol acetate ( alpha-TAc ) ( inactivated functional hydroxyl ) indicating that TAM-induced <e2>hemolysis</e2> is not related to oxidative membrane damage .
D024502_D006461 NONE The <e2>hemolytic</e2> effect of TAM is prevented by low concentrations of alpha-tocopherol ( alpha-T ) and <e1>alpha-tocopherol acetate</e1> ( alpha-TAc ) ( inactivated functional hydroxyl ) indicating that TAM-induced hemolysis is not related to oxidative membrane damage .
D024502_D006461 NONE The hemolytic effect of TAM is prevented by low concentrations of alpha-tocopherol ( alpha-T ) and <e1>alpha-tocopherol acetate</e1> ( alpha-TAc ) ( inactivated functional hydroxyl ) indicating that TAM-induced <e2>hemolysis</e2> is not related to oxidative membrane damage .
D024502_D006461 NONE The <e2>hemolytic</e2> effect of TAM is prevented by low concentrations of alpha-tocopherol ( alpha-T ) and alpha-tocopherol acetate ( <e1>alpha-TAc</e1> ) ( inactivated functional hydroxyl ) indicating that TAM-induced hemolysis is not related to oxidative membrane damage .
D024502_D006461 NONE The hemolytic effect of TAM is prevented by low concentrations of alpha-tocopherol ( alpha-T ) and alpha-tocopherol acetate ( <e1>alpha-TAc</e1> ) ( inactivated functional hydroxyl ) indicating that TAM-induced <e2>hemolysis</e2> is not related to oxidative membrane damage .
D017665_D006461 NONE The <e2>hemolytic</e2> effect of TAM is prevented by low concentrations of alpha-tocopherol ( alpha-T ) and alpha-tocopherol acetate ( alpha-TAc ) ( inactivated functional <e1>hydroxyl</e1> ) indicating that TAM-induced hemolysis is not related to oxidative membrane damage .
D017665_D006461 NONE The hemolytic effect of TAM is prevented by low concentrations of alpha-tocopherol ( alpha-T ) and alpha-tocopherol acetate ( alpha-TAc ) ( inactivated functional <e1>hydroxyl</e1> ) indicating that TAM-induced <e2>hemolysis</e2> is not related to oxidative membrane damage .
D010100_D006461 NONE This was further evidenced by absence of <e1>oxygen</e1> consumption and hemoglobin oxidation both determined in parallel with TAM-induced <e2>hemolysis</e2> .
D011188_D006461 NONE <e2>Hemolysis</e2> caused by TAM was not preceded by the leakage of <e1>K(+</e1> ) from the cells , also excluding a colloid-osmotic type mechanism of hemolysis , according to the effects on osmotic fragility curves .
D011188_D006461 NONE Hemolysis caused by TAM was not preceded by the leakage of <e1>K(+</e1> ) from the cells , also excluding a colloid-osmotic type mechanism of <e2>hemolysis</e2> , according to the effects on osmotic fragility curves .
D024505_D006461 NONE These effects suggest that the protection from <e2>hemolysis</e2> by <e1>tocopherols</e1> is related to a decreased TAM incorporation in condensed membranes and the structural damage of the erythrocyte membrane is consequently avoided .
10683478
D001058_D007035 CID <e1>Apomorphine</e1> , a nonselective dopamine agonist , was selected due to its biphasic behavioral effects , its ability to induce <e2>hypothermia</e2> , and to produce distinct changes to dopamine turnover in the rodent brain .
D001058_D007035 CID Moreover , test conditions can impact upon other physiological responses to <e1>apomorphine</e1> such as drug-induced <e2>hypothermia</e2> .
D018491_D007035 NONE Apomorphine , a nonselective <e1>dopamine agonist</e1> , was selected due to its biphasic behavioral effects , its ability to induce <e2>hypothermia</e2> , and to produce distinct changes to dopamine turnover in the rodent brain .
D004298_D007035 NONE Apomorphine , a nonselective dopamine agonist , was selected due to its biphasic behavioral effects , its ability to induce <e2>hypothermia</e2> , and to produce distinct changes to <e1>dopamine</e1> turnover in the rodent brain .
D001058_D006948 CID In rats , detection of <e1>apomorphine-induced</e1> <e2>hyperactivity</e2> was facilitated by a period of acclimatization to the test conditions .
12041669
D000961_D000741 NONE <e1>Antithymocyte globulin</e1> in the treatment of D-penicillamine-induced <e2>aplastic anemia</e2> .
D000961_D000741 NONE A patient who received <e1>antithymocyte globulin</e1> therapy for <e2>aplastic anemia</e2> due to D-penicillamine therapy is described .
D000961_D000741 NONE Use of <e1>antithymocyte globulin</e1> may be the optimal treatment of D-penicillamine-induced <e2>aplastic anemia</e2> .
D010396_D000741 CID Antithymocyte globulin in the treatment of <e1>D-penicillamine-induced</e1> <e2>aplastic anemia</e2> .
D010396_D000741 CID A patient who received antithymocyte globulin therapy for <e2>aplastic anemia</e2> due to <e1>D-penicillamine</e1> therapy is described .
D010396_D000741 CID Use of antithymocyte globulin may be the optimal treatment of <e1>D-penicillamine-induced</e1> <e2>aplastic anemia</e2> .
12536034
D002220_D004832 CID The authors present three patients with de novo <e2>absence epilepsy</e2> after administration of <e1>carbamazepine</e1> and vigabatrin .
D020888_D004832 CID The authors present three patients with de novo <e2>absence epilepsy</e2> after administration of carbamazepine and <e1>vigabatrin</e1> .
D005680_D004832 NONE The <e1>gamma-aminobutyric acid-transmitted</e1> thalamocortical circuitry accounts for a major part of the underlying neurophysiology of the <e2>absence epilepsy</e2> .
10365197
D003042_D019964 CID <e1>Cocaine-induced</e1> <e2>mood disorder</e2> : prevalence rates and psychiatric symptoms in an outpatient cocaine-dependent sample .
D003042_D019964 CID Cocaine-induced <e2>mood disorder</e2> : prevalence rates and psychiatric symptoms in an outpatient <e1>cocaine-dependent</e1> sample .
D003042_D019964 CID 243 <e1>cocaine-dependent</e1> outpatients with cocaine-induced <e2>mood disorder</e2> ( CIMD ) , other mood disorders , or no mood disorder were compared on measures of psychiatric symptoms .
D003042_D019964 CID 243 <e1>cocaine-dependent</e1> outpatients with cocaine-induced mood disorder ( CIMD ) , other <e2>mood disorders</e2> , or no mood disorder were compared on measures of psychiatric symptoms .
D003042_D019964 CID 243 <e1>cocaine-dependent</e1> outpatients with cocaine-induced mood disorder ( CIMD ) , other mood disorders , or no <e2>mood disorder</e2> were compared on measures of psychiatric symptoms .
D003042_D019964 CID 243 cocaine-dependent outpatients with <e1>cocaine-induced</e1> <e2>mood disorder</e2> ( CIMD ) , other mood disorders , or no mood disorder were compared on measures of psychiatric symptoms .
D003042_D019964 CID 243 cocaine-dependent outpatients with <e1>cocaine-induced</e1> mood disorder ( CIMD ) , other <e2>mood disorders</e2> , or no mood disorder were compared on measures of psychiatric symptoms .
D003042_D019964 CID 243 cocaine-dependent outpatients with <e1>cocaine-induced</e1> mood disorder ( CIMD ) , other mood disorders , or no <e2>mood disorder</e2> were compared on measures of psychiatric symptoms .
D003042_D001523 NONE <e1>Cocaine-induced</e1> mood disorder : prevalence rates and <e2>psychiatric</e2> symptoms in an outpatient cocaine-dependent sample .
D003042_D001523 NONE Cocaine-induced mood disorder : prevalence rates and <e2>psychiatric</e2> symptoms in an outpatient <e1>cocaine-dependent</e1> sample .
D003042_D001523 NONE 243 <e1>cocaine-dependent</e1> outpatients with cocaine-induced mood disorder ( CIMD ) , other mood disorders , or no mood disorder were compared on measures of <e2>psychiatric</e2> symptoms .
D003042_D001523 NONE 243 cocaine-dependent outpatients with <e1>cocaine-induced</e1> mood disorder ( CIMD ) , other mood disorders , or no mood disorder were compared on measures of <e2>psychiatric</e2> symptoms .
D003042_D019970 NONE 243 <e1>cocaine-dependent</e1> outpatients with cocaine-induced mood disorder ( <e2>CIMD</e2> ) , other mood disorders , or no mood disorder were compared on measures of psychiatric symptoms .
D003042_D019970 NONE 243 cocaine-dependent outpatients with <e1>cocaine-induced</e1> mood disorder ( <e2>CIMD</e2> ) , other mood disorders , or no mood disorder were compared on measures of psychiatric symptoms .
16160878
D014579_D006973 NONE Intracerebroventricular ( i.c.v. ) injection of <e1>U-II</e1> causes <e2>hypertension</e2> and bradycardia and stimulates prolactin and thyrotropin secretion .
D014579_D001919 NONE Intracerebroventricular ( i.c.v. ) injection of <e1>U-II</e1> causes hypertension and <e2>bradycardia</e2> and stimulates prolactin and thyrotropin secretion .
D014579_D010409 NONE Whatever was the dose , the central administration of <e1>U-II</e1> had no effect on body temperature , nociception , apomorphine-induced <e2>penile erection</e2> and climbing behavior , and stress-induced plasma corticosterone level .
D001058_D010409 CID Whatever was the dose , the central administration of U-II had no effect on body temperature , nociception , <e1>apomorphine-induced</e1> <e2>penile erection</e2> and climbing behavior , and stress-induced plasma corticosterone level .
D003345_D010409 NONE Whatever was the dose , the central administration of U-II had no effect on body temperature , nociception , apomorphine-induced <e2>penile erection</e2> and climbing behavior , and stress-induced plasma <e1>corticosterone</e1> level .
D014579_D001523 NONE These data suggest that <e1>U-II</e1> may be involved in some aspects of <e2>psychiatric disorders</e2> .
2385256
D008274_D009157 CID <e2>Myasthenia gravis</e2> presenting as weakness after <e1>magnesium</e1> administration .
D008274_D009157 CID Although paralysis after <e1>magnesium</e1> administration has been described in patients with known <e2>myasthenia gravis</e2> , it has not previously been reported to be the initial or only manifestation of the disease .
D008274_D009468 NONE We studied a patient with no prior history of <e2>neuromuscular disease</e2> who became virtually quadriplegic after parenteral <e1>magnesium</e1> administration for preeclampsia .
D008274_D011782 NONE We studied a patient with no prior history of neuromuscular disease who became virtually <e2>quadriplegic</e2> after parenteral <e1>magnesium</e1> administration for preeclampsia .
D008274_D011225 NONE We studied a patient with no prior history of neuromuscular disease who became virtually quadriplegic after parenteral <e1>magnesium</e1> administration for <e2>preeclampsia</e2> .
D008274_D010243 NONE Although <e2>paralysis</e2> after <e1>magnesium</e1> administration has been described in patients with known myasthenia gravis , it has not previously been reported to be the initial or only manifestation of the disease .
D008274_D020511 NONE Patients who are unusually sensitive to the neuromuscular effects of <e1>magnesium</e1> should be suspected of having an underlying <e2>disorder of neuromuscular transmission</e2> .
3076126
D008148_D009135 NONE <e2>Myopathy</e2> , associated in some cases with myoglobinuria , and in 2 cases with transient renal failure , has been rarely reported with <e1>lovastatin</e1> , especially in patients concomitantly treated with cyclosporin , gemfibrozil or niacin .
D008148_D009212 CID Myopathy , associated in some cases with <e2>myoglobinuria</e2> , and in 2 cases with transient renal failure , has been rarely reported with <e1>lovastatin</e1> , especially in patients concomitantly treated with cyclosporin , gemfibrozil or niacin .
D008148_D051437 CID Myopathy , associated in some cases with myoglobinuria , and in 2 cases with transient <e2>renal failure</e2> , has been rarely reported with <e1>lovastatin</e1> , especially in patients concomitantly treated with cyclosporin , gemfibrozil or niacin .
D016572_D009135 CID <e2>Myopathy</e2> , associated in some cases with myoglobinuria , and in 2 cases with transient renal failure , has been rarely reported with lovastatin , especially in patients concomitantly treated with <e1>cyclosporin</e1> , gemfibrozil or niacin .
D016572_D009212 NONE Myopathy , associated in some cases with <e2>myoglobinuria</e2> , and in 2 cases with transient renal failure , has been rarely reported with lovastatin , especially in patients concomitantly treated with <e1>cyclosporin</e1> , gemfibrozil or niacin .
D016572_D051437 NONE Myopathy , associated in some cases with myoglobinuria , and in 2 cases with transient <e2>renal failure</e2> , has been rarely reported with lovastatin , especially in patients concomitantly treated with <e1>cyclosporin</e1> , gemfibrozil or niacin .
D015248_D009135 CID <e2>Myopathy</e2> , associated in some cases with myoglobinuria , and in 2 cases with transient renal failure , has been rarely reported with lovastatin , especially in patients concomitantly treated with cyclosporin , <e1>gemfibrozil</e1> or niacin .
D015248_D009212 NONE Myopathy , associated in some cases with <e2>myoglobinuria</e2> , and in 2 cases with transient renal failure , has been rarely reported with lovastatin , especially in patients concomitantly treated with cyclosporin , <e1>gemfibrozil</e1> or niacin .
D015248_D051437 NONE Myopathy , associated in some cases with myoglobinuria , and in 2 cases with transient <e2>renal failure</e2> , has been rarely reported with lovastatin , especially in patients concomitantly treated with cyclosporin , <e1>gemfibrozil</e1> or niacin .
D009525_D009135 CID <e2>Myopathy</e2> , associated in some cases with myoglobinuria , and in 2 cases with transient renal failure , has been rarely reported with lovastatin , especially in patients concomitantly treated with cyclosporin , gemfibrozil or <e1>niacin</e1> .
D009525_D009212 NONE Myopathy , associated in some cases with <e2>myoglobinuria</e2> , and in 2 cases with transient renal failure , has been rarely reported with lovastatin , especially in patients concomitantly treated with cyclosporin , gemfibrozil or <e1>niacin</e1> .
D009525_D051437 NONE Myopathy , associated in some cases with myoglobinuria , and in 2 cases with transient <e2>renal failure</e2> , has been rarely reported with lovastatin , especially in patients concomitantly treated with cyclosporin , gemfibrozil or <e1>niacin</e1> .
1592014
D003042_D012640 CID <e2>Seizures</e2> induced by the <e1>cocaine</e1> metabolite benzoylecgonine in rats .
D003042_D012640 CID The half-life ( t1/2 ) of <e1>cocaine</e1> is relatively short , but some of the consequences of its use , such as <e2>seizures</e2> and strokes , can occur hours after exposure .
D003042_D012640 CID We evaluated the potential of the major metabolite of <e1>cocaine</e1> , benzoylecgonine ( BE ) , to cause <e2>seizures</e2> .
D003042_D012640 CID BE-Induced <e2>seizures</e2> occurred more frequently and had significantly longer latencies than those induced by equimolar amounts of <e1>cocaine</e1> .
D003042_D012640 CID Whereas <e1>cocaine-induced</e1> <e2>seizures</e2> were best characterized as brief , generalized , and tonic and resulted in death , those induced by BE were prolonged , often multiple and mixed in type , and rarely resulted in death .
D003042_D012640 CID BE-Injected rats that did not have <e2>seizures</e2> had significantly more locomotor activity than <e1>cocaine-injected</e1> animals without seizures .
D003042_D012640 CID BE-Injected rats that did not have seizures had significantly more locomotor activity than <e1>cocaine-injected</e1> animals without <e2>seizures</e2> .
D003042_D012640 CID The finding that <e1>cocaine-</e1> and BE-induced <e2>seizures</e2> differ in several respects suggests more than one mechanism for cocaine-induced seizures and emphasizes the importance of a cocaine metabolite , BE .
D003042_D012640 CID The finding that <e1>cocaine-</e1> and BE-induced seizures differ in several respects suggests more than one mechanism for cocaine-induced <e2>seizures</e2> and emphasizes the importance of a cocaine metabolite , BE .
D003042_D012640 CID The finding that cocaine- and BE-induced <e2>seizures</e2> differ in several respects suggests more than one mechanism for <e1>cocaine-induced</e1> seizures and emphasizes the importance of a cocaine metabolite , BE .
D003042_D012640 CID The finding that cocaine- and BE-induced seizures differ in several respects suggests more than one mechanism for <e1>cocaine-induced</e1> <e2>seizures</e2> and emphasizes the importance of a cocaine metabolite , BE .
D003042_D012640 CID The finding that cocaine- and BE-induced <e2>seizures</e2> differ in several respects suggests more than one mechanism for cocaine-induced seizures and emphasizes the importance of a <e1>cocaine</e1> metabolite , BE .
D003042_D012640 CID The finding that cocaine- and BE-induced seizures differ in several respects suggests more than one mechanism for cocaine-induced <e2>seizures</e2> and emphasizes the importance of a <e1>cocaine</e1> metabolite , BE .
C005618_D012640 CID <e2>Seizures</e2> induced by the cocaine metabolite <e1>benzoylecgonine</e1> in rats .
C005618_D012640 CID We evaluated the potential of the major metabolite of cocaine , <e1>benzoylecgonine</e1> ( BE ) , to cause <e2>seizures</e2> .
C005618_D012640 CID We evaluated the potential of the major metabolite of cocaine , benzoylecgonine ( <e1>BE</e1> ) , to cause <e2>seizures</e2> .
C005618_D012640 CID <e1>BE-Induced</e1> <e2>seizures</e2> occurred more frequently and had significantly longer latencies than those induced by equimolar amounts of cocaine .
C005618_D012640 CID Whereas cocaine-induced <e2>seizures</e2> were best characterized as brief , generalized , and tonic and resulted in death , those induced by <e1>BE</e1> were prolonged , often multiple and mixed in type , and rarely resulted in death .
C005618_D012640 CID <e1>BE-Injected</e1> rats that did not have <e2>seizures</e2> had significantly more locomotor activity than cocaine-injected animals without seizures .
C005618_D012640 CID <e1>BE-Injected</e1> rats that did not have seizures had significantly more locomotor activity than cocaine-injected animals without <e2>seizures</e2> .
C005618_D012640 CID The finding that cocaine- and <e1>BE-induced</e1> <e2>seizures</e2> differ in several respects suggests more than one mechanism for cocaine-induced seizures and emphasizes the importance of a cocaine metabolite , BE .
C005618_D012640 CID The finding that cocaine- and <e1>BE-induced</e1> seizures differ in several respects suggests more than one mechanism for cocaine-induced <e2>seizures</e2> and emphasizes the importance of a cocaine metabolite , BE .
C005618_D012640 CID The finding that cocaine- and BE-induced <e2>seizures</e2> differ in several respects suggests more than one mechanism for cocaine-induced seizures and emphasizes the importance of a cocaine metabolite , <e1>BE</e1> .
C005618_D012640 CID The finding that cocaine- and BE-induced seizures differ in several respects suggests more than one mechanism for cocaine-induced <e2>seizures</e2> and emphasizes the importance of a cocaine metabolite , <e1>BE</e1> .
D003042_D020521 NONE The half-life ( t1/2 ) of <e1>cocaine</e1> is relatively short , but some of the consequences of its use , such as seizures and <e2>strokes</e2> , can occur hours after exposure .
D003042_D003643 NONE Whereas <e1>cocaine-induced</e1> seizures were best characterized as brief , generalized , and tonic and resulted in <e2>death</e2> , those induced by BE were prolonged , often multiple and mixed in type , and rarely resulted in death .
D003042_D003643 NONE Whereas <e1>cocaine-induced</e1> seizures were best characterized as brief , generalized , and tonic and resulted in death , those induced by BE were prolonged , often multiple and mixed in type , and rarely resulted in <e2>death</e2> .
C005618_D003643 NONE Whereas cocaine-induced seizures were best characterized as brief , generalized , and tonic and resulted in <e2>death</e2> , those induced by <e1>BE</e1> were prolonged , often multiple and mixed in type , and rarely resulted in death .
C005618_D003643 NONE Whereas cocaine-induced seizures were best characterized as brief , generalized , and tonic and resulted in death , those induced by <e1>BE</e1> were prolonged , often multiple and mixed in type , and rarely resulted in <e2>death</e2> .
1867351
D015767_D008288 NONE Therefore , certain limitations for <e2>malaria</e2> prophylaxis and treatment with <e1>mefloquine</e1> are recommended .
21029050
D013390_D001049 CID Butyrylcholinesterase gene mutations in patients with prolonged <e2>apnea</e2> after <e1>succinylcholine</e1> for electroconvulsive therapy .
D013390_D001049 CID CONCLUSION : eleven of 13 patients with a prolonged duration of action of <e1>succinylcholine</e1> had mutations in BCHE , indicating that this is the possible reason for a prolonged period of <e2>apnea</e2> .
322550
D009599_D007022 CID Pulmonary shunt and cardiovascular responses to CPAP during <e1>nitroprusside-induced</e1> <e2>hypotension</e2> .
D009599_D007022 CID Ten cm H2O CPAP before <e1>nitroprusside</e1> infusion produced a further <e2>decrease in arterial blood pressure</e2> and significantly increased heart rate and decreased cardiac output and QS/QT .
D009599_D007022 CID <e1>Nitroprusside</e1> caused significant <e2>decreases in arterial blood pressure</e2> and systemic vascular resistance and increases in heart rate , but did not change cardiac output or QS/QT .
D009599_D007022 NONE During <e1>nitroprusside</e1> infusion low levels of CPAP do not markedly alter cardiovascular dynamics , but high levels of CPAP ( 10 cm H2O ) , while decreasing QS/QT , produce marked <e2>decreases in arterial blood pressure and cardiac output</e2> .
D014867_D007022 NONE Ten cm <e1>H2O</e1> CPAP before nitroprusside infusion produced a further <e2>decrease in arterial blood pressure</e2> and significantly increased heart rate and decreased cardiac output and QS/QT .
D014867_D007022 NONE During nitroprusside infusion low levels of CPAP do not markedly alter cardiovascular dynamics , but high levels of CPAP ( 10 cm <e1>H2O</e1> ) , while decreasing QS/QT , produce marked <e2>decreases in arterial blood pressure and cardiac output</e2> .
D014867_D002303 NONE Ten cm <e1>H2O</e1> CPAP before nitroprusside infusion produced a further decrease in arterial blood pressure and significantly increased heart rate and <e2>decreased cardiac output</e2> and QS/QT .
D014867_D002303 NONE During nitroprusside infusion low levels of CPAP do not markedly alter cardiovascular dynamics , but high levels of CPAP ( 10 cm <e1>H2O</e1> ) , while decreasing QS/QT , produce marked <e2>decreases in arterial blood pressure and cardiac output</e2> .
D009599_D002303 NONE Ten cm H2O CPAP before <e1>nitroprusside</e1> infusion produced a further decrease in arterial blood pressure and significantly increased heart rate and <e2>decreased cardiac output</e2> and QS/QT .
D009599_D002303 NONE During <e1>nitroprusside</e1> infusion low levels of CPAP do not markedly alter cardiovascular dynamics , but high levels of CPAP ( 10 cm H2O ) , while decreasing QS/QT , produce marked <e2>decreases in arterial blood pressure and cardiac output</e2> .
3031535
D013759_D002375 CID Noradrenergic involvement in <e2>catalepsy</e2> induced by <e1>delta 9-tetrahydrocannabinol</e1> .
D013759_D002375 CID These results indicate that noradrenergic neurons have an important role in the manifestation of <e2>catalepsy</e2> induced by <e1>THC</e1> , whereas dopaminergic neurons are important in catalepsy induced by haloperidol .
D013759_D002375 CID These results indicate that noradrenergic neurons have an important role in the manifestation of catalepsy induced by <e1>THC</e1> , whereas dopaminergic neurons are important in <e2>catalepsy</e2> induced by haloperidol .
D006220_D002375 CID These results indicate that noradrenergic neurons have an important role in the manifestation of <e2>catalepsy</e2> induced by THC , whereas dopaminergic neurons are important in catalepsy induced by <e1>haloperidol</e1> .
D006220_D002375 CID These results indicate that noradrenergic neurons have an important role in the manifestation of catalepsy induced by THC , whereas dopaminergic neurons are important in <e2>catalepsy</e2> induced by <e1>haloperidol</e1> .
9284778
-1_D008107 NONE Epidemic of <e2>liver disease</e2> caused by <e1>hydrochlorofluorocarbons</e1> used as ozone-sparing substitutes of chlorofluorocarbons .
D010126_D008107 NONE Epidemic of <e2>liver disease</e2> caused by hydrochlorofluorocarbons used as <e1>ozone-sparing</e1> substitutes of chlorofluorocarbons .
D017402_D008107 NONE Epidemic of <e2>liver disease</e2> caused by hydrochlorofluorocarbons used as ozone-sparing substitutes of <e1>chlorofluorocarbons</e1> .
C067411_D008107 CID We investigated an epidemic of <e2>liver disease</e2> in nine industrial workers who had had repeated accidental exposure to a mixture of <e1>1,1-dichloro-2,2,2-trifluoroethane</e1> ( HCFC 123 ) and 1-chloro-1,2,2,2-tetrafluoroethane ( HCFC 124 ) .
C067411_D008107 CID We investigated an epidemic of <e2>liver disease</e2> in nine industrial workers who had had repeated accidental exposure to a mixture of 1,1-dichloro-2,2,2-trifluoroethane ( <e1>HCFC 123</e1> ) and 1-chloro-1,2,2,2-tetrafluoroethane ( HCFC 124 ) .
C067411_D008107 CID We aimed to test whether <e1>HCFCs 123 and 124</e1> can result in serious <e2>liver disease</e2> .
C072959_D008107 CID We investigated an epidemic of <e2>liver disease</e2> in nine industrial workers who had had repeated accidental exposure to a mixture of 1,1-dichloro-2,2,2-trifluoroethane ( HCFC 123 ) and <e1>1-chloro-1,2,2,2-tetrafluoroethane</e1> ( HCFC 124 ) .
C072959_D008107 CID We investigated an epidemic of <e2>liver disease</e2> in nine industrial workers who had had repeated accidental exposure to a mixture of 1,1-dichloro-2,2,2-trifluoroethane ( HCFC 123 ) and 1-chloro-1,2,2,2-tetrafluoroethane ( <e1>HCFC 124</e1> ) .
C072959_D008107 CID We aimed to test whether <e1>HCFCs 123 and 124</e1> can result in serious <e2>liver disease</e2> .
D006221_D056486 NONE Both compounds are metabolised in the same way as <e1>1-bromo-1-chloro-2,2,2-trifluoroethane</e1> ( halothane ) to form reactive trifluoroacetyl halide intermediates , which have been implicated in the <e2>hepatotoxicity</e2> of halothane .
D006221_D056486 NONE Both compounds are metabolised in the same way as 1-bromo-1-chloro-2,2,2-trifluoroethane ( <e1>halothane</e1> ) to form reactive trifluoroacetyl halide intermediates , which have been implicated in the <e2>hepatotoxicity</e2> of halothane .
D006221_D056486 NONE Both compounds are metabolised in the same way as 1-bromo-1-chloro-2,2,2-trifluoroethane ( halothane ) to form reactive trifluoroacetyl halide intermediates , which have been implicated in the <e2>hepatotoxicity</e2> of <e1>halothane</e1> .
D014269_D056486 NONE Both compounds are metabolised in the same way as 1-bromo-1-chloro-2,2,2-trifluoroethane ( halothane ) to form reactive <e1>trifluoroacetyl</e1> halide intermediates , which have been implicated in the <e2>hepatotoxicity</e2> of halothane .
D014269_D056486 NONE Although the exact mechanism of <e2>hepatotoxicity</e2> of these agents is not known , the results suggest that <e1>trifluoroacetyl-altered</e1> liver proteins are involved .
C067411_D056486 NONE INTERPRETATION : Repeated exposure of human beings to <e1>HCFCs 123 and 124</e1> can result in serious <e2>liver injury</e2> in a large proportion of the exposed population .
C072959_D056486 NONE INTERPRETATION : Repeated exposure of human beings to <e1>HCFCs 123 and 124</e1> can result in serious <e2>liver injury</e2> in a large proportion of the exposed population .
8752018
D008094_D003072 CID <e1>Lithium-associated</e1> <e2>cognitive and functional deficits</e2> reduced by a switch to divalproex sodium : a case series .
D008094_D003072 CID Although much has been written about the management of the more common adverse effects of <e1>lithium</e1> , such as polyuria and tremor , more subtle lithium side effects such as <e2>cognitive deficits</e2> , loss of creativity , and functional impairments remain understudied .
D008094_D003072 CID Although much has been written about the management of the more common adverse effects of <e1>lithium</e1> , such as polyuria and tremor , more subtle lithium side effects such as cognitive deficits , <e2>loss of creativity</e2> , and functional impairments remain understudied .
D008094_D003072 CID Although much has been written about the management of the more common adverse effects of <e1>lithium</e1> , such as polyuria and tremor , more subtle lithium side effects such as cognitive deficits , loss of creativity , and <e2>functional impairments</e2> remain understudied .
D008094_D003072 CID Although much has been written about the management of the more common adverse effects of lithium , such as polyuria and tremor , more subtle <e1>lithium</e1> side effects such as <e2>cognitive deficits</e2> , loss of creativity , and functional impairments remain understudied .
D008094_D003072 CID Although much has been written about the management of the more common adverse effects of lithium , such as polyuria and tremor , more subtle <e1>lithium</e1> side effects such as cognitive deficits , <e2>loss of creativity</e2> , and functional impairments remain understudied .
D008094_D003072 CID Although much has been written about the management of the more common adverse effects of lithium , such as polyuria and tremor , more subtle <e1>lithium</e1> side effects such as cognitive deficits , loss of creativity , and <e2>functional impairments</e2> remain understudied .
D008094_D003072 CID This report summarizes our experience in switching bipolar patients from <e1>lithium</e1> to divalproex sodium to alleviate such <e2>cognitive and functional impairments</e2> .
D008094_D003072 CID RESULTS : We report seven cases where substitution of <e1>lithium</e1> , either fully or partially , with divalproex sodium was extremely helpful in reducing the <e2>cognitive , motivational , or creative deficits</e2> attributed to lithium in our bipolar patients .
D008094_D003072 CID RESULTS : We report seven cases where substitution of lithium , either fully or partially , with divalproex sodium was extremely helpful in reducing the <e2>cognitive , motivational , or creative deficits</e2> attributed to <e1>lithium</e1> in our bipolar patients .
D008094_D003072 CID CONCLUSION : In this preliminary report , divalproex sodium was a superior alternative to <e1>lithium</e1> in bipolar patients experiencing <e2>cognitive deficits</e2> , loss of creativity , and functional impairments .
D008094_D003072 CID CONCLUSION : In this preliminary report , divalproex sodium was a superior alternative to <e1>lithium</e1> in bipolar patients experiencing cognitive deficits , <e2>loss of creativity</e2> , and functional impairments .
D008094_D003072 CID CONCLUSION : In this preliminary report , divalproex sodium was a superior alternative to <e1>lithium</e1> in bipolar patients experiencing cognitive deficits , loss of creativity , and <e2>functional impairments</e2> .
D014635_D003072 NONE Lithium-associated <e2>cognitive and functional deficits</e2> reduced by a switch to <e1>divalproex sodium</e1> : a case series .
D014635_D003072 NONE This report summarizes our experience in switching bipolar patients from lithium to <e1>divalproex sodium</e1> to alleviate such <e2>cognitive and functional impairments</e2> .
D014635_D003072 NONE RESULTS : We report seven cases where substitution of lithium , either fully or partially , with <e1>divalproex sodium</e1> was extremely helpful in reducing the <e2>cognitive , motivational , or creative deficits</e2> attributed to lithium in our bipolar patients .
D014635_D003072 NONE CONCLUSION : In this preliminary report , <e1>divalproex sodium</e1> was a superior alternative to lithium in bipolar patients experiencing <e2>cognitive deficits</e2> , loss of creativity , and functional impairments .
D014635_D003072 NONE CONCLUSION : In this preliminary report , <e1>divalproex sodium</e1> was a superior alternative to lithium in bipolar patients experiencing cognitive deficits , <e2>loss of creativity</e2> , and functional impairments .
D014635_D003072 NONE CONCLUSION : In this preliminary report , <e1>divalproex sodium</e1> was a superior alternative to lithium in bipolar patients experiencing cognitive deficits , loss of creativity , and <e2>functional impairments</e2> .
D008094_D001714 NONE BACKGROUND : <e1>Lithium</e1> remains a first-line treatment for the acute and maintenance treatment of <e2>bipolar disorder</e2> .
D008094_D001714 NONE This report summarizes our experience in switching <e2>bipolar</e2> patients from <e1>lithium</e1> to divalproex sodium to alleviate such cognitive and functional impairments .
D008094_D001714 NONE RESULTS : We report seven cases where substitution of <e1>lithium</e1> , either fully or partially , with divalproex sodium was extremely helpful in reducing the cognitive , motivational , or creative deficits attributed to lithium in our <e2>bipolar</e2> patients .
D008094_D001714 NONE RESULTS : We report seven cases where substitution of lithium , either fully or partially , with divalproex sodium was extremely helpful in reducing the cognitive , motivational , or creative deficits attributed to <e1>lithium</e1> in our <e2>bipolar</e2> patients .
D008094_D001714 NONE CONCLUSION : In this preliminary report , divalproex sodium was a superior alternative to <e1>lithium</e1> in <e2>bipolar</e2> patients experiencing cognitive deficits , loss of creativity , and functional impairments .
D008094_D011141 NONE Although much has been written about the management of the more common adverse effects of <e1>lithium</e1> , such as <e2>polyuria</e2> and tremor , more subtle lithium side effects such as cognitive deficits , loss of creativity , and functional impairments remain understudied .
D008094_D011141 NONE Although much has been written about the management of the more common adverse effects of lithium , such as <e2>polyuria</e2> and tremor , more subtle <e1>lithium</e1> side effects such as cognitive deficits , loss of creativity , and functional impairments remain understudied .
D008094_D014202 NONE Although much has been written about the management of the more common adverse effects of <e1>lithium</e1> , such as polyuria and <e2>tremor</e2> , more subtle lithium side effects such as cognitive deficits , loss of creativity , and functional impairments remain understudied .
D008094_D014202 NONE Although much has been written about the management of the more common adverse effects of lithium , such as polyuria and <e2>tremor</e2> , more subtle <e1>lithium</e1> side effects such as cognitive deficits , loss of creativity , and functional impairments remain understudied .
D014635_D001714 NONE This report summarizes our experience in switching <e2>bipolar</e2> patients from lithium to <e1>divalproex sodium</e1> to alleviate such cognitive and functional impairments .
D014635_D001714 NONE RESULTS : We report seven cases where substitution of lithium , either fully or partially , with <e1>divalproex sodium</e1> was extremely helpful in reducing the cognitive , motivational , or creative deficits attributed to lithium in our <e2>bipolar</e2> patients .
D014635_D001714 NONE CONCLUSION : In this preliminary report , <e1>divalproex sodium</e1> was a superior alternative to lithium in <e2>bipolar</e2> patients experiencing cognitive deficits , loss of creativity , and functional impairments .
7516729
D014700_D001919 CID Dose-dependent <e2>bradycardia</e2> induced by <e1>verapamil</e1> was potentiated by LNa , LCa , and HCa .
6727060
D008787_D004409 CID A case of <e2>tardive dyskinesia</e2> caused by <e1>metoclopramide</e1> .
D008787_D004409 CID <e2>Abnormal involuntary movements</e2> appeared in the mouth , tongue , neck and abdomen of a 64-year-old male patient after he took <e1>metoclopramide</e1> for gastrointestinal disorder in a regimen of 30 mg per day for a total of about 260 days .
D008787_D004409 CID When the <e1>metoclopramide</e1> administration was discontinued , the <e2>abnormal movements</e2> gradually improved to a considerable extent .
D008787_D005767 NONE Abnormal involuntary movements appeared in the mouth , tongue , neck and abdomen of a 64-year-old male patient after he took <e1>metoclopramide</e1> for <e2>gastrointestinal disorder</e2> in a regimen of 30 mg per day for a total of about 260 days .
983936
D001241_D009202 NONE Effects of <e1>acetylsalicylic acid</e1> , dipyridamole , and hydrocortisone on epinephrine-induced <e2>myocardial injury</e2> in dogs .
D004176_D009202 NONE Effects of acetylsalicylic acid , <e1>dipyridamole</e1> , and hydrocortisone on epinephrine-induced <e2>myocardial injury</e2> in dogs .
D006854_D009202 NONE Effects of acetylsalicylic acid , dipyridamole , and <e1>hydrocortisone</e1> on epinephrine-induced <e2>myocardial injury</e2> in dogs .
D004837_D009202 CID Effects of acetylsalicylic acid , dipyridamole , and hydrocortisone on <e1>epinephrine-induced</e1> <e2>myocardial injury</e2> in dogs .
D004837_D009202 CID A reproducible model for producing diffuse <e2>myocardial injury</e2> ( <e1>epinephrine</e1> infusion ) has been developed to study the cardioprotective effects of agents or maneuvers which might alter the evolution of acute myocardial infarction .
D004837_D009203 NONE A reproducible model for producing diffuse myocardial injury ( <e1>epinephrine</e1> infusion ) has been developed to study the cardioprotective effects of agents or maneuvers which might alter the evolution of acute <e2>myocardial infarction</e2> .
11431197
D011899_D009395 CID <e1>Ranitidine-induced</e1> acute <e2>interstitial nephritis</e2> in a cadaveric renal allograft .
D011899_D009395 CID We report a case of <e1>ranitidine-induced</e1> acute <e2>interstitial nephritis</e2> in a recipient of a cadaveric renal allograft presenting with acute allograft dysfunction within 48 hours of exposure to the drug .
12757899
D004958_D012640 NONE <e1>Estradiol</e1> reduces <e2>seizure-induced</e2> hippocampal injury in ovariectomized female but not in male rats .
D004958_D012640 NONE These findings suggest that the effects of <e1>estradiol</e1> on <e2>seizure</e2> threshold and damage may be altered by sex-related differences in the hormonal environment .
D004958_D001930 NONE <e1>Estradiol</e1> reduces seizure-induced <e2>hippocampal injury</e2> in ovariectomized female but not in male rats .
D007608_D001930 NONE Estrogens protect ovariectomized rats from <e2>hippocampal injury</e2> induced by <e1>kainic acid-induced</e1> status epilepticus ( SE ) .
D007608_D013226 NONE Estrogens protect ovariectomized rats from hippocampal injury induced by <e1>kainic acid-induced</e1> <e2>status epilepticus</e2> ( SE ) .
D007608_D013226 NONE Estrogens protect ovariectomized rats from hippocampal injury induced by <e1>kainic acid-induced</e1> status epilepticus ( <e2>SE</e2> ) .
D004958_D013226 NONE We compared the effects of <e1>17beta-estradiol</e1> in adult male and ovariectomized female rats subjected to lithium-pilocarpine-induced <e2>SE</e2> .
D008094_D013226 CID We compared the effects of 17beta-estradiol in adult male and ovariectomized female rats subjected to <e1>lithium-pilocarpine-induced</e1> <e2>SE</e2> .
D010862_D013226 CID We compared the effects of 17beta-estradiol in adult male and ovariectomized female rats subjected to <e1>lithium-pilocarpine-induced</e1> <e2>SE</e2> .
D012834_D013226 NONE The extent of <e1>silver-stained</e1> CA3 and CA1 hippocampal neurons was evaluated 2 days after <e2>SE</e2> .
8073369
C007112_D001176 CID However , <e1>coniine</e1> has failed to produce <e2>arthrogryposis</e2> in rats or mice and is only weakly teratogenic in rabbits .
C007112_D001176 CID In summary , the chick embryo provides a reliable and simple experimental animal model of <e1>coniine-induced</e1> <e2>arthrogryposis</e2> .
C007112_D009140 NONE The <e2>deformations</e2> caused by both <e1>coniine</e1> and nicotine sulfate were excessive flexion or extension of one or more toes .
C007112_D009140 NONE The deformations caused by both <e1>coniine</e1> and nicotine sulfate were <e2>excessive flexion or extension of one or more toes</e2> .
D009538_D009140 NONE The <e2>deformations</e2> caused by both coniine and <e1>nicotine</e1> sulfate were excessive flexion or extension of one or more toes .
D009538_D009140 NONE The deformations caused by both coniine and <e1>nicotine</e1> sulfate were <e2>excessive flexion or extension of one or more toes</e2> .
D009538_D002543 CID No histopathological alterations or differences in bone formation were seen in the limbs or toes of any chicks from any group ; however , extensive <e2>cranial hemorrhage</e2> occurred in all <e1>nicotine</e1> sulfate-treated chicks .
15863244
C106876_D064420 NONE Comparison of developmental <e2>toxicity</e2> of selective and non-selective cyclooxygenase-2 inhibitors in CRL:(WI)WUBR Wistar rats -- <e1>DFU</e1> and piroxicam study .
C106876_D064420 NONE The aim of the experiment was to evaluate the developmental <e2>toxicity</e2> of the non-selective ( piroxicam ) and selective ( <e1>DFU</e1> ; 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl ) phenyl-2(5H)-furanon ) COX-2 inhibitors .
C106876_D064420 NONE The aim of the experiment was to evaluate the developmental <e2>toxicity</e2> of the non-selective ( piroxicam ) and selective ( DFU ; <e1>5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl ) phenyl-2(5H)-furanon</e1> ) COX-2 inhibitors .
C106876_D064420 NONE Decrease of fetal length was the only signs of the <e1>DFU</e1> developmental <e2>toxicity</e2> observed in pups exposed to the highest compound dose .
D010894_D064420 NONE Comparison of developmental <e2>toxicity</e2> of selective and non-selective cyclooxygenase-2 inhibitors in CRL:(WI)WUBR Wistar rats -- DFU and <e1>piroxicam</e1> study .
D010894_D064420 NONE The aim of the experiment was to evaluate the developmental <e2>toxicity</e2> of the non-selective ( <e1>piroxicam</e1> ) and selective ( DFU ; 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl ) phenyl-2(5H)-furanon ) COX-2 inhibitors .
D010894_D064420 NONE RESULTS : Maternal <e2>toxicity</e2> , intrauterine growth retardation , and increase of external and skeletal variations were found in rats treated with the highest dose of <e1>piroxicam</e1> .
D010894_D006345 NONE The pooled statistical analysis for <e2>ventricular septal ( VSD ) and midline ( MD ) defects</e2> was performed for rat fetuses exposed to <e1>piroxicam</e1> , selective and non-selective COX-2 inhibitor based on present and historic data .
D010894_D009436 NONE The pooled statistical analysis for <e2>ventricular septal ( VSD ) and midline ( MD ) defects</e2> was performed for rat fetuses exposed to <e1>piroxicam</e1> , selective and non-selective COX-2 inhibitor based on present and historic data .
D010894_D005317 CID RESULTS : Maternal toxicity , <e2>intrauterine growth retardation</e2> , and increase of external and skeletal variations were found in rats treated with the highest dose of <e1>piroxicam</e1> .
D010894_D009139 CID RESULTS : Maternal toxicity , intrauterine growth retardation , and <e2>increase of external and skeletal variations</e2> were found in rats treated with the highest dose of <e1>piroxicam</e1> .
9495837
C087567_D000647 NONE <e1>(+/-)-PG-9</e1> ( 10 - 40 mg kg-1 i.p. ) was able to prevent <e2>amnesia</e2> induced by scopolamine ( 1 mg kg-1 i.p. ) and dicyclomine ( 2 mg kg-1 i.p. ) in the mouse passive-avoidance test .
C087567_D000647 NONE Affinity profiles of <e1>(+/-)-PG-9</e1> for muscarinic receptor subtypes , determined by functional studies ( rabbit vas deferens for M1 , guinea pig atrium for M2 , guinea pig ileum for M3 and immature guinea pig uterus for putative M4 ) , have shown an M4/M1 selectivity ratio of 10.2 that might be responsible for the antinociception and the <e2>anti-amnesic</e2> effect induced by (+/-)-PG-9 through an increase in acetylcholine extracellular levels .
C087567_D000647 NONE Affinity profiles of (+/-)-PG-9 for muscarinic receptor subtypes , determined by functional studies ( rabbit vas deferens for M1 , guinea pig atrium for M2 , guinea pig ileum for M3 and immature guinea pig uterus for putative M4 ) , have shown an M4/M1 selectivity ratio of 10.2 that might be responsible for the antinociception and the <e2>anti-amnesic</e2> effect induced by <e1>(+/-)-PG-9</e1> through an increase in acetylcholine extracellular levels .
D012601_D000647 CID (+/-)-PG-9 ( 10 - 40 mg kg-1 i.p. ) was able to prevent <e2>amnesia</e2> induced by <e1>scopolamine</e1> ( 1 mg kg-1 i.p. ) and dicyclomine ( 2 mg kg-1 i.p. ) in the mouse passive-avoidance test .
D004025_D000647 CID (+/-)-PG-9 ( 10 - 40 mg kg-1 i.p. ) was able to prevent <e2>amnesia</e2> induced by scopolamine ( 1 mg kg-1 i.p. ) and <e1>dicyclomine</e1> ( 2 mg kg-1 i.p. ) in the mouse passive-avoidance test .
D000109_D000647 NONE Affinity profiles of (+/-)-PG-9 for muscarinic receptor subtypes , determined by functional studies ( rabbit vas deferens for M1 , guinea pig atrium for M2 , guinea pig ileum for M3 and immature guinea pig uterus for putative M4 ) , have shown an M4/M1 selectivity ratio of 10.2 that might be responsible for the antinociception and the <e2>anti-amnesic</e2> effect induced by (+/-)-PG-9 through an increase in <e1>acetylcholine</e1> extracellular levels .
11875660
D001374_D009436 NONE We observed the <e2>exencephaly</e2> induced by <e1>5-azacytidine</e1> at embryonic day 13.5 ( E13.5 ) , let the embryos develop exo utero until E18.5 , and re-observed the same embryos at E18.5 .
17532790
D007980_D004409 CID Proteomic analysis of striatal proteins in the rat model of <e1>L-DOPA-induced</e1> <e2>dyskinesia</e2> .
D007980_D004409 CID <e1>L-DOPA-induced</e1> <e2>dyskinesia</e2> ( LID ) is among the motor complications that arise in Parkinson 's disease ( PD ) patients after a prolonged treatment with L-DOPA .
D007980_D004409 CID <e1>L-DOPA-induced</e1> dyskinesia ( <e2>LID</e2> ) is among the motor complications that arise in Parkinson 's disease ( PD ) patients after a prolonged treatment with L-DOPA .
D007980_D004409 CID L-DOPA-induced <e2>dyskinesia</e2> ( LID ) is among the motor complications that arise in Parkinson 's disease ( PD ) patients after a prolonged treatment with <e1>L-DOPA</e1> .
D007980_D004409 CID L-DOPA-induced dyskinesia ( <e2>LID</e2> ) is among the motor complications that arise in Parkinson 's disease ( PD ) patients after a prolonged treatment with <e1>L-DOPA</e1> .
D007980_D004409 CID Rats treated with <e1>L-DOPA</e1> were allocated to two groups based on the presence or absence of <e2>LID</e2> .
D007980_D010300 NONE <e1>L-DOPA-induced</e1> dyskinesia ( LID ) is among the motor complications that arise in <e2>Parkinson 's disease</e2> ( PD ) patients after a prolonged treatment with L-DOPA .
D007980_D010300 NONE <e1>L-DOPA-induced</e1> dyskinesia ( LID ) is among the motor complications that arise in Parkinson 's disease ( <e2>PD</e2> ) patients after a prolonged treatment with L-DOPA .
D007980_D010300 NONE L-DOPA-induced dyskinesia ( LID ) is among the motor complications that arise in <e2>Parkinson 's disease</e2> ( PD ) patients after a prolonged treatment with <e1>L-DOPA</e1> .
D007980_D010300 NONE L-DOPA-induced dyskinesia ( LID ) is among the motor complications that arise in Parkinson 's disease ( <e2>PD</e2> ) patients after a prolonged treatment with <e1>L-DOPA</e1> .
D007980_D010300 NONE In the present study , we investigated the changes occurring at the protein level in striatal samples obtained from the unilaterally 6-hydroxydopamine-lesion rat model of <e2>PD</e2> treated with saline , <e1>L-DOPA</e1> or bromocriptine using two-dimensional difference gel electrophoresis and mass spectrometry ( MS ) .
D016627_D010300 NONE In the present study , we investigated the changes occurring at the protein level in striatal samples obtained from the unilaterally <e1>6-hydroxydopamine-lesion</e1> rat model of <e2>PD</e2> treated with saline , L-DOPA or bromocriptine using two-dimensional difference gel electrophoresis and mass spectrometry ( MS ) .
D001971_D010300 NONE In the present study , we investigated the changes occurring at the protein level in striatal samples obtained from the unilaterally 6-hydroxydopamine-lesion rat model of <e2>PD</e2> treated with saline , L-DOPA or <e1>bromocriptine</e1> using two-dimensional difference gel electrophoresis and mass spectrometry ( MS ) .
11198499
C023754_D007022 CID <e2>Hypotension</e2> following the initiation of <e1>tizanidine</e1> in a patient treated with an angiotensin converting enzyme inhibitor for chronic hypertension .
C023754_D007022 CID The authors present a 10-year-old boy chronically treated with lisinopril , an angiotensin converting enzyme inhibitor , to control hypertension who developed <e2>hypotension</e2> following the addition of <e1>tizanidine</e1> , an alpha-2 agonist , for the treatment of spasticity .
C023754_D006973 NONE Hypotension following the initiation of <e1>tizanidine</e1> in a patient treated with an angiotensin converting enzyme inhibitor for chronic <e2>hypertension</e2> .
C023754_D006973 NONE The authors present a 10-year-old boy chronically treated with lisinopril , an angiotensin converting enzyme inhibitor , to control <e2>hypertension</e2> who developed hypotension following the addition of <e1>tizanidine</e1> , an alpha-2 agonist , for the treatment of spasticity .
C023754_D006973 NONE The possible interaction of <e1>tizanidine</e1> and other antihypertensive agents should be kept in mind when prescribing therapy to treat either <e2>hypertension</e2> or spasticity in such patients .
D000809_D007022 NONE <e2>Hypotension</e2> following the initiation of tizanidine in a patient treated with an <e1>angiotensin</e1> converting enzyme inhibitor for chronic hypertension .
D000809_D007022 NONE Adults chronically treated with <e1>angiotensin</e1> converting enzyme inhibitors may have a limited ability to respond to <e2>hypotension</e2> when the sympathetic response is simultaneously blocked .
D000809_D007022 NONE The authors present a 10-year-old boy chronically treated with lisinopril , an <e1>angiotensin</e1> converting enzyme inhibitor , to control hypertension who developed <e2>hypotension</e2> following the addition of tizanidine , an alpha-2 agonist , for the treatment of spasticity .
D000809_D006973 NONE Hypotension following the initiation of tizanidine in a patient treated with an <e1>angiotensin</e1> converting enzyme inhibitor for chronic <e2>hypertension</e2> .
D000809_D006973 NONE The authors present a 10-year-old boy chronically treated with lisinopril , an <e1>angiotensin</e1> converting enzyme inhibitor , to control <e2>hypertension</e2> who developed hypotension following the addition of tizanidine , an alpha-2 agonist , for the treatment of spasticity .
D017706_D006973 NONE The authors present a 10-year-old boy chronically treated with <e1>lisinopril</e1> , an angiotensin converting enzyme inhibitor , to control <e2>hypertension</e2> who developed hypotension following the addition of tizanidine , an alpha-2 agonist , for the treatment of spasticity .
D017706_D007022 CID The authors present a 10-year-old boy chronically treated with <e1>lisinopril</e1> , an angiotensin converting enzyme inhibitor , to control hypertension who developed <e2>hypotension</e2> following the addition of tizanidine , an alpha-2 agonist , for the treatment of spasticity .
D017706_D009128 NONE The authors present a 10-year-old boy chronically treated with <e1>lisinopril</e1> , an angiotensin converting enzyme inhibitor , to control hypertension who developed hypotension following the addition of tizanidine , an alpha-2 agonist , for the treatment of <e2>spasticity</e2> .
D000809_D009128 NONE The authors present a 10-year-old boy chronically treated with lisinopril , an <e1>angiotensin</e1> converting enzyme inhibitor , to control hypertension who developed hypotension following the addition of tizanidine , an alpha-2 agonist , for the treatment of <e2>spasticity</e2> .
C023754_D009128 NONE The authors present a 10-year-old boy chronically treated with lisinopril , an angiotensin converting enzyme inhibitor , to control hypertension who developed hypotension following the addition of <e1>tizanidine</e1> , an alpha-2 agonist , for the treatment of <e2>spasticity</e2> .
C023754_D009128 NONE The possible interaction of <e1>tizanidine</e1> and other antihypertensive agents should be kept in mind when prescribing therapy to treat either hypertension or <e2>spasticity</e2> in such patients .
8423889
D005473_D009069 CID Increase of <e2>Parkinson disability</e2> after <e1>fluoxetine</e1> medication .
D005473_D009069 CID We report the increased amount of <e2>motor disability</e2> in four patients with idiopathic Parkinson 's disease after exposure to the antidepressant <e1>fluoxetine</e1> .
D000928_D009069 NONE We report the increased amount of <e2>motor disability</e2> in four patients with idiopathic Parkinson 's disease after exposure to the <e1>antidepressant</e1> fluoxetine .
D000928_D010300 NONE We report the increased amount of motor disability in four patients with <e2>idiopathic Parkinson 's disease</e2> after exposure to the <e1>antidepressant</e1> fluoxetine .
D005473_D010300 NONE We report the increased amount of motor disability in four patients with <e2>idiopathic Parkinson 's disease</e2> after exposure to the antidepressant <e1>fluoxetine</e1> .
D005473_D010300 NONE The possibility of a clinically relevant dopamine-antagonistic capacity of <e1>fluoxetine</e1> in <e2>Parkinson 's disease</e2> patients must be considered .
D004298_D010300 NONE The possibility of a clinically relevant <e1>dopamine-antagonistic</e1> capacity of fluoxetine in <e2>Parkinson 's disease</e2> patients must be considered .
1420741
D005672_D003424 NONE Treatment of <e2>Crohn 's disease</e2> with <e1>fusidic acid</e1> : an antibiotic with immunosuppressive properties similar to cyclosporin .
D005672_D003424 NONE Because of the need for the development of new treatments for <e2>Crohn 's disease</e2> , a pilot study was undertaken to estimate the pharmacodynamics and tolerability of <e1>fusidic acid</e1> treatment in chronic active , therapy-resistant patients .
D005672_D003424 NONE The results of this pilot study suggest that <e1>fusidic acid</e1> may be of benefit in selected chronic active <e2>Crohn 's disease</e2> patients in whom conventional treatment is ineffective .
D016572_D003424 NONE Treatment of <e2>Crohn 's disease</e2> with fusidic acid : an antibiotic with immunosuppressive properties similar to <e1>cyclosporin</e1> .
D005672_D015212 NONE Because there seems to exist a scientific rationale for the use of <e1>fusidic acid</e1> at the cytokine level in <e2>inflammatory bowel disease</e2> , we suggest that the role of this treatment should be further investigated .
18703024
D006220_D002375 CID No changes in <e1>haloperidol-induced</e1> <e2>catalepsy</e2> or MK-801-induced locomotion were seen following PD .
D016291_D002375 NONE No changes in haloperidol-induced <e2>catalepsy</e2> or <e1>MK-801-induced</e1> locomotion were seen following PD .
11679859
D011346_D017109 CID Intravenous administration of <e1>prochlorperazine</e1> by 15-minute infusion versus 2-minute bolus does not affect the incidence of <e2>akathisia</e2> : a prospective , randomized , controlled trial .
D011346_D017109 CID STUDY OBJECTIVE : We sought to compare the rate of <e2>akathisia</e2> after administration of intravenous <e1>prochlorperazine</e1> as a 2-minute bolus or 15-minute infusion .
D011346_D017109 CID CONCLUSION : A 50 % reduction in the incidence of <e2>akathisia</e2> when <e1>prochlorperazine</e1> was administered by means of 15-minute intravenous infusion versus a 2-minute intravenous push was not detected .
D011346_D006261 NONE Patients aged 18 years or older treated with <e1>prochlorperazine</e1> for <e2>headache</e2> , nausea , or vomiting were eligible for inclusion .
D011346_D006261 NONE The efficacy of <e1>prochlorperazine</e1> in the treatment of <e2>headache</e2> and nausea likewise did not appear to be affected by the rate of administration , although no formal statistical comparisons were made .
D011346_D009325 NONE Patients aged 18 years or older treated with <e1>prochlorperazine</e1> for headache , <e2>nausea</e2> , or vomiting were eligible for inclusion .
D011346_D009325 NONE The efficacy of <e1>prochlorperazine</e1> in the treatment of headache and <e2>nausea</e2> likewise did not appear to be affected by the rate of administration , although no formal statistical comparisons were made .
D011346_D014839 NONE Patients aged 18 years or older treated with <e1>prochlorperazine</e1> for headache , nausea , or <e2>vomiting</e2> were eligible for inclusion .
3828020
D010665_D002544 CID <e2>Cerebral infarction</e2> with a single oral dose of <e1>phenylpropanolamine</e1> .
D010665_D002544 CID We report the case of a young woman who suffered a <e2>cerebral infarction</e2> after taking a single oral dose of <e1>PPA</e1> .
2396046
D002794_D006528 CID No hepatic preneoplastic nodules or <e2>hepatocellular carcinomas</e2> developed in rats fed the plain <e1>choline-supplemented</e1> diet , while one preneoplastic nodule and one hepatocellular carcinoma developed in two rats fed the same diet containing phenobarbital .
D002794_D006528 CID No hepatic preneoplastic nodules or hepatocellular carcinomas developed in rats fed the plain <e1>choline-supplemented</e1> diet , while one preneoplastic nodule and one <e2>hepatocellular carcinoma</e2> developed in two rats fed the same diet containing phenobarbital .
D002794_D006528 CID The incidence of preneoplastic nodules and of <e2>hepatocellular carcinomas</e2> was 10 % and 37 % , respectively , in rats fed the plain <e1>choline-devoid</e1> diet , and 17 % and 30 % , in rats fed the phenobarbital-containing choline-devoid diet .
D002794_D006528 CID The incidence of preneoplastic nodules and of <e2>hepatocellular carcinomas</e2> was 10 % and 37 % , respectively , in rats fed the plain choline-devoid diet , and 17 % and 30 % , in rats fed the phenobarbital-containing <e1>choline-devoid</e1> diet .
D010634_D006528 NONE No hepatic preneoplastic nodules or <e2>hepatocellular carcinomas</e2> developed in rats fed the plain choline-supplemented diet , while one preneoplastic nodule and one hepatocellular carcinoma developed in two rats fed the same diet containing <e1>phenobarbital</e1> .
D010634_D006528 NONE No hepatic preneoplastic nodules or hepatocellular carcinomas developed in rats fed the plain choline-supplemented diet , while one preneoplastic nodule and one <e2>hepatocellular carcinoma</e2> developed in two rats fed the same diet containing <e1>phenobarbital</e1> .
D010634_D006528 NONE The incidence of preneoplastic nodules and of <e2>hepatocellular carcinomas</e2> was 10 % and 37 % , respectively , in rats fed the plain choline-devoid diet , and 17 % and 30 % , in rats fed the <e1>phenobarbital-containing</e1> choline-devoid diet .
9698967
D008619_D006973 CID An <e2>increase in blood pressure</e2> , accompanied by atrial fibrillation , agitation , incomprehensible shouts and loss of consciousness , was observed in an elderly , ASA classification group II , cardiovascularly medicated male , 12 min after performance of axillary block with <e1>mepivacaine</e1> 850 mg containing adrenaline 0.225 mg , for correction of Dupuytren 's contracture .
D008619_D001281 CID An increase in blood pressure , accompanied by <e2>atrial fibrillation</e2> , agitation , incomprehensible shouts and loss of consciousness , was observed in an elderly , ASA classification group II , cardiovascularly medicated male , 12 min after performance of axillary block with <e1>mepivacaine</e1> 850 mg containing adrenaline 0.225 mg , for correction of Dupuytren 's contracture .
D008619_D011595 NONE An increase in blood pressure , accompanied by atrial fibrillation , <e2>agitation</e2> , incomprehensible shouts and loss of consciousness , was observed in an elderly , ASA classification group II , cardiovascularly medicated male , 12 min after performance of axillary block with <e1>mepivacaine</e1> 850 mg containing adrenaline 0.225 mg , for correction of Dupuytren 's contracture .
D008619_D019954 NONE An increase in blood pressure , accompanied by atrial fibrillation , agitation , <e2>incomprehensible shouts</e2> and loss of consciousness , was observed in an elderly , ASA classification group II , cardiovascularly medicated male , 12 min after performance of axillary block with <e1>mepivacaine</e1> 850 mg containing adrenaline 0.225 mg , for correction of Dupuytren 's contracture .
D008619_D014474 NONE An increase in blood pressure , accompanied by atrial fibrillation , agitation , incomprehensible shouts and <e2>loss of consciousness</e2> , was observed in an elderly , ASA classification group II , cardiovascularly medicated male , 12 min after performance of axillary block with <e1>mepivacaine</e1> 850 mg containing adrenaline 0.225 mg , for correction of Dupuytren 's contracture .
D008619_D004387 NONE An increase in blood pressure , accompanied by atrial fibrillation , agitation , incomprehensible shouts and loss of consciousness , was observed in an elderly , ASA classification group II , cardiovascularly medicated male , 12 min after performance of axillary block with <e1>mepivacaine</e1> 850 mg containing adrenaline 0.225 mg , for correction of <e2>Dupuytren 's contracture</e2> .
D004837_D006973 CID An <e2>increase in blood pressure</e2> , accompanied by atrial fibrillation , agitation , incomprehensible shouts and loss of consciousness , was observed in an elderly , ASA classification group II , cardiovascularly medicated male , 12 min after performance of axillary block with mepivacaine 850 mg containing <e1>adrenaline</e1> 0.225 mg , for correction of Dupuytren 's contracture .
D004837_D001281 CID An increase in blood pressure , accompanied by <e2>atrial fibrillation</e2> , agitation , incomprehensible shouts and loss of consciousness , was observed in an elderly , ASA classification group II , cardiovascularly medicated male , 12 min after performance of axillary block with mepivacaine 850 mg containing <e1>adrenaline</e1> 0.225 mg , for correction of Dupuytren 's contracture .
D004837_D011595 NONE An increase in blood pressure , accompanied by atrial fibrillation , <e2>agitation</e2> , incomprehensible shouts and loss of consciousness , was observed in an elderly , ASA classification group II , cardiovascularly medicated male , 12 min after performance of axillary block with mepivacaine 850 mg containing <e1>adrenaline</e1> 0.225 mg , for correction of Dupuytren 's contracture .
D004837_D019954 NONE An increase in blood pressure , accompanied by atrial fibrillation , agitation , <e2>incomprehensible shouts</e2> and loss of consciousness , was observed in an elderly , ASA classification group II , cardiovascularly medicated male , 12 min after performance of axillary block with mepivacaine 850 mg containing <e1>adrenaline</e1> 0.225 mg , for correction of Dupuytren 's contracture .
D004837_D014474 NONE An increase in blood pressure , accompanied by atrial fibrillation , agitation , incomprehensible shouts and <e2>loss of consciousness</e2> , was observed in an elderly , ASA classification group II , cardiovascularly medicated male , 12 min after performance of axillary block with mepivacaine 850 mg containing <e1>adrenaline</e1> 0.225 mg , for correction of Dupuytren 's contracture .
D004837_D004387 NONE An increase in blood pressure , accompanied by atrial fibrillation , agitation , incomprehensible shouts and loss of consciousness , was observed in an elderly , ASA classification group II , cardiovascularly medicated male , 12 min after performance of axillary block with mepivacaine 850 mg containing <e1>adrenaline</e1> 0.225 mg , for correction of <e2>Dupuytren 's contracture</e2> .
1616457
D010424_D000647 CID Learning of rats under <e2>amnesia</e2> caused by <e1>pentobarbital</e1> .
D010424_D000647 CID Dissociated learning of rats in the normal state and the state of <e2>amnesia</e2> produced by <e1>pentobarbital</e1> ( 15 mg/kg , ip ) was carried out .
12589964
D004317_D009202 CID Evaluation of cardiac troponin I and T levels as markers of <e2>myocardial damage</e2> in <e1>doxorubicin-induced</e1> cardiomyopathy rats , and their relationship with echocardiographic and histological findings .
D004317_D009202 CID Evaluation of cardiac troponin I and T levels as markers of myocardial damage in <e1>doxorubicin-induced</e1> <e2>cardiomyopathy</e2> rats , and their relationship with echocardiographic and histological findings .
D004317_D009202 CID We investigated the diagnostic value of cTnI and cTnT for the diagnosis of <e2>myocardial damage</e2> in a rat model of <e1>doxorubicin</e1> (DOX)-induced cardiomyopathy , and we examined the relationship between serial cTnI and cTnT with the development of cardiac disorders monitored by echocardiography and histological examinations in this model .
D004317_D009202 CID We investigated the diagnostic value of cTnI and cTnT for the diagnosis of myocardial damage in a rat model of <e1>doxorubicin</e1> (DOX)-induced <e2>cardiomyopathy</e2> , and we examined the relationship between serial cTnI and cTnT with the development of cardiac disorders monitored by echocardiography and histological examinations in this model .
D004317_D009202 CID We investigated the diagnostic value of cTnI and cTnT for the diagnosis of <e2>myocardial damage</e2> in a rat model of doxorubicin <e1>(DOX)-induced</e1> cardiomyopathy , and we examined the relationship between serial cTnI and cTnT with the development of cardiac disorders monitored by echocardiography and histological examinations in this model .
D004317_D009202 CID We investigated the diagnostic value of cTnI and cTnT for the diagnosis of myocardial damage in a rat model of doxorubicin <e1>(DOX)-induced</e1> <e2>cardiomyopathy</e2> , and we examined the relationship between serial cTnI and cTnT with the development of cardiac disorders monitored by echocardiography and histological examinations in this model .
D004317_D009202 CID CONCLUSIONS : Among markers of ischemic injury after <e1>DOX</e1> in rats , cTnT showed the greatest ability to detect <e2>myocardial damage</e2> assessed by echocardiographic detection and histological changes .
D004317_D006331 NONE We investigated the diagnostic value of cTnI and cTnT for the diagnosis of myocardial damage in a rat model of <e1>doxorubicin</e1> (DOX)-induced cardiomyopathy , and we examined the relationship between serial cTnI and cTnT with the development of <e2>cardiac disorders</e2> monitored by echocardiography and histological examinations in this model .
D004317_D006331 NONE We investigated the diagnostic value of cTnI and cTnT for the diagnosis of myocardial damage in a rat model of doxorubicin <e1>(DOX)-induced</e1> cardiomyopathy , and we examined the relationship between serial cTnI and cTnT with the development of <e2>cardiac disorders</e2> monitored by echocardiography and histological examinations in this model .
D004317_D064420 NONE RESULTS : Eighteen of the <e1>DOX</e1> rats died prematurely of general <e2>toxicity</e2> during the 9-week period .
D004317_D005355 NONE Histological evaluation of hearts from all rats given <e1>DOX</e1> revealed significant slight degrees of perivascular and interstitial <e2>fibrosis</e2> .
D004317_D017202 NONE CONCLUSIONS : Among markers of <e2>ischemic injury</e2> after <e1>DOX</e1> in rats , cTnT showed the greatest ability to detect myocardial damage assessed by echocardiographic detection and histological changes .
D004317_D066126 NONE Although there was a discrepancy between the amount of cTnI and cTnT after <e1>DOX</e1> , probably due to heterogeneity in cross-reactivities of mAbs to various cTnI and cTnT forms , it is likely that cTnT in rats after DOX indicates cell damage determined by the magnitude of injury induced and that cTnT should be a useful marker for the prediction of experimentally induced <e2>cardiotoxicity</e2> and possibly for cardioprotective experiments .
D004317_D066126 NONE Although there was a discrepancy between the amount of cTnI and cTnT after DOX , probably due to heterogeneity in cross-reactivities of mAbs to various cTnI and cTnT forms , it is likely that cTnT in rats after <e1>DOX</e1> indicates cell damage determined by the magnitude of injury induced and that cTnT should be a useful marker for the prediction of experimentally induced <e2>cardiotoxicity</e2> and possibly for cardioprotective experiments .
11379838
D000928_D001714 CID <e1>Antidepressant-induced</e1> <e2>mania</e2> in bipolar patients : identification of risk factors .
D000928_D001714 CID <e1>Antidepressant-induced</e1> mania in <e2>bipolar</e2> patients : identification of risk factors .
D000928_D001714 CID BACKGROUND : Concerns about possible risks of switching to <e2>mania</e2> associated with <e1>antidepressants</e1> continue to interfere with the establishment of an optimal treatment paradigm for bipolar depression .
D000928_D001714 CID BACKGROUND : Concerns about possible risks of switching to mania associated with <e1>antidepressants</e1> continue to interfere with the establishment of an optimal treatment paradigm for <e2>bipolar depression</e2> .
D000928_D001714 CID Patients who experienced a <e2>manic</e2> or hypomanic switch were compared with those who did not on several variables including age , sex , diagnosis ( DSM-IV bipolar I vs. bipolar II ) , number of previous manic episodes , type of <e1>antidepressant</e1> therapy used ( electroconvulsive therapy vs. antidepressant drugs and , more particularly , selective serotonin reuptake inhibitors [ SSRIs ] ) , use and type of mood stabilizers ( lithium vs. anticonvulsants ) , and temperament of the patient , assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview .
D000928_D001714 CID Patients who experienced a manic or <e2>hypomanic</e2> switch were compared with those who did not on several variables including age , sex , diagnosis ( DSM-IV bipolar I vs. bipolar II ) , number of previous manic episodes , type of <e1>antidepressant</e1> therapy used ( electroconvulsive therapy vs. antidepressant drugs and , more particularly , selective serotonin reuptake inhibitors [ SSRIs ] ) , use and type of mood stabilizers ( lithium vs. anticonvulsants ) , and temperament of the patient , assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview .
D000928_D001714 CID Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age , sex , diagnosis ( <e2>DSM-IV bipolar I</e2> vs. bipolar II ) , number of previous manic episodes , type of <e1>antidepressant</e1> therapy used ( electroconvulsive therapy vs. antidepressant drugs and , more particularly , selective serotonin reuptake inhibitors [ SSRIs ] ) , use and type of mood stabilizers ( lithium vs. anticonvulsants ) , and temperament of the patient , assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview .
D000928_D001714 CID Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age , sex , diagnosis ( DSM-IV bipolar I vs. <e2>bipolar II</e2> ) , number of previous manic episodes , type of <e1>antidepressant</e1> therapy used ( electroconvulsive therapy vs. antidepressant drugs and , more particularly , selective serotonin reuptake inhibitors [ SSRIs ] ) , use and type of mood stabilizers ( lithium vs. anticonvulsants ) , and temperament of the patient , assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview .
D000928_D001714 CID Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age , sex , diagnosis ( DSM-IV bipolar I vs. bipolar II ) , number of previous <e2>manic</e2> episodes , type of <e1>antidepressant</e1> therapy used ( electroconvulsive therapy vs. antidepressant drugs and , more particularly , selective serotonin reuptake inhibitors [ SSRIs ] ) , use and type of mood stabilizers ( lithium vs. anticonvulsants ) , and temperament of the patient , assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview .
D000928_D001714 CID Patients who experienced a <e2>manic</e2> or hypomanic switch were compared with those who did not on several variables including age , sex , diagnosis ( DSM-IV bipolar I vs. bipolar II ) , number of previous manic episodes , type of antidepressant therapy used ( electroconvulsive therapy vs. <e1>antidepressant</e1> drugs and , more particularly , selective serotonin reuptake inhibitors [ SSRIs ] ) , use and type of mood stabilizers ( lithium vs. anticonvulsants ) , and temperament of the patient , assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview .
D000928_D001714 CID Patients who experienced a manic or <e2>hypomanic</e2> switch were compared with those who did not on several variables including age , sex , diagnosis ( DSM-IV bipolar I vs. bipolar II ) , number of previous manic episodes , type of antidepressant therapy used ( electroconvulsive therapy vs. <e1>antidepressant</e1> drugs and , more particularly , selective serotonin reuptake inhibitors [ SSRIs ] ) , use and type of mood stabilizers ( lithium vs. anticonvulsants ) , and temperament of the patient , assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview .
D000928_D001714 CID Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age , sex , diagnosis ( <e2>DSM-IV bipolar I</e2> vs. bipolar II ) , number of previous manic episodes , type of antidepressant therapy used ( electroconvulsive therapy vs. <e1>antidepressant</e1> drugs and , more particularly , selective serotonin reuptake inhibitors [ SSRIs ] ) , use and type of mood stabilizers ( lithium vs. anticonvulsants ) , and temperament of the patient , assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview .
D000928_D001714 CID Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age , sex , diagnosis ( DSM-IV bipolar I vs. <e2>bipolar II</e2> ) , number of previous manic episodes , type of antidepressant therapy used ( electroconvulsive therapy vs. <e1>antidepressant</e1> drugs and , more particularly , selective serotonin reuptake inhibitors [ SSRIs ] ) , use and type of mood stabilizers ( lithium vs. anticonvulsants ) , and temperament of the patient , assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview .
D000928_D001714 CID Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age , sex , diagnosis ( DSM-IV bipolar I vs. bipolar II ) , number of previous <e2>manic</e2> episodes , type of antidepressant therapy used ( electroconvulsive therapy vs. <e1>antidepressant</e1> drugs and , more particularly , selective serotonin reuptake inhibitors [ SSRIs ] ) , use and type of mood stabilizers ( lithium vs. anticonvulsants ) , and temperament of the patient , assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview .
D017367_D001714 CID Patients who experienced a <e2>manic</e2> or hypomanic switch were compared with those who did not on several variables including age , sex , diagnosis ( DSM-IV bipolar I vs. bipolar II ) , number of previous manic episodes , type of antidepressant therapy used ( electroconvulsive therapy vs. antidepressant drugs and , more particularly , selective <e1>serotonin reuptake inhibitors</e1> [ SSRIs ] ) , use and type of mood stabilizers ( lithium vs. anticonvulsants ) , and temperament of the patient , assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview .
D017367_D001714 CID Patients who experienced a manic or <e2>hypomanic</e2> switch were compared with those who did not on several variables including age , sex , diagnosis ( DSM-IV bipolar I vs. bipolar II ) , number of previous manic episodes , type of antidepressant therapy used ( electroconvulsive therapy vs. antidepressant drugs and , more particularly , selective <e1>serotonin reuptake inhibitors</e1> [ SSRIs ] ) , use and type of mood stabilizers ( lithium vs. anticonvulsants ) , and temperament of the patient , assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview .
D017367_D001714 CID Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age , sex , diagnosis ( <e2>DSM-IV bipolar I</e2> vs. bipolar II ) , number of previous manic episodes , type of antidepressant therapy used ( electroconvulsive therapy vs. antidepressant drugs and , more particularly , selective <e1>serotonin reuptake inhibitors</e1> [ SSRIs ] ) , use and type of mood stabilizers ( lithium vs. anticonvulsants ) , and temperament of the patient , assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview .
D017367_D001714 CID Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age , sex , diagnosis ( DSM-IV bipolar I vs. <e2>bipolar II</e2> ) , number of previous manic episodes , type of antidepressant therapy used ( electroconvulsive therapy vs. antidepressant drugs and , more particularly , selective <e1>serotonin reuptake inhibitors</e1> [ SSRIs ] ) , use and type of mood stabilizers ( lithium vs. anticonvulsants ) , and temperament of the patient , assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview .
D017367_D001714 CID Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age , sex , diagnosis ( DSM-IV bipolar I vs. bipolar II ) , number of previous <e2>manic</e2> episodes , type of antidepressant therapy used ( electroconvulsive therapy vs. antidepressant drugs and , more particularly , selective <e1>serotonin reuptake inhibitors</e1> [ SSRIs ] ) , use and type of mood stabilizers ( lithium vs. anticonvulsants ) , and temperament of the patient , assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview .
D017367_D001714 CID Patients who experienced a <e2>manic</e2> or hypomanic switch were compared with those who did not on several variables including age , sex , diagnosis ( DSM-IV bipolar I vs. bipolar II ) , number of previous manic episodes , type of antidepressant therapy used ( electroconvulsive therapy vs. antidepressant drugs and , more particularly , selective serotonin reuptake inhibitors [ <e1>SSRIs</e1> ] ) , use and type of mood stabilizers ( lithium vs. anticonvulsants ) , and temperament of the patient , assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview .
D017367_D001714 CID Patients who experienced a manic or <e2>hypomanic</e2> switch were compared with those who did not on several variables including age , sex , diagnosis ( DSM-IV bipolar I vs. bipolar II ) , number of previous manic episodes , type of antidepressant therapy used ( electroconvulsive therapy vs. antidepressant drugs and , more particularly , selective serotonin reuptake inhibitors [ <e1>SSRIs</e1> ] ) , use and type of mood stabilizers ( lithium vs. anticonvulsants ) , and temperament of the patient , assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview .
D017367_D001714 CID Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age , sex , diagnosis ( <e2>DSM-IV bipolar I</e2> vs. bipolar II ) , number of previous manic episodes , type of antidepressant therapy used ( electroconvulsive therapy vs. antidepressant drugs and , more particularly , selective serotonin reuptake inhibitors [ <e1>SSRIs</e1> ] ) , use and type of mood stabilizers ( lithium vs. anticonvulsants ) , and temperament of the patient , assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview .
D017367_D001714 CID Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age , sex , diagnosis ( DSM-IV bipolar I vs. <e2>bipolar II</e2> ) , number of previous manic episodes , type of antidepressant therapy used ( electroconvulsive therapy vs. antidepressant drugs and , more particularly , selective serotonin reuptake inhibitors [ <e1>SSRIs</e1> ] ) , use and type of mood stabilizers ( lithium vs. anticonvulsants ) , and temperament of the patient , assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview .
D017367_D001714 CID Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age , sex , diagnosis ( DSM-IV bipolar I vs. bipolar II ) , number of previous <e2>manic</e2> episodes , type of antidepressant therapy used ( electroconvulsive therapy vs. antidepressant drugs and , more particularly , selective serotonin reuptake inhibitors [ <e1>SSRIs</e1> ] ) , use and type of mood stabilizers ( lithium vs. anticonvulsants ) , and temperament of the patient , assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview .
D017367_D001714 CID RESULTS : Switches to <e2>hypomania</e2> or mania occurred in 27 % of all patients ( N = 12 ) ( and in 24 % of the subgroup of patients treated with <e1>SSRIs</e1> [ 8/33 ] ) ; 16 % ( N = 7 ) experienced manic episodes , and 11 % ( N = 5 ) experienced hypomanic episodes .
D017367_D001714 CID RESULTS : Switches to hypomania or <e2>mania</e2> occurred in 27 % of all patients ( N = 12 ) ( and in 24 % of the subgroup of patients treated with <e1>SSRIs</e1> [ 8/33 ] ) ; 16 % ( N = 7 ) experienced manic episodes , and 11 % ( N = 5 ) experienced hypomanic episodes .
D017367_D001714 CID RESULTS : Switches to hypomania or mania occurred in 27 % of all patients ( N = 12 ) ( and in 24 % of the subgroup of patients treated with <e1>SSRIs</e1> [ 8/33 ] ) ; 16 % ( N = 7 ) experienced <e2>manic</e2> episodes , and 11 % ( N = 5 ) experienced hypomanic episodes .
D017367_D001714 CID RESULTS : Switches to hypomania or mania occurred in 27 % of all patients ( N = 12 ) ( and in 24 % of the subgroup of patients treated with <e1>SSRIs</e1> [ 8/33 ] ) ; 16 % ( N = 7 ) experienced manic episodes , and 11 % ( N = 5 ) experienced <e2>hypomanic</e2> episodes .
D008094_D001714 NONE Patients who experienced a <e2>manic</e2> or hypomanic switch were compared with those who did not on several variables including age , sex , diagnosis ( DSM-IV bipolar I vs. bipolar II ) , number of previous manic episodes , type of antidepressant therapy used ( electroconvulsive therapy vs. antidepressant drugs and , more particularly , selective serotonin reuptake inhibitors [ SSRIs ] ) , use and type of mood stabilizers ( <e1>lithium</e1> vs. anticonvulsants ) , and temperament of the patient , assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview .
D008094_D001714 NONE Patients who experienced a manic or <e2>hypomanic</e2> switch were compared with those who did not on several variables including age , sex , diagnosis ( DSM-IV bipolar I vs. bipolar II ) , number of previous manic episodes , type of antidepressant therapy used ( electroconvulsive therapy vs. antidepressant drugs and , more particularly , selective serotonin reuptake inhibitors [ SSRIs ] ) , use and type of mood stabilizers ( <e1>lithium</e1> vs. anticonvulsants ) , and temperament of the patient , assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview .
D008094_D001714 NONE Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age , sex , diagnosis ( <e2>DSM-IV bipolar I</e2> vs. bipolar II ) , number of previous manic episodes , type of antidepressant therapy used ( electroconvulsive therapy vs. antidepressant drugs and , more particularly , selective serotonin reuptake inhibitors [ SSRIs ] ) , use and type of mood stabilizers ( <e1>lithium</e1> vs. anticonvulsants ) , and temperament of the patient , assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview .
D008094_D001714 NONE Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age , sex , diagnosis ( DSM-IV bipolar I vs. <e2>bipolar II</e2> ) , number of previous manic episodes , type of antidepressant therapy used ( electroconvulsive therapy vs. antidepressant drugs and , more particularly , selective serotonin reuptake inhibitors [ SSRIs ] ) , use and type of mood stabilizers ( <e1>lithium</e1> vs. anticonvulsants ) , and temperament of the patient , assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview .
D008094_D001714 NONE Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age , sex , diagnosis ( DSM-IV bipolar I vs. bipolar II ) , number of previous <e2>manic</e2> episodes , type of antidepressant therapy used ( electroconvulsive therapy vs. antidepressant drugs and , more particularly , selective serotonin reuptake inhibitors [ SSRIs ] ) , use and type of mood stabilizers ( <e1>lithium</e1> vs. anticonvulsants ) , and temperament of the patient , assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview .
7977601
11206082
C036150_D012640 CID Two mouse lines selected for differential sensitivities to <e1>beta-carboline-induced</e1> <e2>seizures</e2> are also differentially sensitive to various pharmacological effects of other GABA(A ) receptor ligands .
C036150_D012640 CID Two mouse lines were selectively bred according to their sensitivity ( BS line ) or resistance ( BR line ) to <e2>seizures</e2> induced by a single i.p. injection of <e1>methyl beta-carboline-3-carboxylate</e1> ( beta-CCM ) , an inverse agonist of the GABA(A ) receptor benzodiazepine site .
C036150_D012640 CID Two mouse lines were selectively bred according to their sensitivity ( BS line ) or resistance ( BR line ) to <e2>seizures</e2> induced by a single i.p. injection of methyl beta-carboline-3-carboxylate ( <e1>beta-CCM</e1> ) , an inverse agonist of the GABA(A ) receptor benzodiazepine site .
D005680_D012640 NONE Two mouse lines selected for differential sensitivities to beta-carboline-induced <e2>seizures</e2> are also differentially sensitive to various pharmacological effects of other <e1>GABA(A</e1> ) receptor ligands .
D005680_D012640 NONE Two mouse lines were selectively bred according to their sensitivity ( BS line ) or resistance ( BR line ) to <e2>seizures</e2> induced by a single i.p. injection of methyl beta-carboline-3-carboxylate ( beta-CCM ) , an inverse agonist of the <e1>GABA(A</e1> ) receptor benzodiazepine site .
D001569_D012640 NONE Two mouse lines were selectively bred according to their sensitivity ( BS line ) or resistance ( BR line ) to <e2>seizures</e2> induced by a single i.p. injection of methyl beta-carboline-3-carboxylate ( beta-CCM ) , an inverse agonist of the GABA(A ) receptor <e1>benzodiazepine</e1> site .
D003975_D012640 NONE We measured <e1>diazepam-induced</e1> anxiolysis with the elevated plus-maze test , diazepam-induced sedation by recording the vigilance states , and picrotoxin- and pentylenetetrazol-induced <e2>seizures</e2> after i.p. injections .
D003975_D012640 NONE We measured diazepam-induced anxiolysis with the elevated plus-maze test , <e1>diazepam-induced</e1> sedation by recording the vigilance states , and picrotoxin- and pentylenetetrazol-induced <e2>seizures</e2> after i.p. injections .
D010852_D012640 CID We measured diazepam-induced anxiolysis with the elevated plus-maze test , diazepam-induced sedation by recording the vigilance states , and <e1>picrotoxin-</e1> and pentylenetetrazol-induced <e2>seizures</e2> after i.p. injections .
D010433_D012640 CID We measured diazepam-induced anxiolysis with the elevated plus-maze test , diazepam-induced sedation by recording the vigilance states , and picrotoxin- and <e1>pentylenetetrazol-induced</e1> <e2>seizures</e2> after i.p. injections .
18951540
D007980_D004409 CID Repetitive transcranial magnetic stimulation for <e1>levodopa-induced</e1> <e2>dyskinesias</e2> in Parkinson 's disease .
D007980_D010300 NONE Repetitive transcranial magnetic stimulation for <e1>levodopa-induced</e1> dyskinesias in <e2>Parkinson 's disease</e2> .
17879945
D019438_D050197 CID We have previously demonstrated that <e1>ritonavir</e1> treatment increases <e2>atherosclerotic lesion</e2> formation in male mice to a greater extent than in female mice .
4027862
D003891_D003693 CID <e1>Desipramine-induced</e1> <e2>delirium</e2> at " subtherapeutic " concentrations : a case report .
D003891_D003693 CID An elderly patient treated with low dose <e1>Desipramine</e1> developed a <e2>delirium</e2> while her plasma level was in the " subtherapeutic " range .
7862923
D002220_D012559 NONE <e1>Carbamazepine</e1> was switched to its 10-keto analogue oxcarbazepine among six difficult-to-treat <e2>schizophrenic</e2> or organic psychotic patients using concomitantly haloperidol , chlorpromazine or clozapine .
D002220_D019965 NONE <e1>Carbamazepine</e1> was switched to its 10-keto analogue oxcarbazepine among six difficult-to-treat schizophrenic or <e2>organic psychotic</e2> patients using concomitantly haloperidol , chlorpromazine or clozapine .
C036006_D012559 NONE Carbamazepine was switched to its 10-keto analogue <e1>oxcarbazepine</e1> among six difficult-to-treat <e2>schizophrenic</e2> or organic psychotic patients using concomitantly haloperidol , chlorpromazine or clozapine .
C036006_D019965 NONE Carbamazepine was switched to its 10-keto analogue <e1>oxcarbazepine</e1> among six difficult-to-treat schizophrenic or <e2>organic psychotic</e2> patients using concomitantly haloperidol , chlorpromazine or clozapine .
D006220_D012559 NONE Carbamazepine was switched to its 10-keto analogue oxcarbazepine among six difficult-to-treat <e2>schizophrenic</e2> or organic psychotic patients using concomitantly <e1>haloperidol</e1> , chlorpromazine or clozapine .
D006220_D019965 NONE Carbamazepine was switched to its 10-keto analogue oxcarbazepine among six difficult-to-treat schizophrenic or <e2>organic psychotic</e2> patients using concomitantly <e1>haloperidol</e1> , chlorpromazine or clozapine .
D002746_D012559 NONE Carbamazepine was switched to its 10-keto analogue oxcarbazepine among six difficult-to-treat <e2>schizophrenic</e2> or organic psychotic patients using concomitantly haloperidol , <e1>chlorpromazine</e1> or clozapine .
D002746_D019965 NONE Carbamazepine was switched to its 10-keto analogue oxcarbazepine among six difficult-to-treat schizophrenic or <e2>organic psychotic</e2> patients using concomitantly haloperidol , <e1>chlorpromazine</e1> or clozapine .
D003024_D012559 NONE Carbamazepine was switched to its 10-keto analogue oxcarbazepine among six difficult-to-treat <e2>schizophrenic</e2> or organic psychotic patients using concomitantly haloperidol , chlorpromazine or <e1>clozapine</e1> .
D003024_D019965 NONE Carbamazepine was switched to its 10-keto analogue oxcarbazepine among six difficult-to-treat schizophrenic or <e2>organic psychotic</e2> patients using concomitantly haloperidol , chlorpromazine or <e1>clozapine</e1> .
18221780
D016202_D010146 NONE Sex differences in <e1>NMDA</e1> antagonist enhancement of morphine antihyperalgesia in a capsaicin model of persistent <e2>pain</e2> : comparisons to two models of acute pain .
D016202_D010146 NONE These findings demonstrate a sexually-dimorphic interaction between <e1>NMDA</e1> antagonists and morphine in a persistent <e2>pain</e2> model that can be distinguished from those observed in acute pain models .
D016202_D059787 NONE Sex differences in <e1>NMDA</e1> antagonist enhancement of morphine antihyperalgesia in a capsaicin model of persistent pain : comparisons to two models of <e2>acute pain</e2> .
D016202_D059787 NONE In <e2>acute pain</e2> models , <e1>N-methyl-D-aspartate</e1> ( NMDA ) antagonists enhance the antinociceptive effects of morphine to a greater extent in males than females .
D016202_D059787 NONE In <e2>acute pain</e2> models , N-methyl-D-aspartate ( <e1>NMDA</e1> ) antagonists enhance the antinociceptive effects of morphine to a greater extent in males than females .
D016202_D059787 NONE These findings demonstrate a sexually-dimorphic interaction between <e1>NMDA</e1> antagonists and morphine in a persistent pain model that can be distinguished from those observed in <e2>acute pain</e2> models .
D009020_D010146 NONE Sex differences in NMDA antagonist enhancement of <e1>morphine</e1> antihyperalgesia in a capsaicin model of persistent <e2>pain</e2> : comparisons to two models of acute pain .
D009020_D010146 NONE These findings demonstrate a sexually-dimorphic interaction between NMDA antagonists and <e1>morphine</e1> in a persistent <e2>pain</e2> model that can be distinguished from those observed in acute pain models .
D009020_D059787 NONE Sex differences in NMDA antagonist enhancement of <e1>morphine</e1> antihyperalgesia in a capsaicin model of persistent pain : comparisons to two models of <e2>acute pain</e2> .
D009020_D059787 NONE In <e2>acute pain</e2> models , N-methyl-D-aspartate ( NMDA ) antagonists enhance the antinociceptive effects of <e1>morphine</e1> to a greater extent in males than females .
D009020_D059787 NONE Enhancement of <e1>morphine</e1> antinociception by dextromethorphan was seen in both males and females in the <e2>acute pain</e2> models , with the magnitude of this effect being greater in males .
D009020_D059787 NONE These findings demonstrate a sexually-dimorphic interaction between NMDA antagonists and <e1>morphine</e1> in a persistent pain model that can be distinguished from those observed in <e2>acute pain</e2> models .
D002211_D010146 NONE Sex differences in NMDA antagonist enhancement of morphine antihyperalgesia in a <e1>capsaicin</e1> model of persistent <e2>pain</e2> : comparisons to two models of acute pain .
D002211_D059787 NONE Sex differences in NMDA antagonist enhancement of morphine antihyperalgesia in a <e1>capsaicin</e1> model of persistent pain : comparisons to two models of <e2>acute pain</e2> .
D002211_D006930 CID To this end , persistent <e2>hyperalgesia</e2> was induced by administration of <e1>capsaicin</e1> in the tail of gonadally intact F344 rats , following which the tail was immersed in a mildly noxious thermal stimulus , and tail-withdrawal latencies measured .
D003915_D059787 NONE Enhancement of morphine antinociception by <e1>dextromethorphan</e1> was seen in both males and females in the <e2>acute pain</e2> models , with the magnitude of this effect being greater in males .
17261653
D003000_D001919 CID <e1>Clonidine-induced</e1> <e2>bradycardia</e2> in conscious alpha2ABC-/- mice was 32.3 % ( 10 microg/kg ) and 26.6 % ( 100 microg/kg ) of the effect in wild-type mice .
7858459
D005472_D003221 CID Acute <e2>confusion</e2> induced by a high-dose infusion of <e1>5-fluorouracil</e1> and folinic acid .
D005472_D003221 CID He developed acute neurologic symptoms of mental <e2>confusion</e2> , disorientation and irritability , and then lapsed into a deep coma , lasting for approximately 40 hours during the first dose ( day 2 ) of <e1>5-fluorouracil</e1> and folinic acid infusion .
D005472_D003221 CID He developed acute neurologic symptoms of mental confusion , <e2>disorientation</e2> and irritability , and then lapsed into a deep coma , lasting for approximately 40 hours during the first dose ( day 2 ) of <e1>5-fluorouracil</e1> and folinic acid infusion .
D002955_D003221 CID Acute <e2>confusion</e2> induced by a high-dose infusion of 5-fluorouracil and <e1>folinic acid</e1> .
D002955_D003221 CID He developed acute neurologic symptoms of mental <e2>confusion</e2> , disorientation and irritability , and then lapsed into a deep coma , lasting for approximately 40 hours during the first dose ( day 2 ) of 5-fluorouracil and <e1>folinic acid</e1> infusion .
D002955_D003221 CID He developed acute neurologic symptoms of mental confusion , <e2>disorientation</e2> and irritability , and then lapsed into a deep coma , lasting for approximately 40 hours during the first dose ( day 2 ) of 5-fluorouracil and <e1>folinic acid</e1> infusion .
D002945_D013274 NONE A 61-year-old man was treated with combination chemotherapy incorporating <e1>cisplatinum</e1> , etoposide , high-dose 5-fluorouracil ( 2,250 mg/m2/24 hours ) and folinic acid for an inoperable <e2>gastric adenocarcinoma</e2> .
D005047_D013274 NONE A 61-year-old man was treated with combination chemotherapy incorporating cisplatinum , <e1>etoposide</e1> , high-dose 5-fluorouracil ( 2,250 mg/m2/24 hours ) and folinic acid for an inoperable <e2>gastric adenocarcinoma</e2> .
D005472_D013274 NONE A 61-year-old man was treated with combination chemotherapy incorporating cisplatinum , etoposide , high-dose <e1>5-fluorouracil</e1> ( 2,250 mg/m2/24 hours ) and folinic acid for an inoperable <e2>gastric adenocarcinoma</e2> .
D002955_D013274 NONE A 61-year-old man was treated with combination chemotherapy incorporating cisplatinum , etoposide , high-dose 5-fluorouracil ( 2,250 mg/m2/24 hours ) and <e1>folinic acid</e1> for an inoperable <e2>gastric adenocarcinoma</e2> .
D005472_D001523 NONE He developed acute neurologic symptoms of mental confusion , disorientation and <e2>irritability</e2> , and then lapsed into a deep coma , lasting for approximately 40 hours during the first dose ( day 2 ) of <e1>5-fluorouracil</e1> and folinic acid infusion .
D005472_D003128 CID He developed acute neurologic symptoms of mental confusion , disorientation and irritability , and then lapsed into a deep <e2>coma</e2> , lasting for approximately 40 hours during the first dose ( day 2 ) of <e1>5-fluorouracil</e1> and folinic acid infusion .
D002955_D001523 NONE He developed acute neurologic symptoms of mental confusion , disorientation and <e2>irritability</e2> , and then lapsed into a deep coma , lasting for approximately 40 hours during the first dose ( day 2 ) of 5-fluorouracil and <e1>folinic acid</e1> infusion .
D002955_D003128 CID He developed acute neurologic symptoms of mental confusion , disorientation and irritability , and then lapsed into a deep <e2>coma</e2> , lasting for approximately 40 hours during the first dose ( day 2 ) of 5-fluorouracil and <e1>folinic acid</e1> infusion .
D002955_D020258 NONE Because <e1>folinic acid</e1> was unlikely to be associated with this condition , <e2>neurotoxicity</e2> due to high-dose 5-fluorouracil was highly suspected .
D005472_D020258 NONE Because folinic acid was unlikely to be associated with this condition , <e2>neurotoxicity</e2> due to high-dose <e1>5-fluorouracil</e1> was highly suspected .
D005472_D020258 NONE The pathogenesis of <e1>5-fluorouracil</e1> <e2>neurotoxicity</e2> may be due to a Krebs cycle blockade by fluoroacetate and fluorocitrate , thiamine deficiency , or dihydrouracil dehydrogenase deficiency .
D005463_D020258 NONE The pathogenesis of 5-fluorouracil <e2>neurotoxicity</e2> may be due to a Krebs cycle blockade by <e1>fluoroacetate</e1> and fluorocitrate , thiamine deficiency , or dihydrouracil dehydrogenase deficiency .
C007744_D020258 NONE The pathogenesis of 5-fluorouracil <e2>neurotoxicity</e2> may be due to a Krebs cycle blockade by fluoroacetate and <e1>fluorocitrate</e1> , thiamine deficiency , or dihydrouracil dehydrogenase deficiency .
D013831_D020258 NONE The pathogenesis of 5-fluorouracil <e2>neurotoxicity</e2> may be due to a Krebs cycle blockade by fluoroacetate and fluorocitrate , <e1>thiamine</e1> deficiency , or dihydrouracil dehydrogenase deficiency .
C007419_D020258 NONE The pathogenesis of 5-fluorouracil <e2>neurotoxicity</e2> may be due to a Krebs cycle blockade by fluoroacetate and fluorocitrate , thiamine deficiency , or <e1>dihydrouracil</e1> dehydrogenase deficiency .
D005472_D009369 NONE High-dose <e1>5-fluorouracil/folinic</e1> acid infusion therapy has recently become a popular regimen for various <e2>cancers</e2> .
D002955_D009369 NONE High-dose <e1>5-fluorouracil/folinic acid</e1> infusion therapy has recently become a popular regimen for various <e2>cancers</e2> .
2234245
D003676_D014786 NONE <e2>Ocular and auditory toxicity</e2> in hemodialyzed patients receiving <e1>desferrioxamine</e1> .
D003676_D014786 NONE During an 18-month period of study 41 hemodialyzed patients receiving <e1>desferrioxamine</e1> ( 10 - 40 mg/kg BW/3 times weekly ) for the first time were monitored for detection of <e2>audiovisual toxicity</e2> .
D003676_D014786 NONE The data indicate that <e2>audiovisual toxicity</e2> is not an infrequent complication in hemodialyzed patients receiving <e1>desferrioxamine</e1> .
D003676_D006311 NONE <e2>Ocular and auditory toxicity</e2> in hemodialyzed patients receiving <e1>desferrioxamine</e1> .
D003676_D006311 NONE During an 18-month period of study 41 hemodialyzed patients receiving <e1>desferrioxamine</e1> ( 10 - 40 mg/kg BW/3 times weekly ) for the first time were monitored for detection of <e2>audiovisual toxicity</e2> .
D003676_D006311 NONE The data indicate that <e2>audiovisual toxicity</e2> is not an infrequent complication in hemodialyzed patients receiving <e1>desferrioxamine</e1> .
D003676_D034381 NONE <e1>Desferrioxamine</e1> withdrawal resulted in a complete recovery of visual function in 1 patient and partial recovery in 3 , and a complete reversal of <e2>hearing loss</e2> in 3 patients and partial recovery in 3 .
D003676_D064420 NONE This <e2>toxicity</e2> appeared in patients receiving the higher doses of <e1>desferrioxamine</e1> or coincided with the normalization of ferritin or aluminium serum levels .
-1_D064420 NONE This <e2>toxicity</e2> appeared in patients receiving the higher doses of desferrioxamine or coincided with the normalization of ferritin or <e1>aluminium</e1> serum levels .
17437408
D010862_D012640 CID A comparable overexpression of Pgp in the BBB was obtained after <e1>pilocarpine-induced</e1> <e2>seizures</e2> in wild-type Wistar rats .
18020536
D001569_D004244 CID However , use of <e1>BZDs/RDs</e1> was associated with <e2>dizziness</e2> , inability to sleep after awaking at night and tiredness in the mornings during the week prior to admission and with stronger depressive symptoms measured at the beginning of the hospital stay .
D001569_D007319 CID However , use of <e1>BZDs/RDs</e1> was associated with dizziness , <e2>inability to sleep</e2> after awaking at night and tiredness in the mornings during the week prior to admission and with stronger depressive symptoms measured at the beginning of the hospital stay .
D001569_D005221 CID However , use of <e1>BZDs/RDs</e1> was associated with dizziness , inability to sleep after awaking at night and <e2>tiredness</e2> in the mornings during the week prior to admission and with stronger depressive symptoms measured at the beginning of the hospital stay .
D001569_D003866 CID However , use of <e1>BZDs/RDs</e1> was associated with dizziness , inability to sleep after awaking at night and tiredness in the mornings during the week prior to admission and with stronger <e2>depressive symptoms</e2> measured at the beginning of the hospital stay .
9625142
D002443_D056486 CID Acute <e2>hepatitis</e2> , autoimmune hemolytic anemia , and erythroblastocytopenia induced by <e1>ceftriaxone</e1> .
D002443_D056486 CID An 80-yr-old man developed acute <e2>hepatitis</e2> shortly after ingesting oral <e1>ceftriaxone</e1> .
D002443_D000744 CID Acute hepatitis , <e2>autoimmune hemolytic anemia</e2> , and erythroblastocytopenia induced by <e1>ceftriaxone</e1> .
D002443_-1 NONE Acute hepatitis , autoimmune hemolytic anemia , and <e2>erythroblastocytopenia</e2> induced by <e1>ceftriaxone</e1> .
D047090_D000744 NONE Although the transaminases gradually returned to baseline after withholding the <e1>beta lactam</e1> antibiotic , there was a gradual increase in serum bilirubin and a decrease in hemoglobin concentration caused by an <e2>autoimmune hemolytic anemia</e2> and erythroblastocytopenia .
D047090_-1 NONE Although the transaminases gradually returned to baseline after withholding the <e1>beta lactam</e1> antibiotic , there was a gradual increase in serum bilirubin and a decrease in hemoglobin concentration caused by an autoimmune hemolytic anemia and <e2>erythroblastocytopenia</e2> .
D001663_D000744 NONE Although the transaminases gradually returned to baseline after withholding the beta lactam antibiotic , there was a gradual increase in serum <e1>bilirubin</e1> and a decrease in hemoglobin concentration caused by an <e2>autoimmune hemolytic anemia</e2> and erythroblastocytopenia .
D001663_-1 NONE Although the transaminases gradually returned to baseline after withholding the beta lactam antibiotic , there was a gradual increase in serum <e1>bilirubin</e1> and a decrease in hemoglobin concentration caused by an autoimmune hemolytic anemia and <e2>erythroblastocytopenia</e2> .
16403073
D007654_D016171 CID <e1>Ketoconazole</e1> induced <e2>torsades de pointes</e2> without concomitant use of QT interval-prolonging drug .
D007654_D016171 CID We report a woman with coronary artery disease who developed a markedly prolonged QT interval and <e2>torsades de pointes</e2> ( TdP ) after taking <e1>ketoconazole</e1> for treatment of fungal infection .
D007654_D016171 CID We report a woman with coronary artery disease who developed a markedly prolonged QT interval and torsades de pointes ( <e2>TdP</e2> ) after taking <e1>ketoconazole</e1> for treatment of fungal infection .
D007654_D016171 CID We postulate that by virtue of its direct blocking action on IKr , <e1>ketoconazole</e1> alone may prolong QT interval and induce <e2>TdP.</e2> This calls for attention when ketoconazole is administered to patients with risk factors for acquired long QT syndrome .
D007654_D016171 CID We postulate that by virtue of its direct blocking action on IKr , ketoconazole alone may prolong QT interval and induce <e2>TdP.</e2> This calls for attention when <e1>ketoconazole</e1> is administered to patients with risk factors for acquired long QT syndrome .
D007654_D003324 NONE We report a woman with <e2>coronary artery disease</e2> who developed a markedly prolonged QT interval and torsades de pointes ( TdP ) after taking <e1>ketoconazole</e1> for treatment of fungal infection .
D007654_D008133 CID We report a woman with coronary artery disease who developed a markedly <e2>prolonged QT interval</e2> and torsades de pointes ( TdP ) after taking <e1>ketoconazole</e1> for treatment of fungal infection .
D007654_D008133 CID We postulate that by virtue of its direct blocking action on IKr , <e1>ketoconazole</e1> alone may prolong QT interval and induce TdP. This calls for attention when ketoconazole is administered to patients with risk factors for acquired <e2>long QT syndrome</e2> .
D007654_D008133 CID We postulate that by virtue of its direct blocking action on IKr , ketoconazole alone may prolong QT interval and induce TdP. This calls for attention when <e1>ketoconazole</e1> is administered to patients with risk factors for acquired <e2>long QT syndrome</e2> .
D007654_D009181 NONE We report a woman with coronary artery disease who developed a markedly prolonged QT interval and torsades de pointes ( TdP ) after taking <e1>ketoconazole</e1> for treatment of <e2>fungal infection</e2> .
3341566
D009599_D006470 NONE Systolic pressure variation is greater during <e2>hemorrhage</e2> than during <e1>sodium nitroprusside-induced</e1> hypotension in ventilated dogs .
D009599_D006470 NONE Mean arterial pressure was decreased to 50 mm Hg for 30 minutes either by <e2>hemorrhage</e2> ( HEM , n = 7 ) or by continuous infusion of <e1>sodium nitroprusside</e1> ( SNP , n = 7 ) .
D009599_D006470 NONE Mean arterial pressure was decreased to 50 mm Hg for 30 minutes either by hemorrhage ( <e2>HEM</e2> , n = 7 ) or by continuous infusion of <e1>sodium nitroprusside</e1> ( SNP , n = 7 ) .
D009599_D006470 NONE Mean arterial pressure was decreased to 50 mm Hg for 30 minutes either by <e2>hemorrhage</e2> ( HEM , n = 7 ) or by continuous infusion of sodium nitroprusside ( <e1>SNP</e1> , n = 7 ) .
D009599_D006470 NONE Mean arterial pressure was decreased to 50 mm Hg for 30 minutes either by hemorrhage ( <e2>HEM</e2> , n = 7 ) or by continuous infusion of sodium nitroprusside ( <e1>SNP</e1> , n = 7 ) .
D009599_D006470 NONE During <e2>HEM-induced</e2> hypotension the cardiac output was significantly lower and systemic vascular resistance higher compared with that in the <e1>SNP</e1> group .
D009599_D006470 NONE The SPV during hypotension was 15.7 +/- 6.7 mm Hg in the <e2>HEM</e2> group , compared with 9.1 +/- 2.0 mm Hg in the <e1>SNP</e1> group ( P less than 0.02 ) .
D009599_D006470 NONE The delta down , which is the measure of decrease of SBP after a mechanical breath , was 20.3 +/- 8.4 and 10.1 +/- 3.8 mm Hg in the <e2>HEM</e2> and <e1>SNP</e1> groups , respectively , during hypotension ( P less than 0.02 ) .
D009599_D007022 CID Systolic pressure variation is greater during hemorrhage than during <e1>sodium nitroprusside-induced</e1> <e2>hypotension</e2> in ventilated dogs .
D009599_D007022 CID During HEM-induced <e2>hypotension</e2> the cardiac output was significantly lower and systemic vascular resistance higher compared with that in the <e1>SNP</e1> group .
D009599_D007022 CID The SPV during <e2>hypotension</e2> was 15.7 +/- 6.7 mm Hg in the HEM group , compared with 9.1 +/- 2.0 mm Hg in the <e1>SNP</e1> group ( P less than 0.02 ) .
D009599_D007022 CID The delta down , which is the measure of decrease of SBP after a mechanical breath , was 20.3 +/- 8.4 and 10.1 +/- 3.8 mm Hg in the HEM and <e1>SNP</e1> groups , respectively , during <e2>hypotension</e2> ( P less than 0.02 ) .
15009014
D002211_D006940 CID <e1>Capsaicin</e1> ( 0.01 - 1 mm ) applied to oral or nasal mucosa induced <e2>increases in dural and cortical blood flow</e2> and provoked lacrimation .
D001285_D006940 NONE The evoked <e2>increases in dural blood flow</e2> were also abolished by topical pre-administration of <e1>atropine</e1> ( 1 mm ) and [ Lys1 , Pro2,5 , Arg3,4 , Tyr6]-VIP ( 0.1 mm ) , a vasoactive intestinal polypeptide ( VIP ) antagonist , onto the exposed dura mater .
19058010
D010936_D009203 NONE Effect of <e1>green tea</e1> and vitamin E combination in isoproterenol induced <e2>myocardial infarction</e2> in rats .
D010936_D009203 NONE The present study was aimed to investigate the combined effects of <e1>green tea</e1> and vitamin E on heart weight , body weight , serum marker enzymes , lipid peroxidation , endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced <e2>myocardial infarction</e2> in rats .
D010936_D009203 NONE These findings indicate the synergistic protective effect of <e1>green tea</e1> and vitamin E during ISO induced <e2>myocardial infarction</e2> in rats .
D014810_D009203 NONE Effect of green tea and <e1>vitamin E</e1> combination in isoproterenol induced <e2>myocardial infarction</e2> in rats .
D014810_D009203 NONE The present study was aimed to investigate the combined effects of green tea and <e1>vitamin E</e1> on heart weight , body weight , serum marker enzymes , lipid peroxidation , endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced <e2>myocardial infarction</e2> in rats .
D014810_D009203 NONE These findings indicate the synergistic protective effect of green tea and <e1>vitamin E</e1> during ISO induced <e2>myocardial infarction</e2> in rats .
D007545_D009203 CID Effect of green tea and vitamin E combination in <e1>isoproterenol</e1> induced <e2>myocardial infarction</e2> in rats .
D007545_D009203 CID The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight , body weight , serum marker enzymes , lipid peroxidation , endogenous antioxidants and membrane bound ATPases in <e1>isoproterenol</e1> (ISO)-induced <e2>myocardial infarction</e2> in rats .
D007545_D009203 CID The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight , body weight , serum marker enzymes , lipid peroxidation , endogenous antioxidants and membrane bound ATPases in isoproterenol <e1>(ISO)-induced</e1> <e2>myocardial infarction</e2> in rats .
D007545_D009203 CID These findings indicate the synergistic protective effect of green tea and vitamin E during <e1>ISO</e1> induced <e2>myocardial infarction</e2> in rats .
2096243
C017367_D019965 CID <e1>Carmofur-induced</e1> <e2>organic mental disorders</e2> .
C017367_D019965 CID <e2>Organic mental disorder</e2> was observed in a 29-year-old female in the prognostic period after the onset of <e1>carmofur-induced</e1> leukoencephalopathy .
C017367_D056784 CID Organic mental disorder was observed in a 29-year-old female in the prognostic period after the onset of <e1>carmofur-induced</e1> <e2>leukoencephalopathy</e2> .
C017367_D056784 CID Consequently , <e1>carmofur-induced</e1> <e2>leukoencephalopathy</e2> may uncommonly result in organic personality syndrome in the residual state .
C017367_D010554 NONE Consequently , <e1>carmofur-induced</e1> leukoencephalopathy may uncommonly result in <e2>organic personality syndrome</e2> in the residual state .
3676049
D007530_D007022 CID Cerebral blood flow and metabolism during <e1>isoflurane-induced</e1> <e2>hypotension</e2> in patients subjected to surgery for cerebral aneurysms .
D007530_D007022 CID Cerebral blood flow and cerebral metabolic rate for oxygen were measured during <e1>isoflurane-induced</e1> <e2>hypotension</e2> in 10 patients subjected to craniotomy for clipping of a cerebral aneurysm .
D007530_D007022 CID Controlled <e2>hypotension</e2> to an average MAP of 50 - 55 mm Hg was induced by increasing the dose of <e1>isoflurane</e1> , and maintained at an inspired concentration of 2.2 +/- 0.2 % .
D007530_D002532 NONE Cerebral blood flow and metabolism during <e1>isoflurane-induced</e1> hypotension in patients subjected to surgery for <e2>cerebral aneurysms</e2> .
D007530_D002532 NONE Cerebral blood flow and cerebral metabolic rate for oxygen were measured during <e1>isoflurane-induced</e1> hypotension in 10 patients subjected to craniotomy for clipping of a <e2>cerebral aneurysm</e2> .
D010100_D007022 NONE Cerebral blood flow and cerebral metabolic rate for <e1>oxygen</e1> were measured during isoflurane-induced <e2>hypotension</e2> in 10 patients subjected to craniotomy for clipping of a cerebral aneurysm .
D010100_D002532 NONE Cerebral blood flow and cerebral metabolic rate for <e1>oxygen</e1> were measured during isoflurane-induced hypotension in 10 patients subjected to craniotomy for clipping of a <e2>cerebral aneurysm</e2> .
D014978_D013345 NONE Flow and metabolism were measured 5 - 13 days after the <e2>subarachnoid haemorrhage</e2> by a modification of the classical Kety-Schmidt technique using <e1>xenon-133</e1> i.v. Anaesthesia was maintained with an inspired isoflurane concentration of 0.75 % ( plus 67 % nitrous oxide in oxygen ) , during which CBF and CMRO2 were 34.3 +/- 2.1 ml/100 g min-1 and 2.32 +/- 0.16 ml/100 g min-1 at PaCO2 4.1 +/- 0.1 kPa ( mean +/- SEM ) .
D007530_D013345 NONE Flow and metabolism were measured 5 - 13 days after the <e2>subarachnoid haemorrhage</e2> by a modification of the classical Kety-Schmidt technique using xenon-133 i.v. Anaesthesia was maintained with an inspired <e1>isoflurane</e1> concentration of 0.75 % ( plus 67 % nitrous oxide in oxygen ) , during which CBF and CMRO2 were 34.3 +/- 2.1 ml/100 g min-1 and 2.32 +/- 0.16 ml/100 g min-1 at PaCO2 4.1 +/- 0.1 kPa ( mean +/- SEM ) .
D009609_D013345 NONE Flow and metabolism were measured 5 - 13 days after the <e2>subarachnoid haemorrhage</e2> by a modification of the classical Kety-Schmidt technique using xenon-133 i.v. Anaesthesia was maintained with an inspired isoflurane concentration of 0.75 % ( plus 67 % <e1>nitrous oxide</e1> in oxygen ) , during which CBF and CMRO2 were 34.3 +/- 2.1 ml/100 g min-1 and 2.32 +/- 0.16 ml/100 g min-1 at PaCO2 4.1 +/- 0.1 kPa ( mean +/- SEM ) .
D010100_D013345 NONE Flow and metabolism were measured 5 - 13 days after the <e2>subarachnoid haemorrhage</e2> by a modification of the classical Kety-Schmidt technique using xenon-133 i.v. Anaesthesia was maintained with an inspired isoflurane concentration of 0.75 % ( plus 67 % nitrous oxide in <e1>oxygen</e1> ) , during which CBF and CMRO2 were 34.3 +/- 2.1 ml/100 g min-1 and 2.32 +/- 0.16 ml/100 g min-1 at PaCO2 4.1 +/- 0.1 kPa ( mean +/- SEM ) .
D008628_D007022 NONE Controlled <e2>hypotension</e2> to an average MAP of 50 - 55 mm <e1>Hg</e1> was induced by increasing the dose of isoflurane , and maintained at an inspired concentration of 2.2 +/- 0.2 % .
D007530_D000783 NONE After the clipping of the <e2>aneurysm</e2> the <e1>isoflurane</e1> concentration was reduced to 0.75 % .
10706004
D012964_D006973 NONE Changes of <e1>sodium</e1> and ATP affinities of the cardiac (Na , K)-ATPase during and after nitric oxide deficient <e2>hypertension</e2> .
D012964_D006973 NONE Changes of sodium and ATP affinities of the cardiac <e1>(Na</e1> , K)-ATPase during and after nitric oxide deficient <e2>hypertension</e2> .
D012964_D006973 NONE In several models of <e2>hypertension</e2> , elevation of intracellular <e1>sodium</e1> level was documented in cardiac tissue .
D012964_D006973 NONE To assess the molecular basis of disturbances in transmembraneous transport of <e1>Na+</e1> , we studied the response of cardiac (Na , K)-ATPase to NO-deficient <e2>hypertension</e2> induced in rats by NO-synthase inhibition with 40 mg/kg/day N(G)-nitro-L-arginine methyl ester ( L-NAME ) for 4 four weeks .
D012964_D006973 NONE To assess the molecular basis of disturbances in transmembraneous transport of Na+ , we studied the response of cardiac <e1>(Na</e1> , K)-ATPase to NO-deficient <e2>hypertension</e2> induced in rats by NO-synthase inhibition with 40 mg/kg/day N(G)-nitro-L-arginine methyl ester ( L-NAME ) for 4 four weeks .
D012964_D006973 NONE After recovery from <e2>hypertension</e2> , the activity of <e1>(Na</e1> , K)-ATPase increased , due to higher affinity of the ATP-binding site , as revealed from the lowered Km value for ATP .
D012964_D006973 NONE Inhibition of NO-synthase induced a reversible <e2>hypertension</e2> accompanied by depressed <e1>Na+-extrusion</e1> from cardiac cells as a consequence of deteriorated Na+-binding properties of the (Na , K)-ATPase .
D012964_D006973 NONE Inhibition of NO-synthase induced a reversible <e2>hypertension</e2> accompanied by depressed Na+-extrusion from cardiac cells as a consequence of deteriorated <e1>Na+-binding</e1> properties of the (Na , K)-ATPase .
D012964_D006973 NONE Inhibition of NO-synthase induced a reversible <e2>hypertension</e2> accompanied by depressed Na+-extrusion from cardiac cells as a consequence of deteriorated Na+-binding properties of the <e1>(Na</e1> , K)-ATPase .
D000255_D006973 NONE Changes of sodium and <e1>ATP</e1> affinities of the cardiac (Na , K)-ATPase during and after nitric oxide deficient <e2>hypertension</e2> .
D000255_D006973 NONE After recovery from <e2>hypertension</e2> , the activity of (Na , K)-ATPase increased , due to higher affinity of the <e1>ATP-binding</e1> site , as revealed from the lowered Km value for ATP .
D000255_D006973 NONE After recovery from <e2>hypertension</e2> , the activity of (Na , K)-ATPase increased , due to higher affinity of the ATP-binding site , as revealed from the lowered Km value for <e1>ATP</e1> .
D011188_D006973 NONE Changes of sodium and ATP affinities of the cardiac (Na , <e1>K)-ATPase</e1> during and after nitric oxide deficient <e2>hypertension</e2> .
D011188_D006973 NONE To assess the molecular basis of disturbances in transmembraneous transport of Na+ , we studied the response of cardiac (Na , <e1>K)-ATPase</e1> to NO-deficient <e2>hypertension</e2> induced in rats by NO-synthase inhibition with 40 mg/kg/day N(G)-nitro-L-arginine methyl ester ( L-NAME ) for 4 four weeks .
D011188_D006973 NONE After recovery from <e2>hypertension</e2> , the activity of (Na , <e1>K)-ATPase</e1> increased , due to higher affinity of the ATP-binding site , as revealed from the lowered Km value for ATP .
D011188_D006973 NONE Inhibition of NO-synthase induced a reversible <e2>hypertension</e2> accompanied by depressed Na+-extrusion from cardiac cells as a consequence of deteriorated Na+-binding properties of the (Na , <e1>K)-ATPase</e1> .
D009569_D006973 CID Changes of sodium and ATP affinities of the cardiac (Na , K)-ATPase during and after <e1>nitric oxide</e1> deficient <e2>hypertension</e2> .
D009569_D006973 CID Inhibition of <e1>NO</e1> synthesis induces sustained <e2>hypertension</e2> .
D009569_D006973 CID To assess the molecular basis of disturbances in transmembraneous transport of Na+ , we studied the response of cardiac (Na , K)-ATPase to <e1>NO-deficient</e1> <e2>hypertension</e2> induced in rats by NO-synthase inhibition with 40 mg/kg/day N(G)-nitro-L-arginine methyl ester ( L-NAME ) for 4 four weeks .
D009569_D006973 CID To assess the molecular basis of disturbances in transmembraneous transport of Na+ , we studied the response of cardiac (Na , K)-ATPase to NO-deficient <e2>hypertension</e2> induced in rats by <e1>NO-synthase</e1> inhibition with 40 mg/kg/day N(G)-nitro-L-arginine methyl ester ( L-NAME ) for 4 four weeks .
D009569_D006973 CID Inhibition of <e1>NO-synthase</e1> induced a reversible <e2>hypertension</e2> accompanied by depressed Na+-extrusion from cardiac cells as a consequence of deteriorated Na+-binding properties of the (Na , K)-ATPase .
D019331_D006973 NONE To assess the molecular basis of disturbances in transmembraneous transport of Na+ , we studied the response of cardiac (Na , K)-ATPase to NO-deficient <e2>hypertension</e2> induced in rats by NO-synthase inhibition with 40 mg/kg/day <e1>N(G)-nitro-L-arginine methyl ester</e1> ( L-NAME ) for 4 four weeks .
D019331_D006973 NONE To assess the molecular basis of disturbances in transmembraneous transport of Na+ , we studied the response of cardiac (Na , K)-ATPase to NO-deficient <e2>hypertension</e2> induced in rats by NO-synthase inhibition with 40 mg/kg/day N(G)-nitro-L-arginine methyl ester ( <e1>L-NAME</e1> ) for 4 four weeks .
D009569_D003866 NONE Inhibition of <e1>NO-synthase</e1> induced a reversible hypertension accompanied by <e2>depressed</e2> Na+-extrusion from cardiac cells as a consequence of deteriorated Na+-binding properties of the (Na , K)-ATPase .
D012964_D003866 NONE Inhibition of NO-synthase induced a reversible hypertension accompanied by <e2>depressed</e2> <e1>Na+-extrusion</e1> from cardiac cells as a consequence of deteriorated Na+-binding properties of the (Na , K)-ATPase .
D012964_D003866 NONE Inhibition of NO-synthase induced a reversible hypertension accompanied by <e2>depressed</e2> Na+-extrusion from cardiac cells as a consequence of deteriorated <e1>Na+-binding</e1> properties of the (Na , K)-ATPase .
D012964_D003866 NONE Inhibition of NO-synthase induced a reversible hypertension accompanied by <e2>depressed</e2> Na+-extrusion from cardiac cells as a consequence of deteriorated Na+-binding properties of the <e1>(Na</e1> , K)-ATPase .
D011188_D003866 NONE Inhibition of NO-synthase induced a reversible hypertension accompanied by <e2>depressed</e2> Na+-extrusion from cardiac cells as a consequence of deteriorated Na+-binding properties of the (Na , <e1>K)-ATPase</e1> .
10737864
D003000_D001919 CID Given that sympathetic neural dominance exhibits a similar developmental pattern , and given that <e1>clonidine</e1> induces sympathetic withdrawal and <e2>bradycardia</e2> , we hypothesized that clonidine 's developmental effects on cardiac rate and ultrasound production would mirror each other .
D003000_D001919 CID Given that sympathetic neural dominance exhibits a similar developmental pattern , and given that clonidine induces sympathetic withdrawal and <e2>bradycardia</e2> , we hypothesized that <e1>clonidine</e1> 's developmental effects on cardiac rate and ultrasound production would mirror each other .
D003000_D001919 CID Age-related changes in ultrasound production corresponded with changes in cardiovascular variables , including baseline cardiac rate and <e1>clonidine-induced</e1> <e2>bradycardia</e2> .
12617329
D006170_D007674 NONE The effect of treatment with <e1>gum Arabic</e1> on gentamicin <e2>nephrotoxicity</e2> in rats : a preliminary study .
D006170_D007674 NONE In the present work we assessed the effect of treatment of rats with <e1>gum Arabic</e1> on acute renal failure induced by gentamicin ( GM ) <e2>nephrotoxicity</e2> .
D006170_D007674 NONE It could be inferred that <e1>gum Arabic</e1> treatment has induced a modest amelioration of some of the histological and biochemical indices of GM <e2>nephrotoxicity</e2> .
D005839_D007674 NONE The effect of treatment with gum Arabic on <e1>gentamicin</e1> <e2>nephrotoxicity</e2> in rats : a preliminary study .
D005839_D007674 NONE In the present work we assessed the effect of treatment of rats with gum Arabic on acute renal failure induced by <e1>gentamicin</e1> ( GM ) <e2>nephrotoxicity</e2> .
D005839_D007674 NONE In the present work we assessed the effect of treatment of rats with gum Arabic on acute renal failure induced by gentamicin ( <e1>GM</e1> ) <e2>nephrotoxicity</e2> .
D005839_D007674 NONE It could be inferred that gum Arabic treatment has induced a modest amelioration of some of the histological and biochemical indices of <e1>GM</e1> <e2>nephrotoxicity</e2> .
D006170_D058186 CID In the present work we assessed the effect of treatment of rats with <e1>gum Arabic</e1> on <e2>acute renal failure</e2> induced by gentamicin ( GM ) nephrotoxicity .
D005839_D058186 CID In the present work we assessed the effect of treatment of rats with gum Arabic on <e2>acute renal failure</e2> induced by <e1>gentamicin</e1> ( GM ) nephrotoxicity .
D005839_D058186 CID In the present work we assessed the effect of treatment of rats with gum Arabic on <e2>acute renal failure</e2> induced by gentamicin ( <e1>GM</e1> ) nephrotoxicity .
D003404_D007674 NONE <e2>Nephrotoxicity</e2> was assessed by measuring the concentrations of <e1>creatinine</e1> and urea in the plasma and reduced glutathione ( GSH ) in the kidney cortex , and by light microscopic examination of kidney sections .
D014508_D007674 NONE <e2>Nephrotoxicity</e2> was assessed by measuring the concentrations of creatinine and <e1>urea</e1> in the plasma and reduced glutathione ( GSH ) in the kidney cortex , and by light microscopic examination of kidney sections .
D005978_D007674 NONE <e2>Nephrotoxicity</e2> was assessed by measuring the concentrations of creatinine and urea in the plasma and reduced <e1>glutathione</e1> ( GSH ) in the kidney cortex , and by light microscopic examination of kidney sections .
D005978_D007674 NONE <e2>Nephrotoxicity</e2> was assessed by measuring the concentrations of creatinine and urea in the plasma and reduced glutathione ( <e1>GSH</e1> ) in the kidney cortex , and by light microscopic examination of kidney sections .
D005839_D007683 NONE The <e1>GM-induced</e1> proximal <e2>tubular necrosis</e2> appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose .
D005839_D007683 NONE The GM-induced proximal <e2>tubular necrosis</e2> appeared to be slightly less severe in rats given <e1>GM</e1> together with gum Arabic than in those given GM and cellulose .
D005839_D007683 NONE The GM-induced proximal <e2>tubular necrosis</e2> appeared to be slightly less severe in rats given GM together with gum Arabic than in those given <e1>GM</e1> and cellulose .
D006170_D007683 NONE The GM-induced proximal <e2>tubular necrosis</e2> appeared to be slightly less severe in rats given GM together with <e1>gum Arabic</e1> than in those given GM and cellulose .
6466532
D006024_D001919 NONE Comparison of i.v. <e1>glycopyrrolate</e1> and atropine in the prevention of <e2>bradycardia</e2> and arrhythmias following repeated doses of suxamethonium in children .
D006024_D001919 NONE The effectiveness of administration of <e1>glycopyrrolate</e1> 5 and 10 micrograms kg-1 and atropine 10 and 20 micrograms kg-1 i.v. immediately before the induction of anaesthesia , to prevent arrhythmia and <e2>bradycardia</e2> following repeated doses of suxamethonium in children , was studied .
D006024_D001145 NONE Comparison of i.v. <e1>glycopyrrolate</e1> and atropine in the prevention of bradycardia and <e2>arrhythmias</e2> following repeated doses of suxamethonium in children .
D006024_D001145 NONE The effectiveness of administration of <e1>glycopyrrolate</e1> 5 and 10 micrograms kg-1 and atropine 10 and 20 micrograms kg-1 i.v. immediately before the induction of anaesthesia , to prevent <e2>arrhythmia</e2> and bradycardia following repeated doses of suxamethonium in children , was studied .
D001285_D001919 NONE Comparison of i.v. glycopyrrolate and <e1>atropine</e1> in the prevention of <e2>bradycardia</e2> and arrhythmias following repeated doses of suxamethonium in children .
D001285_D001919 NONE The effectiveness of administration of glycopyrrolate 5 and 10 micrograms kg-1 and <e1>atropine</e1> 10 and 20 micrograms kg-1 i.v. immediately before the induction of anaesthesia , to prevent arrhythmia and <e2>bradycardia</e2> following repeated doses of suxamethonium in children , was studied .
D001285_D001145 NONE Comparison of i.v. glycopyrrolate and <e1>atropine</e1> in the prevention of bradycardia and <e2>arrhythmias</e2> following repeated doses of suxamethonium in children .
D001285_D001145 NONE The effectiveness of administration of glycopyrrolate 5 and 10 micrograms kg-1 and <e1>atropine</e1> 10 and 20 micrograms kg-1 i.v. immediately before the induction of anaesthesia , to prevent <e2>arrhythmia</e2> and bradycardia following repeated doses of suxamethonium in children , was studied .
D013390_D001919 CID Comparison of i.v. glycopyrrolate and atropine in the prevention of <e2>bradycardia</e2> and arrhythmias following repeated doses of <e1>suxamethonium</e1> in children .
D013390_D001919 CID The effectiveness of administration of glycopyrrolate 5 and 10 micrograms kg-1 and atropine 10 and 20 micrograms kg-1 i.v. immediately before the induction of anaesthesia , to prevent arrhythmia and <e2>bradycardia</e2> following repeated doses of <e1>suxamethonium</e1> in children , was studied .
D013390_D001145 NONE Comparison of i.v. glycopyrrolate and atropine in the prevention of bradycardia and <e2>arrhythmias</e2> following repeated doses of <e1>suxamethonium</e1> in children .
D013390_D001145 NONE The effectiveness of administration of glycopyrrolate 5 and 10 micrograms kg-1 and atropine 10 and 20 micrograms kg-1 i.v. immediately before the induction of anaesthesia , to prevent <e2>arrhythmia</e2> and bradycardia following repeated doses of <e1>suxamethonium</e1> in children , was studied .
9199746
D000583_D064420 NONE Macula <e2>toxicity</e2> after intravitreal <e1>amikacin</e1> .
D000617_D009877 NONE BACKGROUND : Although intravitreal <e1>aminoglycosides</e1> have substantially improved visual prognosis in <e2>endophthalmitis</e2> , macular infarction may impair full visual recovery .
D000617_D007238 NONE BACKGROUND : Although intravitreal <e1>aminoglycosides</e1> have substantially improved visual prognosis in endophthalmitis , macular <e2>infarction</e2> may impair full visual recovery .
D000583_D012164 CID METHODS : We present a case of presumed <e1>amikacin</e1> <e2>retinal toxicity</e2> following treatment with amikacin and vancomycin for alpha-haemolytic streptococcal endophthalmitis .
D000583_D012164 CID METHODS : We present a case of presumed amikacin <e2>retinal toxicity</e2> following treatment with <e1>amikacin</e1> and vancomycin for alpha-haemolytic streptococcal endophthalmitis .
D000583_D013290 NONE METHODS : We present a case of presumed <e1>amikacin</e1> retinal toxicity following treatment with amikacin and vancomycin for alpha-haemolytic <e2>streptococcal endophthalmitis</e2> .
D000583_D013290 NONE METHODS : We present a case of presumed amikacin retinal toxicity following treatment with <e1>amikacin</e1> and vancomycin for alpha-haemolytic <e2>streptococcal endophthalmitis</e2> .
D014640_D012164 NONE METHODS : We present a case of presumed amikacin <e2>retinal toxicity</e2> following treatment with amikacin and <e1>vancomycin</e1> for alpha-haemolytic streptococcal endophthalmitis .
D014640_D013290 NONE METHODS : We present a case of presumed amikacin retinal toxicity following treatment with amikacin and <e1>vancomycin</e1> for alpha-haemolytic <e2>streptococcal endophthalmitis</e2> .
D019793_D013684 NONE Fundus <e1>fluorescein</e1> angiography confirmed macular capillary closure and <e2>telangiectasis</e2> .
17175308
D020123_D011507 CID <e2>Proteinuria</e2> after conversion to <e1>sirolimus</e1> in renal transplant recipients .
D020123_D011507 CID More recently , <e2>proteinuria</e2> has been reported as a consequence of <e1>sirolimus</e1> therapy , although the mechanism has remained unclear .
D020123_D011507 CID We retrospectively examined the records of 25 renal transplant patients , who developed or displayed increased <e2>proteinuria</e2> after <e1>SRL</e1> conversion .
D020123_D011507 CID Heavy <e2>proteinuria</e2> was common after the use of <e1>SRL</e1> as rescue therapy for renal transplantation .
D020123_D051436 NONE The patient cohort ( 14 men , 11 women ) was treated with <e1>SRL</e1> as conversion therapy , due to <e2>chronic allograft nephropathy</e2> ( CAN ) ( n = 15 ) neoplasia ( n = 8) ; Kaposi 's sarcoma , Four skin cancers , One intestinal tumors , One renal cell carsinom ) or BK virus nephropathy ( n = 2 ) .
D020123_D007674 NONE The patient cohort ( 14 men , 11 women ) was treated with <e1>SRL</e1> as conversion therapy , due to chronic allograft nephropathy ( <e2>CAN</e2> ) ( n = 15 ) neoplasia ( n = 8) ; Kaposi 's sarcoma , Four skin cancers , One intestinal tumors , One renal cell carsinom ) or BK virus nephropathy ( n = 2 ) .
D020123_D007674 NONE The patient cohort ( 14 men , 11 women ) was treated with <e1>SRL</e1> as conversion therapy , due to chronic allograft nephropathy ( CAN ) ( n = 15 ) neoplasia ( n = 8) ; Kaposi 's sarcoma , Four skin cancers , One intestinal tumors , One renal cell carsinom ) or BK virus <e2>nephropathy</e2> ( n = 2 ) .
D020123_D009369 NONE The patient cohort ( 14 men , 11 women ) was treated with <e1>SRL</e1> as conversion therapy , due to chronic allograft nephropathy ( CAN ) ( n = 15 ) <e2>neoplasia</e2> ( n = 8) ; Kaposi 's sarcoma , Four skin cancers , One intestinal tumors , One renal cell carsinom ) or BK virus nephropathy ( n = 2 ) .
D020123_D012514 NONE The patient cohort ( 14 men , 11 women ) was treated with <e1>SRL</e1> as conversion therapy , due to chronic allograft nephropathy ( CAN ) ( n = 15 ) neoplasia ( n = 8) ; <e2>Kaposi 's sarcoma</e2> , Four skin cancers , One intestinal tumors , One renal cell carsinom ) or BK virus nephropathy ( n = 2 ) .
D020123_D012878 NONE The patient cohort ( 14 men , 11 women ) was treated with <e1>SRL</e1> as conversion therapy , due to chronic allograft nephropathy ( CAN ) ( n = 15 ) neoplasia ( n = 8) ; Kaposi 's sarcoma , Four <e2>skin cancers</e2> , One intestinal tumors , One renal cell carsinom ) or BK virus nephropathy ( n = 2 ) .
D020123_D007414 NONE The patient cohort ( 14 men , 11 women ) was treated with <e1>SRL</e1> as conversion therapy , due to chronic allograft nephropathy ( CAN ) ( n = 15 ) neoplasia ( n = 8) ; Kaposi 's sarcoma , Four skin cancers , One <e2>intestinal tumors</e2> , One renal cell carsinom ) or BK virus nephropathy ( n = 2 ) .
D020123_D002292 NONE The patient cohort ( 14 men , 11 women ) was treated with <e1>SRL</e1> as conversion therapy , due to chronic allograft nephropathy ( CAN ) ( n = 15 ) neoplasia ( n = 8) ; Kaposi 's sarcoma , Four skin cancers , One intestinal tumors , One <e2>renal cell carsinom</e2> ) or BK virus nephropathy ( n = 2 ) .
3750012
D010396_D009157 CID <e2>Myasthenia gravis</e2> caused by <e1>penicillamine</e1> and chloroquine therapy for rheumatoid arthritis .
D010396_D009157 CID We have described a unique patient who had reversible and dose-related <e2>myasthenia gravis</e2> after <e1>penicillamine</e1> and chloroquine therapy for rheumatoid arthritis .
D010396_D001172 NONE Myasthenia gravis caused by <e1>penicillamine</e1> and chloroquine therapy for <e2>rheumatoid arthritis</e2> .
D010396_D001172 NONE We have described a unique patient who had reversible and dose-related myasthenia gravis after <e1>penicillamine</e1> and chloroquine therapy for <e2>rheumatoid arthritis</e2> .
D002738_D009157 CID <e2>Myasthenia gravis</e2> caused by penicillamine and <e1>chloroquine</e1> therapy for rheumatoid arthritis .
D002738_D009157 CID We have described a unique patient who had reversible and dose-related <e2>myasthenia gravis</e2> after penicillamine and <e1>chloroquine</e1> therapy for rheumatoid arthritis .
D002738_D001172 NONE Myasthenia gravis caused by penicillamine and <e1>chloroquine</e1> therapy for <e2>rheumatoid arthritis</e2> .
D002738_D001172 NONE We have described a unique patient who had reversible and dose-related myasthenia gravis after penicillamine and <e1>chloroquine</e1> therapy for <e2>rheumatoid arthritis</e2> .
18186898
D019259_D006509 NONE <e1>Lamivudine</e1> was added because of de nova <e2>hepatitis B infection</e2> during her follow-up .
D016559_D000138 NONE Although <e1>tacrolimus</e1> was suspected to be the cause of late post-transplant renal <e2>acidosis</e2> and was replaced by sirolimus , acidosis , and electrolyte imbalance got worse .
D016559_D000138 NONE Although <e1>tacrolimus</e1> was suspected to be the cause of late post-transplant renal acidosis and was replaced by sirolimus , <e2>acidosis</e2> , and electrolyte imbalance got worse .
D020123_D000138 NONE Although tacrolimus was suspected to be the cause of late post-transplant renal <e2>acidosis</e2> and was replaced by <e1>sirolimus</e1> , acidosis , and electrolyte imbalance got worse .
D020123_D000138 NONE Although tacrolimus was suspected to be the cause of late post-transplant renal acidosis and was replaced by <e1>sirolimus</e1> , <e2>acidosis</e2> , and electrolyte imbalance got worse .
D016559_D005198 CID We suggest that our patient 's <e2>tubular dysfunction</e2> and myopathy may have resulted from mitochondrial dysfunction which is triggered by <e1>tacrolimus</e1> and augmented by lamivudine .
D016559_D009135 CID We suggest that our patient 's tubular dysfunction and <e2>myopathy</e2> may have resulted from mitochondrial dysfunction which is triggered by <e1>tacrolimus</e1> and augmented by lamivudine .
D016559_D028361 NONE We suggest that our patient 's tubular dysfunction and myopathy may have resulted from <e2>mitochondrial dysfunction</e2> which is triggered by <e1>tacrolimus</e1> and augmented by lamivudine .
D019259_D005198 CID We suggest that our patient 's <e2>tubular dysfunction</e2> and myopathy may have resulted from mitochondrial dysfunction which is triggered by tacrolimus and augmented by <e1>lamivudine</e1> .
D019259_D009135 CID We suggest that our patient 's tubular dysfunction and <e2>myopathy</e2> may have resulted from mitochondrial dysfunction which is triggered by tacrolimus and augmented by <e1>lamivudine</e1> .
D019259_D028361 NONE We suggest that our patient 's tubular dysfunction and myopathy may have resulted from <e2>mitochondrial dysfunction</e2> which is triggered by tacrolimus and augmented by <e1>lamivudine</e1> .
16330293
12084448
D007069_D001927 CID <e1>Ifosfamide</e1> <e2>encephalopathy</e2> presenting with asterixis .
D007069_D020820 NONE <e1>Ifosfamide</e1> encephalopathy presenting with <e2>asterixis</e2> .
D007069_D020820 NONE The administration of <e1>ifosfamide</e1> was discontinued and within 12 h the <e2>asterixis</e2> resolved completely .
D007069_D020820 NONE In the patient described , the presence of <e2>asterixis</e2> during infusion of <e1>ifosfamide</e1> , normal laboratory findings and imaging studies and the resolution of symptoms following the discontinuation of the drug suggest that negative myoclonus is associated with the use of IFX .
D007069_D020820 NONE In the patient described , the presence of <e2>asterixis</e2> during infusion of ifosfamide , normal laboratory findings and imaging studies and the resolution of symptoms following the discontinuation of the drug suggest that negative myoclonus is associated with the use of <e1>IFX</e1> .
D007069_D009207 CID We report a case of a 51-year-old man who developed severe , disabling negative <e2>myoclonus</e2> of the upper and lower extremities after the infusion of <e1>ifosfamide</e1> for plasmacytoma .
D007069_D009207 CID In the patient described , the presence of asterixis during infusion of <e1>ifosfamide</e1> , normal laboratory findings and imaging studies and the resolution of symptoms following the discontinuation of the drug suggest that negative <e2>myoclonus</e2> is associated with the use of IFX .
D007069_D009207 CID In the patient described , the presence of asterixis during infusion of ifosfamide , normal laboratory findings and imaging studies and the resolution of symptoms following the discontinuation of the drug suggest that negative <e2>myoclonus</e2> is associated with the use of <e1>IFX</e1> .
D007069_D010954 NONE We report a case of a 51-year-old man who developed severe , disabling negative myoclonus of the upper and lower extremities after the infusion of <e1>ifosfamide</e1> for <e2>plasmacytoma</e2> .
15458908
D020849_D010024 NONE METHODS : The Multiple Outcomes of <e1>Raloxifene</e1> Evaluation , a multicenter , randomized , double-blind trial , enrolled 7,705 postmenopausal women with <e2>osteoporosis</e2> .
D020849_D054556 CID RESULTS : During a mean follow-up of 3.3 years , <e1>raloxifene</e1> was associated with an increased risk for <e2>venous thromboembolism</e2> ( relative risk [ RR ] 2.1 ; 95 % confidence interval [ CI ] 1.2 - 3.8 ) .
D020849_D054556 CID CONCLUSION : <e1>Raloxifene</e1> was associated with an increased risk for <e2>venous thromboembolism</e2> , but there was no increased risk for cataracts , gallbladder disease , endometrial hyperplasia , or endometrial cancer .
D020849_D002386 NONE <e1>Raloxifene</e1> did not increase risk for <e2>cataracts</e2> ( RR 0.9 ; 95 % CI 0.8 - 1.1 ) , gallbladder disease ( RR 1.0 ; 95 % CI 0.7 - 1.3 ) , endometrial hyperplasia ( RR 1.3 ; 95 % CI 0.4 - 5.1 ) , or endometrial cancer ( RR 0.9 ; 95 % CI 0.3 - 2.7 ) .
D020849_D002386 NONE CONCLUSION : <e1>Raloxifene</e1> was associated with an increased risk for venous thromboembolism , but there was no increased risk for <e2>cataracts</e2> , gallbladder disease , endometrial hyperplasia , or endometrial cancer .
D020849_D005705 NONE <e1>Raloxifene</e1> did not increase risk for cataracts ( RR 0.9 ; 95 % CI 0.8 - 1.1 ) , <e2>gallbladder disease</e2> ( RR 1.0 ; 95 % CI 0.7 - 1.3 ) , endometrial hyperplasia ( RR 1.3 ; 95 % CI 0.4 - 5.1 ) , or endometrial cancer ( RR 0.9 ; 95 % CI 0.3 - 2.7 ) .
D020849_D005705 NONE CONCLUSION : <e1>Raloxifene</e1> was associated with an increased risk for venous thromboembolism , but there was no increased risk for cataracts , <e2>gallbladder disease</e2> , endometrial hyperplasia , or endometrial cancer .
D020849_D004714 NONE <e1>Raloxifene</e1> did not increase risk for cataracts ( RR 0.9 ; 95 % CI 0.8 - 1.1 ) , gallbladder disease ( RR 1.0 ; 95 % CI 0.7 - 1.3 ) , <e2>endometrial hyperplasia</e2> ( RR 1.3 ; 95 % CI 0.4 - 5.1 ) , or endometrial cancer ( RR 0.9 ; 95 % CI 0.3 - 2.7 ) .
D020849_D004714 NONE CONCLUSION : <e1>Raloxifene</e1> was associated with an increased risk for venous thromboembolism , but there was no increased risk for cataracts , gallbladder disease , <e2>endometrial hyperplasia</e2> , or endometrial cancer .
D020849_D016889 NONE <e1>Raloxifene</e1> did not increase risk for cataracts ( RR 0.9 ; 95 % CI 0.8 - 1.1 ) , gallbladder disease ( RR 1.0 ; 95 % CI 0.7 - 1.3 ) , endometrial hyperplasia ( RR 1.3 ; 95 % CI 0.4 - 5.1 ) , or <e2>endometrial cancer</e2> ( RR 0.9 ; 95 % CI 0.3 - 2.7 ) .
D020849_D016889 NONE CONCLUSION : <e1>Raloxifene</e1> was associated with an increased risk for venous thromboembolism , but there was no increased risk for cataracts , gallbladder disease , endometrial hyperplasia , or <e2>endometrial cancer</e2> .
17491223
D004280_D017202 CID Assessment of a new non-invasive index of cardiac performance for detection of <e1>dobutamine-induced</e1> <e2>myocardial ischemia</e2> .
D004280_D017202 CID BACKGROUND : Electrocardiography has a very low sensitivity in detecting <e1>dobutamine-induced</e1> <e2>myocardial ischemia</e2> .
D004280_D017202 CID OBJECTIVES : To assess the added diagnostic value of a new cardiac performance index ( dP/dtejc ) measurement , based on brachial artery flow changes , as compared to standard 12-lead ECG , for detecting <e1>dobutamine-induced</e1> <e2>myocardial ischemia</e2> , using Tc99m-Sestamibi single-photon emission computed tomography as the gold standard of comparison to assess the presence or absence of ischemia .
D004280_D007511 NONE OBJECTIVES : To assess the added diagnostic value of a new cardiac performance index ( dP/dtejc ) measurement , based on brachial artery flow changes , as compared to standard 12-lead ECG , for detecting <e1>dobutamine-induced</e1> myocardial ischemia , using Tc99m-Sestamibi single-photon emission computed tomography as the gold standard of comparison to assess the presence or absence of <e2>ischemia</e2> .
D017256_D017202 NONE OBJECTIVES : To assess the added diagnostic value of a new cardiac performance index ( dP/dtejc ) measurement , based on brachial artery flow changes , as compared to standard 12-lead ECG , for detecting dobutamine-induced <e2>myocardial ischemia</e2> , using <e1>Tc99m-Sestamibi</e1> single-photon emission computed tomography as the gold standard of comparison to assess the presence or absence of ischemia .
D017256_D007511 NONE OBJECTIVES : To assess the added diagnostic value of a new cardiac performance index ( dP/dtejc ) measurement , based on brachial artery flow changes , as compared to standard 12-lead ECG , for detecting dobutamine-induced myocardial ischemia , using <e1>Tc99m-Sestamibi</e1> single-photon emission computed tomography as the gold standard of comparison to assess the presence or absence of <e2>ischemia</e2> .
10091617
D012642_D007024 CID <e1>Selegiline-induced</e1> <e2>postural hypotension</e2> in Parkinson 's disease : a longitudinal study on the effects of drug withdrawal .
D012642_D007024 CID Recently , we found that therapy with <e1>selegiline</e1> and L-dopa was associated with selective <e2>systolic orthostatic hypotension</e2> which was abolished by withdrawal of selegiline .
D012642_D007024 CID Recently , we found that therapy with selegiline and L-dopa was associated with selective <e2>systolic orthostatic hypotension</e2> which was abolished by withdrawal of <e1>selegiline</e1> .
D012642_D007024 CID The aims of this study were to confirm our previous findings in a separate cohort of patients and to determine the time course of the cardiovascular consequences of stopping <e1>selegiline</e1> in the expectation that this might shed light on the mechanisms by which the drug causes <e2>orthostatic hypotension</e2> .
D012642_D007024 CID RESULTS : Head-up tilt caused <e2>systolic orthostatic hypotension</e2> which was marked in six of 20 PD patients on <e1>selegiline</e1> , one of whom lost consciousness with unrecordable blood pressures .
D012642_D007024 CID <e2>Orthostatic hypotension</e2> was ameliorated 4 days after withdrawal of <e1>selegiline</e1> and totally abolished 7 days after discontinuation of the drug .
D012642_D007024 CID Stopping <e1>selegiline</e1> also significantly <e2>reduced the supine systolic and diastolic blood pressures</e2> consistent with a previously undescribed supine pressor action .
D012642_D007024 CID CONCLUSION : This study confirms our previous finding that <e1>selegiline</e1> in combination with L-dopa is associated with selective <e2>orthostatic hypotension</e2> .
D012642_D010300 NONE <e1>Selegiline-induced</e1> postural hypotension in <e2>Parkinson 's disease</e2> : a longitudinal study on the effects of drug withdrawal .
D012642_D010300 NONE OBJECTIVES : The United Kingdom <e2>Parkinson 's Disease</e2> Research Group ( UKPDRG ) trial found an increased mortality in patients with Parkinson 's disease ( PD ) randomized to receive 10 mg <e1>selegiline</e1> per day and L-dopa compared with those taking L-dopa alone .
D012642_D010300 NONE OBJECTIVES : The United Kingdom Parkinson 's Disease Research Group ( UKPDRG ) trial found an increased mortality in patients with <e2>Parkinson 's disease</e2> ( PD ) randomized to receive 10 mg <e1>selegiline</e1> per day and L-dopa compared with those taking L-dopa alone .
D012642_D010300 NONE OBJECTIVES : The United Kingdom Parkinson 's Disease Research Group ( UKPDRG ) trial found an increased mortality in patients with Parkinson 's disease ( <e2>PD</e2> ) randomized to receive 10 mg <e1>selegiline</e1> per day and L-dopa compared with those taking L-dopa alone .
D012642_D010300 NONE METHODS : The cardiovascular responses to standing and head-up tilt were studied repeatedly in <e2>PD</e2> patients receiving <e1>selegiline</e1> and as the drug was withdrawn .
D012642_D010300 NONE RESULTS : Head-up tilt caused systolic orthostatic hypotension which was marked in six of 20 <e2>PD</e2> patients on <e1>selegiline</e1> , one of whom lost consciousness with unrecordable blood pressures .
D007980_D010300 NONE OBJECTIVES : The United Kingdom <e2>Parkinson 's Disease</e2> Research Group ( UKPDRG ) trial found an increased mortality in patients with Parkinson 's disease ( PD ) randomized to receive 10 mg selegiline per day and <e1>L-dopa</e1> compared with those taking L-dopa alone .
D007980_D010300 NONE OBJECTIVES : The United Kingdom Parkinson 's Disease Research Group ( UKPDRG ) trial found an increased mortality in patients with <e2>Parkinson 's disease</e2> ( PD ) randomized to receive 10 mg selegiline per day and <e1>L-dopa</e1> compared with those taking L-dopa alone .
D007980_D010300 NONE OBJECTIVES : The United Kingdom Parkinson 's Disease Research Group ( UKPDRG ) trial found an increased mortality in patients with Parkinson 's disease ( <e2>PD</e2> ) randomized to receive 10 mg selegiline per day and <e1>L-dopa</e1> compared with those taking L-dopa alone .
D007980_D010300 NONE OBJECTIVES : The United Kingdom <e2>Parkinson 's Disease</e2> Research Group ( UKPDRG ) trial found an increased mortality in patients with Parkinson 's disease ( PD ) randomized to receive 10 mg selegiline per day and L-dopa compared with those taking <e1>L-dopa</e1> alone .
D007980_D010300 NONE OBJECTIVES : The United Kingdom Parkinson 's Disease Research Group ( UKPDRG ) trial found an increased mortality in patients with <e2>Parkinson 's disease</e2> ( PD ) randomized to receive 10 mg selegiline per day and L-dopa compared with those taking <e1>L-dopa</e1> alone .
D007980_D010300 NONE OBJECTIVES : The United Kingdom Parkinson 's Disease Research Group ( UKPDRG ) trial found an increased mortality in patients with Parkinson 's disease ( <e2>PD</e2> ) randomized to receive 10 mg selegiline per day and L-dopa compared with those taking <e1>L-dopa</e1> alone .
D007980_D007024 NONE Recently , we found that therapy with selegiline and <e1>L-dopa</e1> was associated with selective <e2>systolic orthostatic hypotension</e2> which was abolished by withdrawal of selegiline .
D007980_D007024 NONE CONCLUSION : This study confirms our previous finding that selegiline in combination with <e1>L-dopa</e1> is associated with selective <e2>orthostatic hypotension</e2> .
2951327
D009638_D013610 NONE Mean arterial pressure ( as a percentage of control +/- SEM ) during randomized infusions of 0.03 , 0.1 , 0.3 , or 1.0 microgram/kg/min was 99 +/- 1 , 95 +/- 1 ( p less than 0.05 ) , 93 +/- 1 ( p less than 0.01 ) , or 79 +/- 6 % ( p less than 0.001 ) , respectively , but no <e2>tachycardia</e2> and no augmentation of the <e1>norepinephrine</e1> release rate ( up to 0.3 microgram/kg/min ) were observed , which is in contrast to comparable hypotension induced by hydralazine or nitroglycerin .
D009638_D007022 NONE Mean arterial pressure ( as a percentage of control +/- SEM ) during randomized infusions of 0.03 , 0.1 , 0.3 , or 1.0 microgram/kg/min was 99 +/- 1 , 95 +/- 1 ( p less than 0.05 ) , 93 +/- 1 ( p less than 0.01 ) , or 79 +/- 6 % ( p less than 0.001 ) , respectively , but no tachycardia and no augmentation of the <e1>norepinephrine</e1> release rate ( up to 0.3 microgram/kg/min ) were observed , which is in contrast to comparable <e2>hypotension</e2> induced by hydralazine or nitroglycerin .
D006830_D013610 NONE Mean arterial pressure ( as a percentage of control +/- SEM ) during randomized infusions of 0.03 , 0.1 , 0.3 , or 1.0 microgram/kg/min was 99 +/- 1 , 95 +/- 1 ( p less than 0.05 ) , 93 +/- 1 ( p less than 0.01 ) , or 79 +/- 6 % ( p less than 0.001 ) , respectively , but no <e2>tachycardia</e2> and no augmentation of the norepinephrine release rate ( up to 0.3 microgram/kg/min ) were observed , which is in contrast to comparable hypotension induced by <e1>hydralazine</e1> or nitroglycerin .
D006830_D007022 CID Mean arterial pressure ( as a percentage of control +/- SEM ) during randomized infusions of 0.03 , 0.1 , 0.3 , or 1.0 microgram/kg/min was 99 +/- 1 , 95 +/- 1 ( p less than 0.05 ) , 93 +/- 1 ( p less than 0.01 ) , or 79 +/- 6 % ( p less than 0.001 ) , respectively , but no tachycardia and no augmentation of the norepinephrine release rate ( up to 0.3 microgram/kg/min ) were observed , which is in contrast to comparable <e2>hypotension</e2> induced by <e1>hydralazine</e1> or nitroglycerin .
D005996_D013610 NONE Mean arterial pressure ( as a percentage of control +/- SEM ) during randomized infusions of 0.03 , 0.1 , 0.3 , or 1.0 microgram/kg/min was 99 +/- 1 , 95 +/- 1 ( p less than 0.05 ) , 93 +/- 1 ( p less than 0.01 ) , or 79 +/- 6 % ( p less than 0.001 ) , respectively , but no <e2>tachycardia</e2> and no augmentation of the norepinephrine release rate ( up to 0.3 microgram/kg/min ) were observed , which is in contrast to comparable hypotension induced by hydralazine or <e1>nitroglycerin</e1> .
D005996_D007022 CID Mean arterial pressure ( as a percentage of control +/- SEM ) during randomized infusions of 0.03 , 0.1 , 0.3 , or 1.0 microgram/kg/min was 99 +/- 1 , 95 +/- 1 ( p less than 0.05 ) , 93 +/- 1 ( p less than 0.01 ) , or 79 +/- 6 % ( p less than 0.001 ) , respectively , but no tachycardia and no augmentation of the norepinephrine release rate ( up to 0.3 microgram/kg/min ) were observed , which is in contrast to comparable <e2>hypotension</e2> induced by hydralazine or <e1>nitroglycerin</e1> .
19657887
D000431_D005483 CID In less than 1 hour after the ingestion of <e1>alcohol</e1> , he developed malaise with <e2>flushing of the face</e2> , tachycardia , and dyspnea .
D000431_D013610 CID In less than 1 hour after the ingestion of <e1>alcohol</e1> , he developed malaise with flushing of the face , <e2>tachycardia</e2> , and dyspnea .
D000431_D004417 CID In less than 1 hour after the ingestion of <e1>alcohol</e1> , he developed malaise with flushing of the face , tachycardia , and <e2>dyspnea</e2> .
D004221_D005483 NONE Five hours after exposure , he developed <e1>disulfiram-like</e1> syndrome with <e2>flushing</e2> , tachycardia , and arterial hypotension after consuming three glasses of wine .
D004221_D013610 NONE Five hours after exposure , he developed <e1>disulfiram-like</e1> syndrome with flushing , <e2>tachycardia</e2> , and arterial hypotension after consuming three glasses of wine .
D004221_D007022 NONE Five hours after exposure , he developed <e1>disulfiram-like</e1> syndrome with flushing , tachycardia , and <e2>arterial hypotension</e2> after consuming three glasses of wine .
2071257
D005997_D000647 NONE Effect of <e1>L-alpha-glyceryl-phosphorylcholine</e1> on <e2>amnesia</e2> caused by scopolamine .
D012601_D000647 NONE Effect of L-alpha-glyceryl-phosphorylcholine on <e2>amnesia</e2> caused by <e1>scopolamine</e1> .
D005997_D008569 NONE The present study was carried out to test the effects of <e1>L-alpha-glycerylphosphorylcholine</e1> ( L-alpha-GFC ) on <e2>memory impairment</e2> induced by scopolamine in man .
D005997_D008569 NONE The present study was carried out to test the effects of L-alpha-glycerylphosphorylcholine ( <e1>L-alpha-GFC</e1> ) on <e2>memory impairment</e2> induced by scopolamine in man .
D012601_D008569 CID The present study was carried out to test the effects of L-alpha-glycerylphosphorylcholine ( L-alpha-GFC ) on <e2>memory impairment</e2> induced by <e1>scopolamine</e1> in man .
D012601_D008569 CID The findings of this study indicate that the drug is able to antagonize <e2>impairment of attention and memory</e2> induced by <e1>scopolamine</e1> .
2375138
D008874_D006323 CID Possible intramuscular <e1>midazolam-associated</e1> <e2>cardiorespiratory arrest</e2> and death .
D008874_D006323 CID This report describes the first published case of <e2>cardiorespiratory arrest</e2> and death associated with intramuscular administration of <e1>midazolam</e1> .
D008874_D003643 NONE Possible intramuscular <e1>midazolam-associated</e1> cardiorespiratory arrest and <e2>death</e2> .
D008874_D003643 NONE This report describes the first published case of cardiorespiratory arrest and <e2>death</e2> associated with intramuscular administration of <e1>midazolam</e1> .
1436384
D000661_D020258 CID Protection against <e1>amphetamine-induced</e1> <e2>neurotoxicity</e2> toward striatal dopamine neurons in rodents by LY274614 , an excitatory amino acid antagonist .
D000661_D020258 CID The data strengthen the evidence that the <e2>neurotoxic</e2> effect of <e1>amphetamine</e1> and related compounds toward nigrostriatal dopamine neurons involves NMDA receptors and that LY274614 is an NMDA receptor antagonist with long-lasting in vivo effects in rats .
D004298_D020258 NONE Protection against amphetamine-induced <e2>neurotoxicity</e2> toward striatal <e1>dopamine</e1> neurons in rodents by LY274614 , an excitatory amino acid antagonist .
D004298_D020258 NONE The data strengthen the evidence that the <e2>neurotoxic</e2> effect of amphetamine and related compounds toward nigrostriatal <e1>dopamine</e1> neurons involves NMDA receptors and that LY274614 is an NMDA receptor antagonist with long-lasting in vivo effects in rats .
C070935_D020258 NONE Protection against amphetamine-induced <e2>neurotoxicity</e2> toward striatal dopamine neurons in rodents by <e1>LY274614</e1> , an excitatory amino acid antagonist .
C070935_D020258 NONE The data strengthen the evidence that the <e2>neurotoxic</e2> effect of amphetamine and related compounds toward nigrostriatal dopamine neurons involves NMDA receptors and that <e1>LY274614</e1> is an NMDA receptor antagonist with long-lasting in vivo effects in rats .
D000596_D020258 NONE Protection against amphetamine-induced <e2>neurotoxicity</e2> toward striatal dopamine neurons in rodents by LY274614 , an excitatory <e1>amino acid</e1> antagonist .
D016202_D020258 NONE The data strengthen the evidence that the <e2>neurotoxic</e2> effect of amphetamine and related compounds toward nigrostriatal dopamine neurons involves <e1>NMDA</e1> receptors and that LY274614 is an NMDA receptor antagonist with long-lasting in vivo effects in rats .
D016202_D020258 NONE The data strengthen the evidence that the <e2>neurotoxic</e2> effect of amphetamine and related compounds toward nigrostriatal dopamine neurons involves NMDA receptors and that LY274614 is an <e1>NMDA</e1> receptor antagonist with long-lasting in vivo effects in rats .
12443032
D003042_D002637 CID <e1>Cocaine</e1> related <e2>chest pain</e2> : are we seeing the tip of an iceberg ?
D003042_D002637 CID In particular , the tendency of <e1>cocaine</e1> to produce <e2>chest pain</e2> ought to be in the mind of the emergency nurse when faced with a young victim of chest pain who is otherwise at low risk .
D003042_D002637 CID In particular , the tendency of <e1>cocaine</e1> to produce chest pain ought to be in the mind of the emergency nurse when faced with a young victim of <e2>chest pain</e2> who is otherwise at low risk .
D003042_D002637 CID The mechanism of <e2>chest pain</e2> related to <e1>cocaine</e1> use is discussed and treatment dilemmas are discussed .
11135224
D017239_D002289 NONE <e1>Paclitaxel</e1> , cisplatin , and gemcitabine combination chemotherapy within a multidisciplinary therapeutic approach in metastatic <e2>nonsmall cell lung carcinoma</e2> .
D017239_D002289 NONE METHODS : The objective of this study was to determine the feasibility , response rate , and toxicity of a <e1>paclitaxel</e1> , cisplatin , and gemcitabine combination to treat metastatic <e2>NSCLC</e2> .
D017239_D002289 NONE Thirty-five consecutive chemotherapy-naive patients with Stage IV <e2>NSCLC</e2> and an Eastern Cooperative Oncology Group performance status of 0 - 2 were treated with a combination of <e1>paclitaxel</e1> ( 135 mg/m(2 ) given intravenously in 3 hours ) on Day 1 , cisplatin ( 120 mg/m(2 ) given intravenously in 6 hours ) on Day 1 , and gemcitabine ( 800 mg/m(2 ) given intravenously in 30 minutes ) on Days 1 and 8 , every 4 weeks .
D017239_D002289 NONE CONCLUSIONS : The combination of <e1>paclitaxel</e1> , cisplatin , and gemcitabine is well tolerated and shows high activity in metastatic <e2>NSCLC</e2> .
D002945_D002289 NONE Paclitaxel , <e1>cisplatin</e1> , and gemcitabine combination chemotherapy within a multidisciplinary therapeutic approach in metastatic <e2>nonsmall cell lung carcinoma</e2> .
D002945_D002289 NONE BACKGROUND : <e1>Cisplatin-based</e1> chemotherapy combinations improve quality of life and survival in advanced <e2>nonsmall cell lung carcinoma</e2> ( NSCLC ) .
D002945_D002289 NONE BACKGROUND : <e1>Cisplatin-based</e1> chemotherapy combinations improve quality of life and survival in advanced nonsmall cell lung carcinoma ( <e2>NSCLC</e2> ) .
D002945_D002289 NONE METHODS : The objective of this study was to determine the feasibility , response rate , and toxicity of a paclitaxel , <e1>cisplatin</e1> , and gemcitabine combination to treat metastatic <e2>NSCLC</e2> .
D002945_D002289 NONE Thirty-five consecutive chemotherapy-naive patients with Stage IV <e2>NSCLC</e2> and an Eastern Cooperative Oncology Group performance status of 0 - 2 were treated with a combination of paclitaxel ( 135 mg/m(2 ) given intravenously in 3 hours ) on Day 1 , <e1>cisplatin</e1> ( 120 mg/m(2 ) given intravenously in 6 hours ) on Day 1 , and gemcitabine ( 800 mg/m(2 ) given intravenously in 30 minutes ) on Days 1 and 8 , every 4 weeks .
D002945_D002289 NONE CONCLUSIONS : The combination of paclitaxel , <e1>cisplatin</e1> , and gemcitabine is well tolerated and shows high activity in metastatic <e2>NSCLC</e2> .
C056507_D002289 NONE Paclitaxel , cisplatin , and <e1>gemcitabine</e1> combination chemotherapy within a multidisciplinary therapeutic approach in metastatic <e2>nonsmall cell lung carcinoma</e2> .
C056507_D002289 NONE METHODS : The objective of this study was to determine the feasibility , response rate , and toxicity of a paclitaxel , cisplatin , and <e1>gemcitabine</e1> combination to treat metastatic <e2>NSCLC</e2> .
C056507_D002289 NONE Thirty-five consecutive chemotherapy-naive patients with Stage IV <e2>NSCLC</e2> and an Eastern Cooperative Oncology Group performance status of 0 - 2 were treated with a combination of paclitaxel ( 135 mg/m(2 ) given intravenously in 3 hours ) on Day 1 , cisplatin ( 120 mg/m(2 ) given intravenously in 6 hours ) on Day 1 , and <e1>gemcitabine</e1> ( 800 mg/m(2 ) given intravenously in 30 minutes ) on Days 1 and 8 , every 4 weeks .
C056507_D002289 NONE CONCLUSIONS : The combination of paclitaxel , cisplatin , and <e1>gemcitabine</e1> is well tolerated and shows high activity in metastatic <e2>NSCLC</e2> .
D017239_D064420 NONE METHODS : The objective of this study was to determine the feasibility , response rate , and <e2>toxicity</e2> of a <e1>paclitaxel</e1> , cisplatin , and gemcitabine combination to treat metastatic NSCLC .
D002945_D064420 NONE METHODS : The objective of this study was to determine the feasibility , response rate , and <e2>toxicity</e2> of a paclitaxel , <e1>cisplatin</e1> , and gemcitabine combination to treat metastatic NSCLC .
C056507_D064420 NONE METHODS : The objective of this study was to determine the feasibility , response rate , and <e2>toxicity</e2> of a paclitaxel , cisplatin , and <e1>gemcitabine</e1> combination to treat metastatic NSCLC .
3403780
D000082_D003128 NONE <e1>Paracetamol-associated</e1> <e2>coma</e2> , metabolic acidosis , renal and hepatic failure .
D000082_D000138 CID <e1>Paracetamol-associated</e1> coma , <e2>metabolic acidosis</e2> , renal and hepatic failure .
D000082_D000138 CID A case of <e2>metabolic acidosis</e2> , acute renal failure and hepatic failure following <e1>paracetamol</e1> ingestion is presented .
D000082_D058186 CID A case of metabolic acidosis , <e2>acute renal failure and hepatic failure</e2> following <e1>paracetamol</e1> ingestion is presented .
D000082_D058186 NONE <e1>Paracetamol-associated</e1> coma , metabolic acidosis , <e2>renal and hepatic failure</e2> .
D000082_D017093 NONE <e1>Paracetamol-associated</e1> coma , metabolic acidosis , <e2>renal and hepatic failure</e2> .
D000082_D017114 CID A case of metabolic acidosis , <e2>acute renal failure and hepatic failure</e2> following <e1>paracetamol</e1> ingestion is presented .
2632720
D007654_D006973 CID Arterial <e2>hypertension</e2> as a complication of prolonged <e1>ketoconazole</e1> treatment .
D007654_D006973 CID Two of 14 patients with Cushing 's syndrome treated on a long-term basis with <e1>ketoconazole</e1> developed sustained <e2>hypertension</e2> .
D007654_D006973 CID In both cases normal plasma and urinary free cortisol levels had been achieved following <e1>ketoconazole</e1> therapy , yet continuous blood pressure monitoring demonstrated <e2>hypertension</e2> 31 ( patient 1 ) and 52 weeks ( patient 2 ) after treatment .
D007654_D006973 CID Our findings show that long-term treatment with high doses of <e1>ketoconazole</e1> may induce enzyme blockade leading to mineralocorticoid-related <e2>hypertension</e2> .
D007654_D003480 NONE Two of 14 patients with <e2>Cushing 's syndrome</e2> treated on a long-term basis with <e1>ketoconazole</e1> developed sustained hypertension .
D006854_D006973 NONE In both cases normal plasma and urinary free <e1>cortisol</e1> levels had been achieved following ketoconazole therapy , yet continuous blood pressure monitoring demonstrated <e2>hypertension</e2> 31 ( patient 1 ) and 52 weeks ( patient 2 ) after treatment .
17042910
C065179_D006973 NONE Anti-oxidant effects of <e1>atorvastatin</e1> in dexamethasone-induced <e2>hypertension</e2> in the rat .
C065179_D006973 NONE <e1>Atorvastatin</e1> ( Ato ) possesses pleiotropic properties that have been reported to improve endothelial function through increased availability of NO and reduced O2- production in various forms of <e2>hypertension</e2> .
C065179_D006973 NONE Atorvastatin ( <e1>Ato</e1> ) possesses pleiotropic properties that have been reported to improve endothelial function through increased availability of NO and reduced O2- production in various forms of <e2>hypertension</e2> .
D003907_D006973 CID Anti-oxidant effects of atorvastatin in <e1>dexamethasone-induced</e1> <e2>hypertension</e2> in the rat .
D003907_D006973 CID 1 . <e1>Dexamethasone</e1> (Dex)-induced <e2>hypertension</e2> is characterized by endothelial dysfunction associated with nitric oxide ( NO ) deficiency and increased superoxide ( O2- ) production .
D003907_D006973 CID 1 . Dexamethasone <e1>(Dex)-induced</e1> <e2>hypertension</e2> is characterized by endothelial dysfunction associated with nitric oxide ( NO ) deficiency and increased superoxide ( O2- ) production .
D009569_D006973 NONE 1 . Dexamethasone (Dex)-induced <e2>hypertension</e2> is characterized by endothelial dysfunction associated with <e1>nitric oxide</e1> ( NO ) deficiency and increased superoxide ( O2- ) production .
D009569_D006973 NONE 1 . Dexamethasone (Dex)-induced <e2>hypertension</e2> is characterized by endothelial dysfunction associated with nitric oxide ( <e1>NO</e1> ) deficiency and increased superoxide ( O2- ) production .
D009569_D006973 NONE Atorvastatin ( Ato ) possesses pleiotropic properties that have been reported to improve endothelial function through increased availability of <e1>NO</e1> and reduced O2- production in various forms of <e2>hypertension</e2> .
D013481_D006973 NONE 1 . Dexamethasone (Dex)-induced <e2>hypertension</e2> is characterized by endothelial dysfunction associated with nitric oxide ( NO ) deficiency and increased <e1>superoxide</e1> ( O2- ) production .
D013481_D006973 NONE 1 . Dexamethasone (Dex)-induced <e2>hypertension</e2> is characterized by endothelial dysfunction associated with nitric oxide ( NO ) deficiency and increased superoxide ( <e1>O2-</e1> ) production .
D013481_D006973 NONE Atorvastatin ( Ato ) possesses pleiotropic properties that have been reported to improve endothelial function through increased availability of NO and reduced <e1>O2-</e1> production in various forms of <e2>hypertension</e2> .
3780846
D009020_D009127 CID On the mechanisms of the development of tolerance to the <e2>muscular rigidity</e2> produced by <e1>morphine</e1> in rats .
D009020_D009127 CID The development of tolerance to the <e2>muscular rigidity</e2> produced by <e1>morphine</e1> was studied in rats .
D009020_D009127 CID Saline-pretreated controls given a test dose of <e1>morphine</e1> ( 20 mg/kg i.p. ) showed a pronounced <e2>rigidity</e2> recorded as tonic activity in the electromyogram .
D009020_D009127 CID Rats treated for 11 days with <e1>morphine</e1> and withdrawn for 36 - 40 h showed differences in the development of tolerance : about half of the animals showed a <e2>rigidity</e2> after the test dose of morphine that was not significantly less than in the controls and were akinetic ( A group ) .
D009020_D009127 CID Rats treated for 11 days with morphine and withdrawn for 36 - 40 h showed differences in the development of tolerance : about half of the animals showed a <e2>rigidity</e2> after the test dose of <e1>morphine</e1> that was not significantly less than in the controls and were akinetic ( A group ) .
D009020_D009127 CID The results suggest that <e2>rigidity</e2> , which is assumed to be due to an action of <e1>morphine</e1> in the striatum , can be antagonized by another process leading to dopaminergic activation in the striatum .
D009020_D018476 CID Rats treated for 11 days with <e1>morphine</e1> and withdrawn for 36 - 40 h showed differences in the development of tolerance : about half of the animals showed a rigidity after the test dose of morphine that was not significantly less than in the controls and were <e2>akinetic</e2> ( A group ) .
D009020_D018476 CID Rats treated for 11 days with morphine and withdrawn for 36 - 40 h showed differences in the development of tolerance : about half of the animals showed a rigidity after the test dose of <e1>morphine</e1> that was not significantly less than in the controls and were <e2>akinetic</e2> ( A group ) .
D006220_D009127 CID In a further series of experiments , <e1>haloperidol</e1> ( 0.2 mg/kg i.p. ) was used in order to block the dopaminergic activation and to estimate the real degree of the tolerance to the <e2>rigidity</e2> without any dopaminergic interference .
D006220_D009127 CID <e1>Haloperidol</e1> enhanced the <e2>rigidity</e2> in the A group .
3693336
D014229_D001714 CID <e1>Triazolam-induced</e1> brief episodes of secondary <e2>mania</e2> in a depressed patient .
D014229_D001714 CID Large doses of <e1>triazolam</e1> repeatedly induced brief episodes of <e2>mania</e2> in a depressed elderly woman .
D014229_D001714 CID <e2>Manic</e2> excitement was coincident with the duration of action of <e1>triazolam</e1> .
D014229_D003866 NONE <e1>Triazolam-induced</e1> brief episodes of secondary mania in a <e2>depressed</e2> patient .
D014229_D003866 NONE Large doses of <e1>triazolam</e1> repeatedly induced brief episodes of mania in a <e2>depressed</e2> elderly woman .
12523465
C022189_D006212 CID <e2>Visual hallucinations</e2> associated with <e1>zonisamide</e1> .
C022189_D006212 CID Although <e2>visual hallucinations</e2> have not been reported as an adverse effect of this agent , we describe three patients who experienced complex visual hallucinations and altered mental status after <e1>zonisamide</e1> treatment was begun or its dosage increased .
C022189_D006212 CID Although visual hallucinations have not been reported as an adverse effect of this agent , we describe three patients who experienced complex <e2>visual hallucinations</e2> and altered mental status after <e1>zonisamide</e1> treatment was begun or its dosage increased .
C022189_D012640 NONE <e1>Zonisamide</e1> is a broad-spectrum antiepileptic drug used to treat various types of <e2>seizures</e2> .
15649445
D012110_D004409 CID Acute <e1>reserpine</e1> and subchronic haloperidol treatments change synaptosomal brain glutamate uptake and elicit <e2>orofacial dyskinesia</e2> in rats .
D012110_D004409 CID <e1>Reserpine-</e1> and haloperidol-induced <e2>orofacial dyskinesia</e2> are putative animal models of tardive dyskinesia ( TD ) whose pathophysiology has been related to free radical generation and oxidative stress .
D012110_D004409 CID <e1>Reserpine-</e1> and haloperidol-induced orofacial dyskinesia are putative animal models of <e2>tardive dyskinesia</e2> ( TD ) whose pathophysiology has been related to free radical generation and oxidative stress .
D012110_D004409 CID <e1>Reserpine-</e1> and haloperidol-induced orofacial dyskinesia are putative animal models of tardive dyskinesia ( <e2>TD</e2> ) whose pathophysiology has been related to free radical generation and oxidative stress .
D012110_D004409 CID In the present study , the authors induced <e2>orofacial dyskinesia</e2> by acute <e1>reserpine</e1> and subchronic haloperidol administration to rats .
D006220_D004409 CID Acute reserpine and subchronic <e1>haloperidol</e1> treatments change synaptosomal brain glutamate uptake and elicit <e2>orofacial dyskinesia</e2> in rats .
D006220_D004409 CID Reserpine- and <e1>haloperidol-induced</e1> <e2>orofacial dyskinesia</e2> are putative animal models of tardive dyskinesia ( TD ) whose pathophysiology has been related to free radical generation and oxidative stress .
D006220_D004409 CID Reserpine- and <e1>haloperidol-induced</e1> orofacial dyskinesia are putative animal models of <e2>tardive dyskinesia</e2> ( TD ) whose pathophysiology has been related to free radical generation and oxidative stress .
D006220_D004409 CID Reserpine- and <e1>haloperidol-induced</e1> orofacial dyskinesia are putative animal models of tardive dyskinesia ( <e2>TD</e2> ) whose pathophysiology has been related to free radical generation and oxidative stress .
D006220_D004409 CID In the present study , the authors induced <e2>orofacial dyskinesia</e2> by acute reserpine and subchronic <e1>haloperidol</e1> administration to rats .
D018698_D004409 NONE Acute reserpine and subchronic haloperidol treatments change synaptosomal brain <e1>glutamate</e1> uptake and elicit <e2>orofacial dyskinesia</e2> in rats .
D018698_D004409 NONE Importantly , a decrease in <e1>glutamate</e1> uptake correlates negatively with an increase in the incidence of <e2>orofacial diskinesia</e2> .
18631865
D020123_D051436 NONE Massive urinary protein excretion has been observed after conversion from calcineurin inhibitors to mammalian target of <e1>rapamycin</e1> ( mToR ) inhibitors , especially sirolimus , in renal transplant recipients with <e2>chronic allograft nephropathy</e2> .
D020123_D051436 NONE Massive urinary protein excretion has been observed after conversion from calcineurin inhibitors to mammalian target of rapamycin ( mToR ) inhibitors , especially <e1>sirolimus</e1> , in renal transplant recipients with <e2>chronic allograft nephropathy</e2> .
D020123_D011507 CID Whether <e2>proteinuria</e2> was due to <e1>sirolimus</e1> or only a consequence of calcineurin inhibitors withdrawal remained unsolved until high range proteinuria has been observed during sirolimus therapy in islet transplantation and in patients who received sirolimus de novo .
D020123_D011507 CID Whether proteinuria was due to <e1>sirolimus</e1> or only a consequence of calcineurin inhibitors withdrawal remained unsolved until high range <e2>proteinuria</e2> has been observed during sirolimus therapy in islet transplantation and in patients who received sirolimus de novo .
D020123_D011507 CID Whether <e2>proteinuria</e2> was due to sirolimus or only a consequence of calcineurin inhibitors withdrawal remained unsolved until high range proteinuria has been observed during <e1>sirolimus</e1> therapy in islet transplantation and in patients who received sirolimus de novo .
D020123_D011507 CID Whether proteinuria was due to sirolimus or only a consequence of calcineurin inhibitors withdrawal remained unsolved until high range <e2>proteinuria</e2> has been observed during <e1>sirolimus</e1> therapy in islet transplantation and in patients who received sirolimus de novo .
D020123_D011507 CID Whether <e2>proteinuria</e2> was due to sirolimus or only a consequence of calcineurin inhibitors withdrawal remained unsolved until high range proteinuria has been observed during sirolimus therapy in islet transplantation and in patients who received <e1>sirolimus</e1> de novo .
D020123_D011507 CID Whether proteinuria was due to sirolimus or only a consequence of calcineurin inhibitors withdrawal remained unsolved until high range <e2>proteinuria</e2> has been observed during sirolimus therapy in islet transplantation and in patients who received <e1>sirolimus</e1> de novo .
1085609
D011736_D012640 NONE Neonatal <e1>pyridoxine</e1> responsive <e2>convulsions</e2> due to isoniazid therapy .
D011736_D012640 NONE The <e2>fits</e2> ceased within 4 hours of administering intramuscular <e1>pyridoxine</e1> , suggesting an aetiology of pyridoxine deficiency secondary to isoniazid medication .
D011736_D012640 NONE The <e2>fits</e2> ceased within 4 hours of administering intramuscular pyridoxine , suggesting an aetiology of <e1>pyridoxine</e1> deficiency secondary to isoniazid medication .
D007538_D012640 CID Neonatal pyridoxine responsive <e2>convulsions</e2> due to <e1>isoniazid</e1> therapy .
D007538_D012640 CID A 17-day-old infant on <e1>isoniazid</e1> therapy 13 mg/kg daily from birth because of maternal tuberculosis was admitted after 4 days of <e2>clonic fits</e2> .
D007538_D012640 CID The <e2>fits</e2> ceased within 4 hours of administering intramuscular pyridoxine , suggesting an aetiology of pyridoxine deficiency secondary to <e1>isoniazid</e1> medication .
D007538_D014376 NONE A 17-day-old infant on <e1>isoniazid</e1> therapy 13 mg/kg daily from birth because of maternal <e2>tuberculosis</e2> was admitted after 4 days of clonic fits .
891050
D003276_D006463 CID A case is reported of the <e2>hemolytic uremic syndrome</e2> ( HUS ) in a woman taking <e1>oral contraceptives</e1> .
D003276_D006463 CID A case is reported of the hemolytic uremic syndrome ( <e2>HUS</e2> ) in a woman taking <e1>oral contraceptives</e1> .
D006493_D001002 NONE She was treated with <e1>heparin</e1> , dipyridamole and hemodialysis ; and after more than three months , her urinary output rose above 500 ml ; and six months after the onset of <e2>anuria</e2> , dialysis treatment was stopped .
D004176_D001002 NONE She was treated with heparin , <e1>dipyridamole</e1> and hemodialysis ; and after more than three months , her urinary output rose above 500 ml ; and six months after the onset of <e2>anuria</e2> , dialysis treatment was stopped .
7199841
C004616_D010243 CID Of the 20 animals that received subarachnoid injection of <e1>2-chloroprocaine-CE</e1> seven ( 35 % ) developed hind-limb <e2>paralysis</e2> .
D002045_D010243 NONE None of the animals that received <e1>bupivacaine</e1> , normal saline , or normal saline titrated to a pH 3.0 developed hind-limb <e2>paralysis</e2> .
C004616_D013118 CID Of the 15 spinal cords of the animals that received <e1>2-chloroprocaine-CE</e1> , 13 showed <e2>subpial necrosis</e2> ; the nerve roots and subarachnoid vessels were normal .
11256525
D019808_D001002 CID Repeated transient <e2>anuria</e2> following <e1>losartan</e1> administration in a patient with a solitary kidney .
D019808_D001002 CID We report the case of a 70-year-old hypertensive man with a solitary kidney and chronic renal insufficiency who developed two episodes of transient <e2>anuria</e2> after <e1>losartan</e1> administration .
D019808_D001002 CID Surprisingly , the first dose of 50 mg of <e1>losartan</e1> resulted in a sudden <e2>anuria</e2> , which lasted eight hours despite high-dose furosemide and amine infusion .
D019808_D001002 CID One week later , by mistake , <e1>losartan</e1> was prescribed again and after the second dose of 50 mg , the patient developed a second episode of transient <e2>anuria</e2> lasting 10 hours .
D019808_D006973 NONE We report the case of a 70-year-old <e2>hypertensive</e2> man with a solitary kidney and chronic renal insufficiency who developed two episodes of transient anuria after <e1>losartan</e1> administration .
D019808_D051436 NONE We report the case of a 70-year-old hypertensive man with a solitary kidney and <e2>chronic renal insufficiency</e2> who developed two episodes of transient anuria after <e1>losartan</e1> administration .
D019808_D006331 NONE Due to severe <e2>systolic dysfunction</e2> <e1>losartan</e1> was prescribed .
D005665_D001002 NONE Surprisingly , the first dose of 50 mg of losartan resulted in a sudden <e2>anuria</e2> , which lasted eight hours despite high-dose <e1>furosemide</e1> and amine infusion .
D000588_D001002 NONE Surprisingly , the first dose of 50 mg of losartan resulted in a sudden <e2>anuria</e2> , which lasted eight hours despite high-dose furosemide and <e1>amine</e1> infusion .
D000809_D012078 NONE In this patient , <e2>renal artery stenosis</e2> combined with heart failure and diuretic therapy certainly resulted in a strong activation of the <e1>renin-angiotensin</e1> system ( RAS ) .
D000809_D006333 NONE In this patient , renal artery stenosis combined with <e2>heart failure</e2> and diuretic therapy certainly resulted in a strong activation of the <e1>renin-angiotensin</e1> system ( RAS ) .
D000804_D014652 NONE This case report highlights the fact that the <e1>angiotensin II</e1> receptor antagonist losartan can cause serious unexpected complications in patients with <e2>renovascular disease</e2> and should be used with extreme caution in this setting .
D019808_D014652 NONE This case report highlights the fact that the angiotensin II receptor antagonist <e1>losartan</e1> can cause serious unexpected complications in patients with <e2>renovascular disease</e2> and should be used with extreme caution in this setting .
3412544
D000082_D014523 NONE Does <e1>paracetamol</e1> cause <e2>urothelial cancer</e2> or renal papillary necrosis ?
D000082_D007681 NONE Does <e1>paracetamol</e1> cause urothelial cancer or <e2>renal papillary necrosis</e2> ?
D000082_D007681 NONE The risk of developing <e2>renal papillary necrosis</e2> or cancer of the renal pelvis , ureter or bladder associated with consumption of either phenacetin or <e1>paracetamol</e1> was calculated from data acquired by questionnaire from 381 cases and 808 controls .
D000082_D007681 NONE By contrast , we were unable to substantiate an increased risk from <e1>paracetamol</e1> consumption for <e2>renal papillary necrosis</e2> or any of these cancers although there was a suggestion of an association with cancer of the ureter .
D010615_D007681 CID The risk of developing <e2>renal papillary necrosis</e2> or cancer of the renal pelvis , ureter or bladder associated with consumption of either <e1>phenacetin</e1> or paracetamol was calculated from data acquired by questionnaire from 381 cases and 808 controls .
D010615_D007681 CID The risk of <e2>renal papillary necrosis</e2> was increased nearly 20-fold by consumption of <e1>phenacetin</e1> , which also increased the risk for cancer of the renal pelvis and bladder but not for ureteric cancer .
D010615_D007680 CID The risk of renal papillary necrosis was increased nearly 20-fold by consumption of <e1>phenacetin</e1> , which also increased the risk for <e2>cancer of the renal pelvis and bladder</e2> but not for ureteric cancer .
D010615_D007680 NONE The risk of developing renal papillary necrosis or <e2>cancer of the renal pelvis , ureter or bladder</e2> associated with consumption of either <e1>phenacetin</e1> or paracetamol was calculated from data acquired by questionnaire from 381 cases and 808 controls .
D010615_D014516 NONE The risk of developing renal papillary necrosis or <e2>cancer of the renal pelvis , ureter or bladder</e2> associated with consumption of either <e1>phenacetin</e1> or paracetamol was calculated from data acquired by questionnaire from 381 cases and 808 controls .
D010615_D014516 NONE The risk of renal papillary necrosis was increased nearly 20-fold by consumption of <e1>phenacetin</e1> , which also increased the risk for cancer of the renal pelvis and bladder but not for <e2>ureteric cancer</e2> .
D010615_D001749 CID The risk of renal papillary necrosis was increased nearly 20-fold by consumption of <e1>phenacetin</e1> , which also increased the risk for <e2>cancer of the renal pelvis and bladder</e2> but not for ureteric cancer .
D010615_D001749 NONE The risk of developing renal papillary necrosis or <e2>cancer of the renal pelvis , ureter or bladder</e2> associated with consumption of either <e1>phenacetin</e1> or paracetamol was calculated from data acquired by questionnaire from 381 cases and 808 controls .
D000082_D007680 NONE The risk of developing renal papillary necrosis or <e2>cancer of the renal pelvis , ureter or bladder</e2> associated with consumption of either phenacetin or <e1>paracetamol</e1> was calculated from data acquired by questionnaire from 381 cases and 808 controls .
D000082_D014516 NONE The risk of developing renal papillary necrosis or <e2>cancer of the renal pelvis , ureter or bladder</e2> associated with consumption of either phenacetin or <e1>paracetamol</e1> was calculated from data acquired by questionnaire from 381 cases and 808 controls .
D000082_D014516 NONE By contrast , we were unable to substantiate an increased risk from <e1>paracetamol</e1> consumption for renal papillary necrosis or any of these cancers although there was a suggestion of an association with <e2>cancer of the ureter</e2> .
D000082_D001749 NONE The risk of developing renal papillary necrosis or <e2>cancer of the renal pelvis , ureter or bladder</e2> associated with consumption of either phenacetin or <e1>paracetamol</e1> was calculated from data acquired by questionnaire from 381 cases and 808 controls .
D000082_D009369 NONE By contrast , we were unable to substantiate an increased risk from <e1>paracetamol</e1> consumption for renal papillary necrosis or any of these <e2>cancers</e2> although there was a suggestion of an association with cancer of the ureter .
9862868
D004997_D002780 CID We used rat models of <e2>intrahepatic cholestasis</e2> by <e1>ethinyl estradiol</e1> ( EE ) treatment and extrahepatic cholestasis by bile duct ligation ( BDL ) to precisely determine the site of TJ damage .
D004997_D002780 CID We used rat models of <e2>intrahepatic cholestasis</e2> by ethinyl estradiol ( <e1>EE</e1> ) treatment and extrahepatic cholestasis by bile duct ligation ( BDL ) to precisely determine the site of TJ damage .
D004997_D001651 NONE We used rat models of intrahepatic cholestasis by <e1>ethinyl estradiol</e1> ( EE ) treatment and <e2>extrahepatic cholestasis</e2> by bile duct ligation ( BDL ) to precisely determine the site of TJ damage .
D004997_D001651 NONE We used rat models of intrahepatic cholestasis by ethinyl estradiol ( <e1>EE</e1> ) treatment and <e2>extrahepatic cholestasis</e2> by bile duct ligation ( BDL ) to precisely determine the site of TJ damage .
2008831
D008755_D000788 NONE Effect of direct intracoronary administration of <e1>methylergonovine</e1> in patients with and without <e2>variant angina</e2> .
D008755_D000788 NONE The effects of intracoronary administration of <e1>methylergonovine</e1> were studied in 21 patients with <e2>variant angina</e2> and 22 patients with atypical chest pain and in others without angina pectoris ( control group ) .
D008755_D000788 NONE These results suggest that spasm provocation tests , which use an intracoronary injection of a relatively low dose of <e1>methylergonovine</e1> , have a high sensitivity in <e2>variant angina</e2> and the vasoreactivity of the right coronary artery may be greater than that of the other coronary arteries .
D008755_D002637 NONE The effects of intracoronary administration of <e1>methylergonovine</e1> were studied in 21 patients with variant angina and 22 patients with atypical <e2>chest pain</e2> and in others without angina pectoris ( control group ) .
D008755_D000787 NONE The effects of intracoronary administration of <e1>methylergonovine</e1> were studied in 21 patients with variant angina and 22 patients with atypical chest pain and in others without <e2>angina pectoris</e2> ( control group ) .
D008755_D013035 NONE These results suggest that <e2>spasm</e2> provocation tests , which use an intracoronary injection of a relatively low dose of <e1>methylergonovine</e1> , have a high sensitivity in variant angina and the vasoreactivity of the right coronary artery may be greater than that of the other coronary arteries .
17020434
D014859_D020521 NONE Pooled data from trials comparing antithrombotic treatment with placebo have shown that <e1>warfarin</e1> reduces the risk of <e2>stroke</e2> by 62 % , and that aspirin alone reduces the risk by 22 % .
D014859_D020521 NONE Overall , in high-risk patients , <e1>warfarin</e1> is superior to aspirin in preventing <e2>strokes</e2> , with a relative risk reduction of 36 % .
D001241_D020521 NONE Pooled data from trials comparing antithrombotic treatment with placebo have shown that warfarin reduces the risk of <e2>stroke</e2> by 62 % , and that <e1>aspirin</e1> alone reduces the risk by 22 % .
D001241_D020521 NONE Overall , in high-risk patients , warfarin is superior to <e1>aspirin</e1> in preventing <e2>strokes</e2> , with a relative risk reduction of 36 % .
C426686_D004617 NONE <e1>Ximelagatran</e1> , an oral direct thrombin inhibitor , was found to be as efficient as vitamin K antagonist drugs in the prevention of <e2>embolic events</e2> , but has been recently withdrawn because of abnormal liver function tests .
C426686_D056486 CID <e1>Ximelagatran</e1> , an oral direct thrombin inhibitor , was found to be as efficient as vitamin K antagonist drugs in the prevention of embolic events , but has been recently withdrawn because of <e2>abnormal liver function</e2> tests .
D014812_D004617 NONE Ximelagatran , an oral direct thrombin inhibitor , was found to be as efficient as <e1>vitamin K</e1> antagonist drugs in the prevention of <e2>embolic events</e2> , but has been recently withdrawn because of abnormal liver function tests .
D014812_D056486 NONE Ximelagatran , an oral direct thrombin inhibitor , was found to be as efficient as <e1>vitamin K</e1> antagonist drugs in the prevention of embolic events , but has been recently withdrawn because of <e2>abnormal liver function</e2> tests .
C055162_D001281 NONE The ACTIVE-W ( <e2>Atrial Fibrillation</e2> <e1>Clopidogrel</e1> Trial with Irbesartan for Prevention of Vascular Events ) study has demonstrated that warfarin is superior to platelet therapy ( clopidogrel plus aspirin ) in the prevention af embolic events .
C055162_D001281 NONE The ACTIVE-W ( <e2>Atrial Fibrillation</e2> Clopidogrel Trial with Irbesartan for Prevention of Vascular Events ) study has demonstrated that warfarin is superior to platelet therapy ( <e1>clopidogrel</e1> plus aspirin ) in the prevention af embolic events .
C055162_D004617 NONE The ACTIVE-W ( Atrial Fibrillation <e1>Clopidogrel</e1> Trial with Irbesartan for Prevention of Vascular Events ) study has demonstrated that warfarin is superior to platelet therapy ( clopidogrel plus aspirin ) in the prevention af <e2>embolic events</e2> .
C055162_D004617 NONE The ACTIVE-W ( Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events ) study has demonstrated that warfarin is superior to platelet therapy ( <e1>clopidogrel</e1> plus aspirin ) in the prevention af <e2>embolic events</e2> .
C081309_D001281 NONE The ACTIVE-W ( <e2>Atrial Fibrillation</e2> Clopidogrel Trial with <e1>Irbesartan</e1> for Prevention of Vascular Events ) study has demonstrated that warfarin is superior to platelet therapy ( clopidogrel plus aspirin ) in the prevention af embolic events .
C081309_D004617 NONE The ACTIVE-W ( Atrial Fibrillation Clopidogrel Trial with <e1>Irbesartan</e1> for Prevention of Vascular Events ) study has demonstrated that warfarin is superior to platelet therapy ( clopidogrel plus aspirin ) in the prevention af <e2>embolic events</e2> .
D014859_D001281 NONE The ACTIVE-W ( <e2>Atrial Fibrillation</e2> Clopidogrel Trial with Irbesartan for Prevention of Vascular Events ) study has demonstrated that <e1>warfarin</e1> is superior to platelet therapy ( clopidogrel plus aspirin ) in the prevention af embolic events .
D014859_D004617 NONE The ACTIVE-W ( Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events ) study has demonstrated that <e1>warfarin</e1> is superior to platelet therapy ( clopidogrel plus aspirin ) in the prevention af <e2>embolic events</e2> .
D001241_D001281 NONE The ACTIVE-W ( <e2>Atrial Fibrillation</e2> Clopidogrel Trial with Irbesartan for Prevention of Vascular Events ) study has demonstrated that warfarin is superior to platelet therapy ( clopidogrel plus <e1>aspirin</e1> ) in the prevention af embolic events .
D001241_D004617 NONE The ACTIVE-W ( Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events ) study has demonstrated that warfarin is superior to platelet therapy ( clopidogrel plus <e1>aspirin</e1> ) in the prevention af <e2>embolic events</e2> .
C479958_D001281 NONE <e1>Idraparinux</e1> , a Factor Xa inhibitor , is being evaluated in patients with <e2>atrial fibrillation</e2> .
D000809_D001281 NONE <e1>Angiotensin-converting</e1> enzyme inhibitors and angiotensin II receptor-blocking drugs hold promise in <e2>atrial fibrillation</e2> through cardiac remodelling .
D000809_D020257 NONE <e1>Angiotensin-converting</e1> enzyme inhibitors and angiotensin II receptor-blocking drugs hold promise in atrial fibrillation through <e2>cardiac remodelling</e2> .
D000804_D001281 NONE Angiotensin-converting enzyme inhibitors and <e1>angiotensin II</e1> receptor-blocking drugs hold promise in <e2>atrial fibrillation</e2> through cardiac remodelling .
D000804_D020257 NONE Angiotensin-converting enzyme inhibitors and <e1>angiotensin II</e1> receptor-blocking drugs hold promise in atrial fibrillation through <e2>cardiac remodelling</e2> .
11745184
D002945_D001943 NONE A Phase II trial of <e1>cisplatin</e1> plus WR-2721 ( amifostine ) for metastatic <e2>breast carcinoma</e2> : an Eastern Cooperative Oncology Group Study ( E8188 ) .
D002945_D001943 NONE BACKGROUND : <e1>Cisplatin</e1> has minimal antitumor activity when used as second- or third-line treatment of metastatic <e2>breast carcinoma</e2> .
D002945_D001943 NONE Although a dose-response effect has been observed with <e1>cisplatin</e1> , the dose-limiting toxicities associated with cisplatin ( e.g. , nephrotoxicity , ototoxicity , and neurotoxicity ) have limited its use as a treatment for <e2>breast carcinoma</e2> .
D002945_D001943 NONE Although a dose-response effect has been observed with cisplatin , the dose-limiting toxicities associated with <e1>cisplatin</e1> ( e.g. , nephrotoxicity , ototoxicity , and neurotoxicity ) have limited its use as a treatment for <e2>breast carcinoma</e2> .
D002945_D001943 NONE METHODS : A Phase II study of the combination of <e1>cisplatin</e1> plus amifostine was conducted in patients with progressive metastatic <e2>breast carcinoma</e2> who had received one , but not more than one , chemotherapy regimen for metastatic disease .
D004999_D001943 NONE A Phase II trial of cisplatin plus <e1>WR-2721</e1> ( amifostine ) for metastatic <e2>breast carcinoma</e2> : an Eastern Cooperative Oncology Group Study ( E8188 ) .
D004999_D001943 NONE A Phase II trial of cisplatin plus WR-2721 ( <e1>amifostine</e1> ) for metastatic <e2>breast carcinoma</e2> : an Eastern Cooperative Oncology Group Study ( E8188 ) .
D004999_D001943 NONE METHODS : A Phase II study of the combination of cisplatin plus <e1>amifostine</e1> was conducted in patients with progressive metastatic <e2>breast carcinoma</e2> who had received one , but not more than one , chemotherapy regimen for metastatic disease .
D002945_D064420 NONE Although a dose-response effect has been observed with <e1>cisplatin</e1> , the dose-limiting <e2>toxicities</e2> associated with cisplatin ( e.g. , nephrotoxicity , ototoxicity , and neurotoxicity ) have limited its use as a treatment for breast carcinoma .
D002945_D064420 NONE Although a dose-response effect has been observed with cisplatin , the dose-limiting <e2>toxicities</e2> associated with <e1>cisplatin</e1> ( e.g. , nephrotoxicity , ototoxicity , and neurotoxicity ) have limited its use as a treatment for breast carcinoma .
D002945_D064420 NONE Neither a tumor-protective effect nor reduced <e2>toxicity</e2> to normal tissues was observed with the addition of amifostine to <e1>cisplatin</e1> in this trial .
D002945_D007674 CID Although a dose-response effect has been observed with <e1>cisplatin</e1> , the dose-limiting toxicities associated with cisplatin ( e.g. , <e2>nephrotoxicity</e2> , ototoxicity , and neurotoxicity ) have limited its use as a treatment for breast carcinoma .
D002945_D007674 CID Although a dose-response effect has been observed with cisplatin , the dose-limiting toxicities associated with <e1>cisplatin</e1> ( e.g. , <e2>nephrotoxicity</e2> , ototoxicity , and neurotoxicity ) have limited its use as a treatment for breast carcinoma .
D002945_D007674 CID Early trials of <e1>cisplatin</e1> and amifostine also suggested that the incidence and severity of cisplatin-induced <e2>nephrotoxicity</e2> , ototoxicity , and neuropathy were reduced .
D002945_D007674 CID Early trials of cisplatin and amifostine also suggested that the incidence and severity of <e1>cisplatin-induced</e1> <e2>nephrotoxicity</e2> , ototoxicity , and neuropathy were reduced .
D002945_D006311 CID Although a dose-response effect has been observed with <e1>cisplatin</e1> , the dose-limiting toxicities associated with cisplatin ( e.g. , nephrotoxicity , <e2>ototoxicity</e2> , and neurotoxicity ) have limited its use as a treatment for breast carcinoma .
D002945_D006311 CID Although a dose-response effect has been observed with cisplatin , the dose-limiting toxicities associated with <e1>cisplatin</e1> ( e.g. , nephrotoxicity , <e2>ototoxicity</e2> , and neurotoxicity ) have limited its use as a treatment for breast carcinoma .
D002945_D006311 CID Early trials of <e1>cisplatin</e1> and amifostine also suggested that the incidence and severity of cisplatin-induced nephrotoxicity , <e2>ototoxicity</e2> , and neuropathy were reduced .
D002945_D006311 CID Early trials of cisplatin and amifostine also suggested that the incidence and severity of <e1>cisplatin-induced</e1> nephrotoxicity , <e2>ototoxicity</e2> , and neuropathy were reduced .
D002945_D020258 NONE Although a dose-response effect has been observed with <e1>cisplatin</e1> , the dose-limiting toxicities associated with cisplatin ( e.g. , nephrotoxicity , ototoxicity , and <e2>neurotoxicity</e2> ) have limited its use as a treatment for breast carcinoma .
D002945_D020258 NONE Although a dose-response effect has been observed with cisplatin , the dose-limiting toxicities associated with <e1>cisplatin</e1> ( e.g. , nephrotoxicity , ototoxicity , and <e2>neurotoxicity</e2> ) have limited its use as a treatment for breast carcinoma .
D002945_D009422 CID Early trials of <e1>cisplatin</e1> and amifostine also suggested that the incidence and severity of cisplatin-induced nephrotoxicity , ototoxicity , and <e2>neuropathy</e2> were reduced .
D002945_D009422 CID Early trials of cisplatin and amifostine also suggested that the incidence and severity of <e1>cisplatin-induced</e1> nephrotoxicity , ototoxicity , and <e2>neuropathy</e2> were reduced .
D004999_D007674 NONE Early trials of cisplatin and <e1>amifostine</e1> also suggested that the incidence and severity of cisplatin-induced <e2>nephrotoxicity</e2> , ototoxicity , and neuropathy were reduced .
D004999_D006311 NONE Early trials of cisplatin and <e1>amifostine</e1> also suggested that the incidence and severity of cisplatin-induced nephrotoxicity , <e2>ototoxicity</e2> , and neuropathy were reduced .
D004999_D009422 NONE Early trials of cisplatin and <e1>amifostine</e1> also suggested that the incidence and severity of cisplatin-induced nephrotoxicity , ototoxicity , and <e2>neuropathy</e2> were reduced .
D004999_D009369 NONE Neither a <e2>tumor-protective</e2> effect nor reduced toxicity to normal tissues was observed with the addition of <e1>amifostine</e1> to cisplatin in this trial .
D004999_D064420 NONE Neither a tumor-protective effect nor reduced <e2>toxicity</e2> to normal tissues was observed with the addition of <e1>amifostine</e1> to cisplatin in this trial .
D002945_D009369 NONE Neither a <e2>tumor-protective</e2> effect nor reduced toxicity to normal tissues was observed with the addition of amifostine to <e1>cisplatin</e1> in this trial .
8410052
D019344_D001480 NONE Focal <e2>injury in the cortex</e2> was produced by infusion of <e1>lactate</e1> at acid pH or by stab caused by needle insertion .
D010862_D002544 CID <e2>Infarcts in substantia nigra pars reticulata</e2> were evoked by prolonged <e1>pilocarpine-induced</e1> status epilepticus .
D010862_D013226 CID Infarcts in substantia nigra pars reticulata were evoked by prolonged <e1>pilocarpine-induced</e1> <e2>status epilepticus</e2> .
14657095
D000666_D002311 CID Reversible <e2>dilated cardiomyopathy</e2> related to <e1>amphotericin B</e1> therapy .
D000666_D002311 CID We describe a patient who developed <e2>dilated cardiomyopathy</e2> and clinical congestive heart failure after 2 months of therapy with <e1>amphotericin B</e1> ( AmB ) for disseminated coccidioidomycosis .
D000666_D002311 CID We describe a patient who developed <e2>dilated cardiomyopathy</e2> and clinical congestive heart failure after 2 months of therapy with amphotericin B ( <e1>AmB</e1> ) for disseminated coccidioidomycosis .
D000666_D006333 CID We describe a patient who developed dilated cardiomyopathy and clinical congestive <e2>heart failure</e2> after 2 months of therapy with <e1>amphotericin B</e1> ( AmB ) for disseminated coccidioidomycosis .
D000666_D006333 CID We describe a patient who developed dilated cardiomyopathy and clinical congestive <e2>heart failure</e2> after 2 months of therapy with amphotericin B ( <e1>AmB</e1> ) for disseminated coccidioidomycosis .
D000666_D006333 CID His echocardiographic abnormalities and <e2>heart failure</e2> resolved after posaconazole was substituted for <e1>AmB.</e1> It is important to recognize the rare and potentially reversible toxicity of AmB.
D000666_D006333 CID His echocardiographic abnormalities and <e2>heart failure</e2> resolved after posaconazole was substituted for AmB. It is important to recognize the rare and potentially reversible toxicity of <e1>AmB.</e1>
D000666_D003047 NONE We describe a patient who developed dilated cardiomyopathy and clinical congestive heart failure after 2 months of therapy with <e1>amphotericin B</e1> ( AmB ) for disseminated <e2>coccidioidomycosis</e2> .
D000666_D003047 NONE We describe a patient who developed dilated cardiomyopathy and clinical congestive heart failure after 2 months of therapy with amphotericin B ( <e1>AmB</e1> ) for disseminated <e2>coccidioidomycosis</e2> .
C101425_D006333 NONE His echocardiographic abnormalities and <e2>heart failure</e2> resolved after <e1>posaconazole</e1> was substituted for AmB. It is important to recognize the rare and potentially reversible toxicity of AmB.
C101425_D064420 NONE His echocardiographic abnormalities and heart failure resolved after <e1>posaconazole</e1> was substituted for AmB. It is important to recognize the rare and potentially reversible <e2>toxicity</e2> of AmB.
D000666_D064420 NONE His echocardiographic abnormalities and heart failure resolved after posaconazole was substituted for <e1>AmB.</e1> It is important to recognize the rare and potentially reversible <e2>toxicity</e2> of AmB.
D000666_D064420 NONE His echocardiographic abnormalities and heart failure resolved after posaconazole was substituted for AmB. It is important to recognize the rare and potentially reversible <e2>toxicity</e2> of <e1>AmB.</e1>
2334618
D009020_D001049 NONE The incidence of postoperative respiratory <e2>apnoea</e2> was compared between five patients receiving a continuous i.v. infusion of <e1>morphine</e1> ( mean 73.6 mg ) and five patients receiving a continuous extradural infusion of 0.25 % bupivacaine ( mean 192 mg ) in the 24-h period following upper abdominal surgery .
D002045_D001049 NONE The incidence of postoperative respiratory <e2>apnoea</e2> was compared between five patients receiving a continuous i.v. infusion of morphine ( mean 73.6 mg ) and five patients receiving a continuous extradural infusion of 0.25 % <e1>bupivacaine</e1> ( mean 192 mg ) in the 24-h period following upper abdominal surgery .
D009020_D020181 CID Both <e2>obstructive ( P less than 0.05 ) and central apnoea</e2> ( P less than 0.05 ) occurred more frequently in patients who had a <e1>morphine</e1> infusion .
D009020_D020182 CID Both <e2>obstructive ( P less than 0.05 ) and central apnoea</e2> ( P less than 0.05 ) occurred more frequently in patients who had a <e1>morphine</e1> infusion .
D009020_D013610 NONE There was also a higher incidence of <e2>tachyarrhythmias</e2> ( P less than 0.05 ) and ventricular ectopic beats ( P less than 0.05 ) in the <e1>morphine</e1> infusion group .
D009020_D018879 CID There was also a higher incidence of tachyarrhythmias ( P less than 0.05 ) and <e2>ventricular ectopic beats</e2> ( P less than 0.05 ) in the <e1>morphine</e1> infusion group .
8437969
D002927_D054138 CID <e2>Sinus arrest</e2> associated with continuous-infusion <e1>cimetidine</e1> .
D002927_D054138 CID A 40-year-old man with leukemia and no history of cardiac disease developed recurrent , brief episodes of apparent <e2>sinus arrest</e2> while receiving continuous-infusion <e1>cimetidine</e1> 50 mg/hour .
D002927_D054138 CID This is the first reported case of <e2>sinus arrest</e2> associated with continuous-infusion <e1>cimetidine</e1> .
D002927_D001919 CID The administration of intermittent intravenous infusions of <e1>cimetidine</e1> is infrequently associated with the development of <e2>bradyarrhythmias</e2> .
D002927_D007938 NONE A 40-year-old man with <e2>leukemia</e2> and no history of cardiac disease developed recurrent , brief episodes of apparent sinus arrest while receiving continuous-infusion <e1>cimetidine</e1> 50 mg/hour .
D002927_D006331 NONE A 40-year-old man with leukemia and no history of <e2>cardiac disease</e2> developed recurrent , brief episodes of apparent sinus arrest while receiving continuous-infusion <e1>cimetidine</e1> 50 mg/hour .
D002927_D001145 NONE The <e2>arrhythmias</e2> were temporally related to <e1>cimetidine</e1> administration , disappeared after dechallenge , and did not recur during ranitidine treatment .
D011899_D001145 NONE The <e2>arrhythmias</e2> were temporally related to cimetidine administration , disappeared after dechallenge , and did not recur during <e1>ranitidine</e1> treatment .
2870085
C047847_D013610 NONE <e1>Flestolol</e1> produced a dose-dependent attenuation of isoproterenol-induced <e2>tachycardia</e2> .
D007545_D013610 CID Flestolol produced a dose-dependent attenuation of <e1>isoproterenol-induced</e1> <e2>tachycardia</e2> .
C047847_D013617 NONE <e1>Flestolol</e1> effectively reduced heart rate in patients with <e2>supraventricular tachyarrhythmia</e2> .
C047847_D000789 NONE In patients with <e2>unstable angina</e2> , <e1>flestolol</e1> infusion was found to be safe and effective in controlling chest pain .
C047847_D002637 NONE In patients with unstable angina , <e1>flestolol</e1> infusion was found to be safe and effective in controlling <e2>chest pain</e2> .
7053303
D002927_D003704 CID There was only one case of <e2>dementia</e2> possibly due to <e1>cimetidine</e1> ( with a drug level of 1.9 microgram/ml 6 hr after a dose ) in a group of 13 patients without liver or kidney disease who had cimetidine levels above 1.25 microgram/ml .
D002927_D003704 CID There was only one case of <e2>dementia</e2> possibly due to cimetidine ( with a drug level of 1.9 microgram/ml 6 hr after a dose ) in a group of 13 patients without liver or kidney disease who had <e1>cimetidine</e1> levels above 1.25 microgram/ml .
D002927_D003704 CID Thus , high <e1>cimetidine</e1> levels alone do not always induce <e2>dementia</e2> .
D002927_D008107 NONE There was only one case of dementia possibly due to <e1>cimetidine</e1> ( with a drug level of 1.9 microgram/ml 6 hr after a dose ) in a group of 13 patients without <e2>liver or kidney disease</e2> who had cimetidine levels above 1.25 microgram/ml .
D002927_D008107 NONE There was only one case of dementia possibly due to cimetidine ( with a drug level of 1.9 microgram/ml 6 hr after a dose ) in a group of 13 patients without <e2>liver or kidney disease</e2> who had <e1>cimetidine</e1> levels above 1.25 microgram/ml .
D002927_D007674 NONE There was only one case of dementia possibly due to <e1>cimetidine</e1> ( with a drug level of 1.9 microgram/ml 6 hr after a dose ) in a group of 13 patients without <e2>liver or kidney disease</e2> who had cimetidine levels above 1.25 microgram/ml .
D002927_D007674 NONE There was only one case of dementia possibly due to cimetidine ( with a drug level of 1.9 microgram/ml 6 hr after a dose ) in a group of 13 patients without <e2>liver or kidney disease</e2> who had <e1>cimetidine</e1> levels above 1.25 microgram/ml .
12921865
D013256_D012640 NONE Protective efficacy of neuroactive <e1>steroids</e1> against cocaine <e2>kindled-seizures</e2> in mice .
D013256_D012640 NONE The present study was designed to evaluate two endogenous and one synthetic neuroactive <e1>steroid</e1> that positively modulate the gamma-aminobutyric acid ( GABA(A ) ) receptor against the increase in sensitivity to the convulsant effects of cocaine engendered by repeated cocaine administration ( <e2>seizure</e2> kindling ) .
D003042_D012640 CID Protective efficacy of neuroactive steroids against <e1>cocaine</e1> <e2>kindled-seizures</e2> in mice .
D003042_D012640 CID The present study was designed to evaluate two endogenous and one synthetic neuroactive steroid that positively modulate the gamma-aminobutyric acid ( GABA(A ) ) receptor against the increase in sensitivity to the convulsant effects of <e1>cocaine</e1> engendered by repeated cocaine administration ( <e2>seizure</e2> kindling ) .
D003042_D012640 CID The present study was designed to evaluate two endogenous and one synthetic neuroactive steroid that positively modulate the gamma-aminobutyric acid ( GABA(A ) ) receptor against the increase in sensitivity to the convulsant effects of cocaine engendered by repeated <e1>cocaine</e1> administration ( <e2>seizure</e2> kindling ) .
D003042_D012640 CID Allopregnanolone ( 3alpha-hydroxy-5alpha-pregnan-20-one ) , pregnanolone ( 3alpha-hydroxy-5beta-pregnan-20-one ) and ganaxolone ( a synthetic derivative of allopregnanolone 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one ) were tested for their ability to suppress the expression ( anticonvulsant effect ) and development ( antiepileptogenic effect ) of <e1>cocaine-kindled</e1> <e2>seizures</e2> in male , Swiss-Webster mice .
D003042_D012640 CID Kindled <e2>seizures</e2> were induced by daily administration of 60 mg/kg <e1>cocaine</e1> for 5 days .
D013256_D009422 NONE Neuroactive <e1>steroids</e1> demonstrate pharmacological actions that have relevance for a host of <e2>neurological and psychiatric disorders</e2> .
D013256_D001523 NONE Neuroactive <e1>steroids</e1> demonstrate pharmacological actions that have relevance for a host of <e2>neurological and psychiatric disorders</e2> .
D005680_D012640 NONE The present study was designed to evaluate two endogenous and one synthetic neuroactive steroid that positively modulate the <e1>gamma-aminobutyric acid</e1> ( GABA(A ) ) receptor against the increase in sensitivity to the convulsant effects of cocaine engendered by repeated cocaine administration ( <e2>seizure</e2> kindling ) .
D005680_D012640 NONE The present study was designed to evaluate two endogenous and one synthetic neuroactive steroid that positively modulate the gamma-aminobutyric acid ( <e1>GABA(A</e1> ) ) receptor against the increase in sensitivity to the convulsant effects of cocaine engendered by repeated cocaine administration ( <e2>seizure</e2> kindling ) .
D005680_D012640 NONE All of these positive <e1>GABA(A</e1> ) modulators suppressed the expression of kindled <e2>seizures</e2> , whereas only allopregnanolone and ganaxolone inhibited the development of kindling .
D011280_D012640 NONE <e1>Allopregnanolone</e1> ( 3alpha-hydroxy-5alpha-pregnan-20-one ) , pregnanolone ( 3alpha-hydroxy-5beta-pregnan-20-one ) and ganaxolone ( a synthetic derivative of allopregnanolone 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one ) were tested for their ability to suppress the expression ( anticonvulsant effect ) and development ( antiepileptogenic effect ) of cocaine-kindled <e2>seizures</e2> in male , Swiss-Webster mice .
D011280_D012640 NONE Allopregnanolone ( <e1>3alpha-hydroxy-5alpha-pregnan-20-one</e1> ) , pregnanolone ( 3alpha-hydroxy-5beta-pregnan-20-one ) and ganaxolone ( a synthetic derivative of allopregnanolone 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one ) were tested for their ability to suppress the expression ( anticonvulsant effect ) and development ( antiepileptogenic effect ) of cocaine-kindled <e2>seizures</e2> in male , Swiss-Webster mice .
D011280_D012640 NONE Allopregnanolone ( 3alpha-hydroxy-5alpha-pregnan-20-one ) , <e1>pregnanolone</e1> ( 3alpha-hydroxy-5beta-pregnan-20-one ) and ganaxolone ( a synthetic derivative of allopregnanolone 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one ) were tested for their ability to suppress the expression ( anticonvulsant effect ) and development ( antiepileptogenic effect ) of cocaine-kindled <e2>seizures</e2> in male , Swiss-Webster mice .
D011280_D012640 NONE Allopregnanolone ( 3alpha-hydroxy-5alpha-pregnan-20-one ) , pregnanolone ( <e1>3alpha-hydroxy-5beta-pregnan-20-one</e1> ) and ganaxolone ( a synthetic derivative of allopregnanolone 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one ) were tested for their ability to suppress the expression ( anticonvulsant effect ) and development ( antiepileptogenic effect ) of cocaine-kindled <e2>seizures</e2> in male , Swiss-Webster mice .
D011280_D012640 NONE Allopregnanolone ( 3alpha-hydroxy-5alpha-pregnan-20-one ) , pregnanolone ( 3alpha-hydroxy-5beta-pregnan-20-one ) and ganaxolone ( a synthetic derivative of <e1>allopregnanolone</e1> 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one ) were tested for their ability to suppress the expression ( anticonvulsant effect ) and development ( antiepileptogenic effect ) of cocaine-kindled <e2>seizures</e2> in male , Swiss-Webster mice .
D011280_D012640 NONE All of these positive GABA(A ) modulators suppressed the expression of kindled <e2>seizures</e2> , whereas only <e1>allopregnanolone</e1> and ganaxolone inhibited the development of kindling .
C105051_D012640 NONE Allopregnanolone ( 3alpha-hydroxy-5alpha-pregnan-20-one ) , pregnanolone ( 3alpha-hydroxy-5beta-pregnan-20-one ) and <e1>ganaxolone</e1> ( a synthetic derivative of allopregnanolone 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one ) were tested for their ability to suppress the expression ( anticonvulsant effect ) and development ( antiepileptogenic effect ) of cocaine-kindled <e2>seizures</e2> in male , Swiss-Webster mice .
C105051_D012640 NONE Allopregnanolone ( 3alpha-hydroxy-5alpha-pregnan-20-one ) , pregnanolone ( 3alpha-hydroxy-5beta-pregnan-20-one ) and ganaxolone ( a synthetic derivative of allopregnanolone <e1>3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one</e1> ) were tested for their ability to suppress the expression ( anticonvulsant effect ) and development ( antiepileptogenic effect ) of cocaine-kindled <e2>seizures</e2> in male , Swiss-Webster mice .
C105051_D012640 NONE All of these positive GABA(A ) modulators suppressed the expression of kindled <e2>seizures</e2> , whereas only allopregnanolone and <e1>ganaxolone</e1> inhibited the development of kindling .
16904497
D013256_D011128 NONE <e2>Cauda equina syndrome</e2> after epidural <e1>steroid</e1> injection : a case report .
D013256_D011843 NONE OBJECTIVE : Conventional treatment methods of lumbusacral <e2>radiculopathy</e2> are physical therapy , epidural <e1>steroid</e1> injections , oral medications , and spinal manipulative therapy .
D014221_D011128 NONE The following case is a report of <e2>cauda equina syndrome</e2> possibly caused by epidural injection of <e1>triamcinolone</e1> and bupivacaine .
D002045_D011128 CID The following case is a report of <e2>cauda equina syndrome</e2> possibly caused by epidural injection of triamcinolone and <e1>bupivacaine</e1> .
D013256_D017116 NONE CLINICAL FEATURES : A 50-year-old woman with <e2>low back and right leg pain</e2> was scheduled for epidural <e1>steroid</e1> injection .
D013256_D010146 NONE CLINICAL FEATURES : A 50-year-old woman with <e2>low back and right leg pain</e2> was scheduled for epidural <e1>steroid</e1> injection .
D013256_D009422 NONE Clinical examination and continued vigilance for <e2>neurologic deterioration</e2> after epidural <e1>steroid</e1> injections is important .
12596116
D015282_D000860 NONE <e1>Octreotide-induced</e1> <e2>hypoxemia</e2> and pulmonary hypertension in premature neonates .
D015282_D006976 CID <e1>Octreotide-induced</e1> hypoxemia and <e2>pulmonary hypertension</e2> in premature neonates .
D015282_D006976 CID <e2>Pulmonary hypertension</e2> developed after administration of a somatostatin analogue , <e1>octreotide</e1> , to enhance resolution of the fistula .
D015282_D005402 NONE Pulmonary hypertension developed after administration of a somatostatin analogue , <e1>octreotide</e1> , to enhance resolution of the <e2>fistula</e2> .
16337777
D010862_D004827 NONE Investigation of mitochondrial involvement in the experimental model of <e2>epilepsy</e2> induced by <e1>pilocarpine</e1> .
D010862_D013226 NONE In this study , we investigated whether increased generation of FR during <e2>status epilepticus</e2> would be sufficient to provoke abnormalities in mtDNA and in the expression and activity of cytochrome c oxidase ( CCO ) , complex IV of the respiratory chain , in the chronic phase of the <e1>pilocarpine</e1> model of temporal lobe epilepsy .
D010862_D004833 CID In this study , we investigated whether increased generation of FR during status epilepticus would be sufficient to provoke abnormalities in mtDNA and in the expression and activity of cytochrome c oxidase ( CCO ) , complex IV of the respiratory chain , in the chronic phase of the <e1>pilocarpine</e1> model of <e2>temporal lobe epilepsy</e2> .
18503483
D016559_D020968 CID Recovery of <e1>tacrolimus-associated</e1> <e2>brachial neuritis</e2> after conversion to everolimus in a pediatric renal transplant recipient -- case report and review of the literature .
C107135_D020968 NONE Recovery of tacrolimus-associated <e2>brachial neuritis</e2> after conversion to <e1>everolimus</e1> in a pediatric renal transplant recipient -- case report and review of the literature .
11334364
D000082_D009336 CID In vivo protection of dna damage associated apoptotic and <e2>necrotic</e2> cell deaths during <e1>acetaminophen-induced</e1> nephrotoxicity , amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract .
D000082_D009336 CID Interestingly , all the drugs , such as , <e1>AAP</e1> , AMI and DOX induced apoptotic death in addition to <e2>necrosis</e2> in the respective organs which was very effectively blocked by GSPE .
D000082_D007674 CID In vivo protection of dna damage associated apoptotic and necrotic cell deaths during <e1>acetaminophen-induced</e1> <e2>nephrotoxicity</e2> , amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract .
D000082_D007674 CID This study assessed the ability of IH636 grape seed proanthocyanidin extract ( GSPE ) to prevent <e1>acetaminophen</e1> (AAP)-induced <e2>nephrotoxicity</e2> , amiodarone (AMI)-induced lung toxicity , and doxorubicin (DOX)-induced cardiotoxicity in mice .
D000082_D007674 CID This study assessed the ability of IH636 grape seed proanthocyanidin extract ( GSPE ) to prevent acetaminophen <e1>(AAP)-induced</e1> <e2>nephrotoxicity</e2> , amiodarone (AMI)-induced lung toxicity , and doxorubicin (DOX)-induced cardiotoxicity in mice .
D000082_D008171 NONE In vivo protection of dna damage associated apoptotic and necrotic cell deaths during <e1>acetaminophen-induced</e1> nephrotoxicity , amiodarone-induced <e2>lung toxicity</e2> and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract .
D000082_D008171 NONE This study assessed the ability of IH636 grape seed proanthocyanidin extract ( GSPE ) to prevent <e1>acetaminophen</e1> (AAP)-induced nephrotoxicity , amiodarone (AMI)-induced <e2>lung toxicity</e2> , and doxorubicin (DOX)-induced cardiotoxicity in mice .
D000082_D008171 NONE This study assessed the ability of IH636 grape seed proanthocyanidin extract ( GSPE ) to prevent acetaminophen <e1>(AAP)-induced</e1> nephrotoxicity , amiodarone (AMI)-induced <e2>lung toxicity</e2> , and doxorubicin (DOX)-induced cardiotoxicity in mice .
D000082_D066126 NONE In vivo protection of dna damage associated apoptotic and necrotic cell deaths during <e1>acetaminophen-induced</e1> nephrotoxicity , amiodarone-induced lung toxicity and doxorubicin-induced <e2>cardiotoxicity</e2> by a novel IH636 grape seed proanthocyanidin extract .
D000082_D066126 NONE This study assessed the ability of IH636 grape seed proanthocyanidin extract ( GSPE ) to prevent <e1>acetaminophen</e1> (AAP)-induced nephrotoxicity , amiodarone (AMI)-induced lung toxicity , and doxorubicin (DOX)-induced <e2>cardiotoxicity</e2> in mice .
D000082_D066126 NONE This study assessed the ability of IH636 grape seed proanthocyanidin extract ( GSPE ) to prevent acetaminophen <e1>(AAP)-induced</e1> nephrotoxicity , amiodarone (AMI)-induced lung toxicity , and doxorubicin (DOX)-induced <e2>cardiotoxicity</e2> in mice .
D000638_D009336 CID In vivo protection of dna damage associated apoptotic and <e2>necrotic</e2> cell deaths during acetaminophen-induced nephrotoxicity , <e1>amiodarone-induced</e1> lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract .
D000638_D009336 CID Interestingly , all the drugs , such as , AAP , <e1>AMI</e1> and DOX induced apoptotic death in addition to <e2>necrosis</e2> in the respective organs which was very effectively blocked by GSPE .
D000638_D007674 NONE In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced <e2>nephrotoxicity</e2> , <e1>amiodarone-induced</e1> lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract .
D000638_D007674 NONE This study assessed the ability of IH636 grape seed proanthocyanidin extract ( GSPE ) to prevent acetaminophen (AAP)-induced <e2>nephrotoxicity</e2> , <e1>amiodarone</e1> (AMI)-induced lung toxicity , and doxorubicin (DOX)-induced cardiotoxicity in mice .
D000638_D007674 NONE This study assessed the ability of IH636 grape seed proanthocyanidin extract ( GSPE ) to prevent acetaminophen (AAP)-induced <e2>nephrotoxicity</e2> , amiodarone <e1>(AMI)-induced</e1> lung toxicity , and doxorubicin (DOX)-induced cardiotoxicity in mice .
D000638_D008171 CID In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity , <e1>amiodarone-induced</e1> <e2>lung toxicity</e2> and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract .
D000638_D008171 CID This study assessed the ability of IH636 grape seed proanthocyanidin extract ( GSPE ) to prevent acetaminophen (AAP)-induced nephrotoxicity , <e1>amiodarone</e1> (AMI)-induced <e2>lung toxicity</e2> , and doxorubicin (DOX)-induced cardiotoxicity in mice .
D000638_D008171 CID This study assessed the ability of IH636 grape seed proanthocyanidin extract ( GSPE ) to prevent acetaminophen (AAP)-induced nephrotoxicity , amiodarone <e1>(AMI)-induced</e1> <e2>lung toxicity</e2> , and doxorubicin (DOX)-induced cardiotoxicity in mice .
D000638_D066126 NONE In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity , <e1>amiodarone-induced</e1> lung toxicity and doxorubicin-induced <e2>cardiotoxicity</e2> by a novel IH636 grape seed proanthocyanidin extract .
D000638_D066126 NONE This study assessed the ability of IH636 grape seed proanthocyanidin extract ( GSPE ) to prevent acetaminophen (AAP)-induced nephrotoxicity , <e1>amiodarone</e1> (AMI)-induced lung toxicity , and doxorubicin (DOX)-induced <e2>cardiotoxicity</e2> in mice .
D000638_D066126 NONE This study assessed the ability of IH636 grape seed proanthocyanidin extract ( GSPE ) to prevent acetaminophen (AAP)-induced nephrotoxicity , amiodarone <e1>(AMI)-induced</e1> lung toxicity , and doxorubicin (DOX)-induced <e2>cardiotoxicity</e2> in mice .
D004317_D009336 CID In vivo protection of dna damage associated apoptotic and <e2>necrotic</e2> cell deaths during acetaminophen-induced nephrotoxicity , amiodarone-induced lung toxicity and <e1>doxorubicin-induced</e1> cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract .
D004317_D009336 CID Interestingly , all the drugs , such as , AAP , AMI and <e1>DOX</e1> induced apoptotic death in addition to <e2>necrosis</e2> in the respective organs which was very effectively blocked by GSPE .
D004317_D007674 NONE In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced <e2>nephrotoxicity</e2> , amiodarone-induced lung toxicity and <e1>doxorubicin-induced</e1> cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract .
D004317_D007674 NONE This study assessed the ability of IH636 grape seed proanthocyanidin extract ( GSPE ) to prevent acetaminophen (AAP)-induced <e2>nephrotoxicity</e2> , amiodarone (AMI)-induced lung toxicity , and <e1>doxorubicin</e1> (DOX)-induced cardiotoxicity in mice .
D004317_D007674 NONE This study assessed the ability of IH636 grape seed proanthocyanidin extract ( GSPE ) to prevent acetaminophen (AAP)-induced <e2>nephrotoxicity</e2> , amiodarone (AMI)-induced lung toxicity , and doxorubicin <e1>(DOX)-induced</e1> cardiotoxicity in mice .
D004317_D008171 NONE In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity , amiodarone-induced <e2>lung toxicity</e2> and <e1>doxorubicin-induced</e1> cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract .
D004317_D008171 NONE This study assessed the ability of IH636 grape seed proanthocyanidin extract ( GSPE ) to prevent acetaminophen (AAP)-induced nephrotoxicity , amiodarone (AMI)-induced <e2>lung toxicity</e2> , and <e1>doxorubicin</e1> (DOX)-induced cardiotoxicity in mice .
D004317_D008171 NONE This study assessed the ability of IH636 grape seed proanthocyanidin extract ( GSPE ) to prevent acetaminophen (AAP)-induced nephrotoxicity , amiodarone (AMI)-induced <e2>lung toxicity</e2> , and doxorubicin <e1>(DOX)-induced</e1> cardiotoxicity in mice .
D004317_D066126 CID In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity , amiodarone-induced lung toxicity and <e1>doxorubicin-induced</e1> <e2>cardiotoxicity</e2> by a novel IH636 grape seed proanthocyanidin extract .
D004317_D066126 CID This study assessed the ability of IH636 grape seed proanthocyanidin extract ( GSPE ) to prevent acetaminophen (AAP)-induced nephrotoxicity , amiodarone (AMI)-induced lung toxicity , and <e1>doxorubicin</e1> (DOX)-induced <e2>cardiotoxicity</e2> in mice .
D004317_D066126 CID This study assessed the ability of IH636 grape seed proanthocyanidin extract ( GSPE ) to prevent acetaminophen (AAP)-induced nephrotoxicity , amiodarone (AMI)-induced lung toxicity , and doxorubicin <e1>(DOX)-induced</e1> <e2>cardiotoxicity</e2> in mice .
C511402_D009336 NONE In vivo protection of dna damage associated apoptotic and <e2>necrotic</e2> cell deaths during acetaminophen-induced nephrotoxicity , amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel <e1>IH636 grape seed proanthocyanidin extract</e1> .
C511402_D009336 NONE Interestingly , all the drugs , such as , AAP , AMI and DOX induced apoptotic death in addition to <e2>necrosis</e2> in the respective organs which was very effectively blocked by <e1>GSPE</e1> .
C511402_D007674 NONE In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced <e2>nephrotoxicity</e2> , amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel <e1>IH636 grape seed proanthocyanidin extract</e1> .
C511402_D007674 NONE This study assessed the ability of <e1>IH636 grape seed proanthocyanidin extract</e1> ( GSPE ) to prevent acetaminophen (AAP)-induced <e2>nephrotoxicity</e2> , amiodarone (AMI)-induced lung toxicity , and doxorubicin (DOX)-induced cardiotoxicity in mice .
C511402_D007674 NONE This study assessed the ability of IH636 grape seed proanthocyanidin extract ( <e1>GSPE</e1> ) to prevent acetaminophen (AAP)-induced <e2>nephrotoxicity</e2> , amiodarone (AMI)-induced lung toxicity , and doxorubicin (DOX)-induced cardiotoxicity in mice .
C511402_D008171 NONE In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity , amiodarone-induced <e2>lung toxicity</e2> and doxorubicin-induced cardiotoxicity by a novel <e1>IH636 grape seed proanthocyanidin extract</e1> .
C511402_D008171 NONE This study assessed the ability of <e1>IH636 grape seed proanthocyanidin extract</e1> ( GSPE ) to prevent acetaminophen (AAP)-induced nephrotoxicity , amiodarone (AMI)-induced <e2>lung toxicity</e2> , and doxorubicin (DOX)-induced cardiotoxicity in mice .
C511402_D008171 NONE This study assessed the ability of IH636 grape seed proanthocyanidin extract ( <e1>GSPE</e1> ) to prevent acetaminophen (AAP)-induced nephrotoxicity , amiodarone (AMI)-induced <e2>lung toxicity</e2> , and doxorubicin (DOX)-induced cardiotoxicity in mice .
C511402_D066126 NONE In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity , amiodarone-induced lung toxicity and doxorubicin-induced <e2>cardiotoxicity</e2> by a novel <e1>IH636 grape seed proanthocyanidin extract</e1> .
C511402_D066126 NONE This study assessed the ability of <e1>IH636 grape seed proanthocyanidin extract</e1> ( GSPE ) to prevent acetaminophen (AAP)-induced nephrotoxicity , amiodarone (AMI)-induced lung toxicity , and doxorubicin (DOX)-induced <e2>cardiotoxicity</e2> in mice .
C511402_D066126 NONE This study assessed the ability of IH636 grape seed proanthocyanidin extract ( <e1>GSPE</e1> ) to prevent acetaminophen (AAP)-induced nephrotoxicity , amiodarone (AMI)-induced lung toxicity , and doxorubicin (DOX)-induced <e2>cardiotoxicity</e2> in mice .
C511402_D017695 NONE Histopathological examination of kidney , heart and lung sections revealed moderate to massive <e2>tissue damage</e2> with a variety of morphological aberrations by all the three drugs in the absence of <e1>GSPE</e1> preexposure than in its presence .
19346865
D008795_D001927 CID Reversible <e2>inferior colliculus lesion</e2> in <e1>metronidazole-induced</e1> encephalopathy : magnetic resonance findings on diffusion-weighted and fluid attenuated inversion recovery imaging .
D008795_D001927 CID Reversible inferior colliculus lesion in <e1>metronidazole-induced</e1> <e2>encephalopathy</e2> : magnetic resonance findings on diffusion-weighted and fluid attenuated inversion recovery imaging .
D008795_D001927 CID OBJECTIVE : This is to present reversible <e2>inferior colliculus lesions</e2> in <e1>metronidazole-induced</e1> encephalopathy , to focus on the diffusion-weighted imaging ( DWI ) and fluid attenuated inversion recovery ( FLAIR ) imaging .
D008795_D001927 CID OBJECTIVE : This is to present reversible inferior colliculus lesions in <e1>metronidazole-induced</e1> <e2>encephalopathy</e2> , to focus on the diffusion-weighted imaging ( DWI ) and fluid attenuated inversion recovery ( FLAIR ) imaging .
D008795_D001927 CID MATERIALS AND METHODS : From November 2005 to September 2007 , 8 patients ( 5 men and 3 women ) were diagnosed as having <e1>metronidazole-induced</e1> <e2>encephalopathy</e2> ( age range ; 43 - 78 years ) .
D008795_D001927 CID CONCLUSIONS : Reversible <e2>inferior colliculus lesions</e2> could be considered as the characteristic for <e1>metronidazole-induced</e1> encephalopathy , next to the dentate nucleus involvement .
D008795_D001927 CID CONCLUSIONS : Reversible inferior colliculus lesions could be considered as the characteristic for <e1>metronidazole-induced</e1> <e2>encephalopathy</e2> , next to the dentate nucleus involvement .
D008795_D007239 NONE They had been taking <e1>metronidazole</e1> ( total dosage , 45 - 120 g ; duration , 30 days to 2 months ) to treat the <e2>infection</e2> in various organs .
3970039
D000477_D015470 CID Patients treated with <e1>alkylating agents</e1> have an increased risk of development of <e2>acute nonlymphocytic leukemia</e2> , and both alkylating agents and azathioprine are associated with the development of non-Hodgkin 's lymphoma .
D000477_D015470 CID Patients treated with alkylating agents have an increased risk of development of <e2>acute nonlymphocytic leukemia</e2> , and both <e1>alkylating agents</e1> and azathioprine are associated with the development of non-Hodgkin 's lymphoma .
D000477_D008228 CID Patients treated with <e1>alkylating agents</e1> have an increased risk of development of acute nonlymphocytic leukemia , and both alkylating agents and azathioprine are associated with the development of <e2>non-Hodgkin 's lymphoma</e2> .
D000477_D008228 CID Patients treated with alkylating agents have an increased risk of development of acute nonlymphocytic leukemia , and both <e1>alkylating agents</e1> and azathioprine are associated with the development of <e2>non-Hodgkin 's lymphoma</e2> .
D001379_D015470 NONE Patients treated with alkylating agents have an increased risk of development of <e2>acute nonlymphocytic leukemia</e2> , and both alkylating agents and <e1>azathioprine</e1> are associated with the development of non-Hodgkin 's lymphoma .
D001379_D008228 CID Patients treated with alkylating agents have an increased risk of development of acute nonlymphocytic leukemia , and both alkylating agents and <e1>azathioprine</e1> are associated with the development of <e2>non-Hodgkin 's lymphoma</e2> .
D003520_D001749 CID <e1>Cyclophosphamide</e1> therapy increases the risk of <e2>carcinoma of the bladder</e2> .
D003520_D002277 CID <e1>Cyclophosphamide</e1> therapy increases the risk of <e2>carcinoma of the bladder</e2> .
D001379_D001172 NONE There have been several long-term studies of patients with <e2>rheumatoid arthritis</e2> treated with <e1>azathioprine</e1> and cyclophosphamide and the incidence of most of the common cancers is not increased .
D001379_D009369 NONE There have been several long-term studies of patients with rheumatoid arthritis treated with <e1>azathioprine</e1> and cyclophosphamide and the incidence of most of the common <e2>cancers</e2> is not increased .
D003520_D001172 NONE There have been several long-term studies of patients with <e2>rheumatoid arthritis</e2> treated with azathioprine and <e1>cyclophosphamide</e1> and the incidence of most of the common cancers is not increased .
D003520_D009369 NONE There have been several long-term studies of patients with rheumatoid arthritis treated with azathioprine and <e1>cyclophosphamide</e1> and the incidence of most of the common <e2>cancers</e2> is not increased .
D000477_D009369 NONE Data on the possible increased risk of <e2>malignancy</e2> in rheumatoid arthritis are still being collected , and until further information is available , the use of immunosuppressive drugs , particularly <e1>alkylating agents</e1> , in the treatment of rheumatoid arthritis should be reserved for patients with severe progressive disease or life-threatening complications .
D000477_D001172 NONE Data on the possible increased risk of malignancy in <e2>rheumatoid arthritis</e2> are still being collected , and until further information is available , the use of immunosuppressive drugs , particularly <e1>alkylating agents</e1> , in the treatment of rheumatoid arthritis should be reserved for patients with severe progressive disease or life-threatening complications .
D000477_D001172 NONE Data on the possible increased risk of malignancy in rheumatoid arthritis are still being collected , and until further information is available , the use of immunosuppressive drugs , particularly <e1>alkylating agents</e1> , in the treatment of <e2>rheumatoid arthritis</e2> should be reserved for patients with severe progressive disease or life-threatening complications .
2266990
D008454_D020388 NONE Randomized , double-blind trial of <e1>mazindol</e1> in <e2>Duchenne dystrophy</e2> .
D008454_D020388 NONE We conducted a 12-month controlled trial of <e1>mazindol</e1> , a putative growth hormone secretion inhibitor , in 83 boys with <e2>Duchenne dystrophy</e2> .
D008454_D020388 NONE <e1>Mazindol</e1> doses not slow the progression of weakness in <e2>Duchenne dystrophy</e2> .
D008454_D001068 CID Side effects attributable to <e1>mazindol</e1> included <e2>decreased appetite</e2> ( 36 % ) , dry mouth ( 10 % ) , behavioral change ( 22 % ) , and gastrointestinal symptoms ( 18 % ) ; mazindol dosage was reduced in 43 % of patients .
D008454_D001068 CID Side effects attributable to mazindol included <e2>decreased appetite</e2> ( 36 % ) , dry mouth ( 10 % ) , behavioral change ( 22 % ) , and gastrointestinal symptoms ( 18 % ) ; <e1>mazindol</e1> dosage was reduced in 43 % of patients .
D008454_D014987 CID Side effects attributable to <e1>mazindol</e1> included decreased appetite ( 36 % ) , <e2>dry mouth</e2> ( 10 % ) , behavioral change ( 22 % ) , and gastrointestinal symptoms ( 18 % ) ; mazindol dosage was reduced in 43 % of patients .
D008454_D014987 CID Side effects attributable to mazindol included decreased appetite ( 36 % ) , <e2>dry mouth</e2> ( 10 % ) , behavioral change ( 22 % ) , and gastrointestinal symptoms ( 18 % ) ; <e1>mazindol</e1> dosage was reduced in 43 % of patients .
D008454_D012817 CID Side effects attributable to <e1>mazindol</e1> included decreased appetite ( 36 % ) , dry mouth ( 10 % ) , behavioral change ( 22 % ) , and <e2>gastrointestinal symptoms</e2> ( 18 % ) ; mazindol dosage was reduced in 43 % of patients .
D008454_D012817 CID Side effects attributable to mazindol included decreased appetite ( 36 % ) , dry mouth ( 10 % ) , behavioral change ( 22 % ) , and <e2>gastrointestinal symptoms</e2> ( 18 % ) ; <e1>mazindol</e1> dosage was reduced in 43 % of patients .
D008454_D018908 NONE <e1>Mazindol</e1> doses not slow the progression of <e2>weakness</e2> in Duchenne dystrophy .
6861444
D009638_D006973 CID Intrarenal infusion of <e1>noradrenaline</e1> caused <e2>hypertension</e2> at doses which did not do so when infused intravenously .
D009638_D006973 CID These results suggest that <e2>hypertension</e2> after chronic intrarenal <e1>noradrenaline</e1> infusion is produced by relatively higher levels of circulating noradrenaline and by triggering of an additional intrarenal pressor mechanism .
D009638_D006973 CID These results suggest that <e2>hypertension</e2> after chronic intrarenal noradrenaline infusion is produced by relatively higher levels of circulating <e1>noradrenaline</e1> and by triggering of an additional intrarenal pressor mechanism .
137340
D009020_D006948 CID Effect of humoral modulators of <e1>morphine-induced</e1> <e2>increase in locomotor activity</e2> of mice .
D009020_D006948 CID The effect of humoral modulators on the <e1>morphine-induced</e1> <e2>increase in locomotor activity</e2> of mice was studied .
D009020_D006948 CID The subcutaneous administration of 10 mg/kg of <e1>morphine-HC1</e1> produced a marked <e2>increase in locomotor activity</e2> in mice .
D009020_D006948 CID The <e1>morphine-induced</e1> <e2>hyperactivity</e2> was potentiated by scopolamine and attenuated by physostigmine .
D009020_D006948 CID In contrast , both methscopolamine and neostigmine , which do not penetrate the blood-brain barrier , had no effect on the <e2>hyperactivity</e2> produced by <e1>morphine</e1> .
D012601_D006948 CID The morphine-induced <e2>hyperactivity</e2> was potentiated by <e1>scopolamine</e1> and attenuated by physostigmine .
D010830_D006948 NONE The morphine-induced <e2>hyperactivity</e2> was potentiated by scopolamine and attenuated by <e1>physostigmine</e1> .
D019832_D006948 NONE In contrast , both <e1>methscopolamine</e1> and neostigmine , which do not penetrate the blood-brain barrier , had no effect on the <e2>hyperactivity</e2> produced by morphine .
D009388_D006948 NONE In contrast , both methscopolamine and <e1>neostigmine</e1> , which do not penetrate the blood-brain barrier , had no effect on the <e2>hyperactivity</e2> produced by morphine .
D010134_D006948 NONE On the other hand , pretreatment with <e1>p-chlorophenylalamine</e1> ( 3 X 320 mg/kg i.p. , 24 hr ) , a serotonin depletor , caused no significant change in the <e2>hyperactivity</e2> .
D012701_D006948 NONE On the other hand , pretreatment with p-chlorophenylalamine ( 3 X 320 mg/kg i.p. , 24 hr ) , a <e1>serotonin</e1> depletor , caused no significant change in the <e2>hyperactivity</e2> .
227508
D003000_D006973 NONE In unanesthetized , spontaneously <e2>hypertensive</e2> rats the decrease in blood pressure and heart rate produced by intravenous <e1>clonidine</e1> , 5 to 20 micrograms/kg , was inhibited or reversed by nalozone , 0.2 to 2 mg/kg .
D003000_D006973 NONE In brain membranes from spontaneously <e2>hypertensive</e2> rats <e1>clonidine</e1> , 10(-8 ) to 10(-5 ) M , did not influence stereoselective binding of [3H]-naloxone ( 8 nM ) , and naloxone , 10(-8 ) to 10(-4 ) M , did not influence clonidine-suppressible binding of [3H]-dihydroergocryptine ( 1 nM ) .
D003000_D006973 NONE In brain membranes from spontaneously <e2>hypertensive</e2> rats clonidine , 10(-8 ) to 10(-5 ) M , did not influence stereoselective binding of [3H]-naloxone ( 8 nM ) , and naloxone , 10(-8 ) to 10(-4 ) M , did not influence <e1>clonidine-suppressible</e1> binding of [3H]-dihydroergocryptine ( 1 nM ) .
-1_D006973 NONE In unanesthetized , spontaneously <e2>hypertensive</e2> rats the decrease in blood pressure and heart rate produced by intravenous clonidine , 5 to 20 micrograms/kg , was inhibited or reversed by <e1>nalozone</e1> , 0.2 to 2 mg/kg .
-1_D006973 NONE In brain membranes from spontaneously <e2>hypertensive</e2> rats clonidine , 10(-8 ) to 10(-5 ) M , did not influence stereoselective binding of <e1>[3H]-naloxone</e1> ( 8 nM ) , and naloxone , 10(-8 ) to 10(-4 ) M , did not influence clonidine-suppressible binding of [3H]-dihydroergocryptine ( 1 nM ) .
-1_D006973 NONE In brain membranes from spontaneously <e2>hypertensive</e2> rats clonidine , 10(-8 ) to 10(-5 ) M , did not influence stereoselective binding of [3H]-naloxone ( 8 nM ) , and naloxone , 10(-8 ) to 10(-4 ) M , did not influence clonidine-suppressible binding of <e1>[3H]-dihydroergocryptine</e1> ( 1 nM ) .
D008750_D007022 CID The <e2>hypotensive</e2> effect of 100 mg/kg <e1>alpha-methyldopa</e1> was also partially reversed by naloxone .
D009270_D007022 NONE The <e2>hypotensive</e2> effect of 100 mg/kg alpha-methyldopa was also partially reversed by <e1>naloxone</e1> .
D009270_D006973 NONE In brain membranes from spontaneously <e2>hypertensive</e2> rats clonidine , 10(-8 ) to 10(-5 ) M , did not influence stereoselective binding of [3H]-naloxone ( 8 nM ) , and <e1>naloxone</e1> , 10(-8 ) to 10(-4 ) M , did not influence clonidine-suppressible binding of [3H]-dihydroergocryptine ( 1 nM ) .
16680561
D003891_D009325 CID Fewer subjects reported adverse events following treatment with <e1>desipramine</e1> alone than when receiving desipramine with cinacalcet ( 33 versus 86 % ) , the most frequent of which ( <e2>nausea</e2> and headache ) have been reported for patients treated with either desipramine or cinacalcet .
D003891_D009325 CID Fewer subjects reported adverse events following treatment with desipramine alone than when receiving <e1>desipramine</e1> with cinacalcet ( 33 versus 86 % ) , the most frequent of which ( <e2>nausea</e2> and headache ) have been reported for patients treated with either desipramine or cinacalcet .
D003891_D009325 CID Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with cinacalcet ( 33 versus 86 % ) , the most frequent of which ( <e2>nausea</e2> and headache ) have been reported for patients treated with either <e1>desipramine</e1> or cinacalcet .
D003891_D006261 CID Fewer subjects reported adverse events following treatment with <e1>desipramine</e1> alone than when receiving desipramine with cinacalcet ( 33 versus 86 % ) , the most frequent of which ( nausea and <e2>headache</e2> ) have been reported for patients treated with either desipramine or cinacalcet .
D003891_D006261 CID Fewer subjects reported adverse events following treatment with desipramine alone than when receiving <e1>desipramine</e1> with cinacalcet ( 33 versus 86 % ) , the most frequent of which ( nausea and <e2>headache</e2> ) have been reported for patients treated with either desipramine or cinacalcet .
D003891_D006261 CID Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with cinacalcet ( 33 versus 86 % ) , the most frequent of which ( nausea and <e2>headache</e2> ) have been reported for patients treated with either <e1>desipramine</e1> or cinacalcet .
C476217_D009325 CID Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with <e1>cinacalcet</e1> ( 33 versus 86 % ) , the most frequent of which ( <e2>nausea</e2> and headache ) have been reported for patients treated with either desipramine or cinacalcet .
C476217_D009325 CID Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with cinacalcet ( 33 versus 86 % ) , the most frequent of which ( <e2>nausea</e2> and headache ) have been reported for patients treated with either desipramine or <e1>cinacalcet</e1> .
C476217_D006261 CID Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with <e1>cinacalcet</e1> ( 33 versus 86 % ) , the most frequent of which ( nausea and <e2>headache</e2> ) have been reported for patients treated with either desipramine or cinacalcet .
C476217_D006261 CID Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with cinacalcet ( 33 versus 86 % ) , the most frequent of which ( nausea and <e2>headache</e2> ) have been reported for patients treated with either desipramine or <e1>cinacalcet</e1> .
7881871
D011692_D007674 CID Time course of lipid peroxidation in <e1>puromycin aminonucleoside-induced</e1> <e2>nephropathy</e2> .
D011692_D007674 CID Reactive oxygen species have been implicated in the pathogenesis of acute <e1>puromycin aminonucleoside</e1> (PAN)-induced <e2>nephropathy</e2> , with antioxidants significantly reducing the proteinuria .
D011692_D007674 CID Reactive oxygen species have been implicated in the pathogenesis of acute puromycin aminonucleoside <e1>(PAN)-induced</e1> <e2>nephropathy</e2> , with antioxidants significantly reducing the proteinuria .
D011692_D007674 CID This study supports the role of lipid peroxidation in mediating the proteinuric injury in <e1>PAN</e1> <e2>nephropathy</e2> .
D010100_D007674 NONE Reactive <e1>oxygen</e1> species have been implicated in the pathogenesis of acute puromycin aminonucleoside (PAN)-induced <e2>nephropathy</e2> , with antioxidants significantly reducing the proteinuria .
D010100_D011507 NONE Reactive <e1>oxygen</e1> species have been implicated in the pathogenesis of acute puromycin aminonucleoside (PAN)-induced nephropathy , with antioxidants significantly reducing the <e2>proteinuria</e2> .
D011692_D011507 CID Reactive oxygen species have been implicated in the pathogenesis of acute <e1>puromycin aminonucleoside</e1> (PAN)-induced nephropathy , with antioxidants significantly reducing the <e2>proteinuria</e2> .
D011692_D011507 CID Reactive oxygen species have been implicated in the pathogenesis of acute puromycin aminonucleoside <e1>(PAN)-induced</e1> nephropathy , with antioxidants significantly reducing the <e2>proteinuria</e2> .
D011692_D011507 CID This study supports the role of lipid peroxidation in mediating the <e2>proteinuric injury</e2> in <e1>PAN</e1> nephropathy .
16740173
6666578
D010396_D001018 CID <e1>D-penicillamine-induced</e1> <e2>angiopathy</e2> in rats .
9249847
D014700_D013611 CID Iatrogenically induced intractable <e2>atrioventricular reentrant tachycardia</e2> after <e1>verapamil</e1> and catheter ablation in a patient with Wolff-Parkinson-White syndrome and idiopathic dilated cardiomyopathy .
D014700_D013611 CID QRS without preexcitation , caused by junctional escape beats after <e1>verapamil</e1> or unidirectional antegrade block of accessory pathway after catheter ablation , established frequent <e2>AVRT</e2> attack .
D014700_D014927 NONE Iatrogenically induced intractable atrioventricular reentrant tachycardia after <e1>verapamil</e1> and catheter ablation in a patient with <e2>Wolff-Parkinson-White syndrome</e2> and idiopathic dilated cardiomyopathy .
D014700_D002311 NONE Iatrogenically induced intractable atrioventricular reentrant tachycardia after <e1>verapamil</e1> and catheter ablation in a patient with Wolff-Parkinson-White syndrome and <e2>idiopathic dilated cardiomyopathy</e2> .
3107448
D005905_D056486 CID <e1>Glyburide-induced</e1> <e2>hepatitis</e2> .
D005905_D056486 CID For <e1>glyburide</e1> , a second-generation sulfonylurea , only two brief reports of <e2>hepatotoxicity</e2> exist .
D005905_D056486 CID Two patients with type II diabetes mellitus developed an <e2>acute hepatitis-like syndrome</e2> soon after initiation of <e1>glyburide</e1> therapy .
D005905_D056486 CID <e1>Glyburide</e1> can produce an <e2>acute hepatitis-like illness</e2> in some persons .
D013453_D056486 NONE Drug-induced <e2>hepatotoxicity</e2> , although common , has been reported only infrequently with <e1>sulfonylureas</e1> .
D013453_D056486 NONE For glyburide , a second-generation <e1>sulfonylurea</e1> , only two brief reports of <e2>hepatotoxicity</e2> exist .
D005905_D003924 NONE Two patients with <e2>type II diabetes mellitus</e2> developed an acute hepatitis-like syndrome soon after initiation of <e1>glyburide</e1> therapy .
6387529
D003975_D016584 NONE Behavioral effects of <e1>diazepam</e1> and propranolol in patients with <e2>panic disorder</e2> and agoraphobia .
D003975_D016584 NONE The effects of oral doses of <e1>diazepam</e1> ( single dose of 10 mg and a median dose of 30 mg/day for 2 weeks ) and propranolol ( single dose of 80 mg and a median dose of 240 mg/day for 2 weeks ) on psychological performance of patients with <e2>panic disorders</e2> and agoraphobia were investigated in a double-blind , randomized and crossover design .
D003975_D000379 NONE Behavioral effects of <e1>diazepam</e1> and propranolol in patients with panic disorder and <e2>agoraphobia</e2> .
D003975_D000379 NONE The effects of oral doses of <e1>diazepam</e1> ( single dose of 10 mg and a median dose of 30 mg/day for 2 weeks ) and propranolol ( single dose of 80 mg and a median dose of 240 mg/day for 2 weeks ) on psychological performance of patients with panic disorders and <e2>agoraphobia</e2> were investigated in a double-blind , randomized and crossover design .
D011433_D016584 NONE Behavioral effects of diazepam and <e1>propranolol</e1> in patients with <e2>panic disorder</e2> and agoraphobia .
D011433_D016584 NONE The effects of oral doses of diazepam ( single dose of 10 mg and a median dose of 30 mg/day for 2 weeks ) and <e1>propranolol</e1> ( single dose of 80 mg and a median dose of 240 mg/day for 2 weeks ) on psychological performance of patients with <e2>panic disorders</e2> and agoraphobia were investigated in a double-blind , randomized and crossover design .
D011433_D000379 NONE Behavioral effects of diazepam and <e1>propranolol</e1> in patients with panic disorder and <e2>agoraphobia</e2> .
D011433_D000379 NONE The effects of oral doses of diazepam ( single dose of 10 mg and a median dose of 30 mg/day for 2 weeks ) and <e1>propranolol</e1> ( single dose of 80 mg and a median dose of 240 mg/day for 2 weeks ) on psychological performance of patients with panic disorders and <e2>agoraphobia</e2> were investigated in a double-blind , randomized and crossover design .
D003975_D008569 CID Both drugs <e2>impaired immediate free recall</e2> but the decrease was greater for <e1>diazepam</e1> than propranolol .
D011433_D008569 CID Both drugs <e2>impaired immediate free recall</e2> but the decrease was greater for diazepam than <e1>propranolol</e1> .
18083142
D009638_D001008 NONE <e1>Norepinephrine</e1> signaling through beta-adrenergic receptors is critical for expression of cocaine-induced <e2>anxiety</e2> .
D009638_D001008 NONE METHODS : In this study , we evaluated the performance of dopamine beta-hydroxylase knockout ( Dbh -/- ) mice , which lack <e1>norepinephrine</e1> ( NE ) , in the elevated plus maze ( EPM ) to examine the contribution of noradrenergic signaling to cocaine-induced <e2>anxiety</e2> .
D009638_D001008 NONE METHODS : In this study , we evaluated the performance of dopamine beta-hydroxylase knockout ( Dbh -/- ) mice , which lack norepinephrine ( <e1>NE</e1> ) , in the elevated plus maze ( EPM ) to examine the contribution of noradrenergic signaling to cocaine-induced <e2>anxiety</e2> .
D003042_D001008 CID Norepinephrine signaling through beta-adrenergic receptors is critical for expression of <e1>cocaine-induced</e1> <e2>anxiety</e2> .
D003042_D001008 CID While the mechanisms underlying <e1>cocaine</e1> 's rewarding effects have been studied extensively , less attention has been paid to the unpleasant behavioral states induced by cocaine , such as <e2>anxiety</e2> .
D003042_D001008 CID While the mechanisms underlying cocaine 's rewarding effects have been studied extensively , less attention has been paid to the unpleasant behavioral states induced by <e1>cocaine</e1> , such as <e2>anxiety</e2> .
D003042_D001008 CID METHODS : In this study , we evaluated the performance of dopamine beta-hydroxylase knockout ( Dbh -/- ) mice , which lack norepinephrine ( NE ) , in the elevated plus maze ( EPM ) to examine the contribution of noradrenergic signaling to <e1>cocaine-induced</e1> <e2>anxiety</e2> .
D003042_D001008 CID RESULTS : We found that <e1>cocaine</e1> dose-dependently increased <e2>anxiety-like</e2> behavior in control ( Dbh +/- ) mice , as measured by a decrease in open arm exploration .
D003042_D001008 CID <e1>Cocaine-induced</e1> <e2>anxiety</e2> was also attenuated in Dbh +/- mice following administration of disulfiram , a dopamine beta-hydroxylase ( DBH ) inhibitor .
D003042_D001008 CID In experiments using specific adrenergic antagonists , we found that pretreatment with the beta-adrenergic receptor antagonist propranolol blocked <e1>cocaine-induced</e1> <e2>anxiety-like</e2> behavior in Dbh +/- and wild-type C57BL6/J mice , while the alpha(1 ) antagonist prazosin and the alpha(2 ) antagonist yohimbine had no effect .
D003042_D001008 CID CONCLUSIONS : These results indicate that noradrenergic signaling via beta-adrenergic receptors is required for <e1>cocaine-induced</e1> <e2>anxiety</e2> in mice .
D004298_D001008 NONE METHODS : In this study , we evaluated the performance of <e1>dopamine</e1> beta-hydroxylase knockout ( Dbh -/- ) mice , which lack norepinephrine ( NE ) , in the elevated plus maze ( EPM ) to examine the contribution of noradrenergic signaling to cocaine-induced <e2>anxiety</e2> .
D004298_D001008 NONE Cocaine-induced <e2>anxiety</e2> was also attenuated in Dbh +/- mice following administration of disulfiram , a <e1>dopamine</e1> beta-hydroxylase ( DBH ) inhibitor .
D004221_D001008 NONE Cocaine-induced <e2>anxiety</e2> was also attenuated in Dbh +/- mice following administration of <e1>disulfiram</e1> , a dopamine beta-hydroxylase ( DBH ) inhibitor .
D011433_D001008 NONE In experiments using specific adrenergic antagonists , we found that pretreatment with the beta-adrenergic receptor antagonist <e1>propranolol</e1> blocked cocaine-induced <e2>anxiety-like</e2> behavior in Dbh +/- and wild-type C57BL6/J mice , while the alpha(1 ) antagonist prazosin and the alpha(2 ) antagonist yohimbine had no effect .
D011224_D001008 NONE In experiments using specific adrenergic antagonists , we found that pretreatment with the beta-adrenergic receptor antagonist propranolol blocked cocaine-induced <e2>anxiety-like</e2> behavior in Dbh +/- and wild-type C57BL6/J mice , while the alpha(1 ) antagonist <e1>prazosin</e1> and the alpha(2 ) antagonist yohimbine had no effect .
D015016_D001008 NONE In experiments using specific adrenergic antagonists , we found that pretreatment with the beta-adrenergic receptor antagonist propranolol blocked cocaine-induced <e2>anxiety-like</e2> behavior in Dbh +/- and wild-type C57BL6/J mice , while the alpha(1 ) antagonist prazosin and the alpha(2 ) antagonist <e1>yohimbine</e1> had no effect .
3173180
D008795_D006463 CID <e2>Haemolytic-uraemic syndrome</e2> after treatment with <e1>metronidazole</e1> .
D008795_D006463 CID This paper describes the clinical features of six children who developed the <e2>haemolytic-uraemic syndrome</e2> after treatment with <e1>metronidazole</e1> .
D008795_D006463 CID While the involvement of <e1>metronidazole</e1> in the aetiology of the <e2>haemolytic-uraemic syndrome</e2> is not established firmly , the action of this drug in sensitizing tissues to oxidation injury and the reported evidence of oxidation changes in the haemolytic-uraemic syndrome suggest a possible link between metronidazole treatment and some cases of the haemolytic-uraemic syndrome .
D008795_D006463 CID While the involvement of <e1>metronidazole</e1> in the aetiology of the haemolytic-uraemic syndrome is not established firmly , the action of this drug in sensitizing tissues to oxidation injury and the reported evidence of oxidation changes in the <e2>haemolytic-uraemic syndrome</e2> suggest a possible link between metronidazole treatment and some cases of the haemolytic-uraemic syndrome .
D008795_D006463 CID While the involvement of <e1>metronidazole</e1> in the aetiology of the haemolytic-uraemic syndrome is not established firmly , the action of this drug in sensitizing tissues to oxidation injury and the reported evidence of oxidation changes in the haemolytic-uraemic syndrome suggest a possible link between metronidazole treatment and some cases of the <e2>haemolytic-uraemic syndrome</e2> .
D008795_D006463 CID While the involvement of metronidazole in the aetiology of the <e2>haemolytic-uraemic syndrome</e2> is not established firmly , the action of this drug in sensitizing tissues to oxidation injury and the reported evidence of oxidation changes in the haemolytic-uraemic syndrome suggest a possible link between <e1>metronidazole</e1> treatment and some cases of the haemolytic-uraemic syndrome .
D008795_D006463 CID While the involvement of metronidazole in the aetiology of the haemolytic-uraemic syndrome is not established firmly , the action of this drug in sensitizing tissues to oxidation injury and the reported evidence of oxidation changes in the <e2>haemolytic-uraemic syndrome</e2> suggest a possible link between <e1>metronidazole</e1> treatment and some cases of the haemolytic-uraemic syndrome .
D008795_D006463 CID While the involvement of metronidazole in the aetiology of the haemolytic-uraemic syndrome is not established firmly , the action of this drug in sensitizing tissues to oxidation injury and the reported evidence of oxidation changes in the haemolytic-uraemic syndrome suggest a possible link between <e1>metronidazole</e1> treatment and some cases of the <e2>haemolytic-uraemic syndrome</e2> .
2578334
D001374_D011230 CID <e1>5-azacytidine</e1> potentiates <e2>initiation induced by carcinogens</e2> in rat liver .
D001374_D011230 CID To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the <e2>initiation of carcinogenic process</e2> , <e1>5-azacytidine</e1> ( 5-AzC ) ( 10 mg/kg ) , an inhibitor of DNA methylation , was given to rats during the phase of repair synthesis induced by the three carcinogens , benzo[a]-pyrene ( 200 mg/kg ) , N-methyl-N-nitrosourea ( 60 mg/kg ) and 1,2-dimethylhydrazine ( 1,2-DMH ) ( 100 mg/kg ) .
D001374_D011230 CID To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the <e2>initiation of carcinogenic process</e2> , 5-azacytidine ( <e1>5-AzC</e1> ) ( 10 mg/kg ) , an inhibitor of DNA methylation , was given to rats during the phase of repair synthesis induced by the three carcinogens , benzo[a]-pyrene ( 200 mg/kg ) , N-methyl-N-nitrosourea ( 60 mg/kg ) and 1,2-dimethylhydrazine ( 1,2-DMH ) ( 100 mg/kg ) .
D001564_D011230 CID To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the <e2>initiation of carcinogenic process</e2> , 5-azacytidine ( 5-AzC ) ( 10 mg/kg ) , an inhibitor of DNA methylation , was given to rats during the phase of repair synthesis induced by the three carcinogens , <e1>benzo[a]-pyrene</e1> ( 200 mg/kg ) , N-methyl-N-nitrosourea ( 60 mg/kg ) and 1,2-dimethylhydrazine ( 1,2-DMH ) ( 100 mg/kg ) .
D008770_D011230 CID To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the <e2>initiation of carcinogenic process</e2> , 5-azacytidine ( 5-AzC ) ( 10 mg/kg ) , an inhibitor of DNA methylation , was given to rats during the phase of repair synthesis induced by the three carcinogens , benzo[a]-pyrene ( 200 mg/kg ) , <e1>N-methyl-N-nitrosourea</e1> ( 60 mg/kg ) and 1,2-dimethylhydrazine ( 1,2-DMH ) ( 100 mg/kg ) .
D019813_D011230 CID To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the <e2>initiation of carcinogenic process</e2> , 5-azacytidine ( 5-AzC ) ( 10 mg/kg ) , an inhibitor of DNA methylation , was given to rats during the phase of repair synthesis induced by the three carcinogens , benzo[a]-pyrene ( 200 mg/kg ) , N-methyl-N-nitrosourea ( 60 mg/kg ) and <e1>1,2-dimethylhydrazine</e1> ( 1,2-DMH ) ( 100 mg/kg ) .
D019813_D011230 CID To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the <e2>initiation of carcinogenic process</e2> , 5-azacytidine ( 5-AzC ) ( 10 mg/kg ) , an inhibitor of DNA methylation , was given to rats during the phase of repair synthesis induced by the three carcinogens , benzo[a]-pyrene ( 200 mg/kg ) , N-methyl-N-nitrosourea ( 60 mg/kg ) and 1,2-dimethylhydrazine ( <e1>1,2-DMH</e1> ) ( 100 mg/kg ) .
8669433
D000082_D007676 NONE Habitual use of <e1>acetaminophen</e1> as a risk factor for <e2>chronic renal failure</e2> : a comparison with phenacetin .
D000082_D007676 NONE However , three case control studies , one each in North Carolina , northern Maryland , and West Berlin , Germany , showed that habitual use of <e1>acetaminophen</e1> is also associated with <e2>chronic renal failure</e2> and ESRD , with a relative risk in the range of 2 to 4 .
D000082_D007676 NONE However , three case control studies , one each in North Carolina , northern Maryland , and West Berlin , Germany , showed that habitual use of <e1>acetaminophen</e1> is also associated with chronic renal failure and <e2>ESRD</e2> , with a relative risk in the range of 2 to 4 .
D000082_D007676 NONE These studies suggest that both phenacetin and <e1>acetaminophen</e1> may contribute to the burden of <e2>ESRD</e2> , with the risk of the latter being somewhat less than that of the former .
D000082_D007676 NONE The possibility that habitual use of <e1>acetaminophen</e1> alone increases the risk of <e2>ESRD</e2> has not been clearly demonstrated , but can not be dismissed .
D010615_D007676 CID Habitual use of acetaminophen as a risk factor for <e2>chronic renal failure</e2> : a comparison with <e1>phenacetin</e1> .
D010615_D007676 CID Six epidemiologic studies in the United States and Europe indicate that habitual use of <e1>phenacetin</e1> is associated with the development of <e2>chronic renal failure</e2> and end-stage renal disease ( ESRD ) , with a relative risk in the range of 4 to 19 .
D010615_D007676 CID Six epidemiologic studies in the United States and Europe indicate that habitual use of <e1>phenacetin</e1> is associated with the development of chronic renal failure and <e2>end-stage renal disease</e2> ( ESRD ) , with a relative risk in the range of 4 to 19 .
D010615_D007676 CID Six epidemiologic studies in the United States and Europe indicate that habitual use of <e1>phenacetin</e1> is associated with the development of chronic renal failure and end-stage renal disease ( <e2>ESRD</e2> ) , with a relative risk in the range of 4 to 19 .
D010615_D007676 CID These studies suggest that both <e1>phenacetin</e1> and acetaminophen may contribute to the burden of <e2>ESRD</e2> , with the risk of the latter being somewhat less than that of the former .
8741744
D009538_D009069 NONE Compared with sham-operated controls , lesions significantly ( p < 0.25 ) blunted the early ( < 60 min ) free-field <e2>locomotor hypoactivity</e2> caused by <e1>nicotine</e1> ( 0.5 mg kg(-1 ) , i.m. ) , enhanced the later ( 60 - 120 min ) nicotine-induced hyperactivity , and raised spontaneous nocturnal activity .
D009538_D009069 NONE Compared with sham-operated controls , lesions significantly ( p < 0.25 ) blunted the early ( < 60 min ) free-field <e2>locomotor hypoactivity</e2> caused by nicotine ( 0.5 mg kg(-1 ) , i.m. ) , enhanced the later ( 60 - 120 min ) <e1>nicotine-induced</e1> hyperactivity , and raised spontaneous nocturnal activity .
D009538_D006948 CID Compared with sham-operated controls , lesions significantly ( p < 0.25 ) blunted the early ( < 60 min ) free-field locomotor hypoactivity caused by <e1>nicotine</e1> ( 0.5 mg kg(-1 ) , i.m. ) , enhanced the later ( 60 - 120 min ) nicotine-induced <e2>hyperactivity</e2> , and raised spontaneous nocturnal activity .
D009538_D006948 CID Compared with sham-operated controls , lesions significantly ( p < 0.25 ) blunted the early ( < 60 min ) free-field locomotor hypoactivity caused by nicotine ( 0.5 mg kg(-1 ) , i.m. ) , enhanced the later ( 60 - 120 min ) <e1>nicotine-induced</e1> <e2>hyperactivity</e2> , and raised spontaneous nocturnal activity .
2894766
D012460_D008180 CID <e1>Sulfasalazine-induced</e1> <e2>lupus erythematosus</e2> .
D012460_D008180 CID It is suggested that the patient had <e1>sulfasalazine-induced</e1> <e2>lupus</e2> , which manifested with serositis and pulmonary parenchymal involvement in the absence of joint symptoms .
D012460_D008180 CID Physicians who use <e1>sulfasalazine</e1> to treat patients with inflammatory bowel disease should be aware of the signs of sulfasalazine-induced <e2>lupus syndrome</e2> .
D012460_D008180 CID Physicians who use sulfasalazine to treat patients with inflammatory bowel disease should be aware of the signs of <e1>sulfasalazine-induced</e1> <e2>lupus syndrome</e2> .
D012460_D011014 CID <e2>Pneumonitis</e2> , bilateral pleural effusions , echocardiographic evidence of cardiac tamponade , and positive autoantibodies developed in a 43-year-old man , who was receiving long-term <e1>sulfasalazine</e1> therapy for chronic ulcerative colitis .
D012460_D010996 CID Pneumonitis , bilateral <e2>pleural effusions</e2> , echocardiographic evidence of cardiac tamponade , and positive autoantibodies developed in a 43-year-old man , who was receiving long-term <e1>sulfasalazine</e1> therapy for chronic ulcerative colitis .
D012460_D002305 CID Pneumonitis , bilateral pleural effusions , echocardiographic evidence of <e2>cardiac tamponade</e2> , and positive autoantibodies developed in a 43-year-old man , who was receiving long-term <e1>sulfasalazine</e1> therapy for chronic ulcerative colitis .
D012460_D003093 NONE Pneumonitis , bilateral pleural effusions , echocardiographic evidence of cardiac tamponade , and positive autoantibodies developed in a 43-year-old man , who was receiving long-term <e1>sulfasalazine</e1> therapy for chronic <e2>ulcerative colitis</e2> .
D012460_D012700 NONE It is suggested that the patient had <e1>sulfasalazine-induced</e1> lupus , which manifested with <e2>serositis</e2> and pulmonary parenchymal involvement in the absence of joint symptoms .
D012460_D015212 NONE Physicians who use <e1>sulfasalazine</e1> to treat patients with <e2>inflammatory bowel disease</e2> should be aware of the signs of sulfasalazine-induced lupus syndrome .
D012460_D015212 NONE Physicians who use sulfasalazine to treat patients with <e2>inflammatory bowel disease</e2> should be aware of the signs of <e1>sulfasalazine-induced</e1> lupus syndrome .
19729346
D010098_D010146 NONE This study measured the objective and subjective neurocognitive effects of a single 10-mg dose of immediate-release <e1>oxycodone</e1> in healthy , older ( > 65 years ) , and middle-aged ( 35 to 55 years ) adults who were not suffering from chronic or significant daily <e2>pain</e2> .
D010098_D059350 NONE This study suggests that for healthy older adults who are not suffering from <e2>chronic pain</e2> , neurocognitive and pharmacodynamic changes in response to a 10-mg dose of immediate-release <e1>oxycodone</e1> are similar to those observed for middle-aged adults .
14513889
D007654_D009422 NONE <e1>Ketoconazole-induced</e1> <e2>neurologic sequelae</e2> .
D007654_D018908 CID A 77-y-old patient developed <e2>weakness of extremities</e2> , legs paralysis , dysarthria and tremor 1 h after ingestion of 200 mg <e1>ketoconazole</e1> for the first time in his life .
D007654_D010243 CID A 77-y-old patient developed weakness of extremities , <e2>legs paralysis</e2> , dysarthria and tremor 1 h after ingestion of 200 mg <e1>ketoconazole</e1> for the first time in his life .
D007654_D004401 CID A 77-y-old patient developed weakness of extremities , legs paralysis , <e2>dysarthria</e2> and tremor 1 h after ingestion of 200 mg <e1>ketoconazole</e1> for the first time in his life .
D007654_D014202 CID A 77-y-old patient developed weakness of extremities , legs paralysis , dysarthria and <e2>tremor</e2> 1 h after ingestion of 200 mg <e1>ketoconazole</e1> for the first time in his life .
20633755
D013390_D001049 CID <e1>Suxamethonium</e1> induced prolonged <e2>apnea</e2> in a patient receiving electroconvulsive therapy .
D013390_D001049 CID <e1>Suxamethonium</e1> causes prolonged <e2>apnea</e2> in patients in whom pseudocholinesterase enzyme gets deactivated by organophosphorus ( OP ) poisons .
D009943_D001049 CID Suxamethonium causes prolonged <e2>apnea</e2> in patients in whom pseudocholinesterase enzyme gets deactivated by <e1>organophosphorus ( OP ) poisons</e1> .
D009943_D001049 CID Prolonged <e2>apnea</e2> in our case ensued because the information about suicidal attempt by <e1>OP compound</e1> was concealed from the treating team .
8319760
D019808_D009401 NONE <e1>Dup 753</e1> prevents the development of puromycin aminonucleoside-induced <e2>nephrosis</e2> .
D011692_D009401 NONE Dup 753 prevents the development of <e1>puromycin aminonucleoside-induced</e1> <e2>nephrosis</e2> .
D011692_D009401 NONE The results suggest a possible involvement of the renin-angiotensin system in the development of <e1>puromycin aminonucleoside-induced</e1> <e2>nephrosis</e2> .
D001806_D009404 NONE The appearance of <e2>nephrotic syndromes</e2> such as proteinuria , hypoalbuminemia , hypercholesterolemia and increase in <e1>blood nitrogen urea</e1> , induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 ( losartan ) , a novel angiotensin II receptor antagonist , at a dose of 1 or 2 mg/kg per day .
D001806_D011507 NONE The appearance of nephrotic syndromes such as <e2>proteinuria</e2> , hypoalbuminemia , hypercholesterolemia and increase in <e1>blood nitrogen urea</e1> , induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 ( losartan ) , a novel angiotensin II receptor antagonist , at a dose of 1 or 2 mg/kg per day .
D001806_D034141 NONE The appearance of nephrotic syndromes such as proteinuria , <e2>hypoalbuminemia</e2> , hypercholesterolemia and increase in <e1>blood nitrogen urea</e1> , induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 ( losartan ) , a novel angiotensin II receptor antagonist , at a dose of 1 or 2 mg/kg per day .
D001806_D006937 NONE The appearance of nephrotic syndromes such as proteinuria , hypoalbuminemia , <e2>hypercholesterolemia</e2> and increase in <e1>blood nitrogen urea</e1> , induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 ( losartan ) , a novel angiotensin II receptor antagonist , at a dose of 1 or 2 mg/kg per day .
D011692_D009404 CID The appearance of <e2>nephrotic syndromes</e2> such as proteinuria , hypoalbuminemia , hypercholesterolemia and increase in blood nitrogen urea , induced in rats by injection of <e1>puromycin aminonucleoside</e1> was markedly inhibited by oral administration of Dup 753 ( losartan ) , a novel angiotensin II receptor antagonist , at a dose of 1 or 2 mg/kg per day .
D011692_D011507 CID The appearance of nephrotic syndromes such as <e2>proteinuria</e2> , hypoalbuminemia , hypercholesterolemia and increase in blood nitrogen urea , induced in rats by injection of <e1>puromycin aminonucleoside</e1> was markedly inhibited by oral administration of Dup 753 ( losartan ) , a novel angiotensin II receptor antagonist , at a dose of 1 or 2 mg/kg per day .
D011692_D034141 CID The appearance of nephrotic syndromes such as proteinuria , <e2>hypoalbuminemia</e2> , hypercholesterolemia and increase in blood nitrogen urea , induced in rats by injection of <e1>puromycin aminonucleoside</e1> was markedly inhibited by oral administration of Dup 753 ( losartan ) , a novel angiotensin II receptor antagonist , at a dose of 1 or 2 mg/kg per day .
D011692_D006937 CID The appearance of nephrotic syndromes such as proteinuria , hypoalbuminemia , <e2>hypercholesterolemia</e2> and increase in blood nitrogen urea , induced in rats by injection of <e1>puromycin aminonucleoside</e1> was markedly inhibited by oral administration of Dup 753 ( losartan ) , a novel angiotensin II receptor antagonist , at a dose of 1 or 2 mg/kg per day .
D019808_D009404 NONE The appearance of <e2>nephrotic syndromes</e2> such as proteinuria , hypoalbuminemia , hypercholesterolemia and increase in blood nitrogen urea , induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of <e1>Dup 753</e1> ( losartan ) , a novel angiotensin II receptor antagonist , at a dose of 1 or 2 mg/kg per day .
D019808_D009404 NONE The appearance of <e2>nephrotic syndromes</e2> such as proteinuria , hypoalbuminemia , hypercholesterolemia and increase in blood nitrogen urea , induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 ( <e1>losartan</e1> ) , a novel angiotensin II receptor antagonist , at a dose of 1 or 2 mg/kg per day .
D019808_D011507 NONE The appearance of nephrotic syndromes such as <e2>proteinuria</e2> , hypoalbuminemia , hypercholesterolemia and increase in blood nitrogen urea , induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of <e1>Dup 753</e1> ( losartan ) , a novel angiotensin II receptor antagonist , at a dose of 1 or 2 mg/kg per day .
D019808_D011507 NONE The appearance of nephrotic syndromes such as <e2>proteinuria</e2> , hypoalbuminemia , hypercholesterolemia and increase in blood nitrogen urea , induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 ( <e1>losartan</e1> ) , a novel angiotensin II receptor antagonist , at a dose of 1 or 2 mg/kg per day .
D019808_D034141 NONE The appearance of nephrotic syndromes such as proteinuria , <e2>hypoalbuminemia</e2> , hypercholesterolemia and increase in blood nitrogen urea , induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of <e1>Dup 753</e1> ( losartan ) , a novel angiotensin II receptor antagonist , at a dose of 1 or 2 mg/kg per day .
D019808_D034141 NONE The appearance of nephrotic syndromes such as proteinuria , <e2>hypoalbuminemia</e2> , hypercholesterolemia and increase in blood nitrogen urea , induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 ( <e1>losartan</e1> ) , a novel angiotensin II receptor antagonist , at a dose of 1 or 2 mg/kg per day .
D019808_D006937 NONE The appearance of nephrotic syndromes such as proteinuria , hypoalbuminemia , <e2>hypercholesterolemia</e2> and increase in blood nitrogen urea , induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of <e1>Dup 753</e1> ( losartan ) , a novel angiotensin II receptor antagonist , at a dose of 1 or 2 mg/kg per day .
D019808_D006937 NONE The appearance of nephrotic syndromes such as proteinuria , hypoalbuminemia , <e2>hypercholesterolemia</e2> and increase in blood nitrogen urea , induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 ( <e1>losartan</e1> ) , a novel angiotensin II receptor antagonist , at a dose of 1 or 2 mg/kg per day .
D000804_D009404 NONE The appearance of <e2>nephrotic syndromes</e2> such as proteinuria , hypoalbuminemia , hypercholesterolemia and increase in blood nitrogen urea , induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 ( losartan ) , a novel <e1>angiotensin II</e1> receptor antagonist , at a dose of 1 or 2 mg/kg per day .
D000804_D011507 NONE The appearance of nephrotic syndromes such as <e2>proteinuria</e2> , hypoalbuminemia , hypercholesterolemia and increase in blood nitrogen urea , induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 ( losartan ) , a novel <e1>angiotensin II</e1> receptor antagonist , at a dose of 1 or 2 mg/kg per day .
D000804_D034141 NONE The appearance of nephrotic syndromes such as proteinuria , <e2>hypoalbuminemia</e2> , hypercholesterolemia and increase in blood nitrogen urea , induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 ( losartan ) , a novel <e1>angiotensin II</e1> receptor antagonist , at a dose of 1 or 2 mg/kg per day .
D000804_D006937 NONE The appearance of nephrotic syndromes such as proteinuria , hypoalbuminemia , <e2>hypercholesterolemia</e2> and increase in blood nitrogen urea , induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 ( losartan ) , a novel <e1>angiotensin II</e1> receptor antagonist , at a dose of 1 or 2 mg/kg per day .
D000809_D009401 NONE The results suggest a possible involvement of the <e1>renin-angiotensin</e1> system in the development of puromycin aminonucleoside-induced <e2>nephrosis</e2> .
11147747
D018490_D014549 CID <e1>Serotonergic antidepressants</e1> and <e2>urinary incontinence</e2> .
D018490_D014549 CID Animal studies suggest that <e2>incontinence</e2> secondary to <e1>serotonergic antidepressants</e1> could be mediated by the 5HT4 receptors found on the bladder .
C047426_D014549 CID This concerns 2 male patients who experienced <e2>incontinence</e2> while taking <e1>venlafaxine</e1> .
C047426_D014549 CID In the present paper the authors describe 2 female patients who developed <e2>incontinence</e2> secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline , as well as a third who developed this side effect on <e1>venlafaxine</e1> .
D012701_D014549 NONE In the present paper the authors describe 2 female patients who developed <e2>incontinence</e2> secondary to the selective <e1>serotonin</e1> reuptake inhibitors paroxetine and sertraline , as well as a third who developed this side effect on venlafaxine .
D017374_D014549 CID In the present paper the authors describe 2 female patients who developed <e2>incontinence</e2> secondary to the selective serotonin reuptake inhibitors <e1>paroxetine</e1> and sertraline , as well as a third who developed this side effect on venlafaxine .
D020280_D014549 CID In the present paper the authors describe 2 female patients who developed <e2>incontinence</e2> secondary to the selective serotonin reuptake inhibitors paroxetine and <e1>sertraline</e1> , as well as a third who developed this side effect on venlafaxine .
D016651_D014549 CID In 2 of the 3 cases the patients were also taking <e1>lithium carbonate</e1> and beta-blockers , both of which could have contributed to the <e2>incontinence</e2> .
20882060
D009496_D002375 NONE Effects of pallidal <e1>neurotensin</e1> on haloperidol-induced <e2>parkinsonian catalepsy</e2> : behavioral and electrophysiological studies .
D009496_D002375 NONE RESULTS : Bilateral infusions of <e1>neurotensin</e1> into the globus pallidus reversed haloperidol-induced <e2>parkinsonian catalepsy</e2> in rats .
D006220_D002375 CID Effects of pallidal neurotensin on <e1>haloperidol-induced</e1> <e2>parkinsonian catalepsy</e2> : behavioral and electrophysiological studies .
D006220_D002375 CID RESULTS : Bilateral infusions of neurotensin into the globus pallidus reversed <e1>haloperidol-induced</e1> <e2>parkinsonian catalepsy</e2> in rats .
D009496_D010302 NONE The present study aimed to investigate the effects of pallidal <e1>neurotensin</e1> on haloperidol-induced <e2>parkinsonian symptoms</e2> .
D006220_D010302 NONE The present study aimed to investigate the effects of pallidal neurotensin on <e1>haloperidol-induced</e1> <e2>parkinsonian symptoms</e2> .
3496378
D014217_D002779 CID Prolonged <e2>cholestasis</e2> after <e1>troleandomycin-induced</e1> acute hepatitis .
D014217_D002779 CID We report the case of a patient in whom <e1>troleandomycin-induced</e1> hepatitis was followed by prolonged anicteric <e2>cholestasis</e2> .
D014217_D002779 CID This observation demonstrates that prolonged <e2>cholestasis</e2> can follow <e1>troleandomycin-induced</e1> acute hepatitis .
D014217_D056486 CID Prolonged cholestasis after <e1>troleandomycin-induced</e1> acute <e2>hepatitis</e2> .
D014217_D056486 CID We report the case of a patient in whom <e1>troleandomycin-induced</e1> <e2>hepatitis</e2> was followed by prolonged anicteric cholestasis .
D014217_D056486 CID This observation demonstrates that prolonged cholestasis can follow <e1>troleandomycin-induced</e1> acute <e2>hepatitis</e2> .
D014217_D007565 CID <e2>Jaundice</e2> occurred after administration of <e1>troleandomycin</e1> for 7 days and was associated with hypereosinophilia .
D014217_D004802 CID Jaundice occurred after administration of <e1>troleandomycin</e1> for 7 days and was associated with <e2>hypereosinophilia</e2> .
16005948
-1_D062787 NONE Evaluation of the anticocaine monoclonal antibody <e1>GNC92H2</e1> as an immunotherapy for <e2>cocaine overdose</e2> .
-1_D062787 NONE The therapeutic potential of the anticocaine antibody <e1>GNC92H2</e1> was examined using a model of <e2>cocaine overdose</e2> .
-1_D062787 NONE The results support the important potential of <e1>GNC92H2</e1> as a therapeutic tool against <e2>cocaine overdose</e2> .
D003042_D062787 NONE The illicit use of <e1>cocaine</e1> continues in epidemic proportions and treatment for <e2>cocaine overdose</e2> remains elusive .
D003042_D064420 NONE Significant blockade of <e1>cocaine</e1> <e2>toxicity</e2> was observed with the higher dose of GNC92H2 ( 190 mg/kg ) , where premorbid behaviors were reduced up to 40 % , seizures up to 77 % and death by 72 % .
D003042_D012640 CID Significant blockade of <e1>cocaine</e1> toxicity was observed with the higher dose of GNC92H2 ( 190 mg/kg ) , where premorbid behaviors were reduced up to 40 % , <e2>seizures</e2> up to 77 % and death by 72 % .
D003042_D003643 NONE Significant blockade of <e1>cocaine</e1> toxicity was observed with the higher dose of GNC92H2 ( 190 mg/kg ) , where premorbid behaviors were reduced up to 40 % , seizures up to 77 % and <e2>death</e2> by 72 % .
D003042_D003643 NONE Importantly , GNC92H2 prevented <e2>death</e2> even <e1>post-cocaine</e1> injection .
-1_D064420 NONE Significant blockade of cocaine <e2>toxicity</e2> was observed with the higher dose of <e1>GNC92H2</e1> ( 190 mg/kg ) , where premorbid behaviors were reduced up to 40 % , seizures up to 77 % and death by 72 % .
-1_D012640 NONE Significant blockade of cocaine toxicity was observed with the higher dose of <e1>GNC92H2</e1> ( 190 mg/kg ) , where premorbid behaviors were reduced up to 40 % , <e2>seizures</e2> up to 77 % and death by 72 % .
-1_D003643 NONE Significant blockade of cocaine toxicity was observed with the higher dose of <e1>GNC92H2</e1> ( 190 mg/kg ) , where premorbid behaviors were reduced up to 40 % , seizures up to 77 % and <e2>death</e2> by 72 % .
-1_D003643 NONE Importantly , <e1>GNC92H2</e1> prevented <e2>death</e2> even post-cocaine injection .
11897407
C067171_D009203 NONE <e1>99mTc-glucarate</e1> for detection of isoproterenol-induced <e2>myocardial infarction</e2> in rats .
C067171_D009203 NONE <e1>99mTc-glucarate</e1> was easy to prepare , stable for 96 h and was used to study its biodistribution in rats with isoproterenol-induced acute <e2>myocardial infarction</e2> .
D007545_D009203 CID 99mTc-glucarate for detection of <e1>isoproterenol-induced</e1> <e2>myocardial infarction</e2> in rats .
D007545_D009203 CID 99mTc-glucarate was easy to prepare , stable for 96 h and was used to study its biodistribution in rats with <e1>isoproterenol-induced</e1> acute <e2>myocardial infarction</e2> .
D007545_D007238 NONE The animal model used to produce <e2>infarction</e2> implies artery ligation but chemical induction can be easily obtained with <e1>isoproterenol</e1> .
D007545_D007238 NONE Histological studies demonstrated that the rats developed an <e2>infarct</e2> 18 h after <e1>isoproterenol</e1> administration .
D005937_D007238 NONE A new <e2>infarct-avid</e2> radiopharmaceutical based on <e1>glucaric acid</e1> was prepared in the hospital radiopharmacy of the INCMNSZ .
567256
D004054_D006394 CID <e2>Angiosarcoma of the liver</e2> associated with <e1>diethylstilbestrol</e1> .
D004054_D006394 CID <e2>Angiosarcoma of the liver</e2> occurred in a 76-year-old man who had been treated for a well-differentiated adenocarcinoma of the liver with <e1>diethylstilbestrol</e1> for 13 years .
D004054_D008113 CID <e2>Angiosarcoma of the liver</e2> associated with <e1>diethylstilbestrol</e1> .
D004054_D008113 CID <e2>Angiosarcoma of the liver</e2> occurred in a 76-year-old man who had been treated for a well-differentiated adenocarcinoma of the liver with <e1>diethylstilbestrol</e1> for 13 years .
D004054_D008113 NONE Angiosarcoma of the liver occurred in a 76-year-old man who had been treated for a well-differentiated <e2>adenocarcinoma of the liver</e2> with <e1>diethylstilbestrol</e1> for 13 years .
D004054_D000230 NONE Angiosarcoma of the liver occurred in a 76-year-old man who had been treated for a well-differentiated <e2>adenocarcinoma of the liver</e2> with <e1>diethylstilbestrol</e1> for 13 years .
15515654
D003676_D006311 NONE No <e2>ototoxic</e2> factor , other than <e1>DFO</e1> , was present in any of the patients .
D003676_D006319 CID Subjects with <e2>SNHL</e2> were submitted to <e1>DFO</e1> reduction or temporary withdrawal .
D003676_D034381 NONE CONCLUSION : The findings are indicative of <e1>DFO</e1> 's contributing role in the development of <e2>hearing impairment</e2> .
18162529
D012313_D006966 NONE Hypothalamic prolactin receptor messenger <e1>ribonucleic acid</e1> levels , prolactin signaling , and <e2>hyperprolactinemic</e2> inhibition of pulsatile luteinizing hormone secretion are dependent on estradiol .
D004958_D006966 NONE Hypothalamic prolactin receptor messenger ribonucleic acid levels , prolactin signaling , and <e2>hyperprolactinemic</e2> inhibition of pulsatile luteinizing hormone secretion are dependent on <e1>estradiol</e1> .
D004958_D006966 NONE Chronic <e2>hyperprolactinemia</e2> induced by the dopamine antagonist sulpiride caused a 40 % reduction LH pulse frequency in ovariectomized rats , but only in the presence of chronic low levels of <e1>estradiol</e1> .
D004967_D006966 NONE We first tested whether chronic <e2>hyperprolactinemia</e2> inhibited two neuroendocrine parameters necessary for female fertility : pulsatile LH secretion and the <e1>estrogen-induced</e1> LH surge .
D004298_D006966 NONE Chronic <e2>hyperprolactinemia</e2> induced by the <e1>dopamine</e1> antagonist sulpiride caused a 40 % reduction LH pulse frequency in ovariectomized rats , but only in the presence of chronic low levels of estradiol .
D013469_D006966 CID Chronic <e2>hyperprolactinemia</e2> induced by the dopamine antagonist <e1>sulpiride</e1> caused a 40 % reduction LH pulse frequency in ovariectomized rats , but only in the presence of chronic low levels of estradiol .
D013256_D006966 NONE These data show that GnRH pulse frequency is inhibited by chronic <e2>hyperprolactinemia</e2> in a <e1>steroid-dependent</e1> manner .
11587867
D014750_D001927 NONE Fatal <e2>myeloencephalopathy</e2> due to accidental intrathecal <e1>vincristin</e1> administration : a report of two cases .
D014750_D054198 NONE We report on two fatal cases of accidental intrathecal <e1>vincristine</e1> instillation in a 5-year old girl with recurrent <e2>acute lymphoblastic leucemia</e2> and a 57-year old man with lymphoblastic lymphoma .
D014750_D054198 NONE We report on two fatal cases of accidental intrathecal <e1>vincristine</e1> instillation in a 5-year old girl with recurrent acute lymphoblastic leucemia and a 57-year old man with <e2>lymphoblastic lymphoma</e2> .
D014750_D003711 CID Histological and immunohistochemical investigations ( HE-LFB , CD-68 , Neurofilament ) revealed <e2>degeneration of myelin and axons</e2> as well as pseudocystic transformation in areas exposed to <e1>vincristine</e1> , accompanied by secondary changes with numerous prominent macrophages .
D014750_D009410 CID Histological and immunohistochemical investigations ( HE-LFB , CD-68 , Neurofilament ) revealed <e2>degeneration of myelin and axons</e2> as well as pseudocystic transformation in areas exposed to <e1>vincristine</e1> , accompanied by secondary changes with numerous prominent macrophages .
D014750_-1 NONE Histological and immunohistochemical investigations ( HE-LFB , CD-68 , Neurofilament ) revealed degeneration of myelin and axons as well as <e2>pseudocystic transformation</e2> in areas exposed to <e1>vincristine</e1> , accompanied by secondary changes with numerous prominent macrophages .
2312209
D007548_D009203 CID <e2>Myocardial infarction</e2> following sublingual administration of <e1>isosorbide dinitrate</e1> .
D007548_D009203 CID A 78-year-old with healed septal necrosis suffered a recurrent <e2>myocardial infarction</e2> of the anterior wall following the administration of <e1>isosorbide dinitrate</e1> 5 mg sublingually .
D007548_D009336 NONE A 78-year-old with healed septal <e2>necrosis</e2> suffered a recurrent myocardial infarction of the anterior wall following the administration of <e1>isosorbide dinitrate</e1> 5 mg sublingually .
6229975
D013999_D009203 NONE Changes in heart size during long-term <e1>timolol</e1> treatment after <e2>myocardial infarction</e2> .
D013999_D009203 NONE The effect of long-term <e1>timolol</e1> treatment on heart size after <e2>myocardial infarction</e2> was evaluated by X-ray in a double-blind study including 241 patients ( placebo 126 , timolol 115 ) .
D013999_D009203 NONE The effect of long-term timolol treatment on heart size after <e2>myocardial infarction</e2> was evaluated by X-ray in a double-blind study including 241 patients ( placebo 126 , <e1>timolol</e1> 115 ) .
D013999_D001919 NONE These differences may be caused by <e1>timolol-induced</e1> <e2>bradycardia</e2> and a compensatory increase in end-diastolic volume .
D013999_D007238 NONE After <e2>re-infarction</e2> , heart size increased in the placebo group and remained unchanged in the <e1>timolol</e1> group .
10901305
D007649_D050723 NONE <e1>Ketamine</e1> sedation for the reduction of children 's <e2>fractures</e2> in the emergency department .
D007649_D050723 NONE The purpose of the present study was to examine the safety and efficacy of <e1>ketamine</e1> for sedation in the treatment of children 's <e2>fractures</e2> in the emergency department .
D007649_D050723 NONE RESULTS : The average time from intravenous administration of <e1>ketamine</e1> to manipulation of the <e2>fracture</e2> or dislocation was one minute and thirty-six seconds ( range , twenty seconds to five minutes ) , and the average time from intramuscular administration to manipulation was four minutes and forty-two seconds ( range , sixty seconds to fifteen minutes ) .
D007649_D050723 NONE CONCLUSIONS : <e1>Ketamine</e1> reliably , safely , and quickly provided adequate sedation to effectively facilitate the reduction of children 's <e2>fractures</e2> in the emergency department at our institution .
D007649_D004204 NONE RESULTS : The average time from intravenous administration of <e1>ketamine</e1> to manipulation of the fracture or <e2>dislocation</e2> was one minute and thirty-six seconds ( range , twenty seconds to five minutes ) , and the average time from intramuscular administration to manipulation was four minutes and forty-two seconds ( range , sixty seconds to fifteen minutes ) .
7988234
D008790_D000799 CID <e2>Angioedema</e2> following the intravenous administration of <e1>metoprolol</e1> .
D008790_D000799 CID During the first day of hospitalization ( while intubated ) , intravenous <e1>metoprolol</e1> was given , resulting in severe <e2>angioedema</e2> .
D017706_D000799 CID A history of <e2>angioedema</e2> secondary to <e1>lisinopril</e1> therapy was elicited .
D013256_D000799 NONE The <e2>angioedema</e2> resolved after therapy with intravenous <e1>steroids</e1> and diphenhydramine hydrochloride .
D004155_D000799 NONE The <e2>angioedema</e2> resolved after therapy with intravenous steroids and <e1>diphenhydramine</e1> hydrochloride .
2054792
D004317_D005334 NONE Effect of <e1>adriamycin</e1> combined with whole body <e2>hyperthermia</e2> on tumor and normal tissues .
D004317_D005334 NONE Thermal enhancement of <e1>Adriamycin-mediated</e1> antitumor activity and normal tissue toxicities by whole body <e2>hyperthermia</e2> were compared using a F344 rat model .
D004317_D005334 NONE Whole body <e2>hyperthermia</e2> ( 120 min at 41.5 degrees C ) enhanced both <e1>Adriamycin-mediated</e1> antitumor activity and toxic side effects .
D004317_D005334 NONE Thus , while whole body <e2>hyperthermia</e2> enhances <e1>Adriamycin-mediated</e1> antitumor effect , normal tissue toxicity is also increased , and the potential therapeutic gain of the combined modality treatment is eroded .
D004317_D009369 NONE Effect of <e1>adriamycin</e1> combined with whole body hyperthermia on <e2>tumor</e2> and normal tissues .
D004317_D064420 NONE Thermal enhancement of <e1>Adriamycin-mediated</e1> antitumor activity and normal tissue <e2>toxicities</e2> by whole body hyperthermia were compared using a F344 rat model .
D004317_D064420 NONE Thus , while whole body hyperthermia enhances <e1>Adriamycin-mediated</e1> antitumor effect , normal tissue <e2>toxicity</e2> is also increased , and the potential therapeutic gain of the combined modality treatment is eroded .
20621845
D002122_D017545 CID Elevation of ADAM10 , ADAM17 , MMP-2 and MMP-9 expression with media degeneration features <e1>CaCl2-induced</e1> <e2>thoracic aortic aneurysm</e2> in a rat model .
D002122_D017545 CID PURPOSE : This study was designed to establish a rat model of <e2>thoracic aortic aneurysm</e2> ( TAA ) by <e1>calcium chloride</e1> ( CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase ( ADAM ) , matrix metalloproteinases ( MMPs ) and their endogenous inhibitors ( TIMPs ) in TAA formation .
D002122_D017545 CID PURPOSE : This study was designed to establish a rat model of thoracic aortic aneurysm ( <e2>TAA</e2> ) by <e1>calcium chloride</e1> ( CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase ( ADAM ) , matrix metalloproteinases ( MMPs ) and their endogenous inhibitors ( TIMPs ) in TAA formation .
D002122_D017545 CID PURPOSE : This study was designed to establish a rat model of thoracic aortic aneurysm ( TAA ) by <e1>calcium chloride</e1> ( CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase ( ADAM ) , matrix metalloproteinases ( MMPs ) and their endogenous inhibitors ( TIMPs ) in <e2>TAA</e2> formation .
D002122_D017545 CID PURPOSE : This study was designed to establish a rat model of <e2>thoracic aortic aneurysm</e2> ( TAA ) by calcium chloride ( <e1>CaCl(2))-induced</e1> arterial injury and to explore the potential role of a disintegrin and metalloproteinase ( ADAM ) , matrix metalloproteinases ( MMPs ) and their endogenous inhibitors ( TIMPs ) in TAA formation .
D002122_D017545 CID PURPOSE : This study was designed to establish a rat model of thoracic aortic aneurysm ( <e2>TAA</e2> ) by calcium chloride ( <e1>CaCl(2))-induced</e1> arterial injury and to explore the potential role of a disintegrin and metalloproteinase ( ADAM ) , matrix metalloproteinases ( MMPs ) and their endogenous inhibitors ( TIMPs ) in TAA formation .
D002122_D017545 CID PURPOSE : This study was designed to establish a rat model of thoracic aortic aneurysm ( TAA ) by calcium chloride ( <e1>CaCl(2))-induced</e1> arterial injury and to explore the potential role of a disintegrin and metalloproteinase ( ADAM ) , matrix metalloproteinases ( MMPs ) and their endogenous inhibitors ( TIMPs ) in <e2>TAA</e2> formation .
D002122_D017545 CID CONCLUSION : This study establishes a <e2>TAA</e2> model by periarterial <e1>CaCl(2 )</e1> exposure in rats , and demonstrates a significant elevation of expression of MMP-2 , MMP-9 , ADAM10 and ADAM17 in the pathogenesis of vascular remodeling .
D002122_D014652 NONE PURPOSE : This study was designed to establish a rat model of thoracic aortic aneurysm ( TAA ) by <e1>calcium chloride</e1> ( CaCl(2))-induced <e2>arterial injury</e2> and to explore the potential role of a disintegrin and metalloproteinase ( ADAM ) , matrix metalloproteinases ( MMPs ) and their endogenous inhibitors ( TIMPs ) in TAA formation .
D002122_D014652 NONE PURPOSE : This study was designed to establish a rat model of thoracic aortic aneurysm ( TAA ) by calcium chloride ( <e1>CaCl(2))-induced</e1> <e2>arterial injury</e2> and to explore the potential role of a disintegrin and metalloproteinase ( ADAM ) , matrix metalloproteinases ( MMPs ) and their endogenous inhibitors ( TIMPs ) in TAA formation .
1835291
D009241_D029424 NONE Acute bronchodilating effects of <e1>ipratropium bromide</e1> and theophylline in <e2>chronic obstructive pulmonary disease</e2> .
D009241_D029424 NONE The bronchodilator effects of a single dose of <e1>ipratropium bromide</e1> aerosol ( 36 micrograms ) and short-acting theophylline tablets ( dose titrated to produce serum levels of 10 - 20 micrograms/mL ) were compared in a double-blind , placebo-controlled crossover study in 21 patients with stable , <e2>chronic obstructive pulmonary disease</e2> .
D009241_D029424 NONE These results show that <e1>ipratropium</e1> is a more potent bronchodilator than oral theophylline in patients with <e2>chronic airflow obstruction</e2> .
D013806_D029424 NONE Acute bronchodilating effects of ipratropium bromide and <e1>theophylline</e1> in <e2>chronic obstructive pulmonary disease</e2> .
D013806_D029424 NONE The bronchodilator effects of a single dose of ipratropium bromide aerosol ( 36 micrograms ) and short-acting <e1>theophylline</e1> tablets ( dose titrated to produce serum levels of 10 - 20 micrograms/mL ) were compared in a double-blind , placebo-controlled crossover study in 21 patients with stable , <e2>chronic obstructive pulmonary disease</e2> .
D013806_D029424 NONE These results show that ipratropium is a more potent bronchodilator than oral <e1>theophylline</e1> in patients with <e2>chronic airflow obstruction</e2> .
D013806_D002318 CID While side effects were rare , those experienced after <e1>theophylline</e1> use did involve the <e2>cardiovascular and gastrointestinal systems</e2> .
D013806_D005767 CID While side effects were rare , those experienced after <e1>theophylline</e1> use did involve the <e2>cardiovascular and gastrointestinal systems</e2> .
347884
D006220_D019967 NONE In the double blind study with <e1>haloperidol</e1> , both substances were found to be highly effective in the treatment of <e2>psychotic syndromes belonging predominantly to the schizophrenia group</e2> .
2445283
D012254_D006478 NONE Tolerance and antiviral effect of <e1>ribavirin</e1> in patients with <e2>Argentine hemorrhagic fever</e2> .
D012254_D006478 NONE Tolerance and antiviral effect of <e1>ribavirin</e1> was studied in 6 patients with <e2>Argentine hemorrhagic fever</e2> ( AHF ) of more than 8 days of evolution .
D012254_D006478 NONE Tolerance and antiviral effect of <e1>ribavirin</e1> was studied in 6 patients with Argentine hemorrhagic fever ( <e2>AHF</e2> ) of more than 8 days of evolution .
D012254_D006478 NONE From these results , we conclude that <e1>ribavirin</e1> has an antiviral effect in advanced cases of <e2>AHF</e2> , and that anemia , the only secondary reaction observed , can be easily managed .
D012254_D006478 NONE The possible beneficial effect of <e1>ribavirin</e1> during the initial days of <e2>AHF</e2> is discussed .
D012254_D014766 NONE Administration of <e1>ribavirin</e1> resulted in a neutralization of <e2>viremia</e2> and a drop of endogenous interferon titers .
D012254_D000740 CID From these results , we conclude that <e1>ribavirin</e1> has an antiviral effect in advanced cases of AHF , and that <e2>anemia</e2> , the only secondary reaction observed , can be easily managed .
17854040
D019259_D006509 NONE Mutations associated with <e1>lamivudine-resistance</e1> in therapy-na ve <e2>hepatitis B virus ( HBV ) infected</e2> patients with and without HIV co-infection : implications for antiretroviral therapy in HBV and HIV co-infected South African patients .
D019259_D006509 NONE Mutations associated with <e1>lamivudine-resistance</e1> in therapy-na ve hepatitis B virus ( HBV ) infected patients with and without HIV co-infection : implications for antiretroviral therapy in <e2>HBV and HIV co-infected</e2> South African patients .
D019259_D006509 NONE This was an exploratory study to investigate <e1>lamivudine-resistant</e1> <e2>hepatitis B</e2> virus ( HBV ) strains in selected lamivudine-na ve HBV carriers with and without human immunodeficiency virus ( HIV ) co-infection in South African patients .
D019259_D006509 NONE This was an exploratory study to investigate lamivudine-resistant <e2>hepatitis B</e2> virus ( HBV ) strains in selected <e1>lamivudine-na</e1> ve HBV carriers with and without human immunodeficiency virus ( HIV ) co-infection in South African patients .
D019259_D006509 NONE Thirty-five <e1>lamivudine-na</e1> ve <e2>HBV infected</e2> patients with or without HIV co-infection were studied : 15 chronic HBV mono-infected patients and 20 HBV-HIV co-infected patients .
D019259_D006509 NONE Thirty-five <e1>lamivudine-na</e1> ve HBV infected patients with or without HIV co-infection were studied : 15 chronic <e2>HBV mono-infected</e2> patients and 20 HBV-HIV co-infected patients .
D019259_D006509 NONE Thirty-five <e1>lamivudine-na</e1> ve HBV infected patients with or without HIV co-infection were studied : 15 chronic HBV mono-infected patients and 20 <e2>HBV-HIV co-infected</e2> patients .
D019259_D006509 NONE HBV <e1>lamivudine-resistant</e1> strains were detected in 3 of 15 mono-infected chronic <e2>hepatitis B</e2> patients and 10 of 20 HBV-HIV co-infected patients .
D019259_D006509 NONE HBV <e1>lamivudine-resistant</e1> strains were detected in 3 of 15 mono-infected chronic hepatitis B patients and 10 of 20 <e2>HBV-HIV co-infected</e2> patients .
D019259_D006509 NONE To the best of our knowledge , this constitutes the first report of HBV <e1>lamivudine-resistant</e1> strains in therapy-na ve <e2>HBV-HIV co-infected</e2> patients .
D019259_D006509 NONE It remains to be seen whether such pre-existing antiviral mutations could result in widespread emergence of HBV resistant strains when <e1>lamivudine-containing</e1> highly active antiretroviral ( ARV ) treatment ( HAART ) regimens become widely applied in South Africa , as this is likely to have potential implications in the management of <e2>HBV-HIV co-infected</e2> patients .
D019259_D015658 NONE Mutations associated with <e1>lamivudine-resistance</e1> in therapy-na ve hepatitis B virus ( HBV ) infected patients with and without <e2>HIV co-infection</e2> : implications for antiretroviral therapy in HBV and HIV co-infected South African patients .
D019259_D015658 NONE Mutations associated with <e1>lamivudine-resistance</e1> in therapy-na ve hepatitis B virus ( HBV ) infected patients with and without HIV co-infection : implications for antiretroviral therapy in <e2>HBV and HIV co-infected</e2> South African patients .
D019259_D015658 NONE This was an exploratory study to investigate <e1>lamivudine-resistant</e1> hepatitis B virus ( HBV ) strains in selected lamivudine-na ve HBV carriers with and without <e2>human immunodeficiency virus ( HIV ) co-infection</e2> in South African patients .
D019259_D015658 NONE This was an exploratory study to investigate lamivudine-resistant hepatitis B virus ( HBV ) strains in selected <e1>lamivudine-na</e1> ve HBV carriers with and without <e2>human immunodeficiency virus ( HIV ) co-infection</e2> in South African patients .
D019259_D015658 NONE Thirty-five <e1>lamivudine-na</e1> ve HBV infected patients with or without <e2>HIV co-infection</e2> were studied : 15 chronic HBV mono-infected patients and 20 HBV-HIV co-infected patients .
D019259_D015658 NONE Thirty-five <e1>lamivudine-na</e1> ve HBV infected patients with or without HIV co-infection were studied : 15 chronic HBV mono-infected patients and 20 <e2>HBV-HIV co-infected</e2> patients .
D019259_D015658 NONE HBV <e1>lamivudine-resistant</e1> strains were detected in 3 of 15 mono-infected chronic hepatitis B patients and 10 of 20 <e2>HBV-HIV co-infected</e2> patients .
D019259_D015658 NONE To the best of our knowledge , this constitutes the first report of HBV <e1>lamivudine-resistant</e1> strains in therapy-na ve <e2>HBV-HIV co-infected</e2> patients .
D019259_D015658 NONE It remains to be seen whether such pre-existing antiviral mutations could result in widespread emergence of HBV resistant strains when <e1>lamivudine-containing</e1> highly active antiretroviral ( ARV ) treatment ( HAART ) regimens become widely applied in South Africa , as this is likely to have potential implications in the management of <e2>HBV-HIV co-infected</e2> patients .
D012964_D006509 NONE Mutations associated with lamivudine-resistance in <e1>therapy-na</e1> ve <e2>hepatitis B virus ( HBV ) infected</e2> patients with and without HIV co-infection : implications for antiretroviral therapy in HBV and HIV co-infected South African patients .
D012964_D006509 NONE Mutations associated with lamivudine-resistance in <e1>therapy-na</e1> ve hepatitis B virus ( HBV ) infected patients with and without HIV co-infection : implications for antiretroviral therapy in <e2>HBV and HIV co-infected</e2> South African patients .
D012964_D006509 NONE This was an exploratory study to investigate lamivudine-resistant <e2>hepatitis B</e2> virus ( HBV ) strains in selected <e1>lamivudine-na</e1> ve HBV carriers with and without human immunodeficiency virus ( HIV ) co-infection in South African patients .
D012964_D006509 NONE Thirty-five <e1>lamivudine-na</e1> ve <e2>HBV infected</e2> patients with or without HIV co-infection were studied : 15 chronic HBV mono-infected patients and 20 HBV-HIV co-infected patients .
D012964_D006509 NONE Thirty-five <e1>lamivudine-na</e1> ve HBV infected patients with or without HIV co-infection were studied : 15 chronic <e2>HBV mono-infected</e2> patients and 20 HBV-HIV co-infected patients .
D012964_D006509 NONE Thirty-five <e1>lamivudine-na</e1> ve HBV infected patients with or without HIV co-infection were studied : 15 chronic HBV mono-infected patients and 20 <e2>HBV-HIV co-infected</e2> patients .
D012964_D006509 NONE To the best of our knowledge , this constitutes the first report of HBV lamivudine-resistant strains in <e1>therapy-na</e1> ve <e2>HBV-HIV co-infected</e2> patients .
D012964_D015658 NONE Mutations associated with lamivudine-resistance in <e1>therapy-na</e1> ve hepatitis B virus ( HBV ) infected patients with and without <e2>HIV co-infection</e2> : implications for antiretroviral therapy in HBV and HIV co-infected South African patients .
D012964_D015658 NONE Mutations associated with lamivudine-resistance in <e1>therapy-na</e1> ve hepatitis B virus ( HBV ) infected patients with and without HIV co-infection : implications for antiretroviral therapy in <e2>HBV and HIV co-infected</e2> South African patients .
D012964_D015658 NONE This was an exploratory study to investigate lamivudine-resistant hepatitis B virus ( HBV ) strains in selected <e1>lamivudine-na</e1> ve HBV carriers with and without <e2>human immunodeficiency virus ( HIV ) co-infection</e2> in South African patients .
D012964_D015658 NONE Thirty-five <e1>lamivudine-na</e1> ve HBV infected patients with or without <e2>HIV co-infection</e2> were studied : 15 chronic HBV mono-infected patients and 20 HBV-HIV co-infected patients .
D012964_D015658 NONE Thirty-five <e1>lamivudine-na</e1> ve HBV infected patients with or without HIV co-infection were studied : 15 chronic HBV mono-infected patients and 20 <e2>HBV-HIV co-infected</e2> patients .
D012964_D015658 NONE To the best of our knowledge , this constitutes the first report of HBV lamivudine-resistant strains in <e1>therapy-na</e1> ve <e2>HBV-HIV co-infected</e2> patients .
7468724
D013726_D002318 CID <e2>Cardiovascular complications</e2> associated with <e1>terbutaline</e1> treatment for preterm labor .
D013726_D002318 CID Severe <e2>cardiovascular complications</e2> occurred in eight of 160 patients treated with <e1>terbutaline</e1> for preterm labor .
D013726_D007752 NONE Cardiovascular complications associated with <e1>terbutaline</e1> treatment for <e2>preterm labor</e2> .
D013726_D007752 NONE Severe cardiovascular complications occurred in eight of 160 patients treated with <e1>terbutaline</e1> for <e2>preterm labor</e2> .
7269015
D002066_D006470 CID <e1>Busulfan-induced</e1> <e2>hemorrhagic cystitis</e2> .
D002066_D006470 CID A case of a <e1>busulfan-induced</e1> <e2>hemorrhage cystitis</e2> is reported .
D002066_D003556 CID <e1>Busulfan-induced</e1> <e2>hemorrhagic cystitis</e2> .
D002066_D003556 CID A case of a <e1>busulfan-induced</e1> <e2>hemorrhage cystitis</e2> is reported .
D002066_D003556 CID The similarity between the histologic appearances of <e1>busulfan</e1> <e2>cystitis</e2> and both radiation and cyclophosphamide-induced cystitis is discussed and the world literature reviewed .
D002066_D003556 CID The similarity between the histologic appearances of <e1>busulfan</e1> cystitis and both radiation and cyclophosphamide-induced <e2>cystitis</e2> is discussed and the world literature reviewed .
D003520_D003556 NONE The similarity between the histologic appearances of busulfan <e2>cystitis</e2> and both radiation and <e1>cyclophosphamide-induced</e1> cystitis is discussed and the world literature reviewed .
D003520_D003556 NONE The similarity between the histologic appearances of busulfan cystitis and both radiation and <e1>cyclophosphamide-induced</e1> <e2>cystitis</e2> is discussed and the world literature reviewed .
D002066_D002277 NONE In view of the known tendency of <e1>busulfan</e1> to induce cellular atypia and <e2>carcinoma</e2> in other sites , periodic urinary cytology is suggested in patients on long-term therapy .
15899738
D003401_D001281 CID Lone <e2>atrial fibrillation</e2> associated with <e1>creatine</e1> monohydrate supplementation .
D003401_D001145 NONE Previous anecdotal reports have linked <e1>creatine</e1> to the development of <e2>arrhythmia</e2> .
12615818
D017373_D054556 CID The risk of <e2>venous thromboembolism</e2> in women prescribed <e1>cyproterone acetate</e1> in combination with ethinyl estradiol : a nested cohort analysis and case-control study .
D017373_D054556 CID Previous studies have demonstrated an increased risk of <e2>venous thromboembolism</e2> ( VTE ) associated with <e1>CPA/EE</e1> compared with conventional combined oral contraceptives ( COCs ) .
D017373_D054556 CID Previous studies have demonstrated an increased risk of venous thromboembolism ( <e2>VTE</e2> ) associated with <e1>CPA/EE</e1> compared with conventional combined oral contraceptives ( COCs ) .
D017373_D054556 CID METHODS : Using the General Practice Research Database we conducted a cohort analysis and case-control study nested within a population of women aged between 15 and 39 years with acne , hirsutism or PCOS to estimate the risk of <e2>VTE</e2> associated with <e1>CPA/EE</e1> .
D017373_D054556 CID CONCLUSIONS : We have demonstrated an increased risk of <e2>VTE</e2> associated with the use of <e1>CPA/EE</e1> in women with acne , hirsutism or PCOS although residual confounding by indication can not be excluded .
D004997_D054556 CID The risk of <e2>venous thromboembolism</e2> in women prescribed cyproterone acetate in combination with <e1>ethinyl estradiol</e1> : a nested cohort analysis and case-control study .
D004997_D054556 CID Previous studies have demonstrated an increased risk of <e2>venous thromboembolism</e2> ( VTE ) associated with <e1>CPA/EE</e1> compared with conventional combined oral contraceptives ( COCs ) .
D004997_D054556 CID Previous studies have demonstrated an increased risk of venous thromboembolism ( <e2>VTE</e2> ) associated with <e1>CPA/EE</e1> compared with conventional combined oral contraceptives ( COCs ) .
D004997_D054556 CID METHODS : Using the General Practice Research Database we conducted a cohort analysis and case-control study nested within a population of women aged between 15 and 39 years with acne , hirsutism or PCOS to estimate the risk of <e2>VTE</e2> associated with <e1>CPA/EE</e1> .
D004997_D054556 CID CONCLUSIONS : We have demonstrated an increased risk of <e2>VTE</e2> associated with the use of <e1>CPA/EE</e1> in women with acne , hirsutism or PCOS although residual confounding by indication can not be excluded .
D017373_D000152 NONE BACKGROUND : <e1>Cyproterone acetate</e1> combined with ethinyl estradiol ( CPA/EE ) is licensed in the UK for the treatment of women with <e2>acne</e2> and hirsutism and is also a treatment option for polycystic ovary syndrome ( PCOS ) .
D017373_D000152 NONE BACKGROUND : Cyproterone acetate combined with ethinyl estradiol ( <e1>CPA/EE</e1> ) is licensed in the UK for the treatment of women with <e2>acne</e2> and hirsutism and is also a treatment option for polycystic ovary syndrome ( PCOS ) .
D017373_D000152 NONE METHODS : Using the General Practice Research Database we conducted a cohort analysis and case-control study nested within a population of women aged between 15 and 39 years with <e2>acne</e2> , hirsutism or PCOS to estimate the risk of VTE associated with <e1>CPA/EE</e1> .
D017373_D000152 NONE CONCLUSIONS : We have demonstrated an increased risk of VTE associated with the use of <e1>CPA/EE</e1> in women with <e2>acne</e2> , hirsutism or PCOS although residual confounding by indication can not be excluded .
D017373_D006628 NONE BACKGROUND : <e1>Cyproterone acetate</e1> combined with ethinyl estradiol ( CPA/EE ) is licensed in the UK for the treatment of women with acne and <e2>hirsutism</e2> and is also a treatment option for polycystic ovary syndrome ( PCOS ) .
D017373_D006628 NONE BACKGROUND : Cyproterone acetate combined with ethinyl estradiol ( <e1>CPA/EE</e1> ) is licensed in the UK for the treatment of women with acne and <e2>hirsutism</e2> and is also a treatment option for polycystic ovary syndrome ( PCOS ) .
D017373_D006628 NONE METHODS : Using the General Practice Research Database we conducted a cohort analysis and case-control study nested within a population of women aged between 15 and 39 years with acne , <e2>hirsutism</e2> or PCOS to estimate the risk of VTE associated with <e1>CPA/EE</e1> .
D017373_D006628 NONE CONCLUSIONS : We have demonstrated an increased risk of VTE associated with the use of <e1>CPA/EE</e1> in women with acne , <e2>hirsutism</e2> or PCOS although residual confounding by indication can not be excluded .
D017373_D011085 NONE BACKGROUND : <e1>Cyproterone acetate</e1> combined with ethinyl estradiol ( CPA/EE ) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for <e2>polycystic ovary syndrome</e2> ( PCOS ) .
D017373_D011085 NONE BACKGROUND : <e1>Cyproterone acetate</e1> combined with ethinyl estradiol ( CPA/EE ) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for polycystic ovary syndrome ( <e2>PCOS</e2> ) .
D017373_D011085 NONE BACKGROUND : Cyproterone acetate combined with ethinyl estradiol ( <e1>CPA/EE</e1> ) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for <e2>polycystic ovary syndrome</e2> ( PCOS ) .
D017373_D011085 NONE BACKGROUND : Cyproterone acetate combined with ethinyl estradiol ( <e1>CPA/EE</e1> ) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for polycystic ovary syndrome ( <e2>PCOS</e2> ) .
D017373_D011085 NONE METHODS : Using the General Practice Research Database we conducted a cohort analysis and case-control study nested within a population of women aged between 15 and 39 years with acne , hirsutism or <e2>PCOS</e2> to estimate the risk of VTE associated with <e1>CPA/EE</e1> .
D017373_D011085 NONE CONCLUSIONS : We have demonstrated an increased risk of VTE associated with the use of <e1>CPA/EE</e1> in women with acne , hirsutism or <e2>PCOS</e2> although residual confounding by indication can not be excluded .
D004997_D000152 NONE BACKGROUND : Cyproterone acetate combined with <e1>ethinyl estradiol</e1> ( CPA/EE ) is licensed in the UK for the treatment of women with <e2>acne</e2> and hirsutism and is also a treatment option for polycystic ovary syndrome ( PCOS ) .
D004997_D000152 NONE BACKGROUND : Cyproterone acetate combined with ethinyl estradiol ( <e1>CPA/EE</e1> ) is licensed in the UK for the treatment of women with <e2>acne</e2> and hirsutism and is also a treatment option for polycystic ovary syndrome ( PCOS ) .
D004997_D000152 NONE METHODS : Using the General Practice Research Database we conducted a cohort analysis and case-control study nested within a population of women aged between 15 and 39 years with <e2>acne</e2> , hirsutism or PCOS to estimate the risk of VTE associated with <e1>CPA/EE</e1> .
D004997_D000152 NONE CONCLUSIONS : We have demonstrated an increased risk of VTE associated with the use of <e1>CPA/EE</e1> in women with <e2>acne</e2> , hirsutism or PCOS although residual confounding by indication can not be excluded .
D004997_D006628 NONE BACKGROUND : Cyproterone acetate combined with <e1>ethinyl estradiol</e1> ( CPA/EE ) is licensed in the UK for the treatment of women with acne and <e2>hirsutism</e2> and is also a treatment option for polycystic ovary syndrome ( PCOS ) .
D004997_D006628 NONE BACKGROUND : Cyproterone acetate combined with ethinyl estradiol ( <e1>CPA/EE</e1> ) is licensed in the UK for the treatment of women with acne and <e2>hirsutism</e2> and is also a treatment option for polycystic ovary syndrome ( PCOS ) .
D004997_D006628 NONE METHODS : Using the General Practice Research Database we conducted a cohort analysis and case-control study nested within a population of women aged between 15 and 39 years with acne , <e2>hirsutism</e2> or PCOS to estimate the risk of VTE associated with <e1>CPA/EE</e1> .
D004997_D006628 NONE CONCLUSIONS : We have demonstrated an increased risk of VTE associated with the use of <e1>CPA/EE</e1> in women with acne , <e2>hirsutism</e2> or PCOS although residual confounding by indication can not be excluded .
D004997_D011085 NONE BACKGROUND : Cyproterone acetate combined with <e1>ethinyl estradiol</e1> ( CPA/EE ) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for <e2>polycystic ovary syndrome</e2> ( PCOS ) .
D004997_D011085 NONE BACKGROUND : Cyproterone acetate combined with <e1>ethinyl estradiol</e1> ( CPA/EE ) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for polycystic ovary syndrome ( <e2>PCOS</e2> ) .
D004997_D011085 NONE BACKGROUND : Cyproterone acetate combined with ethinyl estradiol ( <e1>CPA/EE</e1> ) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for <e2>polycystic ovary syndrome</e2> ( PCOS ) .
D004997_D011085 NONE BACKGROUND : Cyproterone acetate combined with ethinyl estradiol ( <e1>CPA/EE</e1> ) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for polycystic ovary syndrome ( <e2>PCOS</e2> ) .
D004997_D011085 NONE METHODS : Using the General Practice Research Database we conducted a cohort analysis and case-control study nested within a population of women aged between 15 and 39 years with acne , hirsutism or <e2>PCOS</e2> to estimate the risk of VTE associated with <e1>CPA/EE</e1> .
D004997_D011085 NONE CONCLUSIONS : We have demonstrated an increased risk of VTE associated with the use of <e1>CPA/EE</e1> in women with acne , hirsutism or <e2>PCOS</e2> although residual confounding by indication can not be excluded .
D003276_D054556 NONE Previous studies have demonstrated an increased risk of <e2>venous thromboembolism</e2> ( VTE ) associated with CPA/EE compared with conventional combined <e1>oral contraceptives</e1> ( COCs ) .
D003276_D054556 NONE Previous studies have demonstrated an increased risk of venous thromboembolism ( <e2>VTE</e2> ) associated with CPA/EE compared with conventional combined <e1>oral contraceptives</e1> ( COCs ) .
12483326
D016190_D005128 NONE Severe <e2>ocular and orbital toxicity</e2> after intracarotid injection of <e1>carboplatin</e1> for recurrent glioblastomas .
D016190_D005128 NONE Generally , <e1>carboplatin</e1> is said to have milder side effects than cisplatin , whose <e2>ocular and orbital toxicity</e2> are well known .
D016190_D005128 NONE However , we experienced a case of severe <e2>ocular and orbital toxicity</e2> after intracarotid injection of <e1>carboplatin</e1> , which is infrequently reported .
D016190_D005128 NONE CONCLUSION : When performing intracarotid injection of <e1>carboplatin</e1> , we must be aware of its potentially blinding <e2>ocular toxicity</e2> .
D016190_D009916 NONE Severe <e2>ocular and orbital toxicity</e2> after intracarotid injection of <e1>carboplatin</e1> for recurrent glioblastomas .
D016190_D009916 NONE Generally , <e1>carboplatin</e1> is said to have milder side effects than cisplatin , whose <e2>ocular and orbital toxicity</e2> are well known .
D016190_D009916 NONE However , we experienced a case of severe <e2>ocular and orbital toxicity</e2> after intracarotid injection of <e1>carboplatin</e1> , which is infrequently reported .
D016190_D005909 NONE Severe ocular and orbital toxicity after intracarotid injection of <e1>carboplatin</e1> for recurrent <e2>glioblastomas</e2> .
D016190_D005909 NONE CASE : A 58-year-old man received an intracarotid injection of <e1>carboplatin</e1> for recurrent <e2>glioblastomas</e2> in his left temporal lobe .
D002945_D005128 NONE Generally , carboplatin is said to have milder side effects than <e1>cisplatin</e1> , whose <e2>ocular and orbital toxicity</e2> are well known .
D002945_D009916 NONE Generally , carboplatin is said to have milder side effects than <e1>cisplatin</e1> , whose <e2>ocular and orbital toxicity</e2> are well known .
D016190_D064420 NONE Various ocular symptoms and findings caused by <e1>carboplatin</e1> <e2>toxicity</e2> were seen .
7292072
D003891_D017180 CID Variant <e2>ventricular tachycardia</e2> in <e1>desipramine</e1> toxicity .
D003891_D017180 CID We report a case of variant <e2>ventricular tachycardia</e2> induced by <e1>desipramine</e1> toxicity .
D003891_D064420 NONE Variant ventricular tachycardia in <e1>desipramine</e1> <e2>toxicity</e2> .
D003891_D064420 NONE We report a case of variant ventricular tachycardia induced by <e1>desipramine</e1> <e2>toxicity</e2> .
9401499
D013988_D000741 CID <e1>Ticlopidine-induced</e1> <e2>aplastic anemia</e2> : report of three Chinese patients and review of the literature .
D013988_D000741 CID In this study , three Chinese patients with <e1>ticlopidine-induced</e1> <e2>aplastic anemia</e2> were reported and another 13 patients in the English literature were reviewed .
D013988_D000741 CID Treatment for <e1>ticlopidine-induced</e1> <e2>aplastic anemia</e2> with colony-stimulating factors seemed to have little effect .
D013988_D000380 CID <e2>Agranulocytosis</e2> occurred 3 - 20 weeks after initiation of <e1>ticlopidine</e1> , so frequent examination of white cell count during treatment is recommended .
9195768
D018170_D010292 CID <e2>Atypical sensations</e2> following the use of subcutaneous <e1>sumatriptan</e1> are common , but of uncertain origin .
17147461
D020123_D011507 CID <e1>Sirolimus-associated</e1> <e2>proteinuria</e2> and renal dysfunction .
D020123_D011507 CID However , clinical reports suggest that , under some circumstances , <e1>sirolimus</e1> is associated with <e2>proteinuria</e2> and acute renal dysfunction .
D020123_D011507 CID The mechanisms of <e1>sirolimus-associated</e1> <e2>proteinuria</e2> are multifactorial and may be due to an increase in glomerular capillary pressure following calcineurin inhibitor withdrawal .
D020123_D011507 CID Although these adverse effects occur in some patients , their occurrence could be minimised by knowledge of the molecular effects of <e1>sirolimus</e1> on the kidney , the use of sirolimus in appropriate patient populations , close monitoring of <e2>proteinuria</e2> and renal function , use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers if proteinuria occurs and withdrawal if needed .
D020123_D011507 CID Although these adverse effects occur in some patients , their occurrence could be minimised by knowledge of the molecular effects of <e1>sirolimus</e1> on the kidney , the use of sirolimus in appropriate patient populations , close monitoring of proteinuria and renal function , use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers if <e2>proteinuria</e2> occurs and withdrawal if needed .
D020123_D011507 CID Although these adverse effects occur in some patients , their occurrence could be minimised by knowledge of the molecular effects of sirolimus on the kidney , the use of <e1>sirolimus</e1> in appropriate patient populations , close monitoring of <e2>proteinuria</e2> and renal function , use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers if proteinuria occurs and withdrawal if needed .
D020123_D011507 CID Although these adverse effects occur in some patients , their occurrence could be minimised by knowledge of the molecular effects of sirolimus on the kidney , the use of <e1>sirolimus</e1> in appropriate patient populations , close monitoring of proteinuria and renal function , use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers if <e2>proteinuria</e2> occurs and withdrawal if needed .
D020123_D007674 CID <e1>Sirolimus-associated</e1> proteinuria and <e2>renal dysfunction</e2> .
D020123_D007674 CID <e1>Sirolimus</e1> represents a major therapeutic advance in the prevention of acute renal allograft rejection and chronic allograft <e2>nephropathy</e2> .
D020123_D007674 CID Because <e1>sirolimus</e1> does not share the vasomotor renal adverse effects exhibited by calcineurin inhibitors , it has been designated a ' <e2>non-nephrotoxic</e2> drug ' .
D020123_D058186 NONE However , clinical reports suggest that , under some circumstances , <e1>sirolimus</e1> is associated with proteinuria and <e2>acute renal dysfunction</e2> .
D020123_D058186 NONE The <e2>acute renal dysfunction</e2> associated with <e1>sirolimus</e1> ( such as in delayed graft function ) may be due to suppression of compensatory renal cell proliferation and survival/repair processes .
D000809_D011507 NONE Although these adverse effects occur in some patients , their occurrence could be minimised by knowledge of the molecular effects of sirolimus on the kidney , the use of sirolimus in appropriate patient populations , close monitoring of <e2>proteinuria</e2> and renal function , use of <e1>angiotensin-converting</e1> enzyme inhibitors or angiotensin II receptor blockers if proteinuria occurs and withdrawal if needed .
D000809_D011507 NONE Although these adverse effects occur in some patients , their occurrence could be minimised by knowledge of the molecular effects of sirolimus on the kidney , the use of sirolimus in appropriate patient populations , close monitoring of proteinuria and renal function , use of <e1>angiotensin-converting</e1> enzyme inhibitors or angiotensin II receptor blockers if <e2>proteinuria</e2> occurs and withdrawal if needed .
D000804_D011507 NONE Although these adverse effects occur in some patients , their occurrence could be minimised by knowledge of the molecular effects of sirolimus on the kidney , the use of sirolimus in appropriate patient populations , close monitoring of <e2>proteinuria</e2> and renal function , use of angiotensin-converting enzyme inhibitors or <e1>angiotensin II</e1> receptor blockers if proteinuria occurs and withdrawal if needed .
D000804_D011507 NONE Although these adverse effects occur in some patients , their occurrence could be minimised by knowledge of the molecular effects of sirolimus on the kidney , the use of sirolimus in appropriate patient populations , close monitoring of proteinuria and renal function , use of angiotensin-converting enzyme inhibitors or <e1>angiotensin II</e1> receptor blockers if <e2>proteinuria</e2> occurs and withdrawal if needed .
12464714
C093622_D008881 NONE Crossover comparison of efficacy and preference for <e1>rizatriptan</e1> 10 mg versus ergotamine/caffeine in <e2>migraine</e2> .
C093622_D008881 NONE <e1>Rizatriptan</e1> is a selective 5-HT(1B/1D ) receptor agonist with rapid oral absorption and early onset of action in the acute treatment of <e2>migraine</e2> .
C093622_D008881 NONE This randomized double- blind crossover outpatient study assessed the preference for 1 <e1>rizatriptan</e1> 10 mg tablet to 2 ergotamine 1 mg/caffeine 100 mg tablets in 439 patients treating a single <e2>migraine</e2> attack with each therapy .
D004878_D008881 NONE Crossover comparison of efficacy and preference for rizatriptan 10 mg versus <e1>ergotamine/caffeine</e1> in <e2>migraine</e2> .
D004878_D008881 NONE This randomized double- blind crossover outpatient study assessed the preference for 1 rizatriptan 10 mg tablet to 2 <e1>ergotamine</e1> 1 mg/caffeine 100 mg tablets in 439 patients treating a single <e2>migraine</e2> attack with each therapy .
D002110_D008881 NONE Crossover comparison of efficacy and preference for rizatriptan 10 mg versus <e1>ergotamine/caffeine</e1> in <e2>migraine</e2> .
D002110_D008881 NONE This randomized double- blind crossover outpatient study assessed the preference for 1 rizatriptan 10 mg tablet to 2 ergotamine 1 <e1>mg/caffeine</e1> 100 mg tablets in 439 patients treating a single <e2>migraine</e2> attack with each therapy .
D012701_D008881 NONE Rizatriptan is a selective <e1>5-HT(1B/1D</e1> ) receptor agonist with rapid oral absorption and early onset of action in the acute treatment of <e2>migraine</e2> .
C093622_D006261 NONE Faster relief of <e2>headache</e2> was the most important reason for preference , cited by 67.3 % of patients preferring <e1>rizatriptan</e1> and 54.2 % of patients who preferred ergotamine/caffeine .
C093622_D006261 NONE <e2>Headache</e2> relief at 2 h was 75.9 % for <e1>rizatriptan</e1> and 47.3 % for ergotamine/caffeine ( p < or = 0.001 ) , with rizatriptan being superior to ergotamine/caffeine within 30 min of dosing .
C093622_D006261 NONE <e2>Headache</e2> relief at 2 h was 75.9 % for rizatriptan and 47.3 % for ergotamine/caffeine ( p < or = 0.001 ) , with <e1>rizatriptan</e1> being superior to ergotamine/caffeine within 30 min of dosing .
D004878_D006261 NONE Faster relief of <e2>headache</e2> was the most important reason for preference , cited by 67.3 % of patients preferring rizatriptan and 54.2 % of patients who preferred <e1>ergotamine/caffeine</e1> .
D004878_D006261 NONE <e2>Headache</e2> relief at 2 h was 75.9 % for rizatriptan and 47.3 % for <e1>ergotamine/caffeine</e1> ( p < or = 0.001 ) , with rizatriptan being superior to ergotamine/caffeine within 30 min of dosing .
D004878_D006261 NONE <e2>Headache</e2> relief at 2 h was 75.9 % for rizatriptan and 47.3 % for ergotamine/caffeine ( p < or = 0.001 ) , with rizatriptan being superior to <e1>ergotamine/caffeine</e1> within 30 min of dosing .
D002110_D006261 NONE Faster relief of <e2>headache</e2> was the most important reason for preference , cited by 67.3 % of patients preferring rizatriptan and 54.2 % of patients who preferred <e1>ergotamine/caffeine</e1> .
D002110_D006261 NONE <e2>Headache</e2> relief at 2 h was 75.9 % for rizatriptan and 47.3 % for <e1>ergotamine/caffeine</e1> ( p < or = 0.001 ) , with rizatriptan being superior to ergotamine/caffeine within 30 min of dosing .
D002110_D006261 NONE <e2>Headache</e2> relief at 2 h was 75.9 % for rizatriptan and 47.3 % for ergotamine/caffeine ( p < or = 0.001 ) , with rizatriptan being superior to <e1>ergotamine/caffeine</e1> within 30 min of dosing .
C093622_D010146 NONE The co-primary endpoint of being <e2>pain</e2> free at 2 h was also in favor of <e1>rizatriptan</e1> .
C093622_D010146 NONE Forty-nine percent of patients were <e2>pain</e2> free 2 h after <e1>rizatriptan</e1> , compared with 24.3 % treated with ergotamine/caffeine ( p < or = 0.001 ) , rizatriptan being superior within 1 h of treatment .
C093622_D010146 NONE Forty-nine percent of patients were <e2>pain</e2> free 2 h after rizatriptan , compared with 24.3 % treated with ergotamine/caffeine ( p < or = 0.001 ) , <e1>rizatriptan</e1> being superior within 1 h of treatment .
C093622_D010146 NONE Almost 36 % of patients taking <e1>rizatriptan</e1> were <e2>pain</e2> free at 2 h and had no recurrence or need for additional medication within 24 h , compared to 20 % of patients on ergotamine/caffeine ( p < or = 0.001 ) .
D004878_D010146 NONE Forty-nine percent of patients were <e2>pain</e2> free 2 h after rizatriptan , compared with 24.3 % treated with <e1>ergotamine/caffeine</e1> ( p < or = 0.001 ) , rizatriptan being superior within 1 h of treatment .
D004878_D010146 NONE Almost 36 % of patients taking rizatriptan were <e2>pain</e2> free at 2 h and had no recurrence or need for additional medication within 24 h , compared to 20 % of patients on <e1>ergotamine/caffeine</e1> ( p < or = 0.001 ) .
D002110_D010146 NONE Forty-nine percent of patients were <e2>pain</e2> free 2 h after rizatriptan , compared with 24.3 % treated with <e1>ergotamine/caffeine</e1> ( p < or = 0.001 ) , rizatriptan being superior within 1 h of treatment .
D002110_D010146 NONE Almost 36 % of patients taking rizatriptan were <e2>pain</e2> free at 2 h and had no recurrence or need for additional medication within 24 h , compared to 20 % of patients on <e1>ergotamine/caffeine</e1> ( p < or = 0.001 ) .
C093622_D009325 CID <e1>Rizatriptan</e1> was also superior to ergotamine/caffeine in the proportions of patients with no <e2>nausea</e2> , vomiting , phonophobia or photophobia and for patients with normal function 2 h after drug intake ( p < or = 0.001 ) .
C093622_D009325 CID The most common adverse events ( incidence > or = 5 % in one group ) after <e1>rizatriptan</e1> and ergotamine/caffeine , respectively , were dizziness ( 6.7 and 5.3 % ) , <e2>nausea</e2> ( 4.2 and 8.5 % ) and somnolence ( 5.5 and 2.3 % ) .
C093622_D014839 NONE <e1>Rizatriptan</e1> was also superior to ergotamine/caffeine in the proportions of patients with no nausea , <e2>vomiting</e2> , phonophobia or photophobia and for patients with normal function 2 h after drug intake ( p < or = 0.001 ) .
C093622_D012001 NONE <e1>Rizatriptan</e1> was also superior to ergotamine/caffeine in the proportions of patients with no nausea , vomiting , <e2>phonophobia</e2> or photophobia and for patients with normal function 2 h after drug intake ( p < or = 0.001 ) .
C093622_D020795 NONE <e1>Rizatriptan</e1> was also superior to ergotamine/caffeine in the proportions of patients with no nausea , vomiting , phonophobia or <e2>photophobia</e2> and for patients with normal function 2 h after drug intake ( p < or = 0.001 ) .
D004878_D009325 NONE Rizatriptan was also superior to <e1>ergotamine/caffeine</e1> in the proportions of patients with no <e2>nausea</e2> , vomiting , phonophobia or photophobia and for patients with normal function 2 h after drug intake ( p < or = 0.001 ) .
D004878_D009325 NONE The most common adverse events ( incidence > or = 5 % in one group ) after rizatriptan and <e1>ergotamine/caffeine</e1> , respectively , were dizziness ( 6.7 and 5.3 % ) , <e2>nausea</e2> ( 4.2 and 8.5 % ) and somnolence ( 5.5 and 2.3 % ) .
D004878_D014839 NONE Rizatriptan was also superior to <e1>ergotamine/caffeine</e1> in the proportions of patients with no nausea , <e2>vomiting</e2> , phonophobia or photophobia and for patients with normal function 2 h after drug intake ( p < or = 0.001 ) .
D004878_D012001 NONE Rizatriptan was also superior to <e1>ergotamine/caffeine</e1> in the proportions of patients with no nausea , vomiting , <e2>phonophobia</e2> or photophobia and for patients with normal function 2 h after drug intake ( p < or = 0.001 ) .
D004878_D020795 NONE Rizatriptan was also superior to <e1>ergotamine/caffeine</e1> in the proportions of patients with no nausea , vomiting , phonophobia or <e2>photophobia</e2> and for patients with normal function 2 h after drug intake ( p < or = 0.001 ) .
D002110_D009325 NONE Rizatriptan was also superior to <e1>ergotamine/caffeine</e1> in the proportions of patients with no <e2>nausea</e2> , vomiting , phonophobia or photophobia and for patients with normal function 2 h after drug intake ( p < or = 0.001 ) .
D002110_D009325 NONE The most common adverse events ( incidence > or = 5 % in one group ) after rizatriptan and <e1>ergotamine/caffeine</e1> , respectively , were dizziness ( 6.7 and 5.3 % ) , <e2>nausea</e2> ( 4.2 and 8.5 % ) and somnolence ( 5.5 and 2.3 % ) .
D002110_D014839 NONE Rizatriptan was also superior to <e1>ergotamine/caffeine</e1> in the proportions of patients with no nausea , <e2>vomiting</e2> , phonophobia or photophobia and for patients with normal function 2 h after drug intake ( p < or = 0.001 ) .
D002110_D012001 NONE Rizatriptan was also superior to <e1>ergotamine/caffeine</e1> in the proportions of patients with no nausea , vomiting , <e2>phonophobia</e2> or photophobia and for patients with normal function 2 h after drug intake ( p < or = 0.001 ) .
D002110_D020795 NONE Rizatriptan was also superior to <e1>ergotamine/caffeine</e1> in the proportions of patients with no nausea , vomiting , phonophobia or <e2>photophobia</e2> and for patients with normal function 2 h after drug intake ( p < or = 0.001 ) .
C093622_D004244 CID The most common adverse events ( incidence > or = 5 % in one group ) after <e1>rizatriptan</e1> and ergotamine/caffeine , respectively , were <e2>dizziness</e2> ( 6.7 and 5.3 % ) , nausea ( 4.2 and 8.5 % ) and somnolence ( 5.5 and 2.3 % ) .
C093622_D006970 NONE The most common adverse events ( incidence > or = 5 % in one group ) after <e1>rizatriptan</e1> and ergotamine/caffeine , respectively , were dizziness ( 6.7 and 5.3 % ) , nausea ( 4.2 and 8.5 % ) and <e2>somnolence</e2> ( 5.5 and 2.3 % ) .
D004878_D004244 NONE The most common adverse events ( incidence > or = 5 % in one group ) after rizatriptan and <e1>ergotamine/caffeine</e1> , respectively , were <e2>dizziness</e2> ( 6.7 and 5.3 % ) , nausea ( 4.2 and 8.5 % ) and somnolence ( 5.5 and 2.3 % ) .
D004878_D006970 NONE The most common adverse events ( incidence > or = 5 % in one group ) after rizatriptan and <e1>ergotamine/caffeine</e1> , respectively , were dizziness ( 6.7 and 5.3 % ) , nausea ( 4.2 and 8.5 % ) and <e2>somnolence</e2> ( 5.5 and 2.3 % ) .
D002110_D004244 NONE The most common adverse events ( incidence > or = 5 % in one group ) after rizatriptan and <e1>ergotamine/caffeine</e1> , respectively , were <e2>dizziness</e2> ( 6.7 and 5.3 % ) , nausea ( 4.2 and 8.5 % ) and somnolence ( 5.5 and 2.3 % ) .
D002110_D006970 NONE The most common adverse events ( incidence > or = 5 % in one group ) after rizatriptan and <e1>ergotamine/caffeine</e1> , respectively , were dizziness ( 6.7 and 5.3 % ) , nausea ( 4.2 and 8.5 % ) and <e2>somnolence</e2> ( 5.5 and 2.3 % ) .
18619688
D004317_D003643 NONE <e1>Adriamycin-induced</e1> autophagic cardiomyocyte <e2>death</e2> plays a pathogenic role in a rat model of heart failure .
D004317_D003643 NONE CONCLUSION : Autophagic cardiomyocyte <e2>death</e2> plays an important role in the pathogenesis of heart failure in rats induced by <e1>adriamycin</e1> .
D004317_D006333 CID <e1>Adriamycin-induced</e1> autophagic cardiomyocyte death plays a pathogenic role in a rat model of <e2>heart failure</e2> .
D004317_D006333 CID BACKGROUND : The mechanisms underlying <e2>heart failure</e2> induced by <e1>adriamycin</e1> are very complicated and still unclear .
D004317_D006333 CID The aim of this study was to investigate whether autophagy was involved in the progression of <e2>heart failure</e2> induced by <e1>adriamycin</e1> , so that we can develop a novel treatment strategy for heart failure .
D004317_D006333 CID The aim of this study was to investigate whether autophagy was involved in the progression of heart failure induced by <e1>adriamycin</e1> , so that we can develop a novel treatment strategy for <e2>heart failure</e2> .
D004317_D006333 CID METHODS : 3-methyladenine ( 3MA ) , a specific inhibitor on autophagy was used in a <e2>heart failure</e2> model of rats induced by <e1>adriamycin</e1> .
D004317_D006333 CID CONCLUSION : Autophagic cardiomyocyte death plays an important role in the pathogenesis of <e2>heart failure</e2> in rats induced by <e1>adriamycin</e1> .
D004317_D006333 CID Mitochondrial injury may be involved in the progression of <e2>heart failure</e2> caused by <e1>adriamycin</e1> via the autophagy pathway .
C025946_D006333 NONE METHODS : <e1>3-methyladenine</e1> ( 3MA ) , a specific inhibitor on autophagy was used in a <e2>heart failure</e2> model of rats induced by adriamycin .
C025946_D006333 NONE METHODS : 3-methyladenine ( <e1>3MA</e1> ) , a specific inhibitor on autophagy was used in a <e2>heart failure</e2> model of rats induced by adriamycin .
11250767
D011441_D014657 NONE <e1>Propylthiouracil-induced</e1> perinuclear-staining antineutrophil cytoplasmic autoantibody-positive <e2>vasculitis</e2> in conjunction with pericarditis .
D011441_D014657 NONE OBJECTIVE : To describe a case of <e1>propylthiouracil-induced</e1> <e2>vasculitis</e2> manifesting with pericarditis .
D011441_D014657 NONE A literature review revealed no prior reports of pericarditis in anti-MPO pANCA-positive <e2>vasculitis</e2> associated with <e1>propylthio- uracil</e1> therapy .
D011441_D014657 NONE CONCLUSION : Pericarditis may be the initial manifestation of drug-induced <e2>vasculitis</e2> attributable to <e1>propylthio- uracil</e1> therapy .
D011441_D010493 CID <e1>Propylthiouracil-induced</e1> perinuclear-staining antineutrophil cytoplasmic autoantibody-positive vasculitis in conjunction with <e2>pericarditis</e2> .
D011441_D010493 CID OBJECTIVE : To describe a case of <e1>propylthiouracil-induced</e1> vasculitis manifesting with <e2>pericarditis</e2> .
D011441_D010493 CID METHODS : We present the first case report of a woman with hyperthyroidism treated with <e1>propylthiouracil</e1> in whom a syndrome of <e2>pericarditis</e2> , fever , and glomerulonephritis developed .
D011441_D010493 CID A literature review revealed no prior reports of <e2>pericarditis</e2> in anti-MPO pANCA-positive vasculitis associated with <e1>propylthio- uracil</e1> therapy .
D011441_D010493 CID CONCLUSION : <e2>Pericarditis</e2> may be the initial manifestation of drug-induced vasculitis attributable to <e1>propylthio- uracil</e1> therapy .
D011441_D006980 NONE METHODS : We present the first case report of a woman with <e2>hyperthyroidism</e2> treated with <e1>propylthiouracil</e1> in whom a syndrome of pericarditis , fever , and glomerulonephritis developed .
D011441_D005334 CID METHODS : We present the first case report of a woman with hyperthyroidism treated with <e1>propylthiouracil</e1> in whom a syndrome of pericarditis , <e2>fever</e2> , and glomerulonephritis developed .
D011441_D005921 CID METHODS : We present the first case report of a woman with hyperthyroidism treated with <e1>propylthiouracil</e1> in whom a syndrome of pericarditis , fever , and <e2>glomerulonephritis</e2> developed .
11706060
D019344_D009202 NONE Combined antiretroviral therapy causes <e2>cardiomyopathy</e2> and elevates plasma <e1>lactate</e1> in transgenic AIDS mice .
D019344_D009202 NONE Highly active antiretroviral therapy ( HAART ) is implicated in <e2>cardiomyopathy</e2> ( CM ) and in elevated plasma <e1>lactate</e1> ( LA ) in AIDS through mechanisms of mitochondrial dysfunction .
D019344_D009202 NONE Highly active antiretroviral therapy ( HAART ) is implicated in cardiomyopathy ( <e2>CM</e2> ) and in elevated plasma <e1>lactate</e1> ( LA ) in AIDS through mechanisms of mitochondrial dysfunction .
D019344_D009202 NONE Highly active antiretroviral therapy ( HAART ) is implicated in <e2>cardiomyopathy</e2> ( CM ) and in elevated plasma lactate ( <e1>LA</e1> ) in AIDS through mechanisms of mitochondrial dysfunction .
D019344_D009202 NONE Highly active antiretroviral therapy ( HAART ) is implicated in cardiomyopathy ( <e2>CM</e2> ) and in elevated plasma lactate ( <e1>LA</e1> ) in AIDS through mechanisms of mitochondrial dysfunction .
D019344_D009202 NONE At termination of the experiments , mice underwent echocardiography , quantitation of abundance of molecular markers of <e2>CM</e2> ( ventricular mRNA encoding atrial natriuretic factor [ ANF ] and sarcoplasmic calcium ATPase [ SERCA2 ] ) , and determination of plasma <e1>LA</e1> .
D019344_D009202 NONE Results show that cumulative HAART caused mitochondrial <e2>CM</e2> with elevated <e1>LA</e1> in AIDS transgenic mice .
D019344_D000163 NONE Combined antiretroviral therapy causes cardiomyopathy and elevates plasma <e1>lactate</e1> in transgenic <e2>AIDS</e2> mice .
D019344_D000163 NONE Highly active antiretroviral therapy ( HAART ) is implicated in cardiomyopathy ( CM ) and in elevated plasma <e1>lactate</e1> ( LA ) in <e2>AIDS</e2> through mechanisms of mitochondrial dysfunction .
D019344_D000163 NONE Highly active antiretroviral therapy ( HAART ) is implicated in cardiomyopathy ( CM ) and in elevated plasma lactate ( <e1>LA</e1> ) in <e2>AIDS</e2> through mechanisms of mitochondrial dysfunction .
D019344_D000163 NONE Results show that cumulative HAART caused mitochondrial CM with elevated <e1>LA</e1> in <e2>AIDS</e2> transgenic mice .
D019344_D028361 NONE Highly active antiretroviral therapy ( HAART ) is implicated in cardiomyopathy ( CM ) and in elevated plasma <e1>lactate</e1> ( LA ) in AIDS through mechanisms of <e2>mitochondrial dysfunction</e2> .
D019344_D028361 NONE Highly active antiretroviral therapy ( HAART ) is implicated in cardiomyopathy ( CM ) and in elevated plasma lactate ( <e1>LA</e1> ) in AIDS through mechanisms of <e2>mitochondrial dysfunction</e2> .
D015215_D000163 NONE To determine mitochondrial events from HAART in vivo , 8-week-old hemizygous transgenic <e2>AIDS</e2> mice ( NL4 - 3Delta gag/pol ; TG ) and wild-type FVB/n littermates were treated with the HAART combination of <e1>zidovudine</e1> , lamivudine , and indinavir or vehicle control for 10 days or 35 days .
D019259_D000163 NONE To determine mitochondrial events from HAART in vivo , 8-week-old hemizygous transgenic <e2>AIDS</e2> mice ( NL4 - 3Delta gag/pol ; TG ) and wild-type FVB/n littermates were treated with the HAART combination of zidovudine , <e1>lamivudine</e1> , and indinavir or vehicle control for 10 days or 35 days .
D019469_D000163 NONE To determine mitochondrial events from HAART in vivo , 8-week-old hemizygous transgenic <e2>AIDS</e2> mice ( NL4 - 3Delta gag/pol ; TG ) and wild-type FVB/n littermates were treated with the HAART combination of zidovudine , lamivudine , and <e1>indinavir</e1> or vehicle control for 10 days or 35 days .
D002118_D009202 NONE At termination of the experiments , mice underwent echocardiography , quantitation of abundance of molecular markers of <e2>CM</e2> ( ventricular mRNA encoding atrial natriuretic factor [ ANF ] and sarcoplasmic <e1>calcium</e1> ATPase [ SERCA2 ] ) , and determination of plasma LA .
9100294
D002118_D018376 NONE <e2>Cardiovascular alterations</e2> in rat fetuses exposed to <e1>calcium</e1> channel blockers .
D002118_D018376 NONE Preclinical toxicologic investigation suggested that a new <e1>calcium</e1> channel blocker , Ro 40 - 5967 , induced <e2>cardiovascular alterations</e2> in rat fetuses exposed to this agent during organogenesis .
D002118_D018376 NONE The present study was designed to investigate the hypothesis that <e1>calcium</e1> channel blockers in general induce <e2>cardiovascular malformations</e2> indicating a pharmacologic class effect .
D002118_D018376 NONE Pregnant rats were administered one of these <e1>calcium</e1> channel blockers during the period of cardiac morphogenesis and the offspring examined on day 20 of gestation for <e2>cardiovascular malformations</e2> .
D002118_D018376 NONE A low incidence of <e2>cardiovascular malformations</e2> was observed after exposure to each of the four <e1>calcium</e1> channel blockers , but this incidence was statistically significant only for verapamil and nifedipine .
D020748_D018376 CID Preclinical toxicologic investigation suggested that a new calcium channel blocker , <e1>Ro 40 - 5967</e1> , induced <e2>cardiovascular alterations</e2> in rat fetuses exposed to this agent during organogenesis .
D014700_D018376 CID A low incidence of <e2>cardiovascular malformations</e2> was observed after exposure to each of the four calcium channel blockers , but this incidence was statistically significant only for <e1>verapamil</e1> and nifedipine .
D009543_D018376 CID A low incidence of <e2>cardiovascular malformations</e2> was observed after exposure to each of the four calcium channel blockers , but this incidence was statistically significant only for verapamil and <e1>nifedipine</e1> .
16867021
D006632_D002375 NONE The present study was designed to study the effect of <e1>histamine</e1> H(3)-receptor ligands on neuroleptic-induced <e2>catalepsy</e2> , apomorphine-induced climbing behavior and amphetamine-induced locomotor activities in mice .
D001058_D002375 NONE The present study was designed to study the effect of histamine H(3)-receptor ligands on neuroleptic-induced <e2>catalepsy</e2> , <e1>apomorphine-induced</e1> climbing behavior and amphetamine-induced locomotor activities in mice .
D001058_D002375 NONE <e2>Catalepsy</e2> was induced by haloperidol ( 2 mg/kg p.o. ) , while <e1>apomorphine</e1> ( 1.5 mg/kg s.c. ) and amphetamine ( 2 mg/kg s.c. ) were used for studying climbing behavior and locomotor activities , respectively .
D001058_D002375 NONE THP exhibited an antipsychotic-like profile by potentiating haloperidol-induced <e2>catalepsy</e2> , reducing amphetamine-induced hyperactivity and reducing <e1>apomorphine-induced</e1> climbing in mice .
D000661_D002375 NONE The present study was designed to study the effect of histamine H(3)-receptor ligands on neuroleptic-induced <e2>catalepsy</e2> , apomorphine-induced climbing behavior and <e1>amphetamine-induced</e1> locomotor activities in mice .
D000661_D002375 NONE <e2>Catalepsy</e2> was induced by haloperidol ( 2 mg/kg p.o. ) , while apomorphine ( 1.5 mg/kg s.c. ) and <e1>amphetamine</e1> ( 2 mg/kg s.c. ) were used for studying climbing behavior and locomotor activities , respectively .
D000661_D002375 NONE THP exhibited an antipsychotic-like profile by potentiating haloperidol-induced <e2>catalepsy</e2> , reducing <e1>amphetamine-induced</e1> hyperactivity and reducing apomorphine-induced climbing in mice .
D006220_D002375 CID <e2>Catalepsy</e2> was induced by <e1>haloperidol</e1> ( 2 mg/kg p.o. ) , while apomorphine ( 1.5 mg/kg s.c. ) and amphetamine ( 2 mg/kg s.c. ) were used for studying climbing behavior and locomotor activities , respectively .
D006220_D002375 CID Administration of THP ( 3.75 , 7.5 and 15 mg/kg i.p. ) 1 h prior to <e1>haloperidol</e1> resulted in a dose-dependent increase in the <e2>catalepsy</e2> times ( P < 0.05 ) .
D006220_D002375 CID THP exhibited an antipsychotic-like profile by potentiating <e1>haloperidol-induced</e1> <e2>catalepsy</e2> , reducing amphetamine-induced hyperactivity and reducing apomorphine-induced climbing in mice .
C069357_D002375 NONE <e1>(R)-alpha-methylhistamine</e1> ( RAMH ) ( 5 microg i.c.v. ) and thioperamide ( THP ) ( 15 mg/kg i.p. ) , per se did not cause <e2>catalepsy</e2> .
C069357_D002375 NONE (R)-alpha-methylhistamine ( <e1>RAMH</e1> ) ( 5 microg i.c.v. ) and thioperamide ( THP ) ( 15 mg/kg i.p. ) , per se did not cause <e2>catalepsy</e2> .
C052075_D002375 CID (R)-alpha-methylhistamine ( RAMH ) ( 5 microg i.c.v. ) and <e1>thioperamide</e1> ( THP ) ( 15 mg/kg i.p. ) , per se did not cause <e2>catalepsy</e2> .
C052075_D002375 CID (R)-alpha-methylhistamine ( RAMH ) ( 5 microg i.c.v. ) and thioperamide ( <e1>THP</e1> ) ( 15 mg/kg i.p. ) , per se did not cause <e2>catalepsy</e2> .
C052075_D002375 CID Administration of <e1>THP</e1> ( 3.75 , 7.5 and 15 mg/kg i.p. ) 1 h prior to haloperidol resulted in a dose-dependent increase in the <e2>catalepsy</e2> times ( P < 0.05 ) .
C052075_D002375 CID <e1>THP</e1> exhibited an antipsychotic-like profile by potentiating haloperidol-induced <e2>catalepsy</e2> , reducing amphetamine-induced hyperactivity and reducing apomorphine-induced climbing in mice .
D000661_D006948 CID On <e1>amphetamine-induced</e1> <e2>hyperactivity</e2> , THP ( 3.75 and 7.5 mg/kg i.p. ) reduced locomotor time , distance traveled and average speed ( P < 0.05 ) .
D000661_D006948 CID THP exhibited an antipsychotic-like profile by potentiating haloperidol-induced catalepsy , reducing <e1>amphetamine-induced</e1> <e2>hyperactivity</e2> and reducing apomorphine-induced climbing in mice .
C052075_D006948 NONE On amphetamine-induced <e2>hyperactivity</e2> , <e1>THP</e1> ( 3.75 and 7.5 mg/kg i.p. ) reduced locomotor time , distance traveled and average speed ( P < 0.05 ) .
C052075_D006948 NONE <e1>THP</e1> exhibited an antipsychotic-like profile by potentiating haloperidol-induced catalepsy , reducing amphetamine-induced <e2>hyperactivity</e2> and reducing apomorphine-induced climbing in mice .
D006220_D006948 NONE THP exhibited an antipsychotic-like profile by potentiating <e1>haloperidol-induced</e1> catalepsy , reducing amphetamine-induced <e2>hyperactivity</e2> and reducing apomorphine-induced climbing in mice .
D001058_D006948 NONE THP exhibited an antipsychotic-like profile by potentiating haloperidol-induced catalepsy , reducing amphetamine-induced <e2>hyperactivity</e2> and reducing <e1>apomorphine-induced</e1> climbing in mice .
19269743
D002211_D010146 CID Explicit episodic memory for sensory-discriminative components of <e1>capsaicin-induced</e1> <e2>pain</e2> : immediate and delayed ratings .
D002211_D010146 CID In order to address long-term <e2>pain</e2> memory , nine healthy male volunteers received intradermal injections of three doses of <e1>capsaicin</e1> ( 0.05 , 1 and 20 microg , separated by 15 min breaks ) , each given three times in a balanced design across three sessions at one week intervals .
D002211_D010146 CID Subjects were able to reliably discriminate <e2>pain</e2> magnitude and duration across <e1>capsaicin</e1> doses ( both p<0.001 ) , regardless of whether first-time ratings were requested immediately , after one hour or after one day .
84204
D002927_D003221 CID Pharmacokinetic and clinical studies in patients with <e1>cimetidine-associated</e1> mental <e2>confusion</e2> .
D002927_D003221 CID 15 cases of <e1>cimetidine-associated</e1> mental <e2>confusion</e2> have been reported .
D002927_D051437 NONE These 6 patients had both <e2>renal and liver dysfunction</e2> ( P less than 0.05 ) , as well as <e1>cimetidine</e1> trough-concentrations of more than 1.25 microgram/ml ( P less than 0.05 ) .
D002927_D008107 NONE These 6 patients had both <e2>renal and liver dysfunction</e2> ( P less than 0.05 ) , as well as <e1>cimetidine</e1> trough-concentrations of more than 1.25 microgram/ml ( P less than 0.05 ) .
11027905
D007649_D009369 NONE Analgesic effect of intravenous <e1>ketamine</e1> in <e2>cancer</e2> patients on morphine therapy : a randomized , controlled , double-blind , crossover , double-dose study .
D007649_D009369 NONE A slow bolus of subhypnotic doses of <e1>ketamine</e1> ( 0.25 mg/kg or 0.50 mg/kg ) was given to 10 <e2>cancer</e2> patients whose pain was unrelieved by morphine in a randomized , double-blind , crossover , double-dose study .
D009020_D009369 NONE Analgesic effect of intravenous ketamine in <e2>cancer</e2> patients on <e1>morphine</e1> therapy : a randomized , controlled , double-blind , crossover , double-dose study .
D009020_D009369 NONE A slow bolus of subhypnotic doses of ketamine ( 0.25 mg/kg or 0.50 mg/kg ) was given to 10 <e2>cancer</e2> patients whose pain was unrelieved by <e1>morphine</e1> in a randomized , double-blind , crossover , double-dose study .
D009020_D010146 NONE <e2>Pain</e2> not responsive to <e1>morphine</e1> is often problematic .
D009020_D010146 NONE A slow bolus of subhypnotic doses of ketamine ( 0.25 mg/kg or 0.50 mg/kg ) was given to 10 cancer patients whose <e2>pain</e2> was unrelieved by <e1>morphine</e1> in a randomized , double-blind , crossover , double-dose study .
D009020_D010146 NONE Ketamine can improve <e1>morphine</e1> analgesia in difficult <e2>pain</e2> syndromes , such as neuropathic pain .
D016202_D010146 NONE Animal and clinical studies have suggested that <e1>N-methyl-D-aspartate</e1> ( NMDA ) antagonists , such as ketamine , may be effective in improving opioid analgesia in difficult <e2>pain</e2> syndromes , such as neuropathic pain .
D016202_D010146 NONE Animal and clinical studies have suggested that N-methyl-D-aspartate ( <e1>NMDA</e1> ) antagonists , such as ketamine , may be effective in improving opioid analgesia in difficult <e2>pain</e2> syndromes , such as neuropathic pain .
D016202_D009437 NONE Animal and clinical studies have suggested that <e1>N-methyl-D-aspartate</e1> ( NMDA ) antagonists , such as ketamine , may be effective in improving opioid analgesia in difficult pain syndromes , such as <e2>neuropathic pain</e2> .
D016202_D009437 NONE Animal and clinical studies have suggested that N-methyl-D-aspartate ( <e1>NMDA</e1> ) antagonists , such as ketamine , may be effective in improving opioid analgesia in difficult pain syndromes , such as <e2>neuropathic pain</e2> .
D007649_D010146 NONE Animal and clinical studies have suggested that N-methyl-D-aspartate ( NMDA ) antagonists , such as <e1>ketamine</e1> , may be effective in improving opioid analgesia in difficult <e2>pain</e2> syndromes , such as neuropathic pain .
D007649_D010146 NONE A slow bolus of subhypnotic doses of <e1>ketamine</e1> ( 0.25 mg/kg or 0.50 mg/kg ) was given to 10 cancer patients whose <e2>pain</e2> was unrelieved by morphine in a randomized , double-blind , crossover , double-dose study .
D007649_D010146 NONE <e1>Ketamine</e1> , but not saline solution , significantly reduced the <e2>pain</e2> intensity in almost all the patients at both doses .
D007649_D010146 NONE <e1>Ketamine</e1> can improve morphine analgesia in difficult <e2>pain</e2> syndromes , such as neuropathic pain .
D007649_D009437 NONE Animal and clinical studies have suggested that N-methyl-D-aspartate ( NMDA ) antagonists , such as <e1>ketamine</e1> , may be effective in improving opioid analgesia in difficult pain syndromes , such as <e2>neuropathic pain</e2> .
D007649_D009437 NONE <e1>Ketamine</e1> can improve morphine analgesia in difficult pain syndromes , such as <e2>neuropathic pain</e2> .
D009020_D009437 NONE Ketamine can improve <e1>morphine</e1> analgesia in difficult pain syndromes , such as <e2>neuropathic pain</e2> .
3409645
D008727_D007172 CID <e2>Impotence</e2> was more common among male patients than controls and was found to be associated with co-morbidity and the taking of <e1>methotrexate</e1> .
7234705
D011342_D017180 CID <e1>Procainamide-induced</e1> polymorphous <e2>ventricular tachycardia</e2> .
D011342_D017180 CID Seven cases of <e1>procainamide-induced</e1> polymorphous <e2>ventricular tachycardia</e2> are presented .
D011342_D017180 CID In four patients , polymorphous <e2>ventricular tachycardia</e2> appeared after intravenous administration of 200 to 400 mg of <e1>procainamide</e1> for the treatment of sustained ventricular tachycardia .
D011342_D017180 CID In four patients , polymorphous ventricular tachycardia appeared after intravenous administration of 200 to 400 mg of <e1>procainamide</e1> for the treatment of sustained <e2>ventricular tachycardia</e2> .
D011342_D017180 CID In the seventh patient , a permanent ventricular pacemaker was inserted and , despite continuation of <e1>procainamide</e1> therapy , polymorphous <e2>ventricular tachycardia</e2> did not reoccur .
D011342_D017180 CID These seven cases demonstrate that <e1>procainamide</e1> can produce an acquired prolonged Q-T syndrome with polymorphous <e2>ventricular tachycardia</e2> .
D011342_D018879 NONE In the remaining three patients , <e1>procainamide</e1> was administered orally for treatment of chronic <e2>premature ventricular contractions</e2> or atrial flutter .
D011342_D001282 NONE In the remaining three patients , <e1>procainamide</e1> was administered orally for treatment of chronic premature ventricular contractions or <e2>atrial flutter</e2> .
D011342_D008133 NONE These seven cases demonstrate that <e1>procainamide</e1> can produce an acquired <e2>prolonged Q-T syndrome</e2> with polymorphous ventricular tachycardia .
1549199
D007980_D064420 NONE While there is no single correct starting dose for <e1>levodopa</e1> therapy , many individuals can be started on either the 25/100 or controlled-release formula , following the general rule not to attempt to titrate carbidopa-levodopa to the point of " normality , " which can lead to <e2>toxicity</e2> .
D007980_D064420 NONE While there is no single correct starting dose for levodopa therapy , many individuals can be started on either the 25/100 or controlled-release formula , following the general rule not to attempt to titrate <e1>carbidopa-levodopa</e1> to the point of " normality , " which can lead to <e2>toxicity</e2> .
D002230_D064420 NONE While there is no single correct starting dose for levodopa therapy , many individuals can be started on either the 25/100 or controlled-release formula , following the general rule not to attempt to titrate <e1>carbidopa-levodopa</e1> to the point of " normality , " which can lead to <e2>toxicity</e2> .
D007980_D005767 CID Other possible adverse effects -- such as <e2>gastrointestinal disorders</e2> , orthostatic hypotension , <e1>levodopa-induced</e1> psychosis , sleep disturbances or parasomnias , or drug interactions -- also require carefully monitored individual treatment .
D007980_D007024 CID Other possible adverse effects -- such as gastrointestinal disorders , <e2>orthostatic hypotension</e2> , <e1>levodopa-induced</e1> psychosis , sleep disturbances or parasomnias , or drug interactions -- also require carefully monitored individual treatment .
D007980_D011618 NONE Other possible adverse effects -- such as gastrointestinal disorders , orthostatic hypotension , <e1>levodopa-induced</e1> <e2>psychosis</e2> , sleep disturbances or parasomnias , or drug interactions -- also require carefully monitored individual treatment .
D007980_D012893 NONE Other possible adverse effects -- such as gastrointestinal disorders , orthostatic hypotension , <e1>levodopa-induced</e1> psychosis , <e2>sleep disturbances</e2> or parasomnias , or drug interactions -- also require carefully monitored individual treatment .
D007980_D020447 CID Other possible adverse effects -- such as gastrointestinal disorders , orthostatic hypotension , <e1>levodopa-induced</e1> psychosis , sleep disturbances or <e2>parasomnias</e2> , or drug interactions -- also require carefully monitored individual treatment .
18308784
C035054_D007859 NONE <e1>Ginsenoside Rg1</e1> restores the <e2>impairment of learning</e2> induced by chronic morphine administration in rats .
C035054_D007859 NONE <e1>Rg1</e1> , as a ginsenoside extracted from Panax ginseng , could ameliorate spatial <e2>learning impairment</e2> .
C035054_D007859 NONE The aim of this study was to investigate the effect of <e1>Rg1</e1> on <e2>learning impairment</e2> by chronic morphine administration and the mechanism responsible for this effect .
D009020_D007859 CID Ginsenoside Rg1 restores the <e2>impairment of learning</e2> induced by chronic <e1>morphine</e1> administration in rats .
D009020_D007859 CID The aim of this study was to investigate the effect of Rg1 on <e2>learning impairment</e2> by chronic <e1>morphine</e1> administration and the mechanism responsible for this effect .
D036145_D007859 NONE Rg1 , as a <e1>ginsenoside</e1> extracted from Panax ginseng , could ameliorate spatial <e2>learning impairment</e2> .
18768591
D004317_D009404 CID Serum- and glucocorticoid-inducible kinase 1 in <e1>doxorubicin-induced</e1> <e2>nephrotic syndrome</e2> .
D004317_D009404 CID <e1>Doxorubicin</e1> treatment resulted in heavy proteinuria ( > 100 mg protein/mg crea ) in 15/44 of sgk1(+/+ ) and 15/44 of sgk1(-/- ) mice leading to severe <e2>nephrotic syndrome</e2> with ascites , lipidemia , and hypoalbuminemia in both genotypes .
D004317_D007674 NONE <e1>Doxorubicin-induced</e1> <e2>nephropathy</e2> leads to epithelial sodium channel (ENaC)-dependent volume retention and renal fibrosis .
D004317_D016055 NONE <e1>Doxorubicin-induced</e1> nephropathy leads to epithelial sodium channel (ENaC)-dependent <e2>volume retention</e2> and renal fibrosis .
D004317_D005355 NONE <e1>Doxorubicin-induced</e1> nephropathy leads to epithelial sodium channel (ENaC)-dependent volume retention and renal <e2>fibrosis</e2> .
D012964_D007674 NONE Doxorubicin-induced <e2>nephropathy</e2> leads to epithelial <e1>sodium</e1> channel (ENaC)-dependent volume retention and renal fibrosis .
D012964_D016055 NONE Doxorubicin-induced nephropathy leads to epithelial <e1>sodium</e1> channel (ENaC)-dependent <e2>volume retention</e2> and renal fibrosis .
D012964_D005355 NONE Doxorubicin-induced nephropathy leads to epithelial <e1>sodium</e1> channel (ENaC)-dependent volume retention and renal <e2>fibrosis</e2> .
D000450_D005355 NONE The <e1>aldosterone-sensitive</e1> serum- and glucocorticoid-inducible kinase SGK1 has been shown to participate in the stimulation of ENaC and to mediate renal <e2>fibrosis</e2> following mineralocorticoid and salt excess .
D004317_D011507 CID <e1>Doxorubicin</e1> treatment resulted in heavy <e2>proteinuria</e2> ( > 100 mg protein/mg crea ) in 15/44 of sgk1(+/+ ) and 15/44 of sgk1(-/- ) mice leading to severe nephrotic syndrome with ascites , lipidemia , and hypoalbuminemia in both genotypes .
D004317_D001201 CID <e1>Doxorubicin</e1> treatment resulted in heavy proteinuria ( > 100 mg protein/mg crea ) in 15/44 of sgk1(+/+ ) and 15/44 of sgk1(-/- ) mice leading to severe nephrotic syndrome with <e2>ascites</e2> , lipidemia , and hypoalbuminemia in both genotypes .
D004317_D006949 CID <e1>Doxorubicin</e1> treatment resulted in heavy proteinuria ( > 100 mg protein/mg crea ) in 15/44 of sgk1(+/+ ) and 15/44 of sgk1(-/- ) mice leading to severe nephrotic syndrome with ascites , <e2>lipidemia</e2> , and hypoalbuminemia in both genotypes .
D004317_D034141 CID <e1>Doxorubicin</e1> treatment resulted in heavy proteinuria ( > 100 mg protein/mg crea ) in 15/44 of sgk1(+/+ ) and 15/44 of sgk1(-/- ) mice leading to severe nephrotic syndrome with ascites , lipidemia , and <e2>hypoalbuminemia</e2> in both genotypes .
D000450_D009404 NONE Plasma <e1>aldosterone</e1> levels increased in <e2>nephrotic</e2> mice of both genotypes and was followed by increased SGK1 protein expression in sgk1(+/+ ) mice .
D012964_D015430 NONE Urinary <e1>sodium</e1> excretion reached signficantly lower values in sgk1(+/+ ) mice ( 15 +/- 5 mumol/mg crea ) than in sgk1(-/- ) mice ( 35 +/- 5 mumol/mg crea ) and was associated with a significantly higher body <e2>weight gain</e2> in sgk1(+/+ ) compared with sgk1(-/- ) mice ( + 6.6 +/- 0.7 vs. + 4.1 +/- 0.8 g ) .
D014508_D009404 NONE During the course of <e2>nephrotic syndrome</e2> , serum <e1>urea</e1> concentrations increased significantly faster in sgk1(-/- ) mice than in sgk1(+/+ ) mice leading to uremia and a reduced median survival in sgk1(-/- ) mice ( 29 vs. 40 days in sgk1(+/+ ) mice ) .
D014508_D014511 NONE During the course of nephrotic syndrome , serum <e1>urea</e1> concentrations increased significantly faster in sgk1(-/- ) mice than in sgk1(+/+ ) mice leading to <e2>uremia</e2> and a reduced median survival in sgk1(-/- ) mice ( 29 vs. 40 days in sgk1(+/+ ) mice ) .
1967484
D013469_D004421 CID <e1>Sulpiride-induced</e1> <e2>tardive dystonia</e2> .
D013469_D004421 CID We studied a 37-year-old man who developed persistent segmental <e2>dystonia</e2> within 2 months after starting <e1>sulpiride</e1> therapy .
D013469_D004421 CID We could not find any previous reports of <e1>sulpiride-induced</e1> <e2>tardive dystonia</e2> .
D013469_D004409 NONE Although initially thought to be free of extrapyramidal side effects , <e1>sulpiride-induced</e1> <e2>tardive dyskinesia</e2> and parkinsonism have been reported occasionally .
D013469_D010302 NONE Although initially thought to be free of extrapyramidal side effects , <e1>sulpiride-induced</e1> tardive dyskinesia and <e2>parkinsonism</e2> have been reported occasionally .
12707296
D001120_D006973 NONE <e1>L-arginine</e1> transport in humans with cortisol-induced <e2>hypertension</e2> .
D001120_D006973 NONE A deficient <e1>L-arginine-nitric</e1> oxide system is implicated in cortisol-induced <e2>hypertension</e2> .
D001120_D006973 NONE We conclude that cortisol-induced <e2>increases in blood pressure</e2> are not associated with abnormalities in the <e1>l-arginine</e1> transport system .
D006854_D006973 NONE L-arginine transport in humans with <e1>cortisol-induced</e1> <e2>hypertension</e2> .
D006854_D006973 NONE A deficient L-arginine-nitric oxide system is implicated in <e1>cortisol-induced</e1> <e2>hypertension</e2> .
D006854_D006973 NONE We conclude that <e1>cortisol-induced</e1> <e2>increases in blood pressure</e2> are not associated with abnormalities in the l-arginine transport system .
D009569_D006973 NONE A deficient <e1>L-arginine-nitric oxide</e1> system is implicated in cortisol-induced <e2>hypertension</e2> .
2440413
D001556_D012640 NONE Differential effects of <e1>gamma-hexachlorocyclohexane</e1> ( lindane ) on pharmacologically-induced <e2>seizures</e2> .
D001556_D012640 NONE Differential effects of gamma-hexachlorocyclohexane ( <e1>lindane</e1> ) on pharmacologically-induced <e2>seizures</e2> .
D001556_D012640 NONE <e1>Gamma-hexachlorocyclohexane</e1> ( gamma-HCH ) , the active ingredient of the insecticide lindane , has been shown to decrease <e2>seizure</e2> threshold to pentylenetrazol ( PTZ ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced seizures 24 h after exposure to gamma-HCH ( Vohland et al. 1981 ) .
D001556_D012640 NONE <e1>Gamma-hexachlorocyclohexane</e1> ( gamma-HCH ) , the active ingredient of the insecticide lindane , has been shown to decrease seizure threshold to pentylenetrazol ( PTZ ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced <e2>seizures</e2> 24 h after exposure to gamma-HCH ( Vohland et al. 1981 ) .
D001556_D012640 NONE Gamma-hexachlorocyclohexane ( <e1>gamma-HCH</e1> ) , the active ingredient of the insecticide lindane , has been shown to decrease <e2>seizure</e2> threshold to pentylenetrazol ( PTZ ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced seizures 24 h after exposure to gamma-HCH ( Vohland et al. 1981 ) .
D001556_D012640 NONE Gamma-hexachlorocyclohexane ( <e1>gamma-HCH</e1> ) , the active ingredient of the insecticide lindane , has been shown to decrease seizure threshold to pentylenetrazol ( PTZ ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced <e2>seizures</e2> 24 h after exposure to gamma-HCH ( Vohland et al. 1981 ) .
D001556_D012640 NONE Gamma-hexachlorocyclohexane ( gamma-HCH ) , the active ingredient of the insecticide <e1>lindane</e1> , has been shown to decrease <e2>seizure</e2> threshold to pentylenetrazol ( PTZ ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced seizures 24 h after exposure to gamma-HCH ( Vohland et al. 1981 ) .
D001556_D012640 NONE Gamma-hexachlorocyclohexane ( gamma-HCH ) , the active ingredient of the insecticide <e1>lindane</e1> , has been shown to decrease seizure threshold to pentylenetrazol ( PTZ ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced <e2>seizures</e2> 24 h after exposure to gamma-HCH ( Vohland et al. 1981 ) .
D001556_D012640 NONE Gamma-hexachlorocyclohexane ( gamma-HCH ) , the active ingredient of the insecticide lindane , has been shown to decrease <e2>seizure</e2> threshold to pentylenetrazol ( PTZ ) 3 h after exposure to <e1>gamma-HCH</e1> and conversely increase threshold to PTZ-induced seizures 24 h after exposure to gamma-HCH ( Vohland et al. 1981 ) .
D001556_D012640 NONE Gamma-hexachlorocyclohexane ( gamma-HCH ) , the active ingredient of the insecticide lindane , has been shown to decrease seizure threshold to pentylenetrazol ( PTZ ) 3 h after exposure to <e1>gamma-HCH</e1> and conversely increase threshold to PTZ-induced <e2>seizures</e2> 24 h after exposure to gamma-HCH ( Vohland et al. 1981 ) .
D001556_D012640 NONE Gamma-hexachlorocyclohexane ( gamma-HCH ) , the active ingredient of the insecticide lindane , has been shown to decrease <e2>seizure</e2> threshold to pentylenetrazol ( PTZ ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced seizures 24 h after exposure to <e1>gamma-HCH</e1> ( Vohland et al. 1981 ) .
D001556_D012640 NONE Gamma-hexachlorocyclohexane ( gamma-HCH ) , the active ingredient of the insecticide lindane , has been shown to decrease seizure threshold to pentylenetrazol ( PTZ ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced <e2>seizures</e2> 24 h after exposure to <e1>gamma-HCH</e1> ( Vohland et al. 1981 ) .
D001556_D012640 NONE In this study , the severity of response to other <e2>seizure-inducing</e2> agents was tested in mice 1 and 24 h after intraperitoneal administration of 80 mg/kg <e1>gamma-HCH</e1> .
D001556_D012640 NONE One hour after the administration of <e1>gamma-HCH</e1> , the activity of <e2>seizure-inducing</e2> agents was increased , regardless of their mechanism , while 24 h after gamma-HCH a differential response was observed .
D001556_D012640 NONE One hour after the administration of gamma-HCH , the activity of <e2>seizure-inducing</e2> agents was increased , regardless of their mechanism , while 24 h after <e1>gamma-HCH</e1> a differential response was observed .
D001556_D012640 NONE The pharmacological challenge data suggest that tolerance may occur to <e2>seizure</e2> activity induced by PTZ and PTX 24 h after <e1>gamma-HCH</e1> , since the response to only these two seizure-inducing agents is decreased .
D001556_D012640 NONE The pharmacological challenge data suggest that tolerance may occur to seizure activity induced by PTZ and PTX 24 h after <e1>gamma-HCH</e1> , since the response to only these two <e2>seizure-inducing</e2> agents is decreased .
D001556_D012640 NONE The in vitro data suggest that the site responsible for the decrease in <e2>seizure</e2> activity 24 h after <e1>gamma-HCH</e1> may be the GABA-A receptor-linked chloride channel .
D010433_D012640 CID Gamma-hexachlorocyclohexane ( gamma-HCH ) , the active ingredient of the insecticide lindane , has been shown to decrease <e2>seizure</e2> threshold to pentylenetrazol ( <e1>PTZ</e1> ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced seizures 24 h after exposure to gamma-HCH ( Vohland et al. 1981 ) .
D010433_D012640 CID Gamma-hexachlorocyclohexane ( gamma-HCH ) , the active ingredient of the insecticide lindane , has been shown to decrease seizure threshold to pentylenetrazol ( <e1>PTZ</e1> ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced <e2>seizures</e2> 24 h after exposure to gamma-HCH ( Vohland et al. 1981 ) .
D010433_D012640 CID Gamma-hexachlorocyclohexane ( gamma-HCH ) , the active ingredient of the insecticide lindane , has been shown to decrease <e2>seizure</e2> threshold to pentylenetrazol ( PTZ ) 3 h after exposure to gamma-HCH and conversely increase threshold to <e1>PTZ-induced</e1> seizures 24 h after exposure to gamma-HCH ( Vohland et al. 1981 ) .
D010433_D012640 CID Gamma-hexachlorocyclohexane ( gamma-HCH ) , the active ingredient of the insecticide lindane , has been shown to decrease seizure threshold to pentylenetrazol ( PTZ ) 3 h after exposure to gamma-HCH and conversely increase threshold to <e1>PTZ-induced</e1> <e2>seizures</e2> 24 h after exposure to gamma-HCH ( Vohland et al. 1981 ) .
D010433_D012640 CID <e2>Seizure</e2> activity due to <e1>PTZ</e1> and picrotoxin ( PTX ) was significantly decreased ; however , seizure activity due to 3-mercaptopropionic acid ( MPA ) , bicuculline ( BCC ) , methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate ( DMCM ) , or strychnine ( STR ) was not different from control .
D010433_D012640 CID Seizure activity due to <e1>PTZ</e1> and picrotoxin ( PTX ) was significantly decreased ; however , <e2>seizure</e2> activity due to 3-mercaptopropionic acid ( MPA ) , bicuculline ( BCC ) , methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate ( DMCM ) , or strychnine ( STR ) was not different from control .
D010433_D012640 CID The pharmacological challenge data suggest that tolerance may occur to <e2>seizure</e2> activity induced by <e1>PTZ</e1> and PTX 24 h after gamma-HCH , since the response to only these two seizure-inducing agents is decreased .
D010433_D012640 CID The pharmacological challenge data suggest that tolerance may occur to seizure activity induced by <e1>PTZ</e1> and PTX 24 h after gamma-HCH , since the response to only these two <e2>seizure-inducing</e2> agents is decreased .
D010852_D012640 CID <e2>Seizure</e2> activity due to PTZ and <e1>picrotoxin</e1> ( PTX ) was significantly decreased ; however , seizure activity due to 3-mercaptopropionic acid ( MPA ) , bicuculline ( BCC ) , methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate ( DMCM ) , or strychnine ( STR ) was not different from control .
D010852_D012640 CID Seizure activity due to PTZ and <e1>picrotoxin</e1> ( PTX ) was significantly decreased ; however , <e2>seizure</e2> activity due to 3-mercaptopropionic acid ( MPA ) , bicuculline ( BCC ) , methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate ( DMCM ) , or strychnine ( STR ) was not different from control .
D010852_D012640 CID <e2>Seizure</e2> activity due to PTZ and picrotoxin ( <e1>PTX</e1> ) was significantly decreased ; however , seizure activity due to 3-mercaptopropionic acid ( MPA ) , bicuculline ( BCC ) , methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate ( DMCM ) , or strychnine ( STR ) was not different from control .
D010852_D012640 CID Seizure activity due to PTZ and picrotoxin ( <e1>PTX</e1> ) was significantly decreased ; however , <e2>seizure</e2> activity due to 3-mercaptopropionic acid ( MPA ) , bicuculline ( BCC ) , methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate ( DMCM ) , or strychnine ( STR ) was not different from control .
D010852_D012640 CID The pharmacological challenge data suggest that tolerance may occur to <e2>seizure</e2> activity induced by PTZ and <e1>PTX</e1> 24 h after gamma-HCH , since the response to only these two seizure-inducing agents is decreased .
D010852_D012640 CID The pharmacological challenge data suggest that tolerance may occur to seizure activity induced by PTZ and <e1>PTX</e1> 24 h after gamma-HCH , since the response to only these two <e2>seizure-inducing</e2> agents is decreased .
D015097_D012640 CID <e2>Seizure</e2> activity due to PTZ and picrotoxin ( PTX ) was significantly decreased ; however , seizure activity due to <e1>3-mercaptopropionic acid</e1> ( MPA ) , bicuculline ( BCC ) , methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate ( DMCM ) , or strychnine ( STR ) was not different from control .
D015097_D012640 CID Seizure activity due to PTZ and picrotoxin ( PTX ) was significantly decreased ; however , <e2>seizure</e2> activity due to <e1>3-mercaptopropionic acid</e1> ( MPA ) , bicuculline ( BCC ) , methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate ( DMCM ) , or strychnine ( STR ) was not different from control .
D015097_D012640 CID <e2>Seizure</e2> activity due to PTZ and picrotoxin ( PTX ) was significantly decreased ; however , seizure activity due to 3-mercaptopropionic acid ( <e1>MPA</e1> ) , bicuculline ( BCC ) , methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate ( DMCM ) , or strychnine ( STR ) was not different from control .
D015097_D012640 CID Seizure activity due to PTZ and picrotoxin ( PTX ) was significantly decreased ; however , <e2>seizure</e2> activity due to 3-mercaptopropionic acid ( <e1>MPA</e1> ) , bicuculline ( BCC ) , methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate ( DMCM ) , or strychnine ( STR ) was not different from control .
D001640_D012640 CID <e2>Seizure</e2> activity due to PTZ and picrotoxin ( PTX ) was significantly decreased ; however , seizure activity due to 3-mercaptopropionic acid ( MPA ) , <e1>bicuculline</e1> ( BCC ) , methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate ( DMCM ) , or strychnine ( STR ) was not different from control .
D001640_D012640 CID Seizure activity due to PTZ and picrotoxin ( PTX ) was significantly decreased ; however , <e2>seizure</e2> activity due to 3-mercaptopropionic acid ( MPA ) , <e1>bicuculline</e1> ( BCC ) , methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate ( DMCM ) , or strychnine ( STR ) was not different from control .
D001640_D012640 CID <e2>Seizure</e2> activity due to PTZ and picrotoxin ( PTX ) was significantly decreased ; however , seizure activity due to 3-mercaptopropionic acid ( MPA ) , bicuculline ( <e1>BCC</e1> ) , methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate ( DMCM ) , or strychnine ( STR ) was not different from control .
D001640_D012640 CID Seizure activity due to PTZ and picrotoxin ( PTX ) was significantly decreased ; however , <e2>seizure</e2> activity due to 3-mercaptopropionic acid ( MPA ) , bicuculline ( <e1>BCC</e1> ) , methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate ( DMCM ) , or strychnine ( STR ) was not different from control .
C034818_D012640 CID <e2>Seizure</e2> activity due to PTZ and picrotoxin ( PTX ) was significantly decreased ; however , seizure activity due to 3-mercaptopropionic acid ( MPA ) , bicuculline ( BCC ) , <e1>methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate</e1> ( DMCM ) , or strychnine ( STR ) was not different from control .
C034818_D012640 CID Seizure activity due to PTZ and picrotoxin ( PTX ) was significantly decreased ; however , <e2>seizure</e2> activity due to 3-mercaptopropionic acid ( MPA ) , bicuculline ( BCC ) , <e1>methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate</e1> ( DMCM ) , or strychnine ( STR ) was not different from control .
C034818_D012640 CID <e2>Seizure</e2> activity due to PTZ and picrotoxin ( PTX ) was significantly decreased ; however , seizure activity due to 3-mercaptopropionic acid ( MPA ) , bicuculline ( BCC ) , methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate ( <e1>DMCM</e1> ) , or strychnine ( STR ) was not different from control .
C034818_D012640 CID Seizure activity due to PTZ and picrotoxin ( PTX ) was significantly decreased ; however , <e2>seizure</e2> activity due to 3-mercaptopropionic acid ( MPA ) , bicuculline ( BCC ) , methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate ( <e1>DMCM</e1> ) , or strychnine ( STR ) was not different from control .
D013331_D012640 CID <e2>Seizure</e2> activity due to PTZ and picrotoxin ( PTX ) was significantly decreased ; however , seizure activity due to 3-mercaptopropionic acid ( MPA ) , bicuculline ( BCC ) , methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate ( DMCM ) , or <e1>strychnine</e1> ( STR ) was not different from control .
D013331_D012640 CID Seizure activity due to PTZ and picrotoxin ( PTX ) was significantly decreased ; however , <e2>seizure</e2> activity due to 3-mercaptopropionic acid ( MPA ) , bicuculline ( BCC ) , methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate ( DMCM ) , or <e1>strychnine</e1> ( STR ) was not different from control .
D013331_D012640 CID <e2>Seizure</e2> activity due to PTZ and picrotoxin ( PTX ) was significantly decreased ; however , seizure activity due to 3-mercaptopropionic acid ( MPA ) , bicuculline ( BCC ) , methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate ( DMCM ) , or strychnine ( <e1>STR</e1> ) was not different from control .
D013331_D012640 CID Seizure activity due to PTZ and picrotoxin ( PTX ) was significantly decreased ; however , <e2>seizure</e2> activity due to 3-mercaptopropionic acid ( MPA ) , bicuculline ( BCC ) , methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate ( DMCM ) , or strychnine ( <e1>STR</e1> ) was not different from control .
D005680_D012640 NONE The in vitro data suggest that the site responsible for the decrease in <e2>seizure</e2> activity 24 h after gamma-HCH may be the <e1>GABA-A</e1> receptor-linked chloride channel .
1527456
D008012_D014012 NONE Treatment of <e2>tinnitus</e2> by intratympanic instillation of <e1>lignocaine</e1> ( lidocaine ) 2 per cent through ventilation tubes .
D008012_D014012 NONE Treatment of <e2>tinnitus</e2> by intratympanic instillation of lignocaine ( <e1>lidocaine</e1> ) 2 per cent through ventilation tubes .
D008012_D014012 NONE This paper presents the results of treating <e2>IST</e2> by intratympanic instillation of <e1>lignocaine</e1> ( lidocaine ) 2 per cent through a grommet , for five weekly courses .
D008012_D014012 NONE This paper presents the results of treating <e2>IST</e2> by intratympanic instillation of lignocaine ( <e1>lidocaine</e1> ) 2 per cent through a grommet , for five weekly courses .
2515254
D005996_D008881 CID Twenty common <e2>migraine</e2> patients received a one sided frontotemporal application of <e1>nitroglycerin</e1> ( 10 patients ) or placebo ointment ( 10 patients ) in a double blind study .
D005996_D008881 CID Early onset <e2>migraine</e2> attacks were induced by <e1>nitroglycerin</e1> in seven out of 10 patients versus no patient in the placebo group .
D005996_D008881 CID Subsequently 20 <e2>migraine</e2> patients , who developed an early onset attack with frontotemporal <e1>nitroglycerin</e1> , received the drug in a second induction test at other body areas .
D005996_D008881 CID Thus the <e2>migraine-inducing</e2> effect of <e1>nitroglycerin</e1> seems to depend on direct stimulation of the habitual site of pain , suggesting that the frontotemporal region is of crucial importance in the development of a migraine crisis .
D005996_D008881 CID Thus the migraine-inducing effect of <e1>nitroglycerin</e1> seems to depend on direct stimulation of the habitual site of pain , suggesting that the frontotemporal region is of crucial importance in the development of a <e2>migraine</e2> crisis .
D005996_D010146 NONE Thus the migraine-inducing effect of <e1>nitroglycerin</e1> seems to depend on direct stimulation of the habitual site of <e2>pain</e2> , suggesting that the frontotemporal region is of crucial importance in the development of a migraine crisis .
20080983
C048833_D012893 NONE OBJECTIVE : The purpose of the present study was to determine the effect of morning-dosed <e1>modafinil</e1> on sleep and <e2>daytime sleepiness</e2> in chronic cocaine users .
C048833_D012893 NONE <e1>Modafinil</e1> was associated with increased daytime sleep latency , as measured by the Multiple Sleep Latency Test , and a nearly significant decrease in subjective <e2>daytime sleepiness</e2> .
C048833_D012893 NONE CONCLUSIONS : Morning-dosed <e1>modafinil</e1> promotes nocturnal sleep , normalizes sleep architecture , and decreases <e2>daytime sleepiness</e2> in abstinent cocaine users .
D003042_D012893 CID OBJECTIVE : The purpose of the present study was to determine the effect of morning-dosed modafinil on sleep and <e2>daytime sleepiness</e2> in chronic <e1>cocaine</e1> users .
D003042_D012893 CID CONCLUSIONS : Morning-dosed modafinil promotes nocturnal sleep , normalizes sleep architecture , and decreases <e2>daytime sleepiness</e2> in abstinent <e1>cocaine</e1> users .
3125768
D015760_D009127 CID Intracranial pressure increases during <e1>alfentanil-induced</e1> <e2>rigidity</e2> .
D015760_D009127 CID Intracranial pressure ( ICP ) was measured during <e1>alfentanil-induced</e1> <e2>rigidity</e2> in rats .
D015760_D009127 CID These observations suggest that <e2>rigidity</e2> should be prevented when <e1>alfentanil</e1> , and , presumably , other opiates , are used in the anesthetic management of patients with ICP problems .
C032943_D009127 NONE These variables returned to baseline when <e2>rigidity</e2> was abolished with <e1>metocurine</e1> .
20698227
D012254_D000743 NONE Can angiogenesis be a target of treatment for <e1>ribavirin</e1> associated <e2>hemolytic anemia</e2> ?
D012254_D006461 NONE BACKGROUND/AIMS : Recently <e1>ribavirin</e1> has been found to inhibit angiogenesis and a number of angiogenesis inhibitors such as sunitinib and sorafenib have been found to cause acute <e2>hemolysis</e2> .
C473478_D006461 CID BACKGROUND/AIMS : Recently ribavirin has been found to inhibit angiogenesis and a number of angiogenesis inhibitors such as <e1>sunitinib</e1> and sorafenib have been found to cause acute <e2>hemolysis</e2> .
C471405_D006461 CID BACKGROUND/AIMS : Recently ribavirin has been found to inhibit angiogenesis and a number of angiogenesis inhibitors such as sunitinib and <e1>sorafenib</e1> have been found to cause acute <e2>hemolysis</e2> .
C100416_D019698 NONE METHODS : Fourteen patients <e2>chronically infected with hepatitis C virus</e2> were treated by <e1>pegylated interferon alpha 2a</e1> and ribavirin .
D012254_D019698 NONE METHODS : Fourteen patients <e2>chronically infected with hepatitis C virus</e2> were treated by pegylated interferon alpha 2a and <e1>ribavirin</e1> .
D012254_D019698 NONE CONCLUSION : This is the first study in the literature investigating a link between angiogenesis soluble markers and <e1>ribavirin</e1> induced anemia in patients with <e2>hepatitis C</e2> and we could not find any relation .
D012254_D000740 NONE CONCLUSION : This is the first study in the literature investigating a link between angiogenesis soluble markers and <e1>ribavirin</e1> induced <e2>anemia</e2> in patients with hepatitis C and we could not find any relation .
18261172
D020123_D011507 CID Development of <e2>proteinuria</e2> after switch to <e1>sirolimus-based</e1> immunosuppression in long-term cardiac transplant patients .
D020123_D011507 CID The novel immunosuppressive ( IS ) drug <e1>sirolmus</e1> ( Srl ) lacks nephrotoxic effects ; however , <e2>proteinuria</e2> associated with Srl has been reported following renal transplantation .
D020123_D011507 CID The novel immunosuppressive ( IS ) drug sirolmus ( <e1>Srl</e1> ) lacks nephrotoxic effects ; however , <e2>proteinuria</e2> associated with Srl has been reported following renal transplantation .
D020123_D011507 CID The novel immunosuppressive ( IS ) drug sirolmus ( Srl ) lacks nephrotoxic effects ; however , <e2>proteinuria</e2> associated with <e1>Srl</e1> has been reported following renal transplantation .
D020123_D011507 CID In cardiac transplantation , the incidence of <e2>proteinuria</e2> associated with <e1>Srl</e1> is unknown .
D020123_D011507 CID Thus , <e2>proteinuria</e2> may develop in cardiac transplant patients after switch to <e1>Srl</e1> , which may have an adverse effect on renal function in these patients .
D020123_D011507 CID <e1>Srl</e1> should be used with ACEi/ARB therapy and patients monitored for <e2>proteinuria</e2> and increased renal dysfunction .
D020123_D007674 NONE The novel immunosuppressive ( IS ) drug <e1>sirolmus</e1> ( Srl ) lacks <e2>nephrotoxic</e2> effects ; however , proteinuria associated with Srl has been reported following renal transplantation .
D020123_D007674 NONE The novel immunosuppressive ( IS ) drug sirolmus ( <e1>Srl</e1> ) lacks <e2>nephrotoxic</e2> effects ; however , proteinuria associated with Srl has been reported following renal transplantation .
D020123_D007674 NONE The novel immunosuppressive ( IS ) drug sirolmus ( Srl ) lacks <e2>nephrotoxic</e2> effects ; however , proteinuria associated with <e1>Srl</e1> has been reported following renal transplantation .
D020123_D007674 NONE <e1>Srl</e1> should be used with ACEi/ARB therapy and patients monitored for proteinuria and increased <e2>renal dysfunction</e2> .
D000806_D011507 NONE <e1>ACE inhibitor</e1> and angiotensin-releasing blocker ( ARB ) therapy reduced <e2>proteinuria</e2> development .
D000806_D011507 NONE Srl should be used with <e1>ACEi/ARB</e1> therapy and patients monitored for <e2>proteinuria</e2> and increased renal dysfunction .
D057911_D011507 NONE ACE inhibitor and <e1>angiotensin-releasing blocker</e1> ( ARB ) therapy reduced <e2>proteinuria</e2> development .
D057911_D011507 NONE ACE inhibitor and angiotensin-releasing blocker ( <e1>ARB</e1> ) therapy reduced <e2>proteinuria</e2> development .
D057911_D011507 NONE Srl should be used with <e1>ACEi/ARB</e1> therapy and patients monitored for <e2>proteinuria</e2> and increased renal dysfunction .
D000806_D007674 NONE Srl should be used with <e1>ACEi/ARB</e1> therapy and patients monitored for proteinuria and increased <e2>renal dysfunction</e2> .
D057911_D007674 NONE Srl should be used with <e1>ACEi/ARB</e1> therapy and patients monitored for proteinuria and increased <e2>renal dysfunction</e2> .
7834920
D012293_D005921 CID Crescentic fibrillary <e2>glomerulonephritis</e2> associated with intermittent <e1>rifampin</e1> therapy for pulmonary tuberculosis .
D012293_D005921 CID This case study reveals an unusual finding of rapidly proliferative crescentic <e2>glomerulonephritis</e2> in a patient treated with <e1>rifampin</e1> who had no other identifiable causes for developing this disease .
D012293_D005921 CID This report documents the unusual occurrence of rapidly progressive <e2>glomerulonephritis</e2> with crescents and fibrillar glomerulonephritis in a patient treated with <e1>rifampin</e1> .
D012293_D005921 CID This report documents the unusual occurrence of rapidly progressive glomerulonephritis with crescents and fibrillar <e2>glomerulonephritis</e2> in a patient treated with <e1>rifampin</e1> .
D012293_D014397 NONE Crescentic fibrillary glomerulonephritis associated with intermittent <e1>rifampin</e1> therapy for <e2>pulmonary tuberculosis</e2> .
D012293_D014397 NONE This patient underwent a 10-month regimen of <e1>rifampin</e1> and isoniazid for <e2>pulmonary tuberculosis</e2> and was discovered to have developed signs of severe renal failure five weeks after completion of therapy .
D012293_D051437 CID This patient underwent a 10-month regimen of <e1>rifampin</e1> and isoniazid for pulmonary tuberculosis and was discovered to have developed signs of severe <e2>renal failure</e2> five weeks after completion of therapy .
D007538_D014397 NONE This patient underwent a 10-month regimen of rifampin and <e1>isoniazid</e1> for <e2>pulmonary tuberculosis</e2> and was discovered to have developed signs of severe renal failure five weeks after completion of therapy .
D007538_D051437 NONE This patient underwent a 10-month regimen of rifampin and <e1>isoniazid</e1> for pulmonary tuberculosis and was discovered to have developed signs of severe <e2>renal failure</e2> five weeks after completion of therapy .
11928786
D016642_D064420 NONE <e1>Bupropion</e1> ( Zyban ) <e2>toxicity</e2> .
D016642_D064420 NONE Bupropion ( <e1>Zyban</e1> ) <e2>toxicity</e2> .
D003975_D012640 NONE Recurrent <e2>seizures</e2> were treated with <e1>diazepam</e1> and broad complex tachycardia was successfully treated with adenosine .
D003975_D013610 NONE Recurrent seizures were treated with <e1>diazepam</e1> and broad complex <e2>tachycardia</e2> was successfully treated with adenosine .
D000241_D012640 NONE Recurrent <e2>seizures</e2> were treated with diazepam and broad complex tachycardia was successfully treated with <e1>adenosine</e1> .
D000241_D013610 NONE Recurrent seizures were treated with diazepam and broad complex <e2>tachycardia</e2> was successfully treated with <e1>adenosine</e1> .
D016642_D020258 NONE <e1>Zyban</e1> caused significant <e2>neurological and cardiovascular toxicity</e2> in overdose .
D016642_D002318 NONE <e1>Zyban</e1> caused significant <e2>neurological and cardiovascular toxicity</e2> in overdose .
D016642_D062787 NONE <e1>Zyban</e1> caused significant neurological and cardiovascular toxicity in <e2>overdose</e2> .
3560095
D005480_D001171 NONE <e1>Flurbiprofen</e1> in the treatment of <e2>juvenile rheumatoid arthritis</e2> .
D005480_D001171 NONE Thirty-four patients with <e2>juvenile rheumatoid arthritis</e2> , who were treated with <e1>flurbiprofen</e1> at a maximum dose of 4 mg/kg/day , had statistically significant decreases from baseline in 6 arthritis indices after 12 weeks of treatment .
D005480_D001168 NONE Thirty-four patients with juvenile rheumatoid arthritis , who were treated with <e1>flurbiprofen</e1> at a maximum dose of 4 mg/kg/day , had statistically significant decreases from baseline in 6 <e2>arthritis</e2> indices after 12 weeks of treatment .
8701950
D016559_D000743 CID <e2>Microangiopathic hemolytic anemia</e2> complicating <e1>FK506</e1> ( tacrolimus ) therapy .
D016559_D000743 CID <e2>Microangiopathic hemolytic anemia</e2> complicating FK506 ( <e1>tacrolimus</e1> ) therapy .
D016559_D000743 CID We describe 3 episodes of <e2>microangiopathic hemolytic anemia</e2> ( MAHA ) in 2 solid organ recipients under <e1>FK506</e1> ( tacrolimus ) therapy .
D016559_D000743 CID We describe 3 episodes of microangiopathic hemolytic anemia ( <e2>MAHA</e2> ) in 2 solid organ recipients under <e1>FK506</e1> ( tacrolimus ) therapy .
D016559_D000743 CID We describe 3 episodes of <e2>microangiopathic hemolytic anemia</e2> ( MAHA ) in 2 solid organ recipients under FK506 ( <e1>tacrolimus</e1> ) therapy .
D016559_D000743 CID We describe 3 episodes of microangiopathic hemolytic anemia ( <e2>MAHA</e2> ) in 2 solid organ recipients under FK506 ( <e1>tacrolimus</e1> ) therapy .
D016559_D000743 CID In both cases , discontinuation of <e1>FK506</e1> and treatment with plasma exchange , fresh frozen plasma replacement , corticosteroids , aspirin , and dipyridamole led to resolution of <e2>MAHA</e2> .
D016559_D000743 CID In one patient , reintroduction of <e1>FK506</e1> led to rapid recurrence of <e2>MAHA</e2> .
D016559_D000743 CID <e1>FK506-associated</e1> <e2>MAHA</e2> is probably rare but physicians must be aware of this severe complication .
D016559_D000743 CID In our experience and according to the literature , <e1>FK506</e1> does not seem to cross-react with cyclosporin A ( CyA ) , an immuno-suppressive drug already known to induce <e2>MAHA</e2> .
D000305_D000743 NONE In both cases , discontinuation of FK506 and treatment with plasma exchange , fresh frozen plasma replacement , <e1>corticosteroids</e1> , aspirin , and dipyridamole led to resolution of <e2>MAHA</e2> .
D001241_D000743 NONE In both cases , discontinuation of FK506 and treatment with plasma exchange , fresh frozen plasma replacement , corticosteroids , <e1>aspirin</e1> , and dipyridamole led to resolution of <e2>MAHA</e2> .
D004176_D000743 NONE In both cases , discontinuation of FK506 and treatment with plasma exchange , fresh frozen plasma replacement , corticosteroids , aspirin , and <e1>dipyridamole</e1> led to resolution of <e2>MAHA</e2> .
D016572_D000743 NONE In our experience and according to the literature , FK506 does not seem to cross-react with <e1>cyclosporin A</e1> ( CyA ) , an immuno-suppressive drug already known to induce <e2>MAHA</e2> .
D016572_D000743 NONE In our experience and according to the literature , FK506 does not seem to cross-react with cyclosporin A ( <e1>CyA</e1> ) , an immuno-suppressive drug already known to induce <e2>MAHA</e2> .
18809400
D008063_D028361 NONE <e1>Alpha-lipoic acid</e1> prevents <e2>mitochondrial damage</e2> and neurotoxicity in experimental chemotherapy neuropathy .
D008063_D028361 NONE The study investigates if <e1>alpha-lipoic acid</e1> is neuroprotective against chemotherapy induced neurotoxicity , if <e2>mitochondrial damage</e2> plays a critical role in toxic neurodegenerative cascade , and if neuroprotective effects of alpha-lipoic acid depend on mitochondria protection .
D008063_D028361 NONE The study investigates if alpha-lipoic acid is neuroprotective against chemotherapy induced neurotoxicity , if <e2>mitochondrial damage</e2> plays a critical role in toxic neurodegenerative cascade , and if neuroprotective effects of <e1>alpha-lipoic acid</e1> depend on mitochondria protection .
D008063_D028361 NONE <e1>Alpha-lipoic acid</e1> exerts neuroprotective effects against chemotherapy induced neurotoxicity in sensory neurons : it rescues the <e2>mitochondrial toxicity</e2> and induces the expression of frataxin , an essential mitochondrial protein with anti-oxidant and chaperone properties .
D008063_D020258 NONE <e1>Alpha-lipoic acid</e1> prevents mitochondrial damage and <e2>neurotoxicity</e2> in experimental chemotherapy neuropathy .
D008063_D020258 NONE The study investigates if <e1>alpha-lipoic acid</e1> is neuroprotective against chemotherapy induced <e2>neurotoxicity</e2> , if mitochondrial damage plays a critical role in toxic neurodegenerative cascade , and if neuroprotective effects of alpha-lipoic acid depend on mitochondria protection .
D008063_D020258 NONE The study investigates if alpha-lipoic acid is neuroprotective against chemotherapy induced <e2>neurotoxicity</e2> , if mitochondrial damage plays a critical role in toxic neurodegenerative cascade , and if neuroprotective effects of <e1>alpha-lipoic acid</e1> depend on mitochondria protection .
D008063_D020258 NONE <e1>Alpha-lipoic acid</e1> exerts neuroprotective effects against chemotherapy induced <e2>neurotoxicity</e2> in sensory neurons : it rescues the mitochondrial toxicity and induces the expression of frataxin , an essential mitochondrial protein with anti-oxidant and chaperone properties .
D008063_D009422 NONE <e1>Alpha-lipoic acid</e1> prevents mitochondrial damage and neurotoxicity in experimental chemotherapy <e2>neuropathy</e2> .
D008063_D009410 NONE The study investigates if <e1>alpha-lipoic acid</e1> is neuroprotective against chemotherapy induced neurotoxicity , if mitochondrial damage plays a critical role in <e2>toxic neurodegenerative cascade</e2> , and if neuroprotective effects of alpha-lipoic acid depend on mitochondria protection .
D008063_D009410 NONE The study investigates if alpha-lipoic acid is neuroprotective against chemotherapy induced neurotoxicity , if mitochondrial damage plays a critical role in <e2>toxic neurodegenerative cascade</e2> , and if neuroprotective effects of <e1>alpha-lipoic acid</e1> depend on mitochondria protection .
D017239_D010523 CID We used an in vitro model of chemotherapy induced <e2>peripheral neuropathy</e2> that closely mimic the in vivo condition by exposing primary cultures of dorsal root ganglion ( DRG ) sensory neurons to <e1>paclitaxel</e1> and cisplatin , two widely used and highly effective chemotherapeutic drugs .
D002945_D010523 CID We used an in vitro model of chemotherapy induced <e2>peripheral neuropathy</e2> that closely mimic the in vivo condition by exposing primary cultures of dorsal root ganglion ( DRG ) sensory neurons to paclitaxel and <e1>cisplatin</e1> , two widely used and highly effective chemotherapeutic drugs .
D008063_D001480 NONE This approach allowed investigating the efficacy of <e1>alpha-lipoic acid</e1> in preventing <e2>axonal damage</e2> and apoptosis and the function and ultrastructural morphology of mitochondria after exposure to toxic agents and alpha-lipoic acid .
D008063_D001480 NONE This approach allowed investigating the efficacy of alpha-lipoic acid in preventing <e2>axonal damage</e2> and apoptosis and the function and ultrastructural morphology of mitochondria after exposure to toxic agents and <e1>alpha-lipoic acid</e1> .
D002945_D028361 NONE Our results demonstrate that both <e1>cisplatin</e1> and paclitaxel cause early <e2>mitochondrial impairment</e2> with loss of membrane potential and induction of autophagic vacuoles in neurons .
D002945_D028361 NONE In conclusion <e2>mitochondrial toxicity</e2> is an early common event both in paclitaxel and <e1>cisplatin</e1> induced neurotoxicity .
D017239_D028361 NONE Our results demonstrate that both cisplatin and <e1>paclitaxel</e1> cause early <e2>mitochondrial impairment</e2> with loss of membrane potential and induction of autophagic vacuoles in neurons .
D017239_D028361 NONE In conclusion <e2>mitochondrial toxicity</e2> is an early common event both in <e1>paclitaxel</e1> and cisplatin induced neurotoxicity .
D017239_D020258 NONE In conclusion mitochondrial toxicity is an early common event both in <e1>paclitaxel</e1> and cisplatin induced <e2>neurotoxicity</e2> .
D002945_D020258 NONE In conclusion mitochondrial toxicity is an early common event both in paclitaxel and <e1>cisplatin</e1> induced <e2>neurotoxicity</e2> .
D008063_D010523 NONE These findings suggest that <e1>alpha-lipoic acid</e1> might reduce the risk of developing <e2>peripheral nerve toxicity</e2> in patients undergoing chemotherapy and encourage further confirmatory clinical trials .
11961407
D014443_D009401 NONE GLEPP1 receptor <e1>tyrosine</e1> phosphatase ( Ptpro ) in rat PAN <e2>nephrosis</e2> .
D011692_D009401 CID GLEPP1 receptor tyrosine phosphatase ( Ptpro ) in rat <e1>PAN</e1> <e2>nephrosis</e2> .
D011692_D009401 CID <e1>Puromycin aminonucleoside</e1> <e2>nephrosis</e2> was induced by single intraperitoneal injection of puromycin aminonucleoside ( PAN , 20 mg/100 g BW ) .
D011692_D009401 CID Puromycin aminonucleoside <e2>nephrosis</e2> was induced by single intraperitoneal injection of <e1>puromycin aminonucleoside</e1> ( PAN , 20 mg/100 g BW ) .
D011692_D009401 CID Puromycin aminonucleoside <e2>nephrosis</e2> was induced by single intraperitoneal injection of puromycin aminonucleoside ( <e1>PAN</e1> , 20 mg/100 g BW ) .
D011692_D011507 CID Tissues were analyzed at 0 , 5 , 7 , 11 , 21 , 45 , 80 and 126 days after <e1>PAN</e1> injection so as to include both the acute phase of <e2>proteinuria</e2> associated with foot process effacement ( days 5 - 11 ) and the chronic phase of proteinuria associated with glomerulosclerosis ( days 45 - 126 ) .
D011692_D011507 CID Tissues were analyzed at 0 , 5 , 7 , 11 , 21 , 45 , 80 and 126 days after <e1>PAN</e1> injection so as to include both the acute phase of proteinuria associated with foot process effacement ( days 5 - 11 ) and the chronic phase of <e2>proteinuria</e2> associated with glomerulosclerosis ( days 45 - 126 ) .
D011692_D005921 NONE Tissues were analyzed at 0 , 5 , 7 , 11 , 21 , 45 , 80 and 126 days after <e1>PAN</e1> injection so as to include both the acute phase of proteinuria associated with foot process effacement ( days 5 - 11 ) and the chronic phase of proteinuria associated with <e2>glomerulosclerosis</e2> ( days 45 - 126 ) .
11581460
D005283_D016055 CID Bladder <e2>retention of urine</e2> as a result of continuous intravenous infusion of <e1>fentanyl</e1> : 2 case reports .
D005283_D009127 NONE Various reported side effects of <e1>fentanyl</e1> administration include <e2>chest wall rigidity</e2> , hypotension , respiratory depression , and bradycardia .
D005283_D007022 CID Various reported side effects of <e1>fentanyl</e1> administration include chest wall rigidity , <e2>hypotension</e2> , respiratory depression , and bradycardia .
D005283_D012131 CID Various reported side effects of <e1>fentanyl</e1> administration include chest wall rigidity , hypotension , <e2>respiratory depression</e2> , and bradycardia .
D005283_D001919 CID Various reported side effects of <e1>fentanyl</e1> administration include chest wall rigidity , hypotension , respiratory depression , and <e2>bradycardia</e2> .
D005283_D001745 CID Here , 2 cases of <e2>urinary bladder retention</e2> leading to renal pelvocalyceal dilatation mimicking hydronephrosis as a result of continuous infusion of <e1>fentanyl</e1> are reported .
D005283_D006869 NONE Here , 2 cases of urinary bladder retention leading to renal pelvocalyceal dilatation mimicking <e2>hydronephrosis</e2> as a result of continuous infusion of <e1>fentanyl</e1> are reported .
2024540
D004656_D006333 NONE Design and analysis of the HYPREN-trial : safety of <e1>enalapril</e1> and prazosin in the initial treatment phase of patients with <e2>congestive heart failure</e2> .
D011224_D006333 NONE Design and analysis of the HYPREN-trial : safety of enalapril and <e1>prazosin</e1> in the initial treatment phase of patients with <e2>congestive heart failure</e2> .
D000806_D006333 NONE Since the introduction of <e1>angiotensin converting enzyme ( ACE ) inhibitors</e1> into the adjunctive treatment of patients with <e2>congestive heart failure</e2> , cases of severe hypotension , especially on the first day of treatment , have occasionally been reported .
D000806_D007022 CID Since the introduction of <e1>angiotensin converting enzyme ( ACE ) inhibitors</e1> into the adjunctive treatment of patients with congestive heart failure , cases of severe <e2>hypotension</e2> , especially on the first day of treatment , have occasionally been reported .
D000806_D007022 CID To assess the safety of the <e1>ACE inhibitor</e1> enalapril a multicenter , randomized , prazosin-controlled trial was designed that compared the incidence and severity of symptomatic <e2>hypotension</e2> on the first day of treatment .
D004656_D007022 NONE To assess the safety of the ACE inhibitor <e1>enalapril</e1> a multicenter , randomized , prazosin-controlled trial was designed that compared the incidence and severity of symptomatic <e2>hypotension</e2> on the first day of treatment .
D004656_D007022 NONE Patients who received <e1>enalapril</e1> experienced clinically and statistically significantly less symptomatic <e2>hypotension</e2> ( 5.2 % ) than the patients who received prazosin ( 12.9 % ) .
D011224_D007022 CID To assess the safety of the ACE inhibitor enalapril a multicenter , randomized , <e1>prazosin-controlled</e1> trial was designed that compared the incidence and severity of symptomatic <e2>hypotension</e2> on the first day of treatment .
D011224_D007022 CID Patients who received enalapril experienced clinically and statistically significantly less symptomatic <e2>hypotension</e2> ( 5.2 % ) than the patients who received <e1>prazosin</e1> ( 12.9 % ) .
19300402
D001920_D006930 NONE <e1>Bradykinin</e1> receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin induced <e2>hyperalgesia</e2> in chemotherapy and diabetic neuropathy rat model .
D001920_D006930 NONE RESULTS : The results of this paper confirm that inhibition of <e1>bradykinin</e1> receptors and inducible NO synthase but not neuronal NO synthase activity reduces <e2>diabetic hyperalgesia</e2> .
D001920_D006930 NONE It was also shown that both products of inducible NO synthase and neuronal NO synthase activation as well as <e1>bradykinin</e1> are involved in <e2>hyperalgesia</e2> produced by vincristine .
D001920_D006930 NONE In streptozotocin-induced <e2>hyperalgesia</e2> , inducible NO synthase participates in pronociceptive activity of <e1>bradykinin</e1> , whereas in vincristine-induced hyperalgesia bradykinin seemed to activate neuronal NO synthase pathway .
D001920_D006930 NONE In streptozotocin-induced hyperalgesia , inducible NO synthase participates in pronociceptive activity of <e1>bradykinin</e1> , whereas in vincristine-induced <e2>hyperalgesia</e2> bradykinin seemed to activate neuronal NO synthase pathway .
D001920_D006930 NONE In streptozotocin-induced <e2>hyperalgesia</e2> , inducible NO synthase participates in pronociceptive activity of bradykinin , whereas in vincristine-induced hyperalgesia <e1>bradykinin</e1> seemed to activate neuronal NO synthase pathway .
D001920_D006930 NONE In streptozotocin-induced hyperalgesia , inducible NO synthase participates in pronociceptive activity of bradykinin , whereas in vincristine-induced <e2>hyperalgesia</e2> <e1>bradykinin</e1> seemed to activate neuronal NO synthase pathway .
D001920_D003929 NONE <e1>Bradykinin</e1> receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin induced hyperalgesia in chemotherapy and <e2>diabetic neuropathy</e2> rat model .
D001920_D003929 NONE PURPOSE : The influence of an irreversible inhibitor of constitutive NO synthase ( L-NOArg ; 1.0 mg/kg ip ) , a relatively selective inhibitor of inducible NO synthase ( L-NIL ; 1.0 mg/kg ip ) and a relatively specific inhibitor of neuronal NO synthase ( 7-NI ; 0.1 mg/kg ip ) , on antihyperalgesic action of selective antagonists of B2 and B1 receptors : D-Arg-[Hyp3,Thi5,D-Tic7,Oic8 ] <e1>bradykinin</e1> ( HOE 140 ; 70 nmol/kg ip ) or des Arg10 HOE 140 ( 70 nmol/kg ip ) respectively , in model of <e2>diabetic ( streptozotocin-induced ) and toxic ( vincristine-induced ) neuropathy</e2> was investigated .
D009569_D006930 NONE Bradykinin receptors antagonists and <e1>nitric oxide</e1> synthase inhibitors in vincristine and streptozotocin induced <e2>hyperalgesia</e2> in chemotherapy and diabetic neuropathy rat model .
D009569_D006930 NONE RESULTS : The results of this paper confirm that inhibition of bradykinin receptors and inducible <e1>NO</e1> synthase but not neuronal NO synthase activity reduces <e2>diabetic hyperalgesia</e2> .
D009569_D006930 NONE RESULTS : The results of this paper confirm that inhibition of bradykinin receptors and inducible NO synthase but not neuronal <e1>NO</e1> synthase activity reduces <e2>diabetic hyperalgesia</e2> .
D009569_D006930 NONE It was also shown that both products of inducible <e1>NO</e1> synthase and neuronal NO synthase activation as well as bradykinin are involved in <e2>hyperalgesia</e2> produced by vincristine .
D009569_D006930 NONE It was also shown that both products of inducible NO synthase and neuronal <e1>NO</e1> synthase activation as well as bradykinin are involved in <e2>hyperalgesia</e2> produced by vincristine .
D009569_D006930 NONE In streptozotocin-induced <e2>hyperalgesia</e2> , inducible <e1>NO</e1> synthase participates in pronociceptive activity of bradykinin , whereas in vincristine-induced hyperalgesia bradykinin seemed to activate neuronal NO synthase pathway .
D009569_D006930 NONE In streptozotocin-induced hyperalgesia , inducible <e1>NO</e1> synthase participates in pronociceptive activity of bradykinin , whereas in vincristine-induced <e2>hyperalgesia</e2> bradykinin seemed to activate neuronal NO synthase pathway .
D009569_D006930 NONE In streptozotocin-induced <e2>hyperalgesia</e2> , inducible NO synthase participates in pronociceptive activity of bradykinin , whereas in vincristine-induced hyperalgesia bradykinin seemed to activate neuronal <e1>NO</e1> synthase pathway .
D009569_D006930 NONE In streptozotocin-induced hyperalgesia , inducible NO synthase participates in pronociceptive activity of bradykinin , whereas in vincristine-induced <e2>hyperalgesia</e2> bradykinin seemed to activate neuronal <e1>NO</e1> synthase pathway .
D009569_D003929 NONE Bradykinin receptors antagonists and <e1>nitric oxide</e1> synthase inhibitors in vincristine and streptozotocin induced hyperalgesia in chemotherapy and <e2>diabetic neuropathy</e2> rat model .
D009569_D003929 NONE PURPOSE : The influence of an irreversible inhibitor of constitutive <e1>NO</e1> synthase ( L-NOArg ; 1.0 mg/kg ip ) , a relatively selective inhibitor of inducible NO synthase ( L-NIL ; 1.0 mg/kg ip ) and a relatively specific inhibitor of neuronal NO synthase ( 7-NI ; 0.1 mg/kg ip ) , on antihyperalgesic action of selective antagonists of B2 and B1 receptors : D-Arg-[Hyp3,Thi5,D-Tic7,Oic8 ] bradykinin ( HOE 140 ; 70 nmol/kg ip ) or des Arg10 HOE 140 ( 70 nmol/kg ip ) respectively , in model of <e2>diabetic ( streptozotocin-induced ) and toxic ( vincristine-induced ) neuropathy</e2> was investigated .
D009569_D003929 NONE PURPOSE : The influence of an irreversible inhibitor of constitutive NO synthase ( L-NOArg ; 1.0 mg/kg ip ) , a relatively selective inhibitor of inducible <e1>NO</e1> synthase ( L-NIL ; 1.0 mg/kg ip ) and a relatively specific inhibitor of neuronal NO synthase ( 7-NI ; 0.1 mg/kg ip ) , on antihyperalgesic action of selective antagonists of B2 and B1 receptors : D-Arg-[Hyp3,Thi5,D-Tic7,Oic8 ] bradykinin ( HOE 140 ; 70 nmol/kg ip ) or des Arg10 HOE 140 ( 70 nmol/kg ip ) respectively , in model of <e2>diabetic ( streptozotocin-induced ) and toxic ( vincristine-induced ) neuropathy</e2> was investigated .
D009569_D003929 NONE PURPOSE : The influence of an irreversible inhibitor of constitutive NO synthase ( L-NOArg ; 1.0 mg/kg ip ) , a relatively selective inhibitor of inducible NO synthase ( L-NIL ; 1.0 mg/kg ip ) and a relatively specific inhibitor of neuronal <e1>NO</e1> synthase ( 7-NI ; 0.1 mg/kg ip ) , on antihyperalgesic action of selective antagonists of B2 and B1 receptors : D-Arg-[Hyp3,Thi5,D-Tic7,Oic8 ] bradykinin ( HOE 140 ; 70 nmol/kg ip ) or des Arg10 HOE 140 ( 70 nmol/kg ip ) respectively , in model of <e2>diabetic ( streptozotocin-induced ) and toxic ( vincristine-induced ) neuropathy</e2> was investigated .
D014750_D006930 CID Bradykinin receptors antagonists and nitric oxide synthase inhibitors in <e1>vincristine</e1> and streptozotocin induced <e2>hyperalgesia</e2> in chemotherapy and diabetic neuropathy rat model .
D014750_D006930 CID It was also shown that both products of inducible NO synthase and neuronal NO synthase activation as well as bradykinin are involved in <e2>hyperalgesia</e2> produced by <e1>vincristine</e1> .
D014750_D006930 CID In streptozotocin-induced <e2>hyperalgesia</e2> , inducible NO synthase participates in pronociceptive activity of bradykinin , whereas in <e1>vincristine-induced</e1> hyperalgesia bradykinin seemed to activate neuronal NO synthase pathway .
D014750_D006930 CID In streptozotocin-induced hyperalgesia , inducible NO synthase participates in pronociceptive activity of bradykinin , whereas in <e1>vincristine-induced</e1> <e2>hyperalgesia</e2> bradykinin seemed to activate neuronal NO synthase pathway .
D014750_D003929 NONE Bradykinin receptors antagonists and nitric oxide synthase inhibitors in <e1>vincristine</e1> and streptozotocin induced hyperalgesia in chemotherapy and <e2>diabetic neuropathy</e2> rat model .
D013311_D006930 CID Bradykinin receptors antagonists and nitric oxide synthase inhibitors in vincristine and <e1>streptozotocin</e1> induced <e2>hyperalgesia</e2> in chemotherapy and diabetic neuropathy rat model .
D013311_D006930 CID In <e1>streptozotocin-induced</e1> <e2>hyperalgesia</e2> , inducible NO synthase participates in pronociceptive activity of bradykinin , whereas in vincristine-induced hyperalgesia bradykinin seemed to activate neuronal NO synthase pathway .
D013311_D006930 CID In <e1>streptozotocin-induced</e1> hyperalgesia , inducible NO synthase participates in pronociceptive activity of bradykinin , whereas in vincristine-induced <e2>hyperalgesia</e2> bradykinin seemed to activate neuronal NO synthase pathway .
D013311_D003929 CID Bradykinin receptors antagonists and nitric oxide synthase inhibitors in vincristine and <e1>streptozotocin</e1> induced hyperalgesia in chemotherapy and <e2>diabetic neuropathy</e2> rat model .
D009569_D010523 NONE PURPOSE : The influence of an irreversible inhibitor of constitutive <e1>NO</e1> synthase ( L-NOArg ; 1.0 mg/kg ip ) , a relatively selective inhibitor of inducible NO synthase ( L-NIL ; 1.0 mg/kg ip ) and a relatively specific inhibitor of neuronal NO synthase ( 7-NI ; 0.1 mg/kg ip ) , on antihyperalgesic action of selective antagonists of B2 and B1 receptors : D-Arg-[Hyp3,Thi5,D-Tic7,Oic8 ] bradykinin ( HOE 140 ; 70 nmol/kg ip ) or des Arg10 HOE 140 ( 70 nmol/kg ip ) respectively , in model of <e2>diabetic ( streptozotocin-induced ) and toxic ( vincristine-induced ) neuropathy</e2> was investigated .
D009569_D010523 NONE PURPOSE : The influence of an irreversible inhibitor of constitutive NO synthase ( L-NOArg ; 1.0 mg/kg ip ) , a relatively selective inhibitor of inducible <e1>NO</e1> synthase ( L-NIL ; 1.0 mg/kg ip ) and a relatively specific inhibitor of neuronal NO synthase ( 7-NI ; 0.1 mg/kg ip ) , on antihyperalgesic action of selective antagonists of B2 and B1 receptors : D-Arg-[Hyp3,Thi5,D-Tic7,Oic8 ] bradykinin ( HOE 140 ; 70 nmol/kg ip ) or des Arg10 HOE 140 ( 70 nmol/kg ip ) respectively , in model of <e2>diabetic ( streptozotocin-induced ) and toxic ( vincristine-induced ) neuropathy</e2> was investigated .
D009569_D010523 NONE PURPOSE : The influence of an irreversible inhibitor of constitutive NO synthase ( L-NOArg ; 1.0 mg/kg ip ) , a relatively selective inhibitor of inducible NO synthase ( L-NIL ; 1.0 mg/kg ip ) and a relatively specific inhibitor of neuronal <e1>NO</e1> synthase ( 7-NI ; 0.1 mg/kg ip ) , on antihyperalgesic action of selective antagonists of B2 and B1 receptors : D-Arg-[Hyp3,Thi5,D-Tic7,Oic8 ] bradykinin ( HOE 140 ; 70 nmol/kg ip ) or des Arg10 HOE 140 ( 70 nmol/kg ip ) respectively , in model of <e2>diabetic ( streptozotocin-induced ) and toxic ( vincristine-induced ) neuropathy</e2> was investigated .
D001920_D010523 NONE PURPOSE : The influence of an irreversible inhibitor of constitutive NO synthase ( L-NOArg ; 1.0 mg/kg ip ) , a relatively selective inhibitor of inducible NO synthase ( L-NIL ; 1.0 mg/kg ip ) and a relatively specific inhibitor of neuronal NO synthase ( 7-NI ; 0.1 mg/kg ip ) , on antihyperalgesic action of selective antagonists of B2 and B1 receptors : D-Arg-[Hyp3,Thi5,D-Tic7,Oic8 ] <e1>bradykinin</e1> ( HOE 140 ; 70 nmol/kg ip ) or des Arg10 HOE 140 ( 70 nmol/kg ip ) respectively , in model of <e2>diabetic ( streptozotocin-induced ) and toxic ( vincristine-induced ) neuropathy</e2> was investigated .
C065679_D003929 NONE PURPOSE : The influence of an irreversible inhibitor of constitutive NO synthase ( L-NOArg ; 1.0 mg/kg ip ) , a relatively selective inhibitor of inducible NO synthase ( L-NIL ; 1.0 mg/kg ip ) and a relatively specific inhibitor of neuronal NO synthase ( 7-NI ; 0.1 mg/kg ip ) , on antihyperalgesic action of selective antagonists of B2 and B1 receptors : D-Arg-[Hyp3,Thi5,D-Tic7,Oic8 ] bradykinin ( <e1>HOE 140</e1> ; 70 nmol/kg ip ) or des Arg10 HOE 140 ( 70 nmol/kg ip ) respectively , in model of <e2>diabetic ( streptozotocin-induced ) and toxic ( vincristine-induced ) neuropathy</e2> was investigated .
C065679_D010523 NONE PURPOSE : The influence of an irreversible inhibitor of constitutive NO synthase ( L-NOArg ; 1.0 mg/kg ip ) , a relatively selective inhibitor of inducible NO synthase ( L-NIL ; 1.0 mg/kg ip ) and a relatively specific inhibitor of neuronal NO synthase ( 7-NI ; 0.1 mg/kg ip ) , on antihyperalgesic action of selective antagonists of B2 and B1 receptors : D-Arg-[Hyp3,Thi5,D-Tic7,Oic8 ] bradykinin ( <e1>HOE 140</e1> ; 70 nmol/kg ip ) or des Arg10 HOE 140 ( 70 nmol/kg ip ) respectively , in model of <e2>diabetic ( streptozotocin-induced ) and toxic ( vincristine-induced ) neuropathy</e2> was investigated .
C065679_D010523 NONE Moreover , L-NOArg and 7-NI but not L-NIL intensify antihyperalgesic activity of <e1>HOE 140</e1> or des-Arg10HOE 140 in <e2>toxic neuropathy</e2> .
C078665_D003929 NONE PURPOSE : The influence of an irreversible inhibitor of constitutive NO synthase ( L-NOArg ; 1.0 mg/kg ip ) , a relatively selective inhibitor of inducible NO synthase ( L-NIL ; 1.0 mg/kg ip ) and a relatively specific inhibitor of neuronal NO synthase ( 7-NI ; 0.1 mg/kg ip ) , on antihyperalgesic action of selective antagonists of B2 and B1 receptors : D-Arg-[Hyp3,Thi5,D-Tic7,Oic8 ] bradykinin ( HOE 140 ; 70 nmol/kg ip ) or <e1>des Arg10 HOE 140</e1> ( 70 nmol/kg ip ) respectively , in model of <e2>diabetic ( streptozotocin-induced ) and toxic ( vincristine-induced ) neuropathy</e2> was investigated .
C078665_D010523 NONE PURPOSE : The influence of an irreversible inhibitor of constitutive NO synthase ( L-NOArg ; 1.0 mg/kg ip ) , a relatively selective inhibitor of inducible NO synthase ( L-NIL ; 1.0 mg/kg ip ) and a relatively specific inhibitor of neuronal NO synthase ( 7-NI ; 0.1 mg/kg ip ) , on antihyperalgesic action of selective antagonists of B2 and B1 receptors : D-Arg-[Hyp3,Thi5,D-Tic7,Oic8 ] bradykinin ( HOE 140 ; 70 nmol/kg ip ) or <e1>des Arg10 HOE 140</e1> ( 70 nmol/kg ip ) respectively , in model of <e2>diabetic ( streptozotocin-induced ) and toxic ( vincristine-induced ) neuropathy</e2> was investigated .
C078665_D010523 NONE Moreover , L-NOArg and 7-NI but not L-NIL intensify antihyperalgesic activity of HOE 140 or <e1>des-Arg10HOE 140</e1> in <e2>toxic neuropathy</e2> .
D001920_D009437 NONE Therefore , concomitant administration of small doses of <e1>bradykinin</e1> receptor antagonists and NO synthase inhibitors can be effective in alleviation of <e2>neuropathic pain</e2> , even in hospital care .
D009569_D009437 NONE Therefore , concomitant administration of small doses of bradykinin receptor antagonists and <e1>NO</e1> synthase inhibitors can be effective in alleviation of <e2>neuropathic pain</e2> , even in hospital care .
11642480
D015283_D004409 CID <e2>Palpebral twitching</e2> in a depressed adolescent on <e1>citalopram</e1> .
D015283_D004409 CID We report a favorable response to treatment with <e1>citalopram</e1> by a 15-year-old boy with major depression who exhibited <e2>palpebral twitching</e2> during his first 2 weeks of treatment .
D015283_D003866 NONE Palpebral twitching in a <e2>depressed</e2> adolescent on <e1>citalopram</e1> .
D015283_D003865 NONE We report a favorable response to treatment with <e1>citalopram</e1> by a 15-year-old boy with <e2>major depression</e2> who exhibited palpebral twitching during his first 2 weeks of treatment .
15859940
D016572_D064420 NONE Other causes include drug-related ( <e1>cyclosporine</e1> , tacrolimus ) <e2>toxicity</e2> , procoagulant status , and antibody-mediated rejection .
D016559_D064420 NONE Other causes include drug-related ( cyclosporine , <e1>tacrolimus</e1> ) <e2>toxicity</e2> , procoagulant status , and antibody-mediated rejection .
D016572_D057049 CID We found that the most-frequent cause of <e2>thrombotic microangiopathy</e2> was drug related , secondary mainly to <e1>cyclosporine</e1> .
8595686
D013874_D010146 NONE <e1>Thiopentone</e1> pretreatment for propofol injection <e2>pain</e2> in ambulatory patients .
D013874_D010146 NONE We conclude that lidocaine reduces the incidence and severity of propofol injection <e2>pain</e2> in ambulatory patients whereas <e1>thiopentone</e1> only reduces its severity .
D015742_D010146 CID Thiopentone pretreatment for <e1>propofol</e1> injection <e2>pain</e2> in ambulatory patients .
D015742_D010146 CID This study investigated <e1>propofol</e1> injection <e2>pain</e2> in patients undergoing ambulatory anaesthesia .
D015742_D010146 CID We conclude that lidocaine reduces the incidence and severity of <e1>propofol</e1> injection <e2>pain</e2> in ambulatory patients whereas thiopentone only reduces its severity .
D008012_D010146 NONE We conclude that <e1>lidocaine</e1> reduces the incidence and severity of propofol injection <e2>pain</e2> in ambulatory patients whereas thiopentone only reduces its severity .
11263551
D016572_D010146 CID The reduction of <e1>cyclosporine-</e1> or tacrolimus trough levels and the administration of calcium channel blockers led to relief of <e2>pain</e2> .
D016572_D010146 CID The Calcineurin-inhibitor Induced <e2>Pain</e2> Syndrome ( CIPS ) is a rare but severe side effect of <e1>cyclosporine</e1> or tacrolimus and is accurately diagnosed by its typical presentation , magnetic resonance imaging and bone scans .
D016559_D010146 CID The reduction of cyclosporine- or <e1>tacrolimus</e1> trough levels and the administration of calcium channel blockers led to relief of <e2>pain</e2> .
D016559_D010146 CID The Calcineurin-inhibitor Induced <e2>Pain</e2> Syndrome ( CIPS ) is a rare but severe side effect of cyclosporine or <e1>tacrolimus</e1> and is accurately diagnosed by its typical presentation , magnetic resonance imaging and bone scans .
D002118_D010146 NONE The reduction of cyclosporine- or tacrolimus trough levels and the administration of <e1>calcium</e1> channel blockers led to relief of <e2>pain</e2> .
D016572_-1 NONE The Calcineurin-inhibitor Induced Pain Syndrome ( <e2>CIPS</e2> ) is a rare but severe side effect of <e1>cyclosporine</e1> or tacrolimus and is accurately diagnosed by its typical presentation , magnetic resonance imaging and bone scans .
D016559_-1 NONE The Calcineurin-inhibitor Induced Pain Syndrome ( <e2>CIPS</e2> ) is a rare but severe side effect of cyclosporine or <e1>tacrolimus</e1> and is accurately diagnosed by its typical presentation , magnetic resonance imaging and bone scans .
2572625
C084599_D056486 CID <e1>Clotiazepam-induced</e1> acute <e2>hepatitis</e2> .
C084599_D056486 CID We report the case of a patient who developed acute <e2>hepatitis</e2> with extensive hepatocellular necrosis , 7 months after the onset of administration of <e1>clotiazepam</e1> , a thienodiazepine derivative .
C084599_D056486 CID The administration of several benzodiazepines , chemically related to <e1>clotiazepam</e1> , did not interfere with recovery and did not induce any relapse of <e2>hepatitis</e2> .
C084599_D056486 CID This observation shows that <e1>clotiazepam</e1> can induce acute <e2>hepatitis</e2> and suggests that there is no cross hepatotoxicity between clotiazepam and several benzodiazepines .
C084599_D056486 CID This observation shows that <e1>clotiazepam</e1> can induce acute hepatitis and suggests that there is no cross <e2>hepatotoxicity</e2> between clotiazepam and several benzodiazepines .
C084599_D056486 CID This observation shows that clotiazepam can induce acute <e2>hepatitis</e2> and suggests that there is no cross hepatotoxicity between <e1>clotiazepam</e1> and several benzodiazepines .
C084599_D056486 CID This observation shows that clotiazepam can induce acute hepatitis and suggests that there is no cross <e2>hepatotoxicity</e2> between <e1>clotiazepam</e1> and several benzodiazepines .
C084599_D047508 NONE We report the case of a patient who developed acute hepatitis with <e2>extensive hepatocellular necrosis</e2> , 7 months after the onset of administration of <e1>clotiazepam</e1> , a thienodiazepine derivative .
C013295_D056486 NONE We report the case of a patient who developed acute <e2>hepatitis</e2> with extensive hepatocellular necrosis , 7 months after the onset of administration of clotiazepam , a <e1>thienodiazepine</e1> derivative .
C013295_D047508 NONE We report the case of a patient who developed acute hepatitis with <e2>extensive hepatocellular necrosis</e2> , 7 months after the onset of administration of clotiazepam , a <e1>thienodiazepine</e1> derivative .
D001569_D056486 NONE The administration of several <e1>benzodiazepines</e1> , chemically related to clotiazepam , did not interfere with recovery and did not induce any relapse of <e2>hepatitis</e2> .
D001569_D056486 NONE This observation shows that clotiazepam can induce acute <e2>hepatitis</e2> and suggests that there is no cross hepatotoxicity between clotiazepam and several <e1>benzodiazepines</e1> .
D001569_D056486 NONE This observation shows that clotiazepam can induce acute hepatitis and suggests that there is no cross <e2>hepatotoxicity</e2> between clotiazepam and several <e1>benzodiazepines</e1> .
10406016
C007789_D002543 NONE Effect of <e1>fucoidan</e1> treatment on collagenase-induced <e2>intracerebral hemorrhage</e2> in rats .
C007789_D002543 NONE We tested the sulfated polysaccharide <e1>fucoidan</e1> , which has been reported to reduce inflammatory brain damage , in a rat model of <e2>intracerebral hemorrhage</e2> induced by injection of bacterial collagenase into the caudate nucleus .
C007789_D001925 NONE We tested the sulfated polysaccharide <e1>fucoidan</e1> , which has been reported to reduce inflammatory <e2>brain damage</e2> , in a rat model of intracerebral hemorrhage induced by injection of bacterial collagenase into the caudate nucleus .
C007789_D020141 CID <e1>Fucoidan-treated</e1> rats exhibited evidence of <e2>impaired blood clotting</e2> and hemodilution , had larger hematomas , and tended to have less inflammation in the vicinity of the hematoma after three days .
C007789_D020141 CID <e1>Fucoidan-treated</e1> rats exhibited evidence of impaired blood clotting and <e2>hemodilution</e2> , had larger hematomas , and tended to have less inflammation in the vicinity of the hematoma after three days .
C007789_D006406 NONE <e1>Fucoidan-treated</e1> rats exhibited evidence of impaired blood clotting and hemodilution , had larger <e2>hematomas</e2> , and tended to have less inflammation in the vicinity of the hematoma after three days .
C007789_D006406 NONE <e1>Fucoidan-treated</e1> rats exhibited evidence of impaired blood clotting and hemodilution , had larger hematomas , and tended to have less inflammation in the vicinity of the <e2>hematoma</e2> after three days .
C007789_D007249 NONE <e1>Fucoidan-treated</e1> rats exhibited evidence of impaired blood clotting and hemodilution , had larger hematomas , and tended to have less <e2>inflammation</e2> in the vicinity of the hematoma after three days .
12820454
D016729_D000740 CID All patients received CAB [ <e1>leuprolide acetate</e1> ( LHRH-A ) 3.75 mg , intramuscularly , every 28 days plus 250 mg flutamide , tid , per Os ] and were evaluated for <e2>anemia</e2> by physical examination and laboratory tests at baseline and 4 subsequent intervals ( 1 , 2 , 3 and 6 months post-CAB ) .
D016729_D000740 CID All patients received CAB [ leuprolide acetate ( <e1>LHRH-A</e1> ) 3.75 mg , intramuscularly , every 28 days plus 250 mg flutamide , tid , per Os ] and were evaluated for <e2>anemia</e2> by physical examination and laboratory tests at baseline and 4 subsequent intervals ( 1 , 2 , 3 and 6 months post-CAB ) .
D005485_D000740 CID All patients received CAB [ leuprolide acetate ( LHRH-A ) 3.75 mg , intramuscularly , every 28 days plus 250 mg <e1>flutamide</e1> , tid , per Os ] and were evaluated for <e2>anemia</e2> by physical examination and laboratory tests at baseline and 4 subsequent intervals ( 1 , 2 , 3 and 6 months post-CAB ) .
2476560
D001556_D012532 NONE Treatment for <e2>scabies</e2> is usually initiated by general practitioners ; most consider <e1>lindane</e1> ( gamma benzene hexachloride ) the treatment of choice .
D001556_D012532 NONE Treatment for <e2>scabies</e2> is usually initiated by general practitioners ; most consider lindane ( <e1>gamma benzene hexachloride</e1> ) the treatment of choice .
D001556_D002493 CID Evidence is accumulating that <e1>lindane</e1> can be <e2>toxic to the central nervous system</e2> and may be associated with aplastic anaemia .
D001556_D000741 CID Evidence is accumulating that <e1>lindane</e1> can be toxic to the central nervous system and may be associated with <e2>aplastic anaemia</e2> .
3560096
D013467_D006947 CID <e2>Hyperkalemia</e2> associated with <e1>sulindac</e1> therapy .
D013467_D006947 CID We describe 4 patients in whom <e2>hyperkalemia</e2> ranging from 6.1 to 6.9 mEq/l developed within 3 to 8 days of <e1>sulindac</e1> administration .
D013467_D006947 CID As no other medications known to effect serum potassium had been given concomitantly , this course of events is suggestive of a cause-and-effect relationship between <e1>sulindac</e1> and <e2>hyperkalemia</e2> .
D007213_D006947 CID <e2>Hyperkalemia</e2> has recently been recognized as a complication of nonsteroidal antiinflammatory agents ( NSAID ) such as <e1>indomethacin</e1> .
D011188_D006947 NONE As no other medications known to effect serum <e1>potassium</e1> had been given concomitantly , this course of events is suggestive of a cause-and-effect relationship between sulindac and <e2>hyperkalemia</e2> .
1009330
C004658_D003556 NONE The results have shown that the degradation product <e1>p-choloroaniline</e1> is not a significant factor in chlorhexidine-digluconate associated erosive <e2>cystitis</e2> .
C010882_D003556 CID The results have shown that the degradation product p-choloroaniline is not a significant factor in <e1>chlorhexidine-digluconate</e1> associated erosive <e2>cystitis</e2> .
D007612_D003556 CID A high percentage of <e1>kanamycin-colistin</e1> and povidone-iodine irrigations were associated with erosive <e2>cystitis</e2> and suggested a possible complication with human usage .
D003091_D003556 CID A high percentage of <e1>kanamycin-colistin</e1> and povidone-iodine irrigations were associated with erosive <e2>cystitis</e2> and suggested a possible complication with human usage .
D011206_D003556 CID A high percentage of kanamycin-colistin and <e1>povidone-iodine</e1> irrigations were associated with erosive <e2>cystitis</e2> and suggested a possible complication with human usage .
C005253_D003556 NONE <e1>Picloxydine</e1> irrigations appeared to have a lower incidence of erosive <e2>cystitis</e2> but further studies would have to be performed before it could be recommended for use in urological procedures .
19387625
D002211_D010146 NONE Attentional modulation of perceived <e2>pain</e2> intensity in <e1>capsaicin-induced</e1> secondary hyperalgesia .
D002211_D010146 NONE However , it is not known that how <e2>pain</e2> intensity ratings are affected by attention in <e1>capsaicin-induced</e1> secondary hyperalgesia .
D002211_D010146 NONE Our findings , showing no interaction between <e1>capsaicin</e1> treatment and attentional modulation suggest that capsaicin-induced secondary hyperalgesia and attention might affect mechanical <e2>pain</e2> through independent mechanisms .
D002211_D010146 NONE Our findings , showing no interaction between capsaicin treatment and attentional modulation suggest that <e1>capsaicin-induced</e1> secondary hyperalgesia and attention might affect mechanical <e2>pain</e2> through independent mechanisms .
D002211_D006930 CID Attentional modulation of perceived pain intensity in <e1>capsaicin-induced</e1> secondary <e2>hyperalgesia</e2> .
D002211_D006930 CID However , it is not known that how pain intensity ratings are affected by attention in <e1>capsaicin-induced</e1> secondary <e2>hyperalgesia</e2> .
D002211_D006930 CID Furthermore , it was found that the magnitude of attentional modulation in secondary <e2>hyperalgesia</e2> is very similar to that of <e1>capsaicin-untreated</e1> , control condition .
D002211_D006930 CID Our findings , showing no interaction between <e1>capsaicin</e1> treatment and attentional modulation suggest that capsaicin-induced secondary <e2>hyperalgesia</e2> and attention might affect mechanical pain through independent mechanisms .
D002211_D006930 CID Our findings , showing no interaction between capsaicin treatment and attentional modulation suggest that <e1>capsaicin-induced</e1> secondary <e2>hyperalgesia</e2> and attention might affect mechanical pain through independent mechanisms .
18821488
C080436_D064420 NONE <e2>Toxicity</e2> in rhesus monkeys following administration of the <e1>8-aminoquinoline</e1> 8-[(4-amino-l-methylbutyl)amino]- 5-(l-hexyloxy)-6-methoxy-4-methylquinoline ( WR242511 ) .
C068820_D064420 NONE <e2>Toxicity</e2> in rhesus monkeys following administration of the 8-aminoquinoline <e1>8-[(4-amino-l-methylbutyl)amino]- 5-(l-hexyloxy)-6-methoxy-4-methylquinoline</e1> ( WR242511 ) .
C068820_D064420 NONE <e2>Toxicity</e2> in rhesus monkeys following administration of the 8-aminoquinoline 8-[(4-amino-l-methylbutyl)amino]- 5-(l-hexyloxy)-6-methoxy-4-methylquinoline ( <e1>WR242511</e1> ) .
C068820_D064420 NONE It is concluded that <e1>WR242511</e1> should not be pursued as a pretreatment for CN poisoning unless the anti-CN characteristics of this compound can be successfully dissociated from those producing undesirable <e2>toxicity</e2> .
C068820_D008708 NONE RESULTS : The selected doses of <e1>WR242511</e1> , which produced significant <e2>methemoglobinemia</e2> in beagle dogs in earlier studies conducted elsewhere , produced very little MHb ( mean < 2.0 % ) in the rhesus monkey .
C068820_D006456 CID Furthermore , transient <e2>hemoglobinuria</e2> was noted approximately 60 minutes postinjection of <e1>WR242511</e1> ( 3.5 or 7.0 mg/kg ) , and 2 lethalities occurred ( one IV and one PO ) following the 7.0 mg/kg dose .
C068820_D011041 NONE It is concluded that <e1>WR242511</e1> should not be pursued as a pretreatment for CN <e2>poisoning</e2> unless the anti-CN characteristics of this compound can be successfully dissociated from those producing undesirable toxicity .
3782049
D008972_D012206 CID A case of massive <e2>rhabdomyolysis</e2> following <e1>molindone</e1> administration .
D008972_D012206 CID The case of a schizophrenic patient is reported to illustrate massive <e2>rhabdomyolysis</e2> and subsequent acute renal failure following <e1>molindone</e1> administration .
D008972_D012559 NONE The case of a <e2>schizophrenic</e2> patient is reported to illustrate massive rhabdomyolysis and subsequent acute renal failure following <e1>molindone</e1> administration .
D008972_D058186 CID The case of a schizophrenic patient is reported to illustrate massive rhabdomyolysis and subsequent <e2>acute renal failure</e2> following <e1>molindone</e1> administration .
8690168
D006497_D003928 NONE Reduction of <e1>heparan sulphate-associated</e1> anionic sites in the glomerular basement membrane of rats with streptozotocin-induced <e2>diabetic nephropathy</e2> .
D013311_D003928 CID Reduction of heparan sulphate-associated anionic sites in the glomerular basement membrane of rats with <e1>streptozotocin-induced</e1> <e2>diabetic nephropathy</e2> .
D006497_D003920 NONE <e1>Heparan sulphate-associated</e1> anionic sites in the glomerular basement membrane were studied in rats 8 months after induction of <e2>diabetes</e2> by streptozotocin and in age- adn sex-matched control rats , employing the cationic dye cuprolinic blue .
D006497_D003920 NONE We conclude that in <e2>streptozotocin-diabetic</e2> rats with an increased urinary albumin excretion , a reduced <e1>heparan sulphate</e1> charge barrier/density is found at the lamina rara externa of the glomerular basement membrane .
D013311_D003920 NONE Heparan sulphate-associated anionic sites in the glomerular basement membrane were studied in rats 8 months after induction of <e2>diabetes</e2> by <e1>streptozotocin</e1> and in age- adn sex-matched control rats , employing the cationic dye cuprolinic blue .
D013311_D003920 NONE We conclude that in <e2><e1>streptozotocin-diabetic</e1></e2> rats with an increased urinary albumin excretion , a reduced heparan sulphate charge barrier/density is found at the lamina rara externa of the glomerular basement membrane .
C015445_D003920 NONE Heparan sulphate-associated anionic sites in the glomerular basement membrane were studied in rats 8 months after induction of <e2>diabetes</e2> by streptozotocin and in age- adn sex-matched control rats , employing the cationic dye <e1>cuprolinic blue</e1> .
1468485
D010100_D006470 NONE Hyperbaric <e1>oxygen</e1> therapy for control of intractable cyclophosphamide-induced <e2>hemorrhagic cystitis</e2> .
D010100_D003556 NONE Hyperbaric <e1>oxygen</e1> therapy for control of intractable cyclophosphamide-induced <e2>hemorrhagic cystitis</e2> .
D003520_D006470 CID Hyperbaric oxygen therapy for control of intractable <e1>cyclophosphamide-induced</e1> <e2>hemorrhagic cystitis</e2> .
D003520_D006470 CID We report a case of intractable <e2>hemorrhagic cystitis</e2> due to <e1>cyclophosphamide</e1> therapy for Wegener 's granulomatosis .
D003520_D006470 CID In future , this form of therapy can offer a safe alternative in the treatment of <e1>cyclophosphamide-induced</e1> <e2>hemorrhagic cystitis</e2> .
D003520_D003556 CID Hyperbaric oxygen therapy for control of intractable <e1>cyclophosphamide-induced</e1> <e2>hemorrhagic cystitis</e2> .
D003520_D003556 CID We report a case of intractable <e2>hemorrhagic cystitis</e2> due to <e1>cyclophosphamide</e1> therapy for Wegener 's granulomatosis .
D003520_D003556 CID In future , this form of therapy can offer a safe alternative in the treatment of <e1>cyclophosphamide-induced</e1> <e2>hemorrhagic cystitis</e2> .
D003520_D014890 NONE We report a case of intractable hemorrhagic cystitis due to <e1>cyclophosphamide</e1> therapy for <e2>Wegener 's granulomatosis</e2> .
D015237_D006470 NONE Conservative treatment , including bladder irrigation with physiological saline and instillation of <e1>prostaglandin F2 alpha</e1> , failed to totally control <e2>hemorrhage</e2> .
88336
D002719_D013375 NONE Three patients received high doses of <e1>chlormethiazole</e1> for alcohol <e2>withdrawal symptoms</e2> , and one took a suicidal overdose of nitrazepam .
D002719_D062787 NONE Three patients received high doses of <e1>chlormethiazole</e1> for alcohol withdrawal symptoms , and one took a suicidal <e2>overdose</e2> of nitrazepam .
D002719_D062787 NONE The patient with nitrazepam <e2>overdose</e2> and two of those with <e1>chlormethiazole</e1> intoxication conformed to the criteria of ' alpha coma ' , showing non-reactive generalized or frontally predominant alpha activity in the EEG .
D000431_D013375 NONE Three patients received high doses of chlormethiazole for <e1>alcohol</e1> <e2>withdrawal symptoms</e2> , and one took a suicidal overdose of nitrazepam .
D000431_D062787 NONE Three patients received high doses of chlormethiazole for <e1>alcohol</e1> withdrawal symptoms , and one took a suicidal <e2>overdose</e2> of nitrazepam .
D009567_D013375 NONE Three patients received high doses of chlormethiazole for alcohol <e2>withdrawal symptoms</e2> , and one took a suicidal overdose of <e1>nitrazepam</e1> .
D009567_D062787 CID Three patients received high doses of chlormethiazole for alcohol withdrawal symptoms , and one took a suicidal <e2>overdose</e2> of <e1>nitrazepam</e1> .
D009567_D062787 CID The patient with <e1>nitrazepam</e1> <e2>overdose</e2> and two of those with chlormethiazole intoxication conformed to the criteria of ' alpha coma ' , showing non-reactive generalized or frontally predominant alpha activity in the EEG .
D009567_D003128 CID The patient with <e1>nitrazepam</e1> overdose and two of those with chlormethiazole intoxication conformed to the criteria of ' alpha <e2>coma</e2> ' , showing non-reactive generalized or frontally predominant alpha activity in the EEG .
D002719_D003128 CID The patient with nitrazepam overdose and two of those with <e1>chlormethiazole</e1> intoxication conformed to the criteria of ' alpha <e2>coma</e2> ' , showing non-reactive generalized or frontally predominant alpha activity in the EEG .
9334596
D013739_D007172 NONE PURPOSE : We reviewed the results of serum <e1>testosterone</e1> and prolactin determination in 1,022 patients referred because of <e2>erectile dysfunction</e2> and compared the data with history , results of physical examination , other etiological investigations and effects of endocrine therapy to refine the rules of cost-effective endocrine screening and to pinpoint actual responsibility for hormonal abnormalities .
D013739_D007172 NONE Most of the other low <e1>testosterone</e1> levels seemed to result from nonorganic hypothalamic dysfunction because of normal serum luteinizing hormone and prolactin and to have only a small role in <e2>erectile dysfunction</e2> ( definite improvement in only 16 of 44 [ 36 % ] after androgen therapy , normal morning or nocturnal erections in 30 % and definite vasculogenic contributions in 42 % ) .
D013739_D007172 NONE CONCLUSIONS : Low prevalences and effects of low <e1>testosterone</e1> and high prolactin in <e2>erectile dysfunction</e2> can not justify their routine determination .
D013739_D020018 CID Every patient was screened for <e1>testosterone</e1> and 451 were screened for prolactin on the basis of <e2>low sexual desire</e2> , gynecomastia or testosterone less than 4 ng./ml .
D013739_D020018 CID Every patient was screened for testosterone and 451 were screened for prolactin on the basis of <e2>low sexual desire</e2> , gynecomastia or <e1>testosterone</e1> less than 4 ng./ml .
D013739_D020018 CID Determining <e1>testosterone</e1> only in cases of <e2>low sexual desire</e2> or abnormal physical examination would have missed 40 % of the cases with low testosterone , including 37 % of those subsequently improved by androgen therapy .
D013739_D020018 CID Determining testosterone only in cases of <e2>low sexual desire</e2> or abnormal physical examination would have missed 40 % of the cases with low <e1>testosterone</e1> , including 37 % of those subsequently improved by androgen therapy .
D013739_D020018 CID We now advocate that before age 50 years <e1>testosterone</e1> be determined only in cases of <e2>low sexual desire</e2> and abnormal physical examination but that it be measured in all men older than 50 years .
D013739_D020018 CID Prolactin should be determined only in cases of <e2>low sexual desire</e2> , gynecomastia and/or <e1>testosterone</e1> less than 4 ng./ml .
D013739_D006177 NONE Every patient was screened for <e1>testosterone</e1> and 451 were screened for prolactin on the basis of low sexual desire , <e2>gynecomastia</e2> or testosterone less than 4 ng./ml .
D013739_D006177 NONE Every patient was screened for testosterone and 451 were screened for prolactin on the basis of low sexual desire , <e2>gynecomastia</e2> or <e1>testosterone</e1> less than 4 ng./ml .
D013739_D006177 NONE Prolactin should be determined only in cases of low sexual desire , <e2>gynecomastia</e2> and/or <e1>testosterone</e1> less than 4 ng./ml .
C004648_D007006 NONE Endocrine therapy consisted of <e1>testosterone heptylate</e1> or human chorionic gonadotropin for <e2>hypogonadism</e2> and bromocriptine for hyperprolactinemia .
C004648_D006966 NONE Endocrine therapy consisted of <e1>testosterone heptylate</e1> or human chorionic gonadotropin for hypogonadism and bromocriptine for <e2>hyperprolactinemia</e2> .
D001971_D007006 NONE Endocrine therapy consisted of testosterone heptylate or human chorionic gonadotropin for <e2>hypogonadism</e2> and <e1>bromocriptine</e1> for hyperprolactinemia .
D001971_D006966 NONE Endocrine therapy consisted of testosterone heptylate or human chorionic gonadotropin for hypogonadism and <e1>bromocriptine</e1> for <e2>hyperprolactinemia</e2> .
D013739_D010911 NONE Two <e2>pituitary tumors</e2> were discovered after <e1>testosterone</e1> determination .
D013739_D007027 NONE Most of the other low <e1>testosterone</e1> levels seemed to result from nonorganic <e2>hypothalamic dysfunction</e2> because of normal serum luteinizing hormone and prolactin and to have only a small role in erectile dysfunction ( definite improvement in only 16 of 44 [ 36 % ] after androgen therapy , normal morning or nocturnal erections in 30 % and definite vasculogenic contributions in 42 % ) .
1919871
D001241_D007681 CID <e2>Renal papillary necrosis</e2> ( RPN ) and a decreased urinary concentrating ability developed during continuous long-term treatment with <e1>aspirin</e1> and paracetamol in female Fischer 344 rats .
D001241_D007681 CID Renal papillary necrosis ( <e2>RPN</e2> ) and a decreased urinary concentrating ability developed during continuous long-term treatment with <e1>aspirin</e1> and paracetamol in female Fischer 344 rats .
D000082_D007681 CID <e2>Renal papillary necrosis</e2> ( RPN ) and a decreased urinary concentrating ability developed during continuous long-term treatment with aspirin and <e1>paracetamol</e1> in female Fischer 344 rats .
D000082_D007681 CID Renal papillary necrosis ( <e2>RPN</e2> ) and a decreased urinary concentrating ability developed during continuous long-term treatment with aspirin and <e1>paracetamol</e1> in female Fischer 344 rats .
8955532
D001920_D006973 NONE Role of activation of <e1>bradykinin</e1> B2 receptors in disruption of the blood-brain barrier during acute <e2>hypertension</e2> .
D001920_D006973 NONE The goal of this study was to determine the role of synthesis/release of <e1>bradykinin</e1> to activate B2 receptors in disruption of the blood-brain barrier during acute <e2>hypertension</e2> .
D001920_D006973 NONE These findings suggest that disruption of the blood-brain barrier during acute <e2>hypertension</e2> is not related to the synthesis/release of <e1>bradykinin</e1> to activate B2 receptors .
D003911_D006973 NONE Permeability of the blood-brain barrier was quantitated by clearance of fluorescent-labeled <e1>dextran</e1> before and during phenylephrine-induced acute <e2>hypertension</e2> in rats treated with vehicle and Hoe-140 ( 0.1 microM ) .
D010656_D006973 CID Permeability of the blood-brain barrier was quantitated by clearance of fluorescent-labeled dextran before and during <e1>phenylephrine-induced</e1> acute <e2>hypertension</e2> in rats treated with vehicle and Hoe-140 ( 0.1 microM ) .
C065679_D006973 NONE Permeability of the blood-brain barrier was quantitated by clearance of fluorescent-labeled dextran before and during phenylephrine-induced acute <e2>hypertension</e2> in rats treated with vehicle and <e1>Hoe-140</e1> ( 0.1 microM ) .
19037603
D019259_D012216 NONE Prophylactic use of <e1>lamivudine</e1> with chronic immunosuppressive therapy for <e2>rheumatologic disorders</e2> .
D019259_D012216 NONE The objective of this study was to report our experience concerning the effectiveness of the prophylactic administration of <e1>lamivudine</e1> in hepatitis B virus surface antigen ( HBs Ag ) positive patients with <e2>rheumatologic disease</e2> .
D019259_D012216 NONE From June 2004 to October 2006 , 11 HBs Ag positive patients with <e2>rheumatologic diseases</e2> , who were on both immunosuppressive and prophylactic <e1>lamivudine</e1> therapies , were retrospectively assessed .
D006514_D012216 NONE The objective of this study was to report our experience concerning the effectiveness of the prophylactic administration of lamivudine in <e1>hepatitis B virus surface antigen</e1> ( HBs Ag ) positive patients with <e2>rheumatologic disease</e2> .
D006514_D012216 NONE The objective of this study was to report our experience concerning the effectiveness of the prophylactic administration of lamivudine in hepatitis B virus surface antigen ( <e1>HBs Ag</e1> ) positive patients with <e2>rheumatologic disease</e2> .
D006514_D012216 NONE From June 2004 to October 2006 , 11 <e1>HBs Ag</e1> positive patients with <e2>rheumatologic diseases</e2> , who were on both immunosuppressive and prophylactic lamivudine therapies , were retrospectively assessed .
809711
D010656_D009203 NONE Reversal by <e1>phenylephrine</e1> of the beneficial effects of intravenous nitroglycerin in patients with <e2>acute myocardial infarction</e2> .
D010656_D009203 NONE Our results suggest that addition of <e1>phenylephrine</e1> to nitroglycerin is not beneficial in the treatment of patients with <e2>acute myocardial infarction</e2> .
D005996_D009203 NONE Reversal by phenylephrine of the beneficial effects of intravenous <e1>nitroglycerin</e1> in patients with <e2>acute myocardial infarction</e2> .
D005996_D009203 NONE <e1>Nitroglycerin</e1> has been shown to reduce ST-segment elevation during <e2>acute myocardial infarction</e2> , an effect potentiated in the dog by agents that reverse nitroglycerin-induced hypotension .
D005996_D009203 NONE Nitroglycerin has been shown to reduce ST-segment elevation during <e2>acute myocardial infarction</e2> , an effect potentiated in the dog by agents that reverse <e1>nitroglycerin-induced</e1> hypotension .
D005996_D009203 NONE Ten patients with acute transmural <e2>myocardial infarctions</e2> received intravenous <e1>nitroglycerin</e1> , sufficient to reduce mean arterial pressure from 107 +/- 6 to 85 +/- 6 mm Hg ( P less than 0.001 ) , for 60 minutes .
D005996_D009203 NONE Our results suggest that addition of phenylephrine to <e1>nitroglycerin</e1> is not beneficial in the treatment of patients with <e2>acute myocardial infarction</e2> .
D005996_D007022 CID <e1>Nitroglycerin</e1> has been shown to reduce ST-segment elevation during acute myocardial infarction , an effect potentiated in the dog by agents that reverse nitroglycerin-induced <e2>hypotension</e2> .
D005996_D007022 CID Nitroglycerin has been shown to reduce ST-segment elevation during acute myocardial infarction , an effect potentiated in the dog by agents that reverse <e1>nitroglycerin-induced</e1> <e2>hypotension</e2> .
17600377
C524754_D003072 NONE A novel compound , <e1>maltolyl p-coumarate</e1> , attenuates <e2>cognitive deficits</e2> and shows neuroprotective effects in vitro and in vivo dementia models .
C524754_D003072 NONE In the present study , we investigated whether <e1>maltolyl p-coumarate</e1> could improve <e2>cognitive decline</e2> in scopolamine-injected rats and in amyloid beta peptide(1 - 42)-infused rats .
C524754_D003072 NONE <e1>Maltolyl p-coumarate</e1> was found to attenuate <e2>cognitive deficits</e2> in both rat models using passive avoidance test and to reduce apoptotic cell death observed in the hippocampus of the amyloid beta peptide(1 - 42)-infused rats .
C524754_D003072 NONE Taking these in vitro and in vivo results together , our study suggests that <e1>maltolyl p-coumarate</e1> is a potentially effective candidate against Alzheimer 's disease that is characterized by wide spread neuronal death and progressive <e2>decline of cognitive function</e2> .
C524754_D003704 NONE A novel compound , <e1>maltolyl p-coumarate</e1> , attenuates cognitive deficits and shows neuroprotective effects in vitro and in vivo <e2>dementia</e2> models .
D012601_D003072 CID In the present study , we investigated whether maltolyl p-coumarate could improve <e2>cognitive decline</e2> in <e1>scopolamine-injected</e1> rats and in amyloid beta peptide(1 - 42)-infused rats .
C544092_D003072 NONE In the present study , we investigated whether maltolyl p-coumarate could improve <e2>cognitive decline</e2> in scopolamine-injected rats and in <e1>amyloid beta peptide(1 - 42)-infused</e1> rats .
C544092_D003072 NONE Maltolyl p-coumarate was found to attenuate <e2>cognitive deficits</e2> in both rat models using passive avoidance test and to reduce apoptotic cell death observed in the hippocampus of the <e1>amyloid beta peptide(1 - 42)-infused</e1> rats .
C524754_D000544 NONE Taking these in vitro and in vivo results together , our study suggests that <e1>maltolyl p-coumarate</e1> is a potentially effective candidate against <e2>Alzheimer 's disease</e2> that is characterized by wide spread neuronal death and progressive decline of cognitive function .
C524754_D009410 NONE Taking these in vitro and in vivo results together , our study suggests that <e1>maltolyl p-coumarate</e1> is a potentially effective candidate against Alzheimer 's disease that is characterized by wide spread <e2>neuronal death</e2> and progressive decline of cognitive function .
10526274
C056507_D002289 NONE <e1>Gemcitabine</e1> plus vinorelbine in <e2>nonsmall cell lung carcinoma</e2> patients age 70 years or older or patients who can not receive cisplatin .
C056507_D002289 NONE In the current study the efficacy and toxicity of the combination of <e1>GEM</e1> and VNB in elderly patients with advanced <e2>NSCLC</e2> or those with some contraindication to receiving cisplatin were assessed .
C030852_D002289 NONE Gemcitabine plus <e1>vinorelbine</e1> in <e2>nonsmall cell lung carcinoma</e2> patients age 70 years or older or patients who can not receive cisplatin .
C030852_D002289 NONE In the current study the efficacy and toxicity of the combination of GEM and <e1>VNB</e1> in elderly patients with advanced <e2>NSCLC</e2> or those with some contraindication to receiving cisplatin were assessed .
D002945_D002289 NONE Gemcitabine plus vinorelbine in <e2>nonsmall cell lung carcinoma</e2> patients age 70 years or older or patients who can not receive <e1>cisplatin</e1> .
D002945_D002289 NONE In the current study the efficacy and toxicity of the combination of GEM and VNB in elderly patients with advanced <e2>NSCLC</e2> or those with some contraindication to receiving <e1>cisplatin</e1> were assessed .
D002945_D002289 NONE METHODS : Forty-nine patients with advanced <e2>NSCLC</e2> were included , 38 of whom were age > /= 70 years and 11 were age < 70 years but who had some contraindication to receiving <e1>cisplatin</e1> .
C030852_D064420 NONE Recent reports indicate that single agent therapy with <e1>vinorelbine</e1> ( VNB ) or gemcitabine ( GEM ) may obtain a response rate of 20 - 30 % in elderly patients , with acceptable <e2>toxicity</e2> and improvement in symptoms and quality of life .
C030852_D064420 NONE Recent reports indicate that single agent therapy with vinorelbine ( <e1>VNB</e1> ) or gemcitabine ( GEM ) may obtain a response rate of 20 - 30 % in elderly patients , with acceptable <e2>toxicity</e2> and improvement in symptoms and quality of life .
C030852_D064420 NONE In the current study the efficacy and <e2>toxicity</e2> of the combination of GEM and <e1>VNB</e1> in elderly patients with advanced NSCLC or those with some contraindication to receiving cisplatin were assessed .
C056507_D064420 NONE Recent reports indicate that single agent therapy with vinorelbine ( VNB ) or <e1>gemcitabine</e1> ( GEM ) may obtain a response rate of 20 - 30 % in elderly patients , with acceptable <e2>toxicity</e2> and improvement in symptoms and quality of life .
C056507_D064420 NONE Recent reports indicate that single agent therapy with vinorelbine ( VNB ) or gemcitabine ( <e1>GEM</e1> ) may obtain a response rate of 20 - 30 % in elderly patients , with acceptable <e2>toxicity</e2> and improvement in symptoms and quality of life .
C056507_D064420 NONE In the current study the efficacy and <e2>toxicity</e2> of the combination of <e1>GEM</e1> and VNB in elderly patients with advanced NSCLC or those with some contraindication to receiving cisplatin were assessed .
D002945_D064420 NONE In the current study the efficacy and <e2>toxicity</e2> of the combination of GEM and VNB in elderly patients with advanced NSCLC or those with some contraindication to receiving <e1>cisplatin</e1> were assessed .
6692345
D001241_D001749 NONE The co-administration of <e1>aspirin</e1> with N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide ( FANFT ) to rats resulted in a reduced incidence of FANFT-induced <e2>bladder carcinomas</e2> but a concomitant induction of forestomach tumors .
D001241_D013274 NONE The co-administration of <e1>aspirin</e1> with N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide ( FANFT ) to rats resulted in a reduced incidence of FANFT-induced bladder carcinomas but a concomitant induction of <e2>forestomach tumors</e2> .
D005200_D001749 CID The co-administration of aspirin with <e1>N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide</e1> ( FANFT ) to rats resulted in a reduced incidence of FANFT-induced <e2>bladder carcinomas</e2> but a concomitant induction of forestomach tumors .
D005200_D001749 CID The co-administration of aspirin with N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide ( <e1>FANFT</e1> ) to rats resulted in a reduced incidence of FANFT-induced <e2>bladder carcinomas</e2> but a concomitant induction of forestomach tumors .
D005200_D001749 CID The co-administration of aspirin with N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide ( FANFT ) to rats resulted in a reduced incidence of <e1>FANFT-induced</e1> <e2>bladder carcinomas</e2> but a concomitant induction of forestomach tumors .
D005200_D013274 CID The co-administration of aspirin with <e1>N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide</e1> ( FANFT ) to rats resulted in a reduced incidence of FANFT-induced bladder carcinomas but a concomitant induction of <e2>forestomach tumors</e2> .
D005200_D013274 CID The co-administration of aspirin with N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide ( <e1>FANFT</e1> ) to rats resulted in a reduced incidence of FANFT-induced bladder carcinomas but a concomitant induction of <e2>forestomach tumors</e2> .
D005200_D013274 CID The co-administration of aspirin with N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide ( FANFT ) to rats resulted in a reduced incidence of <e1>FANFT-induced</e1> bladder carcinomas but a concomitant induction of <e2>forestomach tumors</e2> .
D005200_D063646 NONE The present results are consistent with the carcinogenicity experiment suggesting that different mechanisms are involved in <e1>FANFT</e1> <e2>carcinogenesis</e2> in the bladder and forestomach , and that aspirin 's effect on FANFT in the forestomach is not due to an irritant effect associated with increased cell proliferation .
D005200_D063646 NONE The present results are consistent with the carcinogenicity experiment suggesting that different mechanisms are involved in FANFT <e2>carcinogenesis</e2> in the bladder and forestomach , and that aspirin 's effect on <e1>FANFT</e1> in the forestomach is not due to an irritant effect associated with increased cell proliferation .
D001241_D063646 NONE The present results are consistent with the carcinogenicity experiment suggesting that different mechanisms are involved in FANFT <e2>carcinogenesis</e2> in the bladder and forestomach , and that <e1>aspirin</e1> 's effect on FANFT in the forestomach is not due to an irritant effect associated with increased cell proliferation .
2950248
D004176_D017202 NONE <e1>Dipyridamole-induced</e1> <e2>myocardial ischemia</e2> .
D004176_D017202 NONE To our knowledge , this has not previously been reported as a side effect of preoperative <e1>dipyridamole</e1> therapy , although dipyridamole-induced <e2>myocardial ischemia</e2> has been demonstrated to occur in animals and humans with coronary artery disease .
D004176_D017202 NONE To our knowledge , this has not previously been reported as a side effect of preoperative dipyridamole therapy , although <e1>dipyridamole-induced</e1> <e2>myocardial ischemia</e2> has been demonstrated to occur in animals and humans with coronary artery disease .
D004176_D000787 CID <e2>Angina</e2> and ischemic electrocardiographic changes occurred after administration of oral <e1>dipyridamole</e1> in four patients awaiting urgent myocardial revascularization procedures .
D004176_D003324 NONE To our knowledge , this has not previously been reported as a side effect of preoperative <e1>dipyridamole</e1> therapy , although dipyridamole-induced myocardial ischemia has been demonstrated to occur in animals and humans with <e2>coronary artery disease</e2> .
D004176_D003324 NONE To our knowledge , this has not previously been reported as a side effect of preoperative dipyridamole therapy , although <e1>dipyridamole-induced</e1> myocardial ischemia has been demonstrated to occur in animals and humans with <e2>coronary artery disease</e2> .
D004176_D007511 NONE Epicardial coronary collateral vessels were demonstrated in all four patients ; a coronary " steal " phenomenon may be the mechanism of the <e1>dipyridamole-induced</e1> <e2>ischemia</e2> observed .
18791946
D002939_D013921 CID Severe <e2>thrombocytopenia</e2> and haemolytic anaemia associated with <e1>ciprofloxacin</e1> : a case report with fatal outcome .
D002939_D013921 CID This case report shows that <e1>ciprofloxacin</e1> may precipitate life-threatening <e2>thrombocytopenia</e2> and haemolytic anaemia , even in the early phases of treatment and without apparent previous exposures .
D002939_D000743 CID Severe thrombocytopenia and <e2>haemolytic anaemia</e2> associated with <e1>ciprofloxacin</e1> : a case report with fatal outcome .
D002939_D000743 CID This case report shows that <e1>ciprofloxacin</e1> may precipitate life-threatening thrombocytopenia and <e2>haemolytic anaemia</e2> , even in the early phases of treatment and without apparent previous exposures .
D002939_D015746 CID A 30-year old Caucasian man reported with <e2>abdominal pain</e2> and jaundice after 3-day administration of oral <e1>ciprofloxacin</e1> for a suspect of urinary tract infection .
D002939_D007565 CID A 30-year old Caucasian man reported with abdominal pain and <e2>jaundice</e2> after 3-day administration of oral <e1>ciprofloxacin</e1> for a suspect of urinary tract infection .
D002939_D014552 NONE A 30-year old Caucasian man reported with abdominal pain and jaundice after 3-day administration of oral <e1>ciprofloxacin</e1> for a suspect of <e2>urinary tract infection</e2> .
17344566
D019821_D003161 CID <e1>Simvastatin-induced</e1> bilateral leg <e2>compartment syndrome</e2> and myonecrosis associated with hypothyroidism .
D019821_D003161 CID A 54-year-old hypothyroid male taking thyroxine and <e1>simvastatin</e1> presented with bilateral leg <e2>compartment syndrome</e2> and myonecrosis .
D019821_D009135 NONE <e1>Simvastatin-induced</e1> bilateral leg compartment syndrome and <e2>myonecrosis</e2> associated with hypothyroidism .
D019821_D009135 NONE A 54-year-old hypothyroid male taking thyroxine and <e1>simvastatin</e1> presented with bilateral leg compartment syndrome and <e2>myonecrosis</e2> .
D019821_D007037 NONE <e1>Simvastatin-induced</e1> bilateral leg compartment syndrome and myonecrosis associated with <e2>hypothyroidism</e2> .
D019821_D007037 NONE A 54-year-old <e2>hypothyroid</e2> male taking thyroxine and <e1>simvastatin</e1> presented with bilateral leg compartment syndrome and myonecrosis .
D013974_D007037 NONE A 54-year-old <e2>hypothyroid</e2> male taking <e1>thyroxine</e1> and simvastatin presented with bilateral leg compartment syndrome and myonecrosis .
D013974_D003161 NONE A 54-year-old hypothyroid male taking <e1>thyroxine</e1> and simvastatin presented with bilateral leg <e2>compartment syndrome</e2> and myonecrosis .
D013974_D009135 NONE A 54-year-old hypothyroid male taking <e1>thyroxine</e1> and simvastatin presented with bilateral leg compartment syndrome and <e2>myonecrosis</e2> .
